data_2ot2_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2ot2 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.905 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.9 t -139.15 141.13 28.59 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 124.317 1.047 . . . . 0.0 108.849 -169.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -59.26 157.63 29.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.887 2.391 . . . . 0.0 112.919 169.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.32 172.67 40.17 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 169.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -99.61 135.73 40.6 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.47 79.97 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 170.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 7.5 tpm_? -80.09 -24.67 40.42 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.561 -0.712 . . . . 0.0 112.406 -169.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.57 158.58 43.74 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -130.0 146.3 34.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 176.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -121.78 -23.64 5.46 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.111 0.965 . . . . 0.0 111.734 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.25 -126.8 1.35 Allowed Glycine 0 C--N 1.333 0.403 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 178.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.4 t30 -63.8 -29.21 70.44 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 117.651 0.726 . . . . 0.0 110.303 169.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.7 mm100 -86.44 151.89 23.14 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.56 0.695 . . . . 0.0 109.235 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.56 166.02 25.4 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.034 1.334 . . . . 0.0 109.568 174.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -114.48 78.25 1.14 Allowed 'General case' 0 C--O 1.234 0.266 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 -173.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.4 t -74.19 123.39 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 -175.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -75.04 107.92 7.43 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 169.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.52 61.22 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 32.0 m 45.94 43.96 10.82 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 127.205 2.202 . . . . 0.0 113.696 176.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.63 -36.66 0.16 Allowed Glycine 0 CA--C 1.525 0.703 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.643 176.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -153.67 152.9 9.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.4 mt-30 -77.47 138.72 39.4 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.059 177.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -117.85 144.95 44.95 Favored 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 126.044 1.737 . . . . 0.0 107.196 171.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -74.58 129.93 38.63 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 169.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.8 t -137.01 136.14 47.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -176.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -82.4 126.26 31.98 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.166 1.386 . . . . 0.0 109.072 176.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 29.4 mt -100.76 10.95 40.51 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 117.95 -1.024 . . . . 0.0 112.971 -175.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 32.4 m -50.84 -36.62 38.5 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 121.285 1.857 . . . . 0.0 112.395 -174.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -74.49 -10.37 59.49 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.5 m -132.2 -17.61 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 119.445 1.021 . . . . 0.0 112.57 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.18 145.91 1.02 Allowed Glycine 0 CA--C 1.529 0.955 0 C-N-CA 125.175 1.369 . . . . 0.0 110.654 -171.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.4 m -73.63 -5.3 39.57 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.734 -0.862 . . . . 0.0 113.067 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.3 m -131.97 151.79 51.51 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.362 1.065 . . . . 0.0 110.027 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -66.08 165.64 13.14 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.876 2.071 . . . . 0.0 109.71 169.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.52 -37.5 57.69 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.29 1.436 . . . . 0.0 112.247 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -85.9 10.21 14.6 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.8 0.84 . . . . 0.0 112.052 -178.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.67 5.27 88.4 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.623 1.106 . . . . 0.0 113.382 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -70.1 132.53 88.24 Favored Pre-proline 0 CA--C 1.537 0.469 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -65.86 141.44 65.11 Favored 'Trans proline' 0 N--CA 1.458 -0.56 0 CA-C-N 121.321 1.507 . . . . 0.0 109.107 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.9 mtt-85 -72.77 8.59 1.43 Allowed 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 114.401 1.26 . . . . 0.0 114.401 -173.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.06 125.46 7.14 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 120.128 1.331 . . . . 0.0 108.712 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.67 -19.32 55.12 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.873 1.225 . . . . 0.0 113.241 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -70.12 167.45 17.72 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 119.061 1.431 . . . . 0.0 108.903 172.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 46.9 m95 -116.04 162.75 16.93 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.782 -0.574 . . . . 0.0 109.532 -179.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -156.61 146.21 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -169.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 83.1 mt -83.82 112.13 19.83 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 169.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.68 127.81 39.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 173.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -140.98 130.23 23.57 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 173.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.5 m 41.68 35.8 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 126.195 1.798 . . . . 0.0 114.541 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.8 6.93 79.11 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.076 -0.847 . . . . 0.0 114.092 175.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -122.41 154.78 37.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.951 1.376 . . . . 0.0 109.694 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.81 104.92 3.58 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 169.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.07 -47.84 60.28 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.261 0.482 . . . . 0.0 109.755 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.1 m -152.05 136.18 16.58 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.92 1.288 . . . . 0.0 108.017 178.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.2 p -84.13 138.72 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 169.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.4 pt -141.93 162.98 19.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 124.652 1.181 . . . . 0.0 110.24 -170.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -77.02 166.18 23.65 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 123.768 0.827 . . . . 0.0 109.84 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.59 -43.14 84.41 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.903 0.881 . . . . 0.0 110.629 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.49 -38.64 87.71 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.002 0.521 . . . . 0.0 110.829 -175.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -67.04 -44.36 80.41 Favored 'General case' 0 C--O 1.232 0.145 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.04 -48.58 79.62 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.9 tmm_? -58.77 -46.81 86.64 Favored 'General case' 0 C--N 1.334 -0.104 0 C-N-CA 124.543 1.137 . . . . 0.0 110.059 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -63.22 -43.12 99.01 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 118.492 0.587 . . . . 0.0 111.292 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -64.16 -42.01 96.92 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 178.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 39.5 mt -65.16 -40.42 94.32 Favored 'General case' 0 CA--C 1.522 -0.13 0 C-N-CA 123.82 0.848 . . . . 0.0 110.599 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -63.64 -41.21 98.26 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 122.982 0.513 . . . . 0.0 110.873 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -66.74 -48.38 69.33 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.276 0.23 . . . . 0.0 110.607 174.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 10.4 tt . . . . . 0 C--O 1.231 0.108 0 C-N-CA 124.433 1.093 . . . . 0.0 111.231 -173.231 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.711 0 N-CA-C 107.831 -2.108 . . . . 0.0 107.831 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.8 m -145.43 158.13 51.31 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 126.473 1.909 . . . . 0.0 108.191 -169.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.79 162.43 26.87 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 121.894 1.729 . . . . 0.0 110.659 169.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.32 164.35 37.14 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 169.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -89.43 127.28 35.82 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 72.6 mt -63.64 112.16 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.9 tpt85 -109.71 -30.63 7.79 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 118.113 -0.946 . . . . 0.0 110.994 -169.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 11.9 p -144.96 158.12 43.91 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 169.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -132.54 141.91 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 105.31 -2.107 . . . . 0.0 105.31 176.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -116.13 -21.71 9.28 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.448 1.099 . . . . 0.0 111.447 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.3 -126.17 1.34 Allowed Glycine 0 C--N 1.334 0.437 0 N-CA-C 106.835 -2.506 . . . . 0.0 106.835 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.0 t30 -62.08 -15.6 46.25 Favored 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 117.37 0.585 . . . . 0.0 112.062 169.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -117.48 156.21 28.39 Favored 'General case' 0 C--O 1.238 0.461 0 O-C-N 121.151 -0.968 . . . . 0.0 109.23 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.39 173.3 13.69 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 125.894 1.678 . . . . 0.0 109.402 -169.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -132.72 109.2 9.52 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 m -84.24 135.25 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 C-N-CA 124.232 1.013 . . . . 0.0 108.605 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -81.11 115.28 20.47 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 169.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 t -87.93 60.59 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 125.427 1.491 . . . . 0.0 107.185 176.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.5 m 50.15 36.42 12.29 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.923 1.689 . . . . 0.0 114.369 176.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.3 -31.86 0.26 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 121.348 -0.845 . . . . 0.0 112.966 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -138.77 140.45 38.98 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 C-N-CA 125.425 1.49 . . . . 0.0 108.818 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -77.63 141.98 39.14 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.098 174.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 56.7 mmt-85 -137.53 144.31 42.07 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 125.014 1.326 . . . . 0.0 108.727 172.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -77.5 149.54 34.96 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.655 0.782 . . . . 0.0 111.068 -172.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.79 143.36 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 124.978 1.311 . . . . 0.0 108.82 177.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -92.8 133.17 36.31 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 124.435 1.094 . . . . 0.0 108.77 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.0 mt -105.49 14.52 28.52 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 118.312 -0.851 . . . . 0.0 112.058 -171.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -45.99 -38.03 7.25 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.333 1.424 . . . . 0.0 113.114 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.2 mt -85.41 -3.86 58.98 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.821 0.848 . . . . 0.0 113.02 -172.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.28 -18.36 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.547 1.067 . . . . 0.0 113.02 -177.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.77 143.51 1.22 Allowed Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.063 1.316 . . . . 0.0 110.759 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.2 m -75.37 -8.89 57.88 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 12.5 p -125.21 152.2 44.86 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.548 1.139 . . . . 0.0 109.015 174.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -77.87 172.19 13.84 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.289 1.036 . . . . 0.0 110.349 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -57.59 -34.97 69.8 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.086 0.954 . . . . 0.0 112.213 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 18.0 p30 -80.41 -3.69 50.73 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.285 1.834 . . . . 0.0 113.102 177.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.38 -4.81 67.27 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.552 -1.138 . . . . 0.0 114.157 172.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -66.22 143.15 98.21 Favored Pre-proline 0 CA--C 1.537 0.454 0 CA-C-N 119.677 1.739 . . . . 0.0 109.087 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -64.42 143.09 81.39 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 121.878 1.719 . . . . 0.0 108.857 169.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 83.0 mtt-85 -72.8 1.6 8.27 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -170.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.0 m -50.24 137.89 6.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 120.994 1.725 . . . . 0.0 111.126 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.74 -26.37 18.72 Favored Glycine 0 CA--C 1.53 0.975 0 C-N-CA 124.759 1.171 . . . . 0.0 112.911 178.306 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -76.1 165.8 24.4 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 118.898 1.349 . . . . 0.0 108.404 173.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -105.18 156.52 18.02 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -144.37 135.17 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 57.5 tp -78.39 133.67 37.5 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 22.3 t -116.33 150.97 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 -178.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.37 133.4 24.22 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 125.368 1.467 . . . . 0.0 107.649 171.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.5 m 42.58 33.48 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 C-N-CA 126.211 1.804 . . . . 0.0 114.641 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.2 7.62 82.88 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 118.966 -0.908 . . . . 0.0 114.106 176.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -120.28 143.81 48.13 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 119.117 1.458 . . . . 0.0 108.191 175.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.0 130.42 46.65 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 28.0 ttt -89.66 -57.88 2.72 Favored 'General case' 0 C--O 1.233 0.236 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 18.5 m -151.99 144.91 24.44 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 124.293 1.037 . . . . 0.0 109.078 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 t -74.12 140.29 17.88 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 105.399 -2.075 . . . . 0.0 105.399 168.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 pt -137.7 160.3 34.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 123.573 0.749 . . . . 0.0 109.821 -173.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -76.96 165.21 24.96 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.691 0.796 . . . . 0.0 109.706 173.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -59.74 -42.83 94.04 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.467 0.707 . . . . 0.0 110.219 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -65.32 -36.38 83.87 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.066 0.547 . . . . 0.0 110.932 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.3 mt-10 -67.7 -35.05 78.09 Favored 'General case' 0 N--CA 1.457 -0.095 0 CA-C-O 119.129 -0.463 . . . . 0.0 110.113 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -47.32 83.67 Favored 'General case' 0 C--N 1.34 0.185 0 CA-C-N 118.95 0.795 . . . . 0.0 110.293 175.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -62.54 -43.55 98.54 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 118.167 0.44 . . . . 0.0 110.725 177.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.75 -40.89 96.71 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 118.131 0.423 . . . . 0.0 111.147 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.8 m -67.07 -42.48 84.64 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.245 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.9 mt -63.94 -39.05 93.26 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 119.204 0.911 . . . . 0.0 110.582 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.94 -46.89 79.69 Favored 'General case' 0 C--O 1.227 -0.091 0 C-N-CA 122.95 0.5 . . . . 0.0 110.585 175.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.41 99.53 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.566 0.621 . . . . 0.0 111.225 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.6 tp . . . . . 0 CA--C 1.528 0.134 0 C-N-CA 123.882 0.873 . . . . 0.0 111.601 -174.331 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.942 0 CA-C-O 119.713 -0.493 . . . . 0.0 112.213 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -146.47 149.5 37.58 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 125.973 1.709 . . . . 0.0 108.184 -172.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -75.05 171.17 18.84 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.232 1.954 . . . . 0.0 112.237 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -156.07 167.84 33.39 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -101.72 136.83 40.9 Favored 'General case' 0 C--O 1.231 0.127 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.5 mt -72.65 82.6 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 125.648 1.579 . . . . 0.0 107.895 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.5 mmt85 -76.6 -27.56 55.83 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.607 -0.683 . . . . 0.0 111.565 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.14 152.18 35.66 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -176.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 63.6 mt -129.65 144.75 37.14 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -121.13 -20.16 6.88 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 124.446 1.098 . . . . 0.0 111.835 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.443 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 164.05 -127.48 1.67 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 106.607 -2.597 . . . . 0.0 106.607 -178.598 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -70.38 14.3 0.13 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 124.462 1.105 . . . . 0.0 112.004 169.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.443 ' H ' ' C ' ' A' ' 14' ' ' GLY . 37.7 mt-30 -140.11 153.8 46.82 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 127.66 2.384 . . . . 0.0 106.636 -176.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.65 167.18 22.68 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.261 1.425 . . . . 0.0 109.106 178.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -121.24 76.31 1.23 Allowed 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 -174.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.5 m -73.03 136.68 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -170.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -79.15 117.72 20.44 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 171.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.4 t -85.04 50.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 125.059 1.343 . . . . 0.0 107.724 177.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 79.3 m 40.59 49.57 2.73 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.166 2.186 . . . . 0.0 113.371 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 176.64 -38.92 0.1 OUTLIER Glycine 0 CA--C 1.526 0.748 0 CA-C-O 119.531 -0.594 . . . . 0.0 112.24 175.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.0 tp -156.26 154.86 5.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 175.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.5 mt-30 -76.94 143.28 39.63 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 122.801 0.441 . . . . 0.0 109.954 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.19 138.17 51.57 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 169.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -73.85 133.83 43.23 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 78.7 t -140.95 130.63 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.684 1.594 . . . . 0.0 107.001 -173.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.22 140.74 45.27 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 124.863 1.265 . . . . 0.0 109.92 175.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.3 mt -113.65 11.85 18.29 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.861 0.864 . . . . 0.0 112.886 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.9 m -53.34 -34.74 58.68 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 120.833 1.651 . . . . 0.0 112.432 -175.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 86.4 mt -73.91 -12.86 60.79 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -176.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 m -133.43 -19.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 119.323 0.965 . . . . 0.0 112.897 -171.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.33 147.03 0.89 Allowed Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.098 1.332 . . . . 0.0 110.831 -171.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.2 m -76.57 -4.38 42.54 Favored 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.842 -0.799 . . . . 0.0 113.002 179.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.1 m -131.94 151.25 51.83 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 124.349 1.059 . . . . 0.0 109.965 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -65.77 165.59 12.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.945 2.098 . . . . 0.0 109.864 169.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -52.96 -37.49 61.18 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.317 1.447 . . . . 0.0 112.152 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -85.35 9.82 14.4 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.721 0.809 . . . . 0.0 112.015 -178.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.87 4.96 88.37 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 124.581 1.086 . . . . 0.0 113.464 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -69.87 132.28 88.82 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -65.92 141.2 63.76 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 CA-C-N 121.303 1.501 . . . . 0.0 109.011 174.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -72.45 13.72 0.32 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -172.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -54.08 129.27 14.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-N 120.227 1.376 . . . . 0.0 108.639 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.65 -17.64 55.61 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.827 1.203 . . . . 0.0 113.414 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -73.34 169.31 17.41 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.511 1.655 . . . . 0.0 109.162 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.7 m95 -120.16 156.59 30.77 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.947 0.899 . . . . 0.0 109.123 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 2.8 m -143.2 144.92 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 123.435 0.694 . . . . 0.0 109.402 178.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 59.3 mt -72.89 147.97 44.82 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 168.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.9 t -131.96 152.68 37.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -130.82 -60.08 0.98 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.974 0.91 . . . . 0.0 109.635 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.3 m -138.36 38.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 123.941 0.896 . . . . 0.0 110.614 -169.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.08 14.66 60.25 Favored Glycine 0 CA--C 1.528 0.906 0 CA-C-O 119.406 -0.663 . . . . 0.0 113.046 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -128.22 137.33 51.98 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 175.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.32 111.74 5.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 172.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 15.5 tpt -71.79 -49.01 42.66 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 118.031 0.378 . . . . 0.0 110.303 -175.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 13.5 m -152.55 151.1 30.27 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 124.959 1.304 . . . . 0.0 108.603 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 18.4 t -78.79 141.01 15.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 171.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.7 pt -138.9 -169.69 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 126.064 1.746 . . . . 0.0 108.794 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -126.97 -179.29 4.76 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.019 1.327 . . . . 0.0 110.125 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -54.92 -44.9 74.64 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.161 0.985 . . . . 0.0 111.249 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.31 -49.22 67.78 Favored 'General case' 0 C--O 1.231 0.131 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -172.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 26.0 mm-40 -64.84 -38.76 92.07 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.776 0.43 . . . . 0.0 110.28 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.41 -51.28 66.43 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 118.372 0.533 . . . . 0.0 110.61 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 63.3 mtt85 -66.91 -36.95 83.43 Favored 'General case' 0 CA--C 1.523 -0.064 0 CA-C-O 118.489 -0.767 . . . . 0.0 110.633 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.72 -43.66 98.42 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 119.121 0.873 . . . . 0.0 110.909 175.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.4 m -64.05 -45.9 86.79 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 122.979 0.512 . . . . 0.0 109.996 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 57.9 mt -64.33 -39.22 93.47 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 118.252 0.478 . . . . 0.0 110.858 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.6 -48.48 72.16 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 123.2 0.6 . . . . 0.0 110.319 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.01 88.54 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 117.872 0.305 . . . . 0.0 111.26 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? . . . . . 0 C--N 1.339 0.117 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.047 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.757 0 N-CA-C 107.114 -2.394 . . . . 0.0 107.114 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.3 m -140.13 166.73 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.564 1.545 . . . . 0.0 109.675 -168.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -54.9 153.54 24.8 Favored 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.565 2.176 . . . . 0.0 113.175 169.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -159.88 164.31 34.14 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 169.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -110.96 130.21 55.65 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.45 1.125 . . . . 0.0 109.204 -172.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.6 mt -66.05 120.98 14.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 52.3 tpt85 -121.11 -22.5 6.09 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 118.182 -0.913 . . . . 0.0 111.651 -175.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.65 155.6 42.57 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 170.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 50.3 mt -133.06 144.67 35.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -126.61 -18.67 4.74 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 123.858 0.863 . . . . 0.0 112.452 -174.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.75 -131.13 2.25 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 107.2 -2.36 . . . . 0.0 107.2 -178.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.5 p-10 -68.33 9.24 0.35 Allowed 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.145 0.978 . . . . 0.0 112.545 169.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -139.39 155.47 47.62 Favored 'General case' 0 C--O 1.239 0.523 0 C-N-CA 126.004 1.722 . . . . 0.0 107.542 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.8 174.88 10.06 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 125.453 1.501 . . . . 0.0 110.757 -176.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -122.18 114.51 20.96 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 178.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 89.1 t -111.83 125.56 69.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 -169.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -72.58 112.21 8.43 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 170.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 t -90.07 59.81 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.3 m 50.02 42.64 24.98 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.336 1.854 . . . . 0.0 113.5 178.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.2 -37.28 0.14 Allowed Glycine 0 CA--C 1.525 0.71 0 O-C-N 121.629 -0.67 . . . . 0.0 112.906 173.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 tp -155.33 155.79 5.46 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 62.8 mt-30 -74.65 147.37 41.61 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.709 0.766 . . . . 0.0 110.871 177.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.14 144.52 51.23 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.456 1.502 . . . . 0.0 107.255 169.293 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -69.84 135.71 49.93 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 169.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.65 121.03 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -173.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -66.64 134.67 52.77 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 169.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.2 tp -117.78 0.44 11.98 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 124.737 1.215 . . . . 0.0 110.358 -169.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.5 m -57.77 -30.84 65.96 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 124.721 1.209 . . . . 0.0 111.211 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 77.0 mt -67.89 -13.98 62.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.078 0.951 . . . . 0.0 112.884 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.74 -8.71 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 119.154 0.888 . . . . 0.0 112.1 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.57 136.22 1.68 Allowed Glycine 0 CA--C 1.525 0.699 0 C-N-CA 125.4 1.476 . . . . 0.0 110.388 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.5 m -75.88 161.19 29.18 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.238 0.615 . . . . 0.0 109.342 169.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.2 m 56.4 177.52 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.774 1.629 . . . . 0.0 112.597 -169.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -133.49 151.91 51.83 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 126.182 1.793 . . . . 0.0 108.221 -170.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.2 -21.58 34.44 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.026 1.331 . . . . 0.0 114.214 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -74.31 -7.2 51.98 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.487 0.585 . . . . 0.0 112.052 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.15 46.92 5.71 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -177.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.67 158.3 60.18 Favored Pre-proline 0 CA--C 1.535 0.399 0 C-N-CA 125.165 1.386 . . . . 0.0 108.664 -176.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -69.0 153.55 72.24 Favored 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 121.958 1.772 . . . . 0.0 109.892 169.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -73.16 3.37 5.7 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.615 0.968 . . . . 0.0 113.615 177.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.53 127.46 15.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-N 120.547 1.521 . . . . 0.0 108.457 -175.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.27 -24.76 30.64 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 124.892 1.234 . . . . 0.0 112.548 -176.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -70.53 162.06 29.49 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.056 1.428 . . . . 0.0 108.84 172.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.4 m95 -113.67 155.87 24.75 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -141.88 143.19 27.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.2 mt -77.32 127.9 33.39 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 103.743 -2.688 . . . . 0.0 103.743 168.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.5 m -131.2 126.65 59.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 119.341 0.973 . . . . 0.0 110.627 -170.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.466 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 3.5 t60 -89.17 -165.88 1.45 Allowed 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 169.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.466 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 18.3 m -47.71 -29.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 C-N-CA 125.815 1.646 . . . . 0.0 114.993 -172.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.74 33.07 0.17 Allowed Glycine 0 C--N 1.338 0.639 0 CA-C-O 118.819 -0.99 . . . . 0.0 112.4 175.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -145.71 134.17 21.97 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.822 1.311 . . . . 0.0 109.128 -174.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.34 117.91 17.66 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 169.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 72.2 mtp -77.31 -49.4 15.08 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.526 1.13 . . . . 0.0 109.056 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.9 m -151.35 162.46 40.87 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 125.851 1.661 . . . . 0.0 108.65 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.7 p -107.52 139.88 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 C-N-CA 124.87 1.268 . . . . 0.0 107.874 172.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.1 pt -141.26 161.75 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.095 1.358 . . . . 0.0 109.896 -173.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -75.44 165.26 25.4 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.916 0.886 . . . . 0.0 110.53 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.53 -40.9 72.43 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 124.729 1.211 . . . . 0.0 111.698 176.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.48 -40.21 67.1 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 122.942 0.497 . . . . 0.0 110.79 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.07 -40.79 97.02 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.091 0.556 . . . . 0.0 109.763 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.91 -48.97 78.05 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.666 -0.207 . . . . 0.0 110.748 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 75.4 mtt85 -64.34 -40.02 95.05 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 119.079 -0.486 . . . . 0.0 110.762 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.7 -42.73 99.79 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.467 0.576 . . . . 0.0 111.047 176.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.4 m -65.16 -43.69 90.92 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.151 0.58 . . . . 0.0 110.334 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.2 mt -61.95 -44.45 96.73 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.394 0.543 . . . . 0.0 109.846 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -63.68 -44.47 93.63 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 118.458 0.572 . . . . 0.0 111.146 179.318 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.36 82.04 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 122.663 0.385 . . . . 0.0 110.316 178.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? . . . . . 0 CA--C 1.528 0.101 0 C-N-CA 123.693 0.797 . . . . 0.0 109.711 178.323 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.763 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.7 m -143.3 163.75 35.33 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 125.208 1.403 . . . . 0.0 110.287 -168.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -53.77 157.13 10.66 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 123.075 2.517 . . . . 0.0 113.874 171.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.71 167.85 37.34 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 126.336 1.922 . . . . 0.0 108.648 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.2 tt0 -116.18 134.25 55.13 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 64.7 mt -75.04 74.86 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 125.649 1.58 . . . . 0.0 107.509 -176.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -70.73 -30.65 67.23 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-O 118.438 -0.792 . . . . 0.0 111.566 -172.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -148.81 155.7 41.31 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 177.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 57.0 mt -132.18 146.85 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -178.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -129.71 -20.06 3.26 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.854 0.862 . . . . 0.0 112.529 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 175.15 -134.47 2.74 Favored Glycine 0 C--N 1.334 0.418 0 N-CA-C 106.243 -2.743 . . . . 0.0 106.243 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.9 t30 -65.86 -15.74 63.2 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 118.386 1.093 . . . . 0.0 110.668 169.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -101.08 153.0 19.93 Favored 'General case' 0 C--O 1.239 0.544 0 C-N-CA 124.954 1.302 . . . . 0.0 109.123 175.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.34 159.52 42.06 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.313 1.445 . . . . 0.0 109.14 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -106.77 86.83 2.39 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.61 127.6 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 -174.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -71.37 106.89 4.06 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 169.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.77 67.24 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.0 48.05 7.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.291 2.236 . . . . 0.0 113.739 178.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 174.77 -42.03 0.12 Allowed Glycine 0 CA--C 1.524 0.646 0 CA-C-O 119.692 -0.505 . . . . 0.0 112.219 172.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -156.97 156.1 4.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 C-N-CA 124.676 1.19 . . . . 0.0 108.175 175.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -67.76 136.06 53.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.23 0.612 . . . . 0.0 110.469 176.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.2 mpt_? -123.88 148.61 46.67 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 106.327 -1.731 . . . . 0.0 106.327 169.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -70.59 136.81 49.5 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.5 t -138.59 131.25 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -83.21 126.22 32.4 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 169.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.1 mt -83.29 36.86 0.53 Allowed 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 123.64 0.776 . . . . 0.0 111.335 -173.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -45.87 -40.33 9.81 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.412 2.285 . . . . 0.0 114.443 -169.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.2 mt -106.23 4.56 28.99 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 118.853 -0.594 . . . . 0.0 112.282 -169.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.3 m -133.97 -26.68 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.981 0.809 . . . . 0.0 111.937 -173.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.89 152.79 1.94 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.095 0.855 . . . . 0.0 110.979 -175.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 m -77.18 -6.86 54.56 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m -126.72 151.58 47.98 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.3 1.04 . . . . 0.0 109.075 175.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.5 t0 -84.51 176.57 8.55 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 124.308 1.043 . . . . 0.0 110.665 -178.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -55.68 -37.08 67.85 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.917 1.287 . . . . 0.0 112.102 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -84.12 -2.0 55.98 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.627 0.771 . . . . 0.0 112.929 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.18 -3.26 66.47 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.323 -1.265 . . . . 0.0 114.241 173.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -67.38 147.81 98.8 Favored Pre-proline 0 CA--C 1.538 0.506 0 CA-C-N 119.91 1.855 . . . . 0.0 109.046 175.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -64.87 141.93 73.51 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.541 1.494 . . . . 0.0 108.743 169.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.4 mtt-85 -70.94 11.39 0.4 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.7 p -56.38 129.23 17.74 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 CA-C-N 119.968 1.258 . . . . 0.0 109.031 -176.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.04 -14.46 57.18 Favored Glycine 0 CA--C 1.534 1.24 0 CA-C-O 118.226 -1.319 . . . . 0.0 113.972 -178.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -70.34 166.03 21.11 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.824 1.812 . . . . 0.0 108.969 170.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -112.25 161.22 16.83 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 121.538 0.685 . . . . 0.0 109.871 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.75 140.9 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 -172.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.8 111.64 12.55 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 104.894 -2.262 . . . . 0.0 104.894 169.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 51.3 t -93.11 132.22 37.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -144.24 130.41 19.63 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 1.7 t 45.74 37.34 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 125.177 1.391 . . . . 0.0 112.688 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.08 16.37 79.6 Favored Glycine 0 CA--C 1.534 1.251 0 O-C-N 120.916 -1.115 . . . . 0.0 114.308 176.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -128.49 161.95 28.35 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 119.315 1.558 . . . . 0.0 109.956 170.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.89 111.34 16.12 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 16.0 tpt -74.02 -51.5 15.67 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.4 m -154.21 138.37 16.51 Favored 'General case' 0 C--N 1.342 0.247 0 C-N-CA 124.305 1.042 . . . . 0.0 108.912 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -77.54 142.42 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 169.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.2 pt -139.91 160.51 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 124.355 1.062 . . . . 0.0 109.84 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -75.27 165.12 25.68 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 123.842 0.857 . . . . 0.0 110.46 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -54.51 -41.68 69.92 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 124.732 1.213 . . . . 0.0 111.467 174.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.4 -39.42 67.98 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 122.988 0.515 . . . . 0.0 110.786 -178.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -64.61 -40.7 95.97 Favored 'General case' 0 N--CA 1.461 0.088 0 C-N-CA 123.009 0.524 . . . . 0.0 109.865 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.43 -49.42 76.92 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.838 0.29 . . . . 0.0 110.562 177.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 76.1 mtt85 -64.45 -40.12 95.12 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-O 119.03 -0.51 . . . . 0.0 110.665 -178.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.93 -41.83 99.61 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 118.602 0.637 . . . . 0.0 111.129 176.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.7 m -65.42 -43.43 90.53 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.813 0.445 . . . . 0.0 110.032 178.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -64.51 -40.04 94.89 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 118.765 0.711 . . . . 0.0 110.549 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -63.21 -44.0 96.54 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 118.202 0.455 . . . . 0.0 110.748 176.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.64 -47.14 86.78 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 122.992 0.517 . . . . 0.0 110.204 175.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.7 mt . . . . . 0 CA--C 1.538 0.498 0 C-N-CA 125.039 1.336 . . . . 0.0 113.35 177.024 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.74 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.1 p -153.04 145.33 17.05 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 126.3 1.84 . . . . 0.0 106.472 -169.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -75.41 168.55 24.31 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.617 1.545 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.42 -176.88 42.24 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 172.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -95.99 137.86 34.46 Favored 'General case' 0 C--O 1.231 0.116 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 178.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 68.9 mt -71.47 78.81 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 171.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -67.51 -30.22 69.83 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.446 -0.784 . . . . 0.0 110.301 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.18 150.01 26.6 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 124.512 1.125 . . . . 0.0 108.051 -173.201 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 49.8 mt -119.98 149.79 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -145.48 65.17 1.24 Allowed 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 126.324 1.85 . . . . 0.0 107.468 -170.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 -124.71 18.71 Favored Glycine 0 C--N 1.338 0.64 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -173.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -68.27 -25.05 64.97 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 122.787 0.435 . . . . 0.0 111.913 172.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -86.1 170.92 11.77 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 121.86 0.838 . . . . 0.0 109.835 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.55 159.79 41.8 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.545 1.538 . . . . 0.0 108.19 169.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.58 75.97 0.95 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.238 -2.134 . . . . 0.0 105.238 177.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 79.3 t -71.74 126.52 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 124.904 1.282 . . . . 0.0 107.563 -172.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -79.26 111.02 15.08 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 174.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.5 t -82.06 60.21 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 C-N-CA 125.668 1.587 . . . . 0.0 107.282 172.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 55.5 m 43.67 41.39 3.53 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.11 2.164 . . . . 0.0 114.432 176.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 161.67 -23.83 0.23 Allowed Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.157 -0.802 . . . . 0.0 113.676 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.7 tp -150.29 149.43 14.45 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 176.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -92.17 139.06 31.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 -179.221 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -129.69 144.97 51.54 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.916 1.287 . . . . 0.0 108.519 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -73.84 137.61 43.91 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 71.6 t -137.03 143.67 34.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -99.8 119.8 38.75 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.164 1.386 . . . . 0.0 107.539 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.9 mt -91.17 12.49 19.91 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 117.88 -1.057 . . . . 0.0 113.03 -172.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -48.65 -36.43 15.91 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 121.29 1.859 . . . . 0.0 113.73 -174.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.0 mt -88.55 -2.63 58.7 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -173.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.07 -19.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 119.344 0.975 . . . . 0.0 112.672 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.0 146.84 2.93 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 125.259 1.409 . . . . 0.0 111.131 -175.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.1 m -74.97 -12.64 60.39 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.49 0.716 . . . . 0.0 112.18 174.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.4 m -117.89 166.34 12.6 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.603 1.161 . . . . 0.0 109.316 172.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -115.65 163.39 15.87 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.185 1.794 . . . . 0.0 110.446 -169.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -54.18 -36.74 63.72 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.397 1.479 . . . . 0.0 111.265 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -74.44 1.22 12.31 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.499 1.52 . . . . 0.0 113.059 -178.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.02 45.61 11.52 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 121.014 -1.054 . . . . 0.0 111.098 174.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.6 pt20 -141.64 151.34 60.08 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.28 1.432 . . . . 0.0 108.611 -177.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -66.52 147.81 82.76 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 122.08 1.853 . . . . 0.0 109.159 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -73.71 7.93 2.2 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.9 m -54.57 133.37 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 120.537 1.517 . . . . 0.0 109.892 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.11 -17.95 34.58 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-O 118.231 -1.316 . . . . 0.0 113.38 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -72.57 164.73 25.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 119.708 1.754 . . . . 0.0 108.735 174.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 33.7 m95 -109.2 154.0 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.0 p -146.61 140.22 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -172.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 65.6 tp -89.24 148.09 23.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 169.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 t -124.99 142.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -103.48 -52.15 3.06 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.915 0.486 . . . . 0.0 110.355 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.4 p -157.81 63.12 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 -38.36 1.81 Allowed Glycine 0 CA--C 1.529 0.946 0 C-N-CA 124.746 1.165 . . . . 0.0 112.034 -172.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -69.49 135.18 49.81 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 118.639 1.22 . . . . 0.0 109.159 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.43 132.03 52.61 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 169.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 21.9 ttt -84.81 -55.28 4.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.3 m -155.82 149.46 25.04 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 124.768 1.227 . . . . 0.0 108.844 -177.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.9 p -74.94 142.78 14.14 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 168.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.9 pt -138.32 169.98 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 C-N-CA 124.104 0.961 . . . . 0.0 109.682 -172.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.38 169.74 8.68 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.754 0.822 . . . . 0.0 109.575 169.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -62.43 -34.39 76.68 Favored 'General case' 0 C--N 1.334 -0.084 0 CA-C-O 118.68 -0.676 . . . . 0.0 112.452 -173.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.85 -39.78 95.01 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.022 0.828 . . . . 0.0 110.743 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -65.96 -41.15 91.61 Favored 'General case' 0 C--O 1.232 0.152 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.24 -50.33 72.17 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 117.916 0.325 . . . . 0.0 110.351 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 43.8 mmt-85 -63.48 -43.48 97.18 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 118.877 -0.582 . . . . 0.0 110.279 -179.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.75 -43.5 98.72 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 118.484 0.584 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.0 m -66.6 -43.55 84.52 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 122.749 0.42 . . . . 0.0 110.128 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.4 mt -63.63 -41.25 98.28 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 119.084 0.856 . . . . 0.0 110.499 178.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -63.31 -44.63 94.43 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 122.874 0.47 . . . . 0.0 110.417 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.18 -48.91 76.38 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.828 0.451 . . . . 0.0 110.76 177.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 56.9 mt . . . . . 0 N--CA 1.463 0.178 0 C-N-CA 123.281 0.633 . . . . 0.0 111.028 -177.659 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.522 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.4 t -142.7 141.7 20.94 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 -170.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -55.47 165.63 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.892 2.395 . . . . 0.0 113.017 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.88 175.67 35.09 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 169.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -116.82 136.43 52.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.8 mt -70.56 96.26 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 N-CA-C 105.931 -1.878 . . . . 0.0 105.931 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -85.56 -42.86 14.0 Favored 'General case' 0 N--CA 1.462 0.132 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 -169.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 p -147.22 158.43 43.95 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.617 1.567 . . . . 0.0 108.112 176.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 52.3 mt -127.46 146.57 33.0 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -177.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -123.96 -19.18 5.74 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.065 0.946 . . . . 0.0 112.294 -176.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.6 -127.58 1.59 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -66.75 2.29 1.44 Allowed 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 123.932 0.893 . . . . 0.0 112.384 169.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -134.28 154.23 51.42 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 126.875 2.07 . . . . 0.0 107.314 -174.186 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.83 155.33 47.3 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.625 1.17 . . . . 0.0 109.382 -179.183 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -99.56 78.7 2.19 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.9 t -68.13 125.8 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 -176.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -75.66 105.18 6.55 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 169.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 t -81.52 63.25 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 37.8 m 48.95 39.52 14.72 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.495 1.918 . . . . 0.0 113.315 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.02 -48.14 0.19 Allowed Glycine 0 CA--C 1.526 0.728 0 CA-C-O 119.255 -0.747 . . . . 0.0 112.01 174.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.0 mm -137.16 143.28 35.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -174.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -71.78 141.88 49.7 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.33 0.586 . . . . 0.0 110.775 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -133.35 144.14 49.43 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 125.622 1.569 . . . . 0.0 106.999 169.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -73.06 134.59 44.63 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 87.6 t -138.3 129.99 37.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -79.57 143.34 34.86 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 122.993 0.517 . . . . 0.0 109.886 174.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 36.3 mt -114.94 15.24 17.32 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.089 0.956 . . . . 0.0 112.668 -169.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.7 m -50.64 -37.32 39.89 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 120.886 1.676 . . . . 0.0 112.463 -177.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.4 mt -77.08 -8.54 57.64 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -174.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.39 -20.11 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 119.517 1.053 . . . . 0.0 112.992 -172.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.16 140.37 0.74 Allowed Glycine 0 CA--C 1.529 0.913 0 C-N-CA 125.244 1.402 . . . . 0.0 110.886 -172.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.8 m -73.82 -17.73 61.03 Favored 'General case' 0 CA--C 1.535 0.374 0 O-C-N 122.024 -0.692 . . . . 0.0 112.313 176.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.9 m -93.0 135.17 34.41 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 123.809 0.843 . . . . 0.0 109.043 175.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -66.38 158.18 29.93 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.093 1.757 . . . . 0.0 109.598 169.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -53.47 -29.96 38.48 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.346 1.459 . . . . 0.0 112.176 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -75.66 -12.67 60.25 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.26 48.63 4.5 Favored Glycine 0 CA--C 1.53 1.029 0 CA-C-N 119.007 0.821 . . . . 0.0 111.166 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -143.75 160.54 50.05 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 126.717 2.007 . . . . 0.0 107.409 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -64.68 141.96 74.85 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 CA-C-N 121.586 1.602 . . . . 0.0 110.538 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -69.53 13.87 0.12 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.5 m -54.93 132.87 18.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 120.354 1.434 . . . . 0.0 110.05 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.65 -17.79 53.05 Favored Glycine 0 CA--C 1.532 1.096 0 CA-C-O 118.479 -1.178 . . . . 0.0 113.458 -178.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -71.94 160.94 31.68 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 119.699 1.75 . . . . 0.0 109.081 174.095 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.3 m95 -107.68 161.17 15.11 Favored 'General case' 0 C--O 1.232 0.178 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 p -154.05 146.19 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -169.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.9 mt -89.89 139.63 30.4 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 172.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.3 t -136.15 143.35 36.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -178.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 5.5 t60 -141.44 -39.05 0.4 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.407 0.683 . . . . 0.0 112.487 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.36 27.08 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 119.026 0.83 . . . . 0.0 112.029 -171.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.99 16.73 80.52 Favored Glycine 0 CA--C 1.534 1.224 0 O-C-N 121.446 -0.784 . . . . 0.0 112.526 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -129.03 144.43 51.19 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 172.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.12 122.59 17.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 171.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 68.5 mtp -76.76 -47.18 22.5 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.4 m -163.74 149.05 10.89 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 126.131 1.772 . . . . 0.0 108.144 176.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.1 t -80.37 145.28 9.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 169.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.2 pt -139.51 161.44 27.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.447 1.499 . . . . 0.0 109.198 -176.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -84.45 173.45 10.87 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.344 0.592 . . . . 0.0 110.894 174.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -69.99 -30.18 67.45 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 121.758 -0.589 . . . . 0.0 112.294 -170.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -73.63 -40.6 63.65 Favored 'General case' 0 N--CA 1.462 0.129 0 O-C-N 121.283 -0.886 . . . . 0.0 109.837 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -61.36 -41.35 96.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.224 0.61 . . . . 0.0 109.917 174.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.43 -49.41 75.57 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 117.983 0.356 . . . . 0.0 110.416 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 86.3 mtm180 -63.7 -40.2 96.19 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 119.13 -0.462 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.2 -41.9 99.24 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 118.759 0.709 . . . . 0.0 110.954 176.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -67.49 -38.64 84.66 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 122.083 -0.386 . . . . 0.0 110.282 178.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 53.0 mt -65.49 -38.03 88.57 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 119.079 0.854 . . . . 0.0 110.67 176.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -64.76 -43.86 91.93 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 118.605 0.639 . . . . 0.0 110.293 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.52 -43.24 99.29 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.962 0.505 . . . . 0.0 111.142 176.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? . . . . . 0 N--CA 1.464 0.255 0 C-N-CA 124.405 1.082 . . . . 0.0 109.909 176.936 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.936 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 98.5 t -143.88 139.39 16.03 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -171.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.83 159.89 31.44 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.666 1.577 . . . . 0.0 112.582 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.3 168.1 33.04 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 172.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -89.9 143.02 27.15 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 174.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 70.0 mt -74.17 76.64 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.32 1.448 . . . . 0.0 107.205 176.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -64.87 -39.18 93.14 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 126.088 1.755 . . . . 0.0 110.916 -177.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.0 m -150.26 153.78 36.78 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.35 147.2 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 178.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -116.39 -22.33 8.84 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.37 1.468 . . . . 0.0 111.565 -169.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 154.29 -122.92 1.3 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 105.094 -3.203 . . . . 0.0 105.094 -177.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -72.81 15.68 0.18 Allowed 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.101 0.961 . . . . 0.0 111.121 168.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.438 ' H ' ' C ' ' A' ' 14' ' ' GLY . 20.6 mt-30 -141.53 169.87 16.79 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 128.03 2.532 . . . . 0.0 106.569 -174.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.78 21.27 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.399 1.08 . . . . 0.0 109.4 173.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.3 mttp -118.26 72.58 0.87 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 105.604 -1.999 . . . . 0.0 105.604 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.5 m -70.13 137.2 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 C-N-CA 124.553 1.141 . . . . 0.0 109.326 -169.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -85.19 111.89 20.23 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 175.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.2 m -80.45 38.94 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 C-N-CA 124.181 0.992 . . . . 0.0 110.979 178.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 75.8 m 48.13 53.53 11.56 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.349 1.86 . . . . 0.0 111.855 -169.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -179.52 -41.3 0.07 OUTLIER Glycine 0 CA--C 1.524 0.62 0 CA-C-O 119.721 -0.488 . . . . 0.0 112.415 173.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.4 tp -156.0 156.06 5.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 -77.12 138.73 39.68 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 173.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -130.9 131.99 44.85 Favored 'General case' 0 C--N 1.333 -0.12 0 C-N-CA 125.466 1.506 . . . . 0.0 107.789 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -72.29 130.96 42.01 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 49.1 t -141.44 133.55 28.68 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 125.683 1.593 . . . . 0.0 107.323 -173.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -64.79 136.71 57.2 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 122.689 0.395 . . . . 0.0 110.407 172.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.9 mt -112.92 0.74 15.21 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.165 -0.921 . . . . 0.0 111.569 173.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.3 m -54.99 -31.75 61.21 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 121.061 1.755 . . . . 0.0 111.724 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 56.8 mt -67.87 -15.26 63.53 Favored 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 113.642 0.979 . . . . 0.0 113.642 178.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.64 -10.83 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.481 1.112 . . . . 0.0 112.79 -175.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.31 141.02 0.83 Allowed Glycine 0 CA--C 1.529 0.922 0 C-N-CA 125.527 1.537 . . . . 0.0 110.397 -170.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.4 m -76.29 -6.2 50.43 Favored 'General case' 0 CA--C 1.536 0.432 0 O-C-N 121.817 -0.813 . . . . 0.0 112.533 174.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 80.4 m -110.32 147.96 32.87 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 124.139 0.976 . . . . 0.0 109.489 175.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -68.94 171.65 7.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 126.635 1.974 . . . . 0.0 110.564 176.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 21.9 mm-40 -58.25 -15.36 9.79 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.149 1.38 . . . . 0.0 113.505 -177.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -117.96 8.66 12.6 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.529 1.532 . . . . 0.0 112.896 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.73 -2.11 69.47 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-O 118.805 -0.997 . . . . 0.0 114.545 170.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -67.01 154.54 92.28 Favored Pre-proline 0 CA--C 1.537 0.444 0 CA-C-N 119.373 1.586 . . . . 0.0 108.797 169.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -64.84 143.32 79.48 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 CA-C-N 121.18 1.457 . . . . 0.0 109.382 169.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.1 mtt-85 -70.51 10.96 0.4 Allowed 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.966 1.098 . . . . 0.0 113.966 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.9 p -56.44 132.34 20.4 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 O-C-N 120.759 -1.213 . . . . 0.0 109.03 -175.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.7 -15.79 49.74 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 118.097 -1.391 . . . . 0.0 114.076 -178.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -69.05 170.28 10.21 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 120.023 1.912 . . . . 0.0 108.906 169.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -119.66 157.62 28.1 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 177.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.3 p -151.56 136.3 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -171.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 81.0 mt -71.35 145.37 49.47 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 169.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 39.1 t -117.06 143.24 27.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 176.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -139.14 118.84 13.09 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 173.154 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . 0.286 29.4 m 44.45 28.87 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.461 2.304 . . . . 0.0 115.686 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 98.81 10.87 48.55 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 121.188 -0.945 . . . . 0.0 114.392 178.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -125.79 146.62 49.71 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 119.044 1.422 . . . . 0.0 108.484 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.12 114.44 3.12 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.615 0.766 . . . . 0.0 109.523 172.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 12.7 tpt -80.91 -42.71 20.96 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 58.3 m -166.02 147.54 6.88 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.865 1.666 . . . . 0.0 108.328 171.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 96.6 t -75.54 143.56 13.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 169.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 33.7 pt -139.36 162.19 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.028 1.331 . . . . 0.0 109.782 -175.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -74.14 165.22 25.53 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-O 121.48 0.657 . . . . 0.0 110.262 172.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -56.62 -43.2 79.99 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.191 1.396 . . . . 0.0 111.318 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.37 -38.85 85.39 Favored 'General case' 0 C--N 1.338 0.1 0 C-N-CA 122.801 0.44 . . . . 0.0 110.825 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -65.97 -40.36 91.18 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.31 -49.38 74.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 117.939 0.336 . . . . 0.0 110.478 178.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 47.6 mtm105 -61.57 -42.17 98.46 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 119.12 -0.467 . . . . 0.0 110.809 179.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.4 -42.83 99.73 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 118.5 0.591 . . . . 0.0 111.102 177.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.7 m -65.84 -41.31 91.92 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.841 0.456 . . . . 0.0 110.273 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.0 mt -65.23 -40.67 94.36 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.981 0.809 . . . . 0.0 110.426 178.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -64.4 -44.1 92.36 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 118.717 0.689 . . . . 0.0 110.696 177.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.3 -46.03 92.01 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.95 0.5 . . . . 0.0 110.509 176.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.0 mt . . . . . 0 C--O 1.227 -0.101 0 CA-C-O 118.771 -0.633 . . . . 0.0 110.758 -179.67 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.315 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 9.0 p -148.44 149.95 32.86 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 123.69 0.796 . . . . 0.0 109.121 -169.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.03 168.58 16.95 Favored 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 122.549 2.166 . . . . 0.0 111.882 169.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.66 172.9 41.27 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.621 2.057 . . . . 0.0 108.621 170.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -116.71 129.58 56.21 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 118.216 1.008 . . . . 0.0 108.982 -177.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 63.8 mt -70.27 127.63 32.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 -178.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -120.99 -29.65 4.54 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 118.247 -0.882 . . . . 0.0 112.448 -170.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.6 155.32 40.09 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.0 mt -132.37 124.81 52.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 N-CA-C 106.642 -1.614 . . . . 0.0 106.642 -177.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -86.89 -32.24 20.3 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.506 0.722 . . . . 0.0 110.4 172.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.58 -114.03 0.58 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 107.69 -2.164 . . . . 0.0 107.69 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -67.22 -0.66 3.6 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.287 1.035 . . . . 0.0 112.997 172.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -135.95 155.57 50.08 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 125.632 1.573 . . . . 0.0 107.438 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.23 151.69 38.8 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.321 1.048 . . . . 0.0 110.04 -171.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.0 tttt -90.85 133.1 35.49 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.23 130.49 72.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 -174.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -82.31 110.0 17.08 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 169.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.5 t -84.4 64.86 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 178.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.6 m 52.76 29.43 7.51 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.615 1.966 . . . . 0.0 114.94 171.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 158.27 -23.67 0.37 Allowed Glycine 0 CA--C 1.525 0.675 0 CA-C-N 119.121 0.873 . . . . 0.0 113.584 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.7 tp -146.45 149.63 15.86 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -88.51 150.27 23.2 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.983 0.42 . . . . 0.0 110.236 -175.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -139.5 150.08 44.71 Favored 'General case' 0 N--CA 1.464 0.227 0 C-N-CA 124.566 1.146 . . . . 0.0 108.703 169.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.54 138.83 35.38 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 169.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 50.5 t -136.38 131.88 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -173.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.34 138.64 37.77 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.468 0.707 . . . . 0.0 109.71 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.99 10.83 16.35 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.946 0.898 . . . . 0.0 112.211 -171.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.9 m -53.1 -34.07 55.03 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 120.265 1.393 . . . . 0.0 111.991 -177.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 85.2 mt -73.38 -12.93 60.99 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.769 0.827 . . . . 0.0 113.136 -176.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.36 -20.3 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 119.516 1.053 . . . . 0.0 113.188 -169.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.54 146.32 6.03 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 124.334 0.968 . . . . 0.0 111.457 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.1 p -74.41 -6.71 49.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.949 1.7 . . . . 0.0 113.581 -176.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.8 m -135.49 157.14 47.64 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 125.385 1.474 . . . . 0.0 108.177 171.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -66.07 165.11 14.06 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.079 1.352 . . . . 0.0 110.451 169.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -53.95 -38.33 64.84 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.935 1.294 . . . . 0.0 111.657 176.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -87.06 11.83 12.83 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.861 0.865 . . . . 0.0 111.85 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.98 6.97 88.48 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 124.583 1.087 . . . . 0.0 113.492 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -67.71 134.2 92.45 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 118.588 1.194 . . . . 0.0 108.206 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.27 143.29 53.62 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.531 2.154 . . . . 0.0 111.44 171.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -69.7 -17.79 63.5 Favored 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 118.043 -0.98 . . . . 0.0 112.836 175.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -55.32 134.82 18.72 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 120.297 1.408 . . . . 0.0 109.125 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.02 -21.27 20.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 124.561 1.077 . . . . 0.0 112.735 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -71.87 159.64 33.94 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 119.09 1.445 . . . . 0.0 108.162 171.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -106.7 158.41 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.67 139.52 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -169.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -83.18 133.08 35.04 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 169.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.2 t -121.44 135.76 60.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 4.7 t60 -137.12 -48.38 0.6 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.269 0.628 . . . . 0.0 111.108 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.4 m -136.3 27.63 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 123.75 0.82 . . . . 0.0 111.205 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.12 15.53 78.56 Favored Glycine 0 CA--C 1.531 1.068 0 O-C-N 121.531 -0.73 . . . . 0.0 112.464 -174.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -126.39 147.8 49.71 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 125.578 1.551 . . . . 0.0 107.095 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.44 105.18 1.4 Allowed 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.379 1.071 . . . . 0.0 108.257 172.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.4 ttt -70.6 -46.17 63.91 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 24.6 m -152.53 158.69 42.89 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.136 1.774 . . . . 0.0 107.445 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 44.1 t -121.0 140.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 174.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.0 pt -141.66 161.93 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 C-N-CA 125.712 1.605 . . . . 0.0 110.081 -171.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -74.66 168.34 20.0 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.669 0.788 . . . . 0.0 110.507 171.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -63.1 -42.29 99.55 Favored 'General case' 0 C--O 1.227 -0.09 0 CA-C-O 119.167 -0.444 . . . . 0.0 111.963 -173.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.83 -41.41 87.49 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.499 0.59 . . . . 0.0 110.315 -173.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.59 -36.43 82.7 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 122.578 0.351 . . . . 0.0 110.49 173.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.88 -40.57 83.54 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-N 119.05 0.841 . . . . 0.0 111.507 176.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 10.0 mmt85 -66.59 -38.83 87.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 119.291 0.95 . . . . 0.0 109.513 178.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.48 -42.71 99.68 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 118.015 0.371 . . . . 0.0 110.919 174.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.6 m -62.06 -40.87 97.24 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.34 0.656 . . . . 0.0 110.417 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 21.4 mt -63.86 -39.15 93.54 Favored 'General case' 0 C--N 1.338 0.073 0 O-C-N 121.668 -0.645 . . . . 0.0 110.943 178.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -68.2 -44.33 76.06 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.383 0.992 . . . . 0.0 110.677 175.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.53 -31.41 70.49 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.247 1.019 . . . . 0.0 111.821 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 62.3 tp . . . . . 0 N--CA 1.454 -0.255 0 C-N-CA 123.558 0.743 . . . . 0.0 110.339 174.444 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.92 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.1 t -139.24 143.41 36.28 Favored Pre-proline 0 CA--C 1.543 0.688 0 C-N-CA 124.296 1.038 . . . . 0.0 109.007 -169.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.25 155.62 24.0 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.632 2.221 . . . . 0.0 112.301 169.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.12 170.66 39.44 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 169.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.1 tt0 -116.3 125.25 51.88 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 123.982 0.913 . . . . 0.0 108.836 -174.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.03 129.33 27.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -114.42 -33.93 5.43 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 118.058 -0.972 . . . . 0.0 111.663 -176.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.4 p -148.15 157.25 43.39 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 47.1 mt -132.51 144.14 37.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -123.15 -19.29 6.07 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.364 1.066 . . . . 0.0 111.875 -176.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.46 -127.18 1.53 Allowed Glycine 0 C--N 1.336 0.562 0 N-CA-C 106.815 -2.514 . . . . 0.0 106.815 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -63.92 -10.23 19.86 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 117.514 0.657 . . . . 0.0 112.365 169.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -119.92 159.2 25.14 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.523 1.129 . . . . 0.0 110.509 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.48 167.72 27.11 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 125.746 1.618 . . . . 0.0 109.544 -172.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.33 132.28 54.52 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 171.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 52.7 t -126.35 123.78 64.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -174.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -72.81 111.13 7.67 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.2 63.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.9 m 47.18 42.47 13.31 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.885 2.074 . . . . 0.0 114.026 175.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.55 -31.17 0.19 Allowed Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.169 174.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -152.41 151.45 11.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 177.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -73.14 137.5 45.19 Favored 'General case' 0 C--O 1.234 0.266 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -122.53 148.26 45.4 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 124.595 1.158 . . . . 0.0 108.188 169.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -72.82 134.71 45.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 123.82 0.848 . . . . 0.0 108.983 172.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -140.5 157.28 24.21 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 C-N-CA 124.787 1.235 . . . . 0.0 108.096 -176.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -112.61 142.58 45.03 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 125.415 1.486 . . . . 0.0 108.815 172.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.9 mt -113.3 7.59 17.78 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.284 1.034 . . . . 0.0 112.328 -169.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 28.9 p -57.55 -29.15 64.16 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.599 1.545 . . . . 0.0 113.124 -173.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -70.53 -16.36 62.88 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.691 0.797 . . . . 0.0 112.534 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 24.2 m -130.0 -12.63 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 C-N-CA 124.606 1.162 . . . . 0.0 112.312 -173.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.62 141.34 1.19 Allowed Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.993 1.282 . . . . 0.0 109.939 -170.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -73.15 -10.58 59.92 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -178.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.4 m -121.36 145.62 47.71 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.229 1.012 . . . . 0.0 109.238 177.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -69.81 157.55 37.14 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.227 1.411 . . . . 0.0 109.894 172.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -51.54 -35.07 39.26 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 125.128 1.371 . . . . 0.0 112.139 176.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -70.45 -8.86 54.2 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.746 0.818 . . . . 0.0 112.417 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.43 25.04 10.42 Favored Glycine 0 CA--C 1.53 1.019 0 CA-C-N 119.6 1.091 . . . . 0.0 113.946 170.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -125.92 149.21 65.36 Favored Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 118.775 1.287 . . . . 0.0 108.26 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.77 143.91 36.59 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 122.966 2.444 . . . . 0.0 111.272 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.1 mtt-85 -70.61 18.79 0.05 Allowed 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 114.421 1.267 . . . . 0.0 114.421 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.2 m -56.55 136.32 19.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 O-C-N 120.394 -1.441 . . . . 0.0 109.547 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.11 -14.64 43.14 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 118.373 -1.237 . . . . 0.0 113.586 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -75.23 152.05 38.36 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 120.134 1.967 . . . . 0.0 109.184 176.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -95.07 150.28 20.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 174.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.2 m -142.2 153.5 18.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 124.663 1.185 . . . . 0.0 109.04 -178.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -85.37 107.09 17.2 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 169.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.0 t -78.02 120.87 29.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -134.62 120.09 19.16 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.0 t 49.58 33.61 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 C-N-CA 125.146 1.378 . . . . 0.0 112.105 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.96 6.94 78.59 Favored Glycine 0 CA--C 1.531 1.094 0 O-C-N 121.029 -1.044 . . . . 0.0 114.054 176.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -119.99 146.03 46.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-N 119.339 1.57 . . . . 0.0 109.055 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.5 104.83 6.23 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 41.0 tpp -68.2 -46.28 71.05 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.72 0.408 . . . . 0.0 110.704 -174.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.2 m -152.02 165.75 33.71 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 125.953 1.701 . . . . 0.0 107.98 -178.568 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 6.5 t -111.38 141.34 27.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.049 1.34 . . . . 0.0 107.742 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 35.8 pt -140.81 165.86 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.767 1.227 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.1 m-80 -80.39 165.48 22.2 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 124.582 1.153 . . . . 0.0 109.889 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -64.65 -32.41 74.06 Favored 'General case' 0 N--CA 1.468 0.425 0 O-C-N 121.763 -0.586 . . . . 0.0 111.505 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.54 -43.11 77.39 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.432 -0.793 . . . . 0.0 110.429 177.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -65.08 -39.32 93.03 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.314 0.646 . . . . 0.0 109.646 178.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.98 -49.55 74.26 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.17 -0.331 . . . . 0.0 110.364 177.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -62.53 -40.01 95.42 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 119.103 -0.475 . . . . 0.0 111.008 179.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -61.48 -43.77 98.28 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 118.494 0.588 . . . . 0.0 110.898 175.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -66.79 -40.49 88.16 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.075 0.55 . . . . 0.0 110.643 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 41.7 mt -63.06 -35.66 81.0 Favored 'General case' 0 C--N 1.338 0.101 0 C-N-CA 124.066 0.946 . . . . 0.0 110.759 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -70.06 -48.89 55.97 Favored 'General case' 0 C--O 1.226 -0.132 0 CA-C-N 118.492 0.587 . . . . 0.0 109.905 171.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.08 -40.49 85.4 Favored 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.617 0.767 . . . . 0.0 111.744 -171.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.0 pp . . . . . 0 CA--C 1.537 0.473 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 179.862 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.717 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.9 m -146.89 168.18 12.01 Favored Pre-proline 0 CA--C 1.543 0.69 0 C-N-CA 125.462 1.505 . . . . 0.0 110.108 -168.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -57.37 162.73 9.43 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.052 2.501 . . . . 0.0 113.37 169.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.86 176.75 41.22 Favored Glycine 0 CA--C 1.526 0.729 0 C-N-CA 125.978 1.752 . . . . 0.0 109.666 170.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.9 tt0 -116.86 136.92 52.58 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 45.6 mt -72.89 71.29 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -68.69 -33.52 74.1 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.156 0.982 . . . . 0.0 111.647 -169.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.3 156.06 43.09 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 174.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt -128.66 146.7 33.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 N-CA-C 106.471 -1.678 . . . . 0.0 106.471 178.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -117.14 -27.27 6.54 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 123.918 0.887 . . . . 0.0 111.415 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.5 -123.17 1.08 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -62.71 -23.52 67.2 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.292 0.637 . . . . 0.0 111.848 169.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 25.2 mm100 -99.04 155.28 17.52 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.022 0.929 . . . . 0.0 109.278 169.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.11 163.13 33.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.014 1.326 . . . . 0.0 109.538 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -110.46 77.72 1.07 Allowed 'General case' 0 C--O 1.234 0.252 0 N-CA-C 105.688 -1.968 . . . . 0.0 105.688 -175.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.0 t -70.85 127.74 33.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -177.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -74.83 107.61 7.03 Favored 'General case' 0 CA--C 1.52 -0.187 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 168.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -84.26 58.09 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -178.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.0 m 45.57 44.6 10.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.274 2.23 . . . . 0.0 113.208 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.26 -38.65 0.14 Allowed Glycine 0 CA--C 1.525 0.713 0 CA-C-O 119.478 -0.624 . . . . 0.0 112.708 176.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.6 tp -153.09 153.79 8.49 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 58.6 mt-30 -73.63 138.04 44.58 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -127.0 144.89 50.9 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 125.608 1.563 . . . . 0.0 107.151 172.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -75.01 131.19 40.45 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 72.9 t -140.16 138.77 37.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 125.126 1.37 . . . . 0.0 107.933 -171.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -80.72 130.64 35.2 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.778 1.631 . . . . 0.0 109.264 175.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.0 mt -105.46 6.66 32.63 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.676 0.79 . . . . 0.0 112.989 -176.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 7.5 m -55.61 -32.67 63.31 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.807 1.64 . . . . 0.0 112.853 -171.527 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.02 -13.95 62.17 Favored 'General case' 0 CA--C 1.538 0.493 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -178.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.33 -15.55 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.372 1.069 . . . . 0.0 112.581 -174.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.91 143.88 1.31 Allowed Glycine 0 CA--C 1.528 0.871 0 C-N-CA 125.394 1.474 . . . . 0.0 110.683 -173.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 m -76.62 -7.32 55.02 Favored 'General case' 0 CA--C 1.536 0.415 0 O-C-N 121.944 -0.739 . . . . 0.0 112.871 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.9 m -114.71 139.57 49.57 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.072 0.949 . . . . 0.0 109.676 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -75.56 155.76 35.7 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 126.809 2.044 . . . . 0.0 109.733 170.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -58.04 -25.96 61.85 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.034 1.334 . . . . 0.0 112.883 -173.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 -71.56 -6.97 44.66 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 121.506 -0.746 . . . . 0.0 112.525 178.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.13 47.44 5.24 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -142.44 153.51 62.49 Favored Pre-proline 0 CA--C 1.535 0.392 0 C-N-CA 125.724 1.61 . . . . 0.0 107.577 -178.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.51 147.23 76.53 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 C-N-CA 121.645 1.563 . . . . 0.0 109.687 174.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -70.88 17.96 0.07 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -175.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.4 t -56.53 126.2 13.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 O-C-N 120.848 -1.157 . . . . 0.0 108.599 -174.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.63 -13.59 66.25 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.324 -1.265 . . . . 0.0 113.632 176.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 80.1 mt-30 -68.04 154.58 41.34 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 119.566 1.683 . . . . 0.0 109.106 174.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.9 m95 -96.19 160.7 14.3 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.53 156.7 4.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -169.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 96.0 mt -101.68 133.0 47.06 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 169.158 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.9 m -128.3 139.07 52.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 118.853 0.751 . . . . 0.0 109.113 -177.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.6 t-80 -142.48 132.77 24.82 Favored 'General case' 0 C--O 1.232 0.132 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 -176.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 36.2 t 59.77 -61.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 128.146 2.579 . . . . 0.0 112.79 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -174.37 21.04 0.06 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.182 1.849 . . . . 0.0 111.596 179.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -132.38 141.86 49.07 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 118.78 1.29 . . . . 0.0 108.69 -172.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.26 124.03 24.88 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 169.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 90.4 mmm -90.86 -49.16 6.6 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 123.148 0.579 . . . . 0.0 109.966 -178.017 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.3 m -149.52 140.85 23.21 Favored 'General case' 0 C--N 1.339 0.145 0 C-N-CA 124.271 1.029 . . . . 0.0 108.775 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 84.0 t -81.78 142.93 13.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 169.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.1 pt -139.58 162.78 26.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 C-N-CA 124.885 1.274 . . . . 0.0 109.647 -173.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -79.67 163.79 24.27 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.658 0.742 . . . . 0.0 110.53 175.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -55.89 -39.35 71.43 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 126.26 1.824 . . . . 0.0 111.729 175.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.59 -50.06 34.51 Favored 'General case' 0 C--N 1.338 0.091 0 O-C-N 121.864 -0.523 . . . . 0.0 110.253 -173.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -72.35 -27.48 62.43 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 119.296 -0.383 . . . . 0.0 110.73 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.29 -52.04 66.98 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.877 0.762 . . . . 0.0 110.056 170.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.8 mtm180 -64.43 -37.64 88.22 Favored 'General case' 0 N--CA 1.46 0.054 0 CA-C-O 118.859 -0.591 . . . . 0.0 110.93 179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -62.65 -40.63 97.64 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 118.971 0.805 . . . . 0.0 111.176 175.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.8 m -65.39 -40.98 94.12 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.978 -0.452 . . . . 0.0 110.035 176.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.4 mt -65.07 -38.34 90.48 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.349 -0.845 . . . . 0.0 110.762 176.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -66.28 -39.11 89.19 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.624 0.647 . . . . 0.0 110.906 177.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.09 -50.46 71.85 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.463 0.705 . . . . 0.0 110.404 173.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.2 mt . . . . . 0 CA--C 1.533 0.296 0 C-N-CA 124.386 1.074 . . . . 0.0 112.6 -179.399 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.709 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.0 t -140.21 139.3 20.68 Favored Pre-proline 0 CA--C 1.54 0.565 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -169.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -76.65 168.98 22.67 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.384 2.056 . . . . 0.0 111.83 173.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -171.02 -174.9 39.18 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 173.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 57.7 tt0 -116.67 131.15 57.02 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 123.659 0.784 . . . . 0.0 108.99 -176.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 89.7 mt -67.06 122.65 18.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 mtm105 -119.62 -10.15 9.66 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 177.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -152.55 151.55 30.81 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 172.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.9 mt -133.19 140.24 47.52 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 172.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -108.01 -23.97 11.79 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.471 1.108 . . . . 0.0 112.438 -174.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.83 -62.37 0.15 Allowed Glycine 0 C--N 1.338 0.666 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 175.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -144.42 27.92 1.36 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.912 1.339 . . . . 0.0 110.381 169.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -137.62 156.2 48.33 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 169.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -144.25 166.54 24.75 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 123.867 0.867 . . . . 0.0 110.001 -170.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -117.38 84.35 2.14 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.22 131.08 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -83.24 109.72 17.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 169.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.8 t -85.35 62.23 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -175.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 56.5 m 48.77 40.7 16.72 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.329 1.852 . . . . 0.0 113.161 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 172.17 -49.0 0.18 Allowed Glycine 0 CA--C 1.525 0.658 0 CA-C-O 119.304 -0.72 . . . . 0.0 112.126 173.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.1 mm -138.0 145.59 28.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 -173.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -73.74 145.72 44.9 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.288 0.566 . . . . 0.0 111.307 175.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -133.84 139.68 46.4 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 125.481 1.512 . . . . 0.0 107.804 170.309 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -71.56 136.2 47.37 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.89 155.17 17.46 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 125.396 1.478 . . . . 0.0 109.162 177.003 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -98.07 141.53 30.9 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 124.636 1.175 . . . . 0.0 110.223 -177.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.7 mp -117.23 15.41 14.9 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.828 1.251 . . . . 0.0 111.871 -170.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.4 p -53.22 -33.65 53.75 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 119.966 1.257 . . . . 0.0 112.267 176.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -77.78 -12.05 59.94 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 123.848 0.859 . . . . 0.0 112.986 -174.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.07 -17.05 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.699 1.136 . . . . 0.0 113.364 -171.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.98 148.95 4.5 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -176.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 m -74.09 -14.22 60.95 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 124.244 1.018 . . . . 0.0 113.23 -174.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -126.19 143.67 51.05 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.975 0.91 . . . . 0.0 109.902 -171.256 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -70.8 155.7 40.45 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 126.463 1.905 . . . . 0.0 109.954 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -58.57 -25.75 62.88 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.638 1.175 . . . . 0.0 112.531 -175.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -61.98 -22.74 65.92 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.74 0.816 . . . . 0.0 112.924 175.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.18 47.38 3.09 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -174.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -142.14 151.26 58.28 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 125.819 1.648 . . . . 0.0 107.488 -178.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -65.72 148.46 86.83 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.882 1.721 . . . . 0.0 109.879 176.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -70.78 16.65 0.08 Allowed 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 -176.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 98.6 t -60.66 133.44 26.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 O-C-N 120.565 -1.334 . . . . 0.0 107.878 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.92 -15.2 56.46 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.303 -1.276 . . . . 0.0 113.064 -178.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 67.9 mt-30 -71.88 149.57 45.04 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 119.818 1.809 . . . . 0.0 108.907 175.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.7 m95 -85.15 152.4 23.4 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 170.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.7 p -146.46 138.42 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 62.9 tp -89.0 128.76 35.71 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 169.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.8 m -124.83 151.34 30.29 Favored 'Isoleucine or valine' 0 C--O 1.235 0.324 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -142.57 148.47 37.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 104.958 -2.238 . . . . 0.0 104.958 169.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.7 m 44.81 28.51 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 126.097 1.759 . . . . 0.0 115.368 171.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.48 14.03 64.4 Favored Glycine 0 CA--C 1.531 1.074 0 CA-C-O 118.472 -1.182 . . . . 0.0 113.857 176.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -129.13 144.11 51.09 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 119.818 1.809 . . . . 0.0 109.692 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.54 112.37 4.66 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 169.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.4 mmt -91.15 -34.89 14.85 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 119.094 -0.479 . . . . 0.0 111.114 -178.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 70.7 m -155.58 144.46 20.59 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 119.276 0.944 . . . . 0.0 109.283 169.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 48.3 t -79.99 140.37 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 169.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.2 pt -135.07 -175.2 1.3 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 C-N-CA 124.156 0.982 . . . . 0.0 108.865 -173.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -131.18 176.58 8.15 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.763 1.225 . . . . 0.0 108.597 178.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 68.4 mm-40 -52.78 -47.78 67.28 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 125.895 1.678 . . . . 0.0 110.908 -171.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -69.47 -40.86 76.86 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.673 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -66.19 -37.8 86.46 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 123.033 0.533 . . . . 0.0 109.568 176.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.94 -45.11 94.03 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 118.513 -0.755 . . . . 0.0 110.37 175.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 28.9 mmt-85 -63.92 -42.43 97.4 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.691 1.132 . . . . 0.0 110.6 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.16 -43.1 99.58 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.513 0.597 . . . . 0.0 110.948 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.7 m -68.18 -37.3 80.79 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 122.75 0.42 . . . . 0.0 110.432 178.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 54.8 mt -67.29 -33.42 75.25 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.122 -0.986 . . . . 0.0 110.658 176.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -67.04 -35.78 80.62 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.842 0.746 . . . . 0.0 111.457 174.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.04 -46.32 81.73 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 121.915 -0.49 . . . . 0.0 109.893 169.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? . . . . . 0 C--N 1.338 0.073 0 C-N-CA 123.629 0.772 . . . . 0.0 110.725 -176.866 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.388 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.8 t -140.32 137.41 17.79 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 -169.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.88 174.42 11.93 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.129 1.886 . . . . 0.0 111.56 174.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.11 -177.52 27.61 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 124.405 1.003 . . . . 0.0 111.065 172.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.7 tt0 -116.77 142.29 47.11 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 173.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 59.6 mt -74.58 85.05 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.1 tpp180 -71.48 -37.14 71.34 Favored 'General case' 0 CA--C 1.527 0.081 0 C-N-CA 124.882 1.273 . . . . 0.0 109.932 -172.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -157.83 144.61 17.91 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.645 1.578 . . . . 0.0 107.224 -175.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 61.4 mt -110.23 149.44 13.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -132.97 -0.19 3.41 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.668 1.187 . . . . 0.0 112.435 -169.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 146.83 -128.1 2.9 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 106.931 -2.468 . . . . 0.0 106.931 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 15.9 t30 -72.51 12.75 0.43 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.79 0.836 . . . . 0.0 110.96 169.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.439 ' H ' ' C ' ' A' ' 14' ' ' GLY . 36.7 mt-30 -140.44 161.68 37.13 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.505 2.322 . . . . 0.0 107.278 -169.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.78 153.41 42.37 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 176.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -104.62 69.6 0.9 Allowed 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 105.884 -1.895 . . . . 0.0 105.884 178.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.7 m -69.21 138.85 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 -171.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -81.2 102.89 10.63 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.09 62.76 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 C-N-CA 125.637 1.575 . . . . 0.0 108.519 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.8 m 43.76 42.49 4.39 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 127.285 2.234 . . . . 0.0 113.23 -179.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.69 -34.7 0.21 Allowed Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.037 -0.868 . . . . 0.0 113.535 177.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.4 tt -150.33 149.36 14.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 118.627 1.213 . . . . 0.0 108.753 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -76.77 135.43 38.98 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 176.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -137.88 137.19 37.83 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 124.4 1.08 . . . . 0.0 108.227 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.51 137.3 54.28 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 122.744 0.417 . . . . 0.0 110.032 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 m -140.81 145.54 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 124.826 1.25 . . . . 0.0 107.955 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -83.49 144.63 29.42 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 5.5 mp -110.36 10.44 23.45 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.029 -0.986 . . . . 0.0 113.207 -169.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.2 m -52.04 -32.18 33.28 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 121.006 1.73 . . . . 0.0 112.809 -177.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.4 mt -68.55 -15.85 63.67 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.38 -18.5 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 124.2 1.0 . . . . 0.0 112.913 -173.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.37 149.74 1.82 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.965 1.269 . . . . 0.0 110.694 -169.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 19.0 m -74.81 -5.1 41.62 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 121.806 -0.82 . . . . 0.0 112.952 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.7 m -126.56 157.68 38.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 124.443 1.097 . . . . 0.0 110.026 178.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -54.57 -53.4 55.08 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 126.756 2.022 . . . . 0.0 112.931 -171.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 176.07 -48.11 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 128.766 2.826 . . . . 0.0 106.793 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -79.71 -40.71 28.34 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.414 1.086 . . . . 0.0 111.144 -178.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 148.18 6.56 0.25 Allowed Glycine 0 CA--C 1.531 1.052 0 CA-C-O 118.7 -1.056 . . . . 0.0 114.089 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 mt-30 -76.99 124.18 87.4 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 119.352 1.576 . . . . 0.0 107.195 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.49 139.69 65.38 Favored 'Trans proline' 0 CA--C 1.534 0.482 0 C-N-CA 122.39 2.06 . . . . 0.0 111.142 174.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.7 mtt-85 -71.2 6.39 1.7 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -177.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.1 t -51.88 129.08 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 120.121 1.328 . . . . 0.0 109.113 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.93 -19.29 54.76 Favored Glycine 0 CA--C 1.53 1.002 0 C-N-CA 124.781 1.181 . . . . 0.0 113.458 178.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -68.32 163.4 23.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.338 1.569 . . . . 0.0 109.179 173.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -105.42 163.04 12.94 Favored 'General case' 0 C--O 1.234 0.238 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.49 148.08 14.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 123.194 0.598 . . . . 0.0 109.425 -169.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 74.9 mt -90.63 141.47 28.74 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 169.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.7 t -132.18 147.82 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -148.26 -45.85 0.16 Allowed 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.89 1.276 . . . . 0.0 109.009 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.6 m -126.97 -166.97 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 126.412 1.885 . . . . 0.0 106.673 171.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -72.37 37.68 0.69 Allowed Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.673 1.13 . . . . 0.0 114.112 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -139.59 147.36 41.01 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.342 1.457 . . . . 0.0 109.288 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.66 104.57 3.96 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 169.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 88.7 mmm -69.05 -45.05 71.38 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 118.369 0.532 . . . . 0.0 110.447 -169.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.5 m -161.76 152.84 18.16 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 126.156 1.783 . . . . 0.0 107.144 169.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -75.11 149.43 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 170.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -141.64 -167.55 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 C-N-CA 126.487 1.915 . . . . 0.0 108.293 176.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -123.63 174.17 7.62 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 125.098 1.359 . . . . 0.0 109.804 175.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -60.0 -40.17 88.31 Favored 'General case' 0 CA--C 1.527 0.083 0 C-N-CA 123.895 0.878 . . . . 0.0 112.399 -172.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.36 -37.81 56.74 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 118.183 0.447 . . . . 0.0 109.923 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -61.8 -36.15 80.27 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.333 0.653 . . . . 0.0 109.878 173.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.52 -42.35 98.45 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.504 -0.748 . . . . 0.0 110.809 174.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.6 mpt_? -64.59 -43.39 93.96 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 119.275 0.943 . . . . 0.0 109.995 177.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -60.27 -40.13 89.29 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.064 0.393 . . . . 0.0 111.065 177.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.4 m -65.67 -43.61 88.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.091 0.557 . . . . 0.0 110.452 176.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 59.4 mt -63.64 -38.9 92.87 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 118.873 0.761 . . . . 0.0 110.639 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -64.69 -45.35 87.01 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 123.408 0.683 . . . . 0.0 110.427 175.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.23 -42.73 99.12 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.425 0.557 . . . . 0.0 110.995 177.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? . . . . . 0 C--O 1.234 0.246 0 C-N-CA 123.514 0.726 . . . . 0.0 109.909 -178.908 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.731 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 10.6 p -148.87 154.05 39.56 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 123.848 0.859 . . . . 0.0 109.54 -169.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -58.54 161.92 13.6 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.711 2.274 . . . . 0.0 113.364 169.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.55 175.35 38.97 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 108.654 -1.779 . . . . 0.0 108.654 169.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -116.89 131.88 56.84 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 176.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.9 mt -66.41 119.06 10.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 177.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.5 tpp180 -107.4 -40.6 5.32 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 118.507 -0.759 . . . . 0.0 109.713 -169.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.9 p -142.37 161.8 37.11 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.493 1.117 . . . . 0.0 108.438 169.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.4 mt -132.64 148.81 31.64 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -179.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -124.54 -24.56 4.19 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.299 1.04 . . . . 0.0 112.028 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.66 -126.74 1.33 Allowed Glycine 0 C--N 1.333 0.416 0 N-CA-C 106.757 -2.537 . . . . 0.0 106.757 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 11.8 t30 -65.48 -24.44 67.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.722 0.761 . . . . 0.0 110.254 169.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -93.39 155.6 17.28 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-O 122.054 0.93 . . . . 0.0 110.282 172.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.64 175.03 11.91 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.65 1.58 . . . . 0.0 108.863 -178.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -128.71 99.83 5.49 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 176.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.3 m -69.12 165.88 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 169.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -111.74 112.95 25.01 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 169.029 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -88.26 60.58 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 -177.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.6 m 46.45 41.31 9.26 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.094 2.157 . . . . 0.0 113.586 178.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.56 -26.95 0.2 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.106 -0.83 . . . . 0.0 114.248 175.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.5 tp -149.34 149.91 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.447 0 CA-C-N 118.646 1.223 . . . . 0.0 107.742 177.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -76.21 147.79 38.15 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 175.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -140.16 132.59 28.51 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 124.563 1.145 . . . . 0.0 108.823 176.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -69.98 140.69 52.99 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 123.976 0.91 . . . . 0.0 110.185 176.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -148.49 167.13 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 126.136 1.774 . . . . 0.0 109.162 -178.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -107.03 143.59 34.92 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 169.623 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 26.6 mt -114.58 21.35 14.59 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.279 1.431 . . . . 0.0 110.854 -173.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.07 -35.45 59.56 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.699 1.199 . . . . 0.0 112.584 -171.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.7 mt -80.34 -8.96 59.72 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.679 0.791 . . . . 0.0 112.617 -176.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.7 m -126.92 -5.83 4.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.253 1.021 . . . . 0.0 111.815 -177.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.27 79.21 Favored Glycine 0 CA--C 1.532 1.099 0 C-N-CA 124.99 1.281 . . . . 0.0 114.918 169.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 m 58.5 -14.28 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 127.167 2.187 . . . . 0.0 116.711 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.6 m -136.5 153.39 51.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 124.828 1.251 . . . . 0.0 109.598 -177.669 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -64.97 157.91 26.94 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.472 1.109 . . . . 0.0 108.899 169.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -48.2 -41.65 27.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.279 1.431 . . . . 0.0 112.445 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -80.73 -16.84 52.86 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 118.91 -0.566 . . . . 0.0 112.152 -176.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.92 -12.6 5.32 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-O 118.504 -1.164 . . . . 0.0 115.817 169.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -66.06 135.36 95.14 Favored Pre-proline 0 N--CA 1.469 0.477 0 CA-C-N 119.662 1.731 . . . . 0.0 109.341 -172.24 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.11 140.33 71.25 Favored 'Trans proline' 0 CA--C 1.534 0.475 0 C-N-CA 121.707 1.605 . . . . 0.0 109.162 171.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -73.42 11.25 0.81 Allowed 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 114.517 1.302 . . . . 0.0 114.517 -172.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.0 m -53.14 133.99 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 120.251 1.387 . . . . 0.0 109.698 176.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.8 -18.61 52.56 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.433 -1.204 . . . . 0.0 112.992 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -73.52 142.18 46.73 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 119.89 1.845 . . . . 0.0 108.974 177.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -85.04 151.24 24.31 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 170.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.69 145.02 14.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -170.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 86.0 mt -79.1 132.74 36.69 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 169.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 50.2 t -118.63 123.69 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -135.04 137.56 43.06 Favored 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.7 m 44.1 28.45 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 C-N-CA 126.61 1.964 . . . . 0.0 115.405 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.76 4.65 58.98 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.698 1.142 . . . . 0.0 113.892 175.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -125.79 144.55 50.59 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 119.093 1.447 . . . . 0.0 109.719 -176.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.16 120.04 16.16 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 169.381 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 25.8 mmt -91.47 -45.52 8.49 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 119.001 -0.523 . . . . 0.0 111.436 -178.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.5 m -152.19 138.47 18.42 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -176.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.1 t -74.12 142.2 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 169.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.53 -169.52 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 125.695 1.598 . . . . 0.0 109.133 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -128.16 174.79 8.95 Favored 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 125.803 1.641 . . . . 0.0 108.791 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -62.51 -36.52 82.83 Favored 'General case' 0 N--CA 1.462 0.129 0 CA-C-O 118.955 -0.545 . . . . 0.0 112.434 -173.318 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.99 -44.67 76.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.936 0.789 . . . . 0.0 109.464 -177.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -64.58 -41.34 96.34 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 123.136 0.574 . . . . 0.0 110.259 176.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -49.14 75.91 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 122.86 0.464 . . . . 0.0 110.431 179.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -64.67 -41.25 96.21 Favored 'General case' 0 N--CA 1.463 0.195 0 C-N-CA 123.156 0.583 . . . . 0.0 110.376 -178.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -62.5 -43.23 99.33 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.397 0.544 . . . . 0.0 110.939 176.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -69.59 -37.46 76.93 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 122.097 -0.377 . . . . 0.0 110.506 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 27.7 mt -62.79 -40.15 96.45 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 119.113 0.87 . . . . 0.0 110.293 176.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -66.32 -43.54 85.92 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.375 0.534 . . . . 0.0 110.701 175.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.7 -43.06 84.9 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.103 0.411 . . . . 0.0 110.478 176.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 1.9 mm? . . . . . 0 CA--C 1.538 0.488 0 C-N-CA 124.994 1.317 . . . . 0.0 113.748 178.335 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.713 0 N-CA-C 108.238 -1.945 . . . . 0.0 108.238 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.0 p -150.67 157.2 36.31 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.613 1.165 . . . . 0.0 109.44 -168.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -67.62 158.37 57.49 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 121.962 1.775 . . . . 0.0 110.477 168.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.45 177.28 39.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 171.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -116.11 138.41 51.28 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 117.565 0.683 . . . . 0.0 109.334 -175.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 60.6 mt -73.7 83.29 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 176.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -76.48 -29.71 56.97 Favored 'General case' 0 N--CA 1.465 0.286 0 O-C-N 121.624 -0.672 . . . . 0.0 111.553 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.73 154.83 38.1 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.747 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 64.5 mt -129.66 147.98 33.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -121.32 -24.87 5.34 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.463 1.105 . . . . 0.0 112.121 -176.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 161.06 -113.0 0.55 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 108.307 -1.917 . . . . 0.0 108.307 178.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -69.37 2.04 3.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.656 0.782 . . . . 0.0 111.875 169.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -139.23 159.3 42.48 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 126.925 2.09 . . . . 0.0 107.679 -170.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 169.14 18.14 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.26 1.424 . . . . 0.0 110.035 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -115.82 73.09 0.83 Allowed 'General case' 0 C--O 1.234 0.241 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 -174.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.0 t -71.56 125.53 30.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 -172.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -77.18 112.05 13.45 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 169.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.9 m -82.56 43.08 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 C-N-CA 124.211 1.005 . . . . 0.0 110.718 177.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 66.7 m 48.5 49.93 17.58 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.077 1.751 . . . . 0.0 112.211 -172.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -177.71 -41.64 0.06 OUTLIER Glycine 0 CA--C 1.524 0.622 0 CA-C-O 119.644 -0.531 . . . . 0.0 112.404 174.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.6 tt -155.86 153.76 7.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -71.96 139.85 48.87 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 170.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 39.2 mmt180 -128.94 142.75 50.83 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 125.273 1.429 . . . . 0.0 107.977 176.246 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.08 131.47 46.65 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.5 t -140.68 129.56 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -83.36 144.19 29.82 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.517 0.727 . . . . 0.0 110.14 174.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.7 mt -109.6 7.85 24.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.312 1.045 . . . . 0.0 113.322 -169.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 25.2 m -53.1 -34.34 56.22 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.987 1.721 . . . . 0.0 112.482 -175.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.3 mt -74.98 -11.09 60.03 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.47 -17.0 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 CA-C-N 119.43 1.013 . . . . 0.0 112.563 -175.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.74 133.18 0.52 Allowed Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.264 1.411 . . . . 0.0 110.781 -175.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 21.4 m -67.86 156.65 36.66 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 169.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.0 m 61.97 145.48 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.227 2.211 . . . . 0.0 112.535 -169.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.95 155.31 38.79 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.207 1.403 . . . . 0.0 109.484 173.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.68 -27.56 62.99 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.646 1.179 . . . . 0.0 112.484 -176.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -62.69 -21.95 66.13 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.813 0.845 . . . . 0.0 113.043 175.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.99 47.9 3.25 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -174.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.9 pt20 -143.18 157.33 60.48 Favored Pre-proline 0 CA--C 1.536 0.426 0 C-N-CA 125.751 1.621 . . . . 0.0 107.93 -178.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -64.51 144.09 83.92 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 121.701 1.601 . . . . 0.0 110.375 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 90.6 mtt-85 -71.5 11.2 0.5 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.358 1.063 . . . . 0.0 113.621 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.1 m -57.45 131.69 21.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 O-C-N 120.616 -1.303 . . . . 0.0 109.817 -173.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 89.7 -17.44 52.63 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 118.306 -1.274 . . . . 0.0 113.413 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -66.57 156.34 35.28 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 119.693 1.746 . . . . 0.0 108.948 172.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.3 m95 -105.15 159.99 15.42 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.3 p -157.06 135.55 3.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -171.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 98.2 mt -75.68 131.37 39.85 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 168.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.72 135.05 64.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 119.344 0.974 . . . . 0.0 108.402 -178.228 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -141.83 120.81 12.83 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.684 1.193 . . . . 0.0 107.945 -169.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.2 t 41.6 47.95 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 126.671 1.988 . . . . 0.0 112.02 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.22 6.95 83.78 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 118.337 -1.257 . . . . 0.0 114.771 172.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.18 149.02 50.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 119.803 1.802 . . . . 0.0 110.017 177.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.47 116.16 7.9 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 169.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.9 ttt -76.75 -48.46 18.64 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.532 0.733 . . . . 0.0 109.497 177.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 65.4 m -163.11 144.54 9.75 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.975 1.31 . . . . 0.0 108.833 171.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.6 t -72.32 146.29 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 169.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 pt -137.8 157.91 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 C-N-CA 125.236 1.414 . . . . 0.0 109.02 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -80.83 169.19 17.89 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 120.927 0.394 . . . . 0.0 110.773 176.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -61.14 -44.57 97.11 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 123.385 0.674 . . . . 0.0 111.993 -173.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.66 -37.1 62.82 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 122.759 0.424 . . . . 0.0 109.953 -174.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 56.4 tt0 -60.27 -39.31 86.37 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.846 1.258 . . . . 0.0 110.033 172.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.96 -44.95 87.71 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.618 -0.676 . . . . 0.0 111.322 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 26.5 mmt-85 -62.49 -40.88 98.13 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 119.103 0.865 . . . . 0.0 110.441 178.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.96 -41.97 99.69 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.887 0.475 . . . . 0.0 110.907 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -65.07 -42.95 93.67 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.62 0.368 . . . . 0.0 110.232 177.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 42.5 mt -62.54 -43.58 98.45 Favored 'General case' 0 C--N 1.338 0.107 0 C-N-CA 123.269 0.628 . . . . 0.0 110.311 178.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.84 -44.95 94.78 Favored 'General case' 0 N--CA 1.46 0.073 0 C-N-CA 123.06 0.544 . . . . 0.0 110.845 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.12 -41.19 98.0 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.903 0.481 . . . . 0.0 111.191 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? . . . . . 0 C--N 1.338 0.104 0 C-N-CA 123.173 0.589 . . . . 0.0 109.577 177.051 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.86 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.6 m -141.61 162.14 48.39 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.036 1.334 . . . . 0.0 109.288 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -56.28 155.81 23.4 Favored 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 122.802 2.334 . . . . 0.0 113.447 172.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -158.32 167.97 34.59 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 107.951 -2.06 . . . . 0.0 107.951 169.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.8 tt0 -116.8 133.57 55.85 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 -178.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.19 97.01 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -83.34 -41.95 17.64 Favored 'General case' 0 N--CA 1.462 0.139 0 O-C-N 121.701 -0.625 . . . . 0.0 109.97 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 p -145.58 157.97 43.91 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 124.651 1.181 . . . . 0.0 108.83 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 54.4 mt -132.78 146.97 31.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 -174.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -123.55 -15.24 7.13 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.393 1.077 . . . . 0.0 112.091 -177.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.452 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 163.89 -131.56 2.48 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 106.459 -2.657 . . . . 0.0 106.459 -178.031 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -74.09 22.48 0.09 Allowed 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 118.057 0.929 . . . . 0.0 111.515 169.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . 0.452 ' H ' ' C ' ' A' ' 14' ' ' GLY . 41.1 mt-30 -140.5 148.61 41.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 126.594 1.958 . . . . 0.0 106.803 -179.056 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.61 163.46 32.0 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 124.454 1.102 . . . . 0.0 109.926 -179.177 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -110.79 78.37 1.11 Allowed 'General case' 0 C--O 1.233 0.232 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.0 m -70.59 130.88 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 123.477 0.711 . . . . 0.0 109.508 -177.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -76.84 111.3 12.22 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 168.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.4 t -84.75 54.67 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.74 45.72 8.31 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.984 2.113 . . . . 0.0 113.215 -177.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.3 -36.07 0.13 Allowed Glycine 0 CA--C 1.526 0.781 0 CA-C-O 119.468 -0.629 . . . . 0.0 113.003 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.8 tt -153.51 151.66 11.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 177.174 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.2 mt-30 -73.79 138.11 44.32 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 172.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -130.75 145.38 51.93 Favored 'General case' 0 N--CA 1.463 0.186 0 C-N-CA 125.261 1.424 . . . . 0.0 107.91 171.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -70.94 144.36 50.6 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 173.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.48 139.76 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -81.5 146.59 30.12 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.11 1.364 . . . . 0.0 110.284 172.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 86.1 mt -117.17 16.0 14.94 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.559 1.143 . . . . 0.0 112.404 -170.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 5.8 p -53.31 -34.98 59.61 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 120.561 1.528 . . . . 0.0 112.854 -176.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 73.9 mt -83.53 -6.04 59.34 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 118.46 -0.781 . . . . 0.0 112.865 -175.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -132.42 -20.41 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 119.536 1.062 . . . . 0.0 112.919 -174.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.29 147.83 7.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -177.32 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.6 m -68.23 -20.78 64.84 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.877 1.271 . . . . 0.0 113.364 -171.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.6 m -127.41 152.34 47.65 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 124.876 1.27 . . . . 0.0 109.283 -175.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -65.49 145.99 55.43 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.344 1.458 . . . . 0.0 109.972 172.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -53.99 -31.01 49.54 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.169 1.388 . . . . 0.0 113.517 -169.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -84.87 -7.86 59.01 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 118.863 0.756 . . . . 0.0 112.986 -178.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.34 52.65 0.76 Allowed Glycine 0 CA--C 1.527 0.793 0 CA-C-N 119.043 0.838 . . . . 0.0 112.728 170.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 30.0 pt20 -144.4 160.65 47.63 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 124.898 1.279 . . . . 0.0 108.697 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -63.74 143.76 87.36 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.627 1.551 . . . . 0.0 109.97 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 79.6 mtt-85 -70.56 12.93 0.21 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -177.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.8 m -57.91 135.1 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 O-C-N 120.59 -1.319 . . . . 0.0 109.984 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.52 -14.57 54.82 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 124.889 1.233 . . . . 0.0 113.484 -178.183 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -73.99 155.17 38.88 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 119.709 1.754 . . . . 0.0 109.373 177.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 83.5 m95 -97.95 159.16 15.11 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -157.07 147.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 91.9 mt -82.99 128.22 34.27 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 20.6 t -111.23 105.26 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -169.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . 0.433 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 6.7 t-160 -77.09 -171.37 1.99 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.903 0.881 . . . . 0.0 109.092 169.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . 0.433 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 36.0 m -52.89 -26.84 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 C-N-CA 124.54 1.136 . . . . 0.0 113.795 -174.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.08 18.15 0.1 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.841 -0.977 . . . . 0.0 113.213 171.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -139.47 142.54 37.36 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 119.094 1.447 . . . . 0.0 109.12 -172.068 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.16 125.54 27.06 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 169.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 46.3 mtt -74.07 -57.59 3.86 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.4 m -157.77 145.21 18.41 Favored 'General case' 0 C--O 1.238 0.462 0 C-N-CA 126.356 1.863 . . . . 0.0 107.643 -176.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.1 m -74.44 148.99 7.68 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 169.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 pt -138.71 168.05 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 125.048 1.339 . . . . 0.0 108.575 -178.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -97.59 174.85 6.44 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.0 0.52 . . . . 0.0 110.134 176.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -62.55 -33.67 75.4 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.715 0.806 . . . . 0.0 111.481 -174.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.84 -49.1 61.25 Favored 'General case' 0 CA--C 1.528 0.129 0 O-C-N 121.72 -0.612 . . . . 0.0 110.251 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -64.25 -38.91 92.73 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 122.777 0.431 . . . . 0.0 110.342 178.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -52.3 65.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 118.049 0.386 . . . . 0.0 110.176 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -64.47 -39.03 93.03 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-O 118.677 -0.678 . . . . 0.0 111.005 -178.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.52 -43.03 99.81 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.088 0.858 . . . . 0.0 110.943 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.7 m -66.99 -42.75 84.51 Favored 'General case' 0 CA--C 1.537 0.466 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.2 mt -64.51 -35.58 81.41 Favored 'General case' 0 CA--C 1.528 0.099 0 O-C-N 121.449 -0.782 . . . . 0.0 110.923 178.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -66.89 -43.47 83.37 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 123.403 0.681 . . . . 0.0 110.672 176.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.29 -47.72 82.75 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.5 mt . . . . . 0 CA--C 1.537 0.463 0 C-N-CA 124.665 1.186 . . . . 0.0 113.699 -178.968 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.781 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.7 t -143.72 146.87 36.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 125.224 1.41 . . . . 0.0 107.583 -169.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -55.83 161.25 8.47 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.69 2.26 . . . . 0.0 113.339 169.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.93 177.3 39.78 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 169.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -116.78 137.19 52.38 Favored 'General case' 0 C--N 1.334 -0.105 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 39.1 mt -76.77 71.85 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 C-N-CA 124.89 1.276 . . . . 0.0 108.129 -175.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -63.76 -30.36 71.46 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 124.363 1.065 . . . . 0.0 112.445 -172.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -149.76 155.81 40.77 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 177.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.1 141.48 45.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -106.77 -28.33 10.22 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 124.039 0.936 . . . . 0.0 110.781 174.023 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.81 -121.88 0.98 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 106.78 -2.528 . . . . 0.0 106.78 177.243 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.4 t30 -65.34 -15.31 62.42 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 116.935 0.368 . . . . 0.0 111.693 169.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -105.85 153.12 22.37 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 172.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -146.71 169.12 19.71 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.33 1.052 . . . . 0.0 110.167 -177.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.39 75.1 1.37 Allowed 'General case' 0 CA--C 1.519 -0.233 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -171.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.6 t -73.6 128.26 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -74.06 106.17 5.62 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 169.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.71 57.85 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.1 m 43.35 48.42 5.9 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 127.566 2.347 . . . . 0.0 113.427 179.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 175.0 -39.26 0.11 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.592 -0.56 . . . . 0.0 112.305 176.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.5 tt -153.69 152.65 9.69 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -69.56 136.54 51.45 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 170.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 22.7 mmm180 -122.36 128.29 50.81 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 175.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -74.79 119.88 19.57 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 176.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.2 m -142.99 172.33 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 125.47 1.508 . . . . 0.0 109.579 -170.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -108.88 143.22 38.38 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 124.729 1.211 . . . . 0.0 111.056 -169.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.7 mt -114.03 9.88 17.41 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.47 1.108 . . . . 0.0 112.734 -175.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 6.4 m -55.06 -33.87 63.09 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.943 1.701 . . . . 0.0 112.154 -172.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.23 -9.82 58.93 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.661 0.785 . . . . 0.0 113.055 -177.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.9 -15.94 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 119.498 1.045 . . . . 0.0 112.651 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.13 147.49 7.2 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 124.983 1.278 . . . . 0.0 110.536 -176.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.5 m -65.57 -21.82 66.63 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.84 1.256 . . . . 0.0 112.184 177.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.3 m -126.71 168.43 14.38 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.452 1.501 . . . . 0.0 109.734 -175.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -117.79 154.02 32.46 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 126.95 2.1 . . . . 0.0 109.239 -169.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -57.78 -25.91 61.17 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.661 1.185 . . . . 0.0 112.711 -173.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -60.85 -23.77 65.38 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 123.863 0.865 . . . . 0.0 113.007 174.37 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.03 47.7 2.59 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -175.237 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -145.7 154.39 51.9 Favored Pre-proline 0 CA--C 1.535 0.375 0 C-N-CA 125.398 1.479 . . . . 0.0 108.638 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -66.48 152.04 81.72 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 121.828 1.685 . . . . 0.0 108.847 169.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 64.7 mtt-85 -70.19 10.57 0.42 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 114.339 1.237 . . . . 0.0 114.339 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.51 137.57 23.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 O-C-N 120.849 -1.157 . . . . 0.0 108.933 -172.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.71 -11.37 33.79 Favored Glycine 0 CA--C 1.532 1.106 0 CA-C-O 118.187 -1.34 . . . . 0.0 114.028 179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -67.64 163.05 22.26 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.91 1.855 . . . . 0.0 109.219 171.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.2 m95 -104.25 155.47 18.72 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.2 p -153.24 142.77 14.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -171.103 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -84.47 113.1 20.96 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 169.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 38.9 t -93.42 137.09 23.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.213 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 178.346 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -137.12 142.83 42.28 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.273 1.029 . . . . 0.0 108.702 175.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 22.5 t 56.37 -75.99 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 127.071 2.148 . . . . 0.0 111.439 -173.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.24 27.8 0.19 Allowed Glycine 0 CA--C 1.535 1.31 0 C-N-CA 127.761 2.6 . . . . 0.0 110.088 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -139.53 144.08 37.71 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 126.215 1.806 . . . . 0.0 107.847 -170.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.74 122.94 17.61 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 169.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 52.0 ttp -80.32 -57.9 3.39 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 171.042 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 17.8 m -150.64 138.03 19.55 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 123.77 0.828 . . . . 0.0 109.517 -172.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.0 t -72.09 144.6 12.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 169.416 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.4 pt -138.29 158.8 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 124.781 1.232 . . . . 0.0 108.846 -176.223 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -81.91 167.84 18.54 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 110.593 175.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -67.37 -33.43 75.21 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.549 0.74 . . . . 0.0 112.341 -169.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.9 -39.94 33.61 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.308 -0.87 . . . . 0.0 109.637 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.2 tt0 -59.8 -40.78 89.52 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.011 1.325 . . . . 0.0 110.146 173.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -50.8 71.31 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.145 0.578 . . . . 0.0 110.662 175.042 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 84.2 mtm180 -63.29 -40.17 96.61 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 119.072 -0.489 . . . . 0.0 111.201 -178.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.25 -43.62 97.5 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 118.582 0.628 . . . . 0.0 110.785 176.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.2 m -65.63 -39.24 91.25 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 119.276 -0.392 . . . . 0.0 110.35 178.625 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 35.8 mt -64.62 -42.21 95.67 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 119.099 0.863 . . . . 0.0 110.536 176.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -64.68 -39.33 93.49 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 123.164 0.586 . . . . 0.0 110.961 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.13 -51.05 63.56 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.495 0.318 . . . . 0.0 110.24 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? . . . . . 0 N--CA 1.462 0.139 0 C-N-CA 124.39 1.076 . . . . 0.0 110.679 -174.278 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.888 0 N-CA-C 111.673 -0.571 . . . . 0.0 111.673 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.3 t -146.69 151.94 43.77 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 -169.599 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_exo -54.92 157.56 12.86 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 122.153 1.902 . . . . 0.0 112.728 169.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.25 172.49 34.71 Favored Glycine 0 CA--C 1.526 0.767 0 C-N-CA 124.474 1.035 . . . . 0.0 110.765 174.206 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -119.81 130.6 54.99 Favored 'General case' 0 CA--C 1.522 -0.108 0 C-N-CA 124.023 0.929 . . . . 0.0 109.032 -176.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.4 mt -69.3 130.26 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 22.3 mmt85 -119.8 -31.73 4.44 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 118.564 -0.731 . . . . 0.0 111.274 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 m -146.93 153.68 40.38 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 20.1 mt -132.49 141.67 44.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 177.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -122.25 -15.41 7.69 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.057 0.943 . . . . 0.0 111.664 -176.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.77 -135.51 3.6 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 107.12 -2.392 . . . . 0.0 107.12 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -66.52 5.0 0.65 Allowed 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 123.972 0.909 . . . . 0.0 113.031 169.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -133.45 153.05 51.94 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 126.138 1.775 . . . . 0.0 107.799 178.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.77 158.09 43.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.763 1.225 . . . . 0.0 110.254 -171.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.73 122.72 37.63 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 170.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.2 t -125.46 123.45 64.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 -173.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -67.71 128.24 35.74 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 172.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -128.42 124.19 61.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 171.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.3 m 50.16 26.45 2.15 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 125.304 1.441 . . . . 0.0 114.376 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.69 -1.33 36.43 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-O 118.451 -1.194 . . . . 0.0 113.766 172.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.6 mm -134.21 132.04 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 119.451 1.625 . . . . 0.0 107.279 -173.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -66.53 140.13 57.97 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.932 0.396 . . . . 0.0 110.526 178.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 20.6 mmt-85 -126.43 149.01 49.55 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.531 1.932 . . . . 0.0 106.789 169.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -80.01 136.07 36.51 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 169.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -137.76 135.77 45.82 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -176.193 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -79.87 140.12 36.88 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.995 1.318 . . . . 0.0 110.033 174.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 42.5 mt -113.98 14.33 18.41 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 124.051 0.941 . . . . 0.0 112.911 -171.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.7 m -52.24 -36.69 53.08 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 120.604 1.547 . . . . 0.0 112.623 -173.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.9 mt -80.74 -6.96 59.17 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 112.927 0.714 . . . . 0.0 112.927 -174.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.6 m -131.98 -17.56 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 119.476 1.034 . . . . 0.0 112.452 -174.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.14 151.54 5.27 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.601 1.096 . . . . 0.0 110.947 -174.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.8 p -74.31 -18.6 60.68 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.558 1.143 . . . . 0.0 112.836 179.742 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.5 m -124.01 150.07 45.31 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.492 1.117 . . . . 0.0 109.442 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.09 161.86 27.1 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.447 1.099 . . . . 0.0 110.625 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -45.98 -41.27 11.56 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.078 1.751 . . . . 0.0 112.087 170.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 30.9 t30 -65.84 -14.72 61.97 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.53 1.132 . . . . 0.0 112.943 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.82 35.14 5.47 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-O 119.027 -0.874 . . . . 0.0 113.835 169.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -142.75 164.22 33.79 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 118.566 1.183 . . . . 0.0 109.192 172.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -51.14 146.4 23.17 Favored 'Trans proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.599 2.866 . . . . 0.0 112.508 175.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -71.06 18.72 0.06 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 114.243 1.201 . . . . 0.0 114.243 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.6 m -58.0 138.09 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 O-C-N 120.234 -1.541 . . . . 0.0 110.005 -176.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.21 -17.61 17.33 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.465 -1.186 . . . . 0.0 113.537 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.9 mt-30 -70.44 161.11 31.13 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.491 1.646 . . . . 0.0 109.447 175.215 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 56.2 m95 -106.21 157.45 17.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -144.65 142.85 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.796 1.239 . . . . 0.0 107.711 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -86.64 116.47 24.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 103.781 -2.674 . . . . 0.0 103.781 169.029 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 31.7 m -116.98 137.04 52.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -171.567 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.93 139.15 36.1 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 33.6 m 45.46 27.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.88 0 C-N-CA 126.457 1.903 . . . . 0.0 115.453 172.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 97.81 7.32 56.65 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.069 176.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.13 141.78 51.08 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 119.706 1.753 . . . . 0.0 109.394 -177.415 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.16 114.45 14.83 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 169.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.9 mmt -88.59 -26.22 22.06 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 122.911 0.484 . . . . 0.0 110.762 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 66.1 m -155.19 156.29 35.43 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 124.714 1.206 . . . . 0.0 108.687 171.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 137.72 34.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 172.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 pt -140.11 159.95 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 C-N-CA 124.55 1.14 . . . . 0.0 110.419 -169.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -81.02 169.07 17.96 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.603 0.761 . . . . 0.0 110.305 173.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -69.38 -30.34 68.3 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -170.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.19 -41.45 61.41 Favored 'General case' 0 N--CA 1.461 0.102 0 O-C-N 121.024 -1.047 . . . . 0.0 109.79 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -61.91 -41.36 97.82 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.565 0.746 . . . . 0.0 109.65 174.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.78 -49.05 77.9 Favored 'General case' 0 C--N 1.34 0.177 0 O-C-N 121.934 -0.479 . . . . 0.0 110.807 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -64.6 -38.58 91.51 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 118.977 -0.535 . . . . 0.0 111.354 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -64.73 -41.54 95.88 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 118.969 0.804 . . . . 0.0 110.856 176.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 24.2 m -68.01 -37.48 81.47 Favored 'General case' 0 CA--C 1.539 0.553 0 O-C-N 122.02 -0.425 . . . . 0.0 110.328 178.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 37.5 mt -62.74 -44.71 95.5 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.43 -0.794 . . . . 0.0 109.761 174.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -62.06 -40.74 96.83 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 118.775 0.716 . . . . 0.0 111.131 177.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.39 -34.42 77.68 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.897 -0.502 . . . . 0.0 111.83 175.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? . . . . . 0 CA--C 1.532 0.275 0 C-N-CA 123.761 0.824 . . . . 0.0 110.66 177.523 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.475 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.9 t -139.51 144.21 38.74 Favored Pre-proline 0 CA--C 1.541 0.615 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 -177.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.35 160.4 47.06 Favored 'Trans proline' 0 CA--C 1.534 0.516 0 C-N-CA 122.534 2.156 . . . . 0.0 111.957 174.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.04 172.92 40.0 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 171.109 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -95.34 137.04 34.93 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.9 mt -69.94 93.3 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 169.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -79.55 -33.59 41.74 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 119.108 -0.472 . . . . 0.0 110.38 -170.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 m -149.48 152.73 36.12 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.419 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.3 mt -131.69 144.41 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -124.02 -20.44 5.35 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.187 0.995 . . . . 0.0 111.967 -178.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.8 -129.54 1.89 Allowed Glycine 0 C--N 1.335 0.499 0 N-CA-C 107.226 -2.35 . . . . 0.0 107.226 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.6 p-10 -65.91 -3.65 5.54 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 117.599 0.699 . . . . 0.0 112.559 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -125.38 157.43 36.83 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.763 1.225 . . . . 0.0 109.602 175.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -154.69 160.42 41.36 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.52 1.528 . . . . 0.0 109.911 -171.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.17 112.17 24.58 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.611 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.7 t -92.13 124.11 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 170.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -84.91 108.7 17.68 Favored 'General case' 0 C--O 1.233 0.218 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 169.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.0 t -83.19 61.02 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 125.858 1.663 . . . . 0.0 107.046 174.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 62.5 m 38.42 45.95 0.89 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 128.044 2.538 . . . . 0.0 114.41 178.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 153.22 -17.12 0.69 Allowed Glycine 0 CA--C 1.526 0.724 0 CA-C-O 119.093 -0.837 . . . . 0.0 113.806 177.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.6 tp -143.83 145.08 22.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 173.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -94.72 134.37 37.4 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 51.2 mtp180 -126.42 118.99 26.13 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -70.49 131.01 43.39 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 173.466 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.5 m -139.79 155.3 24.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.11 0.964 . . . . 0.0 109.374 179.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -84.35 146.48 27.68 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.721 0.808 . . . . 0.0 109.524 171.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 mt -112.25 3.17 16.95 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.424 1.09 . . . . 0.0 112.573 -173.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.6 m -59.03 -26.17 64.33 Favored 'General case' 0 CA--C 1.544 0.725 0 CA-C-N 120.595 1.543 . . . . 0.0 112.227 -173.207 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.7 mt -65.67 -19.96 66.11 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 121.608 -0.683 . . . . 0.0 112.708 176.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -129.25 -10.92 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.785 1.234 . . . . 0.0 112.013 -174.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.35 139.94 0.96 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 125.365 1.46 . . . . 0.0 109.916 -170.232 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 18.3 m -71.11 -12.17 61.36 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.934 -0.745 . . . . 0.0 112.833 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.4 m -119.36 146.42 45.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.655 1.182 . . . . 0.0 109.311 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -79.94 160.55 25.92 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 124.156 0.982 . . . . 0.0 110.087 176.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.7 -33.27 22.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.216 1.406 . . . . 0.0 112.421 173.18 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -67.44 -13.4 62.0 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.09 31.52 5.9 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 118.893 -0.948 . . . . 0.0 114.428 169.323 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -146.11 167.57 13.75 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 118.813 1.307 . . . . 0.0 109.003 172.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -50.59 150.75 11.42 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 123.394 2.729 . . . . 0.0 112.837 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 87.4 mtt-85 -74.21 20.99 0.1 Allowed 'General case' 0 CA--C 1.541 0.627 0 O-C-N 121.143 -0.973 . . . . 0.0 113.332 177.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.6 m -56.26 131.94 19.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 O-C-N 120.783 -1.198 . . . . 0.0 109.658 -176.458 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.97 -11.88 55.64 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 118.055 -1.414 . . . . 0.0 113.968 177.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -70.34 169.43 13.89 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.631 1.716 . . . . 0.0 109.692 172.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -118.56 149.58 41.1 Favored 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.686 0.794 . . . . 0.0 109.58 -178.21 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -147.51 156.51 9.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 124.555 1.142 . . . . 0.0 109.417 -175.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 92.9 mt -84.47 140.12 31.71 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 168.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.1 m -132.04 127.33 57.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -144.07 -29.47 0.49 Allowed 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -169.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.8 m -136.2 20.37 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 118.665 0.666 . . . . 0.0 112.362 -169.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.59 10.16 73.82 Favored Glycine 0 CA--C 1.532 1.149 0 O-C-N 121.45 -0.781 . . . . 0.0 112.629 -175.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 70.1 m-85 -135.44 153.58 51.73 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.222 1.409 . . . . 0.0 107.937 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.91 105.37 2.79 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 169.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.09 -39.28 75.66 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.882 0.873 . . . . 0.0 110.929 -170.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.5 m -160.29 155.21 24.4 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 125.369 1.467 . . . . 0.0 108.563 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.1 t -78.08 146.72 7.82 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 169.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.4 pt -138.26 161.15 31.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 C-N-CA 125.502 1.521 . . . . 0.0 108.53 177.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -73.97 163.58 27.72 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-O 121.932 0.872 . . . . 0.0 110.583 174.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -57.68 -40.97 80.66 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 126.402 1.881 . . . . 0.0 111.809 178.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.87 -34.72 29.93 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.801 0.841 . . . . 0.0 110.801 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 60.7 tt0 -62.52 -34.35 76.73 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.641 1.176 . . . . 0.0 110.287 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.26 -43.03 87.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 122.002 -0.437 . . . . 0.0 111.359 171.325 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.8 mmt85 -69.7 -41.33 75.54 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 118.416 0.553 . . . . 0.0 109.609 -177.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.13 -40.24 93.05 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 122.54 0.336 . . . . 0.0 110.67 175.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -66.61 -41.26 88.69 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.154 0.582 . . . . 0.0 110.57 177.196 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.6 mt -62.18 -40.61 96.63 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 119.448 1.022 . . . . 0.0 110.313 175.296 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -64.79 -41.79 95.56 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 118.113 0.415 . . . . 0.0 110.843 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.96 -41.77 97.0 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 118.56 0.618 . . . . 0.0 111.083 174.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.1 tm? . . . . . 0 CA--C 1.53 0.174 0 C-N-CA 123.824 0.85 . . . . 0.0 109.804 -179.172 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.894 0 CA-C-O 119.728 -0.485 . . . . 0.0 113.789 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.2 t -146.76 148.23 32.53 Favored Pre-proline 0 CA--C 1.544 0.715 0 C-N-CA 126.249 1.82 . . . . 0.0 106.998 -171.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -57.44 163.79 8.03 Favored 'Trans proline' 0 CA--C 1.536 0.609 0 C-N-CA 122.432 2.088 . . . . 0.0 112.426 169.144 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -160.46 163.33 33.93 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 58.3 tt0 -116.93 131.79 56.86 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 94.6 mt -70.36 117.66 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.475 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -90.19 -32.77 16.47 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 118.666 -0.683 . . . . 0.0 110.502 172.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.12 152.92 35.51 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -170.115 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.8 mt -132.43 141.03 46.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 172.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -120.84 -18.86 7.51 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.425 1.09 . . . . 0.0 111.47 -176.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.22 -126.6 1.36 Allowed Glycine 0 C--N 1.336 0.538 0 N-CA-C 107.146 -2.382 . . . . 0.0 107.146 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -67.28 -8.63 33.52 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 117.052 0.426 . . . . 0.0 112.11 169.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -119.81 159.44 24.57 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 125.486 1.514 . . . . 0.0 109.538 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.04 177.09 10.51 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 126.177 1.791 . . . . 0.0 109.568 -170.085 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -129.31 126.97 40.17 Favored 'General case' 0 CA--C 1.516 -0.363 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 1.6 m -119.47 138.7 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 C-N-CA 125.001 1.32 . . . . 0.0 108.357 -177.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -85.36 107.88 17.57 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 104.497 -2.408 . . . . 0.0 104.497 168.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -81.49 57.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 C-N-CA 125.362 1.465 . . . . 0.0 107.971 -176.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 50.7 m 45.42 43.34 8.53 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.007 2.123 . . . . 0.0 113.159 -177.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 170.28 -42.57 0.2 Allowed Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.303 -0.72 . . . . 0.0 112.641 175.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.4 pt -141.8 150.17 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 C-N-CA 124.562 1.145 . . . . 0.0 109.514 -179.183 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -76.99 138.25 39.49 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -136.77 148.55 47.3 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 124.927 1.291 . . . . 0.0 109.307 173.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -68.05 148.22 51.3 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 169.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.48 143.27 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 173.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -92.36 145.23 24.63 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.593 0.757 . . . . 0.0 109.44 170.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 46.9 mt -112.53 13.48 20.08 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 118.2 -0.905 . . . . 0.0 112.959 -170.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 46.7 m -50.66 -37.13 39.15 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 120.889 1.677 . . . . 0.0 112.539 -178.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.8 mt -75.74 -11.71 60.04 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.41 -17.86 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 119.445 1.021 . . . . 0.0 113.343 -169.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.35 146.44 3.03 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.698 1.142 . . . . 0.0 111.139 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 p -75.88 -17.68 59.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.662 1.185 . . . . 0.0 112.552 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.2 m -112.84 161.95 16.36 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.432 1.093 . . . . 0.0 109.2 174.008 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -106.72 -179.41 3.93 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 124.701 1.2 . . . . 0.0 113.171 -169.397 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 23.0 mp0 -67.41 -14.37 62.87 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.895 2.078 . . . . 0.0 112.627 -176.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.4 m-80 -96.7 -37.32 10.36 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.176 0.99 . . . . 0.0 110.185 -178.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.79 28.59 1.04 Allowed Glycine 0 CA--C 1.53 1.025 0 C-N-CA 125.299 1.428 . . . . 0.0 112.507 178.257 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -127.63 158.24 70.68 Favored Pre-proline 0 CA--C 1.538 0.5 0 CA-C-N 119.149 1.474 . . . . 0.0 109.316 -176.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.36 144.43 85.81 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.867 1.712 . . . . 0.0 109.548 174.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.9 mtt-85 -69.54 13.14 0.14 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 114.619 1.34 . . . . 0.0 114.619 -174.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.6 t -53.62 131.02 15.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-N 120.379 1.445 . . . . 0.0 108.446 176.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.36 -14.59 54.08 Favored Glycine 0 CA--C 1.53 0.978 0 CA-C-O 118.531 -1.15 . . . . 0.0 113.589 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -77.05 162.02 27.84 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 119.715 1.758 . . . . 0.0 109.195 176.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -106.43 151.25 25.17 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.0 m -140.78 150.38 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 177.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -88.36 124.99 34.47 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 103.662 -2.718 . . . . 0.0 103.662 168.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.86 156.99 18.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 6.3 t-80 -154.02 -32.83 0.11 Allowed 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 123.0 0.52 . . . . 0.0 111.315 -175.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.2 m -133.79 -163.24 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 170.183 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -68.06 19.91 0.33 Allowed Glycine 0 CA--C 1.538 1.471 0 CA-C-N 119.64 1.109 . . . . 0.0 114.817 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -133.9 139.82 46.42 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.768 1.627 . . . . 0.0 107.956 -179.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.06 116.11 10.05 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 170.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 86.6 mmm -74.33 -43.69 55.63 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.1 p -155.71 153.03 29.31 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.781 0.833 . . . . 0.0 110.067 179.297 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.6 t -79.65 143.38 12.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 169.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.2 pt -138.55 160.76 31.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 124.175 0.99 . . . . 0.0 108.849 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 -80.62 164.91 22.52 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -53.91 -41.85 68.09 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 123.608 0.763 . . . . 0.0 111.439 170.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.62 -37.08 85.96 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.857 0.463 . . . . 0.0 110.99 -177.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -71.1 -38.84 72.36 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 177.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.98 -48.7 80.6 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 118.415 0.552 . . . . 0.0 110.157 174.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.3 mtt180 -61.62 -43.26 99.18 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 123.489 0.715 . . . . 0.0 110.45 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.93 -41.35 99.46 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.688 0.676 . . . . 0.0 111.295 177.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.5 m -64.69 -41.47 96.02 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 122.807 0.443 . . . . 0.0 110.096 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 83.7 mt -66.51 -36.85 83.72 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 119.053 0.842 . . . . 0.0 110.941 177.222 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -66.05 -40.66 91.12 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 118.607 0.64 . . . . 0.0 110.822 177.273 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.03 -52.37 63.14 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 122.704 0.402 . . . . 0.0 109.997 173.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 6.6 tt . . . . . 0 C--O 1.233 0.187 0 C-N-CA 124.44 1.096 . . . . 0.0 109.984 -175.824 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.484 1.229 0 CA-C-O 119.281 -0.39 . . . . 0.0 110.029 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 59.0 m -62.84 158.24 19.39 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 118.763 0.711 . . . . 0.0 110.939 177.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.5 tt -153.5 154.71 7.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 176.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.82 56.89 0.16 Allowed Glycine 0 CA--C 1.528 0.905 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -174.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.9 t -139.15 141.13 28.59 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 124.317 1.047 . . . . 0.0 108.849 -169.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -59.26 157.63 29.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.887 2.391 . . . . 0.0 112.919 169.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.32 172.67 40.17 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 169.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -99.61 135.73 40.6 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.47 79.97 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 170.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 7.5 tpm_? -80.09 -24.67 40.42 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.561 -0.712 . . . . 0.0 112.406 -169.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.57 158.58 43.74 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -130.0 146.3 34.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 176.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -121.78 -23.64 5.46 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.111 0.965 . . . . 0.0 111.734 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.25 -126.8 1.35 Allowed Glycine 0 C--N 1.333 0.403 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 178.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.4 t30 -63.8 -29.21 70.44 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 117.651 0.726 . . . . 0.0 110.303 169.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.7 mm100 -86.44 151.89 23.14 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.56 0.695 . . . . 0.0 109.235 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.56 166.02 25.4 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.034 1.334 . . . . 0.0 109.568 174.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -114.48 78.25 1.14 Allowed 'General case' 0 C--O 1.234 0.266 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 -173.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.4 t -74.19 123.39 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 -175.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -75.04 107.92 7.43 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 169.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.52 61.22 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 32.0 m 45.94 43.96 10.82 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 127.205 2.202 . . . . 0.0 113.696 176.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.63 -36.66 0.16 Allowed Glycine 0 CA--C 1.525 0.703 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.643 176.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -153.67 152.9 9.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.4 mt-30 -77.47 138.72 39.4 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.059 177.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -117.85 144.95 44.95 Favored 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 126.044 1.737 . . . . 0.0 107.196 171.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -74.58 129.93 38.63 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 169.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.8 t -137.01 136.14 47.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -176.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -82.4 126.26 31.98 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.166 1.386 . . . . 0.0 109.072 176.145 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 29.4 mt -100.76 10.95 40.51 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 117.95 -1.024 . . . . 0.0 112.971 -175.75 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 32.4 m -50.84 -36.62 38.5 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 121.285 1.857 . . . . 0.0 112.395 -174.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -74.49 -10.37 59.49 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.5 m -132.2 -17.61 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 119.445 1.021 . . . . 0.0 112.57 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.18 145.91 1.02 Allowed Glycine 0 CA--C 1.529 0.955 0 C-N-CA 125.175 1.369 . . . . 0.0 110.654 -171.217 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.4 m -73.63 -5.3 39.57 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.734 -0.862 . . . . 0.0 113.067 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.3 m -131.97 151.79 51.51 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.362 1.065 . . . . 0.0 110.027 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -66.08 165.64 13.14 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.876 2.071 . . . . 0.0 109.71 169.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.52 -37.5 57.69 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.29 1.436 . . . . 0.0 112.247 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -85.9 10.21 14.6 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.8 0.84 . . . . 0.0 112.052 -178.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.67 5.27 88.4 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.623 1.106 . . . . 0.0 113.382 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -70.1 132.53 88.24 Favored Pre-proline 0 CA--C 1.537 0.469 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -65.86 141.44 65.11 Favored 'Trans proline' 0 N--CA 1.458 -0.56 0 CA-C-N 121.321 1.507 . . . . 0.0 109.107 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.9 mtt-85 -72.77 8.59 1.43 Allowed 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 114.401 1.26 . . . . 0.0 114.401 -173.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.06 125.46 7.14 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 120.128 1.331 . . . . 0.0 108.712 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.67 -19.32 55.12 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.873 1.225 . . . . 0.0 113.241 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -70.12 167.45 17.72 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 119.061 1.431 . . . . 0.0 108.903 172.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 46.9 m95 -116.04 162.75 16.93 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.782 -0.574 . . . . 0.0 109.532 -179.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -156.61 146.21 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -169.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 83.1 mt -83.82 112.13 19.83 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 169.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.68 127.81 39.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 173.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -140.98 130.23 23.57 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 173.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.5 m 41.68 35.8 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 126.195 1.798 . . . . 0.0 114.541 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.8 6.93 79.11 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.076 -0.847 . . . . 0.0 114.092 175.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -122.41 154.78 37.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.951 1.376 . . . . 0.0 109.694 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.81 104.92 3.58 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 169.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.07 -47.84 60.28 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.261 0.482 . . . . 0.0 109.755 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.1 m -152.05 136.18 16.58 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.92 1.288 . . . . 0.0 108.017 178.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.2 p -84.13 138.72 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 169.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.4 pt -141.93 162.98 19.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 124.652 1.181 . . . . 0.0 110.24 -170.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -77.02 166.18 23.65 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 123.768 0.827 . . . . 0.0 109.84 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.59 -43.14 84.41 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.903 0.881 . . . . 0.0 110.629 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.49 -38.64 87.71 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.002 0.521 . . . . 0.0 110.829 -175.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -67.04 -44.36 80.41 Favored 'General case' 0 C--O 1.232 0.145 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.04 -48.58 79.62 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.9 tmm_? -58.77 -46.81 86.64 Favored 'General case' 0 C--N 1.334 -0.104 0 C-N-CA 124.543 1.137 . . . . 0.0 110.059 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -63.22 -43.12 99.01 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 118.492 0.587 . . . . 0.0 111.292 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -64.16 -42.01 96.92 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 178.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 39.5 mt -65.16 -40.42 94.32 Favored 'General case' 0 CA--C 1.522 -0.13 0 C-N-CA 123.82 0.848 . . . . 0.0 110.599 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -63.64 -41.21 98.26 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 122.982 0.513 . . . . 0.0 110.873 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -66.74 -48.38 69.33 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.276 0.23 . . . . 0.0 110.607 174.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 10.4 tt -61.99 -44.96 95.63 Favored 'General case' 0 C--O 1.231 0.108 0 C-N-CA 124.433 1.093 . . . . 0.0 111.231 -173.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -72.22 -18.29 61.85 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -176.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -55.39 -32.41 62.61 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 119.142 0.883 . . . . 0.0 112.857 -169.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -65.43 -17.62 64.69 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.149 0.98 . . . . 0.0 113.272 -178.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -140.86 -19.43 0.82 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 119.691 1.132 . . . . 0.0 113.809 -173.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -60.21 -22.34 62.86 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 119.592 1.087 . . . . 0.0 112.344 173.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 16.1 m -65.27 -7.61 4.7 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 125.425 1.49 . . . . 0.0 113.362 174.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -136.48 157.21 75.72 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 124.82 1.248 . . . . 0.0 109.408 -178.069 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -65.81 -7.61 17.17 Favored 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 123.108 2.539 . . . . 0.0 113.133 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -52.27 -29.75 24.56 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 124.719 1.208 . . . . 0.0 112.2 170.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.0 p -58.01 -37.1 59.38 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 118.648 0.658 . . . . 0.0 111.465 174.488 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -75.74 -42.22 26.63 Favored Glycine 0 C--N 1.337 0.601 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 178.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.88 -40.16 83.56 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-N 117.436 0.618 . . . . 0.0 110.926 177.119 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 39.1 tp -64.77 -58.46 6.19 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 124.099 0.959 . . . . 0.0 109.703 172.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 60.6 tp -57.78 -45.24 86.26 Favored 'General case' 0 N--CA 1.463 0.194 0 C-N-CA 123.76 0.824 . . . . 0.0 111.979 -169.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -95.67 6.56 48.63 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 123.487 0.715 . . . . 0.0 111.808 -176.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.12 -177.28 37.72 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.382 0.991 . . . . 0.0 111.483 178.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -118.13 15.65 14.09 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 125.164 1.385 . . . . 0.0 110.672 -177.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -74.79 6.34 4.07 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.092 1.357 . . . . 0.0 112.76 177.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.251 1.139 0 C-N-CA 126.947 2.099 . . . . 0.0 108.751 -175.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.5 ptt? . . . . . 0 N--CA 1.484 1.234 0 N-CA-C 110.489 -0.189 . . . . 0.0 110.489 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 71.5 m -66.52 150.8 48.44 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 169.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.8 tp -81.72 59.05 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 CA-C-O 122.651 1.215 . . . . 0.0 108.889 173.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.28 54.3 0.75 Allowed Glycine 0 CA--C 1.525 0.711 0 C-N-CA 127.186 2.327 . . . . 0.0 107.831 -175.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.8 m -145.43 158.13 51.31 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 126.473 1.909 . . . . 0.0 108.191 -169.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.79 162.43 26.87 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 121.894 1.729 . . . . 0.0 110.659 169.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.32 164.35 37.14 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 169.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -89.43 127.28 35.82 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 72.6 mt -63.64 112.16 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.9 tpt85 -109.71 -30.63 7.79 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 118.113 -0.946 . . . . 0.0 110.994 -169.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 11.9 p -144.96 158.12 43.91 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 169.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -132.54 141.91 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 105.31 -2.107 . . . . 0.0 105.31 176.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -116.13 -21.71 9.28 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.448 1.099 . . . . 0.0 111.447 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.3 -126.17 1.34 Allowed Glycine 0 C--N 1.334 0.437 0 N-CA-C 106.835 -2.506 . . . . 0.0 106.835 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.0 t30 -62.08 -15.6 46.25 Favored 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 117.37 0.585 . . . . 0.0 112.062 169.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -117.48 156.21 28.39 Favored 'General case' 0 C--O 1.238 0.461 0 O-C-N 121.151 -0.968 . . . . 0.0 109.23 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.39 173.3 13.69 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 125.894 1.678 . . . . 0.0 109.402 -169.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -132.72 109.2 9.52 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 m -84.24 135.25 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 C-N-CA 124.232 1.013 . . . . 0.0 108.605 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -81.11 115.28 20.47 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 169.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 t -87.93 60.59 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 125.427 1.491 . . . . 0.0 107.185 176.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.5 m 50.15 36.42 12.29 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.923 1.689 . . . . 0.0 114.369 176.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.3 -31.86 0.26 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 121.348 -0.845 . . . . 0.0 112.966 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -138.77 140.45 38.98 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 C-N-CA 125.425 1.49 . . . . 0.0 108.818 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -77.63 141.98 39.14 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.098 174.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 56.7 mmt-85 -137.53 144.31 42.07 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 125.014 1.326 . . . . 0.0 108.727 172.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -77.5 149.54 34.96 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.655 0.782 . . . . 0.0 111.068 -172.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.79 143.36 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 124.978 1.311 . . . . 0.0 108.82 177.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -92.8 133.17 36.31 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 124.435 1.094 . . . . 0.0 108.77 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.0 mt -105.49 14.52 28.52 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 118.312 -0.851 . . . . 0.0 112.058 -171.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -45.99 -38.03 7.25 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.333 1.424 . . . . 0.0 113.114 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.2 mt -85.41 -3.86 58.98 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.821 0.848 . . . . 0.0 113.02 -172.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.28 -18.36 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.547 1.067 . . . . 0.0 113.02 -177.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.77 143.51 1.22 Allowed Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.063 1.316 . . . . 0.0 110.759 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.2 m -75.37 -8.89 57.88 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 12.5 p -125.21 152.2 44.86 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.548 1.139 . . . . 0.0 109.015 174.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -77.87 172.19 13.84 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.289 1.036 . . . . 0.0 110.349 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -57.59 -34.97 69.8 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.086 0.954 . . . . 0.0 112.213 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 18.0 p30 -80.41 -3.69 50.73 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.285 1.834 . . . . 0.0 113.102 177.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.38 -4.81 67.27 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.552 -1.138 . . . . 0.0 114.157 172.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -66.22 143.15 98.21 Favored Pre-proline 0 CA--C 1.537 0.454 0 CA-C-N 119.677 1.739 . . . . 0.0 109.087 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -64.42 143.09 81.39 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 121.878 1.719 . . . . 0.0 108.857 169.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 83.0 mtt-85 -72.8 1.6 8.27 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -170.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.0 m -50.24 137.89 6.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 120.994 1.725 . . . . 0.0 111.126 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.74 -26.37 18.72 Favored Glycine 0 CA--C 1.53 0.975 0 C-N-CA 124.759 1.171 . . . . 0.0 112.911 178.306 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -76.1 165.8 24.4 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 118.898 1.349 . . . . 0.0 108.404 173.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -105.18 156.52 18.02 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -144.37 135.17 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 57.5 tp -78.39 133.67 37.5 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 22.3 t -116.33 150.97 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 -178.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.37 133.4 24.22 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 125.368 1.467 . . . . 0.0 107.649 171.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.5 m 42.58 33.48 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 C-N-CA 126.211 1.804 . . . . 0.0 114.641 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.2 7.62 82.88 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 118.966 -0.908 . . . . 0.0 114.106 176.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -120.28 143.81 48.13 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 119.117 1.458 . . . . 0.0 108.191 175.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.0 130.42 46.65 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 28.0 ttt -89.66 -57.88 2.72 Favored 'General case' 0 C--O 1.233 0.236 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 18.5 m -151.99 144.91 24.44 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 124.293 1.037 . . . . 0.0 109.078 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 t -74.12 140.29 17.88 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 105.399 -2.075 . . . . 0.0 105.399 168.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 pt -137.7 160.3 34.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 123.573 0.749 . . . . 0.0 109.821 -173.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -76.96 165.21 24.96 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.691 0.796 . . . . 0.0 109.706 173.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -59.74 -42.83 94.04 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.467 0.707 . . . . 0.0 110.219 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -65.32 -36.38 83.87 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.066 0.547 . . . . 0.0 110.932 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.3 mt-10 -67.7 -35.05 78.09 Favored 'General case' 0 N--CA 1.457 -0.095 0 CA-C-O 119.129 -0.463 . . . . 0.0 110.113 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -47.32 83.67 Favored 'General case' 0 C--N 1.34 0.185 0 CA-C-N 118.95 0.795 . . . . 0.0 110.293 175.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -62.54 -43.55 98.54 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 118.167 0.44 . . . . 0.0 110.725 177.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.75 -40.89 96.71 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 118.131 0.423 . . . . 0.0 111.147 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.8 m -67.07 -42.48 84.64 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.245 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.9 mt -63.94 -39.05 93.26 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 119.204 0.911 . . . . 0.0 110.582 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.94 -46.89 79.69 Favored 'General case' 0 C--O 1.227 -0.091 0 C-N-CA 122.95 0.5 . . . . 0.0 110.585 175.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.41 99.53 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.566 0.621 . . . . 0.0 111.225 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.6 tp -65.05 -35.64 81.81 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 123.882 0.873 . . . . 0.0 111.601 -174.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -81.52 -39.64 24.38 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.022 0.828 . . . . 0.0 110.474 172.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -57.6 -42.68 83.73 Favored 'General case' 0 N--CA 1.462 0.143 0 C-N-CA 123.449 0.7 . . . . 0.0 111.563 -177.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 28.3 ptm -63.83 -10.04 18.19 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -177.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -115.82 -21.51 9.55 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 119.407 1.003 . . . . 0.0 111.144 173.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -64.65 -36.43 84.24 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.219 0.608 . . . . 0.0 111.246 171.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.1 m -61.96 -45.52 98.53 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 118.037 0.381 . . . . 0.0 110.731 176.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -169.56 144.35 2.42 Favored Pre-proline 0 CA--C 1.539 0.521 0 C-N-CA 126.852 2.061 . . . . 0.0 107.423 169.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -73.51 -14.36 24.96 Favored 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.52 2.147 . . . . 0.0 112.679 -178.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -56.87 -27.32 60.27 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 125.016 1.326 . . . . 0.0 113.003 -175.067 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 38.7 t -58.23 -29.21 36.86 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 C-N-CA 123.886 0.875 . . . . 0.0 110.905 176.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.92 -38.94 94.88 Favored Glycine 0 CA--C 1.529 0.967 0 O-C-N 121.04 -1.038 . . . . 0.0 111.461 175.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -73.83 7.93 2.27 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.123 0.969 . . . . 0.0 113.121 178.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 38.2 tp -121.09 -42.17 2.5 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 125.77 1.628 . . . . 0.0 109.35 171.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 45.2 tp -65.47 -38.81 90.88 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-N 118.708 0.685 . . . . 0.0 111.202 177.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 24.1 p90 -138.61 36.34 2.22 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.521 1.528 . . . . 0.0 109.843 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -156.11 -174.44 25.91 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 175.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -137.63 29.79 2.62 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.312 1.045 . . . . 0.0 109.459 -175.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -71.33 -13.2 61.8 Favored 'General case' 0 CA--C 1.544 0.715 0 O-C-N 121.208 -0.933 . . . . 0.0 111.157 176.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 59.5 tptt . . . . . 0 C--O 1.249 1.038 0 C-N-CA 127.323 2.249 . . . . 0.0 105.732 175.887 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mpt? . . . . . 0 N--CA 1.483 1.214 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 58.3 m -64.58 165.2 10.48 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.191 0.596 . . . . 0.0 110.287 171.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.7 pt -77.47 57.9 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 124.682 1.193 . . . . 0.0 111.181 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -75.51 49.78 2.39 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 126.354 1.931 . . . . 0.0 112.213 177.08 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -146.47 149.5 37.58 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 125.973 1.709 . . . . 0.0 108.184 -172.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -75.05 171.17 18.84 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.232 1.954 . . . . 0.0 112.237 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -156.07 167.84 33.39 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -101.72 136.83 40.9 Favored 'General case' 0 C--O 1.231 0.127 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.5 mt -72.65 82.6 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 125.648 1.579 . . . . 0.0 107.895 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.5 mmt85 -76.6 -27.56 55.83 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.607 -0.683 . . . . 0.0 111.565 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.14 152.18 35.66 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -176.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 63.6 mt -129.65 144.75 37.14 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -121.13 -20.16 6.88 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 124.446 1.098 . . . . 0.0 111.835 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.443 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 164.05 -127.48 1.67 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 106.607 -2.597 . . . . 0.0 106.607 -178.598 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -70.38 14.3 0.13 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 124.462 1.105 . . . . 0.0 112.004 169.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.443 ' H ' ' C ' ' A' ' 14' ' ' GLY . 37.7 mt-30 -140.11 153.8 46.82 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 127.66 2.384 . . . . 0.0 106.636 -176.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.65 167.18 22.68 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.261 1.425 . . . . 0.0 109.106 178.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -121.24 76.31 1.23 Allowed 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 -174.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.5 m -73.03 136.68 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -170.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -79.15 117.72 20.44 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 171.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.4 t -85.04 50.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 125.059 1.343 . . . . 0.0 107.724 177.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 79.3 m 40.59 49.57 2.73 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.166 2.186 . . . . 0.0 113.371 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 176.64 -38.92 0.1 OUTLIER Glycine 0 CA--C 1.526 0.748 0 CA-C-O 119.531 -0.594 . . . . 0.0 112.24 175.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.0 tp -156.26 154.86 5.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 175.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.5 mt-30 -76.94 143.28 39.63 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 122.801 0.441 . . . . 0.0 109.954 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.19 138.17 51.57 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 169.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -73.85 133.83 43.23 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 78.7 t -140.95 130.63 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.684 1.594 . . . . 0.0 107.001 -173.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.22 140.74 45.27 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 124.863 1.265 . . . . 0.0 109.92 175.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.3 mt -113.65 11.85 18.29 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.861 0.864 . . . . 0.0 112.886 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.9 m -53.34 -34.74 58.68 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 120.833 1.651 . . . . 0.0 112.432 -175.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 86.4 mt -73.91 -12.86 60.79 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -176.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 m -133.43 -19.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 119.323 0.965 . . . . 0.0 112.897 -171.477 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.33 147.03 0.89 Allowed Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.098 1.332 . . . . 0.0 110.831 -171.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.2 m -76.57 -4.38 42.54 Favored 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.842 -0.799 . . . . 0.0 113.002 179.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.1 m -131.94 151.25 51.83 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 124.349 1.059 . . . . 0.0 109.965 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -65.77 165.59 12.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.945 2.098 . . . . 0.0 109.864 169.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -52.96 -37.49 61.18 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.317 1.447 . . . . 0.0 112.152 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -85.35 9.82 14.4 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.721 0.809 . . . . 0.0 112.015 -178.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.87 4.96 88.37 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 124.581 1.086 . . . . 0.0 113.464 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -69.87 132.28 88.82 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -65.92 141.2 63.76 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 CA-C-N 121.303 1.501 . . . . 0.0 109.011 174.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -72.45 13.72 0.32 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -172.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -54.08 129.27 14.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-N 120.227 1.376 . . . . 0.0 108.639 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.65 -17.64 55.61 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.827 1.203 . . . . 0.0 113.414 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -73.34 169.31 17.41 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.511 1.655 . . . . 0.0 109.162 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.7 m95 -120.16 156.59 30.77 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.947 0.899 . . . . 0.0 109.123 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 2.8 m -143.2 144.92 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 123.435 0.694 . . . . 0.0 109.402 178.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 59.3 mt -72.89 147.97 44.82 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 168.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.9 t -131.96 152.68 37.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -130.82 -60.08 0.98 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.974 0.91 . . . . 0.0 109.635 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.3 m -138.36 38.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 123.941 0.896 . . . . 0.0 110.614 -169.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.08 14.66 60.25 Favored Glycine 0 CA--C 1.528 0.906 0 CA-C-O 119.406 -0.663 . . . . 0.0 113.046 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -128.22 137.33 51.98 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 175.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.32 111.74 5.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 172.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 15.5 tpt -71.79 -49.01 42.66 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 118.031 0.378 . . . . 0.0 110.303 -175.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 13.5 m -152.55 151.1 30.27 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 124.959 1.304 . . . . 0.0 108.603 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 18.4 t -78.79 141.01 15.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 171.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.7 pt -138.9 -169.69 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 126.064 1.746 . . . . 0.0 108.794 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -126.97 -179.29 4.76 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.019 1.327 . . . . 0.0 110.125 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -54.92 -44.9 74.64 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.161 0.985 . . . . 0.0 111.249 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.31 -49.22 67.78 Favored 'General case' 0 C--O 1.231 0.131 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -172.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 26.0 mm-40 -64.84 -38.76 92.07 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.776 0.43 . . . . 0.0 110.28 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.41 -51.28 66.43 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 118.372 0.533 . . . . 0.0 110.61 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 63.3 mtt85 -66.91 -36.95 83.43 Favored 'General case' 0 CA--C 1.523 -0.064 0 CA-C-O 118.489 -0.767 . . . . 0.0 110.633 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.72 -43.66 98.42 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 119.121 0.873 . . . . 0.0 110.909 175.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.4 m -64.05 -45.9 86.79 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 122.979 0.512 . . . . 0.0 109.996 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 57.9 mt -64.33 -39.22 93.47 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 118.252 0.478 . . . . 0.0 110.858 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.6 -48.48 72.16 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 123.2 0.6 . . . . 0.0 110.319 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.01 88.54 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 117.872 0.305 . . . . 0.0 111.26 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -66.46 -56.18 12.17 Favored 'General case' 0 C--N 1.339 0.117 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.047 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -66.09 -28.12 68.58 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 118.406 0.548 . . . . 0.0 111.435 -174.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -54.22 -29.19 45.54 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.959 0.904 . . . . 0.0 112.452 176.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 24.8 mmt -65.77 -12.5 54.48 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.551 0.741 . . . . 0.0 112.975 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -133.44 -39.33 0.91 Allowed 'General case' 0 C--N 1.341 0.214 0 C-N-CA 124.244 1.018 . . . . 0.0 111.143 -172.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -59.57 -23.26 62.76 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 125.795 1.638 . . . . 0.0 113.015 -174.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 3.3 m -52.55 -33.82 18.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.147 0.979 . . . . 0.0 112.733 172.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -73.83 -55.0 3.44 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-O 117.775 -1.107 . . . . 0.0 111.698 -174.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.36 -27.24 55.28 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 CA-C-N 121.656 1.627 . . . . 0.0 111.813 173.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -65.39 -51.7 58.59 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 119.0 0.818 . . . . 0.0 111.056 177.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.8 p -68.01 -32.36 55.88 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 CA-C-N 118.691 0.678 . . . . 0.0 110.231 178.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.94 -50.28 69.38 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 174.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -64.64 -42.4 95.49 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 117.763 0.781 . . . . 0.0 111.114 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 35.4 tp -56.49 -49.14 75.55 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 123.682 0.793 . . . . 0.0 110.072 177.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 60.2 tp -65.6 -56.45 12.14 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 122.761 0.424 . . . . 0.0 110.445 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 54.8 t80 -66.27 -34.84 78.9 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 123.212 0.605 . . . . 0.0 112.11 -169.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.23 0.88 64.21 Favored Glycine 0 CA--C 1.528 0.87 0 CA-C-O 118.294 -1.281 . . . . 0.0 113.114 -175.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 48.6 54.74 10.09 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-N 118.849 1.324 . . . . 0.0 109.358 -169.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 69.4 -59.88 0.48 Allowed 'General case' 0 C--O 1.234 0.275 0 C-N-CA 128.917 2.887 . . . . 0.0 111.652 -169.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 24.5 pttm . . . . . 0 C--O 1.249 1.075 0 C-N-CA 124.455 1.102 . . . . 0.0 109.521 -171.528 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 98.0 mtp . . . . . 0 N--CA 1.484 1.254 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 92.6 m -135.45 157.35 47.11 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 125.32 1.448 . . . . 0.0 108.585 176.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 47.4 pt -65.56 150.38 10.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 169.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.82 48.74 0.09 OUTLIER Glycine 0 CA--C 1.526 0.757 0 N-CA-C 107.114 -2.394 . . . . 0.0 107.114 -175.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.3 m -140.13 166.73 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.564 1.545 . . . . 0.0 109.675 -168.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -54.9 153.54 24.8 Favored 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.565 2.176 . . . . 0.0 113.175 169.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -159.88 164.31 34.14 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 169.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -110.96 130.21 55.65 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.45 1.125 . . . . 0.0 109.204 -172.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.6 mt -66.05 120.98 14.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 52.3 tpt85 -121.11 -22.5 6.09 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 118.182 -0.913 . . . . 0.0 111.651 -175.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.65 155.6 42.57 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 170.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 50.3 mt -133.06 144.67 35.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -126.61 -18.67 4.74 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 123.858 0.863 . . . . 0.0 112.452 -174.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.75 -131.13 2.25 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 107.2 -2.36 . . . . 0.0 107.2 -178.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.5 p-10 -68.33 9.24 0.35 Allowed 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.145 0.978 . . . . 0.0 112.545 169.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -139.39 155.47 47.62 Favored 'General case' 0 C--O 1.239 0.523 0 C-N-CA 126.004 1.722 . . . . 0.0 107.542 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.8 174.88 10.06 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 125.453 1.501 . . . . 0.0 110.757 -176.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -122.18 114.51 20.96 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 178.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 89.1 t -111.83 125.56 69.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 -169.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -72.58 112.21 8.43 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 170.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 t -90.07 59.81 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.3 m 50.02 42.64 24.98 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.336 1.854 . . . . 0.0 113.5 178.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.2 -37.28 0.14 Allowed Glycine 0 CA--C 1.525 0.71 0 O-C-N 121.629 -0.67 . . . . 0.0 112.906 173.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 tp -155.33 155.79 5.46 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 62.8 mt-30 -74.65 147.37 41.61 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.709 0.766 . . . . 0.0 110.871 177.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.14 144.52 51.23 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.456 1.502 . . . . 0.0 107.255 169.293 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -69.84 135.71 49.93 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 169.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.65 121.03 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -173.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -66.64 134.67 52.77 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 169.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.2 tp -117.78 0.44 11.98 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 124.737 1.215 . . . . 0.0 110.358 -169.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.5 m -57.77 -30.84 65.96 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 124.721 1.209 . . . . 0.0 111.211 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 77.0 mt -67.89 -13.98 62.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.078 0.951 . . . . 0.0 112.884 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.74 -8.71 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 119.154 0.888 . . . . 0.0 112.1 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.57 136.22 1.68 Allowed Glycine 0 CA--C 1.525 0.699 0 C-N-CA 125.4 1.476 . . . . 0.0 110.388 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.5 m -75.88 161.19 29.18 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.238 0.615 . . . . 0.0 109.342 169.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.2 m 56.4 177.52 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.774 1.629 . . . . 0.0 112.597 -169.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -133.49 151.91 51.83 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 126.182 1.793 . . . . 0.0 108.221 -170.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.2 -21.58 34.44 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.026 1.331 . . . . 0.0 114.214 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -74.31 -7.2 51.98 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.487 0.585 . . . . 0.0 112.052 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.15 46.92 5.71 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -177.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.67 158.3 60.18 Favored Pre-proline 0 CA--C 1.535 0.399 0 C-N-CA 125.165 1.386 . . . . 0.0 108.664 -176.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -69.0 153.55 72.24 Favored 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 121.958 1.772 . . . . 0.0 109.892 169.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -73.16 3.37 5.7 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.615 0.968 . . . . 0.0 113.615 177.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.53 127.46 15.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-N 120.547 1.521 . . . . 0.0 108.457 -175.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.27 -24.76 30.64 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 124.892 1.234 . . . . 0.0 112.548 -176.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -70.53 162.06 29.49 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.056 1.428 . . . . 0.0 108.84 172.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.4 m95 -113.67 155.87 24.75 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -141.88 143.19 27.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.2 mt -77.32 127.9 33.39 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 103.743 -2.688 . . . . 0.0 103.743 168.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.5 m -131.2 126.65 59.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 119.341 0.973 . . . . 0.0 110.627 -170.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.466 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 3.5 t60 -89.17 -165.88 1.45 Allowed 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 169.522 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.466 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 18.3 m -47.71 -29.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 C-N-CA 125.815 1.646 . . . . 0.0 114.993 -172.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.74 33.07 0.17 Allowed Glycine 0 C--N 1.338 0.639 0 CA-C-O 118.819 -0.99 . . . . 0.0 112.4 175.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -145.71 134.17 21.97 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.822 1.311 . . . . 0.0 109.128 -174.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.34 117.91 17.66 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 169.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 72.2 mtp -77.31 -49.4 15.08 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.526 1.13 . . . . 0.0 109.056 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.9 m -151.35 162.46 40.87 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 125.851 1.661 . . . . 0.0 108.65 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.7 p -107.52 139.88 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 C-N-CA 124.87 1.268 . . . . 0.0 107.874 172.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.1 pt -141.26 161.75 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.095 1.358 . . . . 0.0 109.896 -173.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -75.44 165.26 25.4 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.916 0.886 . . . . 0.0 110.53 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.53 -40.9 72.43 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 124.729 1.211 . . . . 0.0 111.698 176.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.48 -40.21 67.1 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 122.942 0.497 . . . . 0.0 110.79 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.07 -40.79 97.02 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.091 0.556 . . . . 0.0 109.763 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.91 -48.97 78.05 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.666 -0.207 . . . . 0.0 110.748 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 75.4 mtt85 -64.34 -40.02 95.05 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 119.079 -0.486 . . . . 0.0 110.762 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.7 -42.73 99.79 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.467 0.576 . . . . 0.0 111.047 176.017 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.4 m -65.16 -43.69 90.92 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.151 0.58 . . . . 0.0 110.334 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.2 mt -61.95 -44.45 96.73 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.394 0.543 . . . . 0.0 109.846 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -63.68 -44.47 93.63 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 118.458 0.572 . . . . 0.0 111.146 179.318 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.36 82.04 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 122.663 0.385 . . . . 0.0 110.316 178.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -60.2 -49.33 78.07 Favored 'General case' 0 CA--C 1.528 0.101 0 C-N-CA 123.693 0.797 . . . . 0.0 109.711 178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -60.24 -40.39 90.06 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 123.462 0.705 . . . . 0.0 110.941 -177.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -63.83 -19.41 65.01 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 119.653 1.115 . . . . 0.0 111.557 -175.447 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 37.8 tpp -85.69 -19.52 30.75 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 125.189 1.396 . . . . 0.0 112.117 -178.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 72.5 m-85 -141.65 -3.79 1.13 Allowed 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 115.244 1.572 . . . . 0.0 115.244 -169.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -58.66 -25.53 62.88 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 120.03 1.286 . . . . 0.0 113.117 -172.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 14.6 m -129.67 45.5 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 C-N-CA 126.098 1.759 . . . . 0.0 108.775 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 79.05 163.93 0.13 Allowed Pre-proline 0 CA--C 1.545 0.771 0 C-N-CA 127.55 2.34 . . . . 0.0 110.534 177.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -57.56 -14.68 17.55 Favored 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 123.529 2.82 . . . . 0.0 115.486 178.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -56.35 -44.33 79.96 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 119.19 0.904 . . . . 0.0 112.091 -175.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 28.3 m -69.61 -29.05 39.93 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-O 119.181 -0.438 . . . . 0.0 111.087 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -68.32 -45.67 68.36 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 176.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -62.65 -39.28 93.39 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 117.61 0.705 . . . . 0.0 111.157 176.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 44.2 tp -65.78 -48.77 70.7 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.339 0.656 . . . . 0.0 110.553 176.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.2 tp -59.31 -51.84 68.21 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 124.076 0.951 . . . . 0.0 109.768 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 28.1 t80 -67.44 -22.66 65.5 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.413 0.685 . . . . 0.0 112.05 -177.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 82.45 19.69 63.69 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 123.725 0.678 . . . . 0.0 112.016 -176.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -69.53 -34.15 73.83 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 117.839 0.82 . . . . 0.0 109.296 170.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -137.58 70.79 1.39 Allowed 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.18 1.392 . . . . 0.0 108.132 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 24.4 ttpt . . . . . 0 C--O 1.251 1.158 0 C-N-CA 125.256 1.422 . . . . 0.0 107.493 178.183 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.8 mmm . . . . . 0 N--CA 1.486 1.359 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 58.2 m -60.1 -39.96 88.0 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.416 0.687 . . . . 0.0 112.677 -172.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.1 pt -142.34 149.09 19.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 C-N-CA 125.06 1.344 . . . . 0.0 108.233 179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.12 46.16 0.09 OUTLIER Glycine 0 CA--C 1.526 0.763 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 -173.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.7 m -143.3 163.75 35.33 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 125.208 1.403 . . . . 0.0 110.287 -168.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -53.77 157.13 10.66 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 123.075 2.517 . . . . 0.0 113.874 171.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.71 167.85 37.34 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 126.336 1.922 . . . . 0.0 108.648 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.2 tt0 -116.18 134.25 55.13 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 64.7 mt -75.04 74.86 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 125.649 1.58 . . . . 0.0 107.509 -176.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -70.73 -30.65 67.23 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-O 118.438 -0.792 . . . . 0.0 111.566 -172.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -148.81 155.7 41.31 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 177.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 57.0 mt -132.18 146.85 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -178.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -129.71 -20.06 3.26 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.854 0.862 . . . . 0.0 112.529 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 175.15 -134.47 2.74 Favored Glycine 0 C--N 1.334 0.418 0 N-CA-C 106.243 -2.743 . . . . 0.0 106.243 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.9 t30 -65.86 -15.74 63.2 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 118.386 1.093 . . . . 0.0 110.668 169.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -101.08 153.0 19.93 Favored 'General case' 0 C--O 1.239 0.544 0 C-N-CA 124.954 1.302 . . . . 0.0 109.123 175.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.34 159.52 42.06 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.313 1.445 . . . . 0.0 109.14 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -106.77 86.83 2.39 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.61 127.6 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 -174.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -71.37 106.89 4.06 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 169.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.77 67.24 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.0 48.05 7.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.291 2.236 . . . . 0.0 113.739 178.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 174.77 -42.03 0.12 Allowed Glycine 0 CA--C 1.524 0.646 0 CA-C-O 119.692 -0.505 . . . . 0.0 112.219 172.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -156.97 156.1 4.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 C-N-CA 124.676 1.19 . . . . 0.0 108.175 175.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -67.76 136.06 53.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.23 0.612 . . . . 0.0 110.469 176.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.2 mpt_? -123.88 148.61 46.67 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 106.327 -1.731 . . . . 0.0 106.327 169.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -70.59 136.81 49.5 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.5 t -138.59 131.25 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -83.21 126.22 32.4 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 169.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.1 mt -83.29 36.86 0.53 Allowed 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 123.64 0.776 . . . . 0.0 111.335 -173.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -45.87 -40.33 9.81 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.412 2.285 . . . . 0.0 114.443 -169.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.2 mt -106.23 4.56 28.99 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 118.853 -0.594 . . . . 0.0 112.282 -169.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.3 m -133.97 -26.68 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.981 0.809 . . . . 0.0 111.937 -173.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.89 152.79 1.94 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.095 0.855 . . . . 0.0 110.979 -175.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 m -77.18 -6.86 54.56 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m -126.72 151.58 47.98 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.3 1.04 . . . . 0.0 109.075 175.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.5 t0 -84.51 176.57 8.55 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 124.308 1.043 . . . . 0.0 110.665 -178.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -55.68 -37.08 67.85 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.917 1.287 . . . . 0.0 112.102 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -84.12 -2.0 55.98 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.627 0.771 . . . . 0.0 112.929 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.18 -3.26 66.47 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.323 -1.265 . . . . 0.0 114.241 173.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -67.38 147.81 98.8 Favored Pre-proline 0 CA--C 1.538 0.506 0 CA-C-N 119.91 1.855 . . . . 0.0 109.046 175.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -64.87 141.93 73.51 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.541 1.494 . . . . 0.0 108.743 169.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.4 mtt-85 -70.94 11.39 0.4 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.7 p -56.38 129.23 17.74 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 CA-C-N 119.968 1.258 . . . . 0.0 109.031 -176.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.04 -14.46 57.18 Favored Glycine 0 CA--C 1.534 1.24 0 CA-C-O 118.226 -1.319 . . . . 0.0 113.972 -178.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -70.34 166.03 21.11 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.824 1.812 . . . . 0.0 108.969 170.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -112.25 161.22 16.83 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 121.538 0.685 . . . . 0.0 109.871 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.75 140.9 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 -172.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.8 111.64 12.55 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 104.894 -2.262 . . . . 0.0 104.894 169.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 51.3 t -93.11 132.22 37.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -144.24 130.41 19.63 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 1.7 t 45.74 37.34 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 125.177 1.391 . . . . 0.0 112.688 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.08 16.37 79.6 Favored Glycine 0 CA--C 1.534 1.251 0 O-C-N 120.916 -1.115 . . . . 0.0 114.308 176.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -128.49 161.95 28.35 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 119.315 1.558 . . . . 0.0 109.956 170.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.89 111.34 16.12 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 16.0 tpt -74.02 -51.5 15.67 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.4 m -154.21 138.37 16.51 Favored 'General case' 0 C--N 1.342 0.247 0 C-N-CA 124.305 1.042 . . . . 0.0 108.912 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -77.54 142.42 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 169.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.2 pt -139.91 160.51 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 124.355 1.062 . . . . 0.0 109.84 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -75.27 165.12 25.68 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 123.842 0.857 . . . . 0.0 110.46 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -54.51 -41.68 69.92 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 124.732 1.213 . . . . 0.0 111.467 174.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.4 -39.42 67.98 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 122.988 0.515 . . . . 0.0 110.786 -178.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -64.61 -40.7 95.97 Favored 'General case' 0 N--CA 1.461 0.088 0 C-N-CA 123.009 0.524 . . . . 0.0 109.865 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.43 -49.42 76.92 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.838 0.29 . . . . 0.0 110.562 177.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 76.1 mtt85 -64.45 -40.12 95.12 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-O 119.03 -0.51 . . . . 0.0 110.665 -178.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.93 -41.83 99.61 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 118.602 0.637 . . . . 0.0 111.129 176.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.7 m -65.42 -43.43 90.53 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.813 0.445 . . . . 0.0 110.032 178.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -64.51 -40.04 94.89 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 118.765 0.711 . . . . 0.0 110.549 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -63.21 -44.0 96.54 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 118.202 0.455 . . . . 0.0 110.748 176.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.64 -47.14 86.78 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 122.992 0.517 . . . . 0.0 110.204 175.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.7 mt -62.33 -3.2 1.25 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.039 1.336 . . . . 0.0 113.35 177.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 23.8 mm-40 -128.29 8.15 6.0 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.813 1.245 . . . . 0.0 112.061 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -150.57 -34.07 0.16 Allowed 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 119.774 1.17 . . . . 0.0 114.132 172.517 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 14.0 tpt -66.12 -16.41 63.93 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 119.228 0.922 . . . . 0.0 112.151 -173.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -120.9 18.9 11.78 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.544 1.538 . . . . 0.0 110.125 -176.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -126.65 -0.17 6.79 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.286 1.434 . . . . 0.0 111.564 -174.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.1 t -75.15 -33.89 30.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 C-N-CA 123.748 0.819 . . . . 0.0 109.408 175.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -59.1 -51.68 80.03 Favored Pre-proline 0 CA--C 1.542 0.661 0 C-N-CA 124.449 1.099 . . . . 0.0 111.436 -177.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -70.03 -20.05 34.05 Favored 'Trans proline' 0 C--N 1.351 0.663 0 CA-C-N 121.032 1.404 . . . . 0.0 112.461 173.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -66.79 -54.23 24.82 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 119.758 1.163 . . . . 0.0 109.784 177.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -69.14 -33.27 57.6 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-O 119.037 -0.506 . . . . 0.0 110.156 178.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.71 -53.95 41.69 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 174.52 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -59.53 -41.52 90.2 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 123.688 0.795 . . . . 0.0 111.365 179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 60.6 tp -61.52 -45.71 93.06 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 122.678 0.391 . . . . 0.0 110.596 176.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 62.4 tp -62.96 -37.95 89.16 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.789 0.835 . . . . 0.0 111.106 178.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 13.6 m-30 -68.36 -10.2 53.31 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.458 0.703 . . . . 0.0 112.429 175.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 68.75 31.31 72.99 Favored Glycine 0 CA--C 1.53 0.984 0 CA-C-N 118.981 0.809 . . . . 0.0 111.175 -175.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -143.62 51.48 1.35 Allowed 'General case' 0 CA--C 1.537 0.473 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 -175.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -52.16 150.62 4.36 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 125.595 1.558 . . . . 0.0 113.559 -169.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 29.8 ttmt . . . . . 0 C--O 1.248 1.011 0 C-N-CA 125.085 1.354 . . . . 0.0 109.721 -178.375 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.484 1.234 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 62.8 m -76.23 62.09 1.71 Allowed 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 124.942 1.297 . . . . 0.0 111.612 -177.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -59.5 163.89 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 124.618 1.167 . . . . 0.0 112.215 -178.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.1 63.38 0.5 Allowed Glycine 0 CA--C 1.526 0.74 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -176.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.1 p -153.04 145.33 17.05 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 126.3 1.84 . . . . 0.0 106.472 -169.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -75.41 168.55 24.31 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.617 1.545 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.42 -176.88 42.24 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 172.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -95.99 137.86 34.46 Favored 'General case' 0 C--O 1.231 0.116 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 178.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 68.9 mt -71.47 78.81 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 171.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -67.51 -30.22 69.83 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.446 -0.784 . . . . 0.0 110.301 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.18 150.01 26.6 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 124.512 1.125 . . . . 0.0 108.051 -173.201 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 49.8 mt -119.98 149.79 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -145.48 65.17 1.24 Allowed 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 126.324 1.85 . . . . 0.0 107.468 -170.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 -124.71 18.71 Favored Glycine 0 C--N 1.338 0.64 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -173.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -68.27 -25.05 64.97 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 122.787 0.435 . . . . 0.0 111.913 172.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -86.1 170.92 11.77 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 121.86 0.838 . . . . 0.0 109.835 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.55 159.79 41.8 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.545 1.538 . . . . 0.0 108.19 169.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.58 75.97 0.95 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.238 -2.134 . . . . 0.0 105.238 177.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 79.3 t -71.74 126.52 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 124.904 1.282 . . . . 0.0 107.563 -172.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -79.26 111.02 15.08 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 174.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.5 t -82.06 60.21 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 C-N-CA 125.668 1.587 . . . . 0.0 107.282 172.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 55.5 m 43.67 41.39 3.53 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.11 2.164 . . . . 0.0 114.432 176.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 161.67 -23.83 0.23 Allowed Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.157 -0.802 . . . . 0.0 113.676 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.7 tp -150.29 149.43 14.45 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 176.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -92.17 139.06 31.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 -179.221 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -129.69 144.97 51.54 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.916 1.287 . . . . 0.0 108.519 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -73.84 137.61 43.91 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 71.6 t -137.03 143.67 34.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -99.8 119.8 38.75 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.164 1.386 . . . . 0.0 107.539 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.9 mt -91.17 12.49 19.91 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 117.88 -1.057 . . . . 0.0 113.03 -172.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -48.65 -36.43 15.91 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 121.29 1.859 . . . . 0.0 113.73 -174.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.0 mt -88.55 -2.63 58.7 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -173.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.07 -19.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 119.344 0.975 . . . . 0.0 112.672 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.0 146.84 2.93 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 125.259 1.409 . . . . 0.0 111.131 -175.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.1 m -74.97 -12.64 60.39 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.49 0.716 . . . . 0.0 112.18 174.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.4 m -117.89 166.34 12.6 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.603 1.161 . . . . 0.0 109.316 172.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -115.65 163.39 15.87 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.185 1.794 . . . . 0.0 110.446 -169.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -54.18 -36.74 63.72 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.397 1.479 . . . . 0.0 111.265 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -74.44 1.22 12.31 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.499 1.52 . . . . 0.0 113.059 -178.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.02 45.61 11.52 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 121.014 -1.054 . . . . 0.0 111.098 174.331 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.6 pt20 -141.64 151.34 60.08 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.28 1.432 . . . . 0.0 108.611 -177.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -66.52 147.81 82.76 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 122.08 1.853 . . . . 0.0 109.159 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -73.71 7.93 2.2 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.9 m -54.57 133.37 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 120.537 1.517 . . . . 0.0 109.892 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.11 -17.95 34.58 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-O 118.231 -1.316 . . . . 0.0 113.38 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -72.57 164.73 25.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 119.708 1.754 . . . . 0.0 108.735 174.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 33.7 m95 -109.2 154.0 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.0 p -146.61 140.22 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -172.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 65.6 tp -89.24 148.09 23.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 169.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 t -124.99 142.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -103.48 -52.15 3.06 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.915 0.486 . . . . 0.0 110.355 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.4 p -157.81 63.12 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 -38.36 1.81 Allowed Glycine 0 CA--C 1.529 0.946 0 C-N-CA 124.746 1.165 . . . . 0.0 112.034 -172.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -69.49 135.18 49.81 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 118.639 1.22 . . . . 0.0 109.159 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.43 132.03 52.61 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 169.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 21.9 ttt -84.81 -55.28 4.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.3 m -155.82 149.46 25.04 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 124.768 1.227 . . . . 0.0 108.844 -177.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.9 p -74.94 142.78 14.14 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 168.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.9 pt -138.32 169.98 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 C-N-CA 124.104 0.961 . . . . 0.0 109.682 -172.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.38 169.74 8.68 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.754 0.822 . . . . 0.0 109.575 169.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -62.43 -34.39 76.68 Favored 'General case' 0 C--N 1.334 -0.084 0 CA-C-O 118.68 -0.676 . . . . 0.0 112.452 -173.171 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.85 -39.78 95.01 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.022 0.828 . . . . 0.0 110.743 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -65.96 -41.15 91.61 Favored 'General case' 0 C--O 1.232 0.152 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.24 -50.33 72.17 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 117.916 0.325 . . . . 0.0 110.351 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 43.8 mmt-85 -63.48 -43.48 97.18 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 118.877 -0.582 . . . . 0.0 110.279 -179.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.75 -43.5 98.72 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 118.484 0.584 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.0 m -66.6 -43.55 84.52 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 122.749 0.42 . . . . 0.0 110.128 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.4 mt -63.63 -41.25 98.28 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 119.084 0.856 . . . . 0.0 110.499 178.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -63.31 -44.63 94.43 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 122.874 0.47 . . . . 0.0 110.417 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.18 -48.91 76.38 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.828 0.451 . . . . 0.0 110.76 177.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 56.9 mt -60.56 -38.91 86.1 Favored 'General case' 0 N--CA 1.463 0.178 0 C-N-CA 123.281 0.633 . . . . 0.0 111.028 -177.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 36.8 mt-30 -66.65 -45.09 80.13 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 118.493 0.588 . . . . 0.0 110.18 174.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.5 m-80 -68.34 -15.9 63.74 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-O 118.582 -0.723 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 66.9 mtt -59.34 -18.52 38.92 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 120.127 1.331 . . . . 0.0 112.004 170.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 80.8 t80 -63.09 -29.71 71.02 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 119.238 0.926 . . . . 0.0 110.826 172.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -98.58 11.78 37.33 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.208 1.403 . . . . 0.0 110.869 175.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 23.9 t 71.73 -23.29 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 C-N-CA 128.041 2.536 . . . . 0.0 114.33 169.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -55.9 -53.98 57.08 Favored Pre-proline 0 CA--C 1.541 0.625 0 N-CA-C 114.397 1.258 . . . . 0.0 114.397 -169.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -74.25 -14.11 23.1 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 CA-C-N 121.739 1.657 . . . . 0.0 112.81 178.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -73.82 -49.23 26.21 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 119.83 1.196 . . . . 0.0 109.625 175.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 28.1 m -68.65 -28.57 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-O 118.95 -0.548 . . . . 0.0 110.504 172.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -56.29 -57.15 20.65 Favored Glycine 0 C--N 1.34 0.768 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 170.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.24 -38.05 76.11 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 117.996 0.898 . . . . 0.0 111.829 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 tm? -63.48 -52.03 63.08 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 122.776 0.43 . . . . 0.0 110.011 176.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 66.0 tp -61.15 -41.65 97.14 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 124.197 0.999 . . . . 0.0 110.876 -179.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 18.2 m-30 -69.85 -9.95 56.68 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.927 0.891 . . . . 0.0 112.472 177.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 73.59 22.52 78.34 Favored Glycine 0 CA--C 1.531 1.05 0 CA-C-N 118.911 0.778 . . . . 0.0 112.253 179.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -77.28 -31.19 54.66 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 118.102 0.951 . . . . 0.0 109.705 173.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 36.4 mm-40 -71.77 -35.57 70.09 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.041 0.536 . . . . 0.0 111.667 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 65.7 tttm . . . . . 0 C--O 1.249 1.055 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -177.815 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.2 ttm . . . . . 0 N--CA 1.481 1.121 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 76.5 m -132.03 134.77 45.92 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 172.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.1 tp -156.54 -173.79 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 C-N-CA 126.691 1.996 . . . . 0.0 106.456 -176.537 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.22 47.08 0.13 Allowed Glycine 0 CA--C 1.522 0.522 0 O-C-N 120.731 -1.231 . . . . 0.0 110.542 178.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.4 t -142.7 141.7 20.94 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 -170.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -55.47 165.63 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.892 2.395 . . . . 0.0 113.017 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.88 175.67 35.09 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 169.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -116.82 136.43 52.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.8 mt -70.56 96.26 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 N-CA-C 105.931 -1.878 . . . . 0.0 105.931 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -85.56 -42.86 14.0 Favored 'General case' 0 N--CA 1.462 0.132 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 -169.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 p -147.22 158.43 43.95 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.617 1.567 . . . . 0.0 108.112 176.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 52.3 mt -127.46 146.57 33.0 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -177.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -123.96 -19.18 5.74 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.065 0.946 . . . . 0.0 112.294 -176.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.6 -127.58 1.59 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -66.75 2.29 1.44 Allowed 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 123.932 0.893 . . . . 0.0 112.384 169.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -134.28 154.23 51.42 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 126.875 2.07 . . . . 0.0 107.314 -174.186 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.83 155.33 47.3 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.625 1.17 . . . . 0.0 109.382 -179.183 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -99.56 78.7 2.19 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.9 t -68.13 125.8 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 -176.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -75.66 105.18 6.55 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 169.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 t -81.52 63.25 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 37.8 m 48.95 39.52 14.72 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.495 1.918 . . . . 0.0 113.315 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.02 -48.14 0.19 Allowed Glycine 0 CA--C 1.526 0.728 0 CA-C-O 119.255 -0.747 . . . . 0.0 112.01 174.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.0 mm -137.16 143.28 35.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -174.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -71.78 141.88 49.7 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.33 0.586 . . . . 0.0 110.775 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -133.35 144.14 49.43 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 125.622 1.569 . . . . 0.0 106.999 169.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -73.06 134.59 44.63 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 87.6 t -138.3 129.99 37.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -79.57 143.34 34.86 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 122.993 0.517 . . . . 0.0 109.886 174.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 36.3 mt -114.94 15.24 17.32 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.089 0.956 . . . . 0.0 112.668 -169.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.7 m -50.64 -37.32 39.89 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 120.886 1.676 . . . . 0.0 112.463 -177.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.4 mt -77.08 -8.54 57.64 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -174.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.39 -20.11 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 119.517 1.053 . . . . 0.0 112.992 -172.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.16 140.37 0.74 Allowed Glycine 0 CA--C 1.529 0.913 0 C-N-CA 125.244 1.402 . . . . 0.0 110.886 -172.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.8 m -73.82 -17.73 61.03 Favored 'General case' 0 CA--C 1.535 0.374 0 O-C-N 122.024 -0.692 . . . . 0.0 112.313 176.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.9 m -93.0 135.17 34.41 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 123.809 0.843 . . . . 0.0 109.043 175.253 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -66.38 158.18 29.93 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.093 1.757 . . . . 0.0 109.598 169.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -53.47 -29.96 38.48 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.346 1.459 . . . . 0.0 112.176 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -75.66 -12.67 60.25 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.26 48.63 4.5 Favored Glycine 0 CA--C 1.53 1.029 0 CA-C-N 119.007 0.821 . . . . 0.0 111.166 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -143.75 160.54 50.05 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 126.717 2.007 . . . . 0.0 107.409 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -64.68 141.96 74.85 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 CA-C-N 121.586 1.602 . . . . 0.0 110.538 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -69.53 13.87 0.12 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.5 m -54.93 132.87 18.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 120.354 1.434 . . . . 0.0 110.05 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.65 -17.79 53.05 Favored Glycine 0 CA--C 1.532 1.096 0 CA-C-O 118.479 -1.178 . . . . 0.0 113.458 -178.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -71.94 160.94 31.68 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 119.699 1.75 . . . . 0.0 109.081 174.095 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.3 m95 -107.68 161.17 15.11 Favored 'General case' 0 C--O 1.232 0.178 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 p -154.05 146.19 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -169.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.9 mt -89.89 139.63 30.4 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 172.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.3 t -136.15 143.35 36.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -178.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 5.5 t60 -141.44 -39.05 0.4 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.407 0.683 . . . . 0.0 112.487 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.36 27.08 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 119.026 0.83 . . . . 0.0 112.029 -171.174 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.99 16.73 80.52 Favored Glycine 0 CA--C 1.534 1.224 0 O-C-N 121.446 -0.784 . . . . 0.0 112.526 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -129.03 144.43 51.19 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 172.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.12 122.59 17.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 171.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 68.5 mtp -76.76 -47.18 22.5 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.4 m -163.74 149.05 10.89 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 126.131 1.772 . . . . 0.0 108.144 176.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.1 t -80.37 145.28 9.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 169.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.2 pt -139.51 161.44 27.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.447 1.499 . . . . 0.0 109.198 -176.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -84.45 173.45 10.87 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.344 0.592 . . . . 0.0 110.894 174.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -69.99 -30.18 67.45 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 121.758 -0.589 . . . . 0.0 112.294 -170.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -73.63 -40.6 63.65 Favored 'General case' 0 N--CA 1.462 0.129 0 O-C-N 121.283 -0.886 . . . . 0.0 109.837 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -61.36 -41.35 96.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.224 0.61 . . . . 0.0 109.917 174.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.43 -49.41 75.57 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 117.983 0.356 . . . . 0.0 110.416 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 86.3 mtm180 -63.7 -40.2 96.19 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 119.13 -0.462 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.2 -41.9 99.24 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 118.759 0.709 . . . . 0.0 110.954 176.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -67.49 -38.64 84.66 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 122.083 -0.386 . . . . 0.0 110.282 178.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 53.0 mt -65.49 -38.03 88.57 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 119.079 0.854 . . . . 0.0 110.67 176.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -64.76 -43.86 91.93 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 118.605 0.639 . . . . 0.0 110.293 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.52 -43.24 99.29 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.962 0.505 . . . . 0.0 111.142 176.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -56.37 -42.76 78.37 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.405 1.082 . . . . 0.0 109.909 176.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -79.88 7.39 8.91 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 124.164 0.986 . . . . 0.0 113.053 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -132.46 -13.2 3.03 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 119.538 1.063 . . . . 0.0 112.996 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 25.7 ptt? -56.55 -30.04 62.67 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 119.884 1.22 . . . . 0.0 112.385 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -90.14 11.3 21.34 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 125.48 1.512 . . . . 0.0 112.253 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -128.91 -36.96 1.76 Allowed 'General case' 0 N--CA 1.464 0.25 0 C-N-CA 124.578 1.151 . . . . 0.0 111.503 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.4 m -70.13 -16.89 20.51 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.605 0 CA-C-N 118.615 0.643 . . . . 0.0 111.411 171.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -138.93 157.12 72.15 Favored Pre-proline 0 CA--C 1.536 0.43 0 C-N-CA 126.607 1.963 . . . . 0.0 106.868 173.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -69.13 -15.26 39.29 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 122.382 2.055 . . . . 0.0 112.359 175.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 35.2 t70 47.09 -118.48 0.89 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 126.013 1.725 . . . . 0.0 109.593 -173.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.4 p -56.42 -27.27 24.29 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 C-N-CA 124.627 1.171 . . . . 0.0 112.329 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -55.48 -23.84 36.46 Favored Glycine 0 CA--C 1.529 0.964 0 C-N-CA 124.62 1.105 . . . . 0.0 112.94 174.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -60.75 -14.75 23.29 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 118.805 1.302 . . . . 0.0 113.624 176.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.7 tp -133.8 -29.21 1.34 Allowed 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.285 1.034 . . . . 0.0 110.881 176.081 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.5 tp -73.89 -25.01 59.8 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 123.836 0.855 . . . . 0.0 111.969 177.17 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 24.8 t80 -129.96 26.91 5.2 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.193 0.997 . . . . 0.0 111.129 -169.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -177.26 168.28 39.94 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 172.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 36.7 mm-40 -61.89 -40.75 96.51 Favored 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 172.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -164.95 169.86 15.94 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 127.863 2.465 . . . . 0.0 106.822 169.434 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 62.3 mttm . . . . . 0 C--O 1.25 1.11 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 172.188 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.0 ttt . . . . . 0 N--CA 1.486 1.332 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 9.8 p -69.69 -23.59 63.46 Favored 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 114.228 1.196 . . . . 0.0 114.228 -174.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.3 pt -62.73 146.95 12.24 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 124.062 0.945 . . . . 0.0 111.826 -172.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -169.36 49.76 0.21 Allowed Glycine 0 CA--C 1.529 0.936 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -172.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 98.5 t -143.88 139.39 16.03 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -171.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.83 159.89 31.44 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.666 1.577 . . . . 0.0 112.582 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.3 168.1 33.04 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 172.294 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -89.9 143.02 27.15 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 174.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 70.0 mt -74.17 76.64 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.32 1.448 . . . . 0.0 107.205 176.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -64.87 -39.18 93.14 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 126.088 1.755 . . . . 0.0 110.916 -177.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.0 m -150.26 153.78 36.78 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.35 147.2 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 178.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -116.39 -22.33 8.84 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.37 1.468 . . . . 0.0 111.565 -169.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 154.29 -122.92 1.3 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 105.094 -3.203 . . . . 0.0 105.094 -177.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -72.81 15.68 0.18 Allowed 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.101 0.961 . . . . 0.0 111.121 168.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.438 ' H ' ' C ' ' A' ' 14' ' ' GLY . 20.6 mt-30 -141.53 169.87 16.79 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 128.03 2.532 . . . . 0.0 106.569 -174.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.78 21.27 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.399 1.08 . . . . 0.0 109.4 173.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.3 mttp -118.26 72.58 0.87 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 105.604 -1.999 . . . . 0.0 105.604 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.5 m -70.13 137.2 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 C-N-CA 124.553 1.141 . . . . 0.0 109.326 -169.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -85.19 111.89 20.23 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 175.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.2 m -80.45 38.94 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 C-N-CA 124.181 0.992 . . . . 0.0 110.979 178.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 75.8 m 48.13 53.53 11.56 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.349 1.86 . . . . 0.0 111.855 -169.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -179.52 -41.3 0.07 OUTLIER Glycine 0 CA--C 1.524 0.62 0 CA-C-O 119.721 -0.488 . . . . 0.0 112.415 173.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.4 tp -156.0 156.06 5.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 -77.12 138.73 39.68 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 173.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -130.9 131.99 44.85 Favored 'General case' 0 C--N 1.333 -0.12 0 C-N-CA 125.466 1.506 . . . . 0.0 107.789 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -72.29 130.96 42.01 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 49.1 t -141.44 133.55 28.68 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 125.683 1.593 . . . . 0.0 107.323 -173.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -64.79 136.71 57.2 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 122.689 0.395 . . . . 0.0 110.407 172.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.9 mt -112.92 0.74 15.21 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.165 -0.921 . . . . 0.0 111.569 173.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.3 m -54.99 -31.75 61.21 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 121.061 1.755 . . . . 0.0 111.724 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 56.8 mt -67.87 -15.26 63.53 Favored 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 113.642 0.979 . . . . 0.0 113.642 178.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.64 -10.83 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.481 1.112 . . . . 0.0 112.79 -175.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.31 141.02 0.83 Allowed Glycine 0 CA--C 1.529 0.922 0 C-N-CA 125.527 1.537 . . . . 0.0 110.397 -170.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.4 m -76.29 -6.2 50.43 Favored 'General case' 0 CA--C 1.536 0.432 0 O-C-N 121.817 -0.813 . . . . 0.0 112.533 174.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 80.4 m -110.32 147.96 32.87 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 124.139 0.976 . . . . 0.0 109.489 175.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -68.94 171.65 7.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 126.635 1.974 . . . . 0.0 110.564 176.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 21.9 mm-40 -58.25 -15.36 9.79 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.149 1.38 . . . . 0.0 113.505 -177.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -117.96 8.66 12.6 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.529 1.532 . . . . 0.0 112.896 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.73 -2.11 69.47 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-O 118.805 -0.997 . . . . 0.0 114.545 170.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -67.01 154.54 92.28 Favored Pre-proline 0 CA--C 1.537 0.444 0 CA-C-N 119.373 1.586 . . . . 0.0 108.797 169.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -64.84 143.32 79.48 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 CA-C-N 121.18 1.457 . . . . 0.0 109.382 169.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.1 mtt-85 -70.51 10.96 0.4 Allowed 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.966 1.098 . . . . 0.0 113.966 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.9 p -56.44 132.34 20.4 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 O-C-N 120.759 -1.213 . . . . 0.0 109.03 -175.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.7 -15.79 49.74 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 118.097 -1.391 . . . . 0.0 114.076 -178.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -69.05 170.28 10.21 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 120.023 1.912 . . . . 0.0 108.906 169.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -119.66 157.62 28.1 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 177.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.3 p -151.56 136.3 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -171.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 81.0 mt -71.35 145.37 49.47 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 169.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 39.1 t -117.06 143.24 27.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 176.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -139.14 118.84 13.09 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 173.154 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . 0.286 29.4 m 44.45 28.87 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.461 2.304 . . . . 0.0 115.686 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 98.81 10.87 48.55 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 121.188 -0.945 . . . . 0.0 114.392 178.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -125.79 146.62 49.71 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 119.044 1.422 . . . . 0.0 108.484 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.12 114.44 3.12 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.615 0.766 . . . . 0.0 109.523 172.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 12.7 tpt -80.91 -42.71 20.96 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 58.3 m -166.02 147.54 6.88 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.865 1.666 . . . . 0.0 108.328 171.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 96.6 t -75.54 143.56 13.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 169.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 33.7 pt -139.36 162.19 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.028 1.331 . . . . 0.0 109.782 -175.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -74.14 165.22 25.53 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-O 121.48 0.657 . . . . 0.0 110.262 172.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -56.62 -43.2 79.99 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.191 1.396 . . . . 0.0 111.318 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.37 -38.85 85.39 Favored 'General case' 0 C--N 1.338 0.1 0 C-N-CA 122.801 0.44 . . . . 0.0 110.825 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -65.97 -40.36 91.18 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.31 -49.38 74.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 117.939 0.336 . . . . 0.0 110.478 178.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 47.6 mtm105 -61.57 -42.17 98.46 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 119.12 -0.467 . . . . 0.0 110.809 179.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.4 -42.83 99.73 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 118.5 0.591 . . . . 0.0 111.102 177.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.7 m -65.84 -41.31 91.92 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.841 0.456 . . . . 0.0 110.273 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.0 mt -65.23 -40.67 94.36 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.981 0.809 . . . . 0.0 110.426 178.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -64.4 -44.1 92.36 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 118.717 0.689 . . . . 0.0 110.696 177.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.3 -46.03 92.01 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.95 0.5 . . . . 0.0 110.509 176.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.0 mt -61.68 -44.92 96.03 Favored 'General case' 0 C--O 1.227 -0.101 0 CA-C-O 118.771 -0.633 . . . . 0.0 110.758 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -61.71 -39.96 93.33 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 119.065 0.848 . . . . 0.0 110.66 178.027 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 15.8 m-80 -63.84 -37.69 88.31 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 118.261 0.482 . . . . 0.0 110.636 175.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 89.6 mtp -78.18 32.07 0.18 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.096 1.758 . . . . 0.0 111.414 172.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 17.9 p90 46.89 32.45 1.82 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 127.276 2.23 . . . . 0.0 113.754 178.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 26.9 t70 47.51 26.87 0.86 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.411 2.284 . . . . 0.0 113.301 -174.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 1.7 t 54.39 23.85 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.953 0 C-N-CA 126.575 1.95 . . . . 0.0 111.866 -176.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -140.88 71.64 29.13 Favored Pre-proline 0 CA--C 1.534 0.355 0 C-N-CA 125.254 1.421 . . . . 0.0 107.366 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -62.7 -21.91 73.42 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.914 2.41 . . . . 0.0 113.173 -169.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -55.36 -24.17 28.07 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 124.868 1.267 . . . . 0.0 112.802 175.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.9 m -122.51 -34.36 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 C-N-CA 124.064 0.946 . . . . 0.0 110.559 171.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.04 -34.73 80.51 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-O 118.938 -0.923 . . . . 0.0 112.742 -177.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -61.58 -27.14 68.42 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 118.846 1.323 . . . . 0.0 112.275 177.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 60.5 tp -94.12 -44.56 7.95 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 123.867 0.867 . . . . 0.0 110.36 177.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -69.15 -36.23 77.19 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.083 0.553 . . . . 0.0 111.701 -174.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -134.8 -21.09 1.72 Allowed 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 123.992 0.917 . . . . 0.0 112.197 -170.05 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -85.3 -150.93 14.03 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 125.062 1.315 . . . . 0.0 111.694 178.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -119.55 11.09 11.97 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 125.688 1.595 . . . . 0.0 112.116 -169.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -69.04 -22.9 64.01 Favored 'General case' 0 CA--C 1.545 0.753 0 O-C-N 121.414 -0.804 . . . . 0.0 110.599 171.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 60.0 tptt . . . . . 0 C--O 1.249 1.036 0 C-N-CA 124.573 1.149 . . . . 0.0 109.823 175.431 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.6 ttt . . . . . 0 N--CA 1.482 1.172 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 56.2 m -63.11 154.3 31.45 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.941 0.496 . . . . 0.0 110.845 178.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 46.4 pt -134.39 -168.54 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 C-N-CA 126.713 2.005 . . . . 0.0 106.959 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.6 67.25 0.08 OUTLIER Glycine 0 CA--C 1.519 0.315 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 -177.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 9.0 p -148.44 149.95 32.86 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 123.69 0.796 . . . . 0.0 109.121 -169.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.03 168.58 16.95 Favored 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 122.549 2.166 . . . . 0.0 111.882 169.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.66 172.9 41.27 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.621 2.057 . . . . 0.0 108.621 170.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -116.71 129.58 56.21 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 118.216 1.008 . . . . 0.0 108.982 -177.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 63.8 mt -70.27 127.63 32.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 -178.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -120.99 -29.65 4.54 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 118.247 -0.882 . . . . 0.0 112.448 -170.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.6 155.32 40.09 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.0 mt -132.37 124.81 52.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 N-CA-C 106.642 -1.614 . . . . 0.0 106.642 -177.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -86.89 -32.24 20.3 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.506 0.722 . . . . 0.0 110.4 172.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.58 -114.03 0.58 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 107.69 -2.164 . . . . 0.0 107.69 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -67.22 -0.66 3.6 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.287 1.035 . . . . 0.0 112.997 172.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -135.95 155.57 50.08 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 125.632 1.573 . . . . 0.0 107.438 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.23 151.69 38.8 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.321 1.048 . . . . 0.0 110.04 -171.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.0 tttt -90.85 133.1 35.49 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.23 130.49 72.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 -174.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -82.31 110.0 17.08 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 169.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.5 t -84.4 64.86 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 178.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.6 m 52.76 29.43 7.51 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.615 1.966 . . . . 0.0 114.94 171.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 158.27 -23.67 0.37 Allowed Glycine 0 CA--C 1.525 0.675 0 CA-C-N 119.121 0.873 . . . . 0.0 113.584 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.7 tp -146.45 149.63 15.86 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -88.51 150.27 23.2 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.983 0.42 . . . . 0.0 110.236 -175.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -139.5 150.08 44.71 Favored 'General case' 0 N--CA 1.464 0.227 0 C-N-CA 124.566 1.146 . . . . 0.0 108.703 169.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.54 138.83 35.38 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 169.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 50.5 t -136.38 131.88 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -173.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.34 138.64 37.77 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.468 0.707 . . . . 0.0 109.71 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.99 10.83 16.35 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.946 0.898 . . . . 0.0 112.211 -171.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.9 m -53.1 -34.07 55.03 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 120.265 1.393 . . . . 0.0 111.991 -177.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 85.2 mt -73.38 -12.93 60.99 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.769 0.827 . . . . 0.0 113.136 -176.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.36 -20.3 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 119.516 1.053 . . . . 0.0 113.188 -169.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.54 146.32 6.03 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 124.334 0.968 . . . . 0.0 111.457 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.1 p -74.41 -6.71 49.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.949 1.7 . . . . 0.0 113.581 -176.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.8 m -135.49 157.14 47.64 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 125.385 1.474 . . . . 0.0 108.177 171.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -66.07 165.11 14.06 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.079 1.352 . . . . 0.0 110.451 169.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -53.95 -38.33 64.84 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.935 1.294 . . . . 0.0 111.657 176.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -87.06 11.83 12.83 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.861 0.865 . . . . 0.0 111.85 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.98 6.97 88.48 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 124.583 1.087 . . . . 0.0 113.492 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -67.71 134.2 92.45 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 118.588 1.194 . . . . 0.0 108.206 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.27 143.29 53.62 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.531 2.154 . . . . 0.0 111.44 171.633 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -69.7 -17.79 63.5 Favored 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 118.043 -0.98 . . . . 0.0 112.836 175.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -55.32 134.82 18.72 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 120.297 1.408 . . . . 0.0 109.125 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.02 -21.27 20.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 124.561 1.077 . . . . 0.0 112.735 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -71.87 159.64 33.94 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 119.09 1.445 . . . . 0.0 108.162 171.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -106.7 158.41 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.67 139.52 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -169.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -83.18 133.08 35.04 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 169.686 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.2 t -121.44 135.76 60.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 4.7 t60 -137.12 -48.38 0.6 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.269 0.628 . . . . 0.0 111.108 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.4 m -136.3 27.63 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 123.75 0.82 . . . . 0.0 111.205 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.12 15.53 78.56 Favored Glycine 0 CA--C 1.531 1.068 0 O-C-N 121.531 -0.73 . . . . 0.0 112.464 -174.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -126.39 147.8 49.71 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 125.578 1.551 . . . . 0.0 107.095 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.44 105.18 1.4 Allowed 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.379 1.071 . . . . 0.0 108.257 172.009 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.4 ttt -70.6 -46.17 63.91 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 24.6 m -152.53 158.69 42.89 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.136 1.774 . . . . 0.0 107.445 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 44.1 t -121.0 140.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 174.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.0 pt -141.66 161.93 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 C-N-CA 125.712 1.605 . . . . 0.0 110.081 -171.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -74.66 168.34 20.0 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.669 0.788 . . . . 0.0 110.507 171.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -63.1 -42.29 99.55 Favored 'General case' 0 C--O 1.227 -0.09 0 CA-C-O 119.167 -0.444 . . . . 0.0 111.963 -173.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.83 -41.41 87.49 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.499 0.59 . . . . 0.0 110.315 -173.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.59 -36.43 82.7 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 122.578 0.351 . . . . 0.0 110.49 173.403 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.88 -40.57 83.54 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-N 119.05 0.841 . . . . 0.0 111.507 176.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 10.0 mmt85 -66.59 -38.83 87.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 119.291 0.95 . . . . 0.0 109.513 178.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.48 -42.71 99.68 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 118.015 0.371 . . . . 0.0 110.919 174.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.6 m -62.06 -40.87 97.24 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.34 0.656 . . . . 0.0 110.417 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 21.4 mt -63.86 -39.15 93.54 Favored 'General case' 0 C--N 1.338 0.073 0 O-C-N 121.668 -0.645 . . . . 0.0 110.943 178.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -68.2 -44.33 76.06 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.383 0.992 . . . . 0.0 110.677 175.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.53 -31.41 70.49 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.247 1.019 . . . . 0.0 111.821 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 62.3 tp -78.79 -59.64 2.7 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 123.558 0.743 . . . . 0.0 110.339 174.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -55.55 -40.97 72.59 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 118.437 -0.792 . . . . 0.0 112.866 -169.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -61.65 -10.76 9.15 Favored 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 -177.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -131.1 11.94 5.09 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 124.458 1.103 . . . . 0.0 112.379 175.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -137.67 -44.88 0.54 Allowed 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 123.786 0.835 . . . . 0.0 111.575 -171.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -67.63 -31.14 70.95 Favored 'General case' 0 N--CA 1.468 0.434 0 O-C-N 121.407 -0.808 . . . . 0.0 110.498 174.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 23.8 m -71.21 -2.93 3.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.694 0 C-N-CA 125.39 1.476 . . . . 0.0 112.678 172.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 81.9 mm-40 -130.96 67.98 81.42 Favored Pre-proline 0 CA--C 1.538 0.491 0 C-N-CA 125.37 1.468 . . . . 0.0 107.748 178.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -63.15 -20.91 72.11 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.718 2.278 . . . . 0.0 113.644 -169.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -65.91 -41.87 90.9 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 119.121 0.873 . . . . 0.0 110.986 171.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 34.2 t -69.67 -34.74 62.56 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 174.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -54.86 -54.36 33.89 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 170.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -62.5 -37.2 85.07 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 117.735 0.767 . . . . 0.0 111.593 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -65.35 -57.63 7.9 Favored 'General case' 0 N--CA 1.456 -0.155 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -85.59 -64.03 1.22 Allowed 'General case' 0 N--CA 1.457 -0.095 0 CA-C-N 118.1 0.409 . . . . 0.0 110.448 -169.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -70.02 -37.87 75.76 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.132 0.424 . . . . 0.0 110.417 -175.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.64 -5.09 82.7 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-O 118.55 -1.139 . . . . 0.0 112.701 176.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 49.81 47.0 23.63 Favored 'General case' 0 CA--C 1.543 0.702 0 CA-C-N 119.002 1.401 . . . . 0.0 110.842 -178.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 66.44 7.05 4.72 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 127.479 2.312 . . . . 0.0 113.677 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 29.6 mtpp . . . . . 0 C--O 1.25 1.095 0 C-N-CA 127.381 2.272 . . . . 0.0 111.111 -179.47 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 55.0 tpp . . . . . 0 N--CA 1.483 1.191 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 17.8 p -150.62 172.86 14.85 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 125.146 1.378 . . . . 0.0 109.074 178.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.9 tt -150.8 150.15 13.67 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 176.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.39 54.79 0.26 Allowed Glycine 0 CA--C 1.529 0.92 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 -175.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.1 t -139.24 143.41 36.28 Favored Pre-proline 0 CA--C 1.543 0.688 0 C-N-CA 124.296 1.038 . . . . 0.0 109.007 -169.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.25 155.62 24.0 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.632 2.221 . . . . 0.0 112.301 169.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.12 170.66 39.44 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 169.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.1 tt0 -116.3 125.25 51.88 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 123.982 0.913 . . . . 0.0 108.836 -174.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.03 129.33 27.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -114.42 -33.93 5.43 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 118.058 -0.972 . . . . 0.0 111.663 -176.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.4 p -148.15 157.25 43.39 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 47.1 mt -132.51 144.14 37.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -123.15 -19.29 6.07 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.364 1.066 . . . . 0.0 111.875 -176.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.46 -127.18 1.53 Allowed Glycine 0 C--N 1.336 0.562 0 N-CA-C 106.815 -2.514 . . . . 0.0 106.815 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -63.92 -10.23 19.86 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 117.514 0.657 . . . . 0.0 112.365 169.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -119.92 159.2 25.14 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.523 1.129 . . . . 0.0 110.509 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.48 167.72 27.11 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 125.746 1.618 . . . . 0.0 109.544 -172.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.33 132.28 54.52 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 171.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 52.7 t -126.35 123.78 64.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -174.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -72.81 111.13 7.67 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.2 63.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.9 m 47.18 42.47 13.31 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.885 2.074 . . . . 0.0 114.026 175.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.55 -31.17 0.19 Allowed Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.169 174.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -152.41 151.45 11.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 177.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -73.14 137.5 45.19 Favored 'General case' 0 C--O 1.234 0.266 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -122.53 148.26 45.4 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 124.595 1.158 . . . . 0.0 108.188 169.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -72.82 134.71 45.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 123.82 0.848 . . . . 0.0 108.983 172.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -140.5 157.28 24.21 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 C-N-CA 124.787 1.235 . . . . 0.0 108.096 -176.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -112.61 142.58 45.03 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 125.415 1.486 . . . . 0.0 108.815 172.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.9 mt -113.3 7.59 17.78 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.284 1.034 . . . . 0.0 112.328 -169.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 28.9 p -57.55 -29.15 64.16 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.599 1.545 . . . . 0.0 113.124 -173.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -70.53 -16.36 62.88 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.691 0.797 . . . . 0.0 112.534 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 24.2 m -130.0 -12.63 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 C-N-CA 124.606 1.162 . . . . 0.0 112.312 -173.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.62 141.34 1.19 Allowed Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.993 1.282 . . . . 0.0 109.939 -170.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -73.15 -10.58 59.92 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -178.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.4 m -121.36 145.62 47.71 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.229 1.012 . . . . 0.0 109.238 177.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -69.81 157.55 37.14 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.227 1.411 . . . . 0.0 109.894 172.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -51.54 -35.07 39.26 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 125.128 1.371 . . . . 0.0 112.139 176.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -70.45 -8.86 54.2 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.746 0.818 . . . . 0.0 112.417 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.43 25.04 10.42 Favored Glycine 0 CA--C 1.53 1.019 0 CA-C-N 119.6 1.091 . . . . 0.0 113.946 170.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -125.92 149.21 65.36 Favored Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 118.775 1.287 . . . . 0.0 108.26 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.77 143.91 36.59 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 122.966 2.444 . . . . 0.0 111.272 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.1 mtt-85 -70.61 18.79 0.05 Allowed 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 114.421 1.267 . . . . 0.0 114.421 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.2 m -56.55 136.32 19.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 O-C-N 120.394 -1.441 . . . . 0.0 109.547 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.11 -14.64 43.14 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 118.373 -1.237 . . . . 0.0 113.586 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -75.23 152.05 38.36 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 120.134 1.967 . . . . 0.0 109.184 176.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -95.07 150.28 20.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 174.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.2 m -142.2 153.5 18.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 124.663 1.185 . . . . 0.0 109.04 -178.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -85.37 107.09 17.2 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 169.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.0 t -78.02 120.87 29.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -134.62 120.09 19.16 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.0 t 49.58 33.61 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 C-N-CA 125.146 1.378 . . . . 0.0 112.105 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.96 6.94 78.59 Favored Glycine 0 CA--C 1.531 1.094 0 O-C-N 121.029 -1.044 . . . . 0.0 114.054 176.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -119.99 146.03 46.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-N 119.339 1.57 . . . . 0.0 109.055 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.5 104.83 6.23 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 41.0 tpp -68.2 -46.28 71.05 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.72 0.408 . . . . 0.0 110.704 -174.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.2 m -152.02 165.75 33.71 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 125.953 1.701 . . . . 0.0 107.98 -178.568 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 6.5 t -111.38 141.34 27.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.049 1.34 . . . . 0.0 107.742 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 35.8 pt -140.81 165.86 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.767 1.227 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.1 m-80 -80.39 165.48 22.2 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 124.582 1.153 . . . . 0.0 109.889 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -64.65 -32.41 74.06 Favored 'General case' 0 N--CA 1.468 0.425 0 O-C-N 121.763 -0.586 . . . . 0.0 111.505 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.54 -43.11 77.39 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.432 -0.793 . . . . 0.0 110.429 177.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -65.08 -39.32 93.03 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.314 0.646 . . . . 0.0 109.646 178.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.98 -49.55 74.26 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.17 -0.331 . . . . 0.0 110.364 177.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -62.53 -40.01 95.42 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 119.103 -0.475 . . . . 0.0 111.008 179.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -61.48 -43.77 98.28 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 118.494 0.588 . . . . 0.0 110.898 175.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -66.79 -40.49 88.16 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.075 0.55 . . . . 0.0 110.643 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 41.7 mt -63.06 -35.66 81.0 Favored 'General case' 0 C--N 1.338 0.101 0 C-N-CA 124.066 0.946 . . . . 0.0 110.759 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -70.06 -48.89 55.97 Favored 'General case' 0 C--O 1.226 -0.132 0 CA-C-N 118.492 0.587 . . . . 0.0 109.905 171.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.08 -40.49 85.4 Favored 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.617 0.767 . . . . 0.0 111.744 -171.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.0 pp -69.83 -10.56 58.89 Favored 'General case' 0 CA--C 1.537 0.473 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -114.9 -19.0 11.15 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.352 1.461 . . . . 0.0 111.093 178.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -55.73 -31.92 62.93 Favored 'General case' 0 CA--C 1.528 0.105 0 C-N-CA 125.848 1.659 . . . . 0.0 112.823 -169.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 96.7 mtp -58.38 -22.02 52.36 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.798 0.839 . . . . 0.0 112.887 177.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -60.67 -22.27 63.7 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-N 119.159 0.89 . . . . 0.0 111.686 174.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -59.18 -22.88 61.66 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.96 0.904 . . . . 0.0 112.581 174.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 34.8 t -76.66 -22.92 15.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.751 0 C-N-CA 123.929 0.892 . . . . 0.0 110.577 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -71.28 150.48 94.31 Favored Pre-proline 0 CA--C 1.539 0.548 0 O-C-N 121.245 -0.91 . . . . 0.0 109.387 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -70.08 -16.69 36.3 Favored 'Trans proline' 0 CA--C 1.535 0.556 0 C-N-CA 122.388 2.058 . . . . 0.0 113.01 -178.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -57.88 -38.06 75.1 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 123.851 0.86 . . . . 0.0 112.578 -174.103 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.5 m -65.09 -17.59 22.19 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 CA-C-N 117.99 0.359 . . . . 0.0 111.966 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -56.93 -32.94 62.9 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 119.292 -0.727 . . . . 0.0 111.871 174.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -63.81 -25.27 68.1 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 118.487 1.144 . . . . 0.0 112.367 177.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.0 tp -91.79 -46.86 7.66 Favored 'General case' 0 CA--C 1.527 0.076 0 C-N-CA 123.581 0.753 . . . . 0.0 109.908 174.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 44.9 tp -68.41 -47.23 67.83 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 123.053 0.541 . . . . 0.0 111.42 -172.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 57.4 m-85 -114.96 -25.06 8.32 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.184 0.994 . . . . 0.0 111.494 -175.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -79.5 -162.18 23.81 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 124.435 1.017 . . . . 0.0 111.392 173.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -121.02 20.97 11.46 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.603 1.161 . . . . 0.0 111.104 -169.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 39.3 mm-40 -71.65 -0.47 10.87 Favored 'General case' 0 CA--C 1.548 0.888 0 O-C-N 121.2 -0.938 . . . . 0.0 112.025 170.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 57.0 mttp . . . . . 0 C--O 1.249 1.036 0 C-N-CA 126.259 1.824 . . . . 0.0 110.288 173.023 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.1 ttt . . . . . 0 N--CA 1.485 1.275 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.2 m -70.46 -41.92 72.16 Favored 'General case' 0 CA--C 1.535 0.378 0 O-C-N 121.7 -0.625 . . . . 0.0 111.66 -174.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.5 pt -145.96 155.12 12.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 126.282 1.833 . . . . 0.0 106.871 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.68 44.39 0.08 OUTLIER Glycine 0 CA--C 1.525 0.717 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 -177.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.9 m -146.89 168.18 12.01 Favored Pre-proline 0 CA--C 1.543 0.69 0 C-N-CA 125.462 1.505 . . . . 0.0 110.108 -168.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -57.37 162.73 9.43 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.052 2.501 . . . . 0.0 113.37 169.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.86 176.75 41.22 Favored Glycine 0 CA--C 1.526 0.729 0 C-N-CA 125.978 1.752 . . . . 0.0 109.666 170.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.9 tt0 -116.86 136.92 52.58 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 45.6 mt -72.89 71.29 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -68.69 -33.52 74.1 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.156 0.982 . . . . 0.0 111.647 -169.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.3 156.06 43.09 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 174.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt -128.66 146.7 33.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 N-CA-C 106.471 -1.678 . . . . 0.0 106.471 178.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -117.14 -27.27 6.54 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 123.918 0.887 . . . . 0.0 111.415 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.5 -123.17 1.08 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -62.71 -23.52 67.2 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.292 0.637 . . . . 0.0 111.848 169.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 25.2 mm100 -99.04 155.28 17.52 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.022 0.929 . . . . 0.0 109.278 169.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.11 163.13 33.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.014 1.326 . . . . 0.0 109.538 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -110.46 77.72 1.07 Allowed 'General case' 0 C--O 1.234 0.252 0 N-CA-C 105.688 -1.968 . . . . 0.0 105.688 -175.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.0 t -70.85 127.74 33.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -177.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -74.83 107.61 7.03 Favored 'General case' 0 CA--C 1.52 -0.187 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 168.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -84.26 58.09 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -178.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.0 m 45.57 44.6 10.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.274 2.23 . . . . 0.0 113.208 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.26 -38.65 0.14 Allowed Glycine 0 CA--C 1.525 0.713 0 CA-C-O 119.478 -0.624 . . . . 0.0 112.708 176.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.6 tp -153.09 153.79 8.49 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 58.6 mt-30 -73.63 138.04 44.58 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -127.0 144.89 50.9 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 125.608 1.563 . . . . 0.0 107.151 172.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -75.01 131.19 40.45 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 72.9 t -140.16 138.77 37.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 125.126 1.37 . . . . 0.0 107.933 -171.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -80.72 130.64 35.2 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.778 1.631 . . . . 0.0 109.264 175.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.0 mt -105.46 6.66 32.63 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.676 0.79 . . . . 0.0 112.989 -176.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 7.5 m -55.61 -32.67 63.31 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.807 1.64 . . . . 0.0 112.853 -171.527 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.02 -13.95 62.17 Favored 'General case' 0 CA--C 1.538 0.493 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -178.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.33 -15.55 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.372 1.069 . . . . 0.0 112.581 -174.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.91 143.88 1.31 Allowed Glycine 0 CA--C 1.528 0.871 0 C-N-CA 125.394 1.474 . . . . 0.0 110.683 -173.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 m -76.62 -7.32 55.02 Favored 'General case' 0 CA--C 1.536 0.415 0 O-C-N 121.944 -0.739 . . . . 0.0 112.871 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.9 m -114.71 139.57 49.57 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.072 0.949 . . . . 0.0 109.676 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -75.56 155.76 35.7 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 126.809 2.044 . . . . 0.0 109.733 170.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -58.04 -25.96 61.85 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.034 1.334 . . . . 0.0 112.883 -173.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 -71.56 -6.97 44.66 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 121.506 -0.746 . . . . 0.0 112.525 178.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.13 47.44 5.24 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -142.44 153.51 62.49 Favored Pre-proline 0 CA--C 1.535 0.392 0 C-N-CA 125.724 1.61 . . . . 0.0 107.577 -178.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.51 147.23 76.53 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 C-N-CA 121.645 1.563 . . . . 0.0 109.687 174.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -70.88 17.96 0.07 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -175.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.4 t -56.53 126.2 13.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 O-C-N 120.848 -1.157 . . . . 0.0 108.599 -174.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.63 -13.59 66.25 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.324 -1.265 . . . . 0.0 113.632 176.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 80.1 mt-30 -68.04 154.58 41.34 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 119.566 1.683 . . . . 0.0 109.106 174.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.9 m95 -96.19 160.7 14.3 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.53 156.7 4.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -169.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 96.0 mt -101.68 133.0 47.06 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 169.158 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.9 m -128.3 139.07 52.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 118.853 0.751 . . . . 0.0 109.113 -177.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.6 t-80 -142.48 132.77 24.82 Favored 'General case' 0 C--O 1.232 0.132 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 -176.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 36.2 t 59.77 -61.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 128.146 2.579 . . . . 0.0 112.79 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -174.37 21.04 0.06 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.182 1.849 . . . . 0.0 111.596 179.245 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -132.38 141.86 49.07 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 118.78 1.29 . . . . 0.0 108.69 -172.718 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.26 124.03 24.88 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 169.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 90.4 mmm -90.86 -49.16 6.6 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 123.148 0.579 . . . . 0.0 109.966 -178.017 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.3 m -149.52 140.85 23.21 Favored 'General case' 0 C--N 1.339 0.145 0 C-N-CA 124.271 1.029 . . . . 0.0 108.775 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 84.0 t -81.78 142.93 13.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 169.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.1 pt -139.58 162.78 26.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 C-N-CA 124.885 1.274 . . . . 0.0 109.647 -173.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -79.67 163.79 24.27 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.658 0.742 . . . . 0.0 110.53 175.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -55.89 -39.35 71.43 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 126.26 1.824 . . . . 0.0 111.729 175.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.59 -50.06 34.51 Favored 'General case' 0 C--N 1.338 0.091 0 O-C-N 121.864 -0.523 . . . . 0.0 110.253 -173.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -72.35 -27.48 62.43 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 119.296 -0.383 . . . . 0.0 110.73 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.29 -52.04 66.98 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.877 0.762 . . . . 0.0 110.056 170.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.8 mtm180 -64.43 -37.64 88.22 Favored 'General case' 0 N--CA 1.46 0.054 0 CA-C-O 118.859 -0.591 . . . . 0.0 110.93 179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -62.65 -40.63 97.64 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 118.971 0.805 . . . . 0.0 111.176 175.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.8 m -65.39 -40.98 94.12 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.978 -0.452 . . . . 0.0 110.035 176.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.4 mt -65.07 -38.34 90.48 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.349 -0.845 . . . . 0.0 110.762 176.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -66.28 -39.11 89.19 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.624 0.647 . . . . 0.0 110.906 177.113 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.09 -50.46 71.85 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.463 0.705 . . . . 0.0 110.404 173.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.2 mt -59.98 -20.3 56.93 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.386 1.074 . . . . 0.0 112.6 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 -93.33 -66.21 0.94 Allowed 'General case' 0 N--CA 1.454 -0.255 0 CA-C-N 118.66 0.664 . . . . 0.0 109.724 174.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -64.24 -29.35 70.45 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 114.028 1.121 . . . . 0.0 114.028 -169.101 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.3 mtp -78.81 -3.89 46.73 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 119.126 0.875 . . . . 0.0 112.185 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -132.0 -23.59 2.21 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.987 0.915 . . . . 0.0 111.934 -172.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -59.9 -16.99 33.8 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 125.497 1.519 . . . . 0.0 112.796 172.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.2 m -61.16 -11.18 4.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 125.117 1.367 . . . . 0.0 112.813 170.015 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -131.69 154.17 81.72 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 125.399 1.479 . . . . 0.0 108.824 176.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.43 -6.0 18.06 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 122.998 2.465 . . . . 0.0 113.446 -176.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -57.76 -42.39 83.91 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 119.129 0.877 . . . . 0.0 112.259 -175.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 27.5 m -71.7 -29.64 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 118.101 0.41 . . . . 0.0 111.097 176.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -61.49 -46.67 93.86 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 173.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.34 -8.1 43.24 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 124.768 1.227 . . . . 0.0 113.5 176.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 57.6 tp -98.18 -42.41 7.45 Favored 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 119.15 0.886 . . . . 0.0 109.905 174.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 60.7 tp -68.09 -39.95 82.74 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.763 0.825 . . . . 0.0 109.984 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -152.12 -158.95 0.95 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 126.379 1.872 . . . . 0.0 106.577 -173.102 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 76.82 -66.98 2.71 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 124.576 1.084 . . . . 0.0 112.666 169.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -138.3 -18.94 1.12 Allowed 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 125.726 1.61 . . . . 0.0 111.43 -176.534 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 46.17 62.59 2.2 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.734 1.614 . . . . 0.0 110.794 -170.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt . . . . . 0 C--O 1.249 1.056 0 C-N-CA 123.998 0.919 . . . . 0.0 111.357 -177.489 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.5 mmt . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 55.5 m -74.55 155.94 37.37 Favored 'General case' 0 CA--C 1.533 0.32 0 O-C-N 121.935 -0.478 . . . . 0.0 109.722 169.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . 0.25 48.4 pt 40.26 45.58 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 126.663 1.985 . . . . 0.0 113.292 175.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.94 69.39 3.08 Favored Glycine 0 CA--C 1.525 0.709 0 C-N-CA 125.007 1.289 . . . . 0.0 110.08 179.489 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.0 t -140.21 139.3 20.68 Favored Pre-proline 0 CA--C 1.54 0.565 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -169.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -76.65 168.98 22.67 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.384 2.056 . . . . 0.0 111.83 173.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -171.02 -174.9 39.18 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 173.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 57.7 tt0 -116.67 131.15 57.02 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 123.659 0.784 . . . . 0.0 108.99 -176.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 89.7 mt -67.06 122.65 18.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 mtm105 -119.62 -10.15 9.66 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 177.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -152.55 151.55 30.81 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 172.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.9 mt -133.19 140.24 47.52 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 172.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -108.01 -23.97 11.79 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.471 1.108 . . . . 0.0 112.438 -174.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.83 -62.37 0.15 Allowed Glycine 0 C--N 1.338 0.666 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 175.24 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -144.42 27.92 1.36 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.912 1.339 . . . . 0.0 110.381 169.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -137.62 156.2 48.33 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 169.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -144.25 166.54 24.75 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 123.867 0.867 . . . . 0.0 110.001 -170.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -117.38 84.35 2.14 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.22 131.08 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -83.24 109.72 17.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 169.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.8 t -85.35 62.23 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -175.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 56.5 m 48.77 40.7 16.72 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.329 1.852 . . . . 0.0 113.161 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 172.17 -49.0 0.18 Allowed Glycine 0 CA--C 1.525 0.658 0 CA-C-O 119.304 -0.72 . . . . 0.0 112.126 173.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.1 mm -138.0 145.59 28.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 -173.216 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -73.74 145.72 44.9 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.288 0.566 . . . . 0.0 111.307 175.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -133.84 139.68 46.4 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 125.481 1.512 . . . . 0.0 107.804 170.309 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -71.56 136.2 47.37 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.89 155.17 17.46 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 125.396 1.478 . . . . 0.0 109.162 177.003 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -98.07 141.53 30.9 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 124.636 1.175 . . . . 0.0 110.223 -177.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.7 mp -117.23 15.41 14.9 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.828 1.251 . . . . 0.0 111.871 -170.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.4 p -53.22 -33.65 53.75 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 119.966 1.257 . . . . 0.0 112.267 176.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -77.78 -12.05 59.94 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 123.848 0.859 . . . . 0.0 112.986 -174.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.07 -17.05 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.699 1.136 . . . . 0.0 113.364 -171.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.98 148.95 4.5 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -176.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 m -74.09 -14.22 60.95 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 124.244 1.018 . . . . 0.0 113.23 -174.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -126.19 143.67 51.05 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.975 0.91 . . . . 0.0 109.902 -171.256 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -70.8 155.7 40.45 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 126.463 1.905 . . . . 0.0 109.954 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -58.57 -25.75 62.88 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.638 1.175 . . . . 0.0 112.531 -175.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -61.98 -22.74 65.92 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.74 0.816 . . . . 0.0 112.924 175.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.18 47.38 3.09 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -174.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -142.14 151.26 58.28 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 125.819 1.648 . . . . 0.0 107.488 -178.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -65.72 148.46 86.83 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.882 1.721 . . . . 0.0 109.879 176.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -70.78 16.65 0.08 Allowed 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 -176.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 98.6 t -60.66 133.44 26.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 O-C-N 120.565 -1.334 . . . . 0.0 107.878 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.92 -15.2 56.46 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.303 -1.276 . . . . 0.0 113.064 -178.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 67.9 mt-30 -71.88 149.57 45.04 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 119.818 1.809 . . . . 0.0 108.907 175.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.7 m95 -85.15 152.4 23.4 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 170.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.7 p -146.46 138.42 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 62.9 tp -89.0 128.76 35.71 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 169.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.8 m -124.83 151.34 30.29 Favored 'Isoleucine or valine' 0 C--O 1.235 0.324 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -142.57 148.47 37.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 104.958 -2.238 . . . . 0.0 104.958 169.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.7 m 44.81 28.51 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 126.097 1.759 . . . . 0.0 115.368 171.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.48 14.03 64.4 Favored Glycine 0 CA--C 1.531 1.074 0 CA-C-O 118.472 -1.182 . . . . 0.0 113.857 176.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -129.13 144.11 51.09 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 119.818 1.809 . . . . 0.0 109.692 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.54 112.37 4.66 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 169.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.4 mmt -91.15 -34.89 14.85 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 119.094 -0.479 . . . . 0.0 111.114 -178.213 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 70.7 m -155.58 144.46 20.59 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 119.276 0.944 . . . . 0.0 109.283 169.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 48.3 t -79.99 140.37 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 169.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.2 pt -135.07 -175.2 1.3 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 C-N-CA 124.156 0.982 . . . . 0.0 108.865 -173.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -131.18 176.58 8.15 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.763 1.225 . . . . 0.0 108.597 178.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 68.4 mm-40 -52.78 -47.78 67.28 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 125.895 1.678 . . . . 0.0 110.908 -171.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -69.47 -40.86 76.86 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.673 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -66.19 -37.8 86.46 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 123.033 0.533 . . . . 0.0 109.568 176.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.94 -45.11 94.03 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 118.513 -0.755 . . . . 0.0 110.37 175.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 28.9 mmt-85 -63.92 -42.43 97.4 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.691 1.132 . . . . 0.0 110.6 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.16 -43.1 99.58 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.513 0.597 . . . . 0.0 110.948 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.7 m -68.18 -37.3 80.79 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 122.75 0.42 . . . . 0.0 110.432 178.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 54.8 mt -67.29 -33.42 75.25 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.122 -0.986 . . . . 0.0 110.658 176.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -67.04 -35.78 80.62 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.842 0.746 . . . . 0.0 111.457 174.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.04 -46.32 81.73 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 121.915 -0.49 . . . . 0.0 109.893 169.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -59.0 -43.54 91.52 Favored 'General case' 0 C--N 1.338 0.073 0 C-N-CA 123.629 0.772 . . . . 0.0 110.725 -176.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 24.2 pt20 -68.46 6.58 0.77 Allowed 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -137.05 12.81 3.09 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.85 1.26 . . . . 0.0 111.004 169.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 26.0 ttt -134.52 -9.34 2.49 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.499 1.52 . . . . 0.0 111.755 -178.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.8 -18.54 13.21 Favored 'General case' 0 CA--C 1.536 0.418 0 O-C-N 120.803 -1.186 . . . . 0.0 112.807 169.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -55.29 -20.8 12.33 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.153 1.781 . . . . 0.0 112.64 169.45 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.6 t -106.65 -11.95 10.18 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 C-N-CA 125.559 1.544 . . . . 0.0 110.312 -176.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -76.13 122.78 87.5 Favored Pre-proline 0 CA--C 1.536 0.43 0 O-C-N 120.837 -1.164 . . . . 0.0 109.262 -176.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -73.39 -15.04 25.21 Favored 'Trans proline' 0 CA--C 1.536 0.585 0 C-N-CA 122.455 2.103 . . . . 0.0 112.527 -177.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -77.11 69.14 3.35 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 124.541 1.137 . . . . 0.0 109.693 175.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.285 26.0 m 51.71 -6.08 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 129.999 3.32 . . . . 0.0 117.095 -176.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -58.28 -42.87 95.71 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-N 120.965 1.711 . . . . 0.0 111.057 175.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -57.02 -31.16 64.85 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.187 0.995 . . . . 0.0 112.59 176.037 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 58.4 tp -80.0 -59.29 2.78 Favored 'General case' 0 C--N 1.338 0.092 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 98.9 mt -61.61 -26.16 67.81 Favored 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 125.058 1.343 . . . . 0.0 112.969 -169.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 -129.91 19.9 5.5 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.367 1.067 . . . . 0.0 111.029 -172.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -153.27 -73.3 0.01 OUTLIER Glycine 0 C--N 1.341 0.806 0 CA-C-N 118.418 0.554 . . . . 0.0 111.903 177.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -69.85 -24.68 63.48 Favored 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 117.632 0.716 . . . . 0.0 111.762 -170.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -135.61 57.06 1.81 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.244 1.418 . . . . 0.0 108.215 177.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 60.0 tptt . . . . . 0 C--O 1.25 1.09 0 C-N-CA 125.452 1.501 . . . . 0.0 107.591 177.677 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.8 tpt . . . . . 0 N--CA 1.483 1.188 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 85.5 m -140.45 175.37 9.66 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 126.628 1.971 . . . . 0.0 106.758 173.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.5 pp -129.89 -171.61 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 169.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.51 61.19 0.25 Allowed Glycine 0 CA--C 1.52 0.388 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.031 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.8 t -140.32 137.41 17.79 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 -169.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.88 174.42 11.93 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.129 1.886 . . . . 0.0 111.56 174.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.11 -177.52 27.61 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 124.405 1.003 . . . . 0.0 111.065 172.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.7 tt0 -116.77 142.29 47.11 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 173.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 59.6 mt -74.58 85.05 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.1 tpp180 -71.48 -37.14 71.34 Favored 'General case' 0 CA--C 1.527 0.081 0 C-N-CA 124.882 1.273 . . . . 0.0 109.932 -172.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -157.83 144.61 17.91 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.645 1.578 . . . . 0.0 107.224 -175.04 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 61.4 mt -110.23 149.44 13.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -132.97 -0.19 3.41 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.668 1.187 . . . . 0.0 112.435 -169.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.439 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 146.83 -128.1 2.9 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 106.931 -2.468 . . . . 0.0 106.931 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 15.9 t30 -72.51 12.75 0.43 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.79 0.836 . . . . 0.0 110.96 169.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.439 ' H ' ' C ' ' A' ' 14' ' ' GLY . 36.7 mt-30 -140.44 161.68 37.13 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.505 2.322 . . . . 0.0 107.278 -169.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.78 153.41 42.37 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 176.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -104.62 69.6 0.9 Allowed 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 105.884 -1.895 . . . . 0.0 105.884 178.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.7 m -69.21 138.85 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 -171.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -81.2 102.89 10.63 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.09 62.76 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 C-N-CA 125.637 1.575 . . . . 0.0 108.519 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.8 m 43.76 42.49 4.39 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 127.285 2.234 . . . . 0.0 113.23 -179.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.69 -34.7 0.21 Allowed Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.037 -0.868 . . . . 0.0 113.535 177.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.4 tt -150.33 149.36 14.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 118.627 1.213 . . . . 0.0 108.753 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -76.77 135.43 38.98 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 176.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -137.88 137.19 37.83 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 124.4 1.08 . . . . 0.0 108.227 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.51 137.3 54.28 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 122.744 0.417 . . . . 0.0 110.032 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 m -140.81 145.54 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 124.826 1.25 . . . . 0.0 107.955 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -83.49 144.63 29.42 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 5.5 mp -110.36 10.44 23.45 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.029 -0.986 . . . . 0.0 113.207 -169.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.2 m -52.04 -32.18 33.28 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 121.006 1.73 . . . . 0.0 112.809 -177.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.4 mt -68.55 -15.85 63.67 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.38 -18.5 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 124.2 1.0 . . . . 0.0 112.913 -173.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.37 149.74 1.82 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.965 1.269 . . . . 0.0 110.694 -169.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 19.0 m -74.81 -5.1 41.62 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 121.806 -0.82 . . . . 0.0 112.952 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.7 m -126.56 157.68 38.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 124.443 1.097 . . . . 0.0 110.026 178.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -54.57 -53.4 55.08 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 126.756 2.022 . . . . 0.0 112.931 -171.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 176.07 -48.11 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 128.766 2.826 . . . . 0.0 106.793 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -79.71 -40.71 28.34 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.414 1.086 . . . . 0.0 111.144 -178.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 148.18 6.56 0.25 Allowed Glycine 0 CA--C 1.531 1.052 0 CA-C-O 118.7 -1.056 . . . . 0.0 114.089 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 mt-30 -76.99 124.18 87.4 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 119.352 1.576 . . . . 0.0 107.195 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.49 139.69 65.38 Favored 'Trans proline' 0 CA--C 1.534 0.482 0 C-N-CA 122.39 2.06 . . . . 0.0 111.142 174.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.7 mtt-85 -71.2 6.39 1.7 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -177.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.1 t -51.88 129.08 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 120.121 1.328 . . . . 0.0 109.113 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.93 -19.29 54.76 Favored Glycine 0 CA--C 1.53 1.002 0 C-N-CA 124.781 1.181 . . . . 0.0 113.458 178.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -68.32 163.4 23.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.338 1.569 . . . . 0.0 109.179 173.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -105.42 163.04 12.94 Favored 'General case' 0 C--O 1.234 0.238 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.49 148.08 14.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 123.194 0.598 . . . . 0.0 109.425 -169.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 74.9 mt -90.63 141.47 28.74 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 169.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.7 t -132.18 147.82 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -148.26 -45.85 0.16 Allowed 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.89 1.276 . . . . 0.0 109.009 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.6 m -126.97 -166.97 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 126.412 1.885 . . . . 0.0 106.673 171.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -72.37 37.68 0.69 Allowed Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.673 1.13 . . . . 0.0 114.112 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -139.59 147.36 41.01 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.342 1.457 . . . . 0.0 109.288 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.66 104.57 3.96 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 169.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 88.7 mmm -69.05 -45.05 71.38 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 118.369 0.532 . . . . 0.0 110.447 -169.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.5 m -161.76 152.84 18.16 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 126.156 1.783 . . . . 0.0 107.144 169.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -75.11 149.43 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 170.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -141.64 -167.55 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 C-N-CA 126.487 1.915 . . . . 0.0 108.293 176.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -123.63 174.17 7.62 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 125.098 1.359 . . . . 0.0 109.804 175.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -60.0 -40.17 88.31 Favored 'General case' 0 CA--C 1.527 0.083 0 C-N-CA 123.895 0.878 . . . . 0.0 112.399 -172.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.36 -37.81 56.74 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 118.183 0.447 . . . . 0.0 109.923 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -61.8 -36.15 80.27 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.333 0.653 . . . . 0.0 109.878 173.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.52 -42.35 98.45 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.504 -0.748 . . . . 0.0 110.809 174.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.6 mpt_? -64.59 -43.39 93.96 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 119.275 0.943 . . . . 0.0 109.995 177.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -60.27 -40.13 89.29 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.064 0.393 . . . . 0.0 111.065 177.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.4 m -65.67 -43.61 88.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.091 0.557 . . . . 0.0 110.452 176.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 59.4 mt -63.64 -38.9 92.87 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 118.873 0.761 . . . . 0.0 110.639 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -64.69 -45.35 87.01 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 123.408 0.683 . . . . 0.0 110.427 175.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.23 -42.73 99.12 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.425 0.557 . . . . 0.0 110.995 177.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -59.81 -55.38 34.92 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 123.514 0.726 . . . . 0.0 109.909 -178.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -68.18 -31.3 70.74 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 117.878 0.308 . . . . 0.0 111.181 -178.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -62.97 -45.63 91.52 Favored 'General case' 0 C--N 1.339 0.137 0 CA-C-N 118.5 0.591 . . . . 0.0 110.675 175.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 76.0 mtm -62.84 -42.94 99.94 Favored 'General case' 0 C--N 1.339 0.113 0 CA-C-N 118.302 0.501 . . . . 0.0 110.452 175.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 38.8 t80 -63.42 -23.11 67.26 Favored 'General case' 0 CA--C 1.54 0.595 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -74.12 -16.09 61.02 Favored 'General case' 0 CA--C 1.539 0.546 0 O-C-N 121.174 -0.954 . . . . 0.0 112.516 175.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 34.8 m -128.29 -8.24 3.71 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 C-N-CA 123.747 0.819 . . . . 0.0 113.14 -172.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 81.9 mm-40 -135.65 141.99 39.22 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 125.207 1.403 . . . . 0.0 107.685 174.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.93 -18.65 21.43 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.645 2.23 . . . . 0.0 113.354 -171.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.3 t70 48.95 38.37 12.24 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 125.647 1.579 . . . . 0.0 112.742 -177.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.1 t 52.51 40.12 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.32 1.448 . . . . 0.0 111.187 -175.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 66.91 15.2 64.46 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 124.892 1.234 . . . . 0.0 112.774 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . 55.62 -2.08 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 128.033 2.533 . . . . 0.0 115.058 -169.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 53.5 tp -63.17 -42.63 99.43 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 120.394 1.452 . . . . 0.0 110.529 -177.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -66.33 -6.84 15.55 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.151 0.981 . . . . 0.0 112.164 177.432 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -133.64 30.3 3.79 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.97 1.708 . . . . 0.0 109.792 -174.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -159.36 -28.87 0.02 OUTLIER Glycine 0 CA--C 1.53 1.014 0 C-N-CA 124.611 1.101 . . . . 0.0 112.529 -177.271 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 53.26 37.79 26.09 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.307 1.443 . . . . 0.0 111.171 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -69.72 -10.11 57.07 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.565 1.146 . . . . 0.0 112.786 -176.525 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 40.6 ttpt . . . . . 0 C--O 1.249 1.057 0 C-N-CA 126.356 1.863 . . . . 0.0 106.387 178.398 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.5 ptm . . . . . 0 N--CA 1.484 1.243 0 N-CA-C 110.386 -0.228 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 84.7 m -69.54 119.78 14.32 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 169.468 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.0 tp -157.41 156.14 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.6 54.69 0.17 Allowed Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -172.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 10.6 p -148.87 154.05 39.56 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 123.848 0.859 . . . . 0.0 109.54 -169.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -58.54 161.92 13.6 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.711 2.274 . . . . 0.0 113.364 169.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.55 175.35 38.97 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 108.654 -1.779 . . . . 0.0 108.654 169.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -116.89 131.88 56.84 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 176.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.9 mt -66.41 119.06 10.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 177.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.5 tpp180 -107.4 -40.6 5.32 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 118.507 -0.759 . . . . 0.0 109.713 -169.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.9 p -142.37 161.8 37.11 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.493 1.117 . . . . 0.0 108.438 169.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.4 mt -132.64 148.81 31.64 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -179.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -124.54 -24.56 4.19 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.299 1.04 . . . . 0.0 112.028 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.66 -126.74 1.33 Allowed Glycine 0 C--N 1.333 0.416 0 N-CA-C 106.757 -2.537 . . . . 0.0 106.757 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 11.8 t30 -65.48 -24.44 67.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.722 0.761 . . . . 0.0 110.254 169.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -93.39 155.6 17.28 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-O 122.054 0.93 . . . . 0.0 110.282 172.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.64 175.03 11.91 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.65 1.58 . . . . 0.0 108.863 -178.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -128.71 99.83 5.49 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 176.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.3 m -69.12 165.88 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 169.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -111.74 112.95 25.01 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 169.029 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -88.26 60.58 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 -177.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.6 m 46.45 41.31 9.26 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.094 2.157 . . . . 0.0 113.586 178.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.56 -26.95 0.2 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.106 -0.83 . . . . 0.0 114.248 175.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.5 tp -149.34 149.91 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.447 0 CA-C-N 118.646 1.223 . . . . 0.0 107.742 177.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -76.21 147.79 38.15 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 175.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -140.16 132.59 28.51 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 124.563 1.145 . . . . 0.0 108.823 176.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -69.98 140.69 52.99 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 123.976 0.91 . . . . 0.0 110.185 176.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -148.49 167.13 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 126.136 1.774 . . . . 0.0 109.162 -178.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -107.03 143.59 34.92 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 169.623 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 26.6 mt -114.58 21.35 14.59 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.279 1.431 . . . . 0.0 110.854 -173.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.07 -35.45 59.56 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.699 1.199 . . . . 0.0 112.584 -171.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.7 mt -80.34 -8.96 59.72 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.679 0.791 . . . . 0.0 112.617 -176.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.7 m -126.92 -5.83 4.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.253 1.021 . . . . 0.0 111.815 -177.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.27 79.21 Favored Glycine 0 CA--C 1.532 1.099 0 C-N-CA 124.99 1.281 . . . . 0.0 114.918 169.609 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 m 58.5 -14.28 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 127.167 2.187 . . . . 0.0 116.711 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.6 m -136.5 153.39 51.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 124.828 1.251 . . . . 0.0 109.598 -177.669 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -64.97 157.91 26.94 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.472 1.109 . . . . 0.0 108.899 169.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -48.2 -41.65 27.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.279 1.431 . . . . 0.0 112.445 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -80.73 -16.84 52.86 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 118.91 -0.566 . . . . 0.0 112.152 -176.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.92 -12.6 5.32 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-O 118.504 -1.164 . . . . 0.0 115.817 169.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -66.06 135.36 95.14 Favored Pre-proline 0 N--CA 1.469 0.477 0 CA-C-N 119.662 1.731 . . . . 0.0 109.341 -172.24 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.11 140.33 71.25 Favored 'Trans proline' 0 CA--C 1.534 0.475 0 C-N-CA 121.707 1.605 . . . . 0.0 109.162 171.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -73.42 11.25 0.81 Allowed 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 114.517 1.302 . . . . 0.0 114.517 -172.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.0 m -53.14 133.99 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 120.251 1.387 . . . . 0.0 109.698 176.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.8 -18.61 52.56 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.433 -1.204 . . . . 0.0 112.992 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -73.52 142.18 46.73 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 119.89 1.845 . . . . 0.0 108.974 177.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -85.04 151.24 24.31 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 170.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.69 145.02 14.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -170.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 86.0 mt -79.1 132.74 36.69 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 169.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 50.2 t -118.63 123.69 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -135.04 137.56 43.06 Favored 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.7 m 44.1 28.45 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 C-N-CA 126.61 1.964 . . . . 0.0 115.405 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.76 4.65 58.98 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.698 1.142 . . . . 0.0 113.892 175.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -125.79 144.55 50.59 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 119.093 1.447 . . . . 0.0 109.719 -176.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.16 120.04 16.16 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 169.381 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 25.8 mmt -91.47 -45.52 8.49 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 119.001 -0.523 . . . . 0.0 111.436 -178.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.5 m -152.19 138.47 18.42 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -176.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.1 t -74.12 142.2 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 169.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.53 -169.52 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 125.695 1.598 . . . . 0.0 109.133 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -128.16 174.79 8.95 Favored 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 125.803 1.641 . . . . 0.0 108.791 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -62.51 -36.52 82.83 Favored 'General case' 0 N--CA 1.462 0.129 0 CA-C-O 118.955 -0.545 . . . . 0.0 112.434 -173.318 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.99 -44.67 76.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.936 0.789 . . . . 0.0 109.464 -177.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -64.58 -41.34 96.34 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 123.136 0.574 . . . . 0.0 110.259 176.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -49.14 75.91 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 122.86 0.464 . . . . 0.0 110.431 179.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -64.67 -41.25 96.21 Favored 'General case' 0 N--CA 1.463 0.195 0 C-N-CA 123.156 0.583 . . . . 0.0 110.376 -178.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -62.5 -43.23 99.33 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.397 0.544 . . . . 0.0 110.939 176.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -69.59 -37.46 76.93 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 122.097 -0.377 . . . . 0.0 110.506 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 27.7 mt -62.79 -40.15 96.45 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 119.113 0.87 . . . . 0.0 110.293 176.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -66.32 -43.54 85.92 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.375 0.534 . . . . 0.0 110.701 175.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.7 -43.06 84.9 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.103 0.411 . . . . 0.0 110.478 176.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -66.18 -5.19 9.34 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.994 1.317 . . . . 0.0 113.748 178.335 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -123.03 -20.44 5.76 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.167 0.987 . . . . 0.0 111.987 -178.127 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -57.72 -32.38 67.35 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 119.261 0.937 . . . . 0.0 113.476 -172.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 1.5 pmm? -72.68 -34.37 67.15 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 118.538 0.608 . . . . 0.0 111.607 177.219 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -79.35 -27.7 42.02 Favored 'General case' 0 C--O 1.226 -0.168 0 C-N-CA 123.423 0.689 . . . . 0.0 110.774 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -59.85 -19.99 54.38 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.32 1.048 . . . . 0.0 112.809 177.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.9 t -63.92 -29.44 47.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 O-C-N 121.533 -0.729 . . . . 0.0 110.932 173.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -66.11 -54.0 29.38 Favored Pre-proline 0 CA--C 1.54 0.569 0 CA-C-O 117.721 -1.133 . . . . 0.0 111.95 -175.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -67.73 -24.65 40.68 Favored 'Trans proline' 0 C--N 1.351 0.673 0 CA-C-N 121.947 1.731 . . . . 0.0 112.163 175.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -67.35 -50.58 59.26 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 118.962 0.801 . . . . 0.0 110.918 177.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.7 p -69.93 -29.45 40.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 O-C-N 121.862 -0.524 . . . . 0.0 110.074 175.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -57.53 -51.05 60.13 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 172.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.1 -44.58 87.75 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 117.862 0.831 . . . . 0.0 110.939 178.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -60.59 -44.27 96.44 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.152 0.581 . . . . 0.0 110.807 178.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -61.65 -43.95 97.89 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 123.665 0.786 . . . . 0.0 109.89 177.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -63.08 -34.85 78.49 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 118.833 -0.603 . . . . 0.0 111.65 179.381 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.405 ' C ' ' H ' ' A' ' 89' ' ' GLU . . . 157.59 -149.98 20.76 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 119.169 0.895 . . . . 0.0 111.735 175.626 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 38.7 mm-40 -71.77 19.41 0.07 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.235 1.414 . . . . 0.0 111.949 175.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . 0.405 ' H ' ' C ' ' A' ' 87' ' ' GLY . 35.1 tt0 -66.15 -35.13 79.67 Favored 'General case' 0 CA--C 1.538 0.508 0 O-C-N 120.887 -1.133 . . . . 0.0 110.169 175.332 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 83.1 tttt . . . . . 0 C--O 1.248 1.005 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 169.704 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 97.4 mmm . . . . . 0 N--CA 1.485 1.298 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 63.8 m -78.32 47.36 0.68 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.012 1.325 . . . . 0.0 112.02 -177.642 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.2 pt -61.01 159.82 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 124.304 1.041 . . . . 0.0 110.307 174.407 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.2 55.11 0.12 Allowed Glycine 0 CA--C 1.525 0.713 0 N-CA-C 108.238 -1.945 . . . . 0.0 108.238 -177.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.0 p -150.67 157.2 36.31 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.613 1.165 . . . . 0.0 109.44 -168.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -67.62 158.37 57.49 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 121.962 1.775 . . . . 0.0 110.477 168.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.45 177.28 39.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 171.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -116.11 138.41 51.28 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 117.565 0.683 . . . . 0.0 109.334 -175.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 60.6 mt -73.7 83.29 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 176.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -76.48 -29.71 56.97 Favored 'General case' 0 N--CA 1.465 0.286 0 O-C-N 121.624 -0.672 . . . . 0.0 111.553 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.73 154.83 38.1 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.747 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 64.5 mt -129.66 147.98 33.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -121.32 -24.87 5.34 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.463 1.105 . . . . 0.0 112.121 -176.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 161.06 -113.0 0.55 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 108.307 -1.917 . . . . 0.0 108.307 178.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -69.37 2.04 3.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.656 0.782 . . . . 0.0 111.875 169.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -139.23 159.3 42.48 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 126.925 2.09 . . . . 0.0 107.679 -170.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 169.14 18.14 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.26 1.424 . . . . 0.0 110.035 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -115.82 73.09 0.83 Allowed 'General case' 0 C--O 1.234 0.241 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 -174.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.0 t -71.56 125.53 30.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 -172.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -77.18 112.05 13.45 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 169.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.9 m -82.56 43.08 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 C-N-CA 124.211 1.005 . . . . 0.0 110.718 177.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 66.7 m 48.5 49.93 17.58 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.077 1.751 . . . . 0.0 112.211 -172.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -177.71 -41.64 0.06 OUTLIER Glycine 0 CA--C 1.524 0.622 0 CA-C-O 119.644 -0.531 . . . . 0.0 112.404 174.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.6 tt -155.86 153.76 7.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -71.96 139.85 48.87 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 170.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 39.2 mmt180 -128.94 142.75 50.83 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 125.273 1.429 . . . . 0.0 107.977 176.246 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.08 131.47 46.65 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.5 t -140.68 129.56 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -83.36 144.19 29.82 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.517 0.727 . . . . 0.0 110.14 174.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.7 mt -109.6 7.85 24.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.312 1.045 . . . . 0.0 113.322 -169.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 25.2 m -53.1 -34.34 56.22 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.987 1.721 . . . . 0.0 112.482 -175.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.3 mt -74.98 -11.09 60.03 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.47 -17.0 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 CA-C-N 119.43 1.013 . . . . 0.0 112.563 -175.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.74 133.18 0.52 Allowed Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.264 1.411 . . . . 0.0 110.781 -175.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 21.4 m -67.86 156.65 36.66 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 169.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.0 m 61.97 145.48 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.227 2.211 . . . . 0.0 112.535 -169.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.95 155.31 38.79 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.207 1.403 . . . . 0.0 109.484 173.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.68 -27.56 62.99 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.646 1.179 . . . . 0.0 112.484 -176.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -62.69 -21.95 66.13 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.813 0.845 . . . . 0.0 113.043 175.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.99 47.9 3.25 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -174.185 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.9 pt20 -143.18 157.33 60.48 Favored Pre-proline 0 CA--C 1.536 0.426 0 C-N-CA 125.751 1.621 . . . . 0.0 107.93 -178.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -64.51 144.09 83.92 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 121.701 1.601 . . . . 0.0 110.375 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 90.6 mtt-85 -71.5 11.2 0.5 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.358 1.063 . . . . 0.0 113.621 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.1 m -57.45 131.69 21.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 O-C-N 120.616 -1.303 . . . . 0.0 109.817 -173.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 89.7 -17.44 52.63 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 118.306 -1.274 . . . . 0.0 113.413 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -66.57 156.34 35.28 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 119.693 1.746 . . . . 0.0 108.948 172.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.3 m95 -105.15 159.99 15.42 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.3 p -157.06 135.55 3.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -171.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 98.2 mt -75.68 131.37 39.85 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 168.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.72 135.05 64.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 119.344 0.974 . . . . 0.0 108.402 -178.228 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -141.83 120.81 12.83 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.684 1.193 . . . . 0.0 107.945 -169.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.2 t 41.6 47.95 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 126.671 1.988 . . . . 0.0 112.02 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.22 6.95 83.78 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 118.337 -1.257 . . . . 0.0 114.771 172.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.18 149.02 50.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 119.803 1.802 . . . . 0.0 110.017 177.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.47 116.16 7.9 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 169.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.9 ttt -76.75 -48.46 18.64 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.532 0.733 . . . . 0.0 109.497 177.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 65.4 m -163.11 144.54 9.75 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.975 1.31 . . . . 0.0 108.833 171.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.6 t -72.32 146.29 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 169.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 pt -137.8 157.91 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 C-N-CA 125.236 1.414 . . . . 0.0 109.02 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -80.83 169.19 17.89 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 120.927 0.394 . . . . 0.0 110.773 176.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -61.14 -44.57 97.11 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 123.385 0.674 . . . . 0.0 111.993 -173.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.66 -37.1 62.82 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 122.759 0.424 . . . . 0.0 109.953 -174.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 56.4 tt0 -60.27 -39.31 86.37 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.846 1.258 . . . . 0.0 110.033 172.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.96 -44.95 87.71 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.618 -0.676 . . . . 0.0 111.322 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 26.5 mmt-85 -62.49 -40.88 98.13 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 119.103 0.865 . . . . 0.0 110.441 178.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.96 -41.97 99.69 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.887 0.475 . . . . 0.0 110.907 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -65.07 -42.95 93.67 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.62 0.368 . . . . 0.0 110.232 177.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 42.5 mt -62.54 -43.58 98.45 Favored 'General case' 0 C--N 1.338 0.107 0 C-N-CA 123.269 0.628 . . . . 0.0 110.311 178.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.84 -44.95 94.78 Favored 'General case' 0 N--CA 1.46 0.073 0 C-N-CA 123.06 0.544 . . . . 0.0 110.845 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.12 -41.19 98.0 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.903 0.481 . . . . 0.0 111.191 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -65.35 -51.12 62.63 Favored 'General case' 0 C--N 1.338 0.104 0 C-N-CA 123.173 0.589 . . . . 0.0 109.577 177.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -61.35 -32.88 72.78 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.915 0.486 . . . . 0.0 111.341 -178.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -56.65 -31.27 64.21 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.306 0.643 . . . . 0.0 112.069 178.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 54.9 mtt -64.42 -14.24 55.65 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.06 0.944 . . . . 0.0 112.624 178.155 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -124.66 -22.29 4.62 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 124.995 1.318 . . . . 0.0 111.157 -176.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -59.67 -30.55 68.84 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 118.981 0.809 . . . . 0.0 111.593 172.341 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 27.9 m -69.96 -8.72 11.18 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.705 0 C-N-CA 124.458 1.103 . . . . 0.0 112.979 174.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -134.67 71.75 70.24 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.647 1.579 . . . . 0.0 107.132 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -63.25 -19.59 68.8 Favored 'Trans proline' 0 CA--C 1.533 0.466 0 C-N-CA 122.681 2.254 . . . . 0.0 113.407 -169.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -60.33 -36.16 77.31 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.02 0.827 . . . . 0.0 111.465 170.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.9 t -81.6 -44.86 20.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 173.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -53.05 -43.3 62.13 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 123.813 0.72 . . . . 0.0 112.424 -177.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.06 -0.27 5.55 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 124.647 1.179 . . . . 0.0 114.094 -179.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 47.8 tp -124.12 -32.08 3.27 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.631 1.172 . . . . 0.0 110.578 174.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.9 tp -65.86 -30.38 70.98 Favored 'General case' 0 CA--C 1.538 0.504 0 O-C-N 121.475 -0.765 . . . . 0.0 110.899 170.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -131.91 29.34 4.43 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.749 1.62 . . . . 0.0 110.052 -178.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -169.96 -160.03 17.27 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -136.94 17.85 3.03 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 124.324 1.049 . . . . 0.0 110.756 -176.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -65.42 143.94 57.38 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 121.258 -0.901 . . . . 0.0 110.207 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 40.6 ttpt . . . . . 0 C--O 1.247 0.964 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 178.35 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.9 tpt . . . . . 0 N--CA 1.482 1.165 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.4 m -61.7 149.81 38.51 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.426 0.69 . . . . 0.0 110.954 178.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.7 tp -154.98 175.73 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 C-N-CA 125.86 1.664 . . . . 0.0 106.864 178.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.11 42.28 5.02 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -169.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.6 m -141.61 162.14 48.39 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.036 1.334 . . . . 0.0 109.288 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -56.28 155.81 23.4 Favored 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 122.802 2.334 . . . . 0.0 113.447 172.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -158.32 167.97 34.59 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 107.951 -2.06 . . . . 0.0 107.951 169.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.8 tt0 -116.8 133.57 55.85 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 -178.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.19 97.01 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -83.34 -41.95 17.64 Favored 'General case' 0 N--CA 1.462 0.139 0 O-C-N 121.701 -0.625 . . . . 0.0 109.97 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 p -145.58 157.97 43.91 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 124.651 1.181 . . . . 0.0 108.83 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 54.4 mt -132.78 146.97 31.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 -174.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -123.55 -15.24 7.13 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.393 1.077 . . . . 0.0 112.091 -177.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.452 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 163.89 -131.56 2.48 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 106.459 -2.657 . . . . 0.0 106.459 -178.031 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -74.09 22.48 0.09 Allowed 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 118.057 0.929 . . . . 0.0 111.515 169.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . 0.452 ' H ' ' C ' ' A' ' 14' ' ' GLY . 41.1 mt-30 -140.5 148.61 41.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 126.594 1.958 . . . . 0.0 106.803 -179.056 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.61 163.46 32.0 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 124.454 1.102 . . . . 0.0 109.926 -179.177 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -110.79 78.37 1.11 Allowed 'General case' 0 C--O 1.233 0.232 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.0 m -70.59 130.88 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 123.477 0.711 . . . . 0.0 109.508 -177.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -76.84 111.3 12.22 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 168.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.4 t -84.75 54.67 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.74 45.72 8.31 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.984 2.113 . . . . 0.0 113.215 -177.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.3 -36.07 0.13 Allowed Glycine 0 CA--C 1.526 0.781 0 CA-C-O 119.468 -0.629 . . . . 0.0 113.003 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.8 tt -153.51 151.66 11.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 177.174 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.2 mt-30 -73.79 138.11 44.32 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 172.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -130.75 145.38 51.93 Favored 'General case' 0 N--CA 1.463 0.186 0 C-N-CA 125.261 1.424 . . . . 0.0 107.91 171.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -70.94 144.36 50.6 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 173.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.48 139.76 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -81.5 146.59 30.12 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.11 1.364 . . . . 0.0 110.284 172.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 86.1 mt -117.17 16.0 14.94 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.559 1.143 . . . . 0.0 112.404 -170.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 5.8 p -53.31 -34.98 59.61 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 120.561 1.528 . . . . 0.0 112.854 -176.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 73.9 mt -83.53 -6.04 59.34 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 118.46 -0.781 . . . . 0.0 112.865 -175.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -132.42 -20.41 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 119.536 1.062 . . . . 0.0 112.919 -174.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.29 147.83 7.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -177.32 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.6 m -68.23 -20.78 64.84 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.877 1.271 . . . . 0.0 113.364 -171.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.6 m -127.41 152.34 47.65 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 124.876 1.27 . . . . 0.0 109.283 -175.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -65.49 145.99 55.43 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.344 1.458 . . . . 0.0 109.972 172.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -53.99 -31.01 49.54 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.169 1.388 . . . . 0.0 113.517 -169.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -84.87 -7.86 59.01 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 118.863 0.756 . . . . 0.0 112.986 -178.045 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.34 52.65 0.76 Allowed Glycine 0 CA--C 1.527 0.793 0 CA-C-N 119.043 0.838 . . . . 0.0 112.728 170.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 30.0 pt20 -144.4 160.65 47.63 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 124.898 1.279 . . . . 0.0 108.697 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -63.74 143.76 87.36 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.627 1.551 . . . . 0.0 109.97 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 79.6 mtt-85 -70.56 12.93 0.21 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -177.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.8 m -57.91 135.1 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 O-C-N 120.59 -1.319 . . . . 0.0 109.984 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.52 -14.57 54.82 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 124.889 1.233 . . . . 0.0 113.484 -178.183 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -73.99 155.17 38.88 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 119.709 1.754 . . . . 0.0 109.373 177.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 83.5 m95 -97.95 159.16 15.11 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -157.07 147.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 91.9 mt -82.99 128.22 34.27 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.129 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 20.6 t -111.23 105.26 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -169.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . 0.433 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 6.7 t-160 -77.09 -171.37 1.99 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.903 0.881 . . . . 0.0 109.092 169.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.433 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 36.0 m -52.89 -26.84 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 C-N-CA 124.54 1.136 . . . . 0.0 113.795 -174.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.08 18.15 0.1 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.841 -0.977 . . . . 0.0 113.213 171.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -139.47 142.54 37.36 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 119.094 1.447 . . . . 0.0 109.12 -172.068 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.16 125.54 27.06 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 169.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 46.3 mtt -74.07 -57.59 3.86 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.4 m -157.77 145.21 18.41 Favored 'General case' 0 C--O 1.238 0.462 0 C-N-CA 126.356 1.863 . . . . 0.0 107.643 -176.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.1 m -74.44 148.99 7.68 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 169.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 pt -138.71 168.05 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 125.048 1.339 . . . . 0.0 108.575 -178.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -97.59 174.85 6.44 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.0 0.52 . . . . 0.0 110.134 176.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -62.55 -33.67 75.4 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.715 0.806 . . . . 0.0 111.481 -174.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.84 -49.1 61.25 Favored 'General case' 0 CA--C 1.528 0.129 0 O-C-N 121.72 -0.612 . . . . 0.0 110.251 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -64.25 -38.91 92.73 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 122.777 0.431 . . . . 0.0 110.342 178.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -52.3 65.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 118.049 0.386 . . . . 0.0 110.176 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -64.47 -39.03 93.03 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-O 118.677 -0.678 . . . . 0.0 111.005 -178.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.52 -43.03 99.81 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.088 0.858 . . . . 0.0 110.943 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.7 m -66.99 -42.75 84.51 Favored 'General case' 0 CA--C 1.537 0.466 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.2 mt -64.51 -35.58 81.41 Favored 'General case' 0 CA--C 1.528 0.099 0 O-C-N 121.449 -0.782 . . . . 0.0 110.923 178.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -66.89 -43.47 83.37 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 123.403 0.681 . . . . 0.0 110.672 176.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.29 -47.72 82.75 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.5 mt -61.93 -8.43 5.1 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.665 1.186 . . . . 0.0 113.699 -178.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -126.55 17.91 7.5 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-N 119.695 1.134 . . . . 0.0 112.51 178.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -147.76 -17.86 0.36 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 114.79 1.404 . . . . 0.0 114.79 169.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 46.0 tpp -60.63 -23.08 64.48 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.102 1.319 . . . . 0.0 112.776 -173.337 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -52.81 -28.24 21.74 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.808 0.843 . . . . 0.0 112.764 173.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -64.46 -12.01 39.41 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.213 1.405 . . . . 0.0 113.198 -179.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 12.8 m -130.95 17.0 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 124.925 1.29 . . . . 0.0 111.1 -179.016 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 14.0 mm-40 -134.55 168.22 18.9 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 124.555 1.142 . . . . 0.0 110.055 -170.517 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -51.72 -21.87 12.21 Favored 'Trans proline' 0 C--N 1.349 0.561 0 C-N-CA 124.203 3.269 . . . . 0.0 116.643 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -62.92 -36.55 83.78 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 118.721 0.691 . . . . 0.0 112.101 -178.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.6 p -158.02 -35.1 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-N 118.362 0.528 . . . . 0.0 111.714 173.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -54.02 -38.52 60.83 Favored Glycine 0 CA--C 1.526 0.759 0 CA-C-N 119.558 1.072 . . . . 0.0 113.241 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -66.6 -20.12 65.93 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 118.193 0.997 . . . . 0.0 113.4 178.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 48.8 tp -90.14 -41.34 11.69 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.399 1.08 . . . . 0.0 109.261 171.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.09 -39.2 91.65 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.411 1.084 . . . . 0.0 110.798 -177.48 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -126.34 36.64 4.46 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.3 1.44 . . . . 0.0 110.612 -170.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -162.4 178.37 38.21 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 176.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -64.49 149.31 48.84 Favored 'General case' 0 C--O 1.238 0.463 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 170.018 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -65.29 156.31 32.43 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-O 121.472 0.653 . . . . 0.0 112.423 -173.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 62.1 mttp . . . . . 0 C--O 1.251 1.156 0 C-N-CA 125.9 1.68 . . . . 0.0 107.434 -169.811 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.6 mtt . . . . . 0 N--CA 1.485 1.314 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 7.0 p -143.75 171.24 14.47 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.269 1.027 . . . . 0.0 109.197 170.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 44.2 mt -133.28 158.37 42.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 -173.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.79 45.69 0.1 OUTLIER Glycine 0 CA--C 1.526 0.781 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 -178.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.7 t -143.72 146.87 36.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 125.224 1.41 . . . . 0.0 107.583 -169.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -55.83 161.25 8.47 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.69 2.26 . . . . 0.0 113.339 169.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.93 177.3 39.78 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 169.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -116.78 137.19 52.38 Favored 'General case' 0 C--N 1.334 -0.105 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 39.1 mt -76.77 71.85 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 C-N-CA 124.89 1.276 . . . . 0.0 108.129 -175.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -63.76 -30.36 71.46 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 124.363 1.065 . . . . 0.0 112.445 -172.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -149.76 155.81 40.77 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 177.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.1 141.48 45.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -106.77 -28.33 10.22 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 124.039 0.936 . . . . 0.0 110.781 174.023 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.81 -121.88 0.98 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 106.78 -2.528 . . . . 0.0 106.78 177.243 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.4 t30 -65.34 -15.31 62.42 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 116.935 0.368 . . . . 0.0 111.693 169.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -105.85 153.12 22.37 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 172.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -146.71 169.12 19.71 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.33 1.052 . . . . 0.0 110.167 -177.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.39 75.1 1.37 Allowed 'General case' 0 CA--C 1.519 -0.233 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -171.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.6 t -73.6 128.26 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -74.06 106.17 5.62 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 169.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.71 57.85 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.1 m 43.35 48.42 5.9 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 127.566 2.347 . . . . 0.0 113.427 179.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 175.0 -39.26 0.11 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.592 -0.56 . . . . 0.0 112.305 176.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.5 tt -153.69 152.65 9.69 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -69.56 136.54 51.45 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 170.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 22.7 mmm180 -122.36 128.29 50.81 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 175.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -74.79 119.88 19.57 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 176.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.2 m -142.99 172.33 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 125.47 1.508 . . . . 0.0 109.579 -170.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -108.88 143.22 38.38 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 124.729 1.211 . . . . 0.0 111.056 -169.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.7 mt -114.03 9.88 17.41 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.47 1.108 . . . . 0.0 112.734 -175.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 6.4 m -55.06 -33.87 63.09 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.943 1.701 . . . . 0.0 112.154 -172.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.23 -9.82 58.93 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.661 0.785 . . . . 0.0 113.055 -177.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.9 -15.94 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 119.498 1.045 . . . . 0.0 112.651 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.13 147.49 7.2 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 124.983 1.278 . . . . 0.0 110.536 -176.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.5 m -65.57 -21.82 66.63 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.84 1.256 . . . . 0.0 112.184 177.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.3 m -126.71 168.43 14.38 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.452 1.501 . . . . 0.0 109.734 -175.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -117.79 154.02 32.46 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 126.95 2.1 . . . . 0.0 109.239 -169.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -57.78 -25.91 61.17 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.661 1.185 . . . . 0.0 112.711 -173.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -60.85 -23.77 65.38 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 123.863 0.865 . . . . 0.0 113.007 174.37 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.03 47.7 2.59 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -175.237 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -145.7 154.39 51.9 Favored Pre-proline 0 CA--C 1.535 0.375 0 C-N-CA 125.398 1.479 . . . . 0.0 108.638 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -66.48 152.04 81.72 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 121.828 1.685 . . . . 0.0 108.847 169.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 64.7 mtt-85 -70.19 10.57 0.42 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 114.339 1.237 . . . . 0.0 114.339 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.51 137.57 23.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 O-C-N 120.849 -1.157 . . . . 0.0 108.933 -172.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.71 -11.37 33.79 Favored Glycine 0 CA--C 1.532 1.106 0 CA-C-O 118.187 -1.34 . . . . 0.0 114.028 179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -67.64 163.05 22.26 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.91 1.855 . . . . 0.0 109.219 171.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.2 m95 -104.25 155.47 18.72 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.2 p -153.24 142.77 14.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -171.103 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -84.47 113.1 20.96 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 169.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 38.9 t -93.42 137.09 23.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.213 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 178.346 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -137.12 142.83 42.28 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.273 1.029 . . . . 0.0 108.702 175.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 22.5 t 56.37 -75.99 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 127.071 2.148 . . . . 0.0 111.439 -173.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.24 27.8 0.19 Allowed Glycine 0 CA--C 1.535 1.31 0 C-N-CA 127.761 2.6 . . . . 0.0 110.088 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -139.53 144.08 37.71 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 126.215 1.806 . . . . 0.0 107.847 -170.144 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.74 122.94 17.61 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 169.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 52.0 ttp -80.32 -57.9 3.39 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 171.042 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 17.8 m -150.64 138.03 19.55 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 123.77 0.828 . . . . 0.0 109.517 -172.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.0 t -72.09 144.6 12.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 169.416 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.4 pt -138.29 158.8 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 124.781 1.232 . . . . 0.0 108.846 -176.223 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -81.91 167.84 18.54 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 110.593 175.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -67.37 -33.43 75.21 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.549 0.74 . . . . 0.0 112.341 -169.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.9 -39.94 33.61 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.308 -0.87 . . . . 0.0 109.637 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.2 tt0 -59.8 -40.78 89.52 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.011 1.325 . . . . 0.0 110.146 173.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -50.8 71.31 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.145 0.578 . . . . 0.0 110.662 175.042 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 84.2 mtm180 -63.29 -40.17 96.61 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 119.072 -0.489 . . . . 0.0 111.201 -178.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.25 -43.62 97.5 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 118.582 0.628 . . . . 0.0 110.785 176.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.2 m -65.63 -39.24 91.25 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 119.276 -0.392 . . . . 0.0 110.35 178.625 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 35.8 mt -64.62 -42.21 95.67 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 119.099 0.863 . . . . 0.0 110.536 176.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -64.68 -39.33 93.49 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 123.164 0.586 . . . . 0.0 110.961 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.13 -51.05 63.56 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.495 0.318 . . . . 0.0 110.24 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -56.11 -47.63 77.72 Favored 'General case' 0 N--CA 1.462 0.139 0 C-N-CA 124.39 1.076 . . . . 0.0 110.679 -174.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -73.52 5.48 3.78 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.619 0.97 . . . . 0.0 113.619 -177.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 -127.96 -29.28 2.57 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 124.334 1.054 . . . . 0.0 111.616 178.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 37.7 mtt -59.83 -19.52 51.43 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 124.161 0.985 . . . . 0.0 113.146 -179.162 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 15.3 p90 -57.3 -22.55 42.64 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 119.713 1.142 . . . . 0.0 112.3 174.002 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -65.19 -19.89 66.18 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.094 0.958 . . . . 0.0 112.775 176.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.5 m -129.1 -18.53 1.85 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 C-N-CA 124.761 1.224 . . . . 0.0 112.369 -174.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -145.28 78.84 12.0 Favored Pre-proline 0 CA--C 1.539 0.53 0 C-N-CA 125.402 1.481 . . . . 0.0 107.913 175.426 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -62.91 -11.72 25.85 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 123.59 2.86 . . . . 0.0 114.191 -170.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -52.59 -38.28 59.76 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.557 0.743 . . . . 0.0 111.309 169.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.9 m -68.89 -28.54 40.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-N 119.255 0.934 . . . . 0.0 110.97 179.24 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -68.64 -49.93 40.22 Favored Glycine 0 C--N 1.338 0.662 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 175.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.12 -44.92 88.01 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 117.565 0.682 . . . . 0.0 110.878 176.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -57.36 -48.87 77.9 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 124.584 1.153 . . . . 0.0 110.304 176.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 68.5 tp -60.46 -40.6 91.79 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.238 0.615 . . . . 0.0 110.499 177.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 13.3 m-30 -64.24 -32.42 74.0 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 118.956 -0.545 . . . . 0.0 111.32 176.072 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 159.68 -20.75 0.26 Allowed Glycine 0 CA--C 1.53 0.999 0 CA-C-O 118.224 -1.32 . . . . 0.0 115.387 169.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -149.33 132.36 16.24 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 119.982 1.891 . . . . 0.0 110.077 -170.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -56.52 157.6 5.05 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 123.546 0.738 . . . . 0.0 111.431 170.299 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 63.7 tttp . . . . . 0 C--O 1.247 0.923 0 C-N-CA 124.601 1.161 . . . . 0.0 108.254 -173.533 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 58.5 ttm . . . . . 0 N--CA 1.484 1.256 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 59.8 m -76.21 47.07 0.44 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.373 1.469 . . . . 0.0 112.498 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.0 pt -61.14 160.02 2.0 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 123.591 0.756 . . . . 0.0 109.648 170.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.25 42.05 0.17 Allowed Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.673 -0.571 . . . . 0.0 111.673 -175.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.3 t -146.69 151.94 43.77 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 -169.599 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_exo -54.92 157.56 12.86 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 122.153 1.902 . . . . 0.0 112.728 169.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.25 172.49 34.71 Favored Glycine 0 CA--C 1.526 0.767 0 C-N-CA 124.474 1.035 . . . . 0.0 110.765 174.206 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -119.81 130.6 54.99 Favored 'General case' 0 CA--C 1.522 -0.108 0 C-N-CA 124.023 0.929 . . . . 0.0 109.032 -176.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.4 mt -69.3 130.26 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 22.3 mmt85 -119.8 -31.73 4.44 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 118.564 -0.731 . . . . 0.0 111.274 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 m -146.93 153.68 40.38 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 20.1 mt -132.49 141.67 44.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 177.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -122.25 -15.41 7.69 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.057 0.943 . . . . 0.0 111.664 -176.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.77 -135.51 3.6 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 107.12 -2.392 . . . . 0.0 107.12 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -66.52 5.0 0.65 Allowed 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 123.972 0.909 . . . . 0.0 113.031 169.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -133.45 153.05 51.94 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 126.138 1.775 . . . . 0.0 107.799 178.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.77 158.09 43.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.763 1.225 . . . . 0.0 110.254 -171.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.73 122.72 37.63 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 170.345 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.2 t -125.46 123.45 64.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 -173.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -67.71 128.24 35.74 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 172.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -128.42 124.19 61.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 171.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.3 m 50.16 26.45 2.15 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 125.304 1.441 . . . . 0.0 114.376 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.69 -1.33 36.43 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-O 118.451 -1.194 . . . . 0.0 113.766 172.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.6 mm -134.21 132.04 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 119.451 1.625 . . . . 0.0 107.279 -173.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -66.53 140.13 57.97 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.932 0.396 . . . . 0.0 110.526 178.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 20.6 mmt-85 -126.43 149.01 49.55 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.531 1.932 . . . . 0.0 106.789 169.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -80.01 136.07 36.51 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 169.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -137.76 135.77 45.82 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -176.193 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -79.87 140.12 36.88 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.995 1.318 . . . . 0.0 110.033 174.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 42.5 mt -113.98 14.33 18.41 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 124.051 0.941 . . . . 0.0 112.911 -171.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.7 m -52.24 -36.69 53.08 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 120.604 1.547 . . . . 0.0 112.623 -173.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.9 mt -80.74 -6.96 59.17 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 112.927 0.714 . . . . 0.0 112.927 -174.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.6 m -131.98 -17.56 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 119.476 1.034 . . . . 0.0 112.452 -174.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.14 151.54 5.27 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.601 1.096 . . . . 0.0 110.947 -174.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.8 p -74.31 -18.6 60.68 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.558 1.143 . . . . 0.0 112.836 179.742 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.5 m -124.01 150.07 45.31 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.492 1.117 . . . . 0.0 109.442 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.09 161.86 27.1 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.447 1.099 . . . . 0.0 110.625 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -45.98 -41.27 11.56 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.078 1.751 . . . . 0.0 112.087 170.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 30.9 t30 -65.84 -14.72 61.97 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.53 1.132 . . . . 0.0 112.943 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.82 35.14 5.47 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-O 119.027 -0.874 . . . . 0.0 113.835 169.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -142.75 164.22 33.79 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 118.566 1.183 . . . . 0.0 109.192 172.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -51.14 146.4 23.17 Favored 'Trans proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.599 2.866 . . . . 0.0 112.508 175.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -71.06 18.72 0.06 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 114.243 1.201 . . . . 0.0 114.243 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.6 m -58.0 138.09 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 O-C-N 120.234 -1.541 . . . . 0.0 110.005 -176.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.21 -17.61 17.33 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.465 -1.186 . . . . 0.0 113.537 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.9 mt-30 -70.44 161.11 31.13 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.491 1.646 . . . . 0.0 109.447 175.215 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 56.2 m95 -106.21 157.45 17.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -144.65 142.85 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.796 1.239 . . . . 0.0 107.711 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -86.64 116.47 24.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 103.781 -2.674 . . . . 0.0 103.781 169.029 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 31.7 m -116.98 137.04 52.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -171.567 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.93 139.15 36.1 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 33.6 m 45.46 27.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.88 0 C-N-CA 126.457 1.903 . . . . 0.0 115.453 172.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 97.81 7.32 56.65 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.069 176.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.13 141.78 51.08 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 119.706 1.753 . . . . 0.0 109.394 -177.415 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.16 114.45 14.83 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 169.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.9 mmt -88.59 -26.22 22.06 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 122.911 0.484 . . . . 0.0 110.762 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 66.1 m -155.19 156.29 35.43 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 124.714 1.206 . . . . 0.0 108.687 171.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 137.72 34.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 172.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 pt -140.11 159.95 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 C-N-CA 124.55 1.14 . . . . 0.0 110.419 -169.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -81.02 169.07 17.96 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.603 0.761 . . . . 0.0 110.305 173.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -69.38 -30.34 68.3 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -170.25 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.19 -41.45 61.41 Favored 'General case' 0 N--CA 1.461 0.102 0 O-C-N 121.024 -1.047 . . . . 0.0 109.79 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -61.91 -41.36 97.82 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.565 0.746 . . . . 0.0 109.65 174.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.78 -49.05 77.9 Favored 'General case' 0 C--N 1.34 0.177 0 O-C-N 121.934 -0.479 . . . . 0.0 110.807 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -64.6 -38.58 91.51 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 118.977 -0.535 . . . . 0.0 111.354 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -64.73 -41.54 95.88 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 118.969 0.804 . . . . 0.0 110.856 176.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 24.2 m -68.01 -37.48 81.47 Favored 'General case' 0 CA--C 1.539 0.553 0 O-C-N 122.02 -0.425 . . . . 0.0 110.328 178.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 37.5 mt -62.74 -44.71 95.5 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.43 -0.794 . . . . 0.0 109.761 174.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -62.06 -40.74 96.83 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 118.775 0.716 . . . . 0.0 111.131 177.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.39 -34.42 77.68 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.897 -0.502 . . . . 0.0 111.83 175.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -75.5 -39.2 58.84 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.761 0.824 . . . . 0.0 110.66 177.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -67.03 -29.75 69.64 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.737 0.815 . . . . 0.0 111.382 175.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -58.43 141.3 51.99 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 172.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 9.7 mmt 64.67 8.74 4.65 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 125.67 1.588 . . . . 0.0 114.201 -178.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -141.33 -41.6 0.38 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 119.905 1.23 . . . . 0.0 112.919 -170.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -133.37 -22.57 1.96 Allowed 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 124.482 1.113 . . . . 0.0 111.835 -170.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 30.1 m -64.69 -16.2 19.21 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 O-C-N 121.688 -0.632 . . . . 0.0 111.088 169.243 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -134.91 157.57 76.81 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 127.908 2.483 . . . . 0.0 105.554 170.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -74.93 31.29 0.36 Allowed 'Trans proline' 0 CA--C 1.544 1.021 0 C-N-CA 123.842 3.028 . . . . 0.0 113.86 -171.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -60.53 -39.45 87.9 Favored 'General case' 0 N--CA 1.465 0.278 0 O-C-N 120.711 -1.243 . . . . 0.0 111.129 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.9 p -59.41 -41.57 84.88 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 C-N-CA 123.106 0.562 . . . . 0.0 110.56 171.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -64.69 -39.59 96.81 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.269 -0.733 . . . . 0.0 111.269 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -60.08 -18.07 44.19 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.889 0.876 . . . . 0.0 112.918 177.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -102.66 -46.49 4.71 Favored 'General case' 0 CA--C 1.528 0.115 0 C-N-CA 124.402 1.081 . . . . 0.0 110.212 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 46.5 tp -64.14 -34.64 78.53 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 123.485 0.714 . . . . 0.0 111.781 -174.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -135.05 -20.25 1.7 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.503 1.121 . . . . 0.0 112.346 -177.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.84 -165.32 35.25 Favored Glycine 0 CA--C 1.527 0.818 0 CA-C-O 122.214 0.897 . . . . 0.0 113.388 -172.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 36.3 mm-40 -70.58 -19.53 62.85 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.977 0.911 . . . . 0.0 112.323 -169.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -80.78 -9.53 59.8 Favored 'General case' 0 CA--C 1.546 0.793 0 CA-C-N 118.515 0.598 . . . . 0.0 111.15 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 54.8 tttp . . . . . 0 C--O 1.251 1.154 0 C-N-CA 124.716 1.206 . . . . 0.0 110.601 178.285 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 97.5 mmm . . . . . 0 N--CA 1.484 1.234 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 63.7 m -78.39 56.36 1.73 Allowed 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.808 1.243 . . . . 0.0 111.485 -176.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 34.8 pt -126.39 21.74 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 C-N-CA 125.006 1.322 . . . . 0.0 111.791 -172.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.77 91.69 0.27 Allowed Glycine 0 CA--C 1.522 0.475 0 C-N-CA 125.833 1.682 . . . . 0.0 110.738 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.9 t -139.51 144.21 38.74 Favored Pre-proline 0 CA--C 1.541 0.615 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 -177.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.35 160.4 47.06 Favored 'Trans proline' 0 CA--C 1.534 0.516 0 C-N-CA 122.534 2.156 . . . . 0.0 111.957 174.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.04 172.92 40.0 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 171.109 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -95.34 137.04 34.93 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.9 mt -69.94 93.3 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 169.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -79.55 -33.59 41.74 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 119.108 -0.472 . . . . 0.0 110.38 -170.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 m -149.48 152.73 36.12 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.419 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.3 mt -131.69 144.41 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -124.02 -20.44 5.35 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.187 0.995 . . . . 0.0 111.967 -178.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.8 -129.54 1.89 Allowed Glycine 0 C--N 1.335 0.499 0 N-CA-C 107.226 -2.35 . . . . 0.0 107.226 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.6 p-10 -65.91 -3.65 5.54 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 117.599 0.699 . . . . 0.0 112.559 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -125.38 157.43 36.83 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.763 1.225 . . . . 0.0 109.602 175.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -154.69 160.42 41.36 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.52 1.528 . . . . 0.0 109.911 -171.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.17 112.17 24.58 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.611 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.7 t -92.13 124.11 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 170.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -84.91 108.7 17.68 Favored 'General case' 0 C--O 1.233 0.218 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 169.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.0 t -83.19 61.02 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 125.858 1.663 . . . . 0.0 107.046 174.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 62.5 m 38.42 45.95 0.89 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 128.044 2.538 . . . . 0.0 114.41 178.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 153.22 -17.12 0.69 Allowed Glycine 0 CA--C 1.526 0.724 0 CA-C-O 119.093 -0.837 . . . . 0.0 113.806 177.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.6 tp -143.83 145.08 22.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 173.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -94.72 134.37 37.4 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 51.2 mtp180 -126.42 118.99 26.13 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -70.49 131.01 43.39 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 173.466 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.5 m -139.79 155.3 24.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.11 0.964 . . . . 0.0 109.374 179.223 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -84.35 146.48 27.68 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.721 0.808 . . . . 0.0 109.524 171.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 mt -112.25 3.17 16.95 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.424 1.09 . . . . 0.0 112.573 -173.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.6 m -59.03 -26.17 64.33 Favored 'General case' 0 CA--C 1.544 0.725 0 CA-C-N 120.595 1.543 . . . . 0.0 112.227 -173.207 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.7 mt -65.67 -19.96 66.11 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 121.608 -0.683 . . . . 0.0 112.708 176.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -129.25 -10.92 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.785 1.234 . . . . 0.0 112.013 -174.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.35 139.94 0.96 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 125.365 1.46 . . . . 0.0 109.916 -170.232 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 18.3 m -71.11 -12.17 61.36 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.934 -0.745 . . . . 0.0 112.833 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.4 m -119.36 146.42 45.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.655 1.182 . . . . 0.0 109.311 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -79.94 160.55 25.92 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 124.156 0.982 . . . . 0.0 110.087 176.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.7 -33.27 22.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.216 1.406 . . . . 0.0 112.421 173.18 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -67.44 -13.4 62.0 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.09 31.52 5.9 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 118.893 -0.948 . . . . 0.0 114.428 169.323 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -146.11 167.57 13.75 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 118.813 1.307 . . . . 0.0 109.003 172.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -50.59 150.75 11.42 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 123.394 2.729 . . . . 0.0 112.837 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 87.4 mtt-85 -74.21 20.99 0.1 Allowed 'General case' 0 CA--C 1.541 0.627 0 O-C-N 121.143 -0.973 . . . . 0.0 113.332 177.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.6 m -56.26 131.94 19.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 O-C-N 120.783 -1.198 . . . . 0.0 109.658 -176.458 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.97 -11.88 55.64 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 118.055 -1.414 . . . . 0.0 113.968 177.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -70.34 169.43 13.89 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.631 1.716 . . . . 0.0 109.692 172.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -118.56 149.58 41.1 Favored 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.686 0.794 . . . . 0.0 109.58 -178.21 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -147.51 156.51 9.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 124.555 1.142 . . . . 0.0 109.417 -175.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 92.9 mt -84.47 140.12 31.71 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 168.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.1 m -132.04 127.33 57.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.744 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -144.07 -29.47 0.49 Allowed 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -169.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.8 m -136.2 20.37 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 118.665 0.666 . . . . 0.0 112.362 -169.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.59 10.16 73.82 Favored Glycine 0 CA--C 1.532 1.149 0 O-C-N 121.45 -0.781 . . . . 0.0 112.629 -175.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 70.1 m-85 -135.44 153.58 51.73 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.222 1.409 . . . . 0.0 107.937 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.91 105.37 2.79 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 169.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.09 -39.28 75.66 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.882 0.873 . . . . 0.0 110.929 -170.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.5 m -160.29 155.21 24.4 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 125.369 1.467 . . . . 0.0 108.563 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.1 t -78.08 146.72 7.82 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 169.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.4 pt -138.26 161.15 31.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 C-N-CA 125.502 1.521 . . . . 0.0 108.53 177.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -73.97 163.58 27.72 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-O 121.932 0.872 . . . . 0.0 110.583 174.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -57.68 -40.97 80.66 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 126.402 1.881 . . . . 0.0 111.809 178.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.87 -34.72 29.93 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.801 0.841 . . . . 0.0 110.801 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 60.7 tt0 -62.52 -34.35 76.73 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.641 1.176 . . . . 0.0 110.287 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.26 -43.03 87.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 122.002 -0.437 . . . . 0.0 111.359 171.325 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.8 mmt85 -69.7 -41.33 75.54 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 118.416 0.553 . . . . 0.0 109.609 -177.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.13 -40.24 93.05 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 122.54 0.336 . . . . 0.0 110.67 175.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -66.61 -41.26 88.69 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.154 0.582 . . . . 0.0 110.57 177.196 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.6 mt -62.18 -40.61 96.63 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 119.448 1.022 . . . . 0.0 110.313 175.296 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -64.79 -41.79 95.56 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 118.113 0.415 . . . . 0.0 110.843 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.96 -41.77 97.0 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 118.56 0.618 . . . . 0.0 111.083 174.371 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -61.0 -52.76 63.65 Favored 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 123.824 0.85 . . . . 0.0 109.804 -179.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -66.53 -31.33 71.98 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.369 0.531 . . . . 0.0 111.588 178.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -66.12 -38.53 88.4 Favored 'General case' 0 CA--C 1.519 -0.213 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 -177.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -51.84 -57.81 8.27 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.233 1.013 . . . . 0.0 110.853 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -73.5 -18.87 61.05 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.852 -0.594 . . . . 0.0 112.283 -178.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -73.69 -31.54 63.48 Favored 'General case' 0 CA--C 1.536 0.404 0 CA-C-N 119.371 0.987 . . . . 0.0 111.982 174.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.7 m -105.1 -15.91 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 118.877 0.762 . . . . 0.0 112.553 -175.343 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 81.6 mm-40 -130.56 55.47 19.1 Favored Pre-proline 0 CA--C 1.543 0.687 0 C-N-CA 124.498 1.119 . . . . 0.0 110.072 173.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -62.31 -22.99 74.93 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.575 2.183 . . . . 0.0 112.72 -176.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -57.48 -23.05 47.69 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 124.862 1.265 . . . . 0.0 112.858 176.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.73 -30.49 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 124.153 0.981 . . . . 0.0 110.226 172.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -54.81 -38.42 64.53 Favored Glycine 0 CA--C 1.528 0.848 0 C-N-CA 124.09 0.852 . . . . 0.0 112.47 175.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -66.64 -7.78 22.9 Favored 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 118.389 1.095 . . . . 0.0 113.576 178.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 59.1 tp -117.22 -43.47 2.84 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 124.314 1.046 . . . . 0.0 110.061 178.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 46.4 tp -66.93 -32.11 73.14 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.849 0.859 . . . . 0.0 111.28 177.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -136.56 33.22 2.74 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.021 1.728 . . . . 0.0 109.677 -176.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -160.5 -167.08 20.52 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 124.224 0.916 . . . . 0.0 110.959 -176.637 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 75.9 mm-40 -125.94 29.12 5.96 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.695 1.198 . . . . 0.0 110.891 -169.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 31.4 tp10 -55.37 -27.72 49.3 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.133 0.973 . . . . 0.0 112.774 179.43 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 87.4 tttt . . . . . 0 C--O 1.249 1.045 0 N-CA-C 106.73 -1.582 . . . . 0.0 106.73 173.075 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 tpt . . . . . 0 N--CA 1.482 1.145 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 92.0 m -135.86 155.13 50.79 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 125.007 1.323 . . . . 0.0 108.736 178.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.8 pt -139.34 46.56 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 126.105 1.762 . . . . 0.0 108.891 -175.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -65.66 68.4 0.11 Allowed Glycine 0 CA--C 1.528 0.894 0 C-N-CA 127.196 2.331 . . . . 0.0 113.789 -174.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.2 t -146.76 148.23 32.53 Favored Pre-proline 0 CA--C 1.544 0.715 0 C-N-CA 126.249 1.82 . . . . 0.0 106.998 -171.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -57.44 163.79 8.03 Favored 'Trans proline' 0 CA--C 1.536 0.609 0 C-N-CA 122.432 2.088 . . . . 0.0 112.426 169.144 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -160.46 163.33 33.93 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.327 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 58.3 tt0 -116.93 131.79 56.86 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 94.6 mt -70.36 117.66 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.475 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -90.19 -32.77 16.47 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 118.666 -0.683 . . . . 0.0 110.502 172.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.12 152.92 35.51 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -170.115 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.8 mt -132.43 141.03 46.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 172.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -120.84 -18.86 7.51 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.425 1.09 . . . . 0.0 111.47 -176.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.22 -126.6 1.36 Allowed Glycine 0 C--N 1.336 0.538 0 N-CA-C 107.146 -2.382 . . . . 0.0 107.146 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -67.28 -8.63 33.52 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 117.052 0.426 . . . . 0.0 112.11 169.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -119.81 159.44 24.57 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 125.486 1.514 . . . . 0.0 109.538 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.04 177.09 10.51 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 126.177 1.791 . . . . 0.0 109.568 -170.085 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -129.31 126.97 40.17 Favored 'General case' 0 CA--C 1.516 -0.363 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.755 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 1.6 m -119.47 138.7 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 C-N-CA 125.001 1.32 . . . . 0.0 108.357 -177.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -85.36 107.88 17.57 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 104.497 -2.408 . . . . 0.0 104.497 168.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -81.49 57.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 C-N-CA 125.362 1.465 . . . . 0.0 107.971 -176.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 50.7 m 45.42 43.34 8.53 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.007 2.123 . . . . 0.0 113.159 -177.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 170.28 -42.57 0.2 Allowed Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.303 -0.72 . . . . 0.0 112.641 175.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.4 pt -141.8 150.17 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 C-N-CA 124.562 1.145 . . . . 0.0 109.514 -179.183 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -76.99 138.25 39.49 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.703 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -136.77 148.55 47.3 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 124.927 1.291 . . . . 0.0 109.307 173.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -68.05 148.22 51.3 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 169.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.48 143.27 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 173.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -92.36 145.23 24.63 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.593 0.757 . . . . 0.0 109.44 170.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 46.9 mt -112.53 13.48 20.08 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 118.2 -0.905 . . . . 0.0 112.959 -170.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 46.7 m -50.66 -37.13 39.15 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 120.889 1.677 . . . . 0.0 112.539 -178.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.8 mt -75.74 -11.71 60.04 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.41 -17.86 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 119.445 1.021 . . . . 0.0 113.343 -169.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.35 146.44 3.03 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.698 1.142 . . . . 0.0 111.139 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 p -75.88 -17.68 59.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.662 1.185 . . . . 0.0 112.552 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.2 m -112.84 161.95 16.36 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.432 1.093 . . . . 0.0 109.2 174.008 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -106.72 -179.41 3.93 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 124.701 1.2 . . . . 0.0 113.171 -169.397 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 23.0 mp0 -67.41 -14.37 62.87 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.895 2.078 . . . . 0.0 112.627 -176.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.4 m-80 -96.7 -37.32 10.36 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.176 0.99 . . . . 0.0 110.185 -178.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.79 28.59 1.04 Allowed Glycine 0 CA--C 1.53 1.025 0 C-N-CA 125.299 1.428 . . . . 0.0 112.507 178.257 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -127.63 158.24 70.68 Favored Pre-proline 0 CA--C 1.538 0.5 0 CA-C-N 119.149 1.474 . . . . 0.0 109.316 -176.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.36 144.43 85.81 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.867 1.712 . . . . 0.0 109.548 174.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.9 mtt-85 -69.54 13.14 0.14 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 114.619 1.34 . . . . 0.0 114.619 -174.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.6 t -53.62 131.02 15.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-N 120.379 1.445 . . . . 0.0 108.446 176.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.36 -14.59 54.08 Favored Glycine 0 CA--C 1.53 0.978 0 CA-C-O 118.531 -1.15 . . . . 0.0 113.589 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -77.05 162.02 27.84 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 119.715 1.758 . . . . 0.0 109.195 176.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -106.43 151.25 25.17 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.0 m -140.78 150.38 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 177.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -88.36 124.99 34.47 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 103.662 -2.718 . . . . 0.0 103.662 168.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.86 156.99 18.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 6.3 t-80 -154.02 -32.83 0.11 Allowed 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 123.0 0.52 . . . . 0.0 111.315 -175.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.2 m -133.79 -163.24 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 170.183 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -68.06 19.91 0.33 Allowed Glycine 0 CA--C 1.538 1.471 0 CA-C-N 119.64 1.109 . . . . 0.0 114.817 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -133.9 139.82 46.42 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.768 1.627 . . . . 0.0 107.956 -179.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.06 116.11 10.05 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 170.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 86.6 mmm -74.33 -43.69 55.63 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.1 p -155.71 153.03 29.31 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.781 0.833 . . . . 0.0 110.067 179.297 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.6 t -79.65 143.38 12.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 169.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.2 pt -138.55 160.76 31.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 124.175 0.99 . . . . 0.0 108.849 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 -80.62 164.91 22.52 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -53.91 -41.85 68.09 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 123.608 0.763 . . . . 0.0 111.439 170.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.62 -37.08 85.96 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.857 0.463 . . . . 0.0 110.99 -177.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -71.1 -38.84 72.36 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 177.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.98 -48.7 80.6 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 118.415 0.552 . . . . 0.0 110.157 174.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.3 mtt180 -61.62 -43.26 99.18 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 123.489 0.715 . . . . 0.0 110.45 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.93 -41.35 99.46 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.688 0.676 . . . . 0.0 111.295 177.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.5 m -64.69 -41.47 96.02 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 122.807 0.443 . . . . 0.0 110.096 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 83.7 mt -66.51 -36.85 83.72 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 119.053 0.842 . . . . 0.0 110.941 177.222 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -66.05 -40.66 91.12 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 118.607 0.64 . . . . 0.0 110.822 177.273 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.03 -52.37 63.14 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 122.704 0.402 . . . . 0.0 109.997 173.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 6.6 tt -55.43 -52.03 64.94 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 124.44 1.096 . . . . 0.0 109.984 -175.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -65.27 -15.63 62.7 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -172.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -121.69 -10.48 8.76 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 119.594 1.088 . . . . 0.0 113.79 -176.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 72.1 mtm -126.63 -5.71 6.39 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 119.423 1.01 . . . . 0.0 113.141 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -125.49 -48.82 1.67 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 119.147 0.885 . . . . 0.0 109.721 175.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -79.51 -16.99 55.06 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 122.73 0.412 . . . . 0.0 111.389 170.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . 0.293 35.6 m 45.35 44.17 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 C-N-CA 126.992 2.117 . . . . 0.0 113.43 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 81.89 141.11 0.06 OUTLIER Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 128.948 2.899 . . . . 0.0 111.313 169.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -63.95 -23.19 68.19 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.543 2.162 . . . . 0.0 112.731 -172.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -53.98 -20.94 7.01 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 125.696 1.598 . . . . 0.0 113.238 175.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.6 p -132.33 -36.25 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 C-N-CA 123.365 0.666 . . . . 0.0 111.108 170.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -67.09 -54.67 19.78 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 119.507 1.049 . . . . 0.0 111.64 -176.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.92 -34.73 77.18 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 117.551 0.675 . . . . 0.0 110.492 178.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 19.7 tp -58.76 -46.25 87.9 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 123.43 0.692 . . . . 0.0 110.696 176.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.3 tt -69.42 -41.63 76.1 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 124.11 0.964 . . . . 0.0 110.66 177.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 82.6 t80 -60.52 -35.12 75.21 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 118.494 0.588 . . . . 0.0 111.332 178.339 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -78.44 0.63 74.76 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 124.539 1.066 . . . . 0.0 113.094 175.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 55.01 26.5 8.1 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.938 2.095 . . . . 0.0 112.211 -176.325 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -73.86 -20.58 60.39 Favored 'General case' 0 CA--C 1.542 0.644 0 O-C-N 121.561 -0.712 . . . . 0.0 110.41 175.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt . . . . . 0 C--O 1.248 1.025 0 C-N-CA 127.219 2.208 . . . . 0.0 106.367 172.226 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.905 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.9 t -139.15 141.13 28.59 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 124.317 1.047 . . . . 0.0 108.849 -169.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -59.26 157.63 29.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.887 2.391 . . . . 0.0 112.919 169.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.32 172.67 40.17 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 169.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -99.61 135.73 40.6 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.47 79.97 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 170.448 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 7.5 tpm_? -80.09 -24.67 40.42 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.561 -0.712 . . . . 0.0 112.406 -169.324 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.57 158.58 43.74 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -130.0 146.3 34.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 176.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -121.78 -23.64 5.46 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.111 0.965 . . . . 0.0 111.734 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.25 -126.8 1.35 Allowed Glycine 0 C--N 1.333 0.403 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 178.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.4 t30 -63.8 -29.21 70.44 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 117.651 0.726 . . . . 0.0 110.303 169.129 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.7 mm100 -86.44 151.89 23.14 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.56 0.695 . . . . 0.0 109.235 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.56 166.02 25.4 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.034 1.334 . . . . 0.0 109.568 174.597 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -114.48 78.25 1.14 Allowed 'General case' 0 C--O 1.234 0.266 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 -173.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.4 t -74.19 123.39 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 -175.311 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -75.04 107.92 7.43 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 169.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.52 61.22 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.208 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 32.0 m 45.94 43.96 10.82 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 127.205 2.202 . . . . 0.0 113.696 176.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.63 -36.66 0.16 Allowed Glycine 0 CA--C 1.525 0.703 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.643 176.1 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -153.67 152.9 9.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.4 mt-30 -77.47 138.72 39.4 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.059 177.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -117.85 144.95 44.95 Favored 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 126.044 1.737 . . . . 0.0 107.196 171.597 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -74.58 129.93 38.63 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 169.737 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.8 t -137.01 136.14 47.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -176.23 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -82.4 126.26 31.98 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.166 1.386 . . . . 0.0 109.072 176.145 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 29.4 mt -100.76 10.95 40.51 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 117.95 -1.024 . . . . 0.0 112.971 -175.75 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 32.4 m -50.84 -36.62 38.5 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 121.285 1.857 . . . . 0.0 112.395 -174.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -74.49 -10.37 59.49 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.5 m -132.2 -17.61 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 119.445 1.021 . . . . 0.0 112.57 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.18 145.91 1.02 Allowed Glycine 0 CA--C 1.529 0.955 0 C-N-CA 125.175 1.369 . . . . 0.0 110.654 -171.217 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.4 m -73.63 -5.3 39.57 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.734 -0.862 . . . . 0.0 113.067 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.3 m -131.97 151.79 51.51 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.362 1.065 . . . . 0.0 110.027 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -66.08 165.64 13.14 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.876 2.071 . . . . 0.0 109.71 169.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.52 -37.5 57.69 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.29 1.436 . . . . 0.0 112.247 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -85.9 10.21 14.6 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.8 0.84 . . . . 0.0 112.052 -178.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.67 5.27 88.4 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.623 1.106 . . . . 0.0 113.382 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -70.1 132.53 88.24 Favored Pre-proline 0 CA--C 1.537 0.469 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.645 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -65.86 141.44 65.11 Favored 'Trans proline' 0 N--CA 1.458 -0.56 0 CA-C-N 121.321 1.507 . . . . 0.0 109.107 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.9 mtt-85 -72.77 8.59 1.43 Allowed 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 114.401 1.26 . . . . 0.0 114.401 -173.365 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.06 125.46 7.14 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 120.128 1.331 . . . . 0.0 108.712 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.67 -19.32 55.12 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.873 1.225 . . . . 0.0 113.241 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -70.12 167.45 17.72 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 119.061 1.431 . . . . 0.0 108.903 172.799 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 46.9 m95 -116.04 162.75 16.93 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.782 -0.574 . . . . 0.0 109.532 -179.01 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -156.61 146.21 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -169.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 83.1 mt -83.82 112.13 19.83 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 169.339 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.68 127.81 39.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 173.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -140.98 130.23 23.57 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 173.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.5 m 41.68 35.8 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 126.195 1.798 . . . . 0.0 114.541 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.8 6.93 79.11 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.076 -0.847 . . . . 0.0 114.092 175.5 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -122.41 154.78 37.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.951 1.376 . . . . 0.0 109.694 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.81 104.92 3.58 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 169.244 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.07 -47.84 60.28 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.261 0.482 . . . . 0.0 109.755 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.1 m -152.05 136.18 16.58 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.92 1.288 . . . . 0.0 108.017 178.33 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.2 p -84.13 138.72 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 169.532 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.4 pt -141.93 162.98 19.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 124.652 1.181 . . . . 0.0 110.24 -170.01 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -77.02 166.18 23.65 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 123.768 0.827 . . . . 0.0 109.84 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.59 -43.14 84.41 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.903 0.881 . . . . 0.0 110.629 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.49 -38.64 87.71 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.002 0.521 . . . . 0.0 110.829 -175.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -67.04 -44.36 80.41 Favored 'General case' 0 C--O 1.232 0.145 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.04 -48.58 79.62 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.9 tmm_? -58.77 -46.81 86.64 Favored 'General case' 0 C--N 1.334 -0.104 0 C-N-CA 124.543 1.137 . . . . 0.0 110.059 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -63.22 -43.12 99.01 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 118.492 0.587 . . . . 0.0 111.292 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -64.16 -42.01 96.92 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 178.756 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 39.5 mt -65.16 -40.42 94.32 Favored 'General case' 0 CA--C 1.522 -0.13 0 C-N-CA 123.82 0.848 . . . . 0.0 110.599 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -63.64 -41.21 98.26 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 122.982 0.513 . . . . 0.0 110.873 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -66.74 -48.38 69.33 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.276 0.23 . . . . 0.0 110.607 174.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 10.4 tt . . . . . 0 C--O 1.231 0.108 0 C-N-CA 124.433 1.093 . . . . 0.0 111.231 -173.231 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.711 0 N-CA-C 107.831 -2.108 . . . . 0.0 107.831 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.8 m -145.43 158.13 51.31 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 126.473 1.909 . . . . 0.0 108.191 -169.407 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.79 162.43 26.87 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 121.894 1.729 . . . . 0.0 110.659 169.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.32 164.35 37.14 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 169.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -89.43 127.28 35.82 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 72.6 mt -63.64 112.16 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.29 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.9 tpt85 -109.71 -30.63 7.79 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 118.113 -0.946 . . . . 0.0 110.994 -169.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 11.9 p -144.96 158.12 43.91 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 169.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -132.54 141.91 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 105.31 -2.107 . . . . 0.0 105.31 176.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -116.13 -21.71 9.28 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.448 1.099 . . . . 0.0 111.447 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.3 -126.17 1.34 Allowed Glycine 0 C--N 1.334 0.437 0 N-CA-C 106.835 -2.506 . . . . 0.0 106.835 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.0 t30 -62.08 -15.6 46.25 Favored 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 117.37 0.585 . . . . 0.0 112.062 169.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -117.48 156.21 28.39 Favored 'General case' 0 C--O 1.238 0.461 0 O-C-N 121.151 -0.968 . . . . 0.0 109.23 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.39 173.3 13.69 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 125.894 1.678 . . . . 0.0 109.402 -169.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -132.72 109.2 9.52 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 m -84.24 135.25 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 C-N-CA 124.232 1.013 . . . . 0.0 108.605 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -81.11 115.28 20.47 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 169.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 t -87.93 60.59 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 125.427 1.491 . . . . 0.0 107.185 176.033 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.5 m 50.15 36.42 12.29 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.923 1.689 . . . . 0.0 114.369 176.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.3 -31.86 0.26 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 121.348 -0.845 . . . . 0.0 112.966 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ILE . . . . . 0.403 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -138.77 140.45 38.98 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 C-N-CA 125.425 1.49 . . . . 0.0 108.818 179.867 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -77.63 141.98 39.14 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.098 174.214 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 56.7 mmt-85 -137.53 144.31 42.07 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 125.014 1.326 . . . . 0.0 108.727 172.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -77.5 149.54 34.96 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.655 0.782 . . . . 0.0 111.068 -172.151 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.79 143.36 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 124.978 1.311 . . . . 0.0 108.82 177.222 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -92.8 133.17 36.31 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 124.435 1.094 . . . . 0.0 108.77 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.0 mt -105.49 14.52 28.52 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 118.312 -0.851 . . . . 0.0 112.058 -171.31 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -45.99 -38.03 7.25 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.333 1.424 . . . . 0.0 113.114 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.2 mt -85.41 -3.86 58.98 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.821 0.848 . . . . 0.0 113.02 -172.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.28 -18.36 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.547 1.067 . . . . 0.0 113.02 -177.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.77 143.51 1.22 Allowed Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.063 1.316 . . . . 0.0 110.759 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.2 m -75.37 -8.89 57.88 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 12.5 p -125.21 152.2 44.86 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.548 1.139 . . . . 0.0 109.015 174.449 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -77.87 172.19 13.84 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.289 1.036 . . . . 0.0 110.349 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -57.59 -34.97 69.8 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.086 0.954 . . . . 0.0 112.213 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 18.0 p30 -80.41 -3.69 50.73 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.285 1.834 . . . . 0.0 113.102 177.043 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.38 -4.81 67.27 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.552 -1.138 . . . . 0.0 114.157 172.133 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -66.22 143.15 98.21 Favored Pre-proline 0 CA--C 1.537 0.454 0 CA-C-N 119.677 1.739 . . . . 0.0 109.087 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -64.42 143.09 81.39 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 121.878 1.719 . . . . 0.0 108.857 169.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 83.0 mtt-85 -72.8 1.6 8.27 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -170.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.0 m -50.24 137.89 6.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 120.994 1.725 . . . . 0.0 111.126 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.74 -26.37 18.72 Favored Glycine 0 CA--C 1.53 0.975 0 C-N-CA 124.759 1.171 . . . . 0.0 112.911 178.306 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -76.1 165.8 24.4 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 118.898 1.349 . . . . 0.0 108.404 173.109 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -105.18 156.52 18.02 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -144.37 135.17 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 57.5 tp -78.39 133.67 37.5 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 22.3 t -116.33 150.97 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 -178.18 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.37 133.4 24.22 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 125.368 1.467 . . . . 0.0 107.649 171.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.5 m 42.58 33.48 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 C-N-CA 126.211 1.804 . . . . 0.0 114.641 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.2 7.62 82.88 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 118.966 -0.908 . . . . 0.0 114.106 176.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -120.28 143.81 48.13 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 119.117 1.458 . . . . 0.0 108.191 175.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.0 130.42 46.65 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.177 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 28.0 ttt -89.66 -57.88 2.72 Favored 'General case' 0 C--O 1.233 0.236 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 18.5 m -151.99 144.91 24.44 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 124.293 1.037 . . . . 0.0 109.078 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 t -74.12 140.29 17.88 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 105.399 -2.075 . . . . 0.0 105.399 168.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 pt -137.7 160.3 34.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 123.573 0.749 . . . . 0.0 109.821 -173.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -76.96 165.21 24.96 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.691 0.796 . . . . 0.0 109.706 173.356 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -59.74 -42.83 94.04 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.467 0.707 . . . . 0.0 110.219 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -65.32 -36.38 83.87 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.066 0.547 . . . . 0.0 110.932 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.3 mt-10 -67.7 -35.05 78.09 Favored 'General case' 0 N--CA 1.457 -0.095 0 CA-C-O 119.129 -0.463 . . . . 0.0 110.113 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -47.32 83.67 Favored 'General case' 0 C--N 1.34 0.185 0 CA-C-N 118.95 0.795 . . . . 0.0 110.293 175.521 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -62.54 -43.55 98.54 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 118.167 0.44 . . . . 0.0 110.725 177.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.75 -40.89 96.71 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 118.131 0.423 . . . . 0.0 111.147 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.8 m -67.07 -42.48 84.64 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.245 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.9 mt -63.94 -39.05 93.26 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 119.204 0.911 . . . . 0.0 110.582 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.94 -46.89 79.69 Favored 'General case' 0 C--O 1.227 -0.091 0 C-N-CA 122.95 0.5 . . . . 0.0 110.585 175.396 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.41 99.53 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.566 0.621 . . . . 0.0 111.225 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.6 tp . . . . . 0 CA--C 1.528 0.134 0 C-N-CA 123.882 0.873 . . . . 0.0 111.601 -174.331 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.942 0 CA-C-O 119.713 -0.493 . . . . 0.0 112.213 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -146.47 149.5 37.58 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 125.973 1.709 . . . . 0.0 108.184 -172.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -75.05 171.17 18.84 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.232 1.954 . . . . 0.0 112.237 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -156.07 167.84 33.39 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -101.72 136.83 40.9 Favored 'General case' 0 C--O 1.231 0.127 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.5 mt -72.65 82.6 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 125.648 1.579 . . . . 0.0 107.895 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.5 mmt85 -76.6 -27.56 55.83 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.607 -0.683 . . . . 0.0 111.565 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.14 152.18 35.66 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -176.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 63.6 mt -129.65 144.75 37.14 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -121.13 -20.16 6.88 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 124.446 1.098 . . . . 0.0 111.835 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.408 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 164.05 -127.48 1.67 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 106.607 -2.597 . . . . 0.0 106.607 -178.598 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -70.38 14.3 0.13 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 124.462 1.105 . . . . 0.0 112.004 169.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.408 ' H ' ' C ' ' A' ' 14' ' ' GLY . 37.7 mt-30 -140.11 153.8 46.82 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 127.66 2.384 . . . . 0.0 106.636 -176.66 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.65 167.18 22.68 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.261 1.425 . . . . 0.0 109.106 178.236 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -121.24 76.31 1.23 Allowed 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 -174.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.5 m -73.03 136.68 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -170.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -79.15 117.72 20.44 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 171.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.4 t -85.04 50.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 125.059 1.343 . . . . 0.0 107.724 177.23 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 79.3 m 40.59 49.57 2.73 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.166 2.186 . . . . 0.0 113.371 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 176.64 -38.92 0.1 OUTLIER Glycine 0 CA--C 1.526 0.748 0 CA-C-O 119.531 -0.594 . . . . 0.0 112.24 175.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.0 tp -156.26 154.86 5.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 175.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.5 mt-30 -76.94 143.28 39.63 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 122.801 0.441 . . . . 0.0 109.954 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.19 138.17 51.57 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 169.816 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -73.85 133.83 43.23 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 78.7 t -140.95 130.63 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.684 1.594 . . . . 0.0 107.001 -173.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.22 140.74 45.27 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 124.863 1.265 . . . . 0.0 109.92 175.659 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.3 mt -113.65 11.85 18.29 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.861 0.864 . . . . 0.0 112.886 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.9 m -53.34 -34.74 58.68 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 120.833 1.651 . . . . 0.0 112.432 -175.502 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 86.4 mt -73.91 -12.86 60.79 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -176.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 m -133.43 -19.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 119.323 0.965 . . . . 0.0 112.897 -171.477 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.33 147.03 0.89 Allowed Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.098 1.332 . . . . 0.0 110.831 -171.177 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.2 m -76.57 -4.38 42.54 Favored 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.842 -0.799 . . . . 0.0 113.002 179.337 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.1 m -131.94 151.25 51.83 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 124.349 1.059 . . . . 0.0 109.965 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -65.77 165.59 12.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.945 2.098 . . . . 0.0 109.864 169.446 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -52.96 -37.49 61.18 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.317 1.447 . . . . 0.0 112.152 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -85.35 9.82 14.4 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.721 0.809 . . . . 0.0 112.015 -178.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.87 4.96 88.37 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 124.581 1.086 . . . . 0.0 113.464 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -69.87 132.28 88.82 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -65.92 141.2 63.76 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 CA-C-N 121.303 1.501 . . . . 0.0 109.011 174.572 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -72.45 13.72 0.32 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -172.394 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -54.08 129.27 14.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-N 120.227 1.376 . . . . 0.0 108.639 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.65 -17.64 55.61 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.827 1.203 . . . . 0.0 113.414 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -73.34 169.31 17.41 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.511 1.655 . . . . 0.0 109.162 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.7 m95 -120.16 156.59 30.77 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.947 0.899 . . . . 0.0 109.123 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 2.8 m -143.2 144.92 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 123.435 0.694 . . . . 0.0 109.402 178.296 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 59.3 mt -72.89 147.97 44.82 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 168.132 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.9 t -131.96 152.68 37.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -130.82 -60.08 0.98 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.974 0.91 . . . . 0.0 109.635 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.3 m -138.36 38.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 123.941 0.896 . . . . 0.0 110.614 -169.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.08 14.66 60.25 Favored Glycine 0 CA--C 1.528 0.906 0 CA-C-O 119.406 -0.663 . . . . 0.0 113.046 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -128.22 137.33 51.98 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 175.174 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.32 111.74 5.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 172.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 15.5 tpt -71.79 -49.01 42.66 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 118.031 0.378 . . . . 0.0 110.303 -175.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 13.5 m -152.55 151.1 30.27 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 124.959 1.304 . . . . 0.0 108.603 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 18.4 t -78.79 141.01 15.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 171.369 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.7 pt -138.9 -169.69 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 126.064 1.746 . . . . 0.0 108.794 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -126.97 -179.29 4.76 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.019 1.327 . . . . 0.0 110.125 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -54.92 -44.9 74.64 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.161 0.985 . . . . 0.0 111.249 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.31 -49.22 67.78 Favored 'General case' 0 C--O 1.231 0.131 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -172.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 26.0 mm-40 -64.84 -38.76 92.07 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.776 0.43 . . . . 0.0 110.28 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.41 -51.28 66.43 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 118.372 0.533 . . . . 0.0 110.61 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 63.3 mtt85 -66.91 -36.95 83.43 Favored 'General case' 0 CA--C 1.523 -0.064 0 CA-C-O 118.489 -0.767 . . . . 0.0 110.633 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.72 -43.66 98.42 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 119.121 0.873 . . . . 0.0 110.909 175.403 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.4 m -64.05 -45.9 86.79 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 122.979 0.512 . . . . 0.0 109.996 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 57.9 mt -64.33 -39.22 93.47 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 118.252 0.478 . . . . 0.0 110.858 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.6 -48.48 72.16 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 123.2 0.6 . . . . 0.0 110.319 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.01 88.54 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 117.872 0.305 . . . . 0.0 111.26 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? . . . . . 0 C--N 1.339 0.117 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.047 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.757 0 N-CA-C 107.114 -2.394 . . . . 0.0 107.114 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.3 m -140.13 166.73 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.564 1.545 . . . . 0.0 109.675 -168.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -54.9 153.54 24.8 Favored 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.565 2.176 . . . . 0.0 113.175 169.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -159.88 164.31 34.14 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 169.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -110.96 130.21 55.65 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.45 1.125 . . . . 0.0 109.204 -172.243 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.6 mt -66.05 120.98 14.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.351 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 52.3 tpt85 -121.11 -22.5 6.09 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 118.182 -0.913 . . . . 0.0 111.651 -175.446 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.65 155.6 42.57 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 170.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 50.3 mt -133.06 144.67 35.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -126.61 -18.67 4.74 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 123.858 0.863 . . . . 0.0 112.452 -174.495 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.75 -131.13 2.25 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 107.2 -2.36 . . . . 0.0 107.2 -178.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.5 p-10 -68.33 9.24 0.35 Allowed 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.145 0.978 . . . . 0.0 112.545 169.417 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -139.39 155.47 47.62 Favored 'General case' 0 C--O 1.239 0.523 0 C-N-CA 126.004 1.722 . . . . 0.0 107.542 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.8 174.88 10.06 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 125.453 1.501 . . . . 0.0 110.757 -176.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -122.18 114.51 20.96 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 178.33 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 89.1 t -111.83 125.56 69.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 -169.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -72.58 112.21 8.43 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 170.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 t -90.07 59.81 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.3 m 50.02 42.64 24.98 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.336 1.854 . . . . 0.0 113.5 178.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.2 -37.28 0.14 Allowed Glycine 0 CA--C 1.525 0.71 0 O-C-N 121.629 -0.67 . . . . 0.0 112.906 173.541 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 tp -155.33 155.79 5.46 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.464 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 62.8 mt-30 -74.65 147.37 41.61 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.709 0.766 . . . . 0.0 110.871 177.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.14 144.52 51.23 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.456 1.502 . . . . 0.0 107.255 169.293 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -69.84 135.71 49.93 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 169.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.65 121.03 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -173.35 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -66.64 134.67 52.77 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 169.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.2 tp -117.78 0.44 11.98 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 124.737 1.215 . . . . 0.0 110.358 -169.983 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.5 m -57.77 -30.84 65.96 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 124.721 1.209 . . . . 0.0 111.211 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 77.0 mt -67.89 -13.98 62.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.078 0.951 . . . . 0.0 112.884 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.74 -8.71 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 119.154 0.888 . . . . 0.0 112.1 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.57 136.22 1.68 Allowed Glycine 0 CA--C 1.525 0.699 0 C-N-CA 125.4 1.476 . . . . 0.0 110.388 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.5 m -75.88 161.19 29.18 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.238 0.615 . . . . 0.0 109.342 169.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.2 m 56.4 177.52 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.774 1.629 . . . . 0.0 112.597 -169.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -133.49 151.91 51.83 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 126.182 1.793 . . . . 0.0 108.221 -170.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.2 -21.58 34.44 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.026 1.331 . . . . 0.0 114.214 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -74.31 -7.2 51.98 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.487 0.585 . . . . 0.0 112.052 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.15 46.92 5.71 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -177.312 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.67 158.3 60.18 Favored Pre-proline 0 CA--C 1.535 0.399 0 C-N-CA 125.165 1.386 . . . . 0.0 108.664 -176.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -69.0 153.55 72.24 Favored 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 121.958 1.772 . . . . 0.0 109.892 169.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -73.16 3.37 5.7 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.615 0.968 . . . . 0.0 113.615 177.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.53 127.46 15.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-N 120.547 1.521 . . . . 0.0 108.457 -175.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.27 -24.76 30.64 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 124.892 1.234 . . . . 0.0 112.548 -176.31 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -70.53 162.06 29.49 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.056 1.428 . . . . 0.0 108.84 172.317 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.4 m95 -113.67 155.87 24.75 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -141.88 143.19 27.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.493 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.2 mt -77.32 127.9 33.39 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 103.743 -2.688 . . . . 0.0 103.743 168.645 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.5 m -131.2 126.65 59.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 119.341 0.973 . . . . 0.0 110.627 -170.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.438 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 3.5 t60 -89.17 -165.88 1.45 Allowed 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 169.522 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.438 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 18.3 m -47.71 -29.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 C-N-CA 125.815 1.646 . . . . 0.0 114.993 -172.55 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.74 33.07 0.17 Allowed Glycine 0 C--N 1.338 0.639 0 CA-C-O 118.819 -0.99 . . . . 0.0 112.4 175.29 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -145.71 134.17 21.97 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.822 1.311 . . . . 0.0 109.128 -174.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.34 117.91 17.66 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 169.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 72.2 mtp -77.31 -49.4 15.08 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.526 1.13 . . . . 0.0 109.056 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.9 m -151.35 162.46 40.87 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 125.851 1.661 . . . . 0.0 108.65 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.7 p -107.52 139.88 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 C-N-CA 124.87 1.268 . . . . 0.0 107.874 172.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.1 pt -141.26 161.75 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.095 1.358 . . . . 0.0 109.896 -173.359 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -75.44 165.26 25.4 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.916 0.886 . . . . 0.0 110.53 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.53 -40.9 72.43 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 124.729 1.211 . . . . 0.0 111.698 176.217 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.48 -40.21 67.1 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 122.942 0.497 . . . . 0.0 110.79 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.07 -40.79 97.02 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.091 0.556 . . . . 0.0 109.763 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.91 -48.97 78.05 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.666 -0.207 . . . . 0.0 110.748 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 75.4 mtt85 -64.34 -40.02 95.05 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 119.079 -0.486 . . . . 0.0 110.762 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.7 -42.73 99.79 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.467 0.576 . . . . 0.0 111.047 176.017 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.4 m -65.16 -43.69 90.92 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.151 0.58 . . . . 0.0 110.334 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.2 mt -61.95 -44.45 96.73 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.394 0.543 . . . . 0.0 109.846 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -63.68 -44.47 93.63 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 118.458 0.572 . . . . 0.0 111.146 179.318 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.36 82.04 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 122.663 0.385 . . . . 0.0 110.316 178.402 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? . . . . . 0 CA--C 1.528 0.101 0 C-N-CA 123.693 0.797 . . . . 0.0 109.711 178.323 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.763 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.7 m -143.3 163.75 35.33 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 125.208 1.403 . . . . 0.0 110.287 -168.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -53.77 157.13 10.66 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 123.075 2.517 . . . . 0.0 113.874 171.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.71 167.85 37.34 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 126.336 1.922 . . . . 0.0 108.648 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.2 tt0 -116.18 134.25 55.13 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.393 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 64.7 mt -75.04 74.86 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 125.649 1.58 . . . . 0.0 107.509 -176.146 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -70.73 -30.65 67.23 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-O 118.438 -0.792 . . . . 0.0 111.566 -172.172 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -148.81 155.7 41.31 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 177.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 57.0 mt -132.18 146.85 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -129.71 -20.06 3.26 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.854 0.862 . . . . 0.0 112.529 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 175.15 -134.47 2.74 Favored Glycine 0 C--N 1.334 0.418 0 N-CA-C 106.243 -2.743 . . . . 0.0 106.243 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.9 t30 -65.86 -15.74 63.2 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 118.386 1.093 . . . . 0.0 110.668 169.057 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -101.08 153.0 19.93 Favored 'General case' 0 C--O 1.239 0.544 0 C-N-CA 124.954 1.302 . . . . 0.0 109.123 175.438 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.34 159.52 42.06 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.313 1.445 . . . . 0.0 109.14 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -106.77 86.83 2.39 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.087 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.61 127.6 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 -174.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -71.37 106.89 4.06 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 169.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.77 67.24 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.0 48.05 7.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.291 2.236 . . . . 0.0 113.739 178.196 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 174.77 -42.03 0.12 Allowed Glycine 0 CA--C 1.524 0.646 0 CA-C-O 119.692 -0.505 . . . . 0.0 112.219 172.108 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -156.97 156.1 4.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 C-N-CA 124.676 1.19 . . . . 0.0 108.175 175.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -67.76 136.06 53.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.23 0.612 . . . . 0.0 110.469 176.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.2 mpt_? -123.88 148.61 46.67 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 106.327 -1.731 . . . . 0.0 106.327 169.481 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -70.59 136.81 49.5 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.5 t -138.59 131.25 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -83.21 126.22 32.4 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 169.738 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.1 mt -83.29 36.86 0.53 Allowed 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 123.64 0.776 . . . . 0.0 111.335 -173.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -45.87 -40.33 9.81 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.412 2.285 . . . . 0.0 114.443 -169.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.2 mt -106.23 4.56 28.99 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 118.853 -0.594 . . . . 0.0 112.282 -169.309 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.3 m -133.97 -26.68 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.981 0.809 . . . . 0.0 111.937 -173.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.89 152.79 1.94 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.095 0.855 . . . . 0.0 110.979 -175.268 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 m -77.18 -6.86 54.56 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m -126.72 151.58 47.98 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.3 1.04 . . . . 0.0 109.075 175.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.5 t0 -84.51 176.57 8.55 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 124.308 1.043 . . . . 0.0 110.665 -178.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -55.68 -37.08 67.85 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.917 1.287 . . . . 0.0 112.102 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -84.12 -2.0 55.98 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.627 0.771 . . . . 0.0 112.929 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.18 -3.26 66.47 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.323 -1.265 . . . . 0.0 114.241 173.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -67.38 147.81 98.8 Favored Pre-proline 0 CA--C 1.538 0.506 0 CA-C-N 119.91 1.855 . . . . 0.0 109.046 175.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -64.87 141.93 73.51 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.541 1.494 . . . . 0.0 108.743 169.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.4 mtt-85 -70.94 11.39 0.4 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.7 p -56.38 129.23 17.74 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 CA-C-N 119.968 1.258 . . . . 0.0 109.031 -176.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.04 -14.46 57.18 Favored Glycine 0 CA--C 1.534 1.24 0 CA-C-O 118.226 -1.319 . . . . 0.0 113.972 -178.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -70.34 166.03 21.11 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.824 1.812 . . . . 0.0 108.969 170.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -112.25 161.22 16.83 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 121.538 0.685 . . . . 0.0 109.871 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.75 140.9 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 -172.43 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.8 111.64 12.55 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 104.894 -2.262 . . . . 0.0 104.894 169.321 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 51.3 t -93.11 132.22 37.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -144.24 130.41 19.63 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 1.7 t 45.74 37.34 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 125.177 1.391 . . . . 0.0 112.688 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.08 16.37 79.6 Favored Glycine 0 CA--C 1.534 1.251 0 O-C-N 120.916 -1.115 . . . . 0.0 114.308 176.289 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -128.49 161.95 28.35 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 119.315 1.558 . . . . 0.0 109.956 170.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.89 111.34 16.12 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.243 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 16.0 tpt -74.02 -51.5 15.67 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.002 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.4 m -154.21 138.37 16.51 Favored 'General case' 0 C--N 1.342 0.247 0 C-N-CA 124.305 1.042 . . . . 0.0 108.912 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -77.54 142.42 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 169.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.2 pt -139.91 160.51 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 124.355 1.062 . . . . 0.0 109.84 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -75.27 165.12 25.68 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 123.842 0.857 . . . . 0.0 110.46 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -54.51 -41.68 69.92 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 124.732 1.213 . . . . 0.0 111.467 174.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.4 -39.42 67.98 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 122.988 0.515 . . . . 0.0 110.786 -178.129 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -64.61 -40.7 95.97 Favored 'General case' 0 N--CA 1.461 0.088 0 C-N-CA 123.009 0.524 . . . . 0.0 109.865 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.43 -49.42 76.92 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.838 0.29 . . . . 0.0 110.562 177.606 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 76.1 mtt85 -64.45 -40.12 95.12 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-O 119.03 -0.51 . . . . 0.0 110.665 -178.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.93 -41.83 99.61 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 118.602 0.637 . . . . 0.0 111.129 176.055 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.7 m -65.42 -43.43 90.53 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.813 0.445 . . . . 0.0 110.032 178.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -64.51 -40.04 94.89 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 118.765 0.711 . . . . 0.0 110.549 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -63.21 -44.0 96.54 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 118.202 0.455 . . . . 0.0 110.748 176.084 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.64 -47.14 86.78 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 122.992 0.517 . . . . 0.0 110.204 175.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.7 mt . . . . . 0 CA--C 1.538 0.498 0 C-N-CA 125.039 1.336 . . . . 0.0 113.35 177.024 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.74 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.1 p -153.04 145.33 17.05 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 126.3 1.84 . . . . 0.0 106.472 -169.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -75.41 168.55 24.31 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.617 1.545 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.42 -176.88 42.24 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 172.532 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -95.99 137.86 34.46 Favored 'General case' 0 C--O 1.231 0.116 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 178.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 68.9 mt -71.47 78.81 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 171.431 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -67.51 -30.22 69.83 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.446 -0.784 . . . . 0.0 110.301 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.18 150.01 26.6 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 124.512 1.125 . . . . 0.0 108.051 -173.201 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 49.8 mt -119.98 149.79 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.708 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -145.48 65.17 1.24 Allowed 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 126.324 1.85 . . . . 0.0 107.468 -170.007 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 -124.71 18.71 Favored Glycine 0 C--N 1.338 0.64 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -173.146 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -68.27 -25.05 64.97 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 122.787 0.435 . . . . 0.0 111.913 172.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -86.1 170.92 11.77 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 121.86 0.838 . . . . 0.0 109.835 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.55 159.79 41.8 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.545 1.538 . . . . 0.0 108.19 169.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.58 75.97 0.95 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.238 -2.134 . . . . 0.0 105.238 177.281 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 79.3 t -71.74 126.52 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 124.904 1.282 . . . . 0.0 107.563 -172.207 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -79.26 111.02 15.08 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 174.196 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.5 t -82.06 60.21 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 C-N-CA 125.668 1.587 . . . . 0.0 107.282 172.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 55.5 m 43.67 41.39 3.53 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.11 2.164 . . . . 0.0 114.432 176.578 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 161.67 -23.83 0.23 Allowed Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.157 -0.802 . . . . 0.0 113.676 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.7 tp -150.29 149.43 14.45 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 176.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -92.17 139.06 31.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 -179.221 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -129.69 144.97 51.54 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.916 1.287 . . . . 0.0 108.519 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -73.84 137.61 43.91 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 71.6 t -137.03 143.67 34.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -99.8 119.8 38.75 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.164 1.386 . . . . 0.0 107.539 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.9 mt -91.17 12.49 19.91 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 117.88 -1.057 . . . . 0.0 113.03 -172.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -48.65 -36.43 15.91 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 121.29 1.859 . . . . 0.0 113.73 -174.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.0 mt -88.55 -2.63 58.7 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -173.268 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.07 -19.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 119.344 0.975 . . . . 0.0 112.672 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.0 146.84 2.93 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 125.259 1.409 . . . . 0.0 111.131 -175.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.1 m -74.97 -12.64 60.39 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.49 0.716 . . . . 0.0 112.18 174.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.4 m -117.89 166.34 12.6 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.603 1.161 . . . . 0.0 109.316 172.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -115.65 163.39 15.87 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.185 1.794 . . . . 0.0 110.446 -169.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -54.18 -36.74 63.72 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.397 1.479 . . . . 0.0 111.265 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 -74.44 1.22 12.31 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.499 1.52 . . . . 0.0 113.059 -178.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.02 45.61 11.52 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 121.014 -1.054 . . . . 0.0 111.098 174.331 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.6 pt20 -141.64 151.34 60.08 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.28 1.432 . . . . 0.0 108.611 -177.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -66.52 147.81 82.76 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 122.08 1.853 . . . . 0.0 109.159 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -73.71 7.93 2.2 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.9 m -54.57 133.37 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 120.537 1.517 . . . . 0.0 109.892 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.11 -17.95 34.58 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-O 118.231 -1.316 . . . . 0.0 113.38 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -72.57 164.73 25.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 119.708 1.754 . . . . 0.0 108.735 174.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 33.7 m95 -109.2 154.0 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.0 p -146.61 140.22 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -172.498 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 65.6 tp -89.24 148.09 23.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 169.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 t -124.99 142.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -103.48 -52.15 3.06 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.915 0.486 . . . . 0.0 110.355 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.4 p -157.81 63.12 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 -38.36 1.81 Allowed Glycine 0 CA--C 1.529 0.946 0 C-N-CA 124.746 1.165 . . . . 0.0 112.034 -172.418 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -69.49 135.18 49.81 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 118.639 1.22 . . . . 0.0 109.159 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.43 132.03 52.61 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 169.273 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 21.9 ttt -84.81 -55.28 4.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.13 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.3 m -155.82 149.46 25.04 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 124.768 1.227 . . . . 0.0 108.844 -177.338 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.9 p -74.94 142.78 14.14 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 168.418 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.9 pt -138.32 169.98 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 C-N-CA 124.104 0.961 . . . . 0.0 109.682 -172.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.38 169.74 8.68 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.754 0.822 . . . . 0.0 109.575 169.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -62.43 -34.39 76.68 Favored 'General case' 0 C--N 1.334 -0.084 0 CA-C-O 118.68 -0.676 . . . . 0.0 112.452 -173.171 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.85 -39.78 95.01 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.022 0.828 . . . . 0.0 110.743 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -65.96 -41.15 91.61 Favored 'General case' 0 C--O 1.232 0.152 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.509 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.24 -50.33 72.17 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 117.916 0.325 . . . . 0.0 110.351 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 43.8 mmt-85 -63.48 -43.48 97.18 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 118.877 -0.582 . . . . 0.0 110.279 -179.012 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.75 -43.5 98.72 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 118.484 0.584 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.0 m -66.6 -43.55 84.52 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 122.749 0.42 . . . . 0.0 110.128 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.4 mt -63.63 -41.25 98.28 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 119.084 0.856 . . . . 0.0 110.499 178.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -63.31 -44.63 94.43 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 122.874 0.47 . . . . 0.0 110.417 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.18 -48.91 76.38 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.828 0.451 . . . . 0.0 110.76 177.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 56.9 mt . . . . . 0 N--CA 1.463 0.178 0 C-N-CA 123.281 0.633 . . . . 0.0 111.028 -177.659 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.522 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.4 t -142.7 141.7 20.94 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 -170.036 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -55.47 165.63 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.892 2.395 . . . . 0.0 113.017 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.88 175.67 35.09 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 169.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -116.82 136.43 52.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.8 mt -70.56 96.26 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 N-CA-C 105.931 -1.878 . . . . 0.0 105.931 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -85.56 -42.86 14.0 Favored 'General case' 0 N--CA 1.462 0.132 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 -169.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 p -147.22 158.43 43.95 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.617 1.567 . . . . 0.0 108.112 176.167 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 52.3 mt -127.46 146.57 33.0 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -177.453 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -123.96 -19.18 5.74 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.065 0.946 . . . . 0.0 112.294 -176.229 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.6 -127.58 1.59 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -66.75 2.29 1.44 Allowed 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 123.932 0.893 . . . . 0.0 112.384 169.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -134.28 154.23 51.42 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 126.875 2.07 . . . . 0.0 107.314 -174.186 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.83 155.33 47.3 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.625 1.17 . . . . 0.0 109.382 -179.183 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -99.56 78.7 2.19 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.9 t -68.13 125.8 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 -176.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -75.66 105.18 6.55 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 169.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 t -81.52 63.25 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 37.8 m 48.95 39.52 14.72 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.495 1.918 . . . . 0.0 113.315 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.02 -48.14 0.19 Allowed Glycine 0 CA--C 1.526 0.728 0 CA-C-O 119.255 -0.747 . . . . 0.0 112.01 174.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.0 mm -137.16 143.28 35.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -174.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -71.78 141.88 49.7 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.33 0.586 . . . . 0.0 110.775 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -133.35 144.14 49.43 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 125.622 1.569 . . . . 0.0 106.999 169.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -73.06 134.59 44.63 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.158 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 87.6 t -138.3 129.99 37.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -79.57 143.34 34.86 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 122.993 0.517 . . . . 0.0 109.886 174.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 36.3 mt -114.94 15.24 17.32 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.089 0.956 . . . . 0.0 112.668 -169.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.7 m -50.64 -37.32 39.89 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 120.886 1.676 . . . . 0.0 112.463 -177.398 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.4 mt -77.08 -8.54 57.64 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -174.45 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.39 -20.11 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 119.517 1.053 . . . . 0.0 112.992 -172.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.16 140.37 0.74 Allowed Glycine 0 CA--C 1.529 0.913 0 C-N-CA 125.244 1.402 . . . . 0.0 110.886 -172.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.8 m -73.82 -17.73 61.03 Favored 'General case' 0 CA--C 1.535 0.374 0 O-C-N 122.024 -0.692 . . . . 0.0 112.313 176.062 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.9 m -93.0 135.17 34.41 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 123.809 0.843 . . . . 0.0 109.043 175.253 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -66.38 158.18 29.93 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.093 1.757 . . . . 0.0 109.598 169.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -53.47 -29.96 38.48 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.346 1.459 . . . . 0.0 112.176 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -75.66 -12.67 60.25 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.26 48.63 4.5 Favored Glycine 0 CA--C 1.53 1.029 0 CA-C-N 119.007 0.821 . . . . 0.0 111.166 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -143.75 160.54 50.05 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 126.717 2.007 . . . . 0.0 107.409 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -64.68 141.96 74.85 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 CA-C-N 121.586 1.602 . . . . 0.0 110.538 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -69.53 13.87 0.12 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.5 m -54.93 132.87 18.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 120.354 1.434 . . . . 0.0 110.05 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.65 -17.79 53.05 Favored Glycine 0 CA--C 1.532 1.096 0 CA-C-O 118.479 -1.178 . . . . 0.0 113.458 -178.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -71.94 160.94 31.68 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 119.699 1.75 . . . . 0.0 109.081 174.095 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.3 m95 -107.68 161.17 15.11 Favored 'General case' 0 C--O 1.232 0.178 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 p -154.05 146.19 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -169.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.9 mt -89.89 139.63 30.4 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 172.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.3 t -136.15 143.35 36.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -178.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 5.5 t60 -141.44 -39.05 0.4 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.407 0.683 . . . . 0.0 112.487 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.36 27.08 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 119.026 0.83 . . . . 0.0 112.029 -171.174 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.99 16.73 80.52 Favored Glycine 0 CA--C 1.534 1.224 0 O-C-N 121.446 -0.784 . . . . 0.0 112.526 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -129.03 144.43 51.19 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 172.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.12 122.59 17.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 171.161 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 68.5 mtp -76.76 -47.18 22.5 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.4 m -163.74 149.05 10.89 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 126.131 1.772 . . . . 0.0 108.144 176.214 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.1 t -80.37 145.28 9.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 169.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.2 pt -139.51 161.44 27.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.447 1.499 . . . . 0.0 109.198 -176.214 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -84.45 173.45 10.87 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.344 0.592 . . . . 0.0 110.894 174.211 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -69.99 -30.18 67.45 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 121.758 -0.589 . . . . 0.0 112.294 -170.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -73.63 -40.6 63.65 Favored 'General case' 0 N--CA 1.462 0.129 0 O-C-N 121.283 -0.886 . . . . 0.0 109.837 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -61.36 -41.35 96.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.224 0.61 . . . . 0.0 109.917 174.397 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.43 -49.41 75.57 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 117.983 0.356 . . . . 0.0 110.416 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 86.3 mtm180 -63.7 -40.2 96.19 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 119.13 -0.462 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.2 -41.9 99.24 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 118.759 0.709 . . . . 0.0 110.954 176.696 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -67.49 -38.64 84.66 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 122.083 -0.386 . . . . 0.0 110.282 178.225 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 53.0 mt -65.49 -38.03 88.57 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 119.079 0.854 . . . . 0.0 110.67 176.289 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -64.76 -43.86 91.93 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 118.605 0.639 . . . . 0.0 110.293 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.52 -43.24 99.29 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.962 0.505 . . . . 0.0 111.142 176.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? . . . . . 0 N--CA 1.464 0.255 0 C-N-CA 124.405 1.082 . . . . 0.0 109.909 176.936 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.936 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 98.5 t -143.88 139.39 16.03 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -171.109 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.83 159.89 31.44 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.666 1.577 . . . . 0.0 112.582 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.3 168.1 33.04 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 172.294 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -89.9 143.02 27.15 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 174.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 70.0 mt -74.17 76.64 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.32 1.448 . . . . 0.0 107.205 176.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -64.87 -39.18 93.14 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 126.088 1.755 . . . . 0.0 110.916 -177.029 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.0 m -150.26 153.78 36.78 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.35 147.2 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 178.142 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -116.39 -22.33 8.84 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.37 1.468 . . . . 0.0 111.565 -169.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 154.29 -122.92 1.3 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 105.094 -3.203 . . . . 0.0 105.094 -177.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -72.81 15.68 0.18 Allowed 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.101 0.961 . . . . 0.0 111.121 168.6 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.419 ' H ' ' C ' ' A' ' 14' ' ' GLY . 20.6 mt-30 -141.53 169.87 16.79 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 128.03 2.532 . . . . 0.0 106.569 -174.523 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.78 21.27 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.399 1.08 . . . . 0.0 109.4 173.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.3 mttp -118.26 72.58 0.87 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 105.604 -1.999 . . . . 0.0 105.604 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.5 m -70.13 137.2 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 C-N-CA 124.553 1.141 . . . . 0.0 109.326 -169.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -85.19 111.89 20.23 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 175.553 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.2 m -80.45 38.94 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 C-N-CA 124.181 0.992 . . . . 0.0 110.979 178.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 75.8 m 48.13 53.53 11.56 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.349 1.86 . . . . 0.0 111.855 -169.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -179.52 -41.3 0.07 OUTLIER Glycine 0 CA--C 1.524 0.62 0 CA-C-O 119.721 -0.488 . . . . 0.0 112.415 173.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.4 tp -156.0 156.06 5.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 -77.12 138.73 39.68 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 173.066 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -130.9 131.99 44.85 Favored 'General case' 0 C--N 1.333 -0.12 0 C-N-CA 125.466 1.506 . . . . 0.0 107.789 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -72.29 130.96 42.01 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 49.1 t -141.44 133.55 28.68 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 125.683 1.593 . . . . 0.0 107.323 -173.764 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -64.79 136.71 57.2 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 122.689 0.395 . . . . 0.0 110.407 172.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.9 mt -112.92 0.74 15.21 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.165 -0.921 . . . . 0.0 111.569 173.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.3 m -54.99 -31.75 61.21 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 121.061 1.755 . . . . 0.0 111.724 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 56.8 mt -67.87 -15.26 63.53 Favored 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 113.642 0.979 . . . . 0.0 113.642 178.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.64 -10.83 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.481 1.112 . . . . 0.0 112.79 -175.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.31 141.02 0.83 Allowed Glycine 0 CA--C 1.529 0.922 0 C-N-CA 125.527 1.537 . . . . 0.0 110.397 -170.157 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.4 m -76.29 -6.2 50.43 Favored 'General case' 0 CA--C 1.536 0.432 0 O-C-N 121.817 -0.813 . . . . 0.0 112.533 174.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 80.4 m -110.32 147.96 32.87 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 124.139 0.976 . . . . 0.0 109.489 175.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -68.94 171.65 7.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 126.635 1.974 . . . . 0.0 110.564 176.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 21.9 mm-40 -58.25 -15.36 9.79 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.149 1.38 . . . . 0.0 113.505 -177.056 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -117.96 8.66 12.6 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.529 1.532 . . . . 0.0 112.896 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.73 -2.11 69.47 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-O 118.805 -0.997 . . . . 0.0 114.545 170.36 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -67.01 154.54 92.28 Favored Pre-proline 0 CA--C 1.537 0.444 0 CA-C-N 119.373 1.586 . . . . 0.0 108.797 169.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -64.84 143.32 79.48 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 CA-C-N 121.18 1.457 . . . . 0.0 109.382 169.686 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.1 mtt-85 -70.51 10.96 0.4 Allowed 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.966 1.098 . . . . 0.0 113.966 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.9 p -56.44 132.34 20.4 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 O-C-N 120.759 -1.213 . . . . 0.0 109.03 -175.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.7 -15.79 49.74 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 118.097 -1.391 . . . . 0.0 114.076 -178.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -69.05 170.28 10.21 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 120.023 1.912 . . . . 0.0 108.906 169.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -119.66 157.62 28.1 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 177.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.3 p -151.56 136.3 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -171.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 81.0 mt -71.35 145.37 49.47 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 169.44 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 39.1 t -117.06 143.24 27.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 176.004 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -139.14 118.84 13.09 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 173.154 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . 0.286 29.4 m 44.45 28.87 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.461 2.304 . . . . 0.0 115.686 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 98.81 10.87 48.55 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 121.188 -0.945 . . . . 0.0 114.392 178.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -125.79 146.62 49.71 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 119.044 1.422 . . . . 0.0 108.484 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.12 114.44 3.12 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.615 0.766 . . . . 0.0 109.523 172.217 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 12.7 tpt -80.91 -42.71 20.96 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 58.3 m -166.02 147.54 6.88 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.865 1.666 . . . . 0.0 108.328 171.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 96.6 t -75.54 143.56 13.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 169.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 33.7 pt -139.36 162.19 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.028 1.331 . . . . 0.0 109.782 -175.635 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -74.14 165.22 25.53 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-O 121.48 0.657 . . . . 0.0 110.262 172.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -56.62 -43.2 79.99 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.191 1.396 . . . . 0.0 111.318 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.37 -38.85 85.39 Favored 'General case' 0 C--N 1.338 0.1 0 C-N-CA 122.801 0.44 . . . . 0.0 110.825 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -65.97 -40.36 91.18 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.31 -49.38 74.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 117.939 0.336 . . . . 0.0 110.478 178.024 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 47.6 mtm105 -61.57 -42.17 98.46 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 119.12 -0.467 . . . . 0.0 110.809 179.359 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.4 -42.83 99.73 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 118.5 0.591 . . . . 0.0 111.102 177.286 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.7 m -65.84 -41.31 91.92 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.841 0.456 . . . . 0.0 110.273 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.0 mt -65.23 -40.67 94.36 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.981 0.809 . . . . 0.0 110.426 178.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -64.4 -44.1 92.36 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 118.717 0.689 . . . . 0.0 110.696 177.114 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.3 -46.03 92.01 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.95 0.5 . . . . 0.0 110.509 176.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.0 mt . . . . . 0 C--O 1.227 -0.101 0 CA-C-O 118.771 -0.633 . . . . 0.0 110.758 -179.67 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.315 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 9.0 p -148.44 149.95 32.86 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 123.69 0.796 . . . . 0.0 109.121 -169.339 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.03 168.58 16.95 Favored 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 122.549 2.166 . . . . 0.0 111.882 169.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.66 172.9 41.27 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.621 2.057 . . . . 0.0 108.621 170.375 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -116.71 129.58 56.21 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 118.216 1.008 . . . . 0.0 108.982 -177.112 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 63.8 mt -70.27 127.63 32.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 -178.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -120.99 -29.65 4.54 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 118.247 -0.882 . . . . 0.0 112.448 -170.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.6 155.32 40.09 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.0 mt -132.37 124.81 52.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 N-CA-C 106.642 -1.614 . . . . 0.0 106.642 -177.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -86.89 -32.24 20.3 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.506 0.722 . . . . 0.0 110.4 172.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.58 -114.03 0.58 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 107.69 -2.164 . . . . 0.0 107.69 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -67.22 -0.66 3.6 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.287 1.035 . . . . 0.0 112.997 172.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -135.95 155.57 50.08 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 125.632 1.573 . . . . 0.0 107.438 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.23 151.69 38.8 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.321 1.048 . . . . 0.0 110.04 -171.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.0 tttt -90.85 133.1 35.49 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.23 130.49 72.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 -174.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -82.31 110.0 17.08 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 169.152 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.5 t -84.4 64.86 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 178.205 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.6 m 52.76 29.43 7.51 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.615 1.966 . . . . 0.0 114.94 171.386 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 158.27 -23.67 0.37 Allowed Glycine 0 CA--C 1.525 0.675 0 CA-C-N 119.121 0.873 . . . . 0.0 113.584 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.7 tp -146.45 149.63 15.86 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -88.51 150.27 23.2 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.983 0.42 . . . . 0.0 110.236 -175.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -139.5 150.08 44.71 Favored 'General case' 0 N--CA 1.464 0.227 0 C-N-CA 124.566 1.146 . . . . 0.0 108.703 169.625 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.54 138.83 35.38 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 169.015 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 50.5 t -136.38 131.88 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -173.641 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.34 138.64 37.77 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.468 0.707 . . . . 0.0 109.71 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.99 10.83 16.35 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.946 0.898 . . . . 0.0 112.211 -171.212 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.9 m -53.1 -34.07 55.03 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 120.265 1.393 . . . . 0.0 111.991 -177.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 85.2 mt -73.38 -12.93 60.99 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.769 0.827 . . . . 0.0 113.136 -176.445 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.36 -20.3 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 119.516 1.053 . . . . 0.0 113.188 -169.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.54 146.32 6.03 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 124.334 0.968 . . . . 0.0 111.457 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.1 p -74.41 -6.71 49.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.949 1.7 . . . . 0.0 113.581 -176.55 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.8 m -135.49 157.14 47.64 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 125.385 1.474 . . . . 0.0 108.177 171.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -66.07 165.11 14.06 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.079 1.352 . . . . 0.0 110.451 169.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -53.95 -38.33 64.84 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.935 1.294 . . . . 0.0 111.657 176.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -87.06 11.83 12.83 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.861 0.865 . . . . 0.0 111.85 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.98 6.97 88.48 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 124.583 1.087 . . . . 0.0 113.492 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -67.71 134.2 92.45 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 118.588 1.194 . . . . 0.0 108.206 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.27 143.29 53.62 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.531 2.154 . . . . 0.0 111.44 171.633 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -69.7 -17.79 63.5 Favored 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 118.043 -0.98 . . . . 0.0 112.836 175.802 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -55.32 134.82 18.72 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 120.297 1.408 . . . . 0.0 109.125 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.02 -21.27 20.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 124.561 1.077 . . . . 0.0 112.735 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -71.87 159.64 33.94 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 119.09 1.445 . . . . 0.0 108.162 171.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -106.7 158.41 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.67 139.52 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -169.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -83.18 133.08 35.04 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 169.686 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.2 t -121.44 135.76 60.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 4.7 t60 -137.12 -48.38 0.6 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.269 0.628 . . . . 0.0 111.108 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.4 m -136.3 27.63 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 123.75 0.82 . . . . 0.0 111.205 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.12 15.53 78.56 Favored Glycine 0 CA--C 1.531 1.068 0 O-C-N 121.531 -0.73 . . . . 0.0 112.464 -174.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -126.39 147.8 49.71 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 125.578 1.551 . . . . 0.0 107.095 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.44 105.18 1.4 Allowed 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.379 1.071 . . . . 0.0 108.257 172.009 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.4 ttt -70.6 -46.17 63.91 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 24.6 m -152.53 158.69 42.89 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.136 1.774 . . . . 0.0 107.445 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 44.1 t -121.0 140.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 174.805 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.0 pt -141.66 161.93 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 C-N-CA 125.712 1.605 . . . . 0.0 110.081 -171.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -74.66 168.34 20.0 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.669 0.788 . . . . 0.0 110.507 171.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -63.1 -42.29 99.55 Favored 'General case' 0 C--O 1.227 -0.09 0 CA-C-O 119.167 -0.444 . . . . 0.0 111.963 -173.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.83 -41.41 87.49 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.499 0.59 . . . . 0.0 110.315 -173.718 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.59 -36.43 82.7 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 122.578 0.351 . . . . 0.0 110.49 173.403 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.88 -40.57 83.54 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-N 119.05 0.841 . . . . 0.0 111.507 176.458 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 10.0 mmt85 -66.59 -38.83 87.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 119.291 0.95 . . . . 0.0 109.513 178.485 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.48 -42.71 99.68 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 118.015 0.371 . . . . 0.0 110.919 174.103 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.6 m -62.06 -40.87 97.24 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.34 0.656 . . . . 0.0 110.417 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 21.4 mt -63.86 -39.15 93.54 Favored 'General case' 0 C--N 1.338 0.073 0 O-C-N 121.668 -0.645 . . . . 0.0 110.943 178.156 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -68.2 -44.33 76.06 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.383 0.992 . . . . 0.0 110.677 175.425 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.53 -31.41 70.49 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.247 1.019 . . . . 0.0 111.821 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 62.3 tp . . . . . 0 N--CA 1.454 -0.255 0 C-N-CA 123.558 0.743 . . . . 0.0 110.339 174.444 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.92 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.1 t -139.24 143.41 36.28 Favored Pre-proline 0 CA--C 1.543 0.688 0 C-N-CA 124.296 1.038 . . . . 0.0 109.007 -169.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.25 155.62 24.0 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.632 2.221 . . . . 0.0 112.301 169.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.12 170.66 39.44 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 169.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.1 tt0 -116.3 125.25 51.88 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 123.982 0.913 . . . . 0.0 108.836 -174.196 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.03 129.33 27.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -114.42 -33.93 5.43 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 118.058 -0.972 . . . . 0.0 111.663 -176.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.4 p -148.15 157.25 43.39 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 47.1 mt -132.51 144.14 37.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -123.15 -19.29 6.07 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.364 1.066 . . . . 0.0 111.875 -176.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.46 -127.18 1.53 Allowed Glycine 0 C--N 1.336 0.562 0 N-CA-C 106.815 -2.514 . . . . 0.0 106.815 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -63.92 -10.23 19.86 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 117.514 0.657 . . . . 0.0 112.365 169.469 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -119.92 159.2 25.14 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.523 1.129 . . . . 0.0 110.509 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.48 167.72 27.11 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 125.746 1.618 . . . . 0.0 109.544 -172.558 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.33 132.28 54.52 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 171.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 52.7 t -126.35 123.78 64.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -174.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -72.81 111.13 7.67 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.2 63.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.9 m 47.18 42.47 13.31 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.885 2.074 . . . . 0.0 114.026 175.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.55 -31.17 0.19 Allowed Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.169 174.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -152.41 151.45 11.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 177.802 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -73.14 137.5 45.19 Favored 'General case' 0 C--O 1.234 0.266 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -122.53 148.26 45.4 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 124.595 1.158 . . . . 0.0 108.188 169.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -72.82 134.71 45.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 123.82 0.848 . . . . 0.0 108.983 172.72 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -140.5 157.28 24.21 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 C-N-CA 124.787 1.235 . . . . 0.0 108.096 -176.788 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -112.61 142.58 45.03 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 125.415 1.486 . . . . 0.0 108.815 172.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.9 mt -113.3 7.59 17.78 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.284 1.034 . . . . 0.0 112.328 -169.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 28.9 p -57.55 -29.15 64.16 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.599 1.545 . . . . 0.0 113.124 -173.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -70.53 -16.36 62.88 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.691 0.797 . . . . 0.0 112.534 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 24.2 m -130.0 -12.63 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 C-N-CA 124.606 1.162 . . . . 0.0 112.312 -173.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.62 141.34 1.19 Allowed Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.993 1.282 . . . . 0.0 109.939 -170.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -73.15 -10.58 59.92 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -178.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.4 m -121.36 145.62 47.71 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.229 1.012 . . . . 0.0 109.238 177.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -69.81 157.55 37.14 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.227 1.411 . . . . 0.0 109.894 172.308 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -51.54 -35.07 39.26 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 125.128 1.371 . . . . 0.0 112.139 176.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -70.45 -8.86 54.2 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.746 0.818 . . . . 0.0 112.417 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.43 25.04 10.42 Favored Glycine 0 CA--C 1.53 1.019 0 CA-C-N 119.6 1.091 . . . . 0.0 113.946 170.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -125.92 149.21 65.36 Favored Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 118.775 1.287 . . . . 0.0 108.26 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.77 143.91 36.59 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 122.966 2.444 . . . . 0.0 111.272 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.1 mtt-85 -70.61 18.79 0.05 Allowed 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 114.421 1.267 . . . . 0.0 114.421 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.2 m -56.55 136.32 19.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 O-C-N 120.394 -1.441 . . . . 0.0 109.547 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.11 -14.64 43.14 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 118.373 -1.237 . . . . 0.0 113.586 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -75.23 152.05 38.36 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 120.134 1.967 . . . . 0.0 109.184 176.392 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -95.07 150.28 20.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 174.126 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.2 m -142.2 153.5 18.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 124.663 1.185 . . . . 0.0 109.04 -178.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -85.37 107.09 17.2 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 169.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.0 t -78.02 120.87 29.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -134.62 120.09 19.16 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.0 t 49.58 33.61 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 C-N-CA 125.146 1.378 . . . . 0.0 112.105 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.96 6.94 78.59 Favored Glycine 0 CA--C 1.531 1.094 0 O-C-N 121.029 -1.044 . . . . 0.0 114.054 176.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -119.99 146.03 46.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-N 119.339 1.57 . . . . 0.0 109.055 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.5 104.83 6.23 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 41.0 tpp -68.2 -46.28 71.05 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.72 0.408 . . . . 0.0 110.704 -174.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.2 m -152.02 165.75 33.71 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 125.953 1.701 . . . . 0.0 107.98 -178.568 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 6.5 t -111.38 141.34 27.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.049 1.34 . . . . 0.0 107.742 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 35.8 pt -140.81 165.86 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.767 1.227 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.1 m-80 -80.39 165.48 22.2 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 124.582 1.153 . . . . 0.0 109.889 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -64.65 -32.41 74.06 Favored 'General case' 0 N--CA 1.468 0.425 0 O-C-N 121.763 -0.586 . . . . 0.0 111.505 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.54 -43.11 77.39 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.432 -0.793 . . . . 0.0 110.429 177.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -65.08 -39.32 93.03 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.314 0.646 . . . . 0.0 109.646 178.015 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.98 -49.55 74.26 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.17 -0.331 . . . . 0.0 110.364 177.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -62.53 -40.01 95.42 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 119.103 -0.475 . . . . 0.0 111.008 179.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -61.48 -43.77 98.28 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 118.494 0.588 . . . . 0.0 110.898 175.59 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -66.79 -40.49 88.16 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.075 0.55 . . . . 0.0 110.643 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 41.7 mt -63.06 -35.66 81.0 Favored 'General case' 0 C--N 1.338 0.101 0 C-N-CA 124.066 0.946 . . . . 0.0 110.759 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -70.06 -48.89 55.97 Favored 'General case' 0 C--O 1.226 -0.132 0 CA-C-N 118.492 0.587 . . . . 0.0 109.905 171.083 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.08 -40.49 85.4 Favored 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.617 0.767 . . . . 0.0 111.744 -171.347 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.0 pp . . . . . 0 CA--C 1.537 0.473 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 179.862 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.717 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.9 m -146.89 168.18 12.01 Favored Pre-proline 0 CA--C 1.543 0.69 0 C-N-CA 125.462 1.505 . . . . 0.0 110.108 -168.634 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -57.37 162.73 9.43 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.052 2.501 . . . . 0.0 113.37 169.666 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.86 176.75 41.22 Favored Glycine 0 CA--C 1.526 0.729 0 C-N-CA 125.978 1.752 . . . . 0.0 109.666 170.212 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.9 tt0 -116.86 136.92 52.58 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 45.6 mt -72.89 71.29 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -68.69 -33.52 74.1 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.156 0.982 . . . . 0.0 111.647 -169.699 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.3 156.06 43.09 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 174.678 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt -128.66 146.7 33.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 N-CA-C 106.471 -1.678 . . . . 0.0 106.471 178.023 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -117.14 -27.27 6.54 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 123.918 0.887 . . . . 0.0 111.415 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.5 -123.17 1.08 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -62.71 -23.52 67.2 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.292 0.637 . . . . 0.0 111.848 169.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 25.2 mm100 -99.04 155.28 17.52 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.022 0.929 . . . . 0.0 109.278 169.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.11 163.13 33.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.014 1.326 . . . . 0.0 109.538 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -110.46 77.72 1.07 Allowed 'General case' 0 C--O 1.234 0.252 0 N-CA-C 105.688 -1.968 . . . . 0.0 105.688 -175.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.0 t -70.85 127.74 33.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -177.619 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -74.83 107.61 7.03 Favored 'General case' 0 CA--C 1.52 -0.187 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 168.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -84.26 58.09 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -178.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.0 m 45.57 44.6 10.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.274 2.23 . . . . 0.0 113.208 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.26 -38.65 0.14 Allowed Glycine 0 CA--C 1.525 0.713 0 CA-C-O 119.478 -0.624 . . . . 0.0 112.708 176.337 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.6 tp -153.09 153.79 8.49 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 58.6 mt-30 -73.63 138.04 44.58 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -127.0 144.89 50.9 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 125.608 1.563 . . . . 0.0 107.151 172.778 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -75.01 131.19 40.45 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 72.9 t -140.16 138.77 37.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 125.126 1.37 . . . . 0.0 107.933 -171.803 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -80.72 130.64 35.2 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.778 1.631 . . . . 0.0 109.264 175.416 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.0 mt -105.46 6.66 32.63 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.676 0.79 . . . . 0.0 112.989 -176.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 7.5 m -55.61 -32.67 63.31 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.807 1.64 . . . . 0.0 112.853 -171.527 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.02 -13.95 62.17 Favored 'General case' 0 CA--C 1.538 0.493 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -178.379 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.33 -15.55 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.372 1.069 . . . . 0.0 112.581 -174.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.91 143.88 1.31 Allowed Glycine 0 CA--C 1.528 0.871 0 C-N-CA 125.394 1.474 . . . . 0.0 110.683 -173.273 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 m -76.62 -7.32 55.02 Favored 'General case' 0 CA--C 1.536 0.415 0 O-C-N 121.944 -0.739 . . . . 0.0 112.871 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.9 m -114.71 139.57 49.57 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.072 0.949 . . . . 0.0 109.676 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -75.56 155.76 35.7 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 126.809 2.044 . . . . 0.0 109.733 170.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -58.04 -25.96 61.85 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.034 1.334 . . . . 0.0 112.883 -173.731 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 -71.56 -6.97 44.66 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 121.506 -0.746 . . . . 0.0 112.525 178.343 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.13 47.44 5.24 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -142.44 153.51 62.49 Favored Pre-proline 0 CA--C 1.535 0.392 0 C-N-CA 125.724 1.61 . . . . 0.0 107.577 -178.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.51 147.23 76.53 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 C-N-CA 121.645 1.563 . . . . 0.0 109.687 174.64 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -70.88 17.96 0.07 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -175.306 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.4 t -56.53 126.2 13.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 O-C-N 120.848 -1.157 . . . . 0.0 108.599 -174.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.63 -13.59 66.25 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.324 -1.265 . . . . 0.0 113.632 176.517 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 80.1 mt-30 -68.04 154.58 41.34 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 119.566 1.683 . . . . 0.0 109.106 174.778 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.9 m95 -96.19 160.7 14.3 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.26 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.53 156.7 4.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -169.482 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 96.0 mt -101.68 133.0 47.06 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 169.158 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.9 m -128.3 139.07 52.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 118.853 0.751 . . . . 0.0 109.113 -177.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.6 t-80 -142.48 132.77 24.82 Favored 'General case' 0 C--O 1.232 0.132 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 -176.518 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 36.2 t 59.77 -61.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 128.146 2.579 . . . . 0.0 112.79 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -174.37 21.04 0.06 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.182 1.849 . . . . 0.0 111.596 179.245 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -132.38 141.86 49.07 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 118.78 1.29 . . . . 0.0 108.69 -172.718 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.26 124.03 24.88 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 169.422 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 90.4 mmm -90.86 -49.16 6.6 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 123.148 0.579 . . . . 0.0 109.966 -178.017 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.3 m -149.52 140.85 23.21 Favored 'General case' 0 C--N 1.339 0.145 0 C-N-CA 124.271 1.029 . . . . 0.0 108.775 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 84.0 t -81.78 142.93 13.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 169.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.1 pt -139.58 162.78 26.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 C-N-CA 124.885 1.274 . . . . 0.0 109.647 -173.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -79.67 163.79 24.27 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.658 0.742 . . . . 0.0 110.53 175.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -55.89 -39.35 71.43 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 126.26 1.824 . . . . 0.0 111.729 175.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.59 -50.06 34.51 Favored 'General case' 0 C--N 1.338 0.091 0 O-C-N 121.864 -0.523 . . . . 0.0 110.253 -173.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -72.35 -27.48 62.43 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 119.296 -0.383 . . . . 0.0 110.73 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.29 -52.04 66.98 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.877 0.762 . . . . 0.0 110.056 170.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.8 mtm180 -64.43 -37.64 88.22 Favored 'General case' 0 N--CA 1.46 0.054 0 CA-C-O 118.859 -0.591 . . . . 0.0 110.93 179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -62.65 -40.63 97.64 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 118.971 0.805 . . . . 0.0 111.176 175.231 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.8 m -65.39 -40.98 94.12 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.978 -0.452 . . . . 0.0 110.035 176.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.4 mt -65.07 -38.34 90.48 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.349 -0.845 . . . . 0.0 110.762 176.601 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -66.28 -39.11 89.19 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.624 0.647 . . . . 0.0 110.906 177.113 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.09 -50.46 71.85 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.463 0.705 . . . . 0.0 110.404 173.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.2 mt . . . . . 0 CA--C 1.533 0.296 0 C-N-CA 124.386 1.074 . . . . 0.0 112.6 -179.399 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.709 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.0 t -140.21 139.3 20.68 Favored Pre-proline 0 CA--C 1.54 0.565 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -169.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -76.65 168.98 22.67 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.384 2.056 . . . . 0.0 111.83 173.8 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -171.02 -174.9 39.18 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 173.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 57.7 tt0 -116.67 131.15 57.02 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 123.659 0.784 . . . . 0.0 108.99 -176.512 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 89.7 mt -67.06 122.65 18.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 mtm105 -119.62 -10.15 9.66 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 177.691 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -152.55 151.55 30.81 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 172.577 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.9 mt -133.19 140.24 47.52 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 172.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -108.01 -23.97 11.79 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.471 1.108 . . . . 0.0 112.438 -174.371 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.83 -62.37 0.15 Allowed Glycine 0 C--N 1.338 0.666 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 175.24 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -144.42 27.92 1.36 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.912 1.339 . . . . 0.0 110.381 169.445 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -137.62 156.2 48.33 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 169.738 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -144.25 166.54 24.75 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 123.867 0.867 . . . . 0.0 110.001 -170.514 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -117.38 84.35 2.14 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.22 131.08 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.744 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -83.24 109.72 17.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 169.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.8 t -85.35 62.23 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -175.819 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 56.5 m 48.77 40.7 16.72 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.329 1.852 . . . . 0.0 113.161 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 172.17 -49.0 0.18 Allowed Glycine 0 CA--C 1.525 0.658 0 CA-C-O 119.304 -0.72 . . . . 0.0 112.126 173.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.1 mm -138.0 145.59 28.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 -173.216 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -73.74 145.72 44.9 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.288 0.566 . . . . 0.0 111.307 175.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -133.84 139.68 46.4 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 125.481 1.512 . . . . 0.0 107.804 170.309 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -71.56 136.2 47.37 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.89 155.17 17.46 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 125.396 1.478 . . . . 0.0 109.162 177.003 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -98.07 141.53 30.9 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 124.636 1.175 . . . . 0.0 110.223 -177.741 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.7 mp -117.23 15.41 14.9 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.828 1.251 . . . . 0.0 111.871 -170.018 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.4 p -53.22 -33.65 53.75 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 119.966 1.257 . . . . 0.0 112.267 176.642 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -77.78 -12.05 59.94 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 123.848 0.859 . . . . 0.0 112.986 -174.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.07 -17.05 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.699 1.136 . . . . 0.0 113.364 -171.135 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.98 148.95 4.5 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -176.291 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 m -74.09 -14.22 60.95 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 124.244 1.018 . . . . 0.0 113.23 -174.213 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -126.19 143.67 51.05 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.975 0.91 . . . . 0.0 109.902 -171.256 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -70.8 155.7 40.45 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 126.463 1.905 . . . . 0.0 109.954 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -58.57 -25.75 62.88 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.638 1.175 . . . . 0.0 112.531 -175.453 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -61.98 -22.74 65.92 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.74 0.816 . . . . 0.0 112.924 175.107 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.18 47.38 3.09 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -174.488 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -142.14 151.26 58.28 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 125.819 1.648 . . . . 0.0 107.488 -178.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -65.72 148.46 86.83 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.882 1.721 . . . . 0.0 109.879 176.213 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -70.78 16.65 0.08 Allowed 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 -176.529 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 98.6 t -60.66 133.44 26.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 O-C-N 120.565 -1.334 . . . . 0.0 107.878 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.92 -15.2 56.46 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.303 -1.276 . . . . 0.0 113.064 -178.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 67.9 mt-30 -71.88 149.57 45.04 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 119.818 1.809 . . . . 0.0 108.907 175.173 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.7 m95 -85.15 152.4 23.4 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 170.024 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.7 p -146.46 138.42 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 62.9 tp -89.0 128.76 35.71 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 169.831 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.8 m -124.83 151.34 30.29 Favored 'Isoleucine or valine' 0 C--O 1.235 0.324 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -142.57 148.47 37.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 104.958 -2.238 . . . . 0.0 104.958 169.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.7 m 44.81 28.51 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 126.097 1.759 . . . . 0.0 115.368 171.295 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.48 14.03 64.4 Favored Glycine 0 CA--C 1.531 1.074 0 CA-C-O 118.472 -1.182 . . . . 0.0 113.857 176.577 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -129.13 144.11 51.09 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 119.818 1.809 . . . . 0.0 109.692 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.54 112.37 4.66 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 169.592 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.4 mmt -91.15 -34.89 14.85 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 119.094 -0.479 . . . . 0.0 111.114 -178.213 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 70.7 m -155.58 144.46 20.59 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 119.276 0.944 . . . . 0.0 109.283 169.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 48.3 t -79.99 140.37 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 169.105 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.2 pt -135.07 -175.2 1.3 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 C-N-CA 124.156 0.982 . . . . 0.0 108.865 -173.454 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -131.18 176.58 8.15 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.763 1.225 . . . . 0.0 108.597 178.417 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 68.4 mm-40 -52.78 -47.78 67.28 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 125.895 1.678 . . . . 0.0 110.908 -171.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -69.47 -40.86 76.86 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.673 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -66.19 -37.8 86.46 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 123.033 0.533 . . . . 0.0 109.568 176.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.94 -45.11 94.03 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 118.513 -0.755 . . . . 0.0 110.37 175.52 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 28.9 mmt-85 -63.92 -42.43 97.4 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.691 1.132 . . . . 0.0 110.6 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.16 -43.1 99.58 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.513 0.597 . . . . 0.0 110.948 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.7 m -68.18 -37.3 80.79 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 122.75 0.42 . . . . 0.0 110.432 178.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 54.8 mt -67.29 -33.42 75.25 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.122 -0.986 . . . . 0.0 110.658 176.518 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -67.04 -35.78 80.62 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.842 0.746 . . . . 0.0 111.457 174.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.04 -46.32 81.73 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 121.915 -0.49 . . . . 0.0 109.893 169.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? . . . . . 0 C--N 1.338 0.073 0 C-N-CA 123.629 0.772 . . . . 0.0 110.725 -176.866 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.388 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.8 t -140.32 137.41 17.79 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 -169.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.88 174.42 11.93 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.129 1.886 . . . . 0.0 111.56 174.196 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.11 -177.52 27.61 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 124.405 1.003 . . . . 0.0 111.065 172.116 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.7 tt0 -116.77 142.29 47.11 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 173.544 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 59.6 mt -74.58 85.05 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.1 tpp180 -71.48 -37.14 71.34 Favored 'General case' 0 CA--C 1.527 0.081 0 C-N-CA 124.882 1.273 . . . . 0.0 109.932 -172.657 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -157.83 144.61 17.91 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.645 1.578 . . . . 0.0 107.224 -175.04 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 61.4 mt -110.23 149.44 13.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -132.97 -0.19 3.41 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.668 1.187 . . . . 0.0 112.435 -169.433 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.405 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 146.83 -128.1 2.9 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 106.931 -2.468 . . . . 0.0 106.931 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 15.9 t30 -72.51 12.75 0.43 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.79 0.836 . . . . 0.0 110.96 169.066 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.405 ' H ' ' C ' ' A' ' 14' ' ' GLY . 36.7 mt-30 -140.44 161.68 37.13 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.505 2.322 . . . . 0.0 107.278 -169.893 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.78 153.41 42.37 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 176.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -104.62 69.6 0.9 Allowed 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 105.884 -1.895 . . . . 0.0 105.884 178.363 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.7 m -69.21 138.85 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 -171.244 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -81.2 102.89 10.63 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.09 62.76 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 C-N-CA 125.637 1.575 . . . . 0.0 108.519 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.8 m 43.76 42.49 4.39 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 127.285 2.234 . . . . 0.0 113.23 -179.732 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.69 -34.7 0.21 Allowed Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.037 -0.868 . . . . 0.0 113.535 177.416 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.4 tt -150.33 149.36 14.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 118.627 1.213 . . . . 0.0 108.753 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -76.77 135.43 38.98 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 176.398 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -137.88 137.19 37.83 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 124.4 1.08 . . . . 0.0 108.227 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.51 137.3 54.28 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 122.744 0.417 . . . . 0.0 110.032 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 m -140.81 145.54 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 124.826 1.25 . . . . 0.0 107.955 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -83.49 144.63 29.42 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 5.5 mp -110.36 10.44 23.45 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.029 -0.986 . . . . 0.0 113.207 -169.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.2 m -52.04 -32.18 33.28 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 121.006 1.73 . . . . 0.0 112.809 -177.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.4 mt -68.55 -15.85 63.67 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.38 -18.5 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 124.2 1.0 . . . . 0.0 112.913 -173.084 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.37 149.74 1.82 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.965 1.269 . . . . 0.0 110.694 -169.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 19.0 m -74.81 -5.1 41.62 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 121.806 -0.82 . . . . 0.0 112.952 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.7 m -126.56 157.68 38.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 124.443 1.097 . . . . 0.0 110.026 178.645 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -54.57 -53.4 55.08 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 126.756 2.022 . . . . 0.0 112.931 -171.016 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 176.07 -48.11 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 128.766 2.826 . . . . 0.0 106.793 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -79.71 -40.71 28.34 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.414 1.086 . . . . 0.0 111.144 -178.058 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 148.18 6.56 0.25 Allowed Glycine 0 CA--C 1.531 1.052 0 CA-C-O 118.7 -1.056 . . . . 0.0 114.089 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 mt-30 -76.99 124.18 87.4 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 119.352 1.576 . . . . 0.0 107.195 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.49 139.69 65.38 Favored 'Trans proline' 0 CA--C 1.534 0.482 0 C-N-CA 122.39 2.06 . . . . 0.0 111.142 174.456 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.7 mtt-85 -71.2 6.39 1.7 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -177.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.1 t -51.88 129.08 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 120.121 1.328 . . . . 0.0 109.113 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.93 -19.29 54.76 Favored Glycine 0 CA--C 1.53 1.002 0 C-N-CA 124.781 1.181 . . . . 0.0 113.458 178.45 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -68.32 163.4 23.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.338 1.569 . . . . 0.0 109.179 173.336 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -105.42 163.04 12.94 Favored 'General case' 0 C--O 1.234 0.238 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.49 148.08 14.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 123.194 0.598 . . . . 0.0 109.425 -169.351 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 74.9 mt -90.63 141.47 28.74 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 169.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.7 t -132.18 147.82 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -148.26 -45.85 0.16 Allowed 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.89 1.276 . . . . 0.0 109.009 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.6 m -126.97 -166.97 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 126.412 1.885 . . . . 0.0 106.673 171.817 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -72.37 37.68 0.69 Allowed Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.673 1.13 . . . . 0.0 114.112 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -139.59 147.36 41.01 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.342 1.457 . . . . 0.0 109.288 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.66 104.57 3.96 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 169.238 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 88.7 mmm -69.05 -45.05 71.38 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 118.369 0.532 . . . . 0.0 110.447 -169.802 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.5 m -161.76 152.84 18.16 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 126.156 1.783 . . . . 0.0 107.144 169.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -75.11 149.43 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 170.044 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -141.64 -167.55 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 C-N-CA 126.487 1.915 . . . . 0.0 108.293 176.507 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -123.63 174.17 7.62 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 125.098 1.359 . . . . 0.0 109.804 175.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -60.0 -40.17 88.31 Favored 'General case' 0 CA--C 1.527 0.083 0 C-N-CA 123.895 0.878 . . . . 0.0 112.399 -172.616 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.36 -37.81 56.74 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 118.183 0.447 . . . . 0.0 109.923 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -61.8 -36.15 80.27 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.333 0.653 . . . . 0.0 109.878 173.607 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.52 -42.35 98.45 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.504 -0.748 . . . . 0.0 110.809 174.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.6 mpt_? -64.59 -43.39 93.96 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 119.275 0.943 . . . . 0.0 109.995 177.446 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -60.27 -40.13 89.29 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.064 0.393 . . . . 0.0 111.065 177.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.4 m -65.67 -43.61 88.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.091 0.557 . . . . 0.0 110.452 176.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 59.4 mt -63.64 -38.9 92.87 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 118.873 0.761 . . . . 0.0 110.639 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -64.69 -45.35 87.01 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 123.408 0.683 . . . . 0.0 110.427 175.433 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.23 -42.73 99.12 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.425 0.557 . . . . 0.0 110.995 177.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? . . . . . 0 C--O 1.234 0.246 0 C-N-CA 123.514 0.726 . . . . 0.0 109.909 -178.908 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.731 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 10.6 p -148.87 154.05 39.56 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 123.848 0.859 . . . . 0.0 109.54 -169.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -58.54 161.92 13.6 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.711 2.274 . . . . 0.0 113.364 169.649 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.55 175.35 38.97 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 108.654 -1.779 . . . . 0.0 108.654 169.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -116.89 131.88 56.84 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 176.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.9 mt -66.41 119.06 10.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 177.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.5 tpp180 -107.4 -40.6 5.32 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 118.507 -0.759 . . . . 0.0 109.713 -169.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.9 p -142.37 161.8 37.11 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.493 1.117 . . . . 0.0 108.438 169.709 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.4 mt -132.64 148.81 31.64 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -179.265 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -124.54 -24.56 4.19 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.299 1.04 . . . . 0.0 112.028 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.66 -126.74 1.33 Allowed Glycine 0 C--N 1.333 0.416 0 N-CA-C 106.757 -2.537 . . . . 0.0 106.757 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 11.8 t30 -65.48 -24.44 67.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.722 0.761 . . . . 0.0 110.254 169.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -93.39 155.6 17.28 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-O 122.054 0.93 . . . . 0.0 110.282 172.119 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.64 175.03 11.91 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.65 1.58 . . . . 0.0 108.863 -178.436 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -128.71 99.83 5.49 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 176.517 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.3 m -69.12 165.88 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 169.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -111.74 112.95 25.01 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 169.029 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -88.26 60.58 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 -177.473 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.6 m 46.45 41.31 9.26 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.094 2.157 . . . . 0.0 113.586 178.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.56 -26.95 0.2 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.106 -0.83 . . . . 0.0 114.248 175.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.5 tp -149.34 149.91 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.447 0 CA-C-N 118.646 1.223 . . . . 0.0 107.742 177.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -76.21 147.79 38.15 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 175.525 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -140.16 132.59 28.51 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 124.563 1.145 . . . . 0.0 108.823 176.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -69.98 140.69 52.99 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 123.976 0.91 . . . . 0.0 110.185 176.576 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -148.49 167.13 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 126.136 1.774 . . . . 0.0 109.162 -178.603 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -107.03 143.59 34.92 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 169.623 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 26.6 mt -114.58 21.35 14.59 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.279 1.431 . . . . 0.0 110.854 -173.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.07 -35.45 59.56 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.699 1.199 . . . . 0.0 112.584 -171.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.7 mt -80.34 -8.96 59.72 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.679 0.791 . . . . 0.0 112.617 -176.513 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.7 m -126.92 -5.83 4.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.253 1.021 . . . . 0.0 111.815 -177.447 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.27 79.21 Favored Glycine 0 CA--C 1.532 1.099 0 C-N-CA 124.99 1.281 . . . . 0.0 114.918 169.609 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 m 58.5 -14.28 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 127.167 2.187 . . . . 0.0 116.711 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.6 m -136.5 153.39 51.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 124.828 1.251 . . . . 0.0 109.598 -177.669 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -64.97 157.91 26.94 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.472 1.109 . . . . 0.0 108.899 169.519 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -48.2 -41.65 27.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.279 1.431 . . . . 0.0 112.445 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -80.73 -16.84 52.86 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 118.91 -0.566 . . . . 0.0 112.152 -176.206 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.92 -12.6 5.32 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-O 118.504 -1.164 . . . . 0.0 115.817 169.479 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -66.06 135.36 95.14 Favored Pre-proline 0 N--CA 1.469 0.477 0 CA-C-N 119.662 1.731 . . . . 0.0 109.341 -172.24 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.11 140.33 71.25 Favored 'Trans proline' 0 CA--C 1.534 0.475 0 C-N-CA 121.707 1.605 . . . . 0.0 109.162 171.439 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -73.42 11.25 0.81 Allowed 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 114.517 1.302 . . . . 0.0 114.517 -172.15 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.0 m -53.14 133.99 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 120.251 1.387 . . . . 0.0 109.698 176.237 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.8 -18.61 52.56 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.433 -1.204 . . . . 0.0 112.992 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -73.52 142.18 46.73 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 119.89 1.845 . . . . 0.0 108.974 177.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -85.04 151.24 24.31 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 170.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.69 145.02 14.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -170.51 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 86.0 mt -79.1 132.74 36.69 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 169.402 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 50.2 t -118.63 123.69 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -135.04 137.56 43.06 Favored 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.7 m 44.1 28.45 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 C-N-CA 126.61 1.964 . . . . 0.0 115.405 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.76 4.65 58.98 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.698 1.142 . . . . 0.0 113.892 175.726 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -125.79 144.55 50.59 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 119.093 1.447 . . . . 0.0 109.719 -176.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.16 120.04 16.16 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 169.381 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 25.8 mmt -91.47 -45.52 8.49 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 119.001 -0.523 . . . . 0.0 111.436 -178.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.5 m -152.19 138.47 18.42 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -176.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.1 t -74.12 142.2 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 169.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.53 -169.52 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 125.695 1.598 . . . . 0.0 109.133 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -128.16 174.79 8.95 Favored 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 125.803 1.641 . . . . 0.0 108.791 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -62.51 -36.52 82.83 Favored 'General case' 0 N--CA 1.462 0.129 0 CA-C-O 118.955 -0.545 . . . . 0.0 112.434 -173.318 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.99 -44.67 76.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.936 0.789 . . . . 0.0 109.464 -177.282 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -64.58 -41.34 96.34 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 123.136 0.574 . . . . 0.0 110.259 176.179 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -49.14 75.91 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 122.86 0.464 . . . . 0.0 110.431 179.542 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -64.67 -41.25 96.21 Favored 'General case' 0 N--CA 1.463 0.195 0 C-N-CA 123.156 0.583 . . . . 0.0 110.376 -178.531 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -62.5 -43.23 99.33 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.397 0.544 . . . . 0.0 110.939 176.64 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -69.59 -37.46 76.93 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 122.097 -0.377 . . . . 0.0 110.506 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 27.7 mt -62.79 -40.15 96.45 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 119.113 0.87 . . . . 0.0 110.293 176.001 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -66.32 -43.54 85.92 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.375 0.534 . . . . 0.0 110.701 175.174 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.7 -43.06 84.9 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.103 0.411 . . . . 0.0 110.478 176.751 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 1.9 mm? . . . . . 0 CA--C 1.538 0.488 0 C-N-CA 124.994 1.317 . . . . 0.0 113.748 178.335 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.713 0 N-CA-C 108.238 -1.945 . . . . 0.0 108.238 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.0 p -150.67 157.2 36.31 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.613 1.165 . . . . 0.0 109.44 -168.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -67.62 158.37 57.49 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 121.962 1.775 . . . . 0.0 110.477 168.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.45 177.28 39.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 171.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -116.11 138.41 51.28 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 117.565 0.683 . . . . 0.0 109.334 -175.489 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 60.6 mt -73.7 83.29 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 176.658 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -76.48 -29.71 56.97 Favored 'General case' 0 N--CA 1.465 0.286 0 O-C-N 121.624 -0.672 . . . . 0.0 111.553 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.73 154.83 38.1 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.747 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 64.5 mt -129.66 147.98 33.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -121.32 -24.87 5.34 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.463 1.105 . . . . 0.0 112.121 -176.762 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 161.06 -113.0 0.55 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 108.307 -1.917 . . . . 0.0 108.307 178.245 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -69.37 2.04 3.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.656 0.782 . . . . 0.0 111.875 169.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -139.23 159.3 42.48 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 126.925 2.09 . . . . 0.0 107.679 -170.683 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 169.14 18.14 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.26 1.424 . . . . 0.0 110.035 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -115.82 73.09 0.83 Allowed 'General case' 0 C--O 1.234 0.241 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 -174.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.0 t -71.56 125.53 30.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 -172.372 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -77.18 112.05 13.45 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 169.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.9 m -82.56 43.08 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 C-N-CA 124.211 1.005 . . . . 0.0 110.718 177.525 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 66.7 m 48.5 49.93 17.58 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.077 1.751 . . . . 0.0 112.211 -172.426 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -177.71 -41.64 0.06 OUTLIER Glycine 0 CA--C 1.524 0.622 0 CA-C-O 119.644 -0.531 . . . . 0.0 112.404 174.789 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.6 tt -155.86 153.76 7.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -71.96 139.85 48.87 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 170.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 39.2 mmt180 -128.94 142.75 50.83 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 125.273 1.429 . . . . 0.0 107.977 176.246 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.08 131.47 46.65 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.953 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.5 t -140.68 129.56 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -83.36 144.19 29.82 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.517 0.727 . . . . 0.0 110.14 174.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.7 mt -109.6 7.85 24.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.312 1.045 . . . . 0.0 113.322 -169.777 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 25.2 m -53.1 -34.34 56.22 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.987 1.721 . . . . 0.0 112.482 -175.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.3 mt -74.98 -11.09 60.03 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.47 -17.0 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 CA-C-N 119.43 1.013 . . . . 0.0 112.563 -175.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.74 133.18 0.52 Allowed Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.264 1.411 . . . . 0.0 110.781 -175.453 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 21.4 m -67.86 156.65 36.66 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 169.753 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.0 m 61.97 145.48 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.227 2.211 . . . . 0.0 112.535 -169.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.95 155.31 38.79 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.207 1.403 . . . . 0.0 109.484 173.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.68 -27.56 62.99 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.646 1.179 . . . . 0.0 112.484 -176.126 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -62.69 -21.95 66.13 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.813 0.845 . . . . 0.0 113.043 175.628 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.99 47.9 3.25 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -174.185 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.9 pt20 -143.18 157.33 60.48 Favored Pre-proline 0 CA--C 1.536 0.426 0 C-N-CA 125.751 1.621 . . . . 0.0 107.93 -178.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -64.51 144.09 83.92 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 121.701 1.601 . . . . 0.0 110.375 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 90.6 mtt-85 -71.5 11.2 0.5 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.358 1.063 . . . . 0.0 113.621 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.1 m -57.45 131.69 21.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 O-C-N 120.616 -1.303 . . . . 0.0 109.817 -173.405 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 89.7 -17.44 52.63 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 118.306 -1.274 . . . . 0.0 113.413 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -66.57 156.34 35.28 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 119.693 1.746 . . . . 0.0 108.948 172.344 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.3 m95 -105.15 159.99 15.42 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.3 p -157.06 135.55 3.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -171.493 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 98.2 mt -75.68 131.37 39.85 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 168.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.72 135.05 64.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 119.344 0.974 . . . . 0.0 108.402 -178.228 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -141.83 120.81 12.83 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.684 1.193 . . . . 0.0 107.945 -169.686 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.2 t 41.6 47.95 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 126.671 1.988 . . . . 0.0 112.02 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.22 6.95 83.78 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 118.337 -1.257 . . . . 0.0 114.771 172.426 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.18 149.02 50.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 119.803 1.802 . . . . 0.0 110.017 177.416 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.47 116.16 7.9 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 169.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.9 ttt -76.75 -48.46 18.64 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.532 0.733 . . . . 0.0 109.497 177.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 65.4 m -163.11 144.54 9.75 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.975 1.31 . . . . 0.0 108.833 171.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.6 t -72.32 146.29 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 169.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 pt -137.8 157.91 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 C-N-CA 125.236 1.414 . . . . 0.0 109.02 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -80.83 169.19 17.89 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 120.927 0.394 . . . . 0.0 110.773 176.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -61.14 -44.57 97.11 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 123.385 0.674 . . . . 0.0 111.993 -173.224 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.66 -37.1 62.82 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 122.759 0.424 . . . . 0.0 109.953 -174.563 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 56.4 tt0 -60.27 -39.31 86.37 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.846 1.258 . . . . 0.0 110.033 172.332 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.96 -44.95 87.71 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.618 -0.676 . . . . 0.0 111.322 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 26.5 mmt-85 -62.49 -40.88 98.13 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 119.103 0.865 . . . . 0.0 110.441 178.549 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.96 -41.97 99.69 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.887 0.475 . . . . 0.0 110.907 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -65.07 -42.95 93.67 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.62 0.368 . . . . 0.0 110.232 177.537 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 42.5 mt -62.54 -43.58 98.45 Favored 'General case' 0 C--N 1.338 0.107 0 C-N-CA 123.269 0.628 . . . . 0.0 110.311 178.247 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.84 -44.95 94.78 Favored 'General case' 0 N--CA 1.46 0.073 0 C-N-CA 123.06 0.544 . . . . 0.0 110.845 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.12 -41.19 98.0 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.903 0.481 . . . . 0.0 111.191 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? . . . . . 0 C--N 1.338 0.104 0 C-N-CA 123.173 0.589 . . . . 0.0 109.577 177.051 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.86 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.6 m -141.61 162.14 48.39 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.036 1.334 . . . . 0.0 109.288 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -56.28 155.81 23.4 Favored 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 122.802 2.334 . . . . 0.0 113.447 172.867 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -158.32 167.97 34.59 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 107.951 -2.06 . . . . 0.0 107.951 169.33 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.8 tt0 -116.8 133.57 55.85 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 -178.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.19 97.01 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.129 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -83.34 -41.95 17.64 Favored 'General case' 0 N--CA 1.462 0.139 0 O-C-N 121.701 -0.625 . . . . 0.0 109.97 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 p -145.58 157.97 43.91 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 124.651 1.181 . . . . 0.0 108.83 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 54.4 mt -132.78 146.97 31.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 -174.044 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -123.55 -15.24 7.13 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.393 1.077 . . . . 0.0 112.091 -177.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 163.89 -131.56 2.48 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 106.459 -2.657 . . . . 0.0 106.459 -178.031 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -74.09 22.48 0.09 Allowed 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 118.057 0.929 . . . . 0.0 111.515 169.315 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLN . . . . . 0.415 ' H ' ' C ' ' A' ' 14' ' ' GLY . 41.1 mt-30 -140.5 148.61 41.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 126.594 1.958 . . . . 0.0 106.803 -179.056 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.61 163.46 32.0 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 124.454 1.102 . . . . 0.0 109.926 -179.177 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -110.79 78.37 1.11 Allowed 'General case' 0 C--O 1.233 0.232 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.0 m -70.59 130.88 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 123.477 0.711 . . . . 0.0 109.508 -177.82 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -76.84 111.3 12.22 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 168.826 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.4 t -84.75 54.67 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.74 45.72 8.31 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.984 2.113 . . . . 0.0 113.215 -177.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.3 -36.07 0.13 Allowed Glycine 0 CA--C 1.526 0.781 0 CA-C-O 119.468 -0.629 . . . . 0.0 113.003 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.8 tt -153.51 151.66 11.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 177.174 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.2 mt-30 -73.79 138.11 44.32 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 172.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -130.75 145.38 51.93 Favored 'General case' 0 N--CA 1.463 0.186 0 C-N-CA 125.261 1.424 . . . . 0.0 107.91 171.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -70.94 144.36 50.6 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 173.53 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.48 139.76 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.222 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -81.5 146.59 30.12 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.11 1.364 . . . . 0.0 110.284 172.58 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 86.1 mt -117.17 16.0 14.94 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.559 1.143 . . . . 0.0 112.404 -170.058 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 5.8 p -53.31 -34.98 59.61 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 120.561 1.528 . . . . 0.0 112.854 -176.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 73.9 mt -83.53 -6.04 59.34 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 118.46 -0.781 . . . . 0.0 112.865 -175.205 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -132.42 -20.41 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 119.536 1.062 . . . . 0.0 112.919 -174.079 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.29 147.83 7.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -177.32 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.6 m -68.23 -20.78 64.84 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.877 1.271 . . . . 0.0 113.364 -171.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.6 m -127.41 152.34 47.65 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 124.876 1.27 . . . . 0.0 109.283 -175.627 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -65.49 145.99 55.43 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.344 1.458 . . . . 0.0 109.972 172.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -53.99 -31.01 49.54 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.169 1.388 . . . . 0.0 113.517 -169.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -84.87 -7.86 59.01 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 118.863 0.756 . . . . 0.0 112.986 -178.045 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.34 52.65 0.76 Allowed Glycine 0 CA--C 1.527 0.793 0 CA-C-N 119.043 0.838 . . . . 0.0 112.728 170.63 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 30.0 pt20 -144.4 160.65 47.63 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 124.898 1.279 . . . . 0.0 108.697 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -63.74 143.76 87.36 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.627 1.551 . . . . 0.0 109.97 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 79.6 mtt-85 -70.56 12.93 0.21 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -177.243 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.8 m -57.91 135.1 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 O-C-N 120.59 -1.319 . . . . 0.0 109.984 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.52 -14.57 54.82 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 124.889 1.233 . . . . 0.0 113.484 -178.183 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -73.99 155.17 38.88 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 119.709 1.754 . . . . 0.0 109.373 177.701 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 83.5 m95 -97.95 159.16 15.11 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -157.07 147.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 91.9 mt -82.99 128.22 34.27 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.129 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 20.6 t -111.23 105.26 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -169.84 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' HIS . . . . . 0.412 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 6.7 t-160 -77.09 -171.37 1.99 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.903 0.881 . . . . 0.0 109.092 169.728 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.412 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 36.0 m -52.89 -26.84 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 C-N-CA 124.54 1.136 . . . . 0.0 113.795 -174.151 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.08 18.15 0.1 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.841 -0.977 . . . . 0.0 113.213 171.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -139.47 142.54 37.36 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 119.094 1.447 . . . . 0.0 109.12 -172.068 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.16 125.54 27.06 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 169.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 46.3 mtt -74.07 -57.59 3.86 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.4 m -157.77 145.21 18.41 Favored 'General case' 0 C--O 1.238 0.462 0 C-N-CA 126.356 1.863 . . . . 0.0 107.643 -176.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.1 m -74.44 148.99 7.68 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 169.081 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 pt -138.71 168.05 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 125.048 1.339 . . . . 0.0 108.575 -178.34 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -97.59 174.85 6.44 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.0 0.52 . . . . 0.0 110.134 176.267 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -62.55 -33.67 75.4 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.715 0.806 . . . . 0.0 111.481 -174.707 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.84 -49.1 61.25 Favored 'General case' 0 CA--C 1.528 0.129 0 O-C-N 121.72 -0.612 . . . . 0.0 110.251 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -64.25 -38.91 92.73 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 122.777 0.431 . . . . 0.0 110.342 178.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -52.3 65.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 118.049 0.386 . . . . 0.0 110.176 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -64.47 -39.03 93.03 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-O 118.677 -0.678 . . . . 0.0 111.005 -178.314 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.52 -43.03 99.81 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.088 0.858 . . . . 0.0 110.943 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.7 m -66.99 -42.75 84.51 Favored 'General case' 0 CA--C 1.537 0.466 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.418 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.2 mt -64.51 -35.58 81.41 Favored 'General case' 0 CA--C 1.528 0.099 0 O-C-N 121.449 -0.782 . . . . 0.0 110.923 178.082 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -66.89 -43.47 83.37 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 123.403 0.681 . . . . 0.0 110.672 176.213 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.29 -47.72 82.75 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.5 mt . . . . . 0 CA--C 1.537 0.463 0 C-N-CA 124.665 1.186 . . . . 0.0 113.699 -178.968 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.781 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.7 t -143.72 146.87 36.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 125.224 1.41 . . . . 0.0 107.583 -169.252 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -55.83 161.25 8.47 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.69 2.26 . . . . 0.0 113.339 169.573 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.93 177.3 39.78 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 169.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -116.78 137.19 52.38 Favored 'General case' 0 C--N 1.334 -0.105 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 39.1 mt -76.77 71.85 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 C-N-CA 124.89 1.276 . . . . 0.0 108.129 -175.72 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -63.76 -30.36 71.46 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 124.363 1.065 . . . . 0.0 112.445 -172.674 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -149.76 155.81 40.77 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 177.601 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.1 141.48 45.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -106.77 -28.33 10.22 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 124.039 0.936 . . . . 0.0 110.781 174.023 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.81 -121.88 0.98 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 106.78 -2.528 . . . . 0.0 106.78 177.243 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.4 t30 -65.34 -15.31 62.42 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 116.935 0.368 . . . . 0.0 111.693 169.621 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -105.85 153.12 22.37 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 172.304 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -146.71 169.12 19.71 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.33 1.052 . . . . 0.0 110.167 -177.667 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.39 75.1 1.37 Allowed 'General case' 0 CA--C 1.519 -0.233 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -171.727 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.6 t -73.6 128.26 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -74.06 106.17 5.62 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 169.538 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.71 57.85 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.784 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.1 m 43.35 48.42 5.9 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 127.566 2.347 . . . . 0.0 113.427 179.553 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 175.0 -39.26 0.11 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.592 -0.56 . . . . 0.0 112.305 176.269 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.5 tt -153.69 152.65 9.69 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -69.56 136.54 51.45 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 170.49 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 22.7 mmm180 -122.36 128.29 50.81 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 175.241 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -74.79 119.88 19.57 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 176.071 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.2 m -142.99 172.33 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 125.47 1.508 . . . . 0.0 109.579 -170.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -108.88 143.22 38.38 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 124.729 1.211 . . . . 0.0 111.056 -169.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.7 mt -114.03 9.88 17.41 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.47 1.108 . . . . 0.0 112.734 -175.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 6.4 m -55.06 -33.87 63.09 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.943 1.701 . . . . 0.0 112.154 -172.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.23 -9.82 58.93 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.661 0.785 . . . . 0.0 113.055 -177.351 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.9 -15.94 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 119.498 1.045 . . . . 0.0 112.651 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.13 147.49 7.2 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 124.983 1.278 . . . . 0.0 110.536 -176.584 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.5 m -65.57 -21.82 66.63 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.84 1.256 . . . . 0.0 112.184 177.536 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.3 m -126.71 168.43 14.38 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.452 1.501 . . . . 0.0 109.734 -175.434 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -117.79 154.02 32.46 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 126.95 2.1 . . . . 0.0 109.239 -169.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -57.78 -25.91 61.17 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.661 1.185 . . . . 0.0 112.711 -173.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -60.85 -23.77 65.38 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 123.863 0.865 . . . . 0.0 113.007 174.37 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.03 47.7 2.59 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -175.237 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -145.7 154.39 51.9 Favored Pre-proline 0 CA--C 1.535 0.375 0 C-N-CA 125.398 1.479 . . . . 0.0 108.638 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -66.48 152.04 81.72 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 121.828 1.685 . . . . 0.0 108.847 169.318 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 64.7 mtt-85 -70.19 10.57 0.42 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 114.339 1.237 . . . . 0.0 114.339 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.51 137.57 23.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 O-C-N 120.849 -1.157 . . . . 0.0 108.933 -172.537 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.71 -11.37 33.79 Favored Glycine 0 CA--C 1.532 1.106 0 CA-C-O 118.187 -1.34 . . . . 0.0 114.028 179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -67.64 163.05 22.26 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.91 1.855 . . . . 0.0 109.219 171.485 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.2 m95 -104.25 155.47 18.72 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.2 p -153.24 142.77 14.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -171.103 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -84.47 113.1 20.96 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 169.643 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 38.9 t -93.42 137.09 23.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.213 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 178.346 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -137.12 142.83 42.28 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.273 1.029 . . . . 0.0 108.702 175.516 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 22.5 t 56.37 -75.99 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 127.071 2.148 . . . . 0.0 111.439 -173.545 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.24 27.8 0.19 Allowed Glycine 0 CA--C 1.535 1.31 0 C-N-CA 127.761 2.6 . . . . 0.0 110.088 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -139.53 144.08 37.71 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 126.215 1.806 . . . . 0.0 107.847 -170.144 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.74 122.94 17.61 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 169.163 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 52.0 ttp -80.32 -57.9 3.39 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 171.042 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 17.8 m -150.64 138.03 19.55 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 123.77 0.828 . . . . 0.0 109.517 -172.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.0 t -72.09 144.6 12.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 169.416 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.4 pt -138.29 158.8 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 124.781 1.232 . . . . 0.0 108.846 -176.223 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -81.91 167.84 18.54 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 110.593 175.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -67.37 -33.43 75.21 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.549 0.74 . . . . 0.0 112.341 -169.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.9 -39.94 33.61 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.308 -0.87 . . . . 0.0 109.637 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.2 tt0 -59.8 -40.78 89.52 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.011 1.325 . . . . 0.0 110.146 173.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -50.8 71.31 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.145 0.578 . . . . 0.0 110.662 175.042 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 84.2 mtm180 -63.29 -40.17 96.61 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 119.072 -0.489 . . . . 0.0 111.201 -178.551 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.25 -43.62 97.5 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 118.582 0.628 . . . . 0.0 110.785 176.201 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.2 m -65.63 -39.24 91.25 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 119.276 -0.392 . . . . 0.0 110.35 178.625 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 35.8 mt -64.62 -42.21 95.67 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 119.099 0.863 . . . . 0.0 110.536 176.887 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -64.68 -39.33 93.49 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 123.164 0.586 . . . . 0.0 110.961 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.13 -51.05 63.56 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.495 0.318 . . . . 0.0 110.24 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? . . . . . 0 N--CA 1.462 0.139 0 C-N-CA 124.39 1.076 . . . . 0.0 110.679 -174.278 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.888 0 N-CA-C 111.673 -0.571 . . . . 0.0 111.673 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.3 t -146.69 151.94 43.77 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 -169.599 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_exo -54.92 157.56 12.86 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 122.153 1.902 . . . . 0.0 112.728 169.535 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.25 172.49 34.71 Favored Glycine 0 CA--C 1.526 0.767 0 C-N-CA 124.474 1.035 . . . . 0.0 110.765 174.206 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -119.81 130.6 54.99 Favored 'General case' 0 CA--C 1.522 -0.108 0 C-N-CA 124.023 0.929 . . . . 0.0 109.032 -176.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.4 mt -69.3 130.26 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 22.3 mmt85 -119.8 -31.73 4.44 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 118.564 -0.731 . . . . 0.0 111.274 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 m -146.93 153.68 40.38 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.841 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 20.1 mt -132.49 141.67 44.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 177.239 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -122.25 -15.41 7.69 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.057 0.943 . . . . 0.0 111.664 -176.832 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.77 -135.51 3.6 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 107.12 -2.392 . . . . 0.0 107.12 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -66.52 5.0 0.65 Allowed 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 123.972 0.909 . . . . 0.0 113.031 169.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -133.45 153.05 51.94 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 126.138 1.775 . . . . 0.0 107.799 178.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.77 158.09 43.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.763 1.225 . . . . 0.0 110.254 -171.443 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.73 122.72 37.63 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 170.345 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.2 t -125.46 123.45 64.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 -173.694 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -67.71 128.24 35.74 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 172.13 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -128.42 124.19 61.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 171.142 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.3 m 50.16 26.45 2.15 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 125.304 1.441 . . . . 0.0 114.376 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.69 -1.33 36.43 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-O 118.451 -1.194 . . . . 0.0 113.766 172.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.6 mm -134.21 132.04 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 119.451 1.625 . . . . 0.0 107.279 -173.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -66.53 140.13 57.97 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.932 0.396 . . . . 0.0 110.526 178.534 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 20.6 mmt-85 -126.43 149.01 49.55 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.531 1.932 . . . . 0.0 106.789 169.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -80.01 136.07 36.51 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 169.49 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -137.76 135.77 45.82 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -176.193 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -79.87 140.12 36.88 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.995 1.318 . . . . 0.0 110.033 174.515 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 42.5 mt -113.98 14.33 18.41 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 124.051 0.941 . . . . 0.0 112.911 -171.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.7 m -52.24 -36.69 53.08 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 120.604 1.547 . . . . 0.0 112.623 -173.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.9 mt -80.74 -6.96 59.17 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 112.927 0.714 . . . . 0.0 112.927 -174.38 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.6 m -131.98 -17.56 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 119.476 1.034 . . . . 0.0 112.452 -174.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.14 151.54 5.27 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.601 1.096 . . . . 0.0 110.947 -174.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.8 p -74.31 -18.6 60.68 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.558 1.143 . . . . 0.0 112.836 179.742 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.5 m -124.01 150.07 45.31 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.492 1.117 . . . . 0.0 109.442 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.09 161.86 27.1 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.447 1.099 . . . . 0.0 110.625 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -45.98 -41.27 11.56 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.078 1.751 . . . . 0.0 112.087 170.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 30.9 t30 -65.84 -14.72 61.97 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.53 1.132 . . . . 0.0 112.943 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.82 35.14 5.47 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-O 119.027 -0.874 . . . . 0.0 113.835 169.541 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -142.75 164.22 33.79 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 118.566 1.183 . . . . 0.0 109.192 172.07 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -51.14 146.4 23.17 Favored 'Trans proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.599 2.866 . . . . 0.0 112.508 175.489 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -71.06 18.72 0.06 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 114.243 1.201 . . . . 0.0 114.243 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.6 m -58.0 138.09 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 O-C-N 120.234 -1.541 . . . . 0.0 110.005 -176.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.21 -17.61 17.33 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.465 -1.186 . . . . 0.0 113.537 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.9 mt-30 -70.44 161.11 31.13 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.491 1.646 . . . . 0.0 109.447 175.215 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 56.2 m95 -106.21 157.45 17.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -144.65 142.85 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.796 1.239 . . . . 0.0 107.711 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -86.64 116.47 24.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 103.781 -2.674 . . . . 0.0 103.781 169.029 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 31.7 m -116.98 137.04 52.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -171.567 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.93 139.15 36.1 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 33.6 m 45.46 27.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.88 0 C-N-CA 126.457 1.903 . . . . 0.0 115.453 172.743 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 97.81 7.32 56.65 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.069 176.294 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.13 141.78 51.08 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 119.706 1.753 . . . . 0.0 109.394 -177.415 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.16 114.45 14.83 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 169.283 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.9 mmt -88.59 -26.22 22.06 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 122.911 0.484 . . . . 0.0 110.762 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 66.1 m -155.19 156.29 35.43 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 124.714 1.206 . . . . 0.0 108.687 171.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 137.72 34.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 172.706 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 pt -140.11 159.95 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 C-N-CA 124.55 1.14 . . . . 0.0 110.419 -169.487 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -81.02 169.07 17.96 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.603 0.761 . . . . 0.0 110.305 173.27 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -69.38 -30.34 68.3 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -170.25 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.19 -41.45 61.41 Favored 'General case' 0 N--CA 1.461 0.102 0 O-C-N 121.024 -1.047 . . . . 0.0 109.79 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -61.91 -41.36 97.82 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.565 0.746 . . . . 0.0 109.65 174.64 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.78 -49.05 77.9 Favored 'General case' 0 C--N 1.34 0.177 0 O-C-N 121.934 -0.479 . . . . 0.0 110.807 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -64.6 -38.58 91.51 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 118.977 -0.535 . . . . 0.0 111.354 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -64.73 -41.54 95.88 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 118.969 0.804 . . . . 0.0 110.856 176.409 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 24.2 m -68.01 -37.48 81.47 Favored 'General case' 0 CA--C 1.539 0.553 0 O-C-N 122.02 -0.425 . . . . 0.0 110.328 178.054 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 37.5 mt -62.74 -44.71 95.5 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.43 -0.794 . . . . 0.0 109.761 174.613 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -62.06 -40.74 96.83 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 118.775 0.716 . . . . 0.0 111.131 177.452 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.39 -34.42 77.68 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.897 -0.502 . . . . 0.0 111.83 175.965 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? . . . . . 0 CA--C 1.532 0.275 0 C-N-CA 123.761 0.824 . . . . 0.0 110.66 177.523 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.475 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.9 t -139.51 144.21 38.74 Favored Pre-proline 0 CA--C 1.541 0.615 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 -177.106 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.35 160.4 47.06 Favored 'Trans proline' 0 CA--C 1.534 0.516 0 C-N-CA 122.534 2.156 . . . . 0.0 111.957 174.526 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.04 172.92 40.0 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 171.109 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -95.34 137.04 34.93 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.9 mt -69.94 93.3 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 169.631 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -79.55 -33.59 41.74 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 119.108 -0.472 . . . . 0.0 110.38 -170.649 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 m -149.48 152.73 36.12 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.419 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.3 mt -131.69 144.41 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -124.02 -20.44 5.35 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.187 0.995 . . . . 0.0 111.967 -178.767 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.8 -129.54 1.89 Allowed Glycine 0 C--N 1.335 0.499 0 N-CA-C 107.226 -2.35 . . . . 0.0 107.226 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.6 p-10 -65.91 -3.65 5.54 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 117.599 0.699 . . . . 0.0 112.559 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -125.38 157.43 36.83 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.763 1.225 . . . . 0.0 109.602 175.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -154.69 160.42 41.36 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.52 1.528 . . . . 0.0 109.911 -171.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.17 112.17 24.58 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.611 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.7 t -92.13 124.11 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 170.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -84.91 108.7 17.68 Favored 'General case' 0 C--O 1.233 0.218 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 169.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.0 t -83.19 61.02 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 125.858 1.663 . . . . 0.0 107.046 174.511 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 62.5 m 38.42 45.95 0.89 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 128.044 2.538 . . . . 0.0 114.41 178.384 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 153.22 -17.12 0.69 Allowed Glycine 0 CA--C 1.526 0.724 0 CA-C-O 119.093 -0.837 . . . . 0.0 113.806 177.501 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.6 tp -143.83 145.08 22.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 173.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -94.72 134.37 37.4 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.601 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 51.2 mtp180 -126.42 118.99 26.13 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -70.49 131.01 43.39 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 173.466 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.5 m -139.79 155.3 24.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.11 0.964 . . . . 0.0 109.374 179.223 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -84.35 146.48 27.68 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.721 0.808 . . . . 0.0 109.524 171.342 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 mt -112.25 3.17 16.95 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.424 1.09 . . . . 0.0 112.573 -173.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.6 m -59.03 -26.17 64.33 Favored 'General case' 0 CA--C 1.544 0.725 0 CA-C-N 120.595 1.543 . . . . 0.0 112.227 -173.207 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.7 mt -65.67 -19.96 66.11 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 121.608 -0.683 . . . . 0.0 112.708 176.508 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -129.25 -10.92 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.785 1.234 . . . . 0.0 112.013 -174.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.35 139.94 0.96 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 125.365 1.46 . . . . 0.0 109.916 -170.232 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 18.3 m -71.11 -12.17 61.36 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.934 -0.745 . . . . 0.0 112.833 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.4 m -119.36 146.42 45.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.655 1.182 . . . . 0.0 109.311 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -79.94 160.55 25.92 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 124.156 0.982 . . . . 0.0 110.087 176.737 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.7 -33.27 22.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.216 1.406 . . . . 0.0 112.421 173.18 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -67.44 -13.4 62.0 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.09 31.52 5.9 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 118.893 -0.948 . . . . 0.0 114.428 169.323 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -146.11 167.57 13.75 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 118.813 1.307 . . . . 0.0 109.003 172.087 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -50.59 150.75 11.42 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 123.394 2.729 . . . . 0.0 112.837 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 87.4 mtt-85 -74.21 20.99 0.1 Allowed 'General case' 0 CA--C 1.541 0.627 0 O-C-N 121.143 -0.973 . . . . 0.0 113.332 177.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.6 m -56.26 131.94 19.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 O-C-N 120.783 -1.198 . . . . 0.0 109.658 -176.458 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.97 -11.88 55.64 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 118.055 -1.414 . . . . 0.0 113.968 177.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -70.34 169.43 13.89 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.631 1.716 . . . . 0.0 109.692 172.124 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -118.56 149.58 41.1 Favored 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.686 0.794 . . . . 0.0 109.58 -178.21 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -147.51 156.51 9.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 124.555 1.142 . . . . 0.0 109.417 -175.137 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 92.9 mt -84.47 140.12 31.71 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 168.255 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.1 m -132.04 127.33 57.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.744 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -144.07 -29.47 0.49 Allowed 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -169.391 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.8 m -136.2 20.37 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 118.665 0.666 . . . . 0.0 112.362 -169.63 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.59 10.16 73.82 Favored Glycine 0 CA--C 1.532 1.149 0 O-C-N 121.45 -0.781 . . . . 0.0 112.629 -175.573 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 70.1 m-85 -135.44 153.58 51.73 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.222 1.409 . . . . 0.0 107.937 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.91 105.37 2.79 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 169.024 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.09 -39.28 75.66 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.882 0.873 . . . . 0.0 110.929 -170.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.5 m -160.29 155.21 24.4 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 125.369 1.467 . . . . 0.0 108.563 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.1 t -78.08 146.72 7.82 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 169.802 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.4 pt -138.26 161.15 31.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 C-N-CA 125.502 1.521 . . . . 0.0 108.53 177.732 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -73.97 163.58 27.72 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-O 121.932 0.872 . . . . 0.0 110.583 174.624 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -57.68 -40.97 80.66 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 126.402 1.881 . . . . 0.0 111.809 178.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.87 -34.72 29.93 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.801 0.841 . . . . 0.0 110.801 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 60.7 tt0 -62.52 -34.35 76.73 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.641 1.176 . . . . 0.0 110.287 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.26 -43.03 87.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 122.002 -0.437 . . . . 0.0 111.359 171.325 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.8 mmt85 -69.7 -41.33 75.54 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 118.416 0.553 . . . . 0.0 109.609 -177.404 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.13 -40.24 93.05 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 122.54 0.336 . . . . 0.0 110.67 175.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -66.61 -41.26 88.69 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.154 0.582 . . . . 0.0 110.57 177.196 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.6 mt -62.18 -40.61 96.63 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 119.448 1.022 . . . . 0.0 110.313 175.296 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -64.79 -41.79 95.56 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 118.113 0.415 . . . . 0.0 110.843 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.96 -41.77 97.0 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 118.56 0.618 . . . . 0.0 111.083 174.371 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.1 tm? . . . . . 0 CA--C 1.53 0.174 0 C-N-CA 123.824 0.85 . . . . 0.0 109.804 -179.172 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.894 0 CA-C-O 119.728 -0.485 . . . . 0.0 113.789 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.2 t -146.76 148.23 32.53 Favored Pre-proline 0 CA--C 1.544 0.715 0 C-N-CA 126.249 1.82 . . . . 0.0 106.998 -171.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -57.44 163.79 8.03 Favored 'Trans proline' 0 CA--C 1.536 0.609 0 C-N-CA 122.432 2.088 . . . . 0.0 112.426 169.144 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -160.46 163.33 33.93 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.327 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 58.3 tt0 -116.93 131.79 56.86 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 94.6 mt -70.36 117.66 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.475 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -90.19 -32.77 16.47 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 118.666 -0.683 . . . . 0.0 110.502 172.643 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.12 152.92 35.51 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -170.115 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.8 mt -132.43 141.03 46.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 172.107 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -120.84 -18.86 7.51 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.425 1.09 . . . . 0.0 111.47 -176.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.22 -126.6 1.36 Allowed Glycine 0 C--N 1.336 0.538 0 N-CA-C 107.146 -2.382 . . . . 0.0 107.146 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -67.28 -8.63 33.52 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 117.052 0.426 . . . . 0.0 112.11 169.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -119.81 159.44 24.57 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 125.486 1.514 . . . . 0.0 109.538 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.04 177.09 10.51 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 126.177 1.791 . . . . 0.0 109.568 -170.085 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -129.31 126.97 40.17 Favored 'General case' 0 CA--C 1.516 -0.363 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.755 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 1.6 m -119.47 138.7 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 C-N-CA 125.001 1.32 . . . . 0.0 108.357 -177.343 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -85.36 107.88 17.57 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 104.497 -2.408 . . . . 0.0 104.497 168.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -81.49 57.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 C-N-CA 125.362 1.465 . . . . 0.0 107.971 -176.359 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 50.7 m 45.42 43.34 8.53 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.007 2.123 . . . . 0.0 113.159 -177.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 170.28 -42.57 0.2 Allowed Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.303 -0.72 . . . . 0.0 112.641 175.783 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.4 pt -141.8 150.17 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 C-N-CA 124.562 1.145 . . . . 0.0 109.514 -179.183 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -76.99 138.25 39.49 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.703 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -136.77 148.55 47.3 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 124.927 1.291 . . . . 0.0 109.307 173.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -68.05 148.22 51.3 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 169.123 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.48 143.27 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 173.426 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -92.36 145.23 24.63 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.593 0.757 . . . . 0.0 109.44 170.761 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 46.9 mt -112.53 13.48 20.08 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 118.2 -0.905 . . . . 0.0 112.959 -170.123 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 46.7 m -50.66 -37.13 39.15 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 120.889 1.677 . . . . 0.0 112.539 -178.197 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.8 mt -75.74 -11.71 60.04 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.41 -17.86 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 119.445 1.021 . . . . 0.0 113.343 -169.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.35 146.44 3.03 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.698 1.142 . . . . 0.0 111.139 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 p -75.88 -17.68 59.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.662 1.185 . . . . 0.0 112.552 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.2 m -112.84 161.95 16.36 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.432 1.093 . . . . 0.0 109.2 174.008 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -106.72 -179.41 3.93 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 124.701 1.2 . . . . 0.0 113.171 -169.397 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 23.0 mp0 -67.41 -14.37 62.87 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.895 2.078 . . . . 0.0 112.627 -176.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.4 m-80 -96.7 -37.32 10.36 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.176 0.99 . . . . 0.0 110.185 -178.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.79 28.59 1.04 Allowed Glycine 0 CA--C 1.53 1.025 0 C-N-CA 125.299 1.428 . . . . 0.0 112.507 178.257 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -127.63 158.24 70.68 Favored Pre-proline 0 CA--C 1.538 0.5 0 CA-C-N 119.149 1.474 . . . . 0.0 109.316 -176.722 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.36 144.43 85.81 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.867 1.712 . . . . 0.0 109.548 174.163 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.9 mtt-85 -69.54 13.14 0.14 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 114.619 1.34 . . . . 0.0 114.619 -174.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.6 t -53.62 131.02 15.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-N 120.379 1.445 . . . . 0.0 108.446 176.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.36 -14.59 54.08 Favored Glycine 0 CA--C 1.53 0.978 0 CA-C-O 118.531 -1.15 . . . . 0.0 113.589 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -77.05 162.02 27.84 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 119.715 1.758 . . . . 0.0 109.195 176.397 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -106.43 151.25 25.17 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.0 m -140.78 150.38 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 177.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -88.36 124.99 34.47 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 103.662 -2.718 . . . . 0.0 103.662 168.673 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.86 156.99 18.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.761 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 6.3 t-80 -154.02 -32.83 0.11 Allowed 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 123.0 0.52 . . . . 0.0 111.315 -175.038 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.2 m -133.79 -163.24 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 170.183 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -68.06 19.91 0.33 Allowed Glycine 0 CA--C 1.538 1.471 0 CA-C-N 119.64 1.109 . . . . 0.0 114.817 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -133.9 139.82 46.42 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.768 1.627 . . . . 0.0 107.956 -179.298 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.06 116.11 10.05 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 170.164 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 86.6 mmm -74.33 -43.69 55.63 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.02 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.1 p -155.71 153.03 29.31 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.781 0.833 . . . . 0.0 110.067 179.297 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.6 t -79.65 143.38 12.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 169.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.2 pt -138.55 160.76 31.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 124.175 0.99 . . . . 0.0 108.849 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 -80.62 164.91 22.52 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -53.91 -41.85 68.09 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 123.608 0.763 . . . . 0.0 111.439 170.456 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.62 -37.08 85.96 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.857 0.463 . . . . 0.0 110.99 -177.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -71.1 -38.84 72.36 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 177.614 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.98 -48.7 80.6 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 118.415 0.552 . . . . 0.0 110.157 174.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.3 mtt180 -61.62 -43.26 99.18 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 123.489 0.715 . . . . 0.0 110.45 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.93 -41.35 99.46 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.688 0.676 . . . . 0.0 111.295 177.167 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.5 m -64.69 -41.47 96.02 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 122.807 0.443 . . . . 0.0 110.096 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 83.7 mt -66.51 -36.85 83.72 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 119.053 0.842 . . . . 0.0 110.941 177.222 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -66.05 -40.66 91.12 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 118.607 0.64 . . . . 0.0 110.822 177.273 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.03 -52.37 63.14 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 122.704 0.402 . . . . 0.0 109.997 173.442 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 6.6 tt . . . . . 0 C--O 1.233 0.187 0 C-N-CA 124.44 1.096 . . . . 0.0 109.984 -175.824 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.484 1.229 0 CA-C-O 119.281 -0.39 . . . . 0.0 110.029 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 59.0 m -62.84 158.24 19.39 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 118.763 0.711 . . . . 0.0 110.939 177.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.5 tt -153.5 154.71 7.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 176.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.82 56.89 0.16 Allowed Glycine 0 CA--C 1.528 0.905 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -174.057 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.9 t -139.15 141.13 28.59 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 124.317 1.047 . . . . 0.0 108.849 -169.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -59.26 157.63 29.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.887 2.391 . . . . 0.0 112.919 169.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.32 172.67 40.17 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 169.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -99.61 135.73 40.6 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.47 79.97 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 170.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 7.5 tpm_? -80.09 -24.67 40.42 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.561 -0.712 . . . . 0.0 112.406 -169.324 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.57 158.58 43.74 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -130.0 146.3 34.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 176.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -121.78 -23.64 5.46 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.111 0.965 . . . . 0.0 111.734 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.25 -126.8 1.35 Allowed Glycine 0 C--N 1.333 0.403 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 178.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.4 t30 -63.8 -29.21 70.44 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 117.651 0.726 . . . . 0.0 110.303 169.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.7 mm100 -86.44 151.89 23.14 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.56 0.695 . . . . 0.0 109.235 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.56 166.02 25.4 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.034 1.334 . . . . 0.0 109.568 174.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -114.48 78.25 1.14 Allowed 'General case' 0 C--O 1.234 0.266 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 -173.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.4 t -74.19 123.39 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 -175.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -75.04 107.92 7.43 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 169.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.52 61.22 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 32.0 m 45.94 43.96 10.82 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 127.205 2.202 . . . . 0.0 113.696 176.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.63 -36.66 0.16 Allowed Glycine 0 CA--C 1.525 0.703 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.643 176.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -153.67 152.9 9.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.4 mt-30 -77.47 138.72 39.4 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.059 177.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -117.85 144.95 44.95 Favored 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 126.044 1.737 . . . . 0.0 107.196 171.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -74.58 129.93 38.63 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 169.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.8 t -137.01 136.14 47.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -176.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -82.4 126.26 31.98 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.166 1.386 . . . . 0.0 109.072 176.145 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 29.4 mt -100.76 10.95 40.51 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 117.95 -1.024 . . . . 0.0 112.971 -175.75 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 32.4 m -50.84 -36.62 38.5 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 121.285 1.857 . . . . 0.0 112.395 -174.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -74.49 -10.37 59.49 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.5 m -132.2 -17.61 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 119.445 1.021 . . . . 0.0 112.57 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.18 145.91 1.02 Allowed Glycine 0 CA--C 1.529 0.955 0 C-N-CA 125.175 1.369 . . . . 0.0 110.654 -171.217 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.4 m -73.63 -5.3 39.57 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.734 -0.862 . . . . 0.0 113.067 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.3 m -131.97 151.79 51.51 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.362 1.065 . . . . 0.0 110.027 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -66.08 165.64 13.14 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.876 2.071 . . . . 0.0 109.71 169.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.52 -37.5 57.69 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.29 1.436 . . . . 0.0 112.247 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -85.9 10.21 14.6 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.8 0.84 . . . . 0.0 112.052 -178.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.67 5.27 88.4 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.623 1.106 . . . . 0.0 113.382 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -70.1 132.53 88.24 Favored Pre-proline 0 CA--C 1.537 0.469 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -65.86 141.44 65.11 Favored 'Trans proline' 0 N--CA 1.458 -0.56 0 CA-C-N 121.321 1.507 . . . . 0.0 109.107 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.9 mtt-85 -72.77 8.59 1.43 Allowed 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 114.401 1.26 . . . . 0.0 114.401 -173.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.06 125.46 7.14 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 120.128 1.331 . . . . 0.0 108.712 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.67 -19.32 55.12 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.873 1.225 . . . . 0.0 113.241 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -70.12 167.45 17.72 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 119.061 1.431 . . . . 0.0 108.903 172.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 46.9 m95 -116.04 162.75 16.93 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.782 -0.574 . . . . 0.0 109.532 -179.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -156.61 146.21 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -169.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 83.1 mt -83.82 112.13 19.83 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 169.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.68 127.81 39.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 173.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -140.98 130.23 23.57 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 173.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.5 m 41.68 35.8 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 126.195 1.798 . . . . 0.0 114.541 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.8 6.93 79.11 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.076 -0.847 . . . . 0.0 114.092 175.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -122.41 154.78 37.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.951 1.376 . . . . 0.0 109.694 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.81 104.92 3.58 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 169.244 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.07 -47.84 60.28 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.261 0.482 . . . . 0.0 109.755 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.1 m -152.05 136.18 16.58 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.92 1.288 . . . . 0.0 108.017 178.33 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.2 p -84.13 138.72 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 169.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.4 pt -141.93 162.98 19.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 124.652 1.181 . . . . 0.0 110.24 -170.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -77.02 166.18 23.65 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 123.768 0.827 . . . . 0.0 109.84 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.59 -43.14 84.41 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.903 0.881 . . . . 0.0 110.629 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.49 -38.64 87.71 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.002 0.521 . . . . 0.0 110.829 -175.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -67.04 -44.36 80.41 Favored 'General case' 0 C--O 1.232 0.145 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.04 -48.58 79.62 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.9 tmm_? -58.77 -46.81 86.64 Favored 'General case' 0 C--N 1.334 -0.104 0 C-N-CA 124.543 1.137 . . . . 0.0 110.059 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -63.22 -43.12 99.01 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 118.492 0.587 . . . . 0.0 111.292 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -64.16 -42.01 96.92 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 178.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 39.5 mt -65.16 -40.42 94.32 Favored 'General case' 0 CA--C 1.522 -0.13 0 C-N-CA 123.82 0.848 . . . . 0.0 110.599 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -63.64 -41.21 98.26 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 122.982 0.513 . . . . 0.0 110.873 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -66.74 -48.38 69.33 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.276 0.23 . . . . 0.0 110.607 174.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 10.4 tt -61.99 -44.96 95.63 Favored 'General case' 0 C--O 1.231 0.108 0 C-N-CA 124.433 1.093 . . . . 0.0 111.231 -173.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -72.22 -18.29 61.85 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -176.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -55.39 -32.41 62.61 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 119.142 0.883 . . . . 0.0 112.857 -169.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -65.43 -17.62 64.69 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.149 0.98 . . . . 0.0 113.272 -178.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -140.86 -19.43 0.82 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 119.691 1.132 . . . . 0.0 113.809 -173.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -60.21 -22.34 62.86 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 119.592 1.087 . . . . 0.0 112.344 173.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 16.1 m -65.27 -7.61 4.7 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 125.425 1.49 . . . . 0.0 113.362 174.098 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -136.48 157.21 75.72 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 124.82 1.248 . . . . 0.0 109.408 -178.069 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -65.81 -7.61 17.17 Favored 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 123.108 2.539 . . . . 0.0 113.133 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -52.27 -29.75 24.56 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 124.719 1.208 . . . . 0.0 112.2 170.088 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.0 p -58.01 -37.1 59.38 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 118.648 0.658 . . . . 0.0 111.465 174.488 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -75.74 -42.22 26.63 Favored Glycine 0 C--N 1.337 0.601 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 178.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.88 -40.16 83.56 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-N 117.436 0.618 . . . . 0.0 110.926 177.119 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 39.1 tp -64.77 -58.46 6.19 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 124.099 0.959 . . . . 0.0 109.703 172.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 60.6 tp -57.78 -45.24 86.26 Favored 'General case' 0 N--CA 1.463 0.194 0 C-N-CA 123.76 0.824 . . . . 0.0 111.979 -169.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -95.67 6.56 48.63 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 123.487 0.715 . . . . 0.0 111.808 -176.078 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.12 -177.28 37.72 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.382 0.991 . . . . 0.0 111.483 178.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -118.13 15.65 14.09 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 125.164 1.385 . . . . 0.0 110.672 -177.56 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -74.79 6.34 4.07 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.092 1.357 . . . . 0.0 112.76 177.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.251 1.139 0 C-N-CA 126.947 2.099 . . . . 0.0 108.751 -175.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.5 ptt? . . . . . 0 N--CA 1.484 1.234 0 N-CA-C 110.489 -0.189 . . . . 0.0 110.489 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 71.5 m -66.52 150.8 48.44 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 169.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.8 tp -81.72 59.05 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 CA-C-O 122.651 1.215 . . . . 0.0 108.889 173.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.28 54.3 0.75 Allowed Glycine 0 CA--C 1.525 0.711 0 C-N-CA 127.186 2.327 . . . . 0.0 107.831 -175.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.8 m -145.43 158.13 51.31 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 126.473 1.909 . . . . 0.0 108.191 -169.407 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.79 162.43 26.87 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 121.894 1.729 . . . . 0.0 110.659 169.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.32 164.35 37.14 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 169.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -89.43 127.28 35.82 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 72.6 mt -63.64 112.16 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.29 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.9 tpt85 -109.71 -30.63 7.79 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 118.113 -0.946 . . . . 0.0 110.994 -169.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 11.9 p -144.96 158.12 43.91 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 169.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -132.54 141.91 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 105.31 -2.107 . . . . 0.0 105.31 176.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -116.13 -21.71 9.28 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.448 1.099 . . . . 0.0 111.447 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.3 -126.17 1.34 Allowed Glycine 0 C--N 1.334 0.437 0 N-CA-C 106.835 -2.506 . . . . 0.0 106.835 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.0 t30 -62.08 -15.6 46.25 Favored 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 117.37 0.585 . . . . 0.0 112.062 169.575 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -117.48 156.21 28.39 Favored 'General case' 0 C--O 1.238 0.461 0 O-C-N 121.151 -0.968 . . . . 0.0 109.23 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.39 173.3 13.69 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 125.894 1.678 . . . . 0.0 109.402 -169.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -132.72 109.2 9.52 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 m -84.24 135.25 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 C-N-CA 124.232 1.013 . . . . 0.0 108.605 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -81.11 115.28 20.47 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 169.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 t -87.93 60.59 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 125.427 1.491 . . . . 0.0 107.185 176.033 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.5 m 50.15 36.42 12.29 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.923 1.689 . . . . 0.0 114.369 176.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.3 -31.86 0.26 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 121.348 -0.845 . . . . 0.0 112.966 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ILE . . . . . 0.403 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -138.77 140.45 38.98 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 C-N-CA 125.425 1.49 . . . . 0.0 108.818 179.867 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -77.63 141.98 39.14 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.098 174.214 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 56.7 mmt-85 -137.53 144.31 42.07 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 125.014 1.326 . . . . 0.0 108.727 172.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -77.5 149.54 34.96 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.655 0.782 . . . . 0.0 111.068 -172.151 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.79 143.36 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 124.978 1.311 . . . . 0.0 108.82 177.222 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -92.8 133.17 36.31 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 124.435 1.094 . . . . 0.0 108.77 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.0 mt -105.49 14.52 28.52 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 118.312 -0.851 . . . . 0.0 112.058 -171.31 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -45.99 -38.03 7.25 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.333 1.424 . . . . 0.0 113.114 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.2 mt -85.41 -3.86 58.98 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.821 0.848 . . . . 0.0 113.02 -172.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.28 -18.36 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.547 1.067 . . . . 0.0 113.02 -177.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.77 143.51 1.22 Allowed Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.063 1.316 . . . . 0.0 110.759 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.2 m -75.37 -8.89 57.88 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 12.5 p -125.21 152.2 44.86 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.548 1.139 . . . . 0.0 109.015 174.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -77.87 172.19 13.84 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.289 1.036 . . . . 0.0 110.349 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -57.59 -34.97 69.8 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.086 0.954 . . . . 0.0 112.213 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 18.0 p30 -80.41 -3.69 50.73 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.285 1.834 . . . . 0.0 113.102 177.043 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.38 -4.81 67.27 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.552 -1.138 . . . . 0.0 114.157 172.133 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -66.22 143.15 98.21 Favored Pre-proline 0 CA--C 1.537 0.454 0 CA-C-N 119.677 1.739 . . . . 0.0 109.087 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -64.42 143.09 81.39 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 121.878 1.719 . . . . 0.0 108.857 169.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 83.0 mtt-85 -72.8 1.6 8.27 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -170.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.0 m -50.24 137.89 6.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 120.994 1.725 . . . . 0.0 111.126 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.74 -26.37 18.72 Favored Glycine 0 CA--C 1.53 0.975 0 C-N-CA 124.759 1.171 . . . . 0.0 112.911 178.306 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -76.1 165.8 24.4 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 118.898 1.349 . . . . 0.0 108.404 173.109 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -105.18 156.52 18.02 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -144.37 135.17 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 57.5 tp -78.39 133.67 37.5 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 22.3 t -116.33 150.97 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 -178.18 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.37 133.4 24.22 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 125.368 1.467 . . . . 0.0 107.649 171.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.5 m 42.58 33.48 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 C-N-CA 126.211 1.804 . . . . 0.0 114.641 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.2 7.62 82.88 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 118.966 -0.908 . . . . 0.0 114.106 176.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -120.28 143.81 48.13 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 119.117 1.458 . . . . 0.0 108.191 175.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.0 130.42 46.65 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.177 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 28.0 ttt -89.66 -57.88 2.72 Favored 'General case' 0 C--O 1.233 0.236 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 18.5 m -151.99 144.91 24.44 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 124.293 1.037 . . . . 0.0 109.078 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 t -74.12 140.29 17.88 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 105.399 -2.075 . . . . 0.0 105.399 168.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 pt -137.7 160.3 34.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 123.573 0.749 . . . . 0.0 109.821 -173.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -76.96 165.21 24.96 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.691 0.796 . . . . 0.0 109.706 173.356 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -59.74 -42.83 94.04 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.467 0.707 . . . . 0.0 110.219 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -65.32 -36.38 83.87 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.066 0.547 . . . . 0.0 110.932 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.3 mt-10 -67.7 -35.05 78.09 Favored 'General case' 0 N--CA 1.457 -0.095 0 CA-C-O 119.129 -0.463 . . . . 0.0 110.113 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -47.32 83.67 Favored 'General case' 0 C--N 1.34 0.185 0 CA-C-N 118.95 0.795 . . . . 0.0 110.293 175.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -62.54 -43.55 98.54 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 118.167 0.44 . . . . 0.0 110.725 177.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.75 -40.89 96.71 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 118.131 0.423 . . . . 0.0 111.147 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.8 m -67.07 -42.48 84.64 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.245 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.9 mt -63.94 -39.05 93.26 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 119.204 0.911 . . . . 0.0 110.582 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.94 -46.89 79.69 Favored 'General case' 0 C--O 1.227 -0.091 0 C-N-CA 122.95 0.5 . . . . 0.0 110.585 175.396 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.41 99.53 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.566 0.621 . . . . 0.0 111.225 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.6 tp -65.05 -35.64 81.81 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 123.882 0.873 . . . . 0.0 111.601 -174.331 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -81.52 -39.64 24.38 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.022 0.828 . . . . 0.0 110.474 172.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -57.6 -42.68 83.73 Favored 'General case' 0 N--CA 1.462 0.143 0 C-N-CA 123.449 0.7 . . . . 0.0 111.563 -177.136 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 28.3 ptm -63.83 -10.04 18.19 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -177.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -115.82 -21.51 9.55 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 119.407 1.003 . . . . 0.0 111.144 173.276 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -64.65 -36.43 84.24 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.219 0.608 . . . . 0.0 111.246 171.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.1 m -61.96 -45.52 98.53 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 118.037 0.381 . . . . 0.0 110.731 176.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -169.56 144.35 2.42 Favored Pre-proline 0 CA--C 1.539 0.521 0 C-N-CA 126.852 2.061 . . . . 0.0 107.423 169.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -73.51 -14.36 24.96 Favored 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.52 2.147 . . . . 0.0 112.679 -178.217 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -56.87 -27.32 60.27 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 125.016 1.326 . . . . 0.0 113.003 -175.067 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 38.7 t -58.23 -29.21 36.86 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 C-N-CA 123.886 0.875 . . . . 0.0 110.905 176.686 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.92 -38.94 94.88 Favored Glycine 0 CA--C 1.529 0.967 0 O-C-N 121.04 -1.038 . . . . 0.0 111.461 175.416 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -73.83 7.93 2.27 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.123 0.969 . . . . 0.0 113.121 178.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 38.2 tp -121.09 -42.17 2.5 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 125.77 1.628 . . . . 0.0 109.35 171.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 45.2 tp -65.47 -38.81 90.88 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-N 118.708 0.685 . . . . 0.0 111.202 177.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 24.1 p90 -138.61 36.34 2.22 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.521 1.528 . . . . 0.0 109.843 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -156.11 -174.44 25.91 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 175.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -137.63 29.79 2.62 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.312 1.045 . . . . 0.0 109.459 -175.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -71.33 -13.2 61.8 Favored 'General case' 0 CA--C 1.544 0.715 0 O-C-N 121.208 -0.933 . . . . 0.0 111.157 176.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 59.5 tptt . . . . . 0 C--O 1.249 1.038 0 C-N-CA 127.323 2.249 . . . . 0.0 105.732 175.887 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mpt? . . . . . 0 N--CA 1.483 1.214 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 58.3 m -64.58 165.2 10.48 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.191 0.596 . . . . 0.0 110.287 171.28 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.7 pt -77.47 57.9 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 124.682 1.193 . . . . 0.0 111.181 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -75.51 49.78 2.39 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 126.354 1.931 . . . . 0.0 112.213 177.08 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -146.47 149.5 37.58 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 125.973 1.709 . . . . 0.0 108.184 -172.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -75.05 171.17 18.84 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.232 1.954 . . . . 0.0 112.237 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -156.07 167.84 33.39 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -101.72 136.83 40.9 Favored 'General case' 0 C--O 1.231 0.127 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.5 mt -72.65 82.6 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 125.648 1.579 . . . . 0.0 107.895 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.5 mmt85 -76.6 -27.56 55.83 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.607 -0.683 . . . . 0.0 111.565 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.14 152.18 35.66 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -176.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 63.6 mt -129.65 144.75 37.14 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -121.13 -20.16 6.88 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 124.446 1.098 . . . . 0.0 111.835 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.408 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 164.05 -127.48 1.67 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 106.607 -2.597 . . . . 0.0 106.607 -178.598 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -70.38 14.3 0.13 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 124.462 1.105 . . . . 0.0 112.004 169.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.408 ' H ' ' C ' ' A' ' 14' ' ' GLY . 37.7 mt-30 -140.11 153.8 46.82 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 127.66 2.384 . . . . 0.0 106.636 -176.66 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.65 167.18 22.68 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.261 1.425 . . . . 0.0 109.106 178.236 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -121.24 76.31 1.23 Allowed 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 -174.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.5 m -73.03 136.68 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -170.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -79.15 117.72 20.44 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 171.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.4 t -85.04 50.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 125.059 1.343 . . . . 0.0 107.724 177.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 79.3 m 40.59 49.57 2.73 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.166 2.186 . . . . 0.0 113.371 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 176.64 -38.92 0.1 OUTLIER Glycine 0 CA--C 1.526 0.748 0 CA-C-O 119.531 -0.594 . . . . 0.0 112.24 175.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.0 tp -156.26 154.86 5.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 175.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.5 mt-30 -76.94 143.28 39.63 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 122.801 0.441 . . . . 0.0 109.954 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.19 138.17 51.57 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 169.816 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -73.85 133.83 43.23 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 78.7 t -140.95 130.63 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.684 1.594 . . . . 0.0 107.001 -173.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.22 140.74 45.27 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 124.863 1.265 . . . . 0.0 109.92 175.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.3 mt -113.65 11.85 18.29 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.861 0.864 . . . . 0.0 112.886 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.9 m -53.34 -34.74 58.68 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 120.833 1.651 . . . . 0.0 112.432 -175.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 86.4 mt -73.91 -12.86 60.79 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -176.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 m -133.43 -19.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 119.323 0.965 . . . . 0.0 112.897 -171.477 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.33 147.03 0.89 Allowed Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.098 1.332 . . . . 0.0 110.831 -171.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.2 m -76.57 -4.38 42.54 Favored 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.842 -0.799 . . . . 0.0 113.002 179.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.1 m -131.94 151.25 51.83 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 124.349 1.059 . . . . 0.0 109.965 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -65.77 165.59 12.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.945 2.098 . . . . 0.0 109.864 169.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -52.96 -37.49 61.18 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.317 1.447 . . . . 0.0 112.152 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -85.35 9.82 14.4 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.721 0.809 . . . . 0.0 112.015 -178.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.87 4.96 88.37 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 124.581 1.086 . . . . 0.0 113.464 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -69.87 132.28 88.82 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -65.92 141.2 63.76 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 CA-C-N 121.303 1.501 . . . . 0.0 109.011 174.572 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -72.45 13.72 0.32 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -172.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -54.08 129.27 14.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-N 120.227 1.376 . . . . 0.0 108.639 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.65 -17.64 55.61 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.827 1.203 . . . . 0.0 113.414 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -73.34 169.31 17.41 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.511 1.655 . . . . 0.0 109.162 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.7 m95 -120.16 156.59 30.77 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.947 0.899 . . . . 0.0 109.123 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 2.8 m -143.2 144.92 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 123.435 0.694 . . . . 0.0 109.402 178.296 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 59.3 mt -72.89 147.97 44.82 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 168.132 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.9 t -131.96 152.68 37.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -130.82 -60.08 0.98 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.974 0.91 . . . . 0.0 109.635 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.3 m -138.36 38.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 123.941 0.896 . . . . 0.0 110.614 -169.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.08 14.66 60.25 Favored Glycine 0 CA--C 1.528 0.906 0 CA-C-O 119.406 -0.663 . . . . 0.0 113.046 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -128.22 137.33 51.98 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 175.174 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.32 111.74 5.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 172.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 15.5 tpt -71.79 -49.01 42.66 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 118.031 0.378 . . . . 0.0 110.303 -175.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 13.5 m -152.55 151.1 30.27 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 124.959 1.304 . . . . 0.0 108.603 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 18.4 t -78.79 141.01 15.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 171.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.7 pt -138.9 -169.69 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 126.064 1.746 . . . . 0.0 108.794 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -126.97 -179.29 4.76 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.019 1.327 . . . . 0.0 110.125 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -54.92 -44.9 74.64 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.161 0.985 . . . . 0.0 111.249 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.31 -49.22 67.78 Favored 'General case' 0 C--O 1.231 0.131 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -172.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 26.0 mm-40 -64.84 -38.76 92.07 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.776 0.43 . . . . 0.0 110.28 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.41 -51.28 66.43 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 118.372 0.533 . . . . 0.0 110.61 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 63.3 mtt85 -66.91 -36.95 83.43 Favored 'General case' 0 CA--C 1.523 -0.064 0 CA-C-O 118.489 -0.767 . . . . 0.0 110.633 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.72 -43.66 98.42 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 119.121 0.873 . . . . 0.0 110.909 175.403 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.4 m -64.05 -45.9 86.79 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 122.979 0.512 . . . . 0.0 109.996 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 57.9 mt -64.33 -39.22 93.47 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 118.252 0.478 . . . . 0.0 110.858 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.6 -48.48 72.16 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 123.2 0.6 . . . . 0.0 110.319 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.01 88.54 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 117.872 0.305 . . . . 0.0 111.26 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -66.46 -56.18 12.17 Favored 'General case' 0 C--N 1.339 0.117 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.047 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -66.09 -28.12 68.58 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 118.406 0.548 . . . . 0.0 111.435 -174.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -54.22 -29.19 45.54 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.959 0.904 . . . . 0.0 112.452 176.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 24.8 mmt -65.77 -12.5 54.48 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.551 0.741 . . . . 0.0 112.975 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -133.44 -39.33 0.91 Allowed 'General case' 0 C--N 1.341 0.214 0 C-N-CA 124.244 1.018 . . . . 0.0 111.143 -172.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -59.57 -23.26 62.76 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 125.795 1.638 . . . . 0.0 113.015 -174.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 3.3 m -52.55 -33.82 18.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.147 0.979 . . . . 0.0 112.733 172.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -73.83 -55.0 3.44 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-O 117.775 -1.107 . . . . 0.0 111.698 -174.376 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.36 -27.24 55.28 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 CA-C-N 121.656 1.627 . . . . 0.0 111.813 173.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -65.39 -51.7 58.59 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 119.0 0.818 . . . . 0.0 111.056 177.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.8 p -68.01 -32.36 55.88 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 CA-C-N 118.691 0.678 . . . . 0.0 110.231 178.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.94 -50.28 69.38 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 174.368 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -64.64 -42.4 95.49 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 117.763 0.781 . . . . 0.0 111.114 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 35.4 tp -56.49 -49.14 75.55 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 123.682 0.793 . . . . 0.0 110.072 177.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 60.2 tp -65.6 -56.45 12.14 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 122.761 0.424 . . . . 0.0 110.445 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 54.8 t80 -66.27 -34.84 78.9 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 123.212 0.605 . . . . 0.0 112.11 -169.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.23 0.88 64.21 Favored Glycine 0 CA--C 1.528 0.87 0 CA-C-O 118.294 -1.281 . . . . 0.0 113.114 -175.543 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 48.6 54.74 10.09 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-N 118.849 1.324 . . . . 0.0 109.358 -169.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 69.4 -59.88 0.48 Allowed 'General case' 0 C--O 1.234 0.275 0 C-N-CA 128.917 2.887 . . . . 0.0 111.652 -169.687 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 24.5 pttm . . . . . 0 C--O 1.249 1.075 0 C-N-CA 124.455 1.102 . . . . 0.0 109.521 -171.528 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 98.0 mtp . . . . . 0 N--CA 1.484 1.254 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 92.6 m -135.45 157.35 47.11 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 125.32 1.448 . . . . 0.0 108.585 176.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 47.4 pt -65.56 150.38 10.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 169.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.82 48.74 0.09 OUTLIER Glycine 0 CA--C 1.526 0.757 0 N-CA-C 107.114 -2.394 . . . . 0.0 107.114 -175.3 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.3 m -140.13 166.73 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.564 1.545 . . . . 0.0 109.675 -168.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -54.9 153.54 24.8 Favored 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.565 2.176 . . . . 0.0 113.175 169.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -159.88 164.31 34.14 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 169.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -110.96 130.21 55.65 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.45 1.125 . . . . 0.0 109.204 -172.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.6 mt -66.05 120.98 14.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.351 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 52.3 tpt85 -121.11 -22.5 6.09 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 118.182 -0.913 . . . . 0.0 111.651 -175.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.65 155.6 42.57 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 170.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 50.3 mt -133.06 144.67 35.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -126.61 -18.67 4.74 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 123.858 0.863 . . . . 0.0 112.452 -174.495 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.75 -131.13 2.25 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 107.2 -2.36 . . . . 0.0 107.2 -178.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.5 p-10 -68.33 9.24 0.35 Allowed 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.145 0.978 . . . . 0.0 112.545 169.417 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -139.39 155.47 47.62 Favored 'General case' 0 C--O 1.239 0.523 0 C-N-CA 126.004 1.722 . . . . 0.0 107.542 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.8 174.88 10.06 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 125.453 1.501 . . . . 0.0 110.757 -176.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -122.18 114.51 20.96 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 178.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 89.1 t -111.83 125.56 69.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 -169.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -72.58 112.21 8.43 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 170.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 t -90.07 59.81 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.3 m 50.02 42.64 24.98 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.336 1.854 . . . . 0.0 113.5 178.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.2 -37.28 0.14 Allowed Glycine 0 CA--C 1.525 0.71 0 O-C-N 121.629 -0.67 . . . . 0.0 112.906 173.541 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 tp -155.33 155.79 5.46 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 62.8 mt-30 -74.65 147.37 41.61 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.709 0.766 . . . . 0.0 110.871 177.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.14 144.52 51.23 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.456 1.502 . . . . 0.0 107.255 169.293 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -69.84 135.71 49.93 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 169.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.65 121.03 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -173.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -66.64 134.67 52.77 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 169.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.2 tp -117.78 0.44 11.98 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 124.737 1.215 . . . . 0.0 110.358 -169.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.5 m -57.77 -30.84 65.96 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 124.721 1.209 . . . . 0.0 111.211 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 77.0 mt -67.89 -13.98 62.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.078 0.951 . . . . 0.0 112.884 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.74 -8.71 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 119.154 0.888 . . . . 0.0 112.1 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.57 136.22 1.68 Allowed Glycine 0 CA--C 1.525 0.699 0 C-N-CA 125.4 1.476 . . . . 0.0 110.388 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.5 m -75.88 161.19 29.18 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.238 0.615 . . . . 0.0 109.342 169.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.2 m 56.4 177.52 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.774 1.629 . . . . 0.0 112.597 -169.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -133.49 151.91 51.83 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 126.182 1.793 . . . . 0.0 108.221 -170.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.2 -21.58 34.44 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.026 1.331 . . . . 0.0 114.214 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -74.31 -7.2 51.98 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.487 0.585 . . . . 0.0 112.052 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.15 46.92 5.71 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -177.312 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.67 158.3 60.18 Favored Pre-proline 0 CA--C 1.535 0.399 0 C-N-CA 125.165 1.386 . . . . 0.0 108.664 -176.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -69.0 153.55 72.24 Favored 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 121.958 1.772 . . . . 0.0 109.892 169.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -73.16 3.37 5.7 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.615 0.968 . . . . 0.0 113.615 177.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.53 127.46 15.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-N 120.547 1.521 . . . . 0.0 108.457 -175.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.27 -24.76 30.64 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 124.892 1.234 . . . . 0.0 112.548 -176.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -70.53 162.06 29.49 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.056 1.428 . . . . 0.0 108.84 172.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.4 m95 -113.67 155.87 24.75 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -141.88 143.19 27.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.493 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.2 mt -77.32 127.9 33.39 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 103.743 -2.688 . . . . 0.0 103.743 168.645 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.5 m -131.2 126.65 59.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 119.341 0.973 . . . . 0.0 110.627 -170.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.438 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 3.5 t60 -89.17 -165.88 1.45 Allowed 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 169.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.438 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 18.3 m -47.71 -29.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 C-N-CA 125.815 1.646 . . . . 0.0 114.993 -172.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.74 33.07 0.17 Allowed Glycine 0 C--N 1.338 0.639 0 CA-C-O 118.819 -0.99 . . . . 0.0 112.4 175.29 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -145.71 134.17 21.97 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.822 1.311 . . . . 0.0 109.128 -174.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.34 117.91 17.66 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 169.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 72.2 mtp -77.31 -49.4 15.08 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.526 1.13 . . . . 0.0 109.056 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.9 m -151.35 162.46 40.87 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 125.851 1.661 . . . . 0.0 108.65 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.7 p -107.52 139.88 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 C-N-CA 124.87 1.268 . . . . 0.0 107.874 172.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.1 pt -141.26 161.75 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.095 1.358 . . . . 0.0 109.896 -173.359 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -75.44 165.26 25.4 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.916 0.886 . . . . 0.0 110.53 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.53 -40.9 72.43 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 124.729 1.211 . . . . 0.0 111.698 176.217 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.48 -40.21 67.1 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 122.942 0.497 . . . . 0.0 110.79 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.07 -40.79 97.02 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.091 0.556 . . . . 0.0 109.763 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.91 -48.97 78.05 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.666 -0.207 . . . . 0.0 110.748 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 75.4 mtt85 -64.34 -40.02 95.05 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 119.079 -0.486 . . . . 0.0 110.762 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.7 -42.73 99.79 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.467 0.576 . . . . 0.0 111.047 176.017 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.4 m -65.16 -43.69 90.92 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.151 0.58 . . . . 0.0 110.334 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.2 mt -61.95 -44.45 96.73 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.394 0.543 . . . . 0.0 109.846 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -63.68 -44.47 93.63 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 118.458 0.572 . . . . 0.0 111.146 179.318 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.36 82.04 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 122.663 0.385 . . . . 0.0 110.316 178.402 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -60.2 -49.33 78.07 Favored 'General case' 0 CA--C 1.528 0.101 0 C-N-CA 123.693 0.797 . . . . 0.0 109.711 178.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -60.24 -40.39 90.06 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 123.462 0.705 . . . . 0.0 110.941 -177.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -63.83 -19.41 65.01 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 119.653 1.115 . . . . 0.0 111.557 -175.447 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 37.8 tpp -85.69 -19.52 30.75 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 125.189 1.396 . . . . 0.0 112.117 -178.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 72.5 m-85 -141.65 -3.79 1.13 Allowed 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 115.244 1.572 . . . . 0.0 115.244 -169.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -58.66 -25.53 62.88 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 120.03 1.286 . . . . 0.0 113.117 -172.507 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 14.6 m -129.67 45.5 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 C-N-CA 126.098 1.759 . . . . 0.0 108.775 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 79.05 163.93 0.13 Allowed Pre-proline 0 CA--C 1.545 0.771 0 C-N-CA 127.55 2.34 . . . . 0.0 110.534 177.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -57.56 -14.68 17.55 Favored 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 123.529 2.82 . . . . 0.0 115.486 178.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -56.35 -44.33 79.96 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 119.19 0.904 . . . . 0.0 112.091 -175.456 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 28.3 m -69.61 -29.05 39.93 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-O 119.181 -0.438 . . . . 0.0 111.087 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -68.32 -45.67 68.36 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 176.258 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -62.65 -39.28 93.39 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 117.61 0.705 . . . . 0.0 111.157 176.658 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 44.2 tp -65.78 -48.77 70.7 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.339 0.656 . . . . 0.0 110.553 176.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.2 tp -59.31 -51.84 68.21 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 124.076 0.951 . . . . 0.0 109.768 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 28.1 t80 -67.44 -22.66 65.5 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.413 0.685 . . . . 0.0 112.05 -177.264 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 82.45 19.69 63.69 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 123.725 0.678 . . . . 0.0 112.016 -176.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -69.53 -34.15 73.83 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 117.839 0.82 . . . . 0.0 109.296 170.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -137.58 70.79 1.39 Allowed 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.18 1.392 . . . . 0.0 108.132 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 24.4 ttpt . . . . . 0 C--O 1.251 1.158 0 C-N-CA 125.256 1.422 . . . . 0.0 107.493 178.183 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.8 mmm . . . . . 0 N--CA 1.486 1.359 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 58.2 m -60.1 -39.96 88.0 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.416 0.687 . . . . 0.0 112.677 -172.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.1 pt -142.34 149.09 19.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 C-N-CA 125.06 1.344 . . . . 0.0 108.233 179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.12 46.16 0.09 OUTLIER Glycine 0 CA--C 1.526 0.763 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 -173.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.7 m -143.3 163.75 35.33 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 125.208 1.403 . . . . 0.0 110.287 -168.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -53.77 157.13 10.66 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 123.075 2.517 . . . . 0.0 113.874 171.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.71 167.85 37.34 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 126.336 1.922 . . . . 0.0 108.648 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.2 tt0 -116.18 134.25 55.13 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.393 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 64.7 mt -75.04 74.86 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 125.649 1.58 . . . . 0.0 107.509 -176.146 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -70.73 -30.65 67.23 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-O 118.438 -0.792 . . . . 0.0 111.566 -172.172 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -148.81 155.7 41.31 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 177.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 57.0 mt -132.18 146.85 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -129.71 -20.06 3.26 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.854 0.862 . . . . 0.0 112.529 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 175.15 -134.47 2.74 Favored Glycine 0 C--N 1.334 0.418 0 N-CA-C 106.243 -2.743 . . . . 0.0 106.243 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.9 t30 -65.86 -15.74 63.2 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 118.386 1.093 . . . . 0.0 110.668 169.057 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -101.08 153.0 19.93 Favored 'General case' 0 C--O 1.239 0.544 0 C-N-CA 124.954 1.302 . . . . 0.0 109.123 175.438 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.34 159.52 42.06 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.313 1.445 . . . . 0.0 109.14 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -106.77 86.83 2.39 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.087 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.61 127.6 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 -174.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -71.37 106.89 4.06 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 169.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.77 67.24 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.0 48.05 7.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.291 2.236 . . . . 0.0 113.739 178.196 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 174.77 -42.03 0.12 Allowed Glycine 0 CA--C 1.524 0.646 0 CA-C-O 119.692 -0.505 . . . . 0.0 112.219 172.108 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -156.97 156.1 4.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 C-N-CA 124.676 1.19 . . . . 0.0 108.175 175.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -67.76 136.06 53.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.23 0.612 . . . . 0.0 110.469 176.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.2 mpt_? -123.88 148.61 46.67 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 106.327 -1.731 . . . . 0.0 106.327 169.481 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -70.59 136.81 49.5 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.5 t -138.59 131.25 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -83.21 126.22 32.4 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 169.738 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.1 mt -83.29 36.86 0.53 Allowed 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 123.64 0.776 . . . . 0.0 111.335 -173.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -45.87 -40.33 9.81 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.412 2.285 . . . . 0.0 114.443 -169.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.2 mt -106.23 4.56 28.99 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 118.853 -0.594 . . . . 0.0 112.282 -169.309 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.3 m -133.97 -26.68 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.981 0.809 . . . . 0.0 111.937 -173.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.89 152.79 1.94 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.095 0.855 . . . . 0.0 110.979 -175.268 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 m -77.18 -6.86 54.56 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m -126.72 151.58 47.98 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.3 1.04 . . . . 0.0 109.075 175.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.5 t0 -84.51 176.57 8.55 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 124.308 1.043 . . . . 0.0 110.665 -178.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -55.68 -37.08 67.85 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.917 1.287 . . . . 0.0 112.102 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -84.12 -2.0 55.98 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.627 0.771 . . . . 0.0 112.929 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.18 -3.26 66.47 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.323 -1.265 . . . . 0.0 114.241 173.594 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -67.38 147.81 98.8 Favored Pre-proline 0 CA--C 1.538 0.506 0 CA-C-N 119.91 1.855 . . . . 0.0 109.046 175.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -64.87 141.93 73.51 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.541 1.494 . . . . 0.0 108.743 169.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.4 mtt-85 -70.94 11.39 0.4 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.7 p -56.38 129.23 17.74 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 CA-C-N 119.968 1.258 . . . . 0.0 109.031 -176.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.04 -14.46 57.18 Favored Glycine 0 CA--C 1.534 1.24 0 CA-C-O 118.226 -1.319 . . . . 0.0 113.972 -178.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -70.34 166.03 21.11 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.824 1.812 . . . . 0.0 108.969 170.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -112.25 161.22 16.83 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 121.538 0.685 . . . . 0.0 109.871 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.75 140.9 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 -172.43 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.8 111.64 12.55 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 104.894 -2.262 . . . . 0.0 104.894 169.321 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 51.3 t -93.11 132.22 37.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -144.24 130.41 19.63 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 1.7 t 45.74 37.34 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 125.177 1.391 . . . . 0.0 112.688 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.08 16.37 79.6 Favored Glycine 0 CA--C 1.534 1.251 0 O-C-N 120.916 -1.115 . . . . 0.0 114.308 176.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -128.49 161.95 28.35 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 119.315 1.558 . . . . 0.0 109.956 170.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.89 111.34 16.12 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.243 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 16.0 tpt -74.02 -51.5 15.67 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.002 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.4 m -154.21 138.37 16.51 Favored 'General case' 0 C--N 1.342 0.247 0 C-N-CA 124.305 1.042 . . . . 0.0 108.912 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -77.54 142.42 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 169.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.2 pt -139.91 160.51 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 124.355 1.062 . . . . 0.0 109.84 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -75.27 165.12 25.68 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 123.842 0.857 . . . . 0.0 110.46 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -54.51 -41.68 69.92 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 124.732 1.213 . . . . 0.0 111.467 174.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.4 -39.42 67.98 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 122.988 0.515 . . . . 0.0 110.786 -178.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -64.61 -40.7 95.97 Favored 'General case' 0 N--CA 1.461 0.088 0 C-N-CA 123.009 0.524 . . . . 0.0 109.865 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.43 -49.42 76.92 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.838 0.29 . . . . 0.0 110.562 177.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 76.1 mtt85 -64.45 -40.12 95.12 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-O 119.03 -0.51 . . . . 0.0 110.665 -178.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.93 -41.83 99.61 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 118.602 0.637 . . . . 0.0 111.129 176.055 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.7 m -65.42 -43.43 90.53 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.813 0.445 . . . . 0.0 110.032 178.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -64.51 -40.04 94.89 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 118.765 0.711 . . . . 0.0 110.549 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -63.21 -44.0 96.54 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 118.202 0.455 . . . . 0.0 110.748 176.084 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.64 -47.14 86.78 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 122.992 0.517 . . . . 0.0 110.204 175.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.7 mt -62.33 -3.2 1.25 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.039 1.336 . . . . 0.0 113.35 177.024 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 23.8 mm-40 -128.29 8.15 6.0 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.813 1.245 . . . . 0.0 112.061 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -150.57 -34.07 0.16 Allowed 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 119.774 1.17 . . . . 0.0 114.132 172.517 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 14.0 tpt -66.12 -16.41 63.93 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 119.228 0.922 . . . . 0.0 112.151 -173.439 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -120.9 18.9 11.78 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.544 1.538 . . . . 0.0 110.125 -176.501 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -126.65 -0.17 6.79 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.286 1.434 . . . . 0.0 111.564 -174.065 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.1 t -75.15 -33.89 30.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 C-N-CA 123.748 0.819 . . . . 0.0 109.408 175.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -59.1 -51.68 80.03 Favored Pre-proline 0 CA--C 1.542 0.661 0 C-N-CA 124.449 1.099 . . . . 0.0 111.436 -177.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -70.03 -20.05 34.05 Favored 'Trans proline' 0 C--N 1.351 0.663 0 CA-C-N 121.032 1.404 . . . . 0.0 112.461 173.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -66.79 -54.23 24.82 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 119.758 1.163 . . . . 0.0 109.784 177.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -69.14 -33.27 57.6 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-O 119.037 -0.506 . . . . 0.0 110.156 178.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.71 -53.95 41.69 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 174.52 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -59.53 -41.52 90.2 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 123.688 0.795 . . . . 0.0 111.365 179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 60.6 tp -61.52 -45.71 93.06 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 122.678 0.391 . . . . 0.0 110.596 176.696 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 62.4 tp -62.96 -37.95 89.16 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.789 0.835 . . . . 0.0 111.106 178.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 13.6 m-30 -68.36 -10.2 53.31 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.458 0.703 . . . . 0.0 112.429 175.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 68.75 31.31 72.99 Favored Glycine 0 CA--C 1.53 0.984 0 CA-C-N 118.981 0.809 . . . . 0.0 111.175 -175.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -143.62 51.48 1.35 Allowed 'General case' 0 CA--C 1.537 0.473 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 -175.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -52.16 150.62 4.36 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 125.595 1.558 . . . . 0.0 113.559 -169.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 29.8 ttmt . . . . . 0 C--O 1.248 1.011 0 C-N-CA 125.085 1.354 . . . . 0.0 109.721 -178.375 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.484 1.234 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 62.8 m -76.23 62.09 1.71 Allowed 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 124.942 1.297 . . . . 0.0 111.612 -177.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -59.5 163.89 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 124.618 1.167 . . . . 0.0 112.215 -178.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.1 63.38 0.5 Allowed Glycine 0 CA--C 1.526 0.74 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -176.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.1 p -153.04 145.33 17.05 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 126.3 1.84 . . . . 0.0 106.472 -169.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -75.41 168.55 24.31 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.617 1.545 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.42 -176.88 42.24 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 172.532 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -95.99 137.86 34.46 Favored 'General case' 0 C--O 1.231 0.116 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 178.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 68.9 mt -71.47 78.81 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 171.431 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -67.51 -30.22 69.83 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.446 -0.784 . . . . 0.0 110.301 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.18 150.01 26.6 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 124.512 1.125 . . . . 0.0 108.051 -173.201 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 49.8 mt -119.98 149.79 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -145.48 65.17 1.24 Allowed 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 126.324 1.85 . . . . 0.0 107.468 -170.007 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 -124.71 18.71 Favored Glycine 0 C--N 1.338 0.64 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -173.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -68.27 -25.05 64.97 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 122.787 0.435 . . . . 0.0 111.913 172.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -86.1 170.92 11.77 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 121.86 0.838 . . . . 0.0 109.835 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.55 159.79 41.8 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.545 1.538 . . . . 0.0 108.19 169.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.58 75.97 0.95 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.238 -2.134 . . . . 0.0 105.238 177.281 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 79.3 t -71.74 126.52 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 124.904 1.282 . . . . 0.0 107.563 -172.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -79.26 111.02 15.08 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 174.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.5 t -82.06 60.21 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 C-N-CA 125.668 1.587 . . . . 0.0 107.282 172.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 55.5 m 43.67 41.39 3.53 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.11 2.164 . . . . 0.0 114.432 176.578 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 161.67 -23.83 0.23 Allowed Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.157 -0.802 . . . . 0.0 113.676 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.7 tp -150.29 149.43 14.45 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 176.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -92.17 139.06 31.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 -179.221 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -129.69 144.97 51.54 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.916 1.287 . . . . 0.0 108.519 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -73.84 137.61 43.91 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 71.6 t -137.03 143.67 34.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -99.8 119.8 38.75 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.164 1.386 . . . . 0.0 107.539 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.9 mt -91.17 12.49 19.91 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 117.88 -1.057 . . . . 0.0 113.03 -172.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -48.65 -36.43 15.91 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 121.29 1.859 . . . . 0.0 113.73 -174.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.0 mt -88.55 -2.63 58.7 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -173.268 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.07 -19.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 119.344 0.975 . . . . 0.0 112.672 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.0 146.84 2.93 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 125.259 1.409 . . . . 0.0 111.131 -175.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.1 m -74.97 -12.64 60.39 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.49 0.716 . . . . 0.0 112.18 174.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.4 m -117.89 166.34 12.6 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.603 1.161 . . . . 0.0 109.316 172.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -115.65 163.39 15.87 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.185 1.794 . . . . 0.0 110.446 -169.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -54.18 -36.74 63.72 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.397 1.479 . . . . 0.0 111.265 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 -74.44 1.22 12.31 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.499 1.52 . . . . 0.0 113.059 -178.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.02 45.61 11.52 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 121.014 -1.054 . . . . 0.0 111.098 174.331 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.6 pt20 -141.64 151.34 60.08 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.28 1.432 . . . . 0.0 108.611 -177.71 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -66.52 147.81 82.76 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 122.08 1.853 . . . . 0.0 109.159 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -73.71 7.93 2.2 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.9 m -54.57 133.37 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 120.537 1.517 . . . . 0.0 109.892 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.11 -17.95 34.58 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-O 118.231 -1.316 . . . . 0.0 113.38 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -72.57 164.73 25.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 119.708 1.754 . . . . 0.0 108.735 174.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 33.7 m95 -109.2 154.0 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.0 p -146.61 140.22 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -172.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 65.6 tp -89.24 148.09 23.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 169.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 t -124.99 142.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -103.48 -52.15 3.06 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.915 0.486 . . . . 0.0 110.355 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.4 p -157.81 63.12 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 -38.36 1.81 Allowed Glycine 0 CA--C 1.529 0.946 0 C-N-CA 124.746 1.165 . . . . 0.0 112.034 -172.418 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -69.49 135.18 49.81 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 118.639 1.22 . . . . 0.0 109.159 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.43 132.03 52.61 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 169.273 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 21.9 ttt -84.81 -55.28 4.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.13 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.3 m -155.82 149.46 25.04 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 124.768 1.227 . . . . 0.0 108.844 -177.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.9 p -74.94 142.78 14.14 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 168.418 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.9 pt -138.32 169.98 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 C-N-CA 124.104 0.961 . . . . 0.0 109.682 -172.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.38 169.74 8.68 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.754 0.822 . . . . 0.0 109.575 169.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -62.43 -34.39 76.68 Favored 'General case' 0 C--N 1.334 -0.084 0 CA-C-O 118.68 -0.676 . . . . 0.0 112.452 -173.171 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.85 -39.78 95.01 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.022 0.828 . . . . 0.0 110.743 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -65.96 -41.15 91.61 Favored 'General case' 0 C--O 1.232 0.152 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.24 -50.33 72.17 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 117.916 0.325 . . . . 0.0 110.351 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 43.8 mmt-85 -63.48 -43.48 97.18 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 118.877 -0.582 . . . . 0.0 110.279 -179.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.75 -43.5 98.72 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 118.484 0.584 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.0 m -66.6 -43.55 84.52 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 122.749 0.42 . . . . 0.0 110.128 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.4 mt -63.63 -41.25 98.28 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 119.084 0.856 . . . . 0.0 110.499 178.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -63.31 -44.63 94.43 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 122.874 0.47 . . . . 0.0 110.417 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.18 -48.91 76.38 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.828 0.451 . . . . 0.0 110.76 177.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 56.9 mt -60.56 -38.91 86.1 Favored 'General case' 0 N--CA 1.463 0.178 0 C-N-CA 123.281 0.633 . . . . 0.0 111.028 -177.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 36.8 mt-30 -66.65 -45.09 80.13 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 118.493 0.588 . . . . 0.0 110.18 174.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.5 m-80 -68.34 -15.9 63.74 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-O 118.582 -0.723 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 66.9 mtt -59.34 -18.52 38.92 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 120.127 1.331 . . . . 0.0 112.004 170.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 80.8 t80 -63.09 -29.71 71.02 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 119.238 0.926 . . . . 0.0 110.826 172.316 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -98.58 11.78 37.33 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.208 1.403 . . . . 0.0 110.869 175.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 23.9 t 71.73 -23.29 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 C-N-CA 128.041 2.536 . . . . 0.0 114.33 169.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -55.9 -53.98 57.08 Favored Pre-proline 0 CA--C 1.541 0.625 0 N-CA-C 114.397 1.258 . . . . 0.0 114.397 -169.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -74.25 -14.11 23.1 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 CA-C-N 121.739 1.657 . . . . 0.0 112.81 178.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -73.82 -49.23 26.21 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 119.83 1.196 . . . . 0.0 109.625 175.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 28.1 m -68.65 -28.57 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-O 118.95 -0.548 . . . . 0.0 110.504 172.428 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -56.29 -57.15 20.65 Favored Glycine 0 C--N 1.34 0.768 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 170.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.24 -38.05 76.11 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 117.996 0.898 . . . . 0.0 111.829 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 tm? -63.48 -52.03 63.08 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 122.776 0.43 . . . . 0.0 110.011 176.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 66.0 tp -61.15 -41.65 97.14 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 124.197 0.999 . . . . 0.0 110.876 -179.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 18.2 m-30 -69.85 -9.95 56.68 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.927 0.891 . . . . 0.0 112.472 177.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 73.59 22.52 78.34 Favored Glycine 0 CA--C 1.531 1.05 0 CA-C-N 118.911 0.778 . . . . 0.0 112.253 179.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -77.28 -31.19 54.66 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 118.102 0.951 . . . . 0.0 109.705 173.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 36.4 mm-40 -71.77 -35.57 70.09 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.041 0.536 . . . . 0.0 111.667 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 65.7 tttm . . . . . 0 C--O 1.249 1.055 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -177.815 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.2 ttm . . . . . 0 N--CA 1.481 1.121 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 76.5 m -132.03 134.77 45.92 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 172.555 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.1 tp -156.54 -173.79 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 C-N-CA 126.691 1.996 . . . . 0.0 106.456 -176.537 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.22 47.08 0.13 Allowed Glycine 0 CA--C 1.522 0.522 0 O-C-N 120.731 -1.231 . . . . 0.0 110.542 178.619 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.4 t -142.7 141.7 20.94 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 -170.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -55.47 165.63 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.892 2.395 . . . . 0.0 113.017 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.88 175.67 35.09 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 169.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -116.82 136.43 52.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.8 mt -70.56 96.26 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 N-CA-C 105.931 -1.878 . . . . 0.0 105.931 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -85.56 -42.86 14.0 Favored 'General case' 0 N--CA 1.462 0.132 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 -169.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 p -147.22 158.43 43.95 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.617 1.567 . . . . 0.0 108.112 176.167 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 52.3 mt -127.46 146.57 33.0 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -177.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -123.96 -19.18 5.74 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.065 0.946 . . . . 0.0 112.294 -176.229 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.6 -127.58 1.59 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -66.75 2.29 1.44 Allowed 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 123.932 0.893 . . . . 0.0 112.384 169.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -134.28 154.23 51.42 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 126.875 2.07 . . . . 0.0 107.314 -174.186 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.83 155.33 47.3 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.625 1.17 . . . . 0.0 109.382 -179.183 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -99.56 78.7 2.19 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.9 t -68.13 125.8 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 -176.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -75.66 105.18 6.55 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 169.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 t -81.52 63.25 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 37.8 m 48.95 39.52 14.72 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.495 1.918 . . . . 0.0 113.315 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.02 -48.14 0.19 Allowed Glycine 0 CA--C 1.526 0.728 0 CA-C-O 119.255 -0.747 . . . . 0.0 112.01 174.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.0 mm -137.16 143.28 35.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -174.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -71.78 141.88 49.7 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.33 0.586 . . . . 0.0 110.775 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -133.35 144.14 49.43 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 125.622 1.569 . . . . 0.0 106.999 169.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -73.06 134.59 44.63 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.158 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 87.6 t -138.3 129.99 37.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -79.57 143.34 34.86 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 122.993 0.517 . . . . 0.0 109.886 174.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 36.3 mt -114.94 15.24 17.32 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.089 0.956 . . . . 0.0 112.668 -169.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.7 m -50.64 -37.32 39.89 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 120.886 1.676 . . . . 0.0 112.463 -177.398 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.4 mt -77.08 -8.54 57.64 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -174.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.39 -20.11 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 119.517 1.053 . . . . 0.0 112.992 -172.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.16 140.37 0.74 Allowed Glycine 0 CA--C 1.529 0.913 0 C-N-CA 125.244 1.402 . . . . 0.0 110.886 -172.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.8 m -73.82 -17.73 61.03 Favored 'General case' 0 CA--C 1.535 0.374 0 O-C-N 122.024 -0.692 . . . . 0.0 112.313 176.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.9 m -93.0 135.17 34.41 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 123.809 0.843 . . . . 0.0 109.043 175.253 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -66.38 158.18 29.93 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.093 1.757 . . . . 0.0 109.598 169.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -53.47 -29.96 38.48 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.346 1.459 . . . . 0.0 112.176 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -75.66 -12.67 60.25 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.26 48.63 4.5 Favored Glycine 0 CA--C 1.53 1.029 0 CA-C-N 119.007 0.821 . . . . 0.0 111.166 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -143.75 160.54 50.05 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 126.717 2.007 . . . . 0.0 107.409 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -64.68 141.96 74.85 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 CA-C-N 121.586 1.602 . . . . 0.0 110.538 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -69.53 13.87 0.12 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.5 m -54.93 132.87 18.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 120.354 1.434 . . . . 0.0 110.05 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.65 -17.79 53.05 Favored Glycine 0 CA--C 1.532 1.096 0 CA-C-O 118.479 -1.178 . . . . 0.0 113.458 -178.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -71.94 160.94 31.68 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 119.699 1.75 . . . . 0.0 109.081 174.095 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.3 m95 -107.68 161.17 15.11 Favored 'General case' 0 C--O 1.232 0.178 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 p -154.05 146.19 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -169.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.9 mt -89.89 139.63 30.4 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 172.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.3 t -136.15 143.35 36.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -178.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 5.5 t60 -141.44 -39.05 0.4 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.407 0.683 . . . . 0.0 112.487 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.36 27.08 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 119.026 0.83 . . . . 0.0 112.029 -171.174 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.99 16.73 80.52 Favored Glycine 0 CA--C 1.534 1.224 0 O-C-N 121.446 -0.784 . . . . 0.0 112.526 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -129.03 144.43 51.19 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 172.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.12 122.59 17.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 171.161 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 68.5 mtp -76.76 -47.18 22.5 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.4 m -163.74 149.05 10.89 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 126.131 1.772 . . . . 0.0 108.144 176.214 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.1 t -80.37 145.28 9.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 169.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.2 pt -139.51 161.44 27.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.447 1.499 . . . . 0.0 109.198 -176.214 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -84.45 173.45 10.87 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.344 0.592 . . . . 0.0 110.894 174.211 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -69.99 -30.18 67.45 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 121.758 -0.589 . . . . 0.0 112.294 -170.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -73.63 -40.6 63.65 Favored 'General case' 0 N--CA 1.462 0.129 0 O-C-N 121.283 -0.886 . . . . 0.0 109.837 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -61.36 -41.35 96.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.224 0.61 . . . . 0.0 109.917 174.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.43 -49.41 75.57 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 117.983 0.356 . . . . 0.0 110.416 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 86.3 mtm180 -63.7 -40.2 96.19 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 119.13 -0.462 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.2 -41.9 99.24 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 118.759 0.709 . . . . 0.0 110.954 176.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -67.49 -38.64 84.66 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 122.083 -0.386 . . . . 0.0 110.282 178.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 53.0 mt -65.49 -38.03 88.57 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 119.079 0.854 . . . . 0.0 110.67 176.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -64.76 -43.86 91.93 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 118.605 0.639 . . . . 0.0 110.293 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.52 -43.24 99.29 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.962 0.505 . . . . 0.0 111.142 176.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -56.37 -42.76 78.37 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.405 1.082 . . . . 0.0 109.909 176.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -79.88 7.39 8.91 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 124.164 0.986 . . . . 0.0 113.053 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -132.46 -13.2 3.03 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 119.538 1.063 . . . . 0.0 112.996 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 25.7 ptt? -56.55 -30.04 62.67 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 119.884 1.22 . . . . 0.0 112.385 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -90.14 11.3 21.34 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 125.48 1.512 . . . . 0.0 112.253 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -128.91 -36.96 1.76 Allowed 'General case' 0 N--CA 1.464 0.25 0 C-N-CA 124.578 1.151 . . . . 0.0 111.503 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.4 m -70.13 -16.89 20.51 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.605 0 CA-C-N 118.615 0.643 . . . . 0.0 111.411 171.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -138.93 157.12 72.15 Favored Pre-proline 0 CA--C 1.536 0.43 0 C-N-CA 126.607 1.963 . . . . 0.0 106.868 173.335 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -69.13 -15.26 39.29 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 122.382 2.055 . . . . 0.0 112.359 175.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 35.2 t70 47.09 -118.48 0.89 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 126.013 1.725 . . . . 0.0 109.593 -173.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.4 p -56.42 -27.27 24.29 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 C-N-CA 124.627 1.171 . . . . 0.0 112.329 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -55.48 -23.84 36.46 Favored Glycine 0 CA--C 1.529 0.964 0 C-N-CA 124.62 1.105 . . . . 0.0 112.94 174.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -60.75 -14.75 23.29 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 118.805 1.302 . . . . 0.0 113.624 176.148 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.7 tp -133.8 -29.21 1.34 Allowed 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.285 1.034 . . . . 0.0 110.881 176.081 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.5 tp -73.89 -25.01 59.8 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 123.836 0.855 . . . . 0.0 111.969 177.17 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 24.8 t80 -129.96 26.91 5.2 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.193 0.997 . . . . 0.0 111.129 -169.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -177.26 168.28 39.94 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 172.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 36.7 mm-40 -61.89 -40.75 96.51 Favored 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 172.127 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -164.95 169.86 15.94 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 127.863 2.465 . . . . 0.0 106.822 169.434 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 62.3 mttm . . . . . 0 C--O 1.25 1.11 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 172.188 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.0 ttt . . . . . 0 N--CA 1.486 1.332 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 9.8 p -69.69 -23.59 63.46 Favored 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 114.228 1.196 . . . . 0.0 114.228 -174.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.3 pt -62.73 146.95 12.24 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 124.062 0.945 . . . . 0.0 111.826 -172.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -169.36 49.76 0.21 Allowed Glycine 0 CA--C 1.529 0.936 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -172.44 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 98.5 t -143.88 139.39 16.03 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -171.109 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.83 159.89 31.44 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.666 1.577 . . . . 0.0 112.582 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.3 168.1 33.04 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 172.294 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -89.9 143.02 27.15 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 174.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 70.0 mt -74.17 76.64 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.32 1.448 . . . . 0.0 107.205 176.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -64.87 -39.18 93.14 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 126.088 1.755 . . . . 0.0 110.916 -177.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.0 m -150.26 153.78 36.78 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.35 147.2 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 178.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -116.39 -22.33 8.84 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.37 1.468 . . . . 0.0 111.565 -169.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 154.29 -122.92 1.3 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 105.094 -3.203 . . . . 0.0 105.094 -177.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -72.81 15.68 0.18 Allowed 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.101 0.961 . . . . 0.0 111.121 168.6 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.419 ' H ' ' C ' ' A' ' 14' ' ' GLY . 20.6 mt-30 -141.53 169.87 16.79 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 128.03 2.532 . . . . 0.0 106.569 -174.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.78 21.27 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.399 1.08 . . . . 0.0 109.4 173.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.3 mttp -118.26 72.58 0.87 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 105.604 -1.999 . . . . 0.0 105.604 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.5 m -70.13 137.2 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 C-N-CA 124.553 1.141 . . . . 0.0 109.326 -169.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -85.19 111.89 20.23 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 175.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.2 m -80.45 38.94 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 C-N-CA 124.181 0.992 . . . . 0.0 110.979 178.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 75.8 m 48.13 53.53 11.56 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.349 1.86 . . . . 0.0 111.855 -169.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -179.52 -41.3 0.07 OUTLIER Glycine 0 CA--C 1.524 0.62 0 CA-C-O 119.721 -0.488 . . . . 0.0 112.415 173.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.4 tp -156.0 156.06 5.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 -77.12 138.73 39.68 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 173.066 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -130.9 131.99 44.85 Favored 'General case' 0 C--N 1.333 -0.12 0 C-N-CA 125.466 1.506 . . . . 0.0 107.789 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -72.29 130.96 42.01 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 49.1 t -141.44 133.55 28.68 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 125.683 1.593 . . . . 0.0 107.323 -173.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -64.79 136.71 57.2 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 122.689 0.395 . . . . 0.0 110.407 172.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.9 mt -112.92 0.74 15.21 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.165 -0.921 . . . . 0.0 111.569 173.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.3 m -54.99 -31.75 61.21 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 121.061 1.755 . . . . 0.0 111.724 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 56.8 mt -67.87 -15.26 63.53 Favored 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 113.642 0.979 . . . . 0.0 113.642 178.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.64 -10.83 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.481 1.112 . . . . 0.0 112.79 -175.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.31 141.02 0.83 Allowed Glycine 0 CA--C 1.529 0.922 0 C-N-CA 125.527 1.537 . . . . 0.0 110.397 -170.157 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.4 m -76.29 -6.2 50.43 Favored 'General case' 0 CA--C 1.536 0.432 0 O-C-N 121.817 -0.813 . . . . 0.0 112.533 174.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 80.4 m -110.32 147.96 32.87 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 124.139 0.976 . . . . 0.0 109.489 175.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -68.94 171.65 7.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 126.635 1.974 . . . . 0.0 110.564 176.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 21.9 mm-40 -58.25 -15.36 9.79 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.149 1.38 . . . . 0.0 113.505 -177.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -117.96 8.66 12.6 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.529 1.532 . . . . 0.0 112.896 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.73 -2.11 69.47 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-O 118.805 -0.997 . . . . 0.0 114.545 170.36 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -67.01 154.54 92.28 Favored Pre-proline 0 CA--C 1.537 0.444 0 CA-C-N 119.373 1.586 . . . . 0.0 108.797 169.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -64.84 143.32 79.48 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 CA-C-N 121.18 1.457 . . . . 0.0 109.382 169.686 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.1 mtt-85 -70.51 10.96 0.4 Allowed 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.966 1.098 . . . . 0.0 113.966 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.9 p -56.44 132.34 20.4 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 O-C-N 120.759 -1.213 . . . . 0.0 109.03 -175.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.7 -15.79 49.74 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 118.097 -1.391 . . . . 0.0 114.076 -178.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -69.05 170.28 10.21 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 120.023 1.912 . . . . 0.0 108.906 169.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -119.66 157.62 28.1 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 177.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.3 p -151.56 136.3 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -171.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 81.0 mt -71.35 145.37 49.47 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 169.44 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 39.1 t -117.06 143.24 27.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 176.004 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -139.14 118.84 13.09 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 173.154 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . 0.286 29.4 m 44.45 28.87 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.461 2.304 . . . . 0.0 115.686 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 98.81 10.87 48.55 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 121.188 -0.945 . . . . 0.0 114.392 178.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -125.79 146.62 49.71 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 119.044 1.422 . . . . 0.0 108.484 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.12 114.44 3.12 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.615 0.766 . . . . 0.0 109.523 172.217 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 12.7 tpt -80.91 -42.71 20.96 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 58.3 m -166.02 147.54 6.88 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.865 1.666 . . . . 0.0 108.328 171.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 96.6 t -75.54 143.56 13.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 169.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 33.7 pt -139.36 162.19 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.028 1.331 . . . . 0.0 109.782 -175.635 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -74.14 165.22 25.53 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-O 121.48 0.657 . . . . 0.0 110.262 172.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -56.62 -43.2 79.99 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.191 1.396 . . . . 0.0 111.318 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.37 -38.85 85.39 Favored 'General case' 0 C--N 1.338 0.1 0 C-N-CA 122.801 0.44 . . . . 0.0 110.825 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -65.97 -40.36 91.18 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.31 -49.38 74.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 117.939 0.336 . . . . 0.0 110.478 178.024 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 47.6 mtm105 -61.57 -42.17 98.46 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 119.12 -0.467 . . . . 0.0 110.809 179.359 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.4 -42.83 99.73 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 118.5 0.591 . . . . 0.0 111.102 177.286 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.7 m -65.84 -41.31 91.92 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.841 0.456 . . . . 0.0 110.273 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.0 mt -65.23 -40.67 94.36 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.981 0.809 . . . . 0.0 110.426 178.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -64.4 -44.1 92.36 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 118.717 0.689 . . . . 0.0 110.696 177.114 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.3 -46.03 92.01 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.95 0.5 . . . . 0.0 110.509 176.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.0 mt -61.68 -44.92 96.03 Favored 'General case' 0 C--O 1.227 -0.101 0 CA-C-O 118.771 -0.633 . . . . 0.0 110.758 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -61.71 -39.96 93.33 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 119.065 0.848 . . . . 0.0 110.66 178.027 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 15.8 m-80 -63.84 -37.69 88.31 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 118.261 0.482 . . . . 0.0 110.636 175.259 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 89.6 mtp -78.18 32.07 0.18 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.096 1.758 . . . . 0.0 111.414 172.268 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 17.9 p90 46.89 32.45 1.82 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 127.276 2.23 . . . . 0.0 113.754 178.439 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 26.9 t70 47.51 26.87 0.86 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.411 2.284 . . . . 0.0 113.301 -174.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 1.7 t 54.39 23.85 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.953 0 C-N-CA 126.575 1.95 . . . . 0.0 111.866 -176.519 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -140.88 71.64 29.13 Favored Pre-proline 0 CA--C 1.534 0.355 0 C-N-CA 125.254 1.421 . . . . 0.0 107.366 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -62.7 -21.91 73.42 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.914 2.41 . . . . 0.0 113.173 -169.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -55.36 -24.17 28.07 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 124.868 1.267 . . . . 0.0 112.802 175.353 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.9 m -122.51 -34.36 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 C-N-CA 124.064 0.946 . . . . 0.0 110.559 171.141 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.04 -34.73 80.51 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-O 118.938 -0.923 . . . . 0.0 112.742 -177.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -61.58 -27.14 68.42 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 118.846 1.323 . . . . 0.0 112.275 177.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 60.5 tp -94.12 -44.56 7.95 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 123.867 0.867 . . . . 0.0 110.36 177.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -69.15 -36.23 77.19 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.083 0.553 . . . . 0.0 111.701 -174.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -134.8 -21.09 1.72 Allowed 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 123.992 0.917 . . . . 0.0 112.197 -170.05 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -85.3 -150.93 14.03 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 125.062 1.315 . . . . 0.0 111.694 178.535 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -119.55 11.09 11.97 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 125.688 1.595 . . . . 0.0 112.116 -169.682 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -69.04 -22.9 64.01 Favored 'General case' 0 CA--C 1.545 0.753 0 O-C-N 121.414 -0.804 . . . . 0.0 110.599 171.579 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 60.0 tptt . . . . . 0 C--O 1.249 1.036 0 C-N-CA 124.573 1.149 . . . . 0.0 109.823 175.431 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.6 ttt . . . . . 0 N--CA 1.482 1.172 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 56.2 m -63.11 154.3 31.45 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.941 0.496 . . . . 0.0 110.845 178.004 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 46.4 pt -134.39 -168.54 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 C-N-CA 126.713 2.005 . . . . 0.0 106.959 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.6 67.25 0.08 OUTLIER Glycine 0 CA--C 1.519 0.315 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 -177.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 9.0 p -148.44 149.95 32.86 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 123.69 0.796 . . . . 0.0 109.121 -169.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.03 168.58 16.95 Favored 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 122.549 2.166 . . . . 0.0 111.882 169.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.66 172.9 41.27 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.621 2.057 . . . . 0.0 108.621 170.375 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -116.71 129.58 56.21 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 118.216 1.008 . . . . 0.0 108.982 -177.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 63.8 mt -70.27 127.63 32.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 -178.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -120.99 -29.65 4.54 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 118.247 -0.882 . . . . 0.0 112.448 -170.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.6 155.32 40.09 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.0 mt -132.37 124.81 52.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 N-CA-C 106.642 -1.614 . . . . 0.0 106.642 -177.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -86.89 -32.24 20.3 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.506 0.722 . . . . 0.0 110.4 172.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.58 -114.03 0.58 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 107.69 -2.164 . . . . 0.0 107.69 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -67.22 -0.66 3.6 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.287 1.035 . . . . 0.0 112.997 172.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -135.95 155.57 50.08 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 125.632 1.573 . . . . 0.0 107.438 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.23 151.69 38.8 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.321 1.048 . . . . 0.0 110.04 -171.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.0 tttt -90.85 133.1 35.49 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.23 130.49 72.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 -174.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -82.31 110.0 17.08 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 169.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.5 t -84.4 64.86 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 178.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.6 m 52.76 29.43 7.51 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.615 1.966 . . . . 0.0 114.94 171.386 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 158.27 -23.67 0.37 Allowed Glycine 0 CA--C 1.525 0.675 0 CA-C-N 119.121 0.873 . . . . 0.0 113.584 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.7 tp -146.45 149.63 15.86 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -88.51 150.27 23.2 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.983 0.42 . . . . 0.0 110.236 -175.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -139.5 150.08 44.71 Favored 'General case' 0 N--CA 1.464 0.227 0 C-N-CA 124.566 1.146 . . . . 0.0 108.703 169.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.54 138.83 35.38 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 169.015 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 50.5 t -136.38 131.88 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -173.641 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.34 138.64 37.77 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.468 0.707 . . . . 0.0 109.71 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.99 10.83 16.35 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.946 0.898 . . . . 0.0 112.211 -171.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.9 m -53.1 -34.07 55.03 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 120.265 1.393 . . . . 0.0 111.991 -177.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 85.2 mt -73.38 -12.93 60.99 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.769 0.827 . . . . 0.0 113.136 -176.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.36 -20.3 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 119.516 1.053 . . . . 0.0 113.188 -169.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.54 146.32 6.03 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 124.334 0.968 . . . . 0.0 111.457 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.1 p -74.41 -6.71 49.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.949 1.7 . . . . 0.0 113.581 -176.55 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.8 m -135.49 157.14 47.64 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 125.385 1.474 . . . . 0.0 108.177 171.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -66.07 165.11 14.06 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.079 1.352 . . . . 0.0 110.451 169.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -53.95 -38.33 64.84 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.935 1.294 . . . . 0.0 111.657 176.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -87.06 11.83 12.83 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.861 0.865 . . . . 0.0 111.85 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.98 6.97 88.48 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 124.583 1.087 . . . . 0.0 113.492 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -67.71 134.2 92.45 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 118.588 1.194 . . . . 0.0 108.206 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.27 143.29 53.62 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.531 2.154 . . . . 0.0 111.44 171.633 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -69.7 -17.79 63.5 Favored 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 118.043 -0.98 . . . . 0.0 112.836 175.802 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -55.32 134.82 18.72 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 120.297 1.408 . . . . 0.0 109.125 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.02 -21.27 20.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 124.561 1.077 . . . . 0.0 112.735 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -71.87 159.64 33.94 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 119.09 1.445 . . . . 0.0 108.162 171.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -106.7 158.41 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.67 139.52 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -169.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -83.18 133.08 35.04 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 169.686 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.2 t -121.44 135.76 60.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 4.7 t60 -137.12 -48.38 0.6 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.269 0.628 . . . . 0.0 111.108 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.4 m -136.3 27.63 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 123.75 0.82 . . . . 0.0 111.205 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.12 15.53 78.56 Favored Glycine 0 CA--C 1.531 1.068 0 O-C-N 121.531 -0.73 . . . . 0.0 112.464 -174.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -126.39 147.8 49.71 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 125.578 1.551 . . . . 0.0 107.095 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.44 105.18 1.4 Allowed 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.379 1.071 . . . . 0.0 108.257 172.009 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.4 ttt -70.6 -46.17 63.91 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 24.6 m -152.53 158.69 42.89 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.136 1.774 . . . . 0.0 107.445 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 44.1 t -121.0 140.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 174.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.0 pt -141.66 161.93 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 C-N-CA 125.712 1.605 . . . . 0.0 110.081 -171.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -74.66 168.34 20.0 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.669 0.788 . . . . 0.0 110.507 171.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -63.1 -42.29 99.55 Favored 'General case' 0 C--O 1.227 -0.09 0 CA-C-O 119.167 -0.444 . . . . 0.0 111.963 -173.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.83 -41.41 87.49 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.499 0.59 . . . . 0.0 110.315 -173.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.59 -36.43 82.7 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 122.578 0.351 . . . . 0.0 110.49 173.403 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.88 -40.57 83.54 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-N 119.05 0.841 . . . . 0.0 111.507 176.458 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 10.0 mmt85 -66.59 -38.83 87.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 119.291 0.95 . . . . 0.0 109.513 178.485 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.48 -42.71 99.68 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 118.015 0.371 . . . . 0.0 110.919 174.103 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.6 m -62.06 -40.87 97.24 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.34 0.656 . . . . 0.0 110.417 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 21.4 mt -63.86 -39.15 93.54 Favored 'General case' 0 C--N 1.338 0.073 0 O-C-N 121.668 -0.645 . . . . 0.0 110.943 178.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -68.2 -44.33 76.06 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.383 0.992 . . . . 0.0 110.677 175.425 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.53 -31.41 70.49 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.247 1.019 . . . . 0.0 111.821 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 62.3 tp -78.79 -59.64 2.7 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 123.558 0.743 . . . . 0.0 110.339 174.444 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -55.55 -40.97 72.59 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 118.437 -0.792 . . . . 0.0 112.866 -169.316 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -61.65 -10.76 9.15 Favored 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 -177.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -131.1 11.94 5.09 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 124.458 1.103 . . . . 0.0 112.379 175.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -137.67 -44.88 0.54 Allowed 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 123.786 0.835 . . . . 0.0 111.575 -171.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -67.63 -31.14 70.95 Favored 'General case' 0 N--CA 1.468 0.434 0 O-C-N 121.407 -0.808 . . . . 0.0 110.498 174.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 23.8 m -71.21 -2.93 3.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.694 0 C-N-CA 125.39 1.476 . . . . 0.0 112.678 172.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 81.9 mm-40 -130.96 67.98 81.42 Favored Pre-proline 0 CA--C 1.538 0.491 0 C-N-CA 125.37 1.468 . . . . 0.0 107.748 178.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -63.15 -20.91 72.11 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.718 2.278 . . . . 0.0 113.644 -169.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -65.91 -41.87 90.9 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 119.121 0.873 . . . . 0.0 110.986 171.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 34.2 t -69.67 -34.74 62.56 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 174.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -54.86 -54.36 33.89 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 170.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -62.5 -37.2 85.07 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 117.735 0.767 . . . . 0.0 111.593 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -65.35 -57.63 7.9 Favored 'General case' 0 N--CA 1.456 -0.155 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -85.59 -64.03 1.22 Allowed 'General case' 0 N--CA 1.457 -0.095 0 CA-C-N 118.1 0.409 . . . . 0.0 110.448 -169.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -70.02 -37.87 75.76 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.132 0.424 . . . . 0.0 110.417 -175.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.64 -5.09 82.7 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-O 118.55 -1.139 . . . . 0.0 112.701 176.652 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 49.81 47.0 23.63 Favored 'General case' 0 CA--C 1.543 0.702 0 CA-C-N 119.002 1.401 . . . . 0.0 110.842 -178.291 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 66.44 7.05 4.72 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 127.479 2.312 . . . . 0.0 113.677 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 29.6 mtpp . . . . . 0 C--O 1.25 1.095 0 C-N-CA 127.381 2.272 . . . . 0.0 111.111 -179.47 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 55.0 tpp . . . . . 0 N--CA 1.483 1.191 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 17.8 p -150.62 172.86 14.85 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 125.146 1.378 . . . . 0.0 109.074 178.037 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.9 tt -150.8 150.15 13.67 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 176.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.39 54.79 0.26 Allowed Glycine 0 CA--C 1.529 0.92 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 -175.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.1 t -139.24 143.41 36.28 Favored Pre-proline 0 CA--C 1.543 0.688 0 C-N-CA 124.296 1.038 . . . . 0.0 109.007 -169.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.25 155.62 24.0 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.632 2.221 . . . . 0.0 112.301 169.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.12 170.66 39.44 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 169.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.1 tt0 -116.3 125.25 51.88 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 123.982 0.913 . . . . 0.0 108.836 -174.196 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.03 129.33 27.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -114.42 -33.93 5.43 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 118.058 -0.972 . . . . 0.0 111.663 -176.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.4 p -148.15 157.25 43.39 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 47.1 mt -132.51 144.14 37.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -123.15 -19.29 6.07 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.364 1.066 . . . . 0.0 111.875 -176.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.46 -127.18 1.53 Allowed Glycine 0 C--N 1.336 0.562 0 N-CA-C 106.815 -2.514 . . . . 0.0 106.815 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -63.92 -10.23 19.86 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 117.514 0.657 . . . . 0.0 112.365 169.469 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -119.92 159.2 25.14 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.523 1.129 . . . . 0.0 110.509 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.48 167.72 27.11 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 125.746 1.618 . . . . 0.0 109.544 -172.558 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.33 132.28 54.52 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 171.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 52.7 t -126.35 123.78 64.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -174.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -72.81 111.13 7.67 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.2 63.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.9 m 47.18 42.47 13.31 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.885 2.074 . . . . 0.0 114.026 175.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.55 -31.17 0.19 Allowed Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.169 174.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -152.41 151.45 11.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 177.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -73.14 137.5 45.19 Favored 'General case' 0 C--O 1.234 0.266 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -122.53 148.26 45.4 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 124.595 1.158 . . . . 0.0 108.188 169.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -72.82 134.71 45.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 123.82 0.848 . . . . 0.0 108.983 172.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -140.5 157.28 24.21 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 C-N-CA 124.787 1.235 . . . . 0.0 108.096 -176.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -112.61 142.58 45.03 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 125.415 1.486 . . . . 0.0 108.815 172.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.9 mt -113.3 7.59 17.78 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.284 1.034 . . . . 0.0 112.328 -169.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 28.9 p -57.55 -29.15 64.16 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.599 1.545 . . . . 0.0 113.124 -173.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -70.53 -16.36 62.88 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.691 0.797 . . . . 0.0 112.534 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 24.2 m -130.0 -12.63 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 C-N-CA 124.606 1.162 . . . . 0.0 112.312 -173.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.62 141.34 1.19 Allowed Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.993 1.282 . . . . 0.0 109.939 -170.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -73.15 -10.58 59.92 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -178.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.4 m -121.36 145.62 47.71 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.229 1.012 . . . . 0.0 109.238 177.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -69.81 157.55 37.14 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.227 1.411 . . . . 0.0 109.894 172.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -51.54 -35.07 39.26 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 125.128 1.371 . . . . 0.0 112.139 176.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -70.45 -8.86 54.2 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.746 0.818 . . . . 0.0 112.417 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.43 25.04 10.42 Favored Glycine 0 CA--C 1.53 1.019 0 CA-C-N 119.6 1.091 . . . . 0.0 113.946 170.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -125.92 149.21 65.36 Favored Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 118.775 1.287 . . . . 0.0 108.26 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.77 143.91 36.59 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 122.966 2.444 . . . . 0.0 111.272 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.1 mtt-85 -70.61 18.79 0.05 Allowed 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 114.421 1.267 . . . . 0.0 114.421 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.2 m -56.55 136.32 19.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 O-C-N 120.394 -1.441 . . . . 0.0 109.547 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.11 -14.64 43.14 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 118.373 -1.237 . . . . 0.0 113.586 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -75.23 152.05 38.36 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 120.134 1.967 . . . . 0.0 109.184 176.392 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -95.07 150.28 20.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 174.126 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.2 m -142.2 153.5 18.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 124.663 1.185 . . . . 0.0 109.04 -178.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -85.37 107.09 17.2 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 169.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.0 t -78.02 120.87 29.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -134.62 120.09 19.16 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.0 t 49.58 33.61 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 C-N-CA 125.146 1.378 . . . . 0.0 112.105 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.96 6.94 78.59 Favored Glycine 0 CA--C 1.531 1.094 0 O-C-N 121.029 -1.044 . . . . 0.0 114.054 176.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -119.99 146.03 46.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-N 119.339 1.57 . . . . 0.0 109.055 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.5 104.83 6.23 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 41.0 tpp -68.2 -46.28 71.05 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.72 0.408 . . . . 0.0 110.704 -174.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.2 m -152.02 165.75 33.71 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 125.953 1.701 . . . . 0.0 107.98 -178.568 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 6.5 t -111.38 141.34 27.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.049 1.34 . . . . 0.0 107.742 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 35.8 pt -140.81 165.86 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.767 1.227 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.1 m-80 -80.39 165.48 22.2 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 124.582 1.153 . . . . 0.0 109.889 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -64.65 -32.41 74.06 Favored 'General case' 0 N--CA 1.468 0.425 0 O-C-N 121.763 -0.586 . . . . 0.0 111.505 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.54 -43.11 77.39 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.432 -0.793 . . . . 0.0 110.429 177.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -65.08 -39.32 93.03 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.314 0.646 . . . . 0.0 109.646 178.015 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.98 -49.55 74.26 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.17 -0.331 . . . . 0.0 110.364 177.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -62.53 -40.01 95.42 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 119.103 -0.475 . . . . 0.0 111.008 179.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -61.48 -43.77 98.28 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 118.494 0.588 . . . . 0.0 110.898 175.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -66.79 -40.49 88.16 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.075 0.55 . . . . 0.0 110.643 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 41.7 mt -63.06 -35.66 81.0 Favored 'General case' 0 C--N 1.338 0.101 0 C-N-CA 124.066 0.946 . . . . 0.0 110.759 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -70.06 -48.89 55.97 Favored 'General case' 0 C--O 1.226 -0.132 0 CA-C-N 118.492 0.587 . . . . 0.0 109.905 171.083 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.08 -40.49 85.4 Favored 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.617 0.767 . . . . 0.0 111.744 -171.347 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.0 pp -69.83 -10.56 58.89 Favored 'General case' 0 CA--C 1.537 0.473 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -114.9 -19.0 11.15 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.352 1.461 . . . . 0.0 111.093 178.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -55.73 -31.92 62.93 Favored 'General case' 0 CA--C 1.528 0.105 0 C-N-CA 125.848 1.659 . . . . 0.0 112.823 -169.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 96.7 mtp -58.38 -22.02 52.36 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.798 0.839 . . . . 0.0 112.887 177.589 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -60.67 -22.27 63.7 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-N 119.159 0.89 . . . . 0.0 111.686 174.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -59.18 -22.88 61.66 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.96 0.904 . . . . 0.0 112.581 174.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 34.8 t -76.66 -22.92 15.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.751 0 C-N-CA 123.929 0.892 . . . . 0.0 110.577 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -71.28 150.48 94.31 Favored Pre-proline 0 CA--C 1.539 0.548 0 O-C-N 121.245 -0.91 . . . . 0.0 109.387 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -70.08 -16.69 36.3 Favored 'Trans proline' 0 CA--C 1.535 0.556 0 C-N-CA 122.388 2.058 . . . . 0.0 113.01 -178.595 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -57.88 -38.06 75.1 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 123.851 0.86 . . . . 0.0 112.578 -174.103 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.5 m -65.09 -17.59 22.19 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 CA-C-N 117.99 0.359 . . . . 0.0 111.966 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -56.93 -32.94 62.9 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 119.292 -0.727 . . . . 0.0 111.871 174.373 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -63.81 -25.27 68.1 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 118.487 1.144 . . . . 0.0 112.367 177.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.0 tp -91.79 -46.86 7.66 Favored 'General case' 0 CA--C 1.527 0.076 0 C-N-CA 123.581 0.753 . . . . 0.0 109.908 174.189 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 44.9 tp -68.41 -47.23 67.83 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 123.053 0.541 . . . . 0.0 111.42 -172.061 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 57.4 m-85 -114.96 -25.06 8.32 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.184 0.994 . . . . 0.0 111.494 -175.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -79.5 -162.18 23.81 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 124.435 1.017 . . . . 0.0 111.392 173.526 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -121.02 20.97 11.46 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.603 1.161 . . . . 0.0 111.104 -169.593 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 39.3 mm-40 -71.65 -0.47 10.87 Favored 'General case' 0 CA--C 1.548 0.888 0 O-C-N 121.2 -0.938 . . . . 0.0 112.025 170.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 57.0 mttp . . . . . 0 C--O 1.249 1.036 0 C-N-CA 126.259 1.824 . . . . 0.0 110.288 173.023 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.1 ttt . . . . . 0 N--CA 1.485 1.275 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.2 m -70.46 -41.92 72.16 Favored 'General case' 0 CA--C 1.535 0.378 0 O-C-N 121.7 -0.625 . . . . 0.0 111.66 -174.712 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.5 pt -145.96 155.12 12.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 126.282 1.833 . . . . 0.0 106.871 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.68 44.39 0.08 OUTLIER Glycine 0 CA--C 1.525 0.717 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 -177.098 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.9 m -146.89 168.18 12.01 Favored Pre-proline 0 CA--C 1.543 0.69 0 C-N-CA 125.462 1.505 . . . . 0.0 110.108 -168.634 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -57.37 162.73 9.43 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.052 2.501 . . . . 0.0 113.37 169.666 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.86 176.75 41.22 Favored Glycine 0 CA--C 1.526 0.729 0 C-N-CA 125.978 1.752 . . . . 0.0 109.666 170.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.9 tt0 -116.86 136.92 52.58 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 45.6 mt -72.89 71.29 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -68.69 -33.52 74.1 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.156 0.982 . . . . 0.0 111.647 -169.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.3 156.06 43.09 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 174.678 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt -128.66 146.7 33.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 N-CA-C 106.471 -1.678 . . . . 0.0 106.471 178.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -117.14 -27.27 6.54 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 123.918 0.887 . . . . 0.0 111.415 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.5 -123.17 1.08 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -62.71 -23.52 67.2 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.292 0.637 . . . . 0.0 111.848 169.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 25.2 mm100 -99.04 155.28 17.52 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.022 0.929 . . . . 0.0 109.278 169.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.11 163.13 33.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.014 1.326 . . . . 0.0 109.538 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -110.46 77.72 1.07 Allowed 'General case' 0 C--O 1.234 0.252 0 N-CA-C 105.688 -1.968 . . . . 0.0 105.688 -175.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.0 t -70.85 127.74 33.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -177.619 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -74.83 107.61 7.03 Favored 'General case' 0 CA--C 1.52 -0.187 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 168.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -84.26 58.09 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -178.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.0 m 45.57 44.6 10.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.274 2.23 . . . . 0.0 113.208 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.26 -38.65 0.14 Allowed Glycine 0 CA--C 1.525 0.713 0 CA-C-O 119.478 -0.624 . . . . 0.0 112.708 176.337 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.6 tp -153.09 153.79 8.49 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 58.6 mt-30 -73.63 138.04 44.58 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -127.0 144.89 50.9 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 125.608 1.563 . . . . 0.0 107.151 172.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -75.01 131.19 40.45 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 72.9 t -140.16 138.77 37.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 125.126 1.37 . . . . 0.0 107.933 -171.803 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -80.72 130.64 35.2 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.778 1.631 . . . . 0.0 109.264 175.416 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.0 mt -105.46 6.66 32.63 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.676 0.79 . . . . 0.0 112.989 -176.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 7.5 m -55.61 -32.67 63.31 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.807 1.64 . . . . 0.0 112.853 -171.527 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.02 -13.95 62.17 Favored 'General case' 0 CA--C 1.538 0.493 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -178.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.33 -15.55 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.372 1.069 . . . . 0.0 112.581 -174.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.91 143.88 1.31 Allowed Glycine 0 CA--C 1.528 0.871 0 C-N-CA 125.394 1.474 . . . . 0.0 110.683 -173.273 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 m -76.62 -7.32 55.02 Favored 'General case' 0 CA--C 1.536 0.415 0 O-C-N 121.944 -0.739 . . . . 0.0 112.871 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.9 m -114.71 139.57 49.57 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.072 0.949 . . . . 0.0 109.676 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -75.56 155.76 35.7 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 126.809 2.044 . . . . 0.0 109.733 170.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -58.04 -25.96 61.85 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.034 1.334 . . . . 0.0 112.883 -173.731 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 -71.56 -6.97 44.66 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 121.506 -0.746 . . . . 0.0 112.525 178.343 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.13 47.44 5.24 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -142.44 153.51 62.49 Favored Pre-proline 0 CA--C 1.535 0.392 0 C-N-CA 125.724 1.61 . . . . 0.0 107.577 -178.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.51 147.23 76.53 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 C-N-CA 121.645 1.563 . . . . 0.0 109.687 174.64 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -70.88 17.96 0.07 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -175.306 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.4 t -56.53 126.2 13.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 O-C-N 120.848 -1.157 . . . . 0.0 108.599 -174.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.63 -13.59 66.25 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.324 -1.265 . . . . 0.0 113.632 176.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 80.1 mt-30 -68.04 154.58 41.34 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 119.566 1.683 . . . . 0.0 109.106 174.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.9 m95 -96.19 160.7 14.3 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.26 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.53 156.7 4.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -169.482 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 96.0 mt -101.68 133.0 47.06 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 169.158 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.9 m -128.3 139.07 52.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 118.853 0.751 . . . . 0.0 109.113 -177.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.6 t-80 -142.48 132.77 24.82 Favored 'General case' 0 C--O 1.232 0.132 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 -176.518 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 36.2 t 59.77 -61.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 128.146 2.579 . . . . 0.0 112.79 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -174.37 21.04 0.06 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.182 1.849 . . . . 0.0 111.596 179.245 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -132.38 141.86 49.07 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 118.78 1.29 . . . . 0.0 108.69 -172.718 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.26 124.03 24.88 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 169.422 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 90.4 mmm -90.86 -49.16 6.6 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 123.148 0.579 . . . . 0.0 109.966 -178.017 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.3 m -149.52 140.85 23.21 Favored 'General case' 0 C--N 1.339 0.145 0 C-N-CA 124.271 1.029 . . . . 0.0 108.775 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 84.0 t -81.78 142.93 13.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 169.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.1 pt -139.58 162.78 26.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 C-N-CA 124.885 1.274 . . . . 0.0 109.647 -173.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -79.67 163.79 24.27 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.658 0.742 . . . . 0.0 110.53 175.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -55.89 -39.35 71.43 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 126.26 1.824 . . . . 0.0 111.729 175.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.59 -50.06 34.51 Favored 'General case' 0 C--N 1.338 0.091 0 O-C-N 121.864 -0.523 . . . . 0.0 110.253 -173.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -72.35 -27.48 62.43 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 119.296 -0.383 . . . . 0.0 110.73 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.29 -52.04 66.98 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.877 0.762 . . . . 0.0 110.056 170.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.8 mtm180 -64.43 -37.64 88.22 Favored 'General case' 0 N--CA 1.46 0.054 0 CA-C-O 118.859 -0.591 . . . . 0.0 110.93 179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -62.65 -40.63 97.64 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 118.971 0.805 . . . . 0.0 111.176 175.231 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.8 m -65.39 -40.98 94.12 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.978 -0.452 . . . . 0.0 110.035 176.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.4 mt -65.07 -38.34 90.48 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.349 -0.845 . . . . 0.0 110.762 176.601 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -66.28 -39.11 89.19 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.624 0.647 . . . . 0.0 110.906 177.113 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.09 -50.46 71.85 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.463 0.705 . . . . 0.0 110.404 173.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.2 mt -59.98 -20.3 56.93 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.386 1.074 . . . . 0.0 112.6 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 -93.33 -66.21 0.94 Allowed 'General case' 0 N--CA 1.454 -0.255 0 CA-C-N 118.66 0.664 . . . . 0.0 109.724 174.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -64.24 -29.35 70.45 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 114.028 1.121 . . . . 0.0 114.028 -169.101 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.3 mtp -78.81 -3.89 46.73 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 119.126 0.875 . . . . 0.0 112.185 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -132.0 -23.59 2.21 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.987 0.915 . . . . 0.0 111.934 -172.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -59.9 -16.99 33.8 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 125.497 1.519 . . . . 0.0 112.796 172.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.2 m -61.16 -11.18 4.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 125.117 1.367 . . . . 0.0 112.813 170.015 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -131.69 154.17 81.72 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 125.399 1.479 . . . . 0.0 108.824 176.686 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.43 -6.0 18.06 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 122.998 2.465 . . . . 0.0 113.446 -176.665 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -57.76 -42.39 83.91 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 119.129 0.877 . . . . 0.0 112.259 -175.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 27.5 m -71.7 -29.64 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 118.101 0.41 . . . . 0.0 111.097 176.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -61.49 -46.67 93.86 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 173.454 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.34 -8.1 43.24 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 124.768 1.227 . . . . 0.0 113.5 176.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 57.6 tp -98.18 -42.41 7.45 Favored 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 119.15 0.886 . . . . 0.0 109.905 174.581 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 60.7 tp -68.09 -39.95 82.74 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.763 0.825 . . . . 0.0 109.984 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -152.12 -158.95 0.95 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 126.379 1.872 . . . . 0.0 106.577 -173.102 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 76.82 -66.98 2.71 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 124.576 1.084 . . . . 0.0 112.666 169.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -138.3 -18.94 1.12 Allowed 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 125.726 1.61 . . . . 0.0 111.43 -176.534 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 46.17 62.59 2.2 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.734 1.614 . . . . 0.0 110.794 -170.463 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt . . . . . 0 C--O 1.249 1.056 0 C-N-CA 123.998 0.919 . . . . 0.0 111.357 -177.489 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.5 mmt . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 55.5 m -74.55 155.94 37.37 Favored 'General case' 0 CA--C 1.533 0.32 0 O-C-N 121.935 -0.478 . . . . 0.0 109.722 169.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . 0.25 48.4 pt 40.26 45.58 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 126.663 1.985 . . . . 0.0 113.292 175.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.94 69.39 3.08 Favored Glycine 0 CA--C 1.525 0.709 0 C-N-CA 125.007 1.289 . . . . 0.0 110.08 179.489 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.0 t -140.21 139.3 20.68 Favored Pre-proline 0 CA--C 1.54 0.565 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -169.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -76.65 168.98 22.67 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.384 2.056 . . . . 0.0 111.83 173.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -171.02 -174.9 39.18 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 173.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 57.7 tt0 -116.67 131.15 57.02 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 123.659 0.784 . . . . 0.0 108.99 -176.512 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 89.7 mt -67.06 122.65 18.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 mtm105 -119.62 -10.15 9.66 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 177.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -152.55 151.55 30.81 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 172.577 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.9 mt -133.19 140.24 47.52 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 172.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -108.01 -23.97 11.79 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.471 1.108 . . . . 0.0 112.438 -174.371 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.83 -62.37 0.15 Allowed Glycine 0 C--N 1.338 0.666 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 175.24 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -144.42 27.92 1.36 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.912 1.339 . . . . 0.0 110.381 169.445 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -137.62 156.2 48.33 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 169.738 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -144.25 166.54 24.75 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 123.867 0.867 . . . . 0.0 110.001 -170.514 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -117.38 84.35 2.14 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.22 131.08 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.744 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -83.24 109.72 17.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 169.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.8 t -85.35 62.23 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -175.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 56.5 m 48.77 40.7 16.72 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.329 1.852 . . . . 0.0 113.161 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 172.17 -49.0 0.18 Allowed Glycine 0 CA--C 1.525 0.658 0 CA-C-O 119.304 -0.72 . . . . 0.0 112.126 173.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.1 mm -138.0 145.59 28.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 -173.216 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -73.74 145.72 44.9 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.288 0.566 . . . . 0.0 111.307 175.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -133.84 139.68 46.4 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 125.481 1.512 . . . . 0.0 107.804 170.309 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -71.56 136.2 47.37 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.89 155.17 17.46 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 125.396 1.478 . . . . 0.0 109.162 177.003 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -98.07 141.53 30.9 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 124.636 1.175 . . . . 0.0 110.223 -177.741 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.7 mp -117.23 15.41 14.9 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.828 1.251 . . . . 0.0 111.871 -170.018 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.4 p -53.22 -33.65 53.75 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 119.966 1.257 . . . . 0.0 112.267 176.642 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -77.78 -12.05 59.94 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 123.848 0.859 . . . . 0.0 112.986 -174.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.07 -17.05 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.699 1.136 . . . . 0.0 113.364 -171.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.98 148.95 4.5 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -176.291 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 m -74.09 -14.22 60.95 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 124.244 1.018 . . . . 0.0 113.23 -174.213 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -126.19 143.67 51.05 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.975 0.91 . . . . 0.0 109.902 -171.256 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -70.8 155.7 40.45 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 126.463 1.905 . . . . 0.0 109.954 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -58.57 -25.75 62.88 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.638 1.175 . . . . 0.0 112.531 -175.453 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -61.98 -22.74 65.92 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.74 0.816 . . . . 0.0 112.924 175.107 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.18 47.38 3.09 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -174.488 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -142.14 151.26 58.28 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 125.819 1.648 . . . . 0.0 107.488 -178.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -65.72 148.46 86.83 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.882 1.721 . . . . 0.0 109.879 176.213 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -70.78 16.65 0.08 Allowed 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 -176.529 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 98.6 t -60.66 133.44 26.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 O-C-N 120.565 -1.334 . . . . 0.0 107.878 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.92 -15.2 56.46 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.303 -1.276 . . . . 0.0 113.064 -178.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 67.9 mt-30 -71.88 149.57 45.04 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 119.818 1.809 . . . . 0.0 108.907 175.173 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.7 m95 -85.15 152.4 23.4 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 170.024 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.7 p -146.46 138.42 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 62.9 tp -89.0 128.76 35.71 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 169.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.8 m -124.83 151.34 30.29 Favored 'Isoleucine or valine' 0 C--O 1.235 0.324 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -142.57 148.47 37.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 104.958 -2.238 . . . . 0.0 104.958 169.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.7 m 44.81 28.51 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 126.097 1.759 . . . . 0.0 115.368 171.295 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.48 14.03 64.4 Favored Glycine 0 CA--C 1.531 1.074 0 CA-C-O 118.472 -1.182 . . . . 0.0 113.857 176.577 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -129.13 144.11 51.09 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 119.818 1.809 . . . . 0.0 109.692 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.54 112.37 4.66 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 169.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.4 mmt -91.15 -34.89 14.85 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 119.094 -0.479 . . . . 0.0 111.114 -178.213 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 70.7 m -155.58 144.46 20.59 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 119.276 0.944 . . . . 0.0 109.283 169.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 48.3 t -79.99 140.37 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 169.105 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.2 pt -135.07 -175.2 1.3 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 C-N-CA 124.156 0.982 . . . . 0.0 108.865 -173.454 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -131.18 176.58 8.15 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.763 1.225 . . . . 0.0 108.597 178.417 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 68.4 mm-40 -52.78 -47.78 67.28 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 125.895 1.678 . . . . 0.0 110.908 -171.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -69.47 -40.86 76.86 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.673 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -66.19 -37.8 86.46 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 123.033 0.533 . . . . 0.0 109.568 176.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.94 -45.11 94.03 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 118.513 -0.755 . . . . 0.0 110.37 175.52 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 28.9 mmt-85 -63.92 -42.43 97.4 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.691 1.132 . . . . 0.0 110.6 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.16 -43.1 99.58 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.513 0.597 . . . . 0.0 110.948 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.7 m -68.18 -37.3 80.79 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 122.75 0.42 . . . . 0.0 110.432 178.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 54.8 mt -67.29 -33.42 75.25 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.122 -0.986 . . . . 0.0 110.658 176.518 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -67.04 -35.78 80.62 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.842 0.746 . . . . 0.0 111.457 174.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.04 -46.32 81.73 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 121.915 -0.49 . . . . 0.0 109.893 169.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -59.0 -43.54 91.52 Favored 'General case' 0 C--N 1.338 0.073 0 C-N-CA 123.629 0.772 . . . . 0.0 110.725 -176.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 24.2 pt20 -68.46 6.58 0.77 Allowed 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -137.05 12.81 3.09 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.85 1.26 . . . . 0.0 111.004 169.549 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 26.0 ttt -134.52 -9.34 2.49 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.499 1.52 . . . . 0.0 111.755 -178.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.8 -18.54 13.21 Favored 'General case' 0 CA--C 1.536 0.418 0 O-C-N 120.803 -1.186 . . . . 0.0 112.807 169.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -55.29 -20.8 12.33 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.153 1.781 . . . . 0.0 112.64 169.45 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.6 t -106.65 -11.95 10.18 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 C-N-CA 125.559 1.544 . . . . 0.0 110.312 -176.012 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -76.13 122.78 87.5 Favored Pre-proline 0 CA--C 1.536 0.43 0 O-C-N 120.837 -1.164 . . . . 0.0 109.262 -176.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -73.39 -15.04 25.21 Favored 'Trans proline' 0 CA--C 1.536 0.585 0 C-N-CA 122.455 2.103 . . . . 0.0 112.527 -177.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -77.11 69.14 3.35 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 124.541 1.137 . . . . 0.0 109.693 175.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.285 26.0 m 51.71 -6.08 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 129.999 3.32 . . . . 0.0 117.095 -176.465 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -58.28 -42.87 95.71 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-N 120.965 1.711 . . . . 0.0 111.057 175.795 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -57.02 -31.16 64.85 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.187 0.995 . . . . 0.0 112.59 176.037 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 58.4 tp -80.0 -59.29 2.78 Favored 'General case' 0 C--N 1.338 0.092 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 98.9 mt -61.61 -26.16 67.81 Favored 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 125.058 1.343 . . . . 0.0 112.969 -169.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 -129.91 19.9 5.5 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.367 1.067 . . . . 0.0 111.029 -172.237 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -153.27 -73.3 0.01 OUTLIER Glycine 0 C--N 1.341 0.806 0 CA-C-N 118.418 0.554 . . . . 0.0 111.903 177.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -69.85 -24.68 63.48 Favored 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 117.632 0.716 . . . . 0.0 111.762 -170.403 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -135.61 57.06 1.81 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.244 1.418 . . . . 0.0 108.215 177.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 60.0 tptt . . . . . 0 C--O 1.25 1.09 0 C-N-CA 125.452 1.501 . . . . 0.0 107.591 177.677 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.8 tpt . . . . . 0 N--CA 1.483 1.188 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 85.5 m -140.45 175.37 9.66 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 126.628 1.971 . . . . 0.0 106.758 173.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.5 pp -129.89 -171.61 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 169.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.51 61.19 0.25 Allowed Glycine 0 CA--C 1.52 0.388 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.031 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.8 t -140.32 137.41 17.79 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 -169.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.88 174.42 11.93 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.129 1.886 . . . . 0.0 111.56 174.196 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.11 -177.52 27.61 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 124.405 1.003 . . . . 0.0 111.065 172.116 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.7 tt0 -116.77 142.29 47.11 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 173.544 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 59.6 mt -74.58 85.05 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.1 tpp180 -71.48 -37.14 71.34 Favored 'General case' 0 CA--C 1.527 0.081 0 C-N-CA 124.882 1.273 . . . . 0.0 109.932 -172.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -157.83 144.61 17.91 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.645 1.578 . . . . 0.0 107.224 -175.04 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 61.4 mt -110.23 149.44 13.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -132.97 -0.19 3.41 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.668 1.187 . . . . 0.0 112.435 -169.433 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.405 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 146.83 -128.1 2.9 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 106.931 -2.468 . . . . 0.0 106.931 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 15.9 t30 -72.51 12.75 0.43 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.79 0.836 . . . . 0.0 110.96 169.066 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.405 ' H ' ' C ' ' A' ' 14' ' ' GLY . 36.7 mt-30 -140.44 161.68 37.13 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.505 2.322 . . . . 0.0 107.278 -169.893 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.78 153.41 42.37 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 176.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -104.62 69.6 0.9 Allowed 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 105.884 -1.895 . . . . 0.0 105.884 178.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.7 m -69.21 138.85 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 -171.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -81.2 102.89 10.63 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.09 62.76 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 C-N-CA 125.637 1.575 . . . . 0.0 108.519 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.8 m 43.76 42.49 4.39 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 127.285 2.234 . . . . 0.0 113.23 -179.732 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.69 -34.7 0.21 Allowed Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.037 -0.868 . . . . 0.0 113.535 177.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.4 tt -150.33 149.36 14.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 118.627 1.213 . . . . 0.0 108.753 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -76.77 135.43 38.98 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 176.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -137.88 137.19 37.83 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 124.4 1.08 . . . . 0.0 108.227 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.51 137.3 54.28 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 122.744 0.417 . . . . 0.0 110.032 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 m -140.81 145.54 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 124.826 1.25 . . . . 0.0 107.955 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -83.49 144.63 29.42 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 5.5 mp -110.36 10.44 23.45 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.029 -0.986 . . . . 0.0 113.207 -169.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.2 m -52.04 -32.18 33.28 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 121.006 1.73 . . . . 0.0 112.809 -177.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.4 mt -68.55 -15.85 63.67 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.38 -18.5 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 124.2 1.0 . . . . 0.0 112.913 -173.084 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.37 149.74 1.82 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.965 1.269 . . . . 0.0 110.694 -169.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 19.0 m -74.81 -5.1 41.62 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 121.806 -0.82 . . . . 0.0 112.952 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.7 m -126.56 157.68 38.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 124.443 1.097 . . . . 0.0 110.026 178.645 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -54.57 -53.4 55.08 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 126.756 2.022 . . . . 0.0 112.931 -171.016 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 176.07 -48.11 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 128.766 2.826 . . . . 0.0 106.793 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -79.71 -40.71 28.34 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.414 1.086 . . . . 0.0 111.144 -178.058 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 148.18 6.56 0.25 Allowed Glycine 0 CA--C 1.531 1.052 0 CA-C-O 118.7 -1.056 . . . . 0.0 114.089 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 mt-30 -76.99 124.18 87.4 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 119.352 1.576 . . . . 0.0 107.195 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.49 139.69 65.38 Favored 'Trans proline' 0 CA--C 1.534 0.482 0 C-N-CA 122.39 2.06 . . . . 0.0 111.142 174.456 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.7 mtt-85 -71.2 6.39 1.7 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -177.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.1 t -51.88 129.08 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 120.121 1.328 . . . . 0.0 109.113 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.93 -19.29 54.76 Favored Glycine 0 CA--C 1.53 1.002 0 C-N-CA 124.781 1.181 . . . . 0.0 113.458 178.45 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -68.32 163.4 23.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.338 1.569 . . . . 0.0 109.179 173.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -105.42 163.04 12.94 Favored 'General case' 0 C--O 1.234 0.238 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.49 148.08 14.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 123.194 0.598 . . . . 0.0 109.425 -169.351 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 74.9 mt -90.63 141.47 28.74 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 169.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.7 t -132.18 147.82 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -148.26 -45.85 0.16 Allowed 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.89 1.276 . . . . 0.0 109.009 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.6 m -126.97 -166.97 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 126.412 1.885 . . . . 0.0 106.673 171.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -72.37 37.68 0.69 Allowed Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.673 1.13 . . . . 0.0 114.112 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -139.59 147.36 41.01 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.342 1.457 . . . . 0.0 109.288 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.66 104.57 3.96 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 169.238 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 88.7 mmm -69.05 -45.05 71.38 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 118.369 0.532 . . . . 0.0 110.447 -169.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.5 m -161.76 152.84 18.16 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 126.156 1.783 . . . . 0.0 107.144 169.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -75.11 149.43 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 170.044 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -141.64 -167.55 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 C-N-CA 126.487 1.915 . . . . 0.0 108.293 176.507 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -123.63 174.17 7.62 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 125.098 1.359 . . . . 0.0 109.804 175.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -60.0 -40.17 88.31 Favored 'General case' 0 CA--C 1.527 0.083 0 C-N-CA 123.895 0.878 . . . . 0.0 112.399 -172.616 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.36 -37.81 56.74 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 118.183 0.447 . . . . 0.0 109.923 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -61.8 -36.15 80.27 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.333 0.653 . . . . 0.0 109.878 173.607 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.52 -42.35 98.45 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.504 -0.748 . . . . 0.0 110.809 174.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.6 mpt_? -64.59 -43.39 93.96 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 119.275 0.943 . . . . 0.0 109.995 177.446 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -60.27 -40.13 89.29 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.064 0.393 . . . . 0.0 111.065 177.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.4 m -65.67 -43.61 88.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.091 0.557 . . . . 0.0 110.452 176.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 59.4 mt -63.64 -38.9 92.87 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 118.873 0.761 . . . . 0.0 110.639 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -64.69 -45.35 87.01 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 123.408 0.683 . . . . 0.0 110.427 175.433 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.23 -42.73 99.12 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.425 0.557 . . . . 0.0 110.995 177.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -59.81 -55.38 34.92 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 123.514 0.726 . . . . 0.0 109.909 -178.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -68.18 -31.3 70.74 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 117.878 0.308 . . . . 0.0 111.181 -178.123 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -62.97 -45.63 91.52 Favored 'General case' 0 C--N 1.339 0.137 0 CA-C-N 118.5 0.591 . . . . 0.0 110.675 175.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 76.0 mtm -62.84 -42.94 99.94 Favored 'General case' 0 C--N 1.339 0.113 0 CA-C-N 118.302 0.501 . . . . 0.0 110.452 175.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 38.8 t80 -63.42 -23.11 67.26 Favored 'General case' 0 CA--C 1.54 0.595 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -74.12 -16.09 61.02 Favored 'General case' 0 CA--C 1.539 0.546 0 O-C-N 121.174 -0.954 . . . . 0.0 112.516 175.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 34.8 m -128.29 -8.24 3.71 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 C-N-CA 123.747 0.819 . . . . 0.0 113.14 -172.607 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 81.9 mm-40 -135.65 141.99 39.22 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 125.207 1.403 . . . . 0.0 107.685 174.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.93 -18.65 21.43 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.645 2.23 . . . . 0.0 113.354 -171.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.3 t70 48.95 38.37 12.24 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 125.647 1.579 . . . . 0.0 112.742 -177.331 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.1 t 52.51 40.12 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.32 1.448 . . . . 0.0 111.187 -175.271 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 66.91 15.2 64.46 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 124.892 1.234 . . . . 0.0 112.774 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . 55.62 -2.08 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 128.033 2.533 . . . . 0.0 115.058 -169.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 53.5 tp -63.17 -42.63 99.43 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 120.394 1.452 . . . . 0.0 110.529 -177.395 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -66.33 -6.84 15.55 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.151 0.981 . . . . 0.0 112.164 177.432 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -133.64 30.3 3.79 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.97 1.708 . . . . 0.0 109.792 -174.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -159.36 -28.87 0.02 OUTLIER Glycine 0 CA--C 1.53 1.014 0 C-N-CA 124.611 1.101 . . . . 0.0 112.529 -177.271 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 53.26 37.79 26.09 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.307 1.443 . . . . 0.0 111.171 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -69.72 -10.11 57.07 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.565 1.146 . . . . 0.0 112.786 -176.525 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 40.6 ttpt . . . . . 0 C--O 1.249 1.057 0 C-N-CA 126.356 1.863 . . . . 0.0 106.387 178.398 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.5 ptm . . . . . 0 N--CA 1.484 1.243 0 N-CA-C 110.386 -0.228 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 84.7 m -69.54 119.78 14.32 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 169.468 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.0 tp -157.41 156.14 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.6 54.69 0.17 Allowed Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -172.539 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 10.6 p -148.87 154.05 39.56 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 123.848 0.859 . . . . 0.0 109.54 -169.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -58.54 161.92 13.6 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.711 2.274 . . . . 0.0 113.364 169.649 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.55 175.35 38.97 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 108.654 -1.779 . . . . 0.0 108.654 169.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -116.89 131.88 56.84 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 176.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.9 mt -66.41 119.06 10.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 177.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.5 tpp180 -107.4 -40.6 5.32 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 118.507 -0.759 . . . . 0.0 109.713 -169.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.9 p -142.37 161.8 37.11 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.493 1.117 . . . . 0.0 108.438 169.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.4 mt -132.64 148.81 31.64 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -179.265 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -124.54 -24.56 4.19 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.299 1.04 . . . . 0.0 112.028 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.66 -126.74 1.33 Allowed Glycine 0 C--N 1.333 0.416 0 N-CA-C 106.757 -2.537 . . . . 0.0 106.757 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 11.8 t30 -65.48 -24.44 67.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.722 0.761 . . . . 0.0 110.254 169.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -93.39 155.6 17.28 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-O 122.054 0.93 . . . . 0.0 110.282 172.119 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.64 175.03 11.91 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.65 1.58 . . . . 0.0 108.863 -178.436 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -128.71 99.83 5.49 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 176.517 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.3 m -69.12 165.88 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 169.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -111.74 112.95 25.01 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 169.029 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -88.26 60.58 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 -177.473 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.6 m 46.45 41.31 9.26 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.094 2.157 . . . . 0.0 113.586 178.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.56 -26.95 0.2 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.106 -0.83 . . . . 0.0 114.248 175.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.5 tp -149.34 149.91 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.447 0 CA-C-N 118.646 1.223 . . . . 0.0 107.742 177.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -76.21 147.79 38.15 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 175.525 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -140.16 132.59 28.51 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 124.563 1.145 . . . . 0.0 108.823 176.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -69.98 140.69 52.99 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 123.976 0.91 . . . . 0.0 110.185 176.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -148.49 167.13 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 126.136 1.774 . . . . 0.0 109.162 -178.603 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -107.03 143.59 34.92 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 169.623 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 26.6 mt -114.58 21.35 14.59 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.279 1.431 . . . . 0.0 110.854 -173.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.07 -35.45 59.56 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.699 1.199 . . . . 0.0 112.584 -171.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.7 mt -80.34 -8.96 59.72 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.679 0.791 . . . . 0.0 112.617 -176.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.7 m -126.92 -5.83 4.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.253 1.021 . . . . 0.0 111.815 -177.447 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.27 79.21 Favored Glycine 0 CA--C 1.532 1.099 0 C-N-CA 124.99 1.281 . . . . 0.0 114.918 169.609 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 m 58.5 -14.28 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 127.167 2.187 . . . . 0.0 116.711 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.6 m -136.5 153.39 51.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 124.828 1.251 . . . . 0.0 109.598 -177.669 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -64.97 157.91 26.94 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.472 1.109 . . . . 0.0 108.899 169.519 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -48.2 -41.65 27.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.279 1.431 . . . . 0.0 112.445 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -80.73 -16.84 52.86 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 118.91 -0.566 . . . . 0.0 112.152 -176.206 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.92 -12.6 5.32 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-O 118.504 -1.164 . . . . 0.0 115.817 169.479 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -66.06 135.36 95.14 Favored Pre-proline 0 N--CA 1.469 0.477 0 CA-C-N 119.662 1.731 . . . . 0.0 109.341 -172.24 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.11 140.33 71.25 Favored 'Trans proline' 0 CA--C 1.534 0.475 0 C-N-CA 121.707 1.605 . . . . 0.0 109.162 171.439 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -73.42 11.25 0.81 Allowed 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 114.517 1.302 . . . . 0.0 114.517 -172.15 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.0 m -53.14 133.99 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 120.251 1.387 . . . . 0.0 109.698 176.237 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.8 -18.61 52.56 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.433 -1.204 . . . . 0.0 112.992 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -73.52 142.18 46.73 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 119.89 1.845 . . . . 0.0 108.974 177.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -85.04 151.24 24.31 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 170.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.69 145.02 14.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -170.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 86.0 mt -79.1 132.74 36.69 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 169.402 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 50.2 t -118.63 123.69 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -135.04 137.56 43.06 Favored 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.7 m 44.1 28.45 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 C-N-CA 126.61 1.964 . . . . 0.0 115.405 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.76 4.65 58.98 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.698 1.142 . . . . 0.0 113.892 175.726 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -125.79 144.55 50.59 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 119.093 1.447 . . . . 0.0 109.719 -176.674 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.16 120.04 16.16 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 169.381 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 25.8 mmt -91.47 -45.52 8.49 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 119.001 -0.523 . . . . 0.0 111.436 -178.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.5 m -152.19 138.47 18.42 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -176.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.1 t -74.12 142.2 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 169.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.53 -169.52 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 125.695 1.598 . . . . 0.0 109.133 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -128.16 174.79 8.95 Favored 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 125.803 1.641 . . . . 0.0 108.791 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -62.51 -36.52 82.83 Favored 'General case' 0 N--CA 1.462 0.129 0 CA-C-O 118.955 -0.545 . . . . 0.0 112.434 -173.318 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.99 -44.67 76.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.936 0.789 . . . . 0.0 109.464 -177.282 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -64.58 -41.34 96.34 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 123.136 0.574 . . . . 0.0 110.259 176.179 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -49.14 75.91 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 122.86 0.464 . . . . 0.0 110.431 179.542 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -64.67 -41.25 96.21 Favored 'General case' 0 N--CA 1.463 0.195 0 C-N-CA 123.156 0.583 . . . . 0.0 110.376 -178.531 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -62.5 -43.23 99.33 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.397 0.544 . . . . 0.0 110.939 176.64 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -69.59 -37.46 76.93 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 122.097 -0.377 . . . . 0.0 110.506 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 27.7 mt -62.79 -40.15 96.45 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 119.113 0.87 . . . . 0.0 110.293 176.001 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -66.32 -43.54 85.92 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.375 0.534 . . . . 0.0 110.701 175.174 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.7 -43.06 84.9 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.103 0.411 . . . . 0.0 110.478 176.751 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -66.18 -5.19 9.34 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.994 1.317 . . . . 0.0 113.748 178.335 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -123.03 -20.44 5.76 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.167 0.987 . . . . 0.0 111.987 -178.127 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -57.72 -32.38 67.35 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 119.261 0.937 . . . . 0.0 113.476 -172.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 1.5 pmm? -72.68 -34.37 67.15 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 118.538 0.608 . . . . 0.0 111.607 177.219 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -79.35 -27.7 42.02 Favored 'General case' 0 C--O 1.226 -0.168 0 C-N-CA 123.423 0.689 . . . . 0.0 110.774 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -59.85 -19.99 54.38 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.32 1.048 . . . . 0.0 112.809 177.376 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.9 t -63.92 -29.44 47.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 O-C-N 121.533 -0.729 . . . . 0.0 110.932 173.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -66.11 -54.0 29.38 Favored Pre-proline 0 CA--C 1.54 0.569 0 CA-C-O 117.721 -1.133 . . . . 0.0 111.95 -175.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -67.73 -24.65 40.68 Favored 'Trans proline' 0 C--N 1.351 0.673 0 CA-C-N 121.947 1.731 . . . . 0.0 112.163 175.128 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -67.35 -50.58 59.26 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 118.962 0.801 . . . . 0.0 110.918 177.693 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.7 p -69.93 -29.45 40.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 O-C-N 121.862 -0.524 . . . . 0.0 110.074 175.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -57.53 -51.05 60.13 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 172.226 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.1 -44.58 87.75 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 117.862 0.831 . . . . 0.0 110.939 178.06 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -60.59 -44.27 96.44 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.152 0.581 . . . . 0.0 110.807 178.298 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -61.65 -43.95 97.89 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 123.665 0.786 . . . . 0.0 109.89 177.706 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -63.08 -34.85 78.49 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 118.833 -0.603 . . . . 0.0 111.65 179.381 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 157.59 -149.98 20.76 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 119.169 0.895 . . . . 0.0 111.735 175.626 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 38.7 mm-40 -71.77 19.41 0.07 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.235 1.414 . . . . 0.0 111.949 175.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -66.15 -35.13 79.67 Favored 'General case' 0 CA--C 1.538 0.508 0 O-C-N 120.887 -1.133 . . . . 0.0 110.169 175.332 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 83.1 tttt . . . . . 0 C--O 1.248 1.005 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 169.704 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 97.4 mmm . . . . . 0 N--CA 1.485 1.298 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 63.8 m -78.32 47.36 0.68 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.012 1.325 . . . . 0.0 112.02 -177.642 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.2 pt -61.01 159.82 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 124.304 1.041 . . . . 0.0 110.307 174.407 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.2 55.11 0.12 Allowed Glycine 0 CA--C 1.525 0.713 0 N-CA-C 108.238 -1.945 . . . . 0.0 108.238 -177.388 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.0 p -150.67 157.2 36.31 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.613 1.165 . . . . 0.0 109.44 -168.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -67.62 158.37 57.49 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 121.962 1.775 . . . . 0.0 110.477 168.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.45 177.28 39.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 171.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -116.11 138.41 51.28 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 117.565 0.683 . . . . 0.0 109.334 -175.489 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 60.6 mt -73.7 83.29 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 176.658 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -76.48 -29.71 56.97 Favored 'General case' 0 N--CA 1.465 0.286 0 O-C-N 121.624 -0.672 . . . . 0.0 111.553 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.73 154.83 38.1 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.747 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 64.5 mt -129.66 147.98 33.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -121.32 -24.87 5.34 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.463 1.105 . . . . 0.0 112.121 -176.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 161.06 -113.0 0.55 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 108.307 -1.917 . . . . 0.0 108.307 178.245 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -69.37 2.04 3.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.656 0.782 . . . . 0.0 111.875 169.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -139.23 159.3 42.48 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 126.925 2.09 . . . . 0.0 107.679 -170.683 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 169.14 18.14 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.26 1.424 . . . . 0.0 110.035 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -115.82 73.09 0.83 Allowed 'General case' 0 C--O 1.234 0.241 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 -174.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.0 t -71.56 125.53 30.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 -172.372 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -77.18 112.05 13.45 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 169.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.9 m -82.56 43.08 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 C-N-CA 124.211 1.005 . . . . 0.0 110.718 177.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 66.7 m 48.5 49.93 17.58 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.077 1.751 . . . . 0.0 112.211 -172.426 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -177.71 -41.64 0.06 OUTLIER Glycine 0 CA--C 1.524 0.622 0 CA-C-O 119.644 -0.531 . . . . 0.0 112.404 174.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.6 tt -155.86 153.76 7.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -71.96 139.85 48.87 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 170.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 39.2 mmt180 -128.94 142.75 50.83 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 125.273 1.429 . . . . 0.0 107.977 176.246 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.08 131.47 46.65 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.5 t -140.68 129.56 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -83.36 144.19 29.82 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.517 0.727 . . . . 0.0 110.14 174.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.7 mt -109.6 7.85 24.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.312 1.045 . . . . 0.0 113.322 -169.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 25.2 m -53.1 -34.34 56.22 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.987 1.721 . . . . 0.0 112.482 -175.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.3 mt -74.98 -11.09 60.03 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.47 -17.0 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 CA-C-N 119.43 1.013 . . . . 0.0 112.563 -175.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.74 133.18 0.52 Allowed Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.264 1.411 . . . . 0.0 110.781 -175.453 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 21.4 m -67.86 156.65 36.66 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 169.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.0 m 61.97 145.48 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.227 2.211 . . . . 0.0 112.535 -169.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.95 155.31 38.79 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.207 1.403 . . . . 0.0 109.484 173.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.68 -27.56 62.99 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.646 1.179 . . . . 0.0 112.484 -176.126 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -62.69 -21.95 66.13 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.813 0.845 . . . . 0.0 113.043 175.628 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.99 47.9 3.25 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -174.185 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.9 pt20 -143.18 157.33 60.48 Favored Pre-proline 0 CA--C 1.536 0.426 0 C-N-CA 125.751 1.621 . . . . 0.0 107.93 -178.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -64.51 144.09 83.92 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 121.701 1.601 . . . . 0.0 110.375 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 90.6 mtt-85 -71.5 11.2 0.5 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.358 1.063 . . . . 0.0 113.621 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.1 m -57.45 131.69 21.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 O-C-N 120.616 -1.303 . . . . 0.0 109.817 -173.405 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 89.7 -17.44 52.63 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 118.306 -1.274 . . . . 0.0 113.413 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -66.57 156.34 35.28 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 119.693 1.746 . . . . 0.0 108.948 172.344 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.3 m95 -105.15 159.99 15.42 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.3 p -157.06 135.55 3.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -171.493 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 98.2 mt -75.68 131.37 39.85 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 168.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.72 135.05 64.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 119.344 0.974 . . . . 0.0 108.402 -178.228 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -141.83 120.81 12.83 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.684 1.193 . . . . 0.0 107.945 -169.686 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.2 t 41.6 47.95 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 126.671 1.988 . . . . 0.0 112.02 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.22 6.95 83.78 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 118.337 -1.257 . . . . 0.0 114.771 172.426 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.18 149.02 50.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 119.803 1.802 . . . . 0.0 110.017 177.416 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.47 116.16 7.9 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 169.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.9 ttt -76.75 -48.46 18.64 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.532 0.733 . . . . 0.0 109.497 177.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 65.4 m -163.11 144.54 9.75 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.975 1.31 . . . . 0.0 108.833 171.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.6 t -72.32 146.29 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 169.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 pt -137.8 157.91 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 C-N-CA 125.236 1.414 . . . . 0.0 109.02 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -80.83 169.19 17.89 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 120.927 0.394 . . . . 0.0 110.773 176.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -61.14 -44.57 97.11 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 123.385 0.674 . . . . 0.0 111.993 -173.224 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.66 -37.1 62.82 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 122.759 0.424 . . . . 0.0 109.953 -174.563 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 56.4 tt0 -60.27 -39.31 86.37 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.846 1.258 . . . . 0.0 110.033 172.332 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.96 -44.95 87.71 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.618 -0.676 . . . . 0.0 111.322 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 26.5 mmt-85 -62.49 -40.88 98.13 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 119.103 0.865 . . . . 0.0 110.441 178.549 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.96 -41.97 99.69 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.887 0.475 . . . . 0.0 110.907 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -65.07 -42.95 93.67 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.62 0.368 . . . . 0.0 110.232 177.537 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 42.5 mt -62.54 -43.58 98.45 Favored 'General case' 0 C--N 1.338 0.107 0 C-N-CA 123.269 0.628 . . . . 0.0 110.311 178.247 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.84 -44.95 94.78 Favored 'General case' 0 N--CA 1.46 0.073 0 C-N-CA 123.06 0.544 . . . . 0.0 110.845 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.12 -41.19 98.0 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.903 0.481 . . . . 0.0 111.191 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -65.35 -51.12 62.63 Favored 'General case' 0 C--N 1.338 0.104 0 C-N-CA 123.173 0.589 . . . . 0.0 109.577 177.051 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -61.35 -32.88 72.78 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.915 0.486 . . . . 0.0 111.341 -178.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -56.65 -31.27 64.21 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.306 0.643 . . . . 0.0 112.069 178.363 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 54.9 mtt -64.42 -14.24 55.65 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.06 0.944 . . . . 0.0 112.624 178.155 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -124.66 -22.29 4.62 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 124.995 1.318 . . . . 0.0 111.157 -176.208 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -59.67 -30.55 68.84 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 118.981 0.809 . . . . 0.0 111.593 172.341 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 27.9 m -69.96 -8.72 11.18 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.705 0 C-N-CA 124.458 1.103 . . . . 0.0 112.979 174.535 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -134.67 71.75 70.24 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.647 1.579 . . . . 0.0 107.132 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -63.25 -19.59 68.8 Favored 'Trans proline' 0 CA--C 1.533 0.466 0 C-N-CA 122.681 2.254 . . . . 0.0 113.407 -169.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -60.33 -36.16 77.31 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.02 0.827 . . . . 0.0 111.465 170.53 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.9 t -81.6 -44.86 20.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 173.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -53.05 -43.3 62.13 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 123.813 0.72 . . . . 0.0 112.424 -177.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.06 -0.27 5.55 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 124.647 1.179 . . . . 0.0 114.094 -179.024 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 47.8 tp -124.12 -32.08 3.27 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.631 1.172 . . . . 0.0 110.578 174.553 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.9 tp -65.86 -30.38 70.98 Favored 'General case' 0 CA--C 1.538 0.504 0 O-C-N 121.475 -0.765 . . . . 0.0 110.899 170.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -131.91 29.34 4.43 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.749 1.62 . . . . 0.0 110.052 -178.191 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -169.96 -160.03 17.27 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -136.94 17.85 3.03 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 124.324 1.049 . . . . 0.0 110.756 -176.206 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -65.42 143.94 57.38 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 121.258 -0.901 . . . . 0.0 110.207 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 40.6 ttpt . . . . . 0 C--O 1.247 0.964 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 178.35 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.9 tpt . . . . . 0 N--CA 1.482 1.165 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.4 m -61.7 149.81 38.51 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.426 0.69 . . . . 0.0 110.954 178.468 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.7 tp -154.98 175.73 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 C-N-CA 125.86 1.664 . . . . 0.0 106.864 178.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.11 42.28 5.02 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -169.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.6 m -141.61 162.14 48.39 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.036 1.334 . . . . 0.0 109.288 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -56.28 155.81 23.4 Favored 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 122.802 2.334 . . . . 0.0 113.447 172.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -158.32 167.97 34.59 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 107.951 -2.06 . . . . 0.0 107.951 169.33 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.8 tt0 -116.8 133.57 55.85 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 -178.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.19 97.01 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.129 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -83.34 -41.95 17.64 Favored 'General case' 0 N--CA 1.462 0.139 0 O-C-N 121.701 -0.625 . . . . 0.0 109.97 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 p -145.58 157.97 43.91 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 124.651 1.181 . . . . 0.0 108.83 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 54.4 mt -132.78 146.97 31.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 -174.044 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -123.55 -15.24 7.13 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.393 1.077 . . . . 0.0 112.091 -177.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 163.89 -131.56 2.48 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 106.459 -2.657 . . . . 0.0 106.459 -178.031 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -74.09 22.48 0.09 Allowed 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 118.057 0.929 . . . . 0.0 111.515 169.315 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLN . . . . . 0.415 ' H ' ' C ' ' A' ' 14' ' ' GLY . 41.1 mt-30 -140.5 148.61 41.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 126.594 1.958 . . . . 0.0 106.803 -179.056 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.61 163.46 32.0 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 124.454 1.102 . . . . 0.0 109.926 -179.177 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -110.79 78.37 1.11 Allowed 'General case' 0 C--O 1.233 0.232 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.0 m -70.59 130.88 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 123.477 0.711 . . . . 0.0 109.508 -177.82 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -76.84 111.3 12.22 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 168.826 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.4 t -84.75 54.67 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.74 45.72 8.31 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.984 2.113 . . . . 0.0 113.215 -177.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.3 -36.07 0.13 Allowed Glycine 0 CA--C 1.526 0.781 0 CA-C-O 119.468 -0.629 . . . . 0.0 113.003 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.8 tt -153.51 151.66 11.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 177.174 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.2 mt-30 -73.79 138.11 44.32 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 172.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -130.75 145.38 51.93 Favored 'General case' 0 N--CA 1.463 0.186 0 C-N-CA 125.261 1.424 . . . . 0.0 107.91 171.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -70.94 144.36 50.6 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 173.53 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.48 139.76 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.222 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -81.5 146.59 30.12 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.11 1.364 . . . . 0.0 110.284 172.58 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 86.1 mt -117.17 16.0 14.94 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.559 1.143 . . . . 0.0 112.404 -170.058 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 5.8 p -53.31 -34.98 59.61 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 120.561 1.528 . . . . 0.0 112.854 -176.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 73.9 mt -83.53 -6.04 59.34 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 118.46 -0.781 . . . . 0.0 112.865 -175.205 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -132.42 -20.41 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 119.536 1.062 . . . . 0.0 112.919 -174.079 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.29 147.83 7.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -177.32 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.6 m -68.23 -20.78 64.84 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.877 1.271 . . . . 0.0 113.364 -171.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.6 m -127.41 152.34 47.65 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 124.876 1.27 . . . . 0.0 109.283 -175.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -65.49 145.99 55.43 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.344 1.458 . . . . 0.0 109.972 172.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -53.99 -31.01 49.54 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.169 1.388 . . . . 0.0 113.517 -169.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -84.87 -7.86 59.01 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 118.863 0.756 . . . . 0.0 112.986 -178.045 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.34 52.65 0.76 Allowed Glycine 0 CA--C 1.527 0.793 0 CA-C-N 119.043 0.838 . . . . 0.0 112.728 170.63 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 30.0 pt20 -144.4 160.65 47.63 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 124.898 1.279 . . . . 0.0 108.697 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -63.74 143.76 87.36 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.627 1.551 . . . . 0.0 109.97 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 79.6 mtt-85 -70.56 12.93 0.21 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -177.243 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.8 m -57.91 135.1 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 O-C-N 120.59 -1.319 . . . . 0.0 109.984 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.52 -14.57 54.82 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 124.889 1.233 . . . . 0.0 113.484 -178.183 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -73.99 155.17 38.88 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 119.709 1.754 . . . . 0.0 109.373 177.701 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 83.5 m95 -97.95 159.16 15.11 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -157.07 147.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 91.9 mt -82.99 128.22 34.27 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.129 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 20.6 t -111.23 105.26 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -169.84 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' HIS . . . . . 0.412 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 6.7 t-160 -77.09 -171.37 1.99 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.903 0.881 . . . . 0.0 109.092 169.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.412 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 36.0 m -52.89 -26.84 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 C-N-CA 124.54 1.136 . . . . 0.0 113.795 -174.151 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.08 18.15 0.1 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.841 -0.977 . . . . 0.0 113.213 171.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -139.47 142.54 37.36 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 119.094 1.447 . . . . 0.0 109.12 -172.068 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.16 125.54 27.06 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 169.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 46.3 mtt -74.07 -57.59 3.86 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.4 m -157.77 145.21 18.41 Favored 'General case' 0 C--O 1.238 0.462 0 C-N-CA 126.356 1.863 . . . . 0.0 107.643 -176.44 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.1 m -74.44 148.99 7.68 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 169.081 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 pt -138.71 168.05 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 125.048 1.339 . . . . 0.0 108.575 -178.34 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -97.59 174.85 6.44 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.0 0.52 . . . . 0.0 110.134 176.267 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -62.55 -33.67 75.4 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.715 0.806 . . . . 0.0 111.481 -174.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.84 -49.1 61.25 Favored 'General case' 0 CA--C 1.528 0.129 0 O-C-N 121.72 -0.612 . . . . 0.0 110.251 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -64.25 -38.91 92.73 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 122.777 0.431 . . . . 0.0 110.342 178.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -52.3 65.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 118.049 0.386 . . . . 0.0 110.176 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -64.47 -39.03 93.03 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-O 118.677 -0.678 . . . . 0.0 111.005 -178.314 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.52 -43.03 99.81 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.088 0.858 . . . . 0.0 110.943 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.7 m -66.99 -42.75 84.51 Favored 'General case' 0 CA--C 1.537 0.466 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.418 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.2 mt -64.51 -35.58 81.41 Favored 'General case' 0 CA--C 1.528 0.099 0 O-C-N 121.449 -0.782 . . . . 0.0 110.923 178.082 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -66.89 -43.47 83.37 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 123.403 0.681 . . . . 0.0 110.672 176.213 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.29 -47.72 82.75 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.5 mt -61.93 -8.43 5.1 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.665 1.186 . . . . 0.0 113.699 -178.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -126.55 17.91 7.5 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-N 119.695 1.134 . . . . 0.0 112.51 178.212 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -147.76 -17.86 0.36 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 114.79 1.404 . . . . 0.0 114.79 169.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 46.0 tpp -60.63 -23.08 64.48 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.102 1.319 . . . . 0.0 112.776 -173.337 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -52.81 -28.24 21.74 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.808 0.843 . . . . 0.0 112.764 173.105 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -64.46 -12.01 39.41 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.213 1.405 . . . . 0.0 113.198 -179.278 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 12.8 m -130.95 17.0 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 124.925 1.29 . . . . 0.0 111.1 -179.016 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 14.0 mm-40 -134.55 168.22 18.9 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 124.555 1.142 . . . . 0.0 110.055 -170.517 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -51.72 -21.87 12.21 Favored 'Trans proline' 0 C--N 1.349 0.561 0 C-N-CA 124.203 3.269 . . . . 0.0 116.643 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -62.92 -36.55 83.78 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 118.721 0.691 . . . . 0.0 112.101 -178.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.6 p -158.02 -35.1 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-N 118.362 0.528 . . . . 0.0 111.714 173.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -54.02 -38.52 60.83 Favored Glycine 0 CA--C 1.526 0.759 0 CA-C-N 119.558 1.072 . . . . 0.0 113.241 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -66.6 -20.12 65.93 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 118.193 0.997 . . . . 0.0 113.4 178.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 48.8 tp -90.14 -41.34 11.69 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.399 1.08 . . . . 0.0 109.261 171.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.09 -39.2 91.65 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.411 1.084 . . . . 0.0 110.798 -177.48 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -126.34 36.64 4.46 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.3 1.44 . . . . 0.0 110.612 -170.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -162.4 178.37 38.21 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 176.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -64.49 149.31 48.84 Favored 'General case' 0 C--O 1.238 0.463 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 170.018 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -65.29 156.31 32.43 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-O 121.472 0.653 . . . . 0.0 112.423 -173.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 62.1 mttp . . . . . 0 C--O 1.251 1.156 0 C-N-CA 125.9 1.68 . . . . 0.0 107.434 -169.811 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.6 mtt . . . . . 0 N--CA 1.485 1.314 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 7.0 p -143.75 171.24 14.47 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.269 1.027 . . . . 0.0 109.197 170.122 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 44.2 mt -133.28 158.37 42.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 -173.162 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.79 45.69 0.1 OUTLIER Glycine 0 CA--C 1.526 0.781 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 -178.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.7 t -143.72 146.87 36.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 125.224 1.41 . . . . 0.0 107.583 -169.252 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -55.83 161.25 8.47 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.69 2.26 . . . . 0.0 113.339 169.573 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.93 177.3 39.78 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 169.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -116.78 137.19 52.38 Favored 'General case' 0 C--N 1.334 -0.105 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 39.1 mt -76.77 71.85 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 C-N-CA 124.89 1.276 . . . . 0.0 108.129 -175.72 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -63.76 -30.36 71.46 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 124.363 1.065 . . . . 0.0 112.445 -172.674 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -149.76 155.81 40.77 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 177.601 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.1 141.48 45.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -106.77 -28.33 10.22 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 124.039 0.936 . . . . 0.0 110.781 174.023 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.81 -121.88 0.98 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 106.78 -2.528 . . . . 0.0 106.78 177.243 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.4 t30 -65.34 -15.31 62.42 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 116.935 0.368 . . . . 0.0 111.693 169.621 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -105.85 153.12 22.37 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 172.304 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -146.71 169.12 19.71 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.33 1.052 . . . . 0.0 110.167 -177.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.39 75.1 1.37 Allowed 'General case' 0 CA--C 1.519 -0.233 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -171.727 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.6 t -73.6 128.26 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -74.06 106.17 5.62 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 169.538 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.71 57.85 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.1 m 43.35 48.42 5.9 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 127.566 2.347 . . . . 0.0 113.427 179.553 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 175.0 -39.26 0.11 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.592 -0.56 . . . . 0.0 112.305 176.269 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.5 tt -153.69 152.65 9.69 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -69.56 136.54 51.45 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 170.49 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 22.7 mmm180 -122.36 128.29 50.81 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 175.241 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -74.79 119.88 19.57 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 176.071 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.2 m -142.99 172.33 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 125.47 1.508 . . . . 0.0 109.579 -170.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -108.88 143.22 38.38 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 124.729 1.211 . . . . 0.0 111.056 -169.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.7 mt -114.03 9.88 17.41 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.47 1.108 . . . . 0.0 112.734 -175.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 6.4 m -55.06 -33.87 63.09 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.943 1.701 . . . . 0.0 112.154 -172.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.23 -9.82 58.93 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.661 0.785 . . . . 0.0 113.055 -177.351 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.9 -15.94 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 119.498 1.045 . . . . 0.0 112.651 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.13 147.49 7.2 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 124.983 1.278 . . . . 0.0 110.536 -176.584 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.5 m -65.57 -21.82 66.63 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.84 1.256 . . . . 0.0 112.184 177.536 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.3 m -126.71 168.43 14.38 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.452 1.501 . . . . 0.0 109.734 -175.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -117.79 154.02 32.46 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 126.95 2.1 . . . . 0.0 109.239 -169.868 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -57.78 -25.91 61.17 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.661 1.185 . . . . 0.0 112.711 -173.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -60.85 -23.77 65.38 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 123.863 0.865 . . . . 0.0 113.007 174.37 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.03 47.7 2.59 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -175.237 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -145.7 154.39 51.9 Favored Pre-proline 0 CA--C 1.535 0.375 0 C-N-CA 125.398 1.479 . . . . 0.0 108.638 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -66.48 152.04 81.72 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 121.828 1.685 . . . . 0.0 108.847 169.318 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 64.7 mtt-85 -70.19 10.57 0.42 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 114.339 1.237 . . . . 0.0 114.339 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.51 137.57 23.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 O-C-N 120.849 -1.157 . . . . 0.0 108.933 -172.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.71 -11.37 33.79 Favored Glycine 0 CA--C 1.532 1.106 0 CA-C-O 118.187 -1.34 . . . . 0.0 114.028 179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -67.64 163.05 22.26 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.91 1.855 . . . . 0.0 109.219 171.485 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.2 m95 -104.25 155.47 18.72 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.2 p -153.24 142.77 14.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -171.103 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -84.47 113.1 20.96 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 169.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 38.9 t -93.42 137.09 23.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.213 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 178.346 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -137.12 142.83 42.28 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.273 1.029 . . . . 0.0 108.702 175.516 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 22.5 t 56.37 -75.99 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 127.071 2.148 . . . . 0.0 111.439 -173.545 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.24 27.8 0.19 Allowed Glycine 0 CA--C 1.535 1.31 0 C-N-CA 127.761 2.6 . . . . 0.0 110.088 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -139.53 144.08 37.71 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 126.215 1.806 . . . . 0.0 107.847 -170.144 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.74 122.94 17.61 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 169.163 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 52.0 ttp -80.32 -57.9 3.39 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 171.042 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 17.8 m -150.64 138.03 19.55 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 123.77 0.828 . . . . 0.0 109.517 -172.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.0 t -72.09 144.6 12.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 169.416 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.4 pt -138.29 158.8 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 124.781 1.232 . . . . 0.0 108.846 -176.223 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -81.91 167.84 18.54 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 110.593 175.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -67.37 -33.43 75.21 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.549 0.74 . . . . 0.0 112.341 -169.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.9 -39.94 33.61 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.308 -0.87 . . . . 0.0 109.637 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.2 tt0 -59.8 -40.78 89.52 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.011 1.325 . . . . 0.0 110.146 173.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -50.8 71.31 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.145 0.578 . . . . 0.0 110.662 175.042 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 84.2 mtm180 -63.29 -40.17 96.61 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 119.072 -0.489 . . . . 0.0 111.201 -178.551 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.25 -43.62 97.5 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 118.582 0.628 . . . . 0.0 110.785 176.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.2 m -65.63 -39.24 91.25 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 119.276 -0.392 . . . . 0.0 110.35 178.625 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 35.8 mt -64.62 -42.21 95.67 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 119.099 0.863 . . . . 0.0 110.536 176.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -64.68 -39.33 93.49 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 123.164 0.586 . . . . 0.0 110.961 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.13 -51.05 63.56 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.495 0.318 . . . . 0.0 110.24 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -56.11 -47.63 77.72 Favored 'General case' 0 N--CA 1.462 0.139 0 C-N-CA 124.39 1.076 . . . . 0.0 110.679 -174.278 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -73.52 5.48 3.78 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.619 0.97 . . . . 0.0 113.619 -177.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 -127.96 -29.28 2.57 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 124.334 1.054 . . . . 0.0 111.616 178.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 37.7 mtt -59.83 -19.52 51.43 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 124.161 0.985 . . . . 0.0 113.146 -179.162 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 15.3 p90 -57.3 -22.55 42.64 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 119.713 1.142 . . . . 0.0 112.3 174.002 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -65.19 -19.89 66.18 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.094 0.958 . . . . 0.0 112.775 176.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.5 m -129.1 -18.53 1.85 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 C-N-CA 124.761 1.224 . . . . 0.0 112.369 -174.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -145.28 78.84 12.0 Favored Pre-proline 0 CA--C 1.539 0.53 0 C-N-CA 125.402 1.481 . . . . 0.0 107.913 175.426 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -62.91 -11.72 25.85 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 123.59 2.86 . . . . 0.0 114.191 -170.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -52.59 -38.28 59.76 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.557 0.743 . . . . 0.0 111.309 169.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.9 m -68.89 -28.54 40.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-N 119.255 0.934 . . . . 0.0 110.97 179.24 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -68.64 -49.93 40.22 Favored Glycine 0 C--N 1.338 0.662 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 175.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.12 -44.92 88.01 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 117.565 0.682 . . . . 0.0 110.878 176.674 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.406 HD13 ' C ' ' A' ' 84' ' ' LEU . 2.7 tm? -57.36 -48.87 77.9 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 124.584 1.153 . . . . 0.0 110.304 176.539 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 68.5 tp -60.46 -40.6 91.79 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.238 0.615 . . . . 0.0 110.499 177.48 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 13.3 m-30 -64.24 -32.42 74.0 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 118.956 -0.545 . . . . 0.0 111.32 176.072 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 159.68 -20.75 0.26 Allowed Glycine 0 CA--C 1.53 0.999 0 CA-C-O 118.224 -1.32 . . . . 0.0 115.387 169.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -149.33 132.36 16.24 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 119.982 1.891 . . . . 0.0 110.077 -170.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -56.52 157.6 5.05 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 123.546 0.738 . . . . 0.0 111.431 170.299 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 63.7 tttp . . . . . 0 C--O 1.247 0.923 0 C-N-CA 124.601 1.161 . . . . 0.0 108.254 -173.533 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 58.5 ttm . . . . . 0 N--CA 1.484 1.256 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 59.8 m -76.21 47.07 0.44 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.373 1.469 . . . . 0.0 112.498 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.0 pt -61.14 160.02 2.0 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 123.591 0.756 . . . . 0.0 109.648 170.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.25 42.05 0.17 Allowed Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.673 -0.571 . . . . 0.0 111.673 -175.626 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.3 t -146.69 151.94 43.77 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 -169.599 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_exo -54.92 157.56 12.86 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 122.153 1.902 . . . . 0.0 112.728 169.535 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.25 172.49 34.71 Favored Glycine 0 CA--C 1.526 0.767 0 C-N-CA 124.474 1.035 . . . . 0.0 110.765 174.206 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -119.81 130.6 54.99 Favored 'General case' 0 CA--C 1.522 -0.108 0 C-N-CA 124.023 0.929 . . . . 0.0 109.032 -176.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.4 mt -69.3 130.26 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 22.3 mmt85 -119.8 -31.73 4.44 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 118.564 -0.731 . . . . 0.0 111.274 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 m -146.93 153.68 40.38 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 20.1 mt -132.49 141.67 44.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 177.239 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -122.25 -15.41 7.69 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.057 0.943 . . . . 0.0 111.664 -176.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.77 -135.51 3.6 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 107.12 -2.392 . . . . 0.0 107.12 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -66.52 5.0 0.65 Allowed 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 123.972 0.909 . . . . 0.0 113.031 169.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -133.45 153.05 51.94 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 126.138 1.775 . . . . 0.0 107.799 178.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.77 158.09 43.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.763 1.225 . . . . 0.0 110.254 -171.443 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.73 122.72 37.63 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 170.345 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.2 t -125.46 123.45 64.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 -173.694 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -67.71 128.24 35.74 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 172.13 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -128.42 124.19 61.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 171.142 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.3 m 50.16 26.45 2.15 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 125.304 1.441 . . . . 0.0 114.376 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.69 -1.33 36.43 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-O 118.451 -1.194 . . . . 0.0 113.766 172.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.6 mm -134.21 132.04 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 119.451 1.625 . . . . 0.0 107.279 -173.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -66.53 140.13 57.97 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.932 0.396 . . . . 0.0 110.526 178.534 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 20.6 mmt-85 -126.43 149.01 49.55 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.531 1.932 . . . . 0.0 106.789 169.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -80.01 136.07 36.51 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 169.49 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -137.76 135.77 45.82 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -176.193 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -79.87 140.12 36.88 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.995 1.318 . . . . 0.0 110.033 174.515 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 42.5 mt -113.98 14.33 18.41 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 124.051 0.941 . . . . 0.0 112.911 -171.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.7 m -52.24 -36.69 53.08 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 120.604 1.547 . . . . 0.0 112.623 -173.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.9 mt -80.74 -6.96 59.17 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 112.927 0.714 . . . . 0.0 112.927 -174.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.6 m -131.98 -17.56 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 119.476 1.034 . . . . 0.0 112.452 -174.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.14 151.54 5.27 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.601 1.096 . . . . 0.0 110.947 -174.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.8 p -74.31 -18.6 60.68 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.558 1.143 . . . . 0.0 112.836 179.742 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.5 m -124.01 150.07 45.31 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.492 1.117 . . . . 0.0 109.442 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.09 161.86 27.1 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.447 1.099 . . . . 0.0 110.625 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -45.98 -41.27 11.56 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.078 1.751 . . . . 0.0 112.087 170.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 30.9 t30 -65.84 -14.72 61.97 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.53 1.132 . . . . 0.0 112.943 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.82 35.14 5.47 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-O 119.027 -0.874 . . . . 0.0 113.835 169.541 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -142.75 164.22 33.79 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 118.566 1.183 . . . . 0.0 109.192 172.07 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -51.14 146.4 23.17 Favored 'Trans proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.599 2.866 . . . . 0.0 112.508 175.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -71.06 18.72 0.06 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 114.243 1.201 . . . . 0.0 114.243 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.6 m -58.0 138.09 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 O-C-N 120.234 -1.541 . . . . 0.0 110.005 -176.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.21 -17.61 17.33 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.465 -1.186 . . . . 0.0 113.537 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.9 mt-30 -70.44 161.11 31.13 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.491 1.646 . . . . 0.0 109.447 175.215 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 56.2 m95 -106.21 157.45 17.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -144.65 142.85 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.796 1.239 . . . . 0.0 107.711 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -86.64 116.47 24.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 103.781 -2.674 . . . . 0.0 103.781 169.029 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 31.7 m -116.98 137.04 52.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -171.567 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.93 139.15 36.1 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 33.6 m 45.46 27.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.88 0 C-N-CA 126.457 1.903 . . . . 0.0 115.453 172.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 97.81 7.32 56.65 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.069 176.294 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.13 141.78 51.08 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 119.706 1.753 . . . . 0.0 109.394 -177.415 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.16 114.45 14.83 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 169.283 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.9 mmt -88.59 -26.22 22.06 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 122.911 0.484 . . . . 0.0 110.762 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 66.1 m -155.19 156.29 35.43 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 124.714 1.206 . . . . 0.0 108.687 171.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 137.72 34.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 172.706 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 pt -140.11 159.95 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 C-N-CA 124.55 1.14 . . . . 0.0 110.419 -169.487 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -81.02 169.07 17.96 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.603 0.761 . . . . 0.0 110.305 173.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -69.38 -30.34 68.3 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -170.25 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.19 -41.45 61.41 Favored 'General case' 0 N--CA 1.461 0.102 0 O-C-N 121.024 -1.047 . . . . 0.0 109.79 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -61.91 -41.36 97.82 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.565 0.746 . . . . 0.0 109.65 174.64 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.78 -49.05 77.9 Favored 'General case' 0 C--N 1.34 0.177 0 O-C-N 121.934 -0.479 . . . . 0.0 110.807 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -64.6 -38.58 91.51 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 118.977 -0.535 . . . . 0.0 111.354 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -64.73 -41.54 95.88 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 118.969 0.804 . . . . 0.0 110.856 176.409 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 24.2 m -68.01 -37.48 81.47 Favored 'General case' 0 CA--C 1.539 0.553 0 O-C-N 122.02 -0.425 . . . . 0.0 110.328 178.054 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 37.5 mt -62.74 -44.71 95.5 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.43 -0.794 . . . . 0.0 109.761 174.613 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -62.06 -40.74 96.83 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 118.775 0.716 . . . . 0.0 111.131 177.452 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.39 -34.42 77.68 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.897 -0.502 . . . . 0.0 111.83 175.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -75.5 -39.2 58.84 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.761 0.824 . . . . 0.0 110.66 177.523 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -67.03 -29.75 69.64 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.737 0.815 . . . . 0.0 111.382 175.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -58.43 141.3 51.99 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 172.184 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 9.7 mmt 64.67 8.74 4.65 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 125.67 1.588 . . . . 0.0 114.201 -178.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -141.33 -41.6 0.38 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 119.905 1.23 . . . . 0.0 112.919 -170.396 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -133.37 -22.57 1.96 Allowed 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 124.482 1.113 . . . . 0.0 111.835 -170.024 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 30.1 m -64.69 -16.2 19.21 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 O-C-N 121.688 -0.632 . . . . 0.0 111.088 169.243 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -134.91 157.57 76.81 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 127.908 2.483 . . . . 0.0 105.554 170.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -74.93 31.29 0.36 Allowed 'Trans proline' 0 CA--C 1.544 1.021 0 C-N-CA 123.842 3.028 . . . . 0.0 113.86 -171.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -60.53 -39.45 87.9 Favored 'General case' 0 N--CA 1.465 0.278 0 O-C-N 120.711 -1.243 . . . . 0.0 111.129 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.9 p -59.41 -41.57 84.88 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 C-N-CA 123.106 0.562 . . . . 0.0 110.56 171.348 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -64.69 -39.59 96.81 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.269 -0.733 . . . . 0.0 111.269 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -60.08 -18.07 44.19 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.889 0.876 . . . . 0.0 112.918 177.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -102.66 -46.49 4.71 Favored 'General case' 0 CA--C 1.528 0.115 0 C-N-CA 124.402 1.081 . . . . 0.0 110.212 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 46.5 tp -64.14 -34.64 78.53 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 123.485 0.714 . . . . 0.0 111.781 -174.774 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -135.05 -20.25 1.7 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.503 1.121 . . . . 0.0 112.346 -177.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.84 -165.32 35.25 Favored Glycine 0 CA--C 1.527 0.818 0 CA-C-O 122.214 0.897 . . . . 0.0 113.388 -172.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 36.3 mm-40 -70.58 -19.53 62.85 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.977 0.911 . . . . 0.0 112.323 -169.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -80.78 -9.53 59.8 Favored 'General case' 0 CA--C 1.546 0.793 0 CA-C-N 118.515 0.598 . . . . 0.0 111.15 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 54.8 tttp . . . . . 0 C--O 1.251 1.154 0 C-N-CA 124.716 1.206 . . . . 0.0 110.601 178.285 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 97.5 mmm . . . . . 0 N--CA 1.484 1.234 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 63.7 m -78.39 56.36 1.73 Allowed 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.808 1.243 . . . . 0.0 111.485 -176.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 34.8 pt -126.39 21.74 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 C-N-CA 125.006 1.322 . . . . 0.0 111.791 -172.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.77 91.69 0.27 Allowed Glycine 0 CA--C 1.522 0.475 0 C-N-CA 125.833 1.682 . . . . 0.0 110.738 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.9 t -139.51 144.21 38.74 Favored Pre-proline 0 CA--C 1.541 0.615 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 -177.106 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.35 160.4 47.06 Favored 'Trans proline' 0 CA--C 1.534 0.516 0 C-N-CA 122.534 2.156 . . . . 0.0 111.957 174.526 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.04 172.92 40.0 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 171.109 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -95.34 137.04 34.93 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.9 mt -69.94 93.3 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 169.631 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -79.55 -33.59 41.74 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 119.108 -0.472 . . . . 0.0 110.38 -170.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 m -149.48 152.73 36.12 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.419 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.3 mt -131.69 144.41 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -124.02 -20.44 5.35 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.187 0.995 . . . . 0.0 111.967 -178.767 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.8 -129.54 1.89 Allowed Glycine 0 C--N 1.335 0.499 0 N-CA-C 107.226 -2.35 . . . . 0.0 107.226 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.6 p-10 -65.91 -3.65 5.54 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 117.599 0.699 . . . . 0.0 112.559 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -125.38 157.43 36.83 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.763 1.225 . . . . 0.0 109.602 175.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -154.69 160.42 41.36 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.52 1.528 . . . . 0.0 109.911 -171.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.17 112.17 24.58 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.611 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.7 t -92.13 124.11 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 170.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -84.91 108.7 17.68 Favored 'General case' 0 C--O 1.233 0.218 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 169.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.0 t -83.19 61.02 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 125.858 1.663 . . . . 0.0 107.046 174.511 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 62.5 m 38.42 45.95 0.89 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 128.044 2.538 . . . . 0.0 114.41 178.384 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 153.22 -17.12 0.69 Allowed Glycine 0 CA--C 1.526 0.724 0 CA-C-O 119.093 -0.837 . . . . 0.0 113.806 177.501 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.6 tp -143.83 145.08 22.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 173.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -94.72 134.37 37.4 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.601 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 51.2 mtp180 -126.42 118.99 26.13 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -70.49 131.01 43.39 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 173.466 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.5 m -139.79 155.3 24.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.11 0.964 . . . . 0.0 109.374 179.223 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -84.35 146.48 27.68 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.721 0.808 . . . . 0.0 109.524 171.342 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 mt -112.25 3.17 16.95 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.424 1.09 . . . . 0.0 112.573 -173.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.6 m -59.03 -26.17 64.33 Favored 'General case' 0 CA--C 1.544 0.725 0 CA-C-N 120.595 1.543 . . . . 0.0 112.227 -173.207 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.7 mt -65.67 -19.96 66.11 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 121.608 -0.683 . . . . 0.0 112.708 176.508 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -129.25 -10.92 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.785 1.234 . . . . 0.0 112.013 -174.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.35 139.94 0.96 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 125.365 1.46 . . . . 0.0 109.916 -170.232 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 18.3 m -71.11 -12.17 61.36 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.934 -0.745 . . . . 0.0 112.833 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.4 m -119.36 146.42 45.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.655 1.182 . . . . 0.0 109.311 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -79.94 160.55 25.92 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 124.156 0.982 . . . . 0.0 110.087 176.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.7 -33.27 22.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.216 1.406 . . . . 0.0 112.421 173.18 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -67.44 -13.4 62.0 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.09 31.52 5.9 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 118.893 -0.948 . . . . 0.0 114.428 169.323 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -146.11 167.57 13.75 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 118.813 1.307 . . . . 0.0 109.003 172.087 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -50.59 150.75 11.42 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 123.394 2.729 . . . . 0.0 112.837 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 87.4 mtt-85 -74.21 20.99 0.1 Allowed 'General case' 0 CA--C 1.541 0.627 0 O-C-N 121.143 -0.973 . . . . 0.0 113.332 177.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.6 m -56.26 131.94 19.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 O-C-N 120.783 -1.198 . . . . 0.0 109.658 -176.458 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.97 -11.88 55.64 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 118.055 -1.414 . . . . 0.0 113.968 177.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -70.34 169.43 13.89 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.631 1.716 . . . . 0.0 109.692 172.124 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -118.56 149.58 41.1 Favored 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.686 0.794 . . . . 0.0 109.58 -178.21 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -147.51 156.51 9.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 124.555 1.142 . . . . 0.0 109.417 -175.137 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 92.9 mt -84.47 140.12 31.71 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 168.255 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.1 m -132.04 127.33 57.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.744 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -144.07 -29.47 0.49 Allowed 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -169.391 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.8 m -136.2 20.37 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 118.665 0.666 . . . . 0.0 112.362 -169.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.59 10.16 73.82 Favored Glycine 0 CA--C 1.532 1.149 0 O-C-N 121.45 -0.781 . . . . 0.0 112.629 -175.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 70.1 m-85 -135.44 153.58 51.73 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.222 1.409 . . . . 0.0 107.937 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.91 105.37 2.79 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 169.024 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.09 -39.28 75.66 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.882 0.873 . . . . 0.0 110.929 -170.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.5 m -160.29 155.21 24.4 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 125.369 1.467 . . . . 0.0 108.563 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.1 t -78.08 146.72 7.82 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 169.802 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.4 pt -138.26 161.15 31.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 C-N-CA 125.502 1.521 . . . . 0.0 108.53 177.732 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -73.97 163.58 27.72 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-O 121.932 0.872 . . . . 0.0 110.583 174.624 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -57.68 -40.97 80.66 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 126.402 1.881 . . . . 0.0 111.809 178.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.87 -34.72 29.93 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.801 0.841 . . . . 0.0 110.801 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 60.7 tt0 -62.52 -34.35 76.73 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.641 1.176 . . . . 0.0 110.287 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.26 -43.03 87.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 122.002 -0.437 . . . . 0.0 111.359 171.325 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.8 mmt85 -69.7 -41.33 75.54 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 118.416 0.553 . . . . 0.0 109.609 -177.404 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.13 -40.24 93.05 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 122.54 0.336 . . . . 0.0 110.67 175.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -66.61 -41.26 88.69 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.154 0.582 . . . . 0.0 110.57 177.196 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.6 mt -62.18 -40.61 96.63 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 119.448 1.022 . . . . 0.0 110.313 175.296 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -64.79 -41.79 95.56 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 118.113 0.415 . . . . 0.0 110.843 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.96 -41.77 97.0 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 118.56 0.618 . . . . 0.0 111.083 174.371 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -61.0 -52.76 63.65 Favored 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 123.824 0.85 . . . . 0.0 109.804 -179.172 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -66.53 -31.33 71.98 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.369 0.531 . . . . 0.0 111.588 178.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -66.12 -38.53 88.4 Favored 'General case' 0 CA--C 1.519 -0.213 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 -177.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -51.84 -57.81 8.27 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.233 1.013 . . . . 0.0 110.853 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -73.5 -18.87 61.05 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.852 -0.594 . . . . 0.0 112.283 -178.368 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -73.69 -31.54 63.48 Favored 'General case' 0 CA--C 1.536 0.404 0 CA-C-N 119.371 0.987 . . . . 0.0 111.982 174.449 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.7 m -105.1 -15.91 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 118.877 0.762 . . . . 0.0 112.553 -175.343 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 81.6 mm-40 -130.56 55.47 19.1 Favored Pre-proline 0 CA--C 1.543 0.687 0 C-N-CA 124.498 1.119 . . . . 0.0 110.072 173.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -62.31 -22.99 74.93 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.575 2.183 . . . . 0.0 112.72 -176.403 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -57.48 -23.05 47.69 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 124.862 1.265 . . . . 0.0 112.858 176.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.73 -30.49 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 124.153 0.981 . . . . 0.0 110.226 172.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -54.81 -38.42 64.53 Favored Glycine 0 CA--C 1.528 0.848 0 C-N-CA 124.09 0.852 . . . . 0.0 112.47 175.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -66.64 -7.78 22.9 Favored 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 118.389 1.095 . . . . 0.0 113.576 178.62 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 59.1 tp -117.22 -43.47 2.84 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 124.314 1.046 . . . . 0.0 110.061 178.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 46.4 tp -66.93 -32.11 73.14 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.849 0.859 . . . . 0.0 111.28 177.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -136.56 33.22 2.74 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.021 1.728 . . . . 0.0 109.677 -176.875 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -160.5 -167.08 20.52 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 124.224 0.916 . . . . 0.0 110.959 -176.637 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 75.9 mm-40 -125.94 29.12 5.96 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.695 1.198 . . . . 0.0 110.891 -169.598 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 31.4 tp10 -55.37 -27.72 49.3 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.133 0.973 . . . . 0.0 112.774 179.43 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 87.4 tttt . . . . . 0 C--O 1.249 1.045 0 N-CA-C 106.73 -1.582 . . . . 0.0 106.73 173.075 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 tpt . . . . . 0 N--CA 1.482 1.145 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 92.0 m -135.86 155.13 50.79 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 125.007 1.323 . . . . 0.0 108.736 178.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.8 pt -139.34 46.56 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 126.105 1.762 . . . . 0.0 108.891 -175.501 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -65.66 68.4 0.11 Allowed Glycine 0 CA--C 1.528 0.894 0 C-N-CA 127.196 2.331 . . . . 0.0 113.789 -174.376 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.2 t -146.76 148.23 32.53 Favored Pre-proline 0 CA--C 1.544 0.715 0 C-N-CA 126.249 1.82 . . . . 0.0 106.998 -171.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -57.44 163.79 8.03 Favored 'Trans proline' 0 CA--C 1.536 0.609 0 C-N-CA 122.432 2.088 . . . . 0.0 112.426 169.144 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -160.46 163.33 33.93 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.327 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 58.3 tt0 -116.93 131.79 56.86 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 94.6 mt -70.36 117.66 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.475 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -90.19 -32.77 16.47 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 118.666 -0.683 . . . . 0.0 110.502 172.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.12 152.92 35.51 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -170.115 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.8 mt -132.43 141.03 46.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 172.107 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -120.84 -18.86 7.51 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.425 1.09 . . . . 0.0 111.47 -176.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.22 -126.6 1.36 Allowed Glycine 0 C--N 1.336 0.538 0 N-CA-C 107.146 -2.382 . . . . 0.0 107.146 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -67.28 -8.63 33.52 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 117.052 0.426 . . . . 0.0 112.11 169.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -119.81 159.44 24.57 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 125.486 1.514 . . . . 0.0 109.538 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.04 177.09 10.51 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 126.177 1.791 . . . . 0.0 109.568 -170.085 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -129.31 126.97 40.17 Favored 'General case' 0 CA--C 1.516 -0.363 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.755 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 1.6 m -119.47 138.7 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 C-N-CA 125.001 1.32 . . . . 0.0 108.357 -177.343 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -85.36 107.88 17.57 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 104.497 -2.408 . . . . 0.0 104.497 168.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -81.49 57.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 C-N-CA 125.362 1.465 . . . . 0.0 107.971 -176.359 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 50.7 m 45.42 43.34 8.53 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.007 2.123 . . . . 0.0 113.159 -177.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 170.28 -42.57 0.2 Allowed Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.303 -0.72 . . . . 0.0 112.641 175.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.4 pt -141.8 150.17 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 C-N-CA 124.562 1.145 . . . . 0.0 109.514 -179.183 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -76.99 138.25 39.49 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.703 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -136.77 148.55 47.3 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 124.927 1.291 . . . . 0.0 109.307 173.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -68.05 148.22 51.3 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 169.123 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.48 143.27 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 173.426 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -92.36 145.23 24.63 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.593 0.757 . . . . 0.0 109.44 170.761 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 46.9 mt -112.53 13.48 20.08 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 118.2 -0.905 . . . . 0.0 112.959 -170.123 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 46.7 m -50.66 -37.13 39.15 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 120.889 1.677 . . . . 0.0 112.539 -178.197 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.8 mt -75.74 -11.71 60.04 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.41 -17.86 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 119.445 1.021 . . . . 0.0 113.343 -169.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.35 146.44 3.03 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.698 1.142 . . . . 0.0 111.139 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 p -75.88 -17.68 59.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.662 1.185 . . . . 0.0 112.552 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.2 m -112.84 161.95 16.36 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.432 1.093 . . . . 0.0 109.2 174.008 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -106.72 -179.41 3.93 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 124.701 1.2 . . . . 0.0 113.171 -169.397 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 23.0 mp0 -67.41 -14.37 62.87 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.895 2.078 . . . . 0.0 112.627 -176.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.4 m-80 -96.7 -37.32 10.36 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.176 0.99 . . . . 0.0 110.185 -178.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.79 28.59 1.04 Allowed Glycine 0 CA--C 1.53 1.025 0 C-N-CA 125.299 1.428 . . . . 0.0 112.507 178.257 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -127.63 158.24 70.68 Favored Pre-proline 0 CA--C 1.538 0.5 0 CA-C-N 119.149 1.474 . . . . 0.0 109.316 -176.722 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.36 144.43 85.81 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.867 1.712 . . . . 0.0 109.548 174.163 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.9 mtt-85 -69.54 13.14 0.14 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 114.619 1.34 . . . . 0.0 114.619 -174.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.6 t -53.62 131.02 15.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-N 120.379 1.445 . . . . 0.0 108.446 176.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.36 -14.59 54.08 Favored Glycine 0 CA--C 1.53 0.978 0 CA-C-O 118.531 -1.15 . . . . 0.0 113.589 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -77.05 162.02 27.84 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 119.715 1.758 . . . . 0.0 109.195 176.397 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -106.43 151.25 25.17 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.0 m -140.78 150.38 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 177.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -88.36 124.99 34.47 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 103.662 -2.718 . . . . 0.0 103.662 168.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.86 156.99 18.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.761 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 6.3 t-80 -154.02 -32.83 0.11 Allowed 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 123.0 0.52 . . . . 0.0 111.315 -175.038 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.2 m -133.79 -163.24 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 170.183 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -68.06 19.91 0.33 Allowed Glycine 0 CA--C 1.538 1.471 0 CA-C-N 119.64 1.109 . . . . 0.0 114.817 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -133.9 139.82 46.42 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.768 1.627 . . . . 0.0 107.956 -179.298 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.06 116.11 10.05 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 170.164 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 86.6 mmm -74.33 -43.69 55.63 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.02 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.1 p -155.71 153.03 29.31 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.781 0.833 . . . . 0.0 110.067 179.297 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.6 t -79.65 143.38 12.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 169.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.2 pt -138.55 160.76 31.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 124.175 0.99 . . . . 0.0 108.849 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 -80.62 164.91 22.52 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -53.91 -41.85 68.09 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 123.608 0.763 . . . . 0.0 111.439 170.456 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.62 -37.08 85.96 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.857 0.463 . . . . 0.0 110.99 -177.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -71.1 -38.84 72.36 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 177.614 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.98 -48.7 80.6 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 118.415 0.552 . . . . 0.0 110.157 174.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.3 mtt180 -61.62 -43.26 99.18 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 123.489 0.715 . . . . 0.0 110.45 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.93 -41.35 99.46 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.688 0.676 . . . . 0.0 111.295 177.167 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.5 m -64.69 -41.47 96.02 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 122.807 0.443 . . . . 0.0 110.096 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 83.7 mt -66.51 -36.85 83.72 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 119.053 0.842 . . . . 0.0 110.941 177.222 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -66.05 -40.66 91.12 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 118.607 0.64 . . . . 0.0 110.822 177.273 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.03 -52.37 63.14 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 122.704 0.402 . . . . 0.0 109.997 173.442 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 6.6 tt -55.43 -52.03 64.94 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 124.44 1.096 . . . . 0.0 109.984 -175.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -65.27 -15.63 62.7 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -172.118 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -121.69 -10.48 8.76 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 119.594 1.088 . . . . 0.0 113.79 -176.768 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 72.1 mtm -126.63 -5.71 6.39 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 119.423 1.01 . . . . 0.0 113.141 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -125.49 -48.82 1.67 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 119.147 0.885 . . . . 0.0 109.721 175.237 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -79.51 -16.99 55.06 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 122.73 0.412 . . . . 0.0 111.389 170.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . 0.293 35.6 m 45.35 44.17 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 C-N-CA 126.992 2.117 . . . . 0.0 113.43 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 81.89 141.11 0.06 OUTLIER Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 128.948 2.899 . . . . 0.0 111.313 169.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' PRO . . . . . 0.452 ' HA ' ' H ' ' A' ' 83' ' ' ALA . 37.5 Cg_endo -63.95 -23.19 68.19 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.543 2.162 . . . . 0.0 112.731 -172.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -53.98 -20.94 7.01 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 125.696 1.598 . . . . 0.0 113.238 175.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.6 p -132.33 -36.25 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 C-N-CA 123.365 0.666 . . . . 0.0 111.108 170.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -67.09 -54.67 19.78 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 119.507 1.049 . . . . 0.0 111.64 -176.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.452 ' H ' ' HA ' ' A' ' 79' ' ' PRO . . . -67.92 -34.73 77.18 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 117.551 0.675 . . . . 0.0 110.492 178.034 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 19.7 tp -58.76 -46.25 87.9 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 123.43 0.692 . . . . 0.0 110.696 176.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.3 tt -69.42 -41.63 76.1 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 124.11 0.964 . . . . 0.0 110.66 177.137 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 82.6 t80 -60.52 -35.12 75.21 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 118.494 0.588 . . . . 0.0 111.332 178.339 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -78.44 0.63 74.76 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 124.539 1.066 . . . . 0.0 113.094 175.062 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 55.01 26.5 8.1 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.938 2.095 . . . . 0.0 112.211 -176.325 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -73.86 -20.58 60.39 Favored 'General case' 0 CA--C 1.542 0.644 0 O-C-N 121.561 -0.712 . . . . 0.0 110.41 175.549 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt . . . . . 0 C--O 1.248 1.025 0 C-N-CA 127.219 2.208 . . . . 0.0 106.367 172.226 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.905 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.9 t -139.15 141.13 28.59 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 124.317 1.047 . . . . 0.0 108.849 -169.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -59.26 157.63 29.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.887 2.391 . . . . 0.0 112.919 169.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.32 172.67 40.17 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 169.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -99.61 135.73 40.6 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.47 79.97 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 170.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 7.5 tpm_? -80.09 -24.67 40.42 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.561 -0.712 . . . . 0.0 112.406 -169.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.57 158.58 43.74 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -130.0 146.3 34.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 176.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -121.78 -23.64 5.46 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.111 0.965 . . . . 0.0 111.734 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.25 -126.8 1.35 Allowed Glycine 0 C--N 1.333 0.403 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 178.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.4 t30 -63.8 -29.21 70.44 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 117.651 0.726 . . . . 0.0 110.303 169.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.7 mm100 -86.44 151.89 23.14 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.56 0.695 . . . . 0.0 109.235 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.56 166.02 25.4 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.034 1.334 . . . . 0.0 109.568 174.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -114.48 78.25 1.14 Allowed 'General case' 0 C--O 1.234 0.266 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 -173.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.4 t -74.19 123.39 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 -175.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -75.04 107.92 7.43 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 169.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.52 61.22 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 32.0 m 45.94 43.96 10.82 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 127.205 2.202 . . . . 0.0 113.696 176.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.63 -36.66 0.16 Allowed Glycine 0 CA--C 1.525 0.703 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.643 176.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -153.67 152.9 9.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.4 mt-30 -77.47 138.72 39.4 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.059 177.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -117.85 144.95 44.95 Favored 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 126.044 1.737 . . . . 0.0 107.196 171.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -74.58 129.93 38.63 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 169.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.8 t -137.01 136.14 47.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -176.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -82.4 126.26 31.98 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.166 1.386 . . . . 0.0 109.072 176.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 29.4 mt -100.76 10.95 40.51 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 117.95 -1.024 . . . . 0.0 112.971 -175.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 32.4 m -50.84 -36.62 38.5 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 121.285 1.857 . . . . 0.0 112.395 -174.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -74.49 -10.37 59.49 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.5 m -132.2 -17.61 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 119.445 1.021 . . . . 0.0 112.57 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.18 145.91 1.02 Allowed Glycine 0 CA--C 1.529 0.955 0 C-N-CA 125.175 1.369 . . . . 0.0 110.654 -171.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.4 m -73.63 -5.3 39.57 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.734 -0.862 . . . . 0.0 113.067 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.3 m -131.97 151.79 51.51 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.362 1.065 . . . . 0.0 110.027 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -66.08 165.64 13.14 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.876 2.071 . . . . 0.0 109.71 169.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.52 -37.5 57.69 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.29 1.436 . . . . 0.0 112.247 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -85.9 10.21 14.6 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.8 0.84 . . . . 0.0 112.052 -178.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.67 5.27 88.4 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.623 1.106 . . . . 0.0 113.382 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -70.1 132.53 88.24 Favored Pre-proline 0 CA--C 1.537 0.469 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -65.86 141.44 65.11 Favored 'Trans proline' 0 N--CA 1.458 -0.56 0 CA-C-N 121.321 1.507 . . . . 0.0 109.107 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.9 mtt-85 -72.77 8.59 1.43 Allowed 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 114.401 1.26 . . . . 0.0 114.401 -173.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.06 125.46 7.14 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 120.128 1.331 . . . . 0.0 108.712 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.67 -19.32 55.12 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.873 1.225 . . . . 0.0 113.241 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -70.12 167.45 17.72 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 119.061 1.431 . . . . 0.0 108.903 172.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 46.9 m95 -116.04 162.75 16.93 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.782 -0.574 . . . . 0.0 109.532 -179.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -156.61 146.21 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -169.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 83.1 mt -83.82 112.13 19.83 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 169.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.68 127.81 39.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 173.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -140.98 130.23 23.57 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 173.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.5 m 41.68 35.8 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 126.195 1.798 . . . . 0.0 114.541 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.8 6.93 79.11 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.076 -0.847 . . . . 0.0 114.092 175.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -122.41 154.78 37.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.951 1.376 . . . . 0.0 109.694 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.81 104.92 3.58 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 169.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.07 -47.84 60.28 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.261 0.482 . . . . 0.0 109.755 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.1 m -152.05 136.18 16.58 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.92 1.288 . . . . 0.0 108.017 178.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.2 p -84.13 138.72 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 169.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.4 pt -141.93 162.98 19.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 124.652 1.181 . . . . 0.0 110.24 -170.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -77.02 166.18 23.65 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 123.768 0.827 . . . . 0.0 109.84 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.59 -43.14 84.41 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.903 0.881 . . . . 0.0 110.629 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.49 -38.64 87.71 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.002 0.521 . . . . 0.0 110.829 -175.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -67.04 -44.36 80.41 Favored 'General case' 0 C--O 1.232 0.145 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.04 -48.58 79.62 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.9 tmm_? -58.77 -46.81 86.64 Favored 'General case' 0 C--N 1.334 -0.104 0 C-N-CA 124.543 1.137 . . . . 0.0 110.059 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -63.22 -43.12 99.01 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 118.492 0.587 . . . . 0.0 111.292 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -64.16 -42.01 96.92 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 178.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 39.5 mt -65.16 -40.42 94.32 Favored 'General case' 0 CA--C 1.522 -0.13 0 C-N-CA 123.82 0.848 . . . . 0.0 110.599 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -63.64 -41.21 98.26 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 122.982 0.513 . . . . 0.0 110.873 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -66.74 -48.38 69.33 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.276 0.23 . . . . 0.0 110.607 174.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 10.4 tt . . . . . 0 C--O 1.231 0.108 0 C-N-CA 124.433 1.093 . . . . 0.0 111.231 -173.231 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.711 0 N-CA-C 107.831 -2.108 . . . . 0.0 107.831 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.8 m -145.43 158.13 51.31 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 126.473 1.909 . . . . 0.0 108.191 -169.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.79 162.43 26.87 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 121.894 1.729 . . . . 0.0 110.659 169.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.32 164.35 37.14 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 169.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -89.43 127.28 35.82 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 72.6 mt -63.64 112.16 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.9 tpt85 -109.71 -30.63 7.79 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 118.113 -0.946 . . . . 0.0 110.994 -169.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 11.9 p -144.96 158.12 43.91 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 169.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -132.54 141.91 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 105.31 -2.107 . . . . 0.0 105.31 176.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -116.13 -21.71 9.28 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.448 1.099 . . . . 0.0 111.447 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.3 -126.17 1.34 Allowed Glycine 0 C--N 1.334 0.437 0 N-CA-C 106.835 -2.506 . . . . 0.0 106.835 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.0 t30 -62.08 -15.6 46.25 Favored 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 117.37 0.585 . . . . 0.0 112.062 169.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -117.48 156.21 28.39 Favored 'General case' 0 C--O 1.238 0.461 0 O-C-N 121.151 -0.968 . . . . 0.0 109.23 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.39 173.3 13.69 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 125.894 1.678 . . . . 0.0 109.402 -169.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -132.72 109.2 9.52 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 m -84.24 135.25 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 C-N-CA 124.232 1.013 . . . . 0.0 108.605 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -81.11 115.28 20.47 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 169.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 t -87.93 60.59 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 125.427 1.491 . . . . 0.0 107.185 176.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.5 m 50.15 36.42 12.29 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.923 1.689 . . . . 0.0 114.369 176.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.3 -31.86 0.26 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 121.348 -0.845 . . . . 0.0 112.966 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . 0.403 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -138.77 140.45 38.98 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 C-N-CA 125.425 1.49 . . . . 0.0 108.818 179.867 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -77.63 141.98 39.14 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.098 174.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 56.7 mmt-85 -137.53 144.31 42.07 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 125.014 1.326 . . . . 0.0 108.727 172.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -77.5 149.54 34.96 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.655 0.782 . . . . 0.0 111.068 -172.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.79 143.36 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 124.978 1.311 . . . . 0.0 108.82 177.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -92.8 133.17 36.31 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 124.435 1.094 . . . . 0.0 108.77 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.0 mt -105.49 14.52 28.52 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 118.312 -0.851 . . . . 0.0 112.058 -171.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -45.99 -38.03 7.25 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.333 1.424 . . . . 0.0 113.114 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.2 mt -85.41 -3.86 58.98 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.821 0.848 . . . . 0.0 113.02 -172.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.28 -18.36 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.547 1.067 . . . . 0.0 113.02 -177.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.77 143.51 1.22 Allowed Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.063 1.316 . . . . 0.0 110.759 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.2 m -75.37 -8.89 57.88 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 12.5 p -125.21 152.2 44.86 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.548 1.139 . . . . 0.0 109.015 174.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -77.87 172.19 13.84 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.289 1.036 . . . . 0.0 110.349 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -57.59 -34.97 69.8 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.086 0.954 . . . . 0.0 112.213 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 18.0 p30 -80.41 -3.69 50.73 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.285 1.834 . . . . 0.0 113.102 177.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.38 -4.81 67.27 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.552 -1.138 . . . . 0.0 114.157 172.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -66.22 143.15 98.21 Favored Pre-proline 0 CA--C 1.537 0.454 0 CA-C-N 119.677 1.739 . . . . 0.0 109.087 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -64.42 143.09 81.39 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 121.878 1.719 . . . . 0.0 108.857 169.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 83.0 mtt-85 -72.8 1.6 8.27 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -170.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.0 m -50.24 137.89 6.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 120.994 1.725 . . . . 0.0 111.126 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.74 -26.37 18.72 Favored Glycine 0 CA--C 1.53 0.975 0 C-N-CA 124.759 1.171 . . . . 0.0 112.911 178.306 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -76.1 165.8 24.4 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 118.898 1.349 . . . . 0.0 108.404 173.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -105.18 156.52 18.02 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -144.37 135.17 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 57.5 tp -78.39 133.67 37.5 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 22.3 t -116.33 150.97 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 -178.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.37 133.4 24.22 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 125.368 1.467 . . . . 0.0 107.649 171.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.5 m 42.58 33.48 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 C-N-CA 126.211 1.804 . . . . 0.0 114.641 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.2 7.62 82.88 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 118.966 -0.908 . . . . 0.0 114.106 176.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -120.28 143.81 48.13 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 119.117 1.458 . . . . 0.0 108.191 175.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.0 130.42 46.65 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.177 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 28.0 ttt -89.66 -57.88 2.72 Favored 'General case' 0 C--O 1.233 0.236 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 18.5 m -151.99 144.91 24.44 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 124.293 1.037 . . . . 0.0 109.078 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 t -74.12 140.29 17.88 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 105.399 -2.075 . . . . 0.0 105.399 168.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 pt -137.7 160.3 34.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 123.573 0.749 . . . . 0.0 109.821 -173.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -76.96 165.21 24.96 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.691 0.796 . . . . 0.0 109.706 173.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -59.74 -42.83 94.04 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.467 0.707 . . . . 0.0 110.219 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -65.32 -36.38 83.87 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.066 0.547 . . . . 0.0 110.932 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.3 mt-10 -67.7 -35.05 78.09 Favored 'General case' 0 N--CA 1.457 -0.095 0 CA-C-O 119.129 -0.463 . . . . 0.0 110.113 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -47.32 83.67 Favored 'General case' 0 C--N 1.34 0.185 0 CA-C-N 118.95 0.795 . . . . 0.0 110.293 175.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -62.54 -43.55 98.54 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 118.167 0.44 . . . . 0.0 110.725 177.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.75 -40.89 96.71 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 118.131 0.423 . . . . 0.0 111.147 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.8 m -67.07 -42.48 84.64 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.245 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.9 mt -63.94 -39.05 93.26 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 119.204 0.911 . . . . 0.0 110.582 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.94 -46.89 79.69 Favored 'General case' 0 C--O 1.227 -0.091 0 C-N-CA 122.95 0.5 . . . . 0.0 110.585 175.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.41 99.53 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.566 0.621 . . . . 0.0 111.225 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.6 tp . . . . . 0 CA--C 1.528 0.134 0 C-N-CA 123.882 0.873 . . . . 0.0 111.601 -174.331 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.942 0 CA-C-O 119.713 -0.493 . . . . 0.0 112.213 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -146.47 149.5 37.58 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 125.973 1.709 . . . . 0.0 108.184 -172.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -75.05 171.17 18.84 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.232 1.954 . . . . 0.0 112.237 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -156.07 167.84 33.39 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -101.72 136.83 40.9 Favored 'General case' 0 C--O 1.231 0.127 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.5 mt -72.65 82.6 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 125.648 1.579 . . . . 0.0 107.895 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.5 mmt85 -76.6 -27.56 55.83 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.607 -0.683 . . . . 0.0 111.565 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.14 152.18 35.66 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -176.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 63.6 mt -129.65 144.75 37.14 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -121.13 -20.16 6.88 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 124.446 1.098 . . . . 0.0 111.835 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.408 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 164.05 -127.48 1.67 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 106.607 -2.597 . . . . 0.0 106.607 -178.598 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -70.38 14.3 0.13 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 124.462 1.105 . . . . 0.0 112.004 169.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.408 ' H ' ' C ' ' A' ' 14' ' ' GLY . 37.7 mt-30 -140.11 153.8 46.82 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 127.66 2.384 . . . . 0.0 106.636 -176.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.65 167.18 22.68 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.261 1.425 . . . . 0.0 109.106 178.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -121.24 76.31 1.23 Allowed 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 -174.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.5 m -73.03 136.68 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -170.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -79.15 117.72 20.44 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 171.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.4 t -85.04 50.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 125.059 1.343 . . . . 0.0 107.724 177.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 79.3 m 40.59 49.57 2.73 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.166 2.186 . . . . 0.0 113.371 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 176.64 -38.92 0.1 OUTLIER Glycine 0 CA--C 1.526 0.748 0 CA-C-O 119.531 -0.594 . . . . 0.0 112.24 175.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.0 tp -156.26 154.86 5.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 175.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.5 mt-30 -76.94 143.28 39.63 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 122.801 0.441 . . . . 0.0 109.954 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.19 138.17 51.57 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 169.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -73.85 133.83 43.23 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 78.7 t -140.95 130.63 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.684 1.594 . . . . 0.0 107.001 -173.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.22 140.74 45.27 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 124.863 1.265 . . . . 0.0 109.92 175.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.3 mt -113.65 11.85 18.29 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.861 0.864 . . . . 0.0 112.886 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.9 m -53.34 -34.74 58.68 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 120.833 1.651 . . . . 0.0 112.432 -175.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 86.4 mt -73.91 -12.86 60.79 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -176.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 m -133.43 -19.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 119.323 0.965 . . . . 0.0 112.897 -171.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.33 147.03 0.89 Allowed Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.098 1.332 . . . . 0.0 110.831 -171.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.2 m -76.57 -4.38 42.54 Favored 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.842 -0.799 . . . . 0.0 113.002 179.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.1 m -131.94 151.25 51.83 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 124.349 1.059 . . . . 0.0 109.965 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -65.77 165.59 12.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.945 2.098 . . . . 0.0 109.864 169.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -52.96 -37.49 61.18 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.317 1.447 . . . . 0.0 112.152 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -85.35 9.82 14.4 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.721 0.809 . . . . 0.0 112.015 -178.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.87 4.96 88.37 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 124.581 1.086 . . . . 0.0 113.464 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -69.87 132.28 88.82 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -65.92 141.2 63.76 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 CA-C-N 121.303 1.501 . . . . 0.0 109.011 174.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -72.45 13.72 0.32 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -172.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -54.08 129.27 14.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-N 120.227 1.376 . . . . 0.0 108.639 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.65 -17.64 55.61 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.827 1.203 . . . . 0.0 113.414 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -73.34 169.31 17.41 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.511 1.655 . . . . 0.0 109.162 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.7 m95 -120.16 156.59 30.77 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.947 0.899 . . . . 0.0 109.123 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 2.8 m -143.2 144.92 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 123.435 0.694 . . . . 0.0 109.402 178.296 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 59.3 mt -72.89 147.97 44.82 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 168.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.9 t -131.96 152.68 37.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -130.82 -60.08 0.98 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.974 0.91 . . . . 0.0 109.635 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.3 m -138.36 38.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 123.941 0.896 . . . . 0.0 110.614 -169.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.08 14.66 60.25 Favored Glycine 0 CA--C 1.528 0.906 0 CA-C-O 119.406 -0.663 . . . . 0.0 113.046 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -128.22 137.33 51.98 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 175.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.32 111.74 5.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 172.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 15.5 tpt -71.79 -49.01 42.66 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 118.031 0.378 . . . . 0.0 110.303 -175.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 13.5 m -152.55 151.1 30.27 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 124.959 1.304 . . . . 0.0 108.603 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 18.4 t -78.79 141.01 15.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 171.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.7 pt -138.9 -169.69 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 126.064 1.746 . . . . 0.0 108.794 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -126.97 -179.29 4.76 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.019 1.327 . . . . 0.0 110.125 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -54.92 -44.9 74.64 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.161 0.985 . . . . 0.0 111.249 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.31 -49.22 67.78 Favored 'General case' 0 C--O 1.231 0.131 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -172.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 26.0 mm-40 -64.84 -38.76 92.07 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.776 0.43 . . . . 0.0 110.28 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.41 -51.28 66.43 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 118.372 0.533 . . . . 0.0 110.61 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 63.3 mtt85 -66.91 -36.95 83.43 Favored 'General case' 0 CA--C 1.523 -0.064 0 CA-C-O 118.489 -0.767 . . . . 0.0 110.633 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.72 -43.66 98.42 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 119.121 0.873 . . . . 0.0 110.909 175.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.4 m -64.05 -45.9 86.79 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 122.979 0.512 . . . . 0.0 109.996 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 57.9 mt -64.33 -39.22 93.47 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 118.252 0.478 . . . . 0.0 110.858 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.6 -48.48 72.16 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 123.2 0.6 . . . . 0.0 110.319 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.01 88.54 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 117.872 0.305 . . . . 0.0 111.26 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? . . . . . 0 C--N 1.339 0.117 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.047 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.757 0 N-CA-C 107.114 -2.394 . . . . 0.0 107.114 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.3 m -140.13 166.73 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.564 1.545 . . . . 0.0 109.675 -168.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -54.9 153.54 24.8 Favored 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.565 2.176 . . . . 0.0 113.175 169.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -159.88 164.31 34.14 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 169.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -110.96 130.21 55.65 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.45 1.125 . . . . 0.0 109.204 -172.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.6 mt -66.05 120.98 14.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 52.3 tpt85 -121.11 -22.5 6.09 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 118.182 -0.913 . . . . 0.0 111.651 -175.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.65 155.6 42.57 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 170.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 50.3 mt -133.06 144.67 35.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -126.61 -18.67 4.74 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 123.858 0.863 . . . . 0.0 112.452 -174.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.75 -131.13 2.25 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 107.2 -2.36 . . . . 0.0 107.2 -178.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.5 p-10 -68.33 9.24 0.35 Allowed 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.145 0.978 . . . . 0.0 112.545 169.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -139.39 155.47 47.62 Favored 'General case' 0 C--O 1.239 0.523 0 C-N-CA 126.004 1.722 . . . . 0.0 107.542 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.8 174.88 10.06 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 125.453 1.501 . . . . 0.0 110.757 -176.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -122.18 114.51 20.96 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 178.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 89.1 t -111.83 125.56 69.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 -169.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -72.58 112.21 8.43 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 170.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 t -90.07 59.81 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.3 m 50.02 42.64 24.98 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.336 1.854 . . . . 0.0 113.5 178.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.2 -37.28 0.14 Allowed Glycine 0 CA--C 1.525 0.71 0 O-C-N 121.629 -0.67 . . . . 0.0 112.906 173.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 tp -155.33 155.79 5.46 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 62.8 mt-30 -74.65 147.37 41.61 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.709 0.766 . . . . 0.0 110.871 177.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.14 144.52 51.23 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.456 1.502 . . . . 0.0 107.255 169.293 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -69.84 135.71 49.93 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 169.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.65 121.03 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -173.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -66.64 134.67 52.77 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 169.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.2 tp -117.78 0.44 11.98 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 124.737 1.215 . . . . 0.0 110.358 -169.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.5 m -57.77 -30.84 65.96 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 124.721 1.209 . . . . 0.0 111.211 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 77.0 mt -67.89 -13.98 62.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.078 0.951 . . . . 0.0 112.884 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.74 -8.71 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 119.154 0.888 . . . . 0.0 112.1 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.57 136.22 1.68 Allowed Glycine 0 CA--C 1.525 0.699 0 C-N-CA 125.4 1.476 . . . . 0.0 110.388 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.5 m -75.88 161.19 29.18 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.238 0.615 . . . . 0.0 109.342 169.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.2 m 56.4 177.52 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.774 1.629 . . . . 0.0 112.597 -169.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -133.49 151.91 51.83 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 126.182 1.793 . . . . 0.0 108.221 -170.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.2 -21.58 34.44 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.026 1.331 . . . . 0.0 114.214 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -74.31 -7.2 51.98 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.487 0.585 . . . . 0.0 112.052 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.15 46.92 5.71 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -177.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.67 158.3 60.18 Favored Pre-proline 0 CA--C 1.535 0.399 0 C-N-CA 125.165 1.386 . . . . 0.0 108.664 -176.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -69.0 153.55 72.24 Favored 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 121.958 1.772 . . . . 0.0 109.892 169.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -73.16 3.37 5.7 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.615 0.968 . . . . 0.0 113.615 177.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.53 127.46 15.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-N 120.547 1.521 . . . . 0.0 108.457 -175.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.27 -24.76 30.64 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 124.892 1.234 . . . . 0.0 112.548 -176.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -70.53 162.06 29.49 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.056 1.428 . . . . 0.0 108.84 172.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.4 m95 -113.67 155.87 24.75 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -141.88 143.19 27.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.2 mt -77.32 127.9 33.39 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 103.743 -2.688 . . . . 0.0 103.743 168.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.5 m -131.2 126.65 59.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 119.341 0.973 . . . . 0.0 110.627 -170.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.438 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 3.5 t60 -89.17 -165.88 1.45 Allowed 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 169.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.438 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 18.3 m -47.71 -29.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 C-N-CA 125.815 1.646 . . . . 0.0 114.993 -172.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.74 33.07 0.17 Allowed Glycine 0 C--N 1.338 0.639 0 CA-C-O 118.819 -0.99 . . . . 0.0 112.4 175.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -145.71 134.17 21.97 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.822 1.311 . . . . 0.0 109.128 -174.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.34 117.91 17.66 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 169.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 72.2 mtp -77.31 -49.4 15.08 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.526 1.13 . . . . 0.0 109.056 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.9 m -151.35 162.46 40.87 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 125.851 1.661 . . . . 0.0 108.65 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.7 p -107.52 139.88 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 C-N-CA 124.87 1.268 . . . . 0.0 107.874 172.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.1 pt -141.26 161.75 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.095 1.358 . . . . 0.0 109.896 -173.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -75.44 165.26 25.4 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.916 0.886 . . . . 0.0 110.53 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.53 -40.9 72.43 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 124.729 1.211 . . . . 0.0 111.698 176.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.48 -40.21 67.1 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 122.942 0.497 . . . . 0.0 110.79 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.07 -40.79 97.02 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.091 0.556 . . . . 0.0 109.763 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.91 -48.97 78.05 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.666 -0.207 . . . . 0.0 110.748 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 75.4 mtt85 -64.34 -40.02 95.05 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 119.079 -0.486 . . . . 0.0 110.762 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.7 -42.73 99.79 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.467 0.576 . . . . 0.0 111.047 176.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.4 m -65.16 -43.69 90.92 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.151 0.58 . . . . 0.0 110.334 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.2 mt -61.95 -44.45 96.73 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.394 0.543 . . . . 0.0 109.846 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -63.68 -44.47 93.63 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 118.458 0.572 . . . . 0.0 111.146 179.318 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.36 82.04 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 122.663 0.385 . . . . 0.0 110.316 178.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? . . . . . 0 CA--C 1.528 0.101 0 C-N-CA 123.693 0.797 . . . . 0.0 109.711 178.323 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.763 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.7 m -143.3 163.75 35.33 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 125.208 1.403 . . . . 0.0 110.287 -168.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -53.77 157.13 10.66 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 123.075 2.517 . . . . 0.0 113.874 171.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.71 167.85 37.34 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 126.336 1.922 . . . . 0.0 108.648 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.2 tt0 -116.18 134.25 55.13 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 64.7 mt -75.04 74.86 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 125.649 1.58 . . . . 0.0 107.509 -176.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -70.73 -30.65 67.23 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-O 118.438 -0.792 . . . . 0.0 111.566 -172.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -148.81 155.7 41.31 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 177.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 57.0 mt -132.18 146.85 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -129.71 -20.06 3.26 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.854 0.862 . . . . 0.0 112.529 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 175.15 -134.47 2.74 Favored Glycine 0 C--N 1.334 0.418 0 N-CA-C 106.243 -2.743 . . . . 0.0 106.243 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.9 t30 -65.86 -15.74 63.2 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 118.386 1.093 . . . . 0.0 110.668 169.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -101.08 153.0 19.93 Favored 'General case' 0 C--O 1.239 0.544 0 C-N-CA 124.954 1.302 . . . . 0.0 109.123 175.438 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.34 159.52 42.06 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.313 1.445 . . . . 0.0 109.14 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -106.77 86.83 2.39 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.61 127.6 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 -174.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -71.37 106.89 4.06 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 169.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.77 67.24 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.0 48.05 7.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.291 2.236 . . . . 0.0 113.739 178.196 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 174.77 -42.03 0.12 Allowed Glycine 0 CA--C 1.524 0.646 0 CA-C-O 119.692 -0.505 . . . . 0.0 112.219 172.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -156.97 156.1 4.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 C-N-CA 124.676 1.19 . . . . 0.0 108.175 175.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -67.76 136.06 53.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.23 0.612 . . . . 0.0 110.469 176.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.2 mpt_? -123.88 148.61 46.67 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 106.327 -1.731 . . . . 0.0 106.327 169.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -70.59 136.81 49.5 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.5 t -138.59 131.25 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -83.21 126.22 32.4 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 169.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.1 mt -83.29 36.86 0.53 Allowed 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 123.64 0.776 . . . . 0.0 111.335 -173.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -45.87 -40.33 9.81 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.412 2.285 . . . . 0.0 114.443 -169.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.2 mt -106.23 4.56 28.99 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 118.853 -0.594 . . . . 0.0 112.282 -169.309 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.3 m -133.97 -26.68 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.981 0.809 . . . . 0.0 111.937 -173.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.89 152.79 1.94 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.095 0.855 . . . . 0.0 110.979 -175.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 m -77.18 -6.86 54.56 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m -126.72 151.58 47.98 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.3 1.04 . . . . 0.0 109.075 175.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.5 t0 -84.51 176.57 8.55 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 124.308 1.043 . . . . 0.0 110.665 -178.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -55.68 -37.08 67.85 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.917 1.287 . . . . 0.0 112.102 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -84.12 -2.0 55.98 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.627 0.771 . . . . 0.0 112.929 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.18 -3.26 66.47 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.323 -1.265 . . . . 0.0 114.241 173.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -67.38 147.81 98.8 Favored Pre-proline 0 CA--C 1.538 0.506 0 CA-C-N 119.91 1.855 . . . . 0.0 109.046 175.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -64.87 141.93 73.51 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.541 1.494 . . . . 0.0 108.743 169.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.4 mtt-85 -70.94 11.39 0.4 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.7 p -56.38 129.23 17.74 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 CA-C-N 119.968 1.258 . . . . 0.0 109.031 -176.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.04 -14.46 57.18 Favored Glycine 0 CA--C 1.534 1.24 0 CA-C-O 118.226 -1.319 . . . . 0.0 113.972 -178.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -70.34 166.03 21.11 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.824 1.812 . . . . 0.0 108.969 170.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -112.25 161.22 16.83 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 121.538 0.685 . . . . 0.0 109.871 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.75 140.9 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 -172.43 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.8 111.64 12.55 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 104.894 -2.262 . . . . 0.0 104.894 169.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 51.3 t -93.11 132.22 37.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -144.24 130.41 19.63 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 1.7 t 45.74 37.34 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 125.177 1.391 . . . . 0.0 112.688 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.08 16.37 79.6 Favored Glycine 0 CA--C 1.534 1.251 0 O-C-N 120.916 -1.115 . . . . 0.0 114.308 176.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -128.49 161.95 28.35 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 119.315 1.558 . . . . 0.0 109.956 170.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.89 111.34 16.12 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 16.0 tpt -74.02 -51.5 15.67 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.4 m -154.21 138.37 16.51 Favored 'General case' 0 C--N 1.342 0.247 0 C-N-CA 124.305 1.042 . . . . 0.0 108.912 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -77.54 142.42 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 169.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.2 pt -139.91 160.51 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 124.355 1.062 . . . . 0.0 109.84 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -75.27 165.12 25.68 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 123.842 0.857 . . . . 0.0 110.46 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -54.51 -41.68 69.92 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 124.732 1.213 . . . . 0.0 111.467 174.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.4 -39.42 67.98 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 122.988 0.515 . . . . 0.0 110.786 -178.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -64.61 -40.7 95.97 Favored 'General case' 0 N--CA 1.461 0.088 0 C-N-CA 123.009 0.524 . . . . 0.0 109.865 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.43 -49.42 76.92 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.838 0.29 . . . . 0.0 110.562 177.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 76.1 mtt85 -64.45 -40.12 95.12 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-O 119.03 -0.51 . . . . 0.0 110.665 -178.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.93 -41.83 99.61 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 118.602 0.637 . . . . 0.0 111.129 176.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.7 m -65.42 -43.43 90.53 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.813 0.445 . . . . 0.0 110.032 178.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -64.51 -40.04 94.89 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 118.765 0.711 . . . . 0.0 110.549 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -63.21 -44.0 96.54 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 118.202 0.455 . . . . 0.0 110.748 176.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.64 -47.14 86.78 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 122.992 0.517 . . . . 0.0 110.204 175.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.7 mt . . . . . 0 CA--C 1.538 0.498 0 C-N-CA 125.039 1.336 . . . . 0.0 113.35 177.024 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.74 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.1 p -153.04 145.33 17.05 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 126.3 1.84 . . . . 0.0 106.472 -169.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -75.41 168.55 24.31 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.617 1.545 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.42 -176.88 42.24 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 172.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -95.99 137.86 34.46 Favored 'General case' 0 C--O 1.231 0.116 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 178.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 68.9 mt -71.47 78.81 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 171.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -67.51 -30.22 69.83 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.446 -0.784 . . . . 0.0 110.301 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.18 150.01 26.6 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 124.512 1.125 . . . . 0.0 108.051 -173.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 49.8 mt -119.98 149.79 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -145.48 65.17 1.24 Allowed 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 126.324 1.85 . . . . 0.0 107.468 -170.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 -124.71 18.71 Favored Glycine 0 C--N 1.338 0.64 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -173.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -68.27 -25.05 64.97 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 122.787 0.435 . . . . 0.0 111.913 172.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -86.1 170.92 11.77 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 121.86 0.838 . . . . 0.0 109.835 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.55 159.79 41.8 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.545 1.538 . . . . 0.0 108.19 169.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.58 75.97 0.95 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.238 -2.134 . . . . 0.0 105.238 177.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 79.3 t -71.74 126.52 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 124.904 1.282 . . . . 0.0 107.563 -172.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -79.26 111.02 15.08 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 174.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.5 t -82.06 60.21 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 C-N-CA 125.668 1.587 . . . . 0.0 107.282 172.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 55.5 m 43.67 41.39 3.53 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.11 2.164 . . . . 0.0 114.432 176.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 161.67 -23.83 0.23 Allowed Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.157 -0.802 . . . . 0.0 113.676 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.7 tp -150.29 149.43 14.45 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 176.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -92.17 139.06 31.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 -179.221 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -129.69 144.97 51.54 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.916 1.287 . . . . 0.0 108.519 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -73.84 137.61 43.91 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 71.6 t -137.03 143.67 34.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -99.8 119.8 38.75 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.164 1.386 . . . . 0.0 107.539 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.9 mt -91.17 12.49 19.91 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 117.88 -1.057 . . . . 0.0 113.03 -172.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -48.65 -36.43 15.91 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 121.29 1.859 . . . . 0.0 113.73 -174.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.0 mt -88.55 -2.63 58.7 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -173.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.07 -19.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 119.344 0.975 . . . . 0.0 112.672 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.0 146.84 2.93 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 125.259 1.409 . . . . 0.0 111.131 -175.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.1 m -74.97 -12.64 60.39 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.49 0.716 . . . . 0.0 112.18 174.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.4 m -117.89 166.34 12.6 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.603 1.161 . . . . 0.0 109.316 172.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -115.65 163.39 15.87 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.185 1.794 . . . . 0.0 110.446 -169.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -54.18 -36.74 63.72 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.397 1.479 . . . . 0.0 111.265 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -74.44 1.22 12.31 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.499 1.52 . . . . 0.0 113.059 -178.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.02 45.61 11.52 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 121.014 -1.054 . . . . 0.0 111.098 174.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.6 pt20 -141.64 151.34 60.08 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.28 1.432 . . . . 0.0 108.611 -177.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -66.52 147.81 82.76 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 122.08 1.853 . . . . 0.0 109.159 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -73.71 7.93 2.2 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.9 m -54.57 133.37 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 120.537 1.517 . . . . 0.0 109.892 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.11 -17.95 34.58 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-O 118.231 -1.316 . . . . 0.0 113.38 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -72.57 164.73 25.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 119.708 1.754 . . . . 0.0 108.735 174.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 33.7 m95 -109.2 154.0 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.0 p -146.61 140.22 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -172.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 65.6 tp -89.24 148.09 23.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 169.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 t -124.99 142.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -103.48 -52.15 3.06 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.915 0.486 . . . . 0.0 110.355 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.4 p -157.81 63.12 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 -38.36 1.81 Allowed Glycine 0 CA--C 1.529 0.946 0 C-N-CA 124.746 1.165 . . . . 0.0 112.034 -172.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -69.49 135.18 49.81 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 118.639 1.22 . . . . 0.0 109.159 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.43 132.03 52.61 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 169.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 21.9 ttt -84.81 -55.28 4.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.13 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.3 m -155.82 149.46 25.04 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 124.768 1.227 . . . . 0.0 108.844 -177.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.9 p -74.94 142.78 14.14 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 168.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.9 pt -138.32 169.98 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 C-N-CA 124.104 0.961 . . . . 0.0 109.682 -172.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.38 169.74 8.68 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.754 0.822 . . . . 0.0 109.575 169.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -62.43 -34.39 76.68 Favored 'General case' 0 C--N 1.334 -0.084 0 CA-C-O 118.68 -0.676 . . . . 0.0 112.452 -173.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.85 -39.78 95.01 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.022 0.828 . . . . 0.0 110.743 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -65.96 -41.15 91.61 Favored 'General case' 0 C--O 1.232 0.152 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.24 -50.33 72.17 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 117.916 0.325 . . . . 0.0 110.351 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 43.8 mmt-85 -63.48 -43.48 97.18 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 118.877 -0.582 . . . . 0.0 110.279 -179.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.75 -43.5 98.72 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 118.484 0.584 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.0 m -66.6 -43.55 84.52 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 122.749 0.42 . . . . 0.0 110.128 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.4 mt -63.63 -41.25 98.28 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 119.084 0.856 . . . . 0.0 110.499 178.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -63.31 -44.63 94.43 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 122.874 0.47 . . . . 0.0 110.417 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.18 -48.91 76.38 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.828 0.451 . . . . 0.0 110.76 177.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 56.9 mt . . . . . 0 N--CA 1.463 0.178 0 C-N-CA 123.281 0.633 . . . . 0.0 111.028 -177.659 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.522 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.4 t -142.7 141.7 20.94 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 -170.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -55.47 165.63 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.892 2.395 . . . . 0.0 113.017 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.88 175.67 35.09 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 169.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -116.82 136.43 52.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.8 mt -70.56 96.26 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 N-CA-C 105.931 -1.878 . . . . 0.0 105.931 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -85.56 -42.86 14.0 Favored 'General case' 0 N--CA 1.462 0.132 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 -169.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 p -147.22 158.43 43.95 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.617 1.567 . . . . 0.0 108.112 176.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 52.3 mt -127.46 146.57 33.0 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -177.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -123.96 -19.18 5.74 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.065 0.946 . . . . 0.0 112.294 -176.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.6 -127.58 1.59 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -66.75 2.29 1.44 Allowed 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 123.932 0.893 . . . . 0.0 112.384 169.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -134.28 154.23 51.42 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 126.875 2.07 . . . . 0.0 107.314 -174.186 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.83 155.33 47.3 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.625 1.17 . . . . 0.0 109.382 -179.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -99.56 78.7 2.19 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.9 t -68.13 125.8 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 -176.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -75.66 105.18 6.55 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 169.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 t -81.52 63.25 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 37.8 m 48.95 39.52 14.72 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.495 1.918 . . . . 0.0 113.315 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.02 -48.14 0.19 Allowed Glycine 0 CA--C 1.526 0.728 0 CA-C-O 119.255 -0.747 . . . . 0.0 112.01 174.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.0 mm -137.16 143.28 35.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -174.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -71.78 141.88 49.7 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.33 0.586 . . . . 0.0 110.775 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -133.35 144.14 49.43 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 125.622 1.569 . . . . 0.0 106.999 169.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -73.06 134.59 44.63 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.158 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 87.6 t -138.3 129.99 37.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -79.57 143.34 34.86 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 122.993 0.517 . . . . 0.0 109.886 174.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 36.3 mt -114.94 15.24 17.32 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.089 0.956 . . . . 0.0 112.668 -169.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.7 m -50.64 -37.32 39.89 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 120.886 1.676 . . . . 0.0 112.463 -177.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.4 mt -77.08 -8.54 57.64 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -174.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.39 -20.11 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 119.517 1.053 . . . . 0.0 112.992 -172.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.16 140.37 0.74 Allowed Glycine 0 CA--C 1.529 0.913 0 C-N-CA 125.244 1.402 . . . . 0.0 110.886 -172.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.8 m -73.82 -17.73 61.03 Favored 'General case' 0 CA--C 1.535 0.374 0 O-C-N 122.024 -0.692 . . . . 0.0 112.313 176.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.9 m -93.0 135.17 34.41 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 123.809 0.843 . . . . 0.0 109.043 175.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -66.38 158.18 29.93 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.093 1.757 . . . . 0.0 109.598 169.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -53.47 -29.96 38.48 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.346 1.459 . . . . 0.0 112.176 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -75.66 -12.67 60.25 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.26 48.63 4.5 Favored Glycine 0 CA--C 1.53 1.029 0 CA-C-N 119.007 0.821 . . . . 0.0 111.166 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -143.75 160.54 50.05 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 126.717 2.007 . . . . 0.0 107.409 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -64.68 141.96 74.85 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 CA-C-N 121.586 1.602 . . . . 0.0 110.538 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -69.53 13.87 0.12 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.5 m -54.93 132.87 18.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 120.354 1.434 . . . . 0.0 110.05 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.65 -17.79 53.05 Favored Glycine 0 CA--C 1.532 1.096 0 CA-C-O 118.479 -1.178 . . . . 0.0 113.458 -178.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -71.94 160.94 31.68 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 119.699 1.75 . . . . 0.0 109.081 174.095 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.3 m95 -107.68 161.17 15.11 Favored 'General case' 0 C--O 1.232 0.178 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 p -154.05 146.19 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -169.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.9 mt -89.89 139.63 30.4 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 172.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.3 t -136.15 143.35 36.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -178.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 5.5 t60 -141.44 -39.05 0.4 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.407 0.683 . . . . 0.0 112.487 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.36 27.08 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 119.026 0.83 . . . . 0.0 112.029 -171.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.99 16.73 80.52 Favored Glycine 0 CA--C 1.534 1.224 0 O-C-N 121.446 -0.784 . . . . 0.0 112.526 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -129.03 144.43 51.19 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 172.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.12 122.59 17.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 171.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 68.5 mtp -76.76 -47.18 22.5 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.4 m -163.74 149.05 10.89 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 126.131 1.772 . . . . 0.0 108.144 176.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.1 t -80.37 145.28 9.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 169.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.2 pt -139.51 161.44 27.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.447 1.499 . . . . 0.0 109.198 -176.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -84.45 173.45 10.87 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.344 0.592 . . . . 0.0 110.894 174.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -69.99 -30.18 67.45 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 121.758 -0.589 . . . . 0.0 112.294 -170.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -73.63 -40.6 63.65 Favored 'General case' 0 N--CA 1.462 0.129 0 O-C-N 121.283 -0.886 . . . . 0.0 109.837 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -61.36 -41.35 96.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.224 0.61 . . . . 0.0 109.917 174.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.43 -49.41 75.57 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 117.983 0.356 . . . . 0.0 110.416 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 86.3 mtm180 -63.7 -40.2 96.19 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 119.13 -0.462 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.2 -41.9 99.24 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 118.759 0.709 . . . . 0.0 110.954 176.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -67.49 -38.64 84.66 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 122.083 -0.386 . . . . 0.0 110.282 178.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 53.0 mt -65.49 -38.03 88.57 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 119.079 0.854 . . . . 0.0 110.67 176.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -64.76 -43.86 91.93 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 118.605 0.639 . . . . 0.0 110.293 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.52 -43.24 99.29 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.962 0.505 . . . . 0.0 111.142 176.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? . . . . . 0 N--CA 1.464 0.255 0 C-N-CA 124.405 1.082 . . . . 0.0 109.909 176.936 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.936 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 98.5 t -143.88 139.39 16.03 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -171.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.83 159.89 31.44 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.666 1.577 . . . . 0.0 112.582 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.3 168.1 33.04 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 172.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -89.9 143.02 27.15 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 174.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 70.0 mt -74.17 76.64 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.32 1.448 . . . . 0.0 107.205 176.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -64.87 -39.18 93.14 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 126.088 1.755 . . . . 0.0 110.916 -177.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.0 m -150.26 153.78 36.78 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.35 147.2 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 178.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -116.39 -22.33 8.84 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.37 1.468 . . . . 0.0 111.565 -169.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 154.29 -122.92 1.3 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 105.094 -3.203 . . . . 0.0 105.094 -177.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -72.81 15.68 0.18 Allowed 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.101 0.961 . . . . 0.0 111.121 168.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.419 ' H ' ' C ' ' A' ' 14' ' ' GLY . 20.6 mt-30 -141.53 169.87 16.79 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 128.03 2.532 . . . . 0.0 106.569 -174.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.78 21.27 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.399 1.08 . . . . 0.0 109.4 173.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.3 mttp -118.26 72.58 0.87 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 105.604 -1.999 . . . . 0.0 105.604 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.5 m -70.13 137.2 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 C-N-CA 124.553 1.141 . . . . 0.0 109.326 -169.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -85.19 111.89 20.23 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 175.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.2 m -80.45 38.94 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 C-N-CA 124.181 0.992 . . . . 0.0 110.979 178.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 75.8 m 48.13 53.53 11.56 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.349 1.86 . . . . 0.0 111.855 -169.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -179.52 -41.3 0.07 OUTLIER Glycine 0 CA--C 1.524 0.62 0 CA-C-O 119.721 -0.488 . . . . 0.0 112.415 173.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.4 tp -156.0 156.06 5.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 -77.12 138.73 39.68 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 173.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -130.9 131.99 44.85 Favored 'General case' 0 C--N 1.333 -0.12 0 C-N-CA 125.466 1.506 . . . . 0.0 107.789 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -72.29 130.96 42.01 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 49.1 t -141.44 133.55 28.68 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 125.683 1.593 . . . . 0.0 107.323 -173.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -64.79 136.71 57.2 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 122.689 0.395 . . . . 0.0 110.407 172.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.9 mt -112.92 0.74 15.21 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.165 -0.921 . . . . 0.0 111.569 173.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.3 m -54.99 -31.75 61.21 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 121.061 1.755 . . . . 0.0 111.724 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 56.8 mt -67.87 -15.26 63.53 Favored 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 113.642 0.979 . . . . 0.0 113.642 178.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.64 -10.83 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.481 1.112 . . . . 0.0 112.79 -175.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.31 141.02 0.83 Allowed Glycine 0 CA--C 1.529 0.922 0 C-N-CA 125.527 1.537 . . . . 0.0 110.397 -170.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.4 m -76.29 -6.2 50.43 Favored 'General case' 0 CA--C 1.536 0.432 0 O-C-N 121.817 -0.813 . . . . 0.0 112.533 174.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 80.4 m -110.32 147.96 32.87 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 124.139 0.976 . . . . 0.0 109.489 175.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -68.94 171.65 7.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 126.635 1.974 . . . . 0.0 110.564 176.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 21.9 mm-40 -58.25 -15.36 9.79 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.149 1.38 . . . . 0.0 113.505 -177.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -117.96 8.66 12.6 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.529 1.532 . . . . 0.0 112.896 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.73 -2.11 69.47 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-O 118.805 -0.997 . . . . 0.0 114.545 170.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -67.01 154.54 92.28 Favored Pre-proline 0 CA--C 1.537 0.444 0 CA-C-N 119.373 1.586 . . . . 0.0 108.797 169.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -64.84 143.32 79.48 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 CA-C-N 121.18 1.457 . . . . 0.0 109.382 169.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.1 mtt-85 -70.51 10.96 0.4 Allowed 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.966 1.098 . . . . 0.0 113.966 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.9 p -56.44 132.34 20.4 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 O-C-N 120.759 -1.213 . . . . 0.0 109.03 -175.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.7 -15.79 49.74 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 118.097 -1.391 . . . . 0.0 114.076 -178.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -69.05 170.28 10.21 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 120.023 1.912 . . . . 0.0 108.906 169.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -119.66 157.62 28.1 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 177.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.3 p -151.56 136.3 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -171.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 81.0 mt -71.35 145.37 49.47 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 169.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 39.1 t -117.06 143.24 27.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 176.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -139.14 118.84 13.09 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 173.154 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . 0.286 29.4 m 44.45 28.87 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.461 2.304 . . . . 0.0 115.686 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 98.81 10.87 48.55 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 121.188 -0.945 . . . . 0.0 114.392 178.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -125.79 146.62 49.71 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 119.044 1.422 . . . . 0.0 108.484 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.12 114.44 3.12 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.615 0.766 . . . . 0.0 109.523 172.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 12.7 tpt -80.91 -42.71 20.96 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 58.3 m -166.02 147.54 6.88 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.865 1.666 . . . . 0.0 108.328 171.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 96.6 t -75.54 143.56 13.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 169.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 33.7 pt -139.36 162.19 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.028 1.331 . . . . 0.0 109.782 -175.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -74.14 165.22 25.53 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-O 121.48 0.657 . . . . 0.0 110.262 172.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -56.62 -43.2 79.99 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.191 1.396 . . . . 0.0 111.318 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.37 -38.85 85.39 Favored 'General case' 0 C--N 1.338 0.1 0 C-N-CA 122.801 0.44 . . . . 0.0 110.825 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -65.97 -40.36 91.18 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.31 -49.38 74.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 117.939 0.336 . . . . 0.0 110.478 178.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 47.6 mtm105 -61.57 -42.17 98.46 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 119.12 -0.467 . . . . 0.0 110.809 179.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.4 -42.83 99.73 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 118.5 0.591 . . . . 0.0 111.102 177.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.7 m -65.84 -41.31 91.92 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.841 0.456 . . . . 0.0 110.273 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.0 mt -65.23 -40.67 94.36 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.981 0.809 . . . . 0.0 110.426 178.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -64.4 -44.1 92.36 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 118.717 0.689 . . . . 0.0 110.696 177.114 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.3 -46.03 92.01 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.95 0.5 . . . . 0.0 110.509 176.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.0 mt . . . . . 0 C--O 1.227 -0.101 0 CA-C-O 118.771 -0.633 . . . . 0.0 110.758 -179.67 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 0.315 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 9.0 p -148.44 149.95 32.86 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 123.69 0.796 . . . . 0.0 109.121 -169.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.03 168.58 16.95 Favored 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 122.549 2.166 . . . . 0.0 111.882 169.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.66 172.9 41.27 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.621 2.057 . . . . 0.0 108.621 170.375 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -116.71 129.58 56.21 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 118.216 1.008 . . . . 0.0 108.982 -177.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 63.8 mt -70.27 127.63 32.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 -178.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -120.99 -29.65 4.54 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 118.247 -0.882 . . . . 0.0 112.448 -170.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.6 155.32 40.09 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.0 mt -132.37 124.81 52.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 N-CA-C 106.642 -1.614 . . . . 0.0 106.642 -177.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -86.89 -32.24 20.3 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.506 0.722 . . . . 0.0 110.4 172.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.58 -114.03 0.58 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 107.69 -2.164 . . . . 0.0 107.69 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -67.22 -0.66 3.6 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.287 1.035 . . . . 0.0 112.997 172.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -135.95 155.57 50.08 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 125.632 1.573 . . . . 0.0 107.438 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.23 151.69 38.8 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.321 1.048 . . . . 0.0 110.04 -171.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.0 tttt -90.85 133.1 35.49 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.23 130.49 72.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 -174.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -82.31 110.0 17.08 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 169.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.5 t -84.4 64.86 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 178.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.6 m 52.76 29.43 7.51 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.615 1.966 . . . . 0.0 114.94 171.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 158.27 -23.67 0.37 Allowed Glycine 0 CA--C 1.525 0.675 0 CA-C-N 119.121 0.873 . . . . 0.0 113.584 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.7 tp -146.45 149.63 15.86 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -88.51 150.27 23.2 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.983 0.42 . . . . 0.0 110.236 -175.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -139.5 150.08 44.71 Favored 'General case' 0 N--CA 1.464 0.227 0 C-N-CA 124.566 1.146 . . . . 0.0 108.703 169.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.54 138.83 35.38 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 169.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 50.5 t -136.38 131.88 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -173.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.34 138.64 37.77 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.468 0.707 . . . . 0.0 109.71 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.99 10.83 16.35 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.946 0.898 . . . . 0.0 112.211 -171.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.9 m -53.1 -34.07 55.03 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 120.265 1.393 . . . . 0.0 111.991 -177.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 85.2 mt -73.38 -12.93 60.99 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.769 0.827 . . . . 0.0 113.136 -176.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.36 -20.3 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 119.516 1.053 . . . . 0.0 113.188 -169.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.54 146.32 6.03 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 124.334 0.968 . . . . 0.0 111.457 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.1 p -74.41 -6.71 49.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.949 1.7 . . . . 0.0 113.581 -176.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.8 m -135.49 157.14 47.64 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 125.385 1.474 . . . . 0.0 108.177 171.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -66.07 165.11 14.06 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.079 1.352 . . . . 0.0 110.451 169.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -53.95 -38.33 64.84 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.935 1.294 . . . . 0.0 111.657 176.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -87.06 11.83 12.83 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.861 0.865 . . . . 0.0 111.85 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.98 6.97 88.48 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 124.583 1.087 . . . . 0.0 113.492 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -67.71 134.2 92.45 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 118.588 1.194 . . . . 0.0 108.206 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.27 143.29 53.62 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.531 2.154 . . . . 0.0 111.44 171.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -69.7 -17.79 63.5 Favored 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 118.043 -0.98 . . . . 0.0 112.836 175.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -55.32 134.82 18.72 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 120.297 1.408 . . . . 0.0 109.125 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.02 -21.27 20.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 124.561 1.077 . . . . 0.0 112.735 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -71.87 159.64 33.94 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 119.09 1.445 . . . . 0.0 108.162 171.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -106.7 158.41 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.67 139.52 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -169.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -83.18 133.08 35.04 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 169.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.2 t -121.44 135.76 60.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 4.7 t60 -137.12 -48.38 0.6 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.269 0.628 . . . . 0.0 111.108 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.4 m -136.3 27.63 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 123.75 0.82 . . . . 0.0 111.205 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.12 15.53 78.56 Favored Glycine 0 CA--C 1.531 1.068 0 O-C-N 121.531 -0.73 . . . . 0.0 112.464 -174.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -126.39 147.8 49.71 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 125.578 1.551 . . . . 0.0 107.095 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.44 105.18 1.4 Allowed 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.379 1.071 . . . . 0.0 108.257 172.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.4 ttt -70.6 -46.17 63.91 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 24.6 m -152.53 158.69 42.89 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.136 1.774 . . . . 0.0 107.445 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 44.1 t -121.0 140.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 174.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.0 pt -141.66 161.93 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 C-N-CA 125.712 1.605 . . . . 0.0 110.081 -171.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -74.66 168.34 20.0 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.669 0.788 . . . . 0.0 110.507 171.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -63.1 -42.29 99.55 Favored 'General case' 0 C--O 1.227 -0.09 0 CA-C-O 119.167 -0.444 . . . . 0.0 111.963 -173.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.83 -41.41 87.49 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.499 0.59 . . . . 0.0 110.315 -173.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.59 -36.43 82.7 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 122.578 0.351 . . . . 0.0 110.49 173.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.88 -40.57 83.54 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-N 119.05 0.841 . . . . 0.0 111.507 176.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 10.0 mmt85 -66.59 -38.83 87.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 119.291 0.95 . . . . 0.0 109.513 178.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.48 -42.71 99.68 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 118.015 0.371 . . . . 0.0 110.919 174.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.6 m -62.06 -40.87 97.24 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.34 0.656 . . . . 0.0 110.417 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 21.4 mt -63.86 -39.15 93.54 Favored 'General case' 0 C--N 1.338 0.073 0 O-C-N 121.668 -0.645 . . . . 0.0 110.943 178.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -68.2 -44.33 76.06 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.383 0.992 . . . . 0.0 110.677 175.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.53 -31.41 70.49 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.247 1.019 . . . . 0.0 111.821 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 62.3 tp . . . . . 0 N--CA 1.454 -0.255 0 C-N-CA 123.558 0.743 . . . . 0.0 110.339 174.444 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.92 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.1 t -139.24 143.41 36.28 Favored Pre-proline 0 CA--C 1.543 0.688 0 C-N-CA 124.296 1.038 . . . . 0.0 109.007 -169.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.25 155.62 24.0 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.632 2.221 . . . . 0.0 112.301 169.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.12 170.66 39.44 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 169.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.1 tt0 -116.3 125.25 51.88 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 123.982 0.913 . . . . 0.0 108.836 -174.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.03 129.33 27.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -114.42 -33.93 5.43 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 118.058 -0.972 . . . . 0.0 111.663 -176.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.4 p -148.15 157.25 43.39 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 47.1 mt -132.51 144.14 37.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -123.15 -19.29 6.07 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.364 1.066 . . . . 0.0 111.875 -176.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.46 -127.18 1.53 Allowed Glycine 0 C--N 1.336 0.562 0 N-CA-C 106.815 -2.514 . . . . 0.0 106.815 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -63.92 -10.23 19.86 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 117.514 0.657 . . . . 0.0 112.365 169.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -119.92 159.2 25.14 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.523 1.129 . . . . 0.0 110.509 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.48 167.72 27.11 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 125.746 1.618 . . . . 0.0 109.544 -172.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.33 132.28 54.52 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 171.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 52.7 t -126.35 123.78 64.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -174.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -72.81 111.13 7.67 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.2 63.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.9 m 47.18 42.47 13.31 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.885 2.074 . . . . 0.0 114.026 175.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.55 -31.17 0.19 Allowed Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.169 174.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -152.41 151.45 11.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 177.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -73.14 137.5 45.19 Favored 'General case' 0 C--O 1.234 0.266 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -122.53 148.26 45.4 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 124.595 1.158 . . . . 0.0 108.188 169.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -72.82 134.71 45.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 123.82 0.848 . . . . 0.0 108.983 172.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -140.5 157.28 24.21 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 C-N-CA 124.787 1.235 . . . . 0.0 108.096 -176.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -112.61 142.58 45.03 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 125.415 1.486 . . . . 0.0 108.815 172.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.9 mt -113.3 7.59 17.78 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.284 1.034 . . . . 0.0 112.328 -169.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 28.9 p -57.55 -29.15 64.16 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.599 1.545 . . . . 0.0 113.124 -173.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -70.53 -16.36 62.88 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.691 0.797 . . . . 0.0 112.534 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 24.2 m -130.0 -12.63 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 C-N-CA 124.606 1.162 . . . . 0.0 112.312 -173.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.62 141.34 1.19 Allowed Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.993 1.282 . . . . 0.0 109.939 -170.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -73.15 -10.58 59.92 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -178.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.4 m -121.36 145.62 47.71 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.229 1.012 . . . . 0.0 109.238 177.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -69.81 157.55 37.14 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.227 1.411 . . . . 0.0 109.894 172.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -51.54 -35.07 39.26 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 125.128 1.371 . . . . 0.0 112.139 176.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -70.45 -8.86 54.2 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.746 0.818 . . . . 0.0 112.417 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.43 25.04 10.42 Favored Glycine 0 CA--C 1.53 1.019 0 CA-C-N 119.6 1.091 . . . . 0.0 113.946 170.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -125.92 149.21 65.36 Favored Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 118.775 1.287 . . . . 0.0 108.26 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.77 143.91 36.59 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 122.966 2.444 . . . . 0.0 111.272 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.1 mtt-85 -70.61 18.79 0.05 Allowed 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 114.421 1.267 . . . . 0.0 114.421 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.2 m -56.55 136.32 19.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 O-C-N 120.394 -1.441 . . . . 0.0 109.547 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.11 -14.64 43.14 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 118.373 -1.237 . . . . 0.0 113.586 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -75.23 152.05 38.36 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 120.134 1.967 . . . . 0.0 109.184 176.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -95.07 150.28 20.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 174.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.2 m -142.2 153.5 18.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 124.663 1.185 . . . . 0.0 109.04 -178.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -85.37 107.09 17.2 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 169.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.0 t -78.02 120.87 29.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -134.62 120.09 19.16 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.0 t 49.58 33.61 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 C-N-CA 125.146 1.378 . . . . 0.0 112.105 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.96 6.94 78.59 Favored Glycine 0 CA--C 1.531 1.094 0 O-C-N 121.029 -1.044 . . . . 0.0 114.054 176.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -119.99 146.03 46.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-N 119.339 1.57 . . . . 0.0 109.055 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.5 104.83 6.23 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 41.0 tpp -68.2 -46.28 71.05 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.72 0.408 . . . . 0.0 110.704 -174.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.2 m -152.02 165.75 33.71 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 125.953 1.701 . . . . 0.0 107.98 -178.568 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 6.5 t -111.38 141.34 27.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.049 1.34 . . . . 0.0 107.742 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 35.8 pt -140.81 165.86 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.767 1.227 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.1 m-80 -80.39 165.48 22.2 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 124.582 1.153 . . . . 0.0 109.889 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -64.65 -32.41 74.06 Favored 'General case' 0 N--CA 1.468 0.425 0 O-C-N 121.763 -0.586 . . . . 0.0 111.505 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.54 -43.11 77.39 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.432 -0.793 . . . . 0.0 110.429 177.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -65.08 -39.32 93.03 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.314 0.646 . . . . 0.0 109.646 178.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.98 -49.55 74.26 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.17 -0.331 . . . . 0.0 110.364 177.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -62.53 -40.01 95.42 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 119.103 -0.475 . . . . 0.0 111.008 179.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -61.48 -43.77 98.28 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 118.494 0.588 . . . . 0.0 110.898 175.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -66.79 -40.49 88.16 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.075 0.55 . . . . 0.0 110.643 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 41.7 mt -63.06 -35.66 81.0 Favored 'General case' 0 C--N 1.338 0.101 0 C-N-CA 124.066 0.946 . . . . 0.0 110.759 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -70.06 -48.89 55.97 Favored 'General case' 0 C--O 1.226 -0.132 0 CA-C-N 118.492 0.587 . . . . 0.0 109.905 171.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.08 -40.49 85.4 Favored 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.617 0.767 . . . . 0.0 111.744 -171.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.0 pp . . . . . 0 CA--C 1.537 0.473 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 179.862 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.717 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.9 m -146.89 168.18 12.01 Favored Pre-proline 0 CA--C 1.543 0.69 0 C-N-CA 125.462 1.505 . . . . 0.0 110.108 -168.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -57.37 162.73 9.43 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.052 2.501 . . . . 0.0 113.37 169.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.86 176.75 41.22 Favored Glycine 0 CA--C 1.526 0.729 0 C-N-CA 125.978 1.752 . . . . 0.0 109.666 170.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.9 tt0 -116.86 136.92 52.58 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 45.6 mt -72.89 71.29 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -68.69 -33.52 74.1 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.156 0.982 . . . . 0.0 111.647 -169.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.3 156.06 43.09 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 174.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt -128.66 146.7 33.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 N-CA-C 106.471 -1.678 . . . . 0.0 106.471 178.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -117.14 -27.27 6.54 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 123.918 0.887 . . . . 0.0 111.415 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.5 -123.17 1.08 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -62.71 -23.52 67.2 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.292 0.637 . . . . 0.0 111.848 169.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 25.2 mm100 -99.04 155.28 17.52 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.022 0.929 . . . . 0.0 109.278 169.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.11 163.13 33.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.014 1.326 . . . . 0.0 109.538 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -110.46 77.72 1.07 Allowed 'General case' 0 C--O 1.234 0.252 0 N-CA-C 105.688 -1.968 . . . . 0.0 105.688 -175.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.0 t -70.85 127.74 33.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -177.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -74.83 107.61 7.03 Favored 'General case' 0 CA--C 1.52 -0.187 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 168.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -84.26 58.09 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -178.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.0 m 45.57 44.6 10.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.274 2.23 . . . . 0.0 113.208 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.26 -38.65 0.14 Allowed Glycine 0 CA--C 1.525 0.713 0 CA-C-O 119.478 -0.624 . . . . 0.0 112.708 176.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.6 tp -153.09 153.79 8.49 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 58.6 mt-30 -73.63 138.04 44.58 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -127.0 144.89 50.9 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 125.608 1.563 . . . . 0.0 107.151 172.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -75.01 131.19 40.45 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 72.9 t -140.16 138.77 37.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 125.126 1.37 . . . . 0.0 107.933 -171.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -80.72 130.64 35.2 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.778 1.631 . . . . 0.0 109.264 175.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.0 mt -105.46 6.66 32.63 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.676 0.79 . . . . 0.0 112.989 -176.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 7.5 m -55.61 -32.67 63.31 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.807 1.64 . . . . 0.0 112.853 -171.527 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.02 -13.95 62.17 Favored 'General case' 0 CA--C 1.538 0.493 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -178.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.33 -15.55 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.372 1.069 . . . . 0.0 112.581 -174.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.91 143.88 1.31 Allowed Glycine 0 CA--C 1.528 0.871 0 C-N-CA 125.394 1.474 . . . . 0.0 110.683 -173.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 m -76.62 -7.32 55.02 Favored 'General case' 0 CA--C 1.536 0.415 0 O-C-N 121.944 -0.739 . . . . 0.0 112.871 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.9 m -114.71 139.57 49.57 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.072 0.949 . . . . 0.0 109.676 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -75.56 155.76 35.7 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 126.809 2.044 . . . . 0.0 109.733 170.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -58.04 -25.96 61.85 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.034 1.334 . . . . 0.0 112.883 -173.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 -71.56 -6.97 44.66 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 121.506 -0.746 . . . . 0.0 112.525 178.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.13 47.44 5.24 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -142.44 153.51 62.49 Favored Pre-proline 0 CA--C 1.535 0.392 0 C-N-CA 125.724 1.61 . . . . 0.0 107.577 -178.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.51 147.23 76.53 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 C-N-CA 121.645 1.563 . . . . 0.0 109.687 174.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -70.88 17.96 0.07 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -175.306 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.4 t -56.53 126.2 13.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 O-C-N 120.848 -1.157 . . . . 0.0 108.599 -174.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.63 -13.59 66.25 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.324 -1.265 . . . . 0.0 113.632 176.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 80.1 mt-30 -68.04 154.58 41.34 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 119.566 1.683 . . . . 0.0 109.106 174.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.9 m95 -96.19 160.7 14.3 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.53 156.7 4.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -169.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 96.0 mt -101.68 133.0 47.06 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 169.158 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.9 m -128.3 139.07 52.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 118.853 0.751 . . . . 0.0 109.113 -177.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.6 t-80 -142.48 132.77 24.82 Favored 'General case' 0 C--O 1.232 0.132 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 -176.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 36.2 t 59.77 -61.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 128.146 2.579 . . . . 0.0 112.79 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -174.37 21.04 0.06 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.182 1.849 . . . . 0.0 111.596 179.245 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -132.38 141.86 49.07 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 118.78 1.29 . . . . 0.0 108.69 -172.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.26 124.03 24.88 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 169.422 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 90.4 mmm -90.86 -49.16 6.6 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 123.148 0.579 . . . . 0.0 109.966 -178.017 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.3 m -149.52 140.85 23.21 Favored 'General case' 0 C--N 1.339 0.145 0 C-N-CA 124.271 1.029 . . . . 0.0 108.775 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 84.0 t -81.78 142.93 13.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 169.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.1 pt -139.58 162.78 26.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 C-N-CA 124.885 1.274 . . . . 0.0 109.647 -173.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -79.67 163.79 24.27 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.658 0.742 . . . . 0.0 110.53 175.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -55.89 -39.35 71.43 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 126.26 1.824 . . . . 0.0 111.729 175.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.59 -50.06 34.51 Favored 'General case' 0 C--N 1.338 0.091 0 O-C-N 121.864 -0.523 . . . . 0.0 110.253 -173.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -72.35 -27.48 62.43 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 119.296 -0.383 . . . . 0.0 110.73 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.29 -52.04 66.98 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.877 0.762 . . . . 0.0 110.056 170.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.8 mtm180 -64.43 -37.64 88.22 Favored 'General case' 0 N--CA 1.46 0.054 0 CA-C-O 118.859 -0.591 . . . . 0.0 110.93 179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -62.65 -40.63 97.64 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 118.971 0.805 . . . . 0.0 111.176 175.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.8 m -65.39 -40.98 94.12 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.978 -0.452 . . . . 0.0 110.035 176.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.4 mt -65.07 -38.34 90.48 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.349 -0.845 . . . . 0.0 110.762 176.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -66.28 -39.11 89.19 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.624 0.647 . . . . 0.0 110.906 177.113 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.09 -50.46 71.85 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.463 0.705 . . . . 0.0 110.404 173.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.2 mt . . . . . 0 CA--C 1.533 0.296 0 C-N-CA 124.386 1.074 . . . . 0.0 112.6 -179.399 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.709 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.0 t -140.21 139.3 20.68 Favored Pre-proline 0 CA--C 1.54 0.565 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -169.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -76.65 168.98 22.67 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.384 2.056 . . . . 0.0 111.83 173.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -171.02 -174.9 39.18 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 173.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 57.7 tt0 -116.67 131.15 57.02 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 123.659 0.784 . . . . 0.0 108.99 -176.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 89.7 mt -67.06 122.65 18.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 mtm105 -119.62 -10.15 9.66 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 177.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -152.55 151.55 30.81 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 172.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.9 mt -133.19 140.24 47.52 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 172.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -108.01 -23.97 11.79 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.471 1.108 . . . . 0.0 112.438 -174.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.83 -62.37 0.15 Allowed Glycine 0 C--N 1.338 0.666 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 175.24 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -144.42 27.92 1.36 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.912 1.339 . . . . 0.0 110.381 169.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -137.62 156.2 48.33 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 169.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -144.25 166.54 24.75 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 123.867 0.867 . . . . 0.0 110.001 -170.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -117.38 84.35 2.14 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.22 131.08 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -83.24 109.72 17.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 169.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.8 t -85.35 62.23 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -175.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 56.5 m 48.77 40.7 16.72 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.329 1.852 . . . . 0.0 113.161 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 172.17 -49.0 0.18 Allowed Glycine 0 CA--C 1.525 0.658 0 CA-C-O 119.304 -0.72 . . . . 0.0 112.126 173.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.1 mm -138.0 145.59 28.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 -173.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -73.74 145.72 44.9 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.288 0.566 . . . . 0.0 111.307 175.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -133.84 139.68 46.4 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 125.481 1.512 . . . . 0.0 107.804 170.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -71.56 136.2 47.37 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.89 155.17 17.46 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 125.396 1.478 . . . . 0.0 109.162 177.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -98.07 141.53 30.9 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 124.636 1.175 . . . . 0.0 110.223 -177.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.7 mp -117.23 15.41 14.9 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.828 1.251 . . . . 0.0 111.871 -170.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.4 p -53.22 -33.65 53.75 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 119.966 1.257 . . . . 0.0 112.267 176.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -77.78 -12.05 59.94 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 123.848 0.859 . . . . 0.0 112.986 -174.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.07 -17.05 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.699 1.136 . . . . 0.0 113.364 -171.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.98 148.95 4.5 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -176.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 m -74.09 -14.22 60.95 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 124.244 1.018 . . . . 0.0 113.23 -174.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -126.19 143.67 51.05 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.975 0.91 . . . . 0.0 109.902 -171.256 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -70.8 155.7 40.45 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 126.463 1.905 . . . . 0.0 109.954 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -58.57 -25.75 62.88 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.638 1.175 . . . . 0.0 112.531 -175.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -61.98 -22.74 65.92 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.74 0.816 . . . . 0.0 112.924 175.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.18 47.38 3.09 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -174.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -142.14 151.26 58.28 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 125.819 1.648 . . . . 0.0 107.488 -178.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -65.72 148.46 86.83 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.882 1.721 . . . . 0.0 109.879 176.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -70.78 16.65 0.08 Allowed 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 -176.529 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 98.6 t -60.66 133.44 26.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 O-C-N 120.565 -1.334 . . . . 0.0 107.878 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.92 -15.2 56.46 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.303 -1.276 . . . . 0.0 113.064 -178.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 67.9 mt-30 -71.88 149.57 45.04 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 119.818 1.809 . . . . 0.0 108.907 175.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.7 m95 -85.15 152.4 23.4 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 170.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.7 p -146.46 138.42 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 62.9 tp -89.0 128.76 35.71 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 169.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.8 m -124.83 151.34 30.29 Favored 'Isoleucine or valine' 0 C--O 1.235 0.324 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -142.57 148.47 37.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 104.958 -2.238 . . . . 0.0 104.958 169.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.7 m 44.81 28.51 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 126.097 1.759 . . . . 0.0 115.368 171.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.48 14.03 64.4 Favored Glycine 0 CA--C 1.531 1.074 0 CA-C-O 118.472 -1.182 . . . . 0.0 113.857 176.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -129.13 144.11 51.09 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 119.818 1.809 . . . . 0.0 109.692 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.54 112.37 4.66 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 169.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.4 mmt -91.15 -34.89 14.85 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 119.094 -0.479 . . . . 0.0 111.114 -178.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 70.7 m -155.58 144.46 20.59 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 119.276 0.944 . . . . 0.0 109.283 169.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 48.3 t -79.99 140.37 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 169.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.2 pt -135.07 -175.2 1.3 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 C-N-CA 124.156 0.982 . . . . 0.0 108.865 -173.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -131.18 176.58 8.15 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.763 1.225 . . . . 0.0 108.597 178.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 68.4 mm-40 -52.78 -47.78 67.28 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 125.895 1.678 . . . . 0.0 110.908 -171.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -69.47 -40.86 76.86 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.673 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -66.19 -37.8 86.46 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 123.033 0.533 . . . . 0.0 109.568 176.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.94 -45.11 94.03 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 118.513 -0.755 . . . . 0.0 110.37 175.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 28.9 mmt-85 -63.92 -42.43 97.4 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.691 1.132 . . . . 0.0 110.6 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.16 -43.1 99.58 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.513 0.597 . . . . 0.0 110.948 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.7 m -68.18 -37.3 80.79 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 122.75 0.42 . . . . 0.0 110.432 178.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 54.8 mt -67.29 -33.42 75.25 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.122 -0.986 . . . . 0.0 110.658 176.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -67.04 -35.78 80.62 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.842 0.746 . . . . 0.0 111.457 174.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.04 -46.32 81.73 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 121.915 -0.49 . . . . 0.0 109.893 169.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? . . . . . 0 C--N 1.338 0.073 0 C-N-CA 123.629 0.772 . . . . 0.0 110.725 -176.866 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 0.388 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.8 t -140.32 137.41 17.79 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 -169.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.88 174.42 11.93 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.129 1.886 . . . . 0.0 111.56 174.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.11 -177.52 27.61 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 124.405 1.003 . . . . 0.0 111.065 172.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.7 tt0 -116.77 142.29 47.11 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 173.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 59.6 mt -74.58 85.05 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.1 tpp180 -71.48 -37.14 71.34 Favored 'General case' 0 CA--C 1.527 0.081 0 C-N-CA 124.882 1.273 . . . . 0.0 109.932 -172.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -157.83 144.61 17.91 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.645 1.578 . . . . 0.0 107.224 -175.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 61.4 mt -110.23 149.44 13.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -132.97 -0.19 3.41 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.668 1.187 . . . . 0.0 112.435 -169.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.405 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 146.83 -128.1 2.9 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 106.931 -2.468 . . . . 0.0 106.931 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 15.9 t30 -72.51 12.75 0.43 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.79 0.836 . . . . 0.0 110.96 169.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.405 ' H ' ' C ' ' A' ' 14' ' ' GLY . 36.7 mt-30 -140.44 161.68 37.13 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.505 2.322 . . . . 0.0 107.278 -169.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.78 153.41 42.37 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 176.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -104.62 69.6 0.9 Allowed 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 105.884 -1.895 . . . . 0.0 105.884 178.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.7 m -69.21 138.85 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 -171.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -81.2 102.89 10.63 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.09 62.76 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 C-N-CA 125.637 1.575 . . . . 0.0 108.519 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.8 m 43.76 42.49 4.39 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 127.285 2.234 . . . . 0.0 113.23 -179.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.69 -34.7 0.21 Allowed Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.037 -0.868 . . . . 0.0 113.535 177.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.4 tt -150.33 149.36 14.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 118.627 1.213 . . . . 0.0 108.753 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -76.77 135.43 38.98 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 176.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -137.88 137.19 37.83 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 124.4 1.08 . . . . 0.0 108.227 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.51 137.3 54.28 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 122.744 0.417 . . . . 0.0 110.032 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 m -140.81 145.54 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 124.826 1.25 . . . . 0.0 107.955 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -83.49 144.63 29.42 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 5.5 mp -110.36 10.44 23.45 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.029 -0.986 . . . . 0.0 113.207 -169.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.2 m -52.04 -32.18 33.28 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 121.006 1.73 . . . . 0.0 112.809 -177.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.4 mt -68.55 -15.85 63.67 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.38 -18.5 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 124.2 1.0 . . . . 0.0 112.913 -173.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.37 149.74 1.82 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.965 1.269 . . . . 0.0 110.694 -169.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 19.0 m -74.81 -5.1 41.62 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 121.806 -0.82 . . . . 0.0 112.952 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.7 m -126.56 157.68 38.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 124.443 1.097 . . . . 0.0 110.026 178.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -54.57 -53.4 55.08 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 126.756 2.022 . . . . 0.0 112.931 -171.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 176.07 -48.11 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 128.766 2.826 . . . . 0.0 106.793 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -79.71 -40.71 28.34 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.414 1.086 . . . . 0.0 111.144 -178.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 148.18 6.56 0.25 Allowed Glycine 0 CA--C 1.531 1.052 0 CA-C-O 118.7 -1.056 . . . . 0.0 114.089 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 mt-30 -76.99 124.18 87.4 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 119.352 1.576 . . . . 0.0 107.195 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.49 139.69 65.38 Favored 'Trans proline' 0 CA--C 1.534 0.482 0 C-N-CA 122.39 2.06 . . . . 0.0 111.142 174.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.7 mtt-85 -71.2 6.39 1.7 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -177.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.1 t -51.88 129.08 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 120.121 1.328 . . . . 0.0 109.113 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.93 -19.29 54.76 Favored Glycine 0 CA--C 1.53 1.002 0 C-N-CA 124.781 1.181 . . . . 0.0 113.458 178.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -68.32 163.4 23.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.338 1.569 . . . . 0.0 109.179 173.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -105.42 163.04 12.94 Favored 'General case' 0 C--O 1.234 0.238 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.49 148.08 14.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 123.194 0.598 . . . . 0.0 109.425 -169.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 74.9 mt -90.63 141.47 28.74 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 169.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.7 t -132.18 147.82 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -148.26 -45.85 0.16 Allowed 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.89 1.276 . . . . 0.0 109.009 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.6 m -126.97 -166.97 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 126.412 1.885 . . . . 0.0 106.673 171.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -72.37 37.68 0.69 Allowed Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.673 1.13 . . . . 0.0 114.112 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -139.59 147.36 41.01 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.342 1.457 . . . . 0.0 109.288 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.66 104.57 3.96 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 169.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 88.7 mmm -69.05 -45.05 71.38 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 118.369 0.532 . . . . 0.0 110.447 -169.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.5 m -161.76 152.84 18.16 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 126.156 1.783 . . . . 0.0 107.144 169.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -75.11 149.43 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 170.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -141.64 -167.55 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 C-N-CA 126.487 1.915 . . . . 0.0 108.293 176.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -123.63 174.17 7.62 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 125.098 1.359 . . . . 0.0 109.804 175.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -60.0 -40.17 88.31 Favored 'General case' 0 CA--C 1.527 0.083 0 C-N-CA 123.895 0.878 . . . . 0.0 112.399 -172.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.36 -37.81 56.74 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 118.183 0.447 . . . . 0.0 109.923 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -61.8 -36.15 80.27 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.333 0.653 . . . . 0.0 109.878 173.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.52 -42.35 98.45 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.504 -0.748 . . . . 0.0 110.809 174.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.6 mpt_? -64.59 -43.39 93.96 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 119.275 0.943 . . . . 0.0 109.995 177.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -60.27 -40.13 89.29 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.064 0.393 . . . . 0.0 111.065 177.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.4 m -65.67 -43.61 88.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.091 0.557 . . . . 0.0 110.452 176.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 59.4 mt -63.64 -38.9 92.87 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 118.873 0.761 . . . . 0.0 110.639 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -64.69 -45.35 87.01 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 123.408 0.683 . . . . 0.0 110.427 175.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.23 -42.73 99.12 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.425 0.557 . . . . 0.0 110.995 177.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? . . . . . 0 C--O 1.234 0.246 0 C-N-CA 123.514 0.726 . . . . 0.0 109.909 -178.908 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.731 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 10.6 p -148.87 154.05 39.56 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 123.848 0.859 . . . . 0.0 109.54 -169.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -58.54 161.92 13.6 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.711 2.274 . . . . 0.0 113.364 169.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.55 175.35 38.97 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 108.654 -1.779 . . . . 0.0 108.654 169.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -116.89 131.88 56.84 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 176.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.9 mt -66.41 119.06 10.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 177.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.5 tpp180 -107.4 -40.6 5.32 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 118.507 -0.759 . . . . 0.0 109.713 -169.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.9 p -142.37 161.8 37.11 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.493 1.117 . . . . 0.0 108.438 169.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.4 mt -132.64 148.81 31.64 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -179.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -124.54 -24.56 4.19 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.299 1.04 . . . . 0.0 112.028 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.66 -126.74 1.33 Allowed Glycine 0 C--N 1.333 0.416 0 N-CA-C 106.757 -2.537 . . . . 0.0 106.757 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 11.8 t30 -65.48 -24.44 67.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.722 0.761 . . . . 0.0 110.254 169.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -93.39 155.6 17.28 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-O 122.054 0.93 . . . . 0.0 110.282 172.119 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.64 175.03 11.91 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.65 1.58 . . . . 0.0 108.863 -178.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -128.71 99.83 5.49 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 176.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.3 m -69.12 165.88 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 169.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -111.74 112.95 25.01 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 169.029 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -88.26 60.58 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 -177.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.6 m 46.45 41.31 9.26 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.094 2.157 . . . . 0.0 113.586 178.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.56 -26.95 0.2 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.106 -0.83 . . . . 0.0 114.248 175.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.5 tp -149.34 149.91 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.447 0 CA-C-N 118.646 1.223 . . . . 0.0 107.742 177.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -76.21 147.79 38.15 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 175.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -140.16 132.59 28.51 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 124.563 1.145 . . . . 0.0 108.823 176.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -69.98 140.69 52.99 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 123.976 0.91 . . . . 0.0 110.185 176.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -148.49 167.13 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 126.136 1.774 . . . . 0.0 109.162 -178.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -107.03 143.59 34.92 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 169.623 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 26.6 mt -114.58 21.35 14.59 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.279 1.431 . . . . 0.0 110.854 -173.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.07 -35.45 59.56 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.699 1.199 . . . . 0.0 112.584 -171.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.7 mt -80.34 -8.96 59.72 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.679 0.791 . . . . 0.0 112.617 -176.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.7 m -126.92 -5.83 4.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.253 1.021 . . . . 0.0 111.815 -177.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.27 79.21 Favored Glycine 0 CA--C 1.532 1.099 0 C-N-CA 124.99 1.281 . . . . 0.0 114.918 169.609 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 m 58.5 -14.28 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 127.167 2.187 . . . . 0.0 116.711 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.6 m -136.5 153.39 51.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 124.828 1.251 . . . . 0.0 109.598 -177.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -64.97 157.91 26.94 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.472 1.109 . . . . 0.0 108.899 169.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -48.2 -41.65 27.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.279 1.431 . . . . 0.0 112.445 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -80.73 -16.84 52.86 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 118.91 -0.566 . . . . 0.0 112.152 -176.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.92 -12.6 5.32 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-O 118.504 -1.164 . . . . 0.0 115.817 169.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -66.06 135.36 95.14 Favored Pre-proline 0 N--CA 1.469 0.477 0 CA-C-N 119.662 1.731 . . . . 0.0 109.341 -172.24 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.11 140.33 71.25 Favored 'Trans proline' 0 CA--C 1.534 0.475 0 C-N-CA 121.707 1.605 . . . . 0.0 109.162 171.439 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -73.42 11.25 0.81 Allowed 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 114.517 1.302 . . . . 0.0 114.517 -172.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.0 m -53.14 133.99 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 120.251 1.387 . . . . 0.0 109.698 176.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.8 -18.61 52.56 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.433 -1.204 . . . . 0.0 112.992 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -73.52 142.18 46.73 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 119.89 1.845 . . . . 0.0 108.974 177.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -85.04 151.24 24.31 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 170.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.69 145.02 14.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -170.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 86.0 mt -79.1 132.74 36.69 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 169.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 50.2 t -118.63 123.69 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -135.04 137.56 43.06 Favored 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.7 m 44.1 28.45 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 C-N-CA 126.61 1.964 . . . . 0.0 115.405 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.76 4.65 58.98 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.698 1.142 . . . . 0.0 113.892 175.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -125.79 144.55 50.59 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 119.093 1.447 . . . . 0.0 109.719 -176.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.16 120.04 16.16 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 169.381 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 25.8 mmt -91.47 -45.52 8.49 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 119.001 -0.523 . . . . 0.0 111.436 -178.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.5 m -152.19 138.47 18.42 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -176.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.1 t -74.12 142.2 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 169.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.53 -169.52 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 125.695 1.598 . . . . 0.0 109.133 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -128.16 174.79 8.95 Favored 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 125.803 1.641 . . . . 0.0 108.791 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -62.51 -36.52 82.83 Favored 'General case' 0 N--CA 1.462 0.129 0 CA-C-O 118.955 -0.545 . . . . 0.0 112.434 -173.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.99 -44.67 76.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.936 0.789 . . . . 0.0 109.464 -177.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -64.58 -41.34 96.34 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 123.136 0.574 . . . . 0.0 110.259 176.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -49.14 75.91 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 122.86 0.464 . . . . 0.0 110.431 179.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -64.67 -41.25 96.21 Favored 'General case' 0 N--CA 1.463 0.195 0 C-N-CA 123.156 0.583 . . . . 0.0 110.376 -178.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -62.5 -43.23 99.33 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.397 0.544 . . . . 0.0 110.939 176.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -69.59 -37.46 76.93 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 122.097 -0.377 . . . . 0.0 110.506 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 27.7 mt -62.79 -40.15 96.45 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 119.113 0.87 . . . . 0.0 110.293 176.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -66.32 -43.54 85.92 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.375 0.534 . . . . 0.0 110.701 175.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.7 -43.06 84.9 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.103 0.411 . . . . 0.0 110.478 176.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 1.9 mm? . . . . . 0 CA--C 1.538 0.488 0 C-N-CA 124.994 1.317 . . . . 0.0 113.748 178.335 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.713 0 N-CA-C 108.238 -1.945 . . . . 0.0 108.238 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.0 p -150.67 157.2 36.31 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.613 1.165 . . . . 0.0 109.44 -168.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -67.62 158.37 57.49 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 121.962 1.775 . . . . 0.0 110.477 168.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.45 177.28 39.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 171.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -116.11 138.41 51.28 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 117.565 0.683 . . . . 0.0 109.334 -175.489 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 60.6 mt -73.7 83.29 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 176.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -76.48 -29.71 56.97 Favored 'General case' 0 N--CA 1.465 0.286 0 O-C-N 121.624 -0.672 . . . . 0.0 111.553 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.73 154.83 38.1 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.747 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 64.5 mt -129.66 147.98 33.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -121.32 -24.87 5.34 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.463 1.105 . . . . 0.0 112.121 -176.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 161.06 -113.0 0.55 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 108.307 -1.917 . . . . 0.0 108.307 178.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -69.37 2.04 3.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.656 0.782 . . . . 0.0 111.875 169.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -139.23 159.3 42.48 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 126.925 2.09 . . . . 0.0 107.679 -170.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 169.14 18.14 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.26 1.424 . . . . 0.0 110.035 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -115.82 73.09 0.83 Allowed 'General case' 0 C--O 1.234 0.241 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 -174.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.0 t -71.56 125.53 30.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 -172.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -77.18 112.05 13.45 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 169.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.9 m -82.56 43.08 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 C-N-CA 124.211 1.005 . . . . 0.0 110.718 177.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 66.7 m 48.5 49.93 17.58 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.077 1.751 . . . . 0.0 112.211 -172.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -177.71 -41.64 0.06 OUTLIER Glycine 0 CA--C 1.524 0.622 0 CA-C-O 119.644 -0.531 . . . . 0.0 112.404 174.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.6 tt -155.86 153.76 7.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -71.96 139.85 48.87 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 170.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 39.2 mmt180 -128.94 142.75 50.83 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 125.273 1.429 . . . . 0.0 107.977 176.246 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.08 131.47 46.65 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.5 t -140.68 129.56 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -83.36 144.19 29.82 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.517 0.727 . . . . 0.0 110.14 174.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.7 mt -109.6 7.85 24.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.312 1.045 . . . . 0.0 113.322 -169.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 25.2 m -53.1 -34.34 56.22 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.987 1.721 . . . . 0.0 112.482 -175.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.3 mt -74.98 -11.09 60.03 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.47 -17.0 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 CA-C-N 119.43 1.013 . . . . 0.0 112.563 -175.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.74 133.18 0.52 Allowed Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.264 1.411 . . . . 0.0 110.781 -175.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 21.4 m -67.86 156.65 36.66 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 169.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.0 m 61.97 145.48 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.227 2.211 . . . . 0.0 112.535 -169.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.95 155.31 38.79 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.207 1.403 . . . . 0.0 109.484 173.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.68 -27.56 62.99 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.646 1.179 . . . . 0.0 112.484 -176.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -62.69 -21.95 66.13 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.813 0.845 . . . . 0.0 113.043 175.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.99 47.9 3.25 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -174.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.9 pt20 -143.18 157.33 60.48 Favored Pre-proline 0 CA--C 1.536 0.426 0 C-N-CA 125.751 1.621 . . . . 0.0 107.93 -178.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -64.51 144.09 83.92 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 121.701 1.601 . . . . 0.0 110.375 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 90.6 mtt-85 -71.5 11.2 0.5 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.358 1.063 . . . . 0.0 113.621 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.1 m -57.45 131.69 21.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 O-C-N 120.616 -1.303 . . . . 0.0 109.817 -173.405 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 89.7 -17.44 52.63 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 118.306 -1.274 . . . . 0.0 113.413 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -66.57 156.34 35.28 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 119.693 1.746 . . . . 0.0 108.948 172.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.3 m95 -105.15 159.99 15.42 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.3 p -157.06 135.55 3.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -171.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 98.2 mt -75.68 131.37 39.85 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 168.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.72 135.05 64.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 119.344 0.974 . . . . 0.0 108.402 -178.228 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -141.83 120.81 12.83 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.684 1.193 . . . . 0.0 107.945 -169.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.2 t 41.6 47.95 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 126.671 1.988 . . . . 0.0 112.02 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.22 6.95 83.78 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 118.337 -1.257 . . . . 0.0 114.771 172.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.18 149.02 50.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 119.803 1.802 . . . . 0.0 110.017 177.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.47 116.16 7.9 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 169.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.9 ttt -76.75 -48.46 18.64 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.532 0.733 . . . . 0.0 109.497 177.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 65.4 m -163.11 144.54 9.75 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.975 1.31 . . . . 0.0 108.833 171.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.6 t -72.32 146.29 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 169.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 pt -137.8 157.91 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 C-N-CA 125.236 1.414 . . . . 0.0 109.02 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -80.83 169.19 17.89 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 120.927 0.394 . . . . 0.0 110.773 176.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -61.14 -44.57 97.11 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 123.385 0.674 . . . . 0.0 111.993 -173.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.66 -37.1 62.82 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 122.759 0.424 . . . . 0.0 109.953 -174.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 56.4 tt0 -60.27 -39.31 86.37 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.846 1.258 . . . . 0.0 110.033 172.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.96 -44.95 87.71 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.618 -0.676 . . . . 0.0 111.322 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 26.5 mmt-85 -62.49 -40.88 98.13 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 119.103 0.865 . . . . 0.0 110.441 178.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.96 -41.97 99.69 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.887 0.475 . . . . 0.0 110.907 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -65.07 -42.95 93.67 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.62 0.368 . . . . 0.0 110.232 177.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 42.5 mt -62.54 -43.58 98.45 Favored 'General case' 0 C--N 1.338 0.107 0 C-N-CA 123.269 0.628 . . . . 0.0 110.311 178.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.84 -44.95 94.78 Favored 'General case' 0 N--CA 1.46 0.073 0 C-N-CA 123.06 0.544 . . . . 0.0 110.845 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.12 -41.19 98.0 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.903 0.481 . . . . 0.0 111.191 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? . . . . . 0 C--N 1.338 0.104 0 C-N-CA 123.173 0.589 . . . . 0.0 109.577 177.051 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.86 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.6 m -141.61 162.14 48.39 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.036 1.334 . . . . 0.0 109.288 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -56.28 155.81 23.4 Favored 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 122.802 2.334 . . . . 0.0 113.447 172.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -158.32 167.97 34.59 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 107.951 -2.06 . . . . 0.0 107.951 169.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.8 tt0 -116.8 133.57 55.85 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 -178.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.19 97.01 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -83.34 -41.95 17.64 Favored 'General case' 0 N--CA 1.462 0.139 0 O-C-N 121.701 -0.625 . . . . 0.0 109.97 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 p -145.58 157.97 43.91 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 124.651 1.181 . . . . 0.0 108.83 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 54.4 mt -132.78 146.97 31.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 -174.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -123.55 -15.24 7.13 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.393 1.077 . . . . 0.0 112.091 -177.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 163.89 -131.56 2.48 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 106.459 -2.657 . . . . 0.0 106.459 -178.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -74.09 22.48 0.09 Allowed 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 118.057 0.929 . . . . 0.0 111.515 169.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . 0.415 ' H ' ' C ' ' A' ' 14' ' ' GLY . 41.1 mt-30 -140.5 148.61 41.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 126.594 1.958 . . . . 0.0 106.803 -179.056 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.61 163.46 32.0 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 124.454 1.102 . . . . 0.0 109.926 -179.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -110.79 78.37 1.11 Allowed 'General case' 0 C--O 1.233 0.232 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.0 m -70.59 130.88 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 123.477 0.711 . . . . 0.0 109.508 -177.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -76.84 111.3 12.22 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 168.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.4 t -84.75 54.67 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.74 45.72 8.31 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.984 2.113 . . . . 0.0 113.215 -177.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.3 -36.07 0.13 Allowed Glycine 0 CA--C 1.526 0.781 0 CA-C-O 119.468 -0.629 . . . . 0.0 113.003 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.8 tt -153.51 151.66 11.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 177.174 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.2 mt-30 -73.79 138.11 44.32 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 172.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -130.75 145.38 51.93 Favored 'General case' 0 N--CA 1.463 0.186 0 C-N-CA 125.261 1.424 . . . . 0.0 107.91 171.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -70.94 144.36 50.6 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 173.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.48 139.76 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -81.5 146.59 30.12 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.11 1.364 . . . . 0.0 110.284 172.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 86.1 mt -117.17 16.0 14.94 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.559 1.143 . . . . 0.0 112.404 -170.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 5.8 p -53.31 -34.98 59.61 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 120.561 1.528 . . . . 0.0 112.854 -176.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 73.9 mt -83.53 -6.04 59.34 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 118.46 -0.781 . . . . 0.0 112.865 -175.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -132.42 -20.41 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 119.536 1.062 . . . . 0.0 112.919 -174.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.29 147.83 7.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -177.32 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.6 m -68.23 -20.78 64.84 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.877 1.271 . . . . 0.0 113.364 -171.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.6 m -127.41 152.34 47.65 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 124.876 1.27 . . . . 0.0 109.283 -175.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -65.49 145.99 55.43 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.344 1.458 . . . . 0.0 109.972 172.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -53.99 -31.01 49.54 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.169 1.388 . . . . 0.0 113.517 -169.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -84.87 -7.86 59.01 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 118.863 0.756 . . . . 0.0 112.986 -178.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.34 52.65 0.76 Allowed Glycine 0 CA--C 1.527 0.793 0 CA-C-N 119.043 0.838 . . . . 0.0 112.728 170.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 30.0 pt20 -144.4 160.65 47.63 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 124.898 1.279 . . . . 0.0 108.697 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -63.74 143.76 87.36 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.627 1.551 . . . . 0.0 109.97 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 79.6 mtt-85 -70.56 12.93 0.21 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -177.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.8 m -57.91 135.1 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 O-C-N 120.59 -1.319 . . . . 0.0 109.984 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.52 -14.57 54.82 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 124.889 1.233 . . . . 0.0 113.484 -178.183 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -73.99 155.17 38.88 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 119.709 1.754 . . . . 0.0 109.373 177.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 83.5 m95 -97.95 159.16 15.11 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -157.07 147.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 91.9 mt -82.99 128.22 34.27 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 20.6 t -111.23 105.26 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -169.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . 0.412 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 6.7 t-160 -77.09 -171.37 1.99 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.903 0.881 . . . . 0.0 109.092 169.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.412 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 36.0 m -52.89 -26.84 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 C-N-CA 124.54 1.136 . . . . 0.0 113.795 -174.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.08 18.15 0.1 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.841 -0.977 . . . . 0.0 113.213 171.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -139.47 142.54 37.36 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 119.094 1.447 . . . . 0.0 109.12 -172.068 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.16 125.54 27.06 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 169.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 46.3 mtt -74.07 -57.59 3.86 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.4 m -157.77 145.21 18.41 Favored 'General case' 0 C--O 1.238 0.462 0 C-N-CA 126.356 1.863 . . . . 0.0 107.643 -176.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.1 m -74.44 148.99 7.68 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 169.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 pt -138.71 168.05 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 125.048 1.339 . . . . 0.0 108.575 -178.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -97.59 174.85 6.44 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.0 0.52 . . . . 0.0 110.134 176.267 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -62.55 -33.67 75.4 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.715 0.806 . . . . 0.0 111.481 -174.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.84 -49.1 61.25 Favored 'General case' 0 CA--C 1.528 0.129 0 O-C-N 121.72 -0.612 . . . . 0.0 110.251 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -64.25 -38.91 92.73 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 122.777 0.431 . . . . 0.0 110.342 178.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -52.3 65.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 118.049 0.386 . . . . 0.0 110.176 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -64.47 -39.03 93.03 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-O 118.677 -0.678 . . . . 0.0 111.005 -178.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.52 -43.03 99.81 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.088 0.858 . . . . 0.0 110.943 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.7 m -66.99 -42.75 84.51 Favored 'General case' 0 CA--C 1.537 0.466 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.418 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.2 mt -64.51 -35.58 81.41 Favored 'General case' 0 CA--C 1.528 0.099 0 O-C-N 121.449 -0.782 . . . . 0.0 110.923 178.082 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -66.89 -43.47 83.37 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 123.403 0.681 . . . . 0.0 110.672 176.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.29 -47.72 82.75 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.5 mt . . . . . 0 CA--C 1.537 0.463 0 C-N-CA 124.665 1.186 . . . . 0.0 113.699 -178.968 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.781 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.7 t -143.72 146.87 36.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 125.224 1.41 . . . . 0.0 107.583 -169.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -55.83 161.25 8.47 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.69 2.26 . . . . 0.0 113.339 169.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.93 177.3 39.78 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 169.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -116.78 137.19 52.38 Favored 'General case' 0 C--N 1.334 -0.105 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 39.1 mt -76.77 71.85 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 C-N-CA 124.89 1.276 . . . . 0.0 108.129 -175.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -63.76 -30.36 71.46 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 124.363 1.065 . . . . 0.0 112.445 -172.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -149.76 155.81 40.77 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 177.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.1 141.48 45.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -106.77 -28.33 10.22 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 124.039 0.936 . . . . 0.0 110.781 174.023 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.81 -121.88 0.98 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 106.78 -2.528 . . . . 0.0 106.78 177.243 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.4 t30 -65.34 -15.31 62.42 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 116.935 0.368 . . . . 0.0 111.693 169.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -105.85 153.12 22.37 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 172.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -146.71 169.12 19.71 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.33 1.052 . . . . 0.0 110.167 -177.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.39 75.1 1.37 Allowed 'General case' 0 CA--C 1.519 -0.233 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -171.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.6 t -73.6 128.26 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -74.06 106.17 5.62 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 169.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.71 57.85 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.1 m 43.35 48.42 5.9 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 127.566 2.347 . . . . 0.0 113.427 179.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 175.0 -39.26 0.11 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.592 -0.56 . . . . 0.0 112.305 176.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.5 tt -153.69 152.65 9.69 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -69.56 136.54 51.45 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 170.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 22.7 mmm180 -122.36 128.29 50.81 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 175.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -74.79 119.88 19.57 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 176.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.2 m -142.99 172.33 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 125.47 1.508 . . . . 0.0 109.579 -170.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -108.88 143.22 38.38 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 124.729 1.211 . . . . 0.0 111.056 -169.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.7 mt -114.03 9.88 17.41 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.47 1.108 . . . . 0.0 112.734 -175.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 6.4 m -55.06 -33.87 63.09 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.943 1.701 . . . . 0.0 112.154 -172.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.23 -9.82 58.93 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.661 0.785 . . . . 0.0 113.055 -177.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.9 -15.94 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 119.498 1.045 . . . . 0.0 112.651 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.13 147.49 7.2 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 124.983 1.278 . . . . 0.0 110.536 -176.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.5 m -65.57 -21.82 66.63 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.84 1.256 . . . . 0.0 112.184 177.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.3 m -126.71 168.43 14.38 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.452 1.501 . . . . 0.0 109.734 -175.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -117.79 154.02 32.46 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 126.95 2.1 . . . . 0.0 109.239 -169.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -57.78 -25.91 61.17 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.661 1.185 . . . . 0.0 112.711 -173.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -60.85 -23.77 65.38 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 123.863 0.865 . . . . 0.0 113.007 174.37 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.03 47.7 2.59 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -175.237 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -145.7 154.39 51.9 Favored Pre-proline 0 CA--C 1.535 0.375 0 C-N-CA 125.398 1.479 . . . . 0.0 108.638 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -66.48 152.04 81.72 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 121.828 1.685 . . . . 0.0 108.847 169.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 64.7 mtt-85 -70.19 10.57 0.42 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 114.339 1.237 . . . . 0.0 114.339 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.51 137.57 23.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 O-C-N 120.849 -1.157 . . . . 0.0 108.933 -172.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.71 -11.37 33.79 Favored Glycine 0 CA--C 1.532 1.106 0 CA-C-O 118.187 -1.34 . . . . 0.0 114.028 179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -67.64 163.05 22.26 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.91 1.855 . . . . 0.0 109.219 171.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.2 m95 -104.25 155.47 18.72 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.2 p -153.24 142.77 14.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -171.103 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -84.47 113.1 20.96 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 169.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 38.9 t -93.42 137.09 23.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.213 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 178.346 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -137.12 142.83 42.28 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.273 1.029 . . . . 0.0 108.702 175.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 22.5 t 56.37 -75.99 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 127.071 2.148 . . . . 0.0 111.439 -173.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.24 27.8 0.19 Allowed Glycine 0 CA--C 1.535 1.31 0 C-N-CA 127.761 2.6 . . . . 0.0 110.088 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -139.53 144.08 37.71 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 126.215 1.806 . . . . 0.0 107.847 -170.144 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.74 122.94 17.61 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 169.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 52.0 ttp -80.32 -57.9 3.39 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 171.042 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 17.8 m -150.64 138.03 19.55 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 123.77 0.828 . . . . 0.0 109.517 -172.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.0 t -72.09 144.6 12.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 169.416 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.4 pt -138.29 158.8 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 124.781 1.232 . . . . 0.0 108.846 -176.223 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -81.91 167.84 18.54 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 110.593 175.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -67.37 -33.43 75.21 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.549 0.74 . . . . 0.0 112.341 -169.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.9 -39.94 33.61 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.308 -0.87 . . . . 0.0 109.637 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.2 tt0 -59.8 -40.78 89.52 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.011 1.325 . . . . 0.0 110.146 173.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -50.8 71.31 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.145 0.578 . . . . 0.0 110.662 175.042 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 84.2 mtm180 -63.29 -40.17 96.61 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 119.072 -0.489 . . . . 0.0 111.201 -178.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.25 -43.62 97.5 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 118.582 0.628 . . . . 0.0 110.785 176.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.2 m -65.63 -39.24 91.25 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 119.276 -0.392 . . . . 0.0 110.35 178.625 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 35.8 mt -64.62 -42.21 95.67 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 119.099 0.863 . . . . 0.0 110.536 176.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -64.68 -39.33 93.49 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 123.164 0.586 . . . . 0.0 110.961 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.13 -51.05 63.56 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.495 0.318 . . . . 0.0 110.24 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? . . . . . 0 N--CA 1.462 0.139 0 C-N-CA 124.39 1.076 . . . . 0.0 110.679 -174.278 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.888 0 N-CA-C 111.673 -0.571 . . . . 0.0 111.673 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.3 t -146.69 151.94 43.77 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 -169.599 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_exo -54.92 157.56 12.86 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 122.153 1.902 . . . . 0.0 112.728 169.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.25 172.49 34.71 Favored Glycine 0 CA--C 1.526 0.767 0 C-N-CA 124.474 1.035 . . . . 0.0 110.765 174.206 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -119.81 130.6 54.99 Favored 'General case' 0 CA--C 1.522 -0.108 0 C-N-CA 124.023 0.929 . . . . 0.0 109.032 -176.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.4 mt -69.3 130.26 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 22.3 mmt85 -119.8 -31.73 4.44 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 118.564 -0.731 . . . . 0.0 111.274 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 m -146.93 153.68 40.38 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 20.1 mt -132.49 141.67 44.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 177.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -122.25 -15.41 7.69 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.057 0.943 . . . . 0.0 111.664 -176.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.77 -135.51 3.6 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 107.12 -2.392 . . . . 0.0 107.12 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -66.52 5.0 0.65 Allowed 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 123.972 0.909 . . . . 0.0 113.031 169.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -133.45 153.05 51.94 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 126.138 1.775 . . . . 0.0 107.799 178.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.77 158.09 43.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.763 1.225 . . . . 0.0 110.254 -171.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.73 122.72 37.63 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 170.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.2 t -125.46 123.45 64.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 -173.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -67.71 128.24 35.74 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 172.13 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -128.42 124.19 61.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 171.142 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.3 m 50.16 26.45 2.15 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 125.304 1.441 . . . . 0.0 114.376 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.69 -1.33 36.43 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-O 118.451 -1.194 . . . . 0.0 113.766 172.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.6 mm -134.21 132.04 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 119.451 1.625 . . . . 0.0 107.279 -173.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -66.53 140.13 57.97 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.932 0.396 . . . . 0.0 110.526 178.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 20.6 mmt-85 -126.43 149.01 49.55 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.531 1.932 . . . . 0.0 106.789 169.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -80.01 136.07 36.51 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 169.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -137.76 135.77 45.82 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -176.193 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -79.87 140.12 36.88 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.995 1.318 . . . . 0.0 110.033 174.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 42.5 mt -113.98 14.33 18.41 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 124.051 0.941 . . . . 0.0 112.911 -171.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.7 m -52.24 -36.69 53.08 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 120.604 1.547 . . . . 0.0 112.623 -173.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.9 mt -80.74 -6.96 59.17 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 112.927 0.714 . . . . 0.0 112.927 -174.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.6 m -131.98 -17.56 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 119.476 1.034 . . . . 0.0 112.452 -174.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.14 151.54 5.27 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.601 1.096 . . . . 0.0 110.947 -174.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.8 p -74.31 -18.6 60.68 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.558 1.143 . . . . 0.0 112.836 179.742 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.5 m -124.01 150.07 45.31 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.492 1.117 . . . . 0.0 109.442 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.09 161.86 27.1 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.447 1.099 . . . . 0.0 110.625 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -45.98 -41.27 11.56 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.078 1.751 . . . . 0.0 112.087 170.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 30.9 t30 -65.84 -14.72 61.97 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.53 1.132 . . . . 0.0 112.943 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.82 35.14 5.47 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-O 119.027 -0.874 . . . . 0.0 113.835 169.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -142.75 164.22 33.79 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 118.566 1.183 . . . . 0.0 109.192 172.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -51.14 146.4 23.17 Favored 'Trans proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.599 2.866 . . . . 0.0 112.508 175.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -71.06 18.72 0.06 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 114.243 1.201 . . . . 0.0 114.243 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.6 m -58.0 138.09 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 O-C-N 120.234 -1.541 . . . . 0.0 110.005 -176.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.21 -17.61 17.33 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.465 -1.186 . . . . 0.0 113.537 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.9 mt-30 -70.44 161.11 31.13 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.491 1.646 . . . . 0.0 109.447 175.215 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 56.2 m95 -106.21 157.45 17.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -144.65 142.85 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.796 1.239 . . . . 0.0 107.711 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -86.64 116.47 24.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 103.781 -2.674 . . . . 0.0 103.781 169.029 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 31.7 m -116.98 137.04 52.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -171.567 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.93 139.15 36.1 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 33.6 m 45.46 27.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.88 0 C-N-CA 126.457 1.903 . . . . 0.0 115.453 172.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 97.81 7.32 56.65 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.069 176.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.13 141.78 51.08 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 119.706 1.753 . . . . 0.0 109.394 -177.415 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.16 114.45 14.83 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 169.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.9 mmt -88.59 -26.22 22.06 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 122.911 0.484 . . . . 0.0 110.762 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 66.1 m -155.19 156.29 35.43 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 124.714 1.206 . . . . 0.0 108.687 171.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 137.72 34.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 172.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 pt -140.11 159.95 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 C-N-CA 124.55 1.14 . . . . 0.0 110.419 -169.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -81.02 169.07 17.96 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.603 0.761 . . . . 0.0 110.305 173.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -69.38 -30.34 68.3 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -170.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.19 -41.45 61.41 Favored 'General case' 0 N--CA 1.461 0.102 0 O-C-N 121.024 -1.047 . . . . 0.0 109.79 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -61.91 -41.36 97.82 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.565 0.746 . . . . 0.0 109.65 174.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.78 -49.05 77.9 Favored 'General case' 0 C--N 1.34 0.177 0 O-C-N 121.934 -0.479 . . . . 0.0 110.807 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -64.6 -38.58 91.51 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 118.977 -0.535 . . . . 0.0 111.354 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -64.73 -41.54 95.88 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 118.969 0.804 . . . . 0.0 110.856 176.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 24.2 m -68.01 -37.48 81.47 Favored 'General case' 0 CA--C 1.539 0.553 0 O-C-N 122.02 -0.425 . . . . 0.0 110.328 178.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 37.5 mt -62.74 -44.71 95.5 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.43 -0.794 . . . . 0.0 109.761 174.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -62.06 -40.74 96.83 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 118.775 0.716 . . . . 0.0 111.131 177.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.39 -34.42 77.68 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.897 -0.502 . . . . 0.0 111.83 175.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? . . . . . 0 CA--C 1.532 0.275 0 C-N-CA 123.761 0.824 . . . . 0.0 110.66 177.523 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.475 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.9 t -139.51 144.21 38.74 Favored Pre-proline 0 CA--C 1.541 0.615 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 -177.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.35 160.4 47.06 Favored 'Trans proline' 0 CA--C 1.534 0.516 0 C-N-CA 122.534 2.156 . . . . 0.0 111.957 174.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.04 172.92 40.0 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 171.109 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -95.34 137.04 34.93 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.9 mt -69.94 93.3 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 169.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -79.55 -33.59 41.74 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 119.108 -0.472 . . . . 0.0 110.38 -170.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 m -149.48 152.73 36.12 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.3 mt -131.69 144.41 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -124.02 -20.44 5.35 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.187 0.995 . . . . 0.0 111.967 -178.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.8 -129.54 1.89 Allowed Glycine 0 C--N 1.335 0.499 0 N-CA-C 107.226 -2.35 . . . . 0.0 107.226 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.6 p-10 -65.91 -3.65 5.54 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 117.599 0.699 . . . . 0.0 112.559 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -125.38 157.43 36.83 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.763 1.225 . . . . 0.0 109.602 175.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -154.69 160.42 41.36 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.52 1.528 . . . . 0.0 109.911 -171.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.17 112.17 24.58 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.611 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.7 t -92.13 124.11 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 170.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -84.91 108.7 17.68 Favored 'General case' 0 C--O 1.233 0.218 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 169.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.0 t -83.19 61.02 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 125.858 1.663 . . . . 0.0 107.046 174.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 62.5 m 38.42 45.95 0.89 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 128.044 2.538 . . . . 0.0 114.41 178.384 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 153.22 -17.12 0.69 Allowed Glycine 0 CA--C 1.526 0.724 0 CA-C-O 119.093 -0.837 . . . . 0.0 113.806 177.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.6 tp -143.83 145.08 22.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 173.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -94.72 134.37 37.4 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 51.2 mtp180 -126.42 118.99 26.13 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -70.49 131.01 43.39 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 173.466 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.5 m -139.79 155.3 24.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.11 0.964 . . . . 0.0 109.374 179.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -84.35 146.48 27.68 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.721 0.808 . . . . 0.0 109.524 171.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 mt -112.25 3.17 16.95 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.424 1.09 . . . . 0.0 112.573 -173.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.6 m -59.03 -26.17 64.33 Favored 'General case' 0 CA--C 1.544 0.725 0 CA-C-N 120.595 1.543 . . . . 0.0 112.227 -173.207 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.7 mt -65.67 -19.96 66.11 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 121.608 -0.683 . . . . 0.0 112.708 176.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -129.25 -10.92 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.785 1.234 . . . . 0.0 112.013 -174.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.35 139.94 0.96 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 125.365 1.46 . . . . 0.0 109.916 -170.232 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 18.3 m -71.11 -12.17 61.36 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.934 -0.745 . . . . 0.0 112.833 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.4 m -119.36 146.42 45.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.655 1.182 . . . . 0.0 109.311 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -79.94 160.55 25.92 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 124.156 0.982 . . . . 0.0 110.087 176.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.7 -33.27 22.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.216 1.406 . . . . 0.0 112.421 173.18 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -67.44 -13.4 62.0 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.09 31.52 5.9 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 118.893 -0.948 . . . . 0.0 114.428 169.323 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -146.11 167.57 13.75 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 118.813 1.307 . . . . 0.0 109.003 172.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -50.59 150.75 11.42 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 123.394 2.729 . . . . 0.0 112.837 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 87.4 mtt-85 -74.21 20.99 0.1 Allowed 'General case' 0 CA--C 1.541 0.627 0 O-C-N 121.143 -0.973 . . . . 0.0 113.332 177.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.6 m -56.26 131.94 19.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 O-C-N 120.783 -1.198 . . . . 0.0 109.658 -176.458 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.97 -11.88 55.64 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 118.055 -1.414 . . . . 0.0 113.968 177.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -70.34 169.43 13.89 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.631 1.716 . . . . 0.0 109.692 172.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -118.56 149.58 41.1 Favored 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.686 0.794 . . . . 0.0 109.58 -178.21 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -147.51 156.51 9.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 124.555 1.142 . . . . 0.0 109.417 -175.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 92.9 mt -84.47 140.12 31.71 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 168.255 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.1 m -132.04 127.33 57.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -144.07 -29.47 0.49 Allowed 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -169.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.8 m -136.2 20.37 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 118.665 0.666 . . . . 0.0 112.362 -169.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.59 10.16 73.82 Favored Glycine 0 CA--C 1.532 1.149 0 O-C-N 121.45 -0.781 . . . . 0.0 112.629 -175.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 70.1 m-85 -135.44 153.58 51.73 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.222 1.409 . . . . 0.0 107.937 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.91 105.37 2.79 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 169.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.09 -39.28 75.66 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.882 0.873 . . . . 0.0 110.929 -170.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.5 m -160.29 155.21 24.4 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 125.369 1.467 . . . . 0.0 108.563 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.1 t -78.08 146.72 7.82 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 169.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.4 pt -138.26 161.15 31.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 C-N-CA 125.502 1.521 . . . . 0.0 108.53 177.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -73.97 163.58 27.72 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-O 121.932 0.872 . . . . 0.0 110.583 174.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -57.68 -40.97 80.66 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 126.402 1.881 . . . . 0.0 111.809 178.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.87 -34.72 29.93 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.801 0.841 . . . . 0.0 110.801 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 60.7 tt0 -62.52 -34.35 76.73 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.641 1.176 . . . . 0.0 110.287 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.26 -43.03 87.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 122.002 -0.437 . . . . 0.0 111.359 171.325 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.8 mmt85 -69.7 -41.33 75.54 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 118.416 0.553 . . . . 0.0 109.609 -177.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.13 -40.24 93.05 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 122.54 0.336 . . . . 0.0 110.67 175.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -66.61 -41.26 88.69 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.154 0.582 . . . . 0.0 110.57 177.196 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.6 mt -62.18 -40.61 96.63 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 119.448 1.022 . . . . 0.0 110.313 175.296 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -64.79 -41.79 95.56 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 118.113 0.415 . . . . 0.0 110.843 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.96 -41.77 97.0 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 118.56 0.618 . . . . 0.0 111.083 174.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.1 tm? . . . . . 0 CA--C 1.53 0.174 0 C-N-CA 123.824 0.85 . . . . 0.0 109.804 -179.172 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.894 0 CA-C-O 119.728 -0.485 . . . . 0.0 113.789 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.2 t -146.76 148.23 32.53 Favored Pre-proline 0 CA--C 1.544 0.715 0 C-N-CA 126.249 1.82 . . . . 0.0 106.998 -171.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -57.44 163.79 8.03 Favored 'Trans proline' 0 CA--C 1.536 0.609 0 C-N-CA 122.432 2.088 . . . . 0.0 112.426 169.144 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -160.46 163.33 33.93 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 58.3 tt0 -116.93 131.79 56.86 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 94.6 mt -70.36 117.66 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.475 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -90.19 -32.77 16.47 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 118.666 -0.683 . . . . 0.0 110.502 172.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.12 152.92 35.51 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -170.115 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.8 mt -132.43 141.03 46.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 172.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -120.84 -18.86 7.51 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.425 1.09 . . . . 0.0 111.47 -176.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.22 -126.6 1.36 Allowed Glycine 0 C--N 1.336 0.538 0 N-CA-C 107.146 -2.382 . . . . 0.0 107.146 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -67.28 -8.63 33.52 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 117.052 0.426 . . . . 0.0 112.11 169.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -119.81 159.44 24.57 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 125.486 1.514 . . . . 0.0 109.538 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.04 177.09 10.51 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 126.177 1.791 . . . . 0.0 109.568 -170.085 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -129.31 126.97 40.17 Favored 'General case' 0 CA--C 1.516 -0.363 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 1.6 m -119.47 138.7 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 C-N-CA 125.001 1.32 . . . . 0.0 108.357 -177.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -85.36 107.88 17.57 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 104.497 -2.408 . . . . 0.0 104.497 168.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -81.49 57.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 C-N-CA 125.362 1.465 . . . . 0.0 107.971 -176.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 50.7 m 45.42 43.34 8.53 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.007 2.123 . . . . 0.0 113.159 -177.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 170.28 -42.57 0.2 Allowed Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.303 -0.72 . . . . 0.0 112.641 175.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.4 pt -141.8 150.17 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 C-N-CA 124.562 1.145 . . . . 0.0 109.514 -179.183 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -76.99 138.25 39.49 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -136.77 148.55 47.3 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 124.927 1.291 . . . . 0.0 109.307 173.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -68.05 148.22 51.3 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 169.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.48 143.27 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 173.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -92.36 145.23 24.63 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.593 0.757 . . . . 0.0 109.44 170.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 46.9 mt -112.53 13.48 20.08 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 118.2 -0.905 . . . . 0.0 112.959 -170.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 46.7 m -50.66 -37.13 39.15 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 120.889 1.677 . . . . 0.0 112.539 -178.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.8 mt -75.74 -11.71 60.04 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.41 -17.86 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 119.445 1.021 . . . . 0.0 113.343 -169.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.35 146.44 3.03 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.698 1.142 . . . . 0.0 111.139 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 p -75.88 -17.68 59.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.662 1.185 . . . . 0.0 112.552 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.2 m -112.84 161.95 16.36 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.432 1.093 . . . . 0.0 109.2 174.008 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -106.72 -179.41 3.93 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 124.701 1.2 . . . . 0.0 113.171 -169.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 23.0 mp0 -67.41 -14.37 62.87 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.895 2.078 . . . . 0.0 112.627 -176.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.4 m-80 -96.7 -37.32 10.36 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.176 0.99 . . . . 0.0 110.185 -178.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.79 28.59 1.04 Allowed Glycine 0 CA--C 1.53 1.025 0 C-N-CA 125.299 1.428 . . . . 0.0 112.507 178.257 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -127.63 158.24 70.68 Favored Pre-proline 0 CA--C 1.538 0.5 0 CA-C-N 119.149 1.474 . . . . 0.0 109.316 -176.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.36 144.43 85.81 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.867 1.712 . . . . 0.0 109.548 174.163 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.9 mtt-85 -69.54 13.14 0.14 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 114.619 1.34 . . . . 0.0 114.619 -174.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.6 t -53.62 131.02 15.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-N 120.379 1.445 . . . . 0.0 108.446 176.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.36 -14.59 54.08 Favored Glycine 0 CA--C 1.53 0.978 0 CA-C-O 118.531 -1.15 . . . . 0.0 113.589 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -77.05 162.02 27.84 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 119.715 1.758 . . . . 0.0 109.195 176.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -106.43 151.25 25.17 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.0 m -140.78 150.38 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 177.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -88.36 124.99 34.47 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 103.662 -2.718 . . . . 0.0 103.662 168.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.86 156.99 18.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 6.3 t-80 -154.02 -32.83 0.11 Allowed 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 123.0 0.52 . . . . 0.0 111.315 -175.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.2 m -133.79 -163.24 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 170.183 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -68.06 19.91 0.33 Allowed Glycine 0 CA--C 1.538 1.471 0 CA-C-N 119.64 1.109 . . . . 0.0 114.817 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -133.9 139.82 46.42 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.768 1.627 . . . . 0.0 107.956 -179.298 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.06 116.11 10.05 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 170.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 86.6 mmm -74.33 -43.69 55.63 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.1 p -155.71 153.03 29.31 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.781 0.833 . . . . 0.0 110.067 179.297 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.6 t -79.65 143.38 12.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 169.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.2 pt -138.55 160.76 31.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 124.175 0.99 . . . . 0.0 108.849 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 -80.62 164.91 22.52 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -53.91 -41.85 68.09 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 123.608 0.763 . . . . 0.0 111.439 170.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.62 -37.08 85.96 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.857 0.463 . . . . 0.0 110.99 -177.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -71.1 -38.84 72.36 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 177.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.98 -48.7 80.6 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 118.415 0.552 . . . . 0.0 110.157 174.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.3 mtt180 -61.62 -43.26 99.18 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 123.489 0.715 . . . . 0.0 110.45 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.93 -41.35 99.46 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.688 0.676 . . . . 0.0 111.295 177.167 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.5 m -64.69 -41.47 96.02 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 122.807 0.443 . . . . 0.0 110.096 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 83.7 mt -66.51 -36.85 83.72 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 119.053 0.842 . . . . 0.0 110.941 177.222 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -66.05 -40.66 91.12 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 118.607 0.64 . . . . 0.0 110.822 177.273 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.03 -52.37 63.14 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 122.704 0.402 . . . . 0.0 109.997 173.442 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 6.6 tt . . . . . 0 C--O 1.233 0.187 0 C-N-CA 124.44 1.096 . . . . 0.0 109.984 -175.824 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.484 1.229 0 CA-C-O 119.281 -0.39 . . . . 0.0 110.029 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 59.0 m -62.84 158.24 19.39 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 118.763 0.711 . . . . 0.0 110.939 177.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.5 tt -153.5 154.71 7.13 Favored 'Isoleucine or valine' 0 C--O 1.236 0.374 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 176.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.82 56.89 0.16 Allowed Glycine 0 CA--C 1.528 0.905 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -174.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 20.9 t -139.15 141.13 28.59 Favored Pre-proline 0 CA--C 1.543 0.706 0 C-N-CA 124.317 1.047 . . . . 0.0 108.849 -169.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_exo -59.26 157.63 29.65 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.887 2.391 . . . . 0.0 112.919 169.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.32 172.67 40.17 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 169.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -99.61 135.73 40.6 Favored 'General case' 0 C--N 1.334 -0.078 0 N-CA-C 107.784 -1.191 . . . . 0.0 107.784 177.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.47 79.97 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.443 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 170.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 7.5 tpm_? -80.09 -24.67 40.42 Favored 'General case' 0 C--O 1.232 0.163 0 O-C-N 121.561 -0.712 . . . . 0.0 112.406 -169.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.57 158.58 43.74 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -130.0 146.3 34.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 176.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -121.78 -23.64 5.46 Favored 'General case' 0 N--CA 1.467 0.406 0 C-N-CA 124.111 0.965 . . . . 0.0 111.734 -179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.25 -126.8 1.35 Allowed Glycine 0 C--N 1.333 0.403 0 N-CA-C 106.163 -2.775 . . . . 0.0 106.163 178.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.4 t30 -63.8 -29.21 70.44 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 117.651 0.726 . . . . 0.0 110.303 169.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 16.7 mm100 -86.44 151.89 23.14 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.56 0.695 . . . . 0.0 109.235 173.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.56 166.02 25.4 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.034 1.334 . . . . 0.0 109.568 174.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 61.4 mtpt -114.48 78.25 1.14 Allowed 'General case' 0 C--O 1.234 0.266 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 -173.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.4 t -74.19 123.39 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 -175.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -75.04 107.92 7.43 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 169.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.52 61.22 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 177.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 32.0 m 45.94 43.96 10.82 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 127.205 2.202 . . . . 0.0 113.696 176.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.63 -36.66 0.16 Allowed Glycine 0 CA--C 1.525 0.703 0 CA-C-O 119.449 -0.639 . . . . 0.0 112.643 176.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -153.67 152.9 9.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.4 mt-30 -77.47 138.72 39.4 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.986 0.422 . . . . 0.0 110.059 177.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -117.85 144.95 44.95 Favored 'General case' 0 N--CA 1.464 0.237 0 C-N-CA 126.044 1.737 . . . . 0.0 107.196 171.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -74.58 129.93 38.63 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 169.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.8 t -137.01 136.14 47.64 Favored 'Isoleucine or valine' 0 C--O 1.232 0.168 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -176.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.1 t0 -82.4 126.26 31.98 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.166 1.386 . . . . 0.0 109.072 176.145 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 29.4 mt -100.76 10.95 40.51 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 117.95 -1.024 . . . . 0.0 112.971 -175.75 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 32.4 m -50.84 -36.62 38.5 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 121.285 1.857 . . . . 0.0 112.395 -174.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.0 mt -74.49 -10.37 59.49 Favored 'General case' 0 CA--C 1.538 0.505 0 N-CA-C 113.216 0.821 . . . . 0.0 113.216 -175.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.5 m -132.2 -17.61 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 119.445 1.021 . . . . 0.0 112.57 -176.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.18 145.91 1.02 Allowed Glycine 0 CA--C 1.529 0.955 0 C-N-CA 125.175 1.369 . . . . 0.0 110.654 -171.217 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.4 m -73.63 -5.3 39.57 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.734 -0.862 . . . . 0.0 113.067 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.3 m -131.97 151.79 51.51 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.362 1.065 . . . . 0.0 110.027 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -66.08 165.64 13.14 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.876 2.071 . . . . 0.0 109.71 169.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 36.3 tt0 -52.52 -37.5 57.69 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.29 1.436 . . . . 0.0 112.247 179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -85.9 10.21 14.6 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 123.8 0.84 . . . . 0.0 112.052 -178.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.67 5.27 88.4 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 124.623 1.106 . . . . 0.0 113.382 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.5 mt-30 -70.1 132.53 88.24 Favored Pre-proline 0 CA--C 1.537 0.469 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -65.86 141.44 65.11 Favored 'Trans proline' 0 N--CA 1.458 -0.56 0 CA-C-N 121.321 1.507 . . . . 0.0 109.107 174.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.9 mtt-85 -72.77 8.59 1.43 Allowed 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 114.401 1.26 . . . . 0.0 114.401 -173.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.06 125.46 7.14 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 120.128 1.331 . . . . 0.0 108.712 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.67 -19.32 55.12 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 124.873 1.225 . . . . 0.0 113.241 177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -70.12 167.45 17.72 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 119.061 1.431 . . . . 0.0 108.903 172.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 46.9 m95 -116.04 162.75 16.93 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.782 -0.574 . . . . 0.0 109.532 -179.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -156.61 146.21 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -169.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 83.1 mt -83.82 112.13 19.83 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 105.654 -1.98 . . . . 0.0 105.654 169.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.68 127.81 39.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 N-CA-C 106.314 -1.736 . . . . 0.0 106.314 173.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -140.98 130.23 23.57 Favored 'General case' 0 N--CA 1.456 -0.161 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 173.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.5 m 41.68 35.8 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 126.195 1.798 . . . . 0.0 114.541 -177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.8 6.93 79.11 Favored Glycine 0 CA--C 1.532 1.155 0 CA-C-O 119.076 -0.847 . . . . 0.0 114.092 175.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -122.41 154.78 37.27 Favored 'General case' 0 C--O 1.235 0.333 0 CA-C-N 118.951 1.376 . . . . 0.0 109.694 178.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.81 104.92 3.58 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 169.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.07 -47.84 60.28 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 118.261 0.482 . . . . 0.0 109.755 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.1 m -152.05 136.18 16.58 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.92 1.288 . . . . 0.0 108.017 178.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.2 p -84.13 138.72 18.71 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 169.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.4 pt -141.93 162.98 19.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 124.652 1.181 . . . . 0.0 110.24 -170.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -77.02 166.18 23.65 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 123.768 0.827 . . . . 0.0 109.84 175.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -57.59 -43.14 84.41 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.903 0.881 . . . . 0.0 110.629 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.49 -38.64 87.71 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 123.002 0.521 . . . . 0.0 110.829 -175.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -67.04 -44.36 80.41 Favored 'General case' 0 C--O 1.232 0.145 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.04 -48.58 79.62 Favored 'General case' 0 N--CA 1.455 -0.191 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 177.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.9 tmm_? -58.77 -46.81 86.64 Favored 'General case' 0 C--N 1.334 -0.104 0 C-N-CA 124.543 1.137 . . . . 0.0 110.059 -179.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -63.22 -43.12 99.01 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 118.492 0.587 . . . . 0.0 111.292 178.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -64.16 -42.01 96.92 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 178.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 39.5 mt -65.16 -40.42 94.32 Favored 'General case' 0 CA--C 1.522 -0.13 0 C-N-CA 123.82 0.848 . . . . 0.0 110.599 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -63.64 -41.21 98.26 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 122.982 0.513 . . . . 0.0 110.873 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -66.74 -48.38 69.33 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.276 0.23 . . . . 0.0 110.607 174.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 10.4 tt -61.99 -44.96 95.63 Favored 'General case' 0 C--O 1.231 0.108 0 C-N-CA 124.433 1.093 . . . . 0.0 111.231 -173.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -72.22 -18.29 61.85 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -176.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -55.39 -32.41 62.61 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 119.142 0.883 . . . . 0.0 112.857 -169.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -65.43 -17.62 64.69 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.149 0.98 . . . . 0.0 113.272 -178.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 39.5 p90 -140.86 -19.43 0.82 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 119.691 1.132 . . . . 0.0 113.809 -173.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -60.21 -22.34 62.86 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 119.592 1.087 . . . . 0.0 112.344 173.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 16.1 m -65.27 -7.61 4.7 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.728 0 C-N-CA 125.425 1.49 . . . . 0.0 113.362 174.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -136.48 157.21 75.72 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 124.82 1.248 . . . . 0.0 109.408 -178.069 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -65.81 -7.61 17.17 Favored 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 123.108 2.539 . . . . 0.0 113.133 177.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -52.27 -29.75 24.56 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 124.719 1.208 . . . . 0.0 112.2 170.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 8.0 p -58.01 -37.1 59.38 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 118.648 0.658 . . . . 0.0 111.465 174.488 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -75.74 -42.22 26.63 Favored Glycine 0 C--N 1.337 0.601 0 N-CA-C 110.246 -1.141 . . . . 0.0 110.246 178.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.88 -40.16 83.56 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-N 117.436 0.618 . . . . 0.0 110.926 177.119 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 39.1 tp -64.77 -58.46 6.19 Favored 'General case' 0 CA--C 1.529 0.165 0 C-N-CA 124.099 0.959 . . . . 0.0 109.703 172.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 60.6 tp -57.78 -45.24 86.26 Favored 'General case' 0 N--CA 1.463 0.194 0 C-N-CA 123.76 0.824 . . . . 0.0 111.979 -169.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -95.67 6.56 48.63 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 123.487 0.715 . . . . 0.0 111.808 -176.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.12 -177.28 37.72 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 124.382 0.991 . . . . 0.0 111.483 178.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -118.13 15.65 14.09 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 125.164 1.385 . . . . 0.0 110.672 -177.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -74.79 6.34 4.07 Favored 'General case' 0 CA--C 1.545 0.759 0 C-N-CA 125.092 1.357 . . . . 0.0 112.76 177.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.251 1.139 0 C-N-CA 126.947 2.099 . . . . 0.0 108.751 -175.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.5 ptt? . . . . . 0 N--CA 1.484 1.234 0 N-CA-C 110.489 -0.189 . . . . 0.0 110.489 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 71.5 m -66.52 150.8 48.44 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 169.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.8 tp -81.72 59.05 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 CA-C-O 122.651 1.215 . . . . 0.0 108.889 173.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -135.28 54.3 0.75 Allowed Glycine 0 CA--C 1.525 0.711 0 C-N-CA 127.186 2.327 . . . . 0.0 107.831 -175.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 13.8 m -145.43 158.13 51.31 Favored Pre-proline 0 CA--C 1.536 0.41 0 C-N-CA 126.473 1.909 . . . . 0.0 108.191 -169.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.79 162.43 26.87 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 121.894 1.729 . . . . 0.0 110.659 169.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.32 164.35 37.14 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.071 -1.212 . . . . 0.0 110.071 169.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.9 tt0 -89.43 127.28 35.82 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 72.6 mt -63.64 112.16 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 178.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.9 tpt85 -109.71 -30.63 7.79 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 118.113 -0.946 . . . . 0.0 110.994 -169.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 11.9 p -144.96 158.12 43.91 Favored 'General case' 0 C--O 1.236 0.395 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 169.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.7 mt -132.54 141.91 43.91 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.289 0 N-CA-C 105.31 -2.107 . . . . 0.0 105.31 176.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -116.13 -21.71 9.28 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 124.448 1.099 . . . . 0.0 111.447 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.3 -126.17 1.34 Allowed Glycine 0 C--N 1.334 0.437 0 N-CA-C 106.835 -2.506 . . . . 0.0 106.835 179.554 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 28.0 t30 -62.08 -15.6 46.25 Favored 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 117.37 0.585 . . . . 0.0 112.062 169.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 61.2 mt-30 -117.48 156.21 28.39 Favored 'General case' 0 C--O 1.238 0.461 0 O-C-N 121.151 -0.968 . . . . 0.0 109.23 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.39 173.3 13.69 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 125.894 1.678 . . . . 0.0 109.402 -169.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 53.4 mttp -132.72 109.2 9.52 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.2 m -84.24 135.25 25.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 C-N-CA 124.232 1.013 . . . . 0.0 108.605 178.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -81.11 115.28 20.47 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 169.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.5 t -87.93 60.59 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 125.427 1.491 . . . . 0.0 107.185 176.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 35.5 m 50.15 36.42 12.29 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 125.923 1.689 . . . . 0.0 114.369 176.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.3 -31.86 0.26 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 121.348 -0.845 . . . . 0.0 112.966 174.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . 0.403 HD13 ' H ' ' A' ' 24' ' ' ILE . 0.1 OUTLIER -138.77 140.45 38.98 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.411 0 C-N-CA 125.425 1.49 . . . . 0.0 108.818 179.867 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -77.63 141.98 39.14 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.098 174.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 56.7 mmt-85 -137.53 144.31 42.07 Favored 'General case' 0 N--CA 1.462 0.155 0 C-N-CA 125.014 1.326 . . . . 0.0 108.727 172.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -77.5 149.54 34.96 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.655 0.782 . . . . 0.0 111.068 -172.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.79 143.36 19.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 C-N-CA 124.978 1.311 . . . . 0.0 108.82 177.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -92.8 133.17 36.31 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 124.435 1.094 . . . . 0.0 108.77 171.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 51.0 mt -105.49 14.52 28.52 Favored 'General case' 0 CA--C 1.532 0.278 0 CA-C-O 118.312 -0.851 . . . . 0.0 112.058 -171.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -45.99 -38.03 7.25 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 120.333 1.424 . . . . 0.0 113.114 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 88.2 mt -85.41 -3.86 58.98 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.821 0.848 . . . . 0.0 113.02 -172.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.28 -18.36 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.547 1.067 . . . . 0.0 113.02 -177.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.77 143.51 1.22 Allowed Glycine 0 CA--C 1.531 1.037 0 C-N-CA 125.063 1.316 . . . . 0.0 110.759 -172.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.2 m -75.37 -8.89 57.88 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 12.5 p -125.21 152.2 44.86 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 124.548 1.139 . . . . 0.0 109.015 174.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.7 t0 -77.87 172.19 13.84 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 124.289 1.036 . . . . 0.0 110.349 178.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -57.59 -34.97 69.8 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.086 0.954 . . . . 0.0 112.213 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 18.0 p30 -80.41 -3.69 50.73 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.285 1.834 . . . . 0.0 113.102 177.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.38 -4.81 67.27 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 118.552 -1.138 . . . . 0.0 114.157 172.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -66.22 143.15 98.21 Favored Pre-proline 0 CA--C 1.537 0.454 0 CA-C-N 119.677 1.739 . . . . 0.0 109.087 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -64.42 143.09 81.39 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 121.878 1.719 . . . . 0.0 108.857 169.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 83.0 mtt-85 -72.8 1.6 8.27 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 114.574 1.324 . . . . 0.0 114.574 -170.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.0 m -50.24 137.89 6.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 120.994 1.725 . . . . 0.0 111.126 176.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.74 -26.37 18.72 Favored Glycine 0 CA--C 1.53 0.975 0 C-N-CA 124.759 1.171 . . . . 0.0 112.911 178.306 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -76.1 165.8 24.4 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 118.898 1.349 . . . . 0.0 108.404 173.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.8 m95 -105.18 156.52 18.02 Favored 'General case' 0 N--CA 1.453 -0.312 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 14.9 p -144.37 135.17 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 106.29 -1.745 . . . . 0.0 106.29 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 57.5 tp -78.39 133.67 37.5 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 22.3 t -116.33 150.97 18.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 -178.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.37 133.4 24.22 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 125.368 1.467 . . . . 0.0 107.649 171.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.5 m 42.58 33.48 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 C-N-CA 126.211 1.804 . . . . 0.0 114.641 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.2 7.62 82.88 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-O 118.966 -0.908 . . . . 0.0 114.106 176.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -120.28 143.81 48.13 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 119.117 1.458 . . . . 0.0 108.191 175.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.0 130.42 46.65 Favored 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.177 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 28.0 ttt -89.66 -57.88 2.72 Favored 'General case' 0 C--O 1.233 0.236 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 18.5 m -151.99 144.91 24.44 Favored 'General case' 0 C--O 1.233 0.191 0 C-N-CA 124.293 1.037 . . . . 0.0 109.078 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 26.8 t -74.12 140.29 17.88 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 105.399 -2.075 . . . . 0.0 105.399 168.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.5 pt -137.7 160.3 34.11 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 123.573 0.749 . . . . 0.0 109.821 -173.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -76.96 165.21 24.96 Favored 'General case' 0 CA--C 1.529 0.171 0 C-N-CA 123.691 0.796 . . . . 0.0 109.706 173.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -59.74 -42.83 94.04 Favored 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 123.467 0.707 . . . . 0.0 110.219 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -65.32 -36.38 83.87 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 123.066 0.547 . . . . 0.0 110.932 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.3 mt-10 -67.7 -35.05 78.09 Favored 'General case' 0 N--CA 1.457 -0.095 0 CA-C-O 119.129 -0.463 . . . . 0.0 110.113 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -47.32 83.67 Favored 'General case' 0 C--N 1.34 0.185 0 CA-C-N 118.95 0.795 . . . . 0.0 110.293 175.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 34.3 mmt180 -62.54 -43.55 98.54 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 118.167 0.44 . . . . 0.0 110.725 177.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.75 -40.89 96.71 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 118.131 0.423 . . . . 0.0 111.147 178.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.8 m -67.07 -42.48 84.64 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.245 178.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 68.9 mt -63.94 -39.05 93.26 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 119.204 0.911 . . . . 0.0 110.582 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.94 -46.89 79.69 Favored 'General case' 0 C--O 1.227 -0.091 0 C-N-CA 122.95 0.5 . . . . 0.0 110.585 175.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.57 -42.41 99.53 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 118.566 0.621 . . . . 0.0 111.225 179.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 52.6 tp -65.05 -35.64 81.81 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 123.882 0.873 . . . . 0.0 111.601 -174.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -81.52 -39.64 24.38 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.022 0.828 . . . . 0.0 110.474 172.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 28.6 t-20 -57.6 -42.68 83.73 Favored 'General case' 0 N--CA 1.462 0.143 0 C-N-CA 123.449 0.7 . . . . 0.0 111.563 -177.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 28.3 ptm -63.83 -10.04 18.19 Favored 'General case' 0 CA--C 1.536 0.437 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -177.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -115.82 -21.51 9.55 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-N 119.407 1.003 . . . . 0.0 111.144 173.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -64.65 -36.43 84.24 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.219 0.608 . . . . 0.0 111.246 171.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 21.1 m -61.96 -45.52 98.53 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 CA-C-N 118.037 0.381 . . . . 0.0 110.731 176.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -169.56 144.35 2.42 Favored Pre-proline 0 CA--C 1.539 0.521 0 C-N-CA 126.852 2.061 . . . . 0.0 107.423 169.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -73.51 -14.36 24.96 Favored 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.52 2.147 . . . . 0.0 112.679 -178.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 31.8 t70 -56.87 -27.32 60.27 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 125.016 1.326 . . . . 0.0 113.003 -175.067 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 38.7 t -58.23 -29.21 36.86 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 C-N-CA 123.886 0.875 . . . . 0.0 110.905 176.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.92 -38.94 94.88 Favored Glycine 0 CA--C 1.529 0.967 0 O-C-N 121.04 -1.038 . . . . 0.0 111.461 175.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -73.83 7.93 2.27 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.123 0.969 . . . . 0.0 113.121 178.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 38.2 tp -121.09 -42.17 2.5 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 125.77 1.628 . . . . 0.0 109.35 171.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 45.2 tp -65.47 -38.81 90.88 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-N 118.708 0.685 . . . . 0.0 111.202 177.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 24.1 p90 -138.61 36.34 2.22 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 125.521 1.528 . . . . 0.0 109.843 -177.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -156.11 -174.44 25.91 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 175.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -137.63 29.79 2.62 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.312 1.045 . . . . 0.0 109.459 -175.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.8 tp10 -71.33 -13.2 61.8 Favored 'General case' 0 CA--C 1.544 0.715 0 O-C-N 121.208 -0.933 . . . . 0.0 111.157 176.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 59.5 tptt . . . . . 0 C--O 1.249 1.038 0 C-N-CA 127.323 2.249 . . . . 0.0 105.732 175.887 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mpt? . . . . . 0 N--CA 1.483 1.214 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 58.3 m -64.58 165.2 10.48 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 123.191 0.596 . . . . 0.0 110.287 171.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 35.7 pt -77.47 57.9 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 C-N-CA 124.682 1.193 . . . . 0.0 111.181 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -75.51 49.78 2.39 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 126.354 1.931 . . . . 0.0 112.213 177.08 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 1.1 m -146.47 149.5 37.58 Favored Pre-proline 0 CA--C 1.536 0.434 0 C-N-CA 125.973 1.709 . . . . 0.0 108.184 -172.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -75.05 171.17 18.84 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 122.232 1.954 . . . . 0.0 112.237 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -156.07 167.84 33.39 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 169.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -101.72 136.83 40.9 Favored 'General case' 0 C--O 1.231 0.127 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.5 mt -72.65 82.6 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 125.648 1.579 . . . . 0.0 107.895 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.5 mmt85 -76.6 -27.56 55.83 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 121.607 -0.683 . . . . 0.0 111.565 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.14 152.18 35.66 Favored 'General case' 0 C--O 1.234 0.278 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 -176.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 63.6 mt -129.65 144.75 37.14 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 N-CA-C 105.746 -1.946 . . . . 0.0 105.746 177.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -121.13 -20.16 6.88 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 124.446 1.098 . . . . 0.0 111.835 -177.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.408 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 164.05 -127.48 1.67 Allowed Glycine 0 C--N 1.335 0.488 0 N-CA-C 106.607 -2.597 . . . . 0.0 106.607 -178.598 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -70.38 14.3 0.13 Allowed 'General case' 0 CA--C 1.549 0.934 0 C-N-CA 124.462 1.105 . . . . 0.0 112.004 169.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.408 ' H ' ' C ' ' A' ' 14' ' ' GLY . 37.7 mt-30 -140.11 153.8 46.82 Favored 'General case' 0 C--O 1.238 0.499 0 C-N-CA 127.66 2.384 . . . . 0.0 106.636 -176.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.65 167.18 22.68 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 125.261 1.425 . . . . 0.0 109.106 178.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -121.24 76.31 1.23 Allowed 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 -174.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 11.5 m -73.03 136.68 24.99 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -170.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -79.15 117.72 20.44 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 171.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 9.4 t -85.04 50.4 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.75 0 C-N-CA 125.059 1.343 . . . . 0.0 107.724 177.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 79.3 m 40.59 49.57 2.73 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 127.166 2.186 . . . . 0.0 113.371 -174.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 176.64 -38.92 0.1 OUTLIER Glycine 0 CA--C 1.526 0.748 0 CA-C-O 119.531 -0.594 . . . . 0.0 112.24 175.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.0 tp -156.26 154.86 5.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 175.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.5 mt-30 -76.94 143.28 39.63 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 122.801 0.441 . . . . 0.0 109.954 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.19 138.17 51.57 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 169.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 13.1 t70 -73.85 133.83 43.23 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 78.7 t -140.95 130.63 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 C-N-CA 125.684 1.594 . . . . 0.0 107.001 -173.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -74.22 140.74 45.27 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 124.863 1.265 . . . . 0.0 109.92 175.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 23.3 mt -113.65 11.85 18.29 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.861 0.864 . . . . 0.0 112.886 -172.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 13.9 m -53.34 -34.74 58.68 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 120.833 1.651 . . . . 0.0 112.432 -175.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 86.4 mt -73.91 -12.86 60.79 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 113.045 0.757 . . . . 0.0 113.045 -176.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 m -133.43 -19.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 119.323 0.965 . . . . 0.0 112.897 -171.477 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.33 147.03 0.89 Allowed Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.098 1.332 . . . . 0.0 110.831 -171.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 10.2 m -76.57 -4.38 42.54 Favored 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.842 -0.799 . . . . 0.0 113.002 179.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.1 m -131.94 151.25 51.83 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 124.349 1.059 . . . . 0.0 109.965 179.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -65.77 165.59 12.5 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 126.945 2.098 . . . . 0.0 109.864 169.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -52.96 -37.49 61.18 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.317 1.447 . . . . 0.0 112.152 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.8 t30 -85.35 9.82 14.4 Favored 'General case' 0 CA--C 1.543 0.675 0 C-N-CA 123.721 0.809 . . . . 0.0 112.015 -178.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.87 4.96 88.37 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 124.581 1.086 . . . . 0.0 113.464 174.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.4 mt-30 -69.87 132.28 88.82 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -65.92 141.2 63.76 Favored 'Trans proline' 0 N--CA 1.459 -0.54 0 CA-C-N 121.303 1.501 . . . . 0.0 109.011 174.572 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -72.45 13.72 0.32 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 114.455 1.28 . . . . 0.0 114.455 -172.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 48.6 t -54.08 129.27 14.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-N 120.227 1.376 . . . . 0.0 108.639 179.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.65 -17.64 55.61 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.827 1.203 . . . . 0.0 113.414 179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -73.34 169.31 17.41 Favored 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 119.511 1.655 . . . . 0.0 109.162 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.7 m95 -120.16 156.59 30.77 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 123.947 0.899 . . . . 0.0 109.123 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 2.8 m -143.2 144.92 23.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 C-N-CA 123.435 0.694 . . . . 0.0 109.402 178.296 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 59.3 mt -72.89 147.97 44.82 Favored 'General case' 0 C--O 1.232 0.179 0 N-CA-C 105.274 -2.121 . . . . 0.0 105.274 168.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.9 t -131.96 152.68 37.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.274 -1.751 . . . . 0.0 106.274 175.265 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -130.82 -60.08 0.98 Allowed 'General case' 0 CA--C 1.531 0.214 0 C-N-CA 123.974 0.91 . . . . 0.0 109.635 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.3 m -138.36 38.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 123.941 0.896 . . . . 0.0 110.614 -169.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.08 14.66 60.25 Favored Glycine 0 CA--C 1.528 0.906 0 CA-C-O 119.406 -0.663 . . . . 0.0 113.046 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 -128.22 137.33 51.98 Favored 'General case' 0 C--O 1.236 0.364 0 N-CA-C 107.049 -1.463 . . . . 0.0 107.049 175.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.32 111.74 5.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 172.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 15.5 tpt -71.79 -49.01 42.66 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 118.031 0.378 . . . . 0.0 110.303 -175.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 13.5 m -152.55 151.1 30.27 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 124.959 1.304 . . . . 0.0 108.603 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 18.4 t -78.79 141.01 15.99 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 171.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.7 pt -138.9 -169.69 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 126.064 1.746 . . . . 0.0 108.794 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.3 p-10 -126.97 -179.29 4.76 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 125.019 1.327 . . . . 0.0 110.125 178.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -54.92 -44.9 74.64 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.161 0.985 . . . . 0.0 111.249 -178.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.31 -49.22 67.78 Favored 'General case' 0 C--O 1.231 0.131 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -172.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 26.0 mm-40 -64.84 -38.76 92.07 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 122.776 0.43 . . . . 0.0 110.28 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.41 -51.28 66.43 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 118.372 0.533 . . . . 0.0 110.61 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 63.3 mtt85 -66.91 -36.95 83.43 Favored 'General case' 0 CA--C 1.523 -0.064 0 CA-C-O 118.489 -0.767 . . . . 0.0 110.633 -178.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.72 -43.66 98.42 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 119.121 0.873 . . . . 0.0 110.909 175.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.4 m -64.05 -45.9 86.79 Favored 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 122.979 0.512 . . . . 0.0 109.996 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 57.9 mt -64.33 -39.22 93.47 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 118.252 0.478 . . . . 0.0 110.858 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.6 -48.48 72.16 Favored 'General case' 0 C--N 1.334 -0.102 0 C-N-CA 123.2 0.6 . . . . 0.0 110.319 177.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.01 88.54 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 117.872 0.305 . . . . 0.0 111.26 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -66.46 -56.18 12.17 Favored 'General case' 0 C--N 1.339 0.117 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.047 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -66.09 -28.12 68.58 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 118.406 0.548 . . . . 0.0 111.435 -174.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -54.22 -29.19 45.54 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 123.959 0.904 . . . . 0.0 112.452 176.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 24.8 mmt -65.77 -12.5 54.48 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.551 0.741 . . . . 0.0 112.975 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -133.44 -39.33 0.91 Allowed 'General case' 0 C--N 1.341 0.214 0 C-N-CA 124.244 1.018 . . . . 0.0 111.143 -172.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -59.57 -23.26 62.76 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 125.795 1.638 . . . . 0.0 113.015 -174.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 3.3 m -52.55 -33.82 18.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.147 0.979 . . . . 0.0 112.733 172.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -73.83 -55.0 3.44 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-O 117.775 -1.107 . . . . 0.0 111.698 -174.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -65.36 -27.24 55.28 Favored 'Trans proline' 0 N--CA 1.457 -0.656 0 CA-C-N 121.656 1.627 . . . . 0.0 111.813 173.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -65.39 -51.7 58.59 Favored 'General case' 0 C--O 1.232 0.151 0 CA-C-N 119.0 0.818 . . . . 0.0 111.056 177.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 5.8 p -68.01 -32.36 55.88 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 CA-C-N 118.691 0.678 . . . . 0.0 110.231 178.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.94 -50.28 69.38 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 174.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -64.64 -42.4 95.49 Favored 'General case' 0 CA--C 1.531 0.212 0 CA-C-N 117.763 0.781 . . . . 0.0 111.114 179.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 35.4 tp -56.49 -49.14 75.55 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 123.682 0.793 . . . . 0.0 110.072 177.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 60.2 tp -65.6 -56.45 12.14 Favored 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 122.761 0.424 . . . . 0.0 110.445 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 54.8 t80 -66.27 -34.84 78.9 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 123.212 0.605 . . . . 0.0 112.11 -169.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.23 0.88 64.21 Favored Glycine 0 CA--C 1.528 0.87 0 CA-C-O 118.294 -1.281 . . . . 0.0 113.114 -175.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 48.6 54.74 10.09 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-N 118.849 1.324 . . . . 0.0 109.358 -169.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 69.4 -59.88 0.48 Allowed 'General case' 0 C--O 1.234 0.275 0 C-N-CA 128.917 2.887 . . . . 0.0 111.652 -169.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 24.5 pttm . . . . . 0 C--O 1.249 1.075 0 C-N-CA 124.455 1.102 . . . . 0.0 109.521 -171.528 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 98.0 mtp . . . . . 0 N--CA 1.484 1.254 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 92.6 m -135.45 157.35 47.11 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 125.32 1.448 . . . . 0.0 108.585 176.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 47.4 pt -65.56 150.38 10.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.491 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 169.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.82 48.74 0.09 OUTLIER Glycine 0 CA--C 1.526 0.757 0 N-CA-C 107.114 -2.394 . . . . 0.0 107.114 -175.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 15.3 m -140.13 166.73 21.53 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.564 1.545 . . . . 0.0 109.675 -168.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -54.9 153.54 24.8 Favored 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 122.565 2.176 . . . . 0.0 113.175 169.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -159.88 164.31 34.14 Favored Glycine 0 CA--C 1.529 0.96 0 N-CA-C 107.953 -2.059 . . . . 0.0 107.953 169.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -110.96 130.21 55.65 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.45 1.125 . . . . 0.0 109.204 -172.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 67.6 mt -66.05 120.98 14.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 177.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 52.3 tpt85 -121.11 -22.5 6.09 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 118.182 -0.913 . . . . 0.0 111.651 -175.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -146.65 155.6 42.57 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 170.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 50.3 mt -133.06 144.67 35.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 175.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.7 t70 -126.61 -18.67 4.74 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 123.858 0.863 . . . . 0.0 112.452 -174.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.75 -131.13 2.25 Favored Glycine 0 C--N 1.335 0.521 0 N-CA-C 107.2 -2.36 . . . . 0.0 107.2 -178.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.5 p-10 -68.33 9.24 0.35 Allowed 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.145 0.978 . . . . 0.0 112.545 169.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -139.39 155.47 47.62 Favored 'General case' 0 C--O 1.239 0.523 0 C-N-CA 126.004 1.722 . . . . 0.0 107.542 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.8 174.88 10.06 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 125.453 1.501 . . . . 0.0 110.757 -176.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -122.18 114.51 20.96 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 178.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 89.1 t -111.83 125.56 69.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 -169.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -72.58 112.21 8.43 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 170.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 t -90.07 59.81 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.485 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 42.3 m 50.02 42.64 24.98 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 126.336 1.854 . . . . 0.0 113.5 178.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.2 -37.28 0.14 Allowed Glycine 0 CA--C 1.525 0.71 0 O-C-N 121.629 -0.67 . . . . 0.0 112.906 173.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 8.8 tp -155.33 155.79 5.46 Favored 'Isoleucine or valine' 0 C--O 1.237 0.417 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 178.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 62.8 mt-30 -74.65 147.37 41.61 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.709 0.766 . . . . 0.0 110.871 177.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -129.14 144.52 51.23 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.456 1.502 . . . . 0.0 107.255 169.293 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -69.84 135.71 49.93 Favored 'General case' 0 C--O 1.234 0.285 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 169.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 53.6 t -141.65 121.03 10.74 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -173.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -66.64 134.67 52.77 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 169.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 13.2 tp -117.78 0.44 11.98 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 124.737 1.215 . . . . 0.0 110.358 -169.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 1.5 m -57.77 -30.84 65.96 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 124.721 1.209 . . . . 0.0 111.211 -178.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 77.0 mt -67.89 -13.98 62.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.078 0.951 . . . . 0.0 112.884 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.7 p -134.74 -8.71 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 CA-C-N 119.154 0.888 . . . . 0.0 112.1 -175.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.57 136.22 1.68 Allowed Glycine 0 CA--C 1.525 0.699 0 C-N-CA 125.4 1.476 . . . . 0.0 110.388 179.198 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.5 m -75.88 161.19 29.18 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 123.238 0.615 . . . . 0.0 109.342 169.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 63.2 m 56.4 177.52 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.774 1.629 . . . . 0.0 112.597 -169.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 5.7 t70 -133.49 151.91 51.83 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 126.182 1.793 . . . . 0.0 108.221 -170.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.2 -21.58 34.44 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 125.026 1.331 . . . . 0.0 114.214 -170.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -74.31 -7.2 51.98 Favored 'General case' 0 CA--C 1.537 0.46 0 CA-C-N 118.487 0.585 . . . . 0.0 112.052 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 84.15 46.92 5.71 Favored Glycine 0 CA--C 1.527 0.787 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 -177.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 29.0 pt20 -142.67 158.3 60.18 Favored Pre-proline 0 CA--C 1.535 0.399 0 C-N-CA 125.165 1.386 . . . . 0.0 108.664 -176.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_endo -69.0 153.55 72.24 Favored 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 121.958 1.772 . . . . 0.0 109.892 169.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -73.16 3.37 5.7 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.615 0.968 . . . . 0.0 113.615 177.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 97.4 t -56.53 127.46 15.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 CA-C-N 120.547 1.521 . . . . 0.0 108.457 -175.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.27 -24.76 30.64 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 124.892 1.234 . . . . 0.0 112.548 -176.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -70.53 162.06 29.49 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.056 1.428 . . . . 0.0 108.84 172.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 43.4 m95 -113.67 155.87 24.75 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -141.88 143.19 27.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.2 mt -77.32 127.9 33.39 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 103.743 -2.688 . . . . 0.0 103.743 168.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.5 m -131.2 126.65 59.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 119.341 0.973 . . . . 0.0 110.627 -170.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.438 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 3.5 t60 -89.17 -165.88 1.45 Allowed 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 169.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.438 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 18.3 m -47.71 -29.19 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 C-N-CA 125.815 1.646 . . . . 0.0 114.993 -172.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -169.74 33.07 0.17 Allowed Glycine 0 C--N 1.338 0.639 0 CA-C-O 118.819 -0.99 . . . . 0.0 112.4 175.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -145.71 134.17 21.97 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 118.822 1.311 . . . . 0.0 109.128 -174.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.34 117.91 17.66 Favored 'General case' 0 N--CA 1.456 -0.156 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 169.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 72.2 mtp -77.31 -49.4 15.08 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 124.526 1.13 . . . . 0.0 109.056 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.9 m -151.35 162.46 40.87 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 125.851 1.661 . . . . 0.0 108.65 178.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.7 p -107.52 139.88 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 C-N-CA 124.87 1.268 . . . . 0.0 107.874 172.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.1 pt -141.26 161.75 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 C-N-CA 125.095 1.358 . . . . 0.0 109.896 -173.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 37.2 m-80 -75.44 165.26 25.4 Favored 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.916 0.886 . . . . 0.0 110.53 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -55.53 -40.9 72.43 Favored 'General case' 0 C--O 1.236 0.345 0 C-N-CA 124.729 1.211 . . . . 0.0 111.698 176.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.48 -40.21 67.1 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 122.942 0.497 . . . . 0.0 110.79 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.07 -40.79 97.02 Favored 'General case' 0 C--O 1.231 0.094 0 C-N-CA 123.091 0.556 . . . . 0.0 109.763 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.91 -48.97 78.05 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 119.666 -0.207 . . . . 0.0 110.748 177.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 75.4 mtt85 -64.34 -40.02 95.05 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 119.079 -0.486 . . . . 0.0 110.762 -178.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.7 -42.73 99.79 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 118.467 0.576 . . . . 0.0 111.047 176.017 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 49.4 m -65.16 -43.69 90.92 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.151 0.58 . . . . 0.0 110.334 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 75.2 mt -61.95 -44.45 96.73 Favored 'General case' 0 C--N 1.34 0.164 0 CA-C-N 118.394 0.543 . . . . 0.0 109.846 178.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -63.68 -44.47 93.63 Favored 'General case' 0 C--O 1.231 0.12 0 CA-C-N 118.458 0.572 . . . . 0.0 111.146 179.318 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.16 -48.36 82.04 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 122.663 0.385 . . . . 0.0 110.316 178.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -60.2 -49.33 78.07 Favored 'General case' 0 CA--C 1.528 0.101 0 C-N-CA 123.693 0.797 . . . . 0.0 109.711 178.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 61.2 tt0 -60.24 -40.39 90.06 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 123.462 0.705 . . . . 0.0 110.941 -177.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -63.83 -19.41 65.01 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 119.653 1.115 . . . . 0.0 111.557 -175.447 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 37.8 tpp -85.69 -19.52 30.75 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 125.189 1.396 . . . . 0.0 112.117 -178.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 72.5 m-85 -141.65 -3.79 1.13 Allowed 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 115.244 1.572 . . . . 0.0 115.244 -169.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -58.66 -25.53 62.88 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 120.03 1.286 . . . . 0.0 113.117 -172.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 14.6 m -129.67 45.5 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 C-N-CA 126.098 1.759 . . . . 0.0 108.775 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 23.4 mm-40 79.05 163.93 0.13 Allowed Pre-proline 0 CA--C 1.545 0.771 0 C-N-CA 127.55 2.34 . . . . 0.0 110.534 177.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -57.56 -14.68 17.55 Favored 'Trans proline' 0 C--N 1.351 0.67 0 C-N-CA 123.529 2.82 . . . . 0.0 115.486 178.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -56.35 -44.33 79.96 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 119.19 0.904 . . . . 0.0 112.091 -175.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 28.3 m -69.61 -29.05 39.93 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-O 119.181 -0.438 . . . . 0.0 111.087 177.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -68.32 -45.67 68.36 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 176.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -62.65 -39.28 93.39 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 117.61 0.705 . . . . 0.0 111.157 176.658 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 44.2 tp -65.78 -48.77 70.7 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.339 0.656 . . . . 0.0 110.553 176.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.2 tp -59.31 -51.84 68.21 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 124.076 0.951 . . . . 0.0 109.768 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 28.1 t80 -67.44 -22.66 65.5 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.413 0.685 . . . . 0.0 112.05 -177.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 82.45 19.69 63.69 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 123.725 0.678 . . . . 0.0 112.016 -176.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -69.53 -34.15 73.83 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 117.839 0.82 . . . . 0.0 109.296 170.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -137.58 70.79 1.39 Allowed 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.18 1.392 . . . . 0.0 108.132 -179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 24.4 ttpt . . . . . 0 C--O 1.251 1.158 0 C-N-CA 125.256 1.422 . . . . 0.0 107.493 178.183 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 94.8 mmm . . . . . 0 N--CA 1.486 1.359 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 58.2 m -60.1 -39.96 88.0 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 123.416 0.687 . . . . 0.0 112.677 -172.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 18.1 pt -142.34 149.09 19.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 C-N-CA 125.06 1.344 . . . . 0.0 108.233 179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.12 46.16 0.09 OUTLIER Glycine 0 CA--C 1.526 0.763 0 N-CA-C 107.619 -2.192 . . . . 0.0 107.619 -173.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.7 m -143.3 163.75 35.33 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 125.208 1.403 . . . . 0.0 110.287 -168.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -53.77 157.13 10.66 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 123.075 2.517 . . . . 0.0 113.874 171.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.71 167.85 37.34 Favored Glycine 0 CA--C 1.528 0.878 0 C-N-CA 126.336 1.922 . . . . 0.0 108.648 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.2 tt0 -116.18 134.25 55.13 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -176.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 64.7 mt -75.04 74.86 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 C-N-CA 125.649 1.58 . . . . 0.0 107.509 -176.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -70.73 -30.65 67.23 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-O 118.438 -0.792 . . . . 0.0 111.566 -172.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -148.81 155.7 41.31 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 177.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 57.0 mt -132.18 146.85 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -129.71 -20.06 3.26 Favored 'General case' 0 N--CA 1.47 0.559 0 C-N-CA 123.854 0.862 . . . . 0.0 112.529 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 175.15 -134.47 2.74 Favored Glycine 0 C--N 1.334 0.418 0 N-CA-C 106.243 -2.743 . . . . 0.0 106.243 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.9 t30 -65.86 -15.74 63.2 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 118.386 1.093 . . . . 0.0 110.668 169.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -101.08 153.0 19.93 Favored 'General case' 0 C--O 1.239 0.544 0 C-N-CA 124.954 1.302 . . . . 0.0 109.123 175.438 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -141.34 159.52 42.06 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.313 1.445 . . . . 0.0 109.14 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -106.77 86.83 2.39 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 179.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.4 t -85.61 127.6 39.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 106.657 -1.608 . . . . 0.0 106.657 -174.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 t0 -71.37 106.89 4.06 Favored 'General case' 0 CA--C 1.52 -0.209 0 N-CA-C 107.352 -1.351 . . . . 0.0 107.352 169.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.7 t -89.77 67.24 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.0 48.05 7.26 Favored 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.291 2.236 . . . . 0.0 113.739 178.196 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 174.77 -42.03 0.12 Allowed Glycine 0 CA--C 1.524 0.646 0 CA-C-O 119.692 -0.505 . . . . 0.0 112.219 172.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -156.97 156.1 4.69 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 C-N-CA 124.676 1.19 . . . . 0.0 108.175 175.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 67.7 mt-30 -67.76 136.06 53.64 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 123.23 0.612 . . . . 0.0 110.469 176.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.2 mpt_? -123.88 148.61 46.67 Favored 'General case' 0 C--O 1.233 0.199 0 N-CA-C 106.327 -1.731 . . . . 0.0 106.327 169.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -70.59 136.81 49.5 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 169.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.5 t -138.59 131.25 38.98 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.316 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 179.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -83.21 126.22 32.4 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 169.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.1 mt -83.29 36.86 0.53 Allowed 'General case' 0 CA--C 1.54 0.563 0 C-N-CA 123.64 0.776 . . . . 0.0 111.335 -173.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -45.87 -40.33 9.81 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.412 2.285 . . . . 0.0 114.443 -169.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.2 mt -106.23 4.56 28.99 Favored 'General case' 0 CA--C 1.533 0.324 0 CA-C-O 118.853 -0.594 . . . . 0.0 112.282 -169.309 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.3 m -133.97 -26.68 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 118.981 0.809 . . . . 0.0 111.937 -173.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.89 152.79 1.94 Allowed Glycine 0 CA--C 1.526 0.777 0 C-N-CA 124.095 0.855 . . . . 0.0 110.979 -175.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 13.8 m -77.18 -6.86 54.56 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -176.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.5 m -126.72 151.58 47.98 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.3 1.04 . . . . 0.0 109.075 175.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.5 t0 -84.51 176.57 8.55 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 124.308 1.043 . . . . 0.0 110.665 -178.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -55.68 -37.08 67.85 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 124.917 1.287 . . . . 0.0 112.102 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 7.9 p-10 -84.12 -2.0 55.98 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.627 0.771 . . . . 0.0 112.929 179.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.18 -3.26 66.47 Favored Glycine 0 CA--C 1.53 1.028 0 CA-C-O 118.323 -1.265 . . . . 0.0 114.241 173.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 8.5 pt20 -67.38 147.81 98.8 Favored Pre-proline 0 CA--C 1.538 0.506 0 CA-C-N 119.91 1.855 . . . . 0.0 109.046 175.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -64.87 141.93 73.51 Favored 'Trans proline' 0 N--CA 1.458 -0.604 0 C-N-CA 121.541 1.494 . . . . 0.0 108.743 169.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.4 mtt-85 -70.94 11.39 0.4 Allowed 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.7 p -56.38 129.23 17.74 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 CA-C-N 119.968 1.258 . . . . 0.0 109.031 -176.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.04 -14.46 57.18 Favored Glycine 0 CA--C 1.534 1.24 0 CA-C-O 118.226 -1.319 . . . . 0.0 113.972 -178.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 75.7 mt-30 -70.34 166.03 21.11 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 119.824 1.812 . . . . 0.0 108.969 170.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -112.25 161.22 16.83 Favored 'General case' 0 N--CA 1.456 -0.143 0 CA-C-O 121.538 0.685 . . . . 0.0 109.871 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.3 p -155.75 140.9 9.9 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 -172.43 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 93.8 mt -76.8 111.64 12.55 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 104.894 -2.262 . . . . 0.0 104.894 169.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 51.3 t -93.11 132.22 37.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 10.4 t60 -144.24 130.41 19.63 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 1.7 t 45.74 37.34 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 C-N-CA 125.177 1.391 . . . . 0.0 112.688 -179.594 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.08 16.37 79.6 Favored Glycine 0 CA--C 1.534 1.251 0 O-C-N 120.916 -1.115 . . . . 0.0 114.308 176.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -128.49 161.95 28.35 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-N 119.315 1.558 . . . . 0.0 109.956 170.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -79.89 111.34 16.12 Favored 'General case' 0 N--CA 1.454 -0.26 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 16.0 tpt -74.02 -51.5 15.67 Favored 'General case' 0 CA--C 1.536 0.418 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 177.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 7.4 m -154.21 138.37 16.51 Favored 'General case' 0 C--N 1.342 0.247 0 C-N-CA 124.305 1.042 . . . . 0.0 108.912 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -77.54 142.42 14.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 169.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.2 pt -139.91 160.51 26.65 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.38 0 C-N-CA 124.355 1.062 . . . . 0.0 109.84 -177.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 34.4 m-80 -75.27 165.12 25.68 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 123.842 0.857 . . . . 0.0 110.46 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 -54.51 -41.68 69.92 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 124.732 1.213 . . . . 0.0 111.467 174.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -72.4 -39.42 67.98 Favored 'General case' 0 CA--C 1.529 0.138 0 C-N-CA 122.988 0.515 . . . . 0.0 110.786 -178.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -64.61 -40.7 95.97 Favored 'General case' 0 N--CA 1.461 0.088 0 C-N-CA 123.009 0.524 . . . . 0.0 109.865 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.43 -49.42 76.92 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.838 0.29 . . . . 0.0 110.562 177.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 76.1 mtt85 -64.45 -40.12 95.12 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-O 119.03 -0.51 . . . . 0.0 110.665 -178.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.93 -41.83 99.61 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 118.602 0.637 . . . . 0.0 111.129 176.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.7 m -65.42 -43.43 90.53 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 122.813 0.445 . . . . 0.0 110.032 178.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 81.6 mt -64.51 -40.04 94.89 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 118.765 0.711 . . . . 0.0 110.549 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -63.21 -44.0 96.54 Favored 'General case' 0 C--O 1.232 0.181 0 CA-C-N 118.202 0.455 . . . . 0.0 110.748 176.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.64 -47.14 86.78 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 122.992 0.517 . . . . 0.0 110.204 175.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 68.7 mt -62.33 -3.2 1.25 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 125.039 1.336 . . . . 0.0 113.35 177.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 23.8 mm-40 -128.29 8.15 6.0 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.813 1.245 . . . . 0.0 112.061 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -150.57 -34.07 0.16 Allowed 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 119.774 1.17 . . . . 0.0 114.132 172.517 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 14.0 tpt -66.12 -16.41 63.93 Favored 'General case' 0 CA--C 1.537 0.48 0 CA-C-N 119.228 0.922 . . . . 0.0 112.151 -173.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -120.9 18.9 11.78 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.544 1.538 . . . . 0.0 110.125 -176.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -126.65 -0.17 6.79 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.286 1.434 . . . . 0.0 111.564 -174.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.1 t -75.15 -33.89 30.0 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 C-N-CA 123.748 0.819 . . . . 0.0 109.408 175.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -59.1 -51.68 80.03 Favored Pre-proline 0 CA--C 1.542 0.661 0 C-N-CA 124.449 1.099 . . . . 0.0 111.436 -177.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -70.03 -20.05 34.05 Favored 'Trans proline' 0 C--N 1.351 0.663 0 CA-C-N 121.032 1.404 . . . . 0.0 112.461 173.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -66.79 -54.23 24.82 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 119.758 1.163 . . . . 0.0 109.784 177.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.8 p -69.14 -33.27 57.6 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-O 119.037 -0.506 . . . . 0.0 110.156 178.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.71 -53.95 41.69 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 174.52 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -59.53 -41.52 90.2 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 123.688 0.795 . . . . 0.0 111.365 179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 60.6 tp -61.52 -45.71 93.06 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 122.678 0.391 . . . . 0.0 110.596 176.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 62.4 tp -62.96 -37.95 89.16 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.789 0.835 . . . . 0.0 111.106 178.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 13.6 m-30 -68.36 -10.2 53.31 Favored 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 123.458 0.703 . . . . 0.0 112.429 175.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 68.75 31.31 72.99 Favored Glycine 0 CA--C 1.53 0.984 0 CA-C-N 118.981 0.809 . . . . 0.0 111.175 -175.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -143.62 51.48 1.35 Allowed 'General case' 0 CA--C 1.537 0.473 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 -175.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -52.16 150.62 4.36 Favored 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 125.595 1.558 . . . . 0.0 113.559 -169.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 29.8 ttmt . . . . . 0 C--O 1.248 1.011 0 C-N-CA 125.085 1.354 . . . . 0.0 109.721 -178.375 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.484 1.234 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 62.8 m -76.23 62.09 1.71 Allowed 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 124.942 1.297 . . . . 0.0 111.612 -177.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -59.5 163.89 0.83 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 124.618 1.167 . . . . 0.0 112.215 -178.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.1 63.38 0.5 Allowed Glycine 0 CA--C 1.526 0.74 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -176.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 7.1 p -153.04 145.33 17.05 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 126.3 1.84 . . . . 0.0 106.472 -169.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -75.41 168.55 24.31 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 121.617 1.545 . . . . 0.0 112.48 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.42 -176.88 42.24 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 172.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -95.99 137.86 34.46 Favored 'General case' 0 C--O 1.231 0.116 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 178.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 68.9 mt -71.47 78.81 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 171.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.4 tpm_? -67.51 -30.22 69.83 Favored 'General case' 0 CA--C 1.531 0.222 0 O-C-N 121.446 -0.784 . . . . 0.0 110.301 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -155.18 150.01 26.6 Favored 'General case' 0 C--O 1.237 0.406 0 C-N-CA 124.512 1.125 . . . . 0.0 108.051 -173.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 49.8 mt -119.98 149.79 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -145.48 65.17 1.24 Allowed 'General case' 0 C--N 1.329 -0.291 0 C-N-CA 126.324 1.85 . . . . 0.0 107.468 -170.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.66 -124.71 18.71 Favored Glycine 0 C--N 1.338 0.64 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -173.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -68.27 -25.05 64.97 Favored 'General case' 0 CA--C 1.533 0.291 0 C-N-CA 122.787 0.435 . . . . 0.0 111.913 172.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 15.2 mm100 -86.1 170.92 11.77 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-O 121.86 0.838 . . . . 0.0 109.835 -179.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.55 159.79 41.8 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.545 1.538 . . . . 0.0 108.19 169.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.58 75.97 0.95 Allowed 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.238 -2.134 . . . . 0.0 105.238 177.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 79.3 t -71.74 126.52 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 124.904 1.282 . . . . 0.0 107.563 -172.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -79.26 111.02 15.08 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 174.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.5 t -82.06 60.21 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 C-N-CA 125.668 1.587 . . . . 0.0 107.282 172.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 55.5 m 43.67 41.39 3.53 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.11 2.164 . . . . 0.0 114.432 176.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 161.67 -23.83 0.23 Allowed Glycine 0 CA--C 1.528 0.859 0 CA-C-O 119.157 -0.802 . . . . 0.0 113.676 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.7 tp -150.29 149.43 14.45 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 176.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 46.2 mt-30 -92.17 139.06 31.0 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 -179.221 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 31.0 mmt180 -129.69 144.97 51.54 Favored 'General case' 0 N--CA 1.464 0.236 0 C-N-CA 124.916 1.287 . . . . 0.0 108.519 178.722 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -73.84 137.61 43.91 Favored 'General case' 0 C--O 1.234 0.257 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 71.6 t -137.03 143.67 34.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -178.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -99.8 119.8 38.75 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.164 1.386 . . . . 0.0 107.539 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 50.9 mt -91.17 12.49 19.91 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-O 117.88 -1.057 . . . . 0.0 113.03 -172.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -48.65 -36.43 15.91 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 121.29 1.859 . . . . 0.0 113.73 -174.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 55.0 mt -88.55 -2.63 58.7 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -173.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.07 -19.57 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 CA-C-N 119.344 0.975 . . . . 0.0 112.672 -177.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.0 146.84 2.93 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 125.259 1.409 . . . . 0.0 111.131 -175.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.1 m -74.97 -12.64 60.39 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 123.49 0.716 . . . . 0.0 112.18 174.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.4 m -117.89 166.34 12.6 Favored 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 124.603 1.161 . . . . 0.0 109.316 172.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -115.65 163.39 15.87 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.185 1.794 . . . . 0.0 110.446 -169.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -54.18 -36.74 63.72 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.397 1.479 . . . . 0.0 111.265 -178.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -74.44 1.22 12.31 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 125.499 1.52 . . . . 0.0 113.059 -178.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.02 45.61 11.52 Favored Glycine 0 C--N 1.341 0.808 0 O-C-N 121.014 -1.054 . . . . 0.0 111.098 174.331 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 26.6 pt20 -141.64 151.34 60.08 Favored Pre-proline 0 CA--C 1.534 0.363 0 C-N-CA 125.28 1.432 . . . . 0.0 108.611 -177.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -66.52 147.81 82.76 Favored 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 122.08 1.853 . . . . 0.0 109.159 169.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 72.6 mtt-85 -73.71 7.93 2.2 Favored 'General case' 0 CA--C 1.538 0.507 0 N-CA-C 114.506 1.298 . . . . 0.0 114.506 -174.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.9 m -54.57 133.37 17.86 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.464 0 CA-C-N 120.537 1.517 . . . . 0.0 109.892 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.11 -17.95 34.58 Favored Glycine 0 CA--C 1.532 1.097 0 CA-C-O 118.231 -1.316 . . . . 0.0 113.38 -178.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -72.57 164.73 25.98 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 119.708 1.754 . . . . 0.0 108.735 174.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 33.7 m95 -109.2 154.0 23.0 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.0 p -146.61 140.22 20.27 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -172.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 65.6 tp -89.24 148.09 23.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 169.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.0 t -124.99 142.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 33.0 t-80 -103.48 -52.15 3.06 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 122.915 0.486 . . . . 0.0 110.355 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 8.4 p -157.81 63.12 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 107.478 -1.305 . . . . 0.0 107.478 -178.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.25 -38.36 1.81 Allowed Glycine 0 CA--C 1.529 0.946 0 C-N-CA 124.746 1.165 . . . . 0.0 112.034 -172.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -69.49 135.18 49.81 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 118.639 1.22 . . . . 0.0 109.159 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.43 132.03 52.61 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 169.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 21.9 ttt -84.81 -55.28 4.17 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.13 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.3 m -155.82 149.46 25.04 Favored 'General case' 0 C--O 1.235 0.297 0 C-N-CA 124.768 1.227 . . . . 0.0 108.844 -177.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.9 p -74.94 142.78 14.14 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.59 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 168.418 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.9 pt -138.32 169.98 17.5 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 C-N-CA 124.104 0.961 . . . . 0.0 109.682 -172.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -101.38 169.74 8.68 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 123.754 0.822 . . . . 0.0 109.575 169.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -62.43 -34.39 76.68 Favored 'General case' 0 C--N 1.334 -0.084 0 CA-C-O 118.68 -0.676 . . . . 0.0 112.452 -173.171 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.85 -39.78 95.01 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.022 0.828 . . . . 0.0 110.743 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 28.4 mt-10 -65.96 -41.15 91.61 Favored 'General case' 0 C--O 1.232 0.152 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.24 -50.33 72.17 Favored 'General case' 0 N--CA 1.455 -0.19 0 CA-C-N 117.916 0.325 . . . . 0.0 110.351 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 43.8 mmt-85 -63.48 -43.48 97.18 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 118.877 -0.582 . . . . 0.0 110.279 -179.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -61.75 -43.5 98.72 Favored 'General case' 0 N--CA 1.462 0.161 0 CA-C-N 118.484 0.584 . . . . 0.0 110.991 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 38.0 m -66.6 -43.55 84.52 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 122.749 0.42 . . . . 0.0 110.128 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 62.4 mt -63.63 -41.25 98.28 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 119.084 0.856 . . . . 0.0 110.499 178.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -63.31 -44.63 94.43 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 122.874 0.47 . . . . 0.0 110.417 178.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.18 -48.91 76.38 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 122.828 0.451 . . . . 0.0 110.76 177.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 56.9 mt -60.56 -38.91 86.1 Favored 'General case' 0 N--CA 1.463 0.178 0 C-N-CA 123.281 0.633 . . . . 0.0 111.028 -177.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 36.8 mt-30 -66.65 -45.09 80.13 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 118.493 0.588 . . . . 0.0 110.18 174.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 16.5 m-80 -68.34 -15.9 63.74 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-O 118.582 -0.723 . . . . 0.0 112.824 -176.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 66.9 mtt -59.34 -18.52 38.92 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 120.127 1.331 . . . . 0.0 112.004 170.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 80.8 t80 -63.09 -29.71 71.02 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 119.238 0.926 . . . . 0.0 110.826 172.316 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -98.58 11.78 37.33 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 125.208 1.403 . . . . 0.0 110.869 175.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 23.9 t 71.73 -23.29 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 C-N-CA 128.041 2.536 . . . . 0.0 114.33 169.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -55.9 -53.98 57.08 Favored Pre-proline 0 CA--C 1.541 0.625 0 N-CA-C 114.397 1.258 . . . . 0.0 114.397 -169.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -74.25 -14.11 23.1 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 CA-C-N 121.739 1.657 . . . . 0.0 112.81 178.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -73.82 -49.23 26.21 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 119.83 1.196 . . . . 0.0 109.625 175.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 28.1 m -68.65 -28.57 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-O 118.95 -0.548 . . . . 0.0 110.504 172.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -56.29 -57.15 20.65 Favored Glycine 0 C--N 1.34 0.768 0 N-CA-C 109.956 -1.257 . . . . 0.0 109.956 170.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.24 -38.05 76.11 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 117.996 0.898 . . . . 0.0 111.829 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.5 tm? -63.48 -52.03 63.08 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 122.776 0.43 . . . . 0.0 110.011 176.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 66.0 tp -61.15 -41.65 97.14 Favored 'General case' 0 CA--C 1.53 0.193 0 C-N-CA 124.197 0.999 . . . . 0.0 110.876 -179.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 18.2 m-30 -69.85 -9.95 56.68 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 123.927 0.891 . . . . 0.0 112.472 177.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 73.59 22.52 78.34 Favored Glycine 0 CA--C 1.531 1.05 0 CA-C-N 118.911 0.778 . . . . 0.0 112.253 179.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -77.28 -31.19 54.66 Favored 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 118.102 0.951 . . . . 0.0 109.705 173.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 36.4 mm-40 -71.77 -35.57 70.09 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.041 0.536 . . . . 0.0 111.667 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 65.7 tttm . . . . . 0 C--O 1.249 1.055 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -177.815 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.2 ttm . . . . . 0 N--CA 1.481 1.121 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 76.5 m -132.03 134.77 45.92 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 172.555 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.1 tp -156.54 -173.79 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 C-N-CA 126.691 1.996 . . . . 0.0 106.456 -176.537 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.22 47.08 0.13 Allowed Glycine 0 CA--C 1.522 0.522 0 O-C-N 120.731 -1.231 . . . . 0.0 110.542 178.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.4 t -142.7 141.7 20.94 Favored Pre-proline 0 CA--C 1.539 0.535 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 -170.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -55.47 165.63 3.14 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.892 2.395 . . . . 0.0 113.017 169.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.88 175.67 35.09 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 169.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -116.82 136.43 52.96 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 179.354 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.8 mt -70.56 96.26 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 N-CA-C 105.931 -1.878 . . . . 0.0 105.931 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -85.56 -42.86 14.0 Favored 'General case' 0 N--CA 1.462 0.132 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 -169.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 p -147.22 158.43 43.95 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.617 1.567 . . . . 0.0 108.112 176.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 52.3 mt -127.46 146.57 33.0 Favored 'Isoleucine or valine' 0 C--O 1.235 0.326 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -177.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -123.96 -19.18 5.74 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 124.065 0.946 . . . . 0.0 112.294 -176.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.6 -127.58 1.59 Allowed Glycine 0 C--N 1.335 0.511 0 N-CA-C 107.437 -2.265 . . . . 0.0 107.437 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 13.2 t30 -66.75 2.29 1.44 Allowed 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 123.932 0.893 . . . . 0.0 112.384 169.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.1 mt-30 -134.28 154.23 51.42 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 126.875 2.07 . . . . 0.0 107.314 -174.186 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -139.83 155.33 47.3 Favored 'General case' 0 N--CA 1.45 -0.445 0 C-N-CA 124.625 1.17 . . . . 0.0 109.382 -179.183 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -99.56 78.7 2.19 Favored 'General case' 0 C--N 1.331 -0.234 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.9 t -68.13 125.8 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 -176.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -75.66 105.18 6.55 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 169.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.6 t -81.52 63.25 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 37.8 m 48.95 39.52 14.72 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 126.495 1.918 . . . . 0.0 113.315 177.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 171.02 -48.14 0.19 Allowed Glycine 0 CA--C 1.526 0.728 0 CA-C-O 119.255 -0.747 . . . . 0.0 112.01 174.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.0 mm -137.16 143.28 35.04 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 -174.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 56.7 mt-30 -71.78 141.88 49.7 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-O 121.33 0.586 . . . . 0.0 110.775 175.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -133.35 144.14 49.43 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 125.622 1.569 . . . . 0.0 106.999 169.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -73.06 134.59 44.63 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 173.158 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 87.6 t -138.3 129.99 37.89 Favored 'Isoleucine or valine' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -79.57 143.34 34.86 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 122.993 0.517 . . . . 0.0 109.886 174.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 36.3 mt -114.94 15.24 17.32 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.089 0.956 . . . . 0.0 112.668 -169.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 44.7 m -50.64 -37.32 39.89 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-N 120.886 1.676 . . . . 0.0 112.463 -177.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.4 mt -77.08 -8.54 57.64 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 113.002 0.741 . . . . 0.0 113.002 -174.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.39 -20.11 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 CA-C-N 119.517 1.053 . . . . 0.0 112.992 -172.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.16 140.37 0.74 Allowed Glycine 0 CA--C 1.529 0.913 0 C-N-CA 125.244 1.402 . . . . 0.0 110.886 -172.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 6.8 m -73.82 -17.73 61.03 Favored 'General case' 0 CA--C 1.535 0.374 0 O-C-N 122.024 -0.692 . . . . 0.0 112.313 176.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 81.9 m -93.0 135.17 34.41 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 123.809 0.843 . . . . 0.0 109.043 175.253 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 21.5 t70 -66.38 158.18 29.93 Favored 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.093 1.757 . . . . 0.0 109.598 169.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -53.47 -29.96 38.48 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 125.346 1.459 . . . . 0.0 112.176 176.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -75.66 -12.67 60.25 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.26 48.63 4.5 Favored Glycine 0 CA--C 1.53 1.029 0 CA-C-N 119.007 0.821 . . . . 0.0 111.166 -176.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -143.75 160.54 50.05 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 126.717 2.007 . . . . 0.0 107.409 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -64.68 141.96 74.85 Favored 'Trans proline' 0 CA--C 1.538 0.723 0 CA-C-N 121.586 1.602 . . . . 0.0 110.538 174.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.7 mtt-85 -69.53 13.87 0.12 Allowed 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 114.611 1.337 . . . . 0.0 114.611 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.5 m -54.93 132.87 18.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 120.354 1.434 . . . . 0.0 110.05 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.65 -17.79 53.05 Favored Glycine 0 CA--C 1.532 1.096 0 CA-C-O 118.479 -1.178 . . . . 0.0 113.458 -178.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 82.9 mt-30 -71.94 160.94 31.68 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-N 119.699 1.75 . . . . 0.0 109.081 174.095 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.3 m95 -107.68 161.17 15.11 Favored 'General case' 0 C--O 1.232 0.178 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.0 p -154.05 146.19 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -169.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 95.9 mt -89.89 139.63 30.4 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 172.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.3 t -136.15 143.35 36.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.322 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -178.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 5.5 t60 -141.44 -39.05 0.4 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 123.407 0.683 . . . . 0.0 112.487 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 18.6 m -132.36 27.08 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-N 119.026 0.83 . . . . 0.0 112.029 -171.174 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.99 16.73 80.52 Favored Glycine 0 CA--C 1.534 1.224 0 O-C-N 121.446 -0.784 . . . . 0.0 112.526 -174.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -129.03 144.43 51.19 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 172.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.12 122.59 17.42 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 171.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 68.5 mtp -76.76 -47.18 22.5 Favored 'General case' 0 CA--C 1.532 0.267 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 175.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.4 m -163.74 149.05 10.89 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 126.131 1.772 . . . . 0.0 108.144 176.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 53.1 t -80.37 145.28 9.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.358 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 169.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.2 pt -139.51 161.44 27.49 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.447 1.499 . . . . 0.0 109.198 -176.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -84.45 173.45 10.87 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.344 0.592 . . . . 0.0 110.894 174.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -69.99 -30.18 67.45 Favored 'General case' 0 CA--C 1.535 0.384 0 O-C-N 121.758 -0.589 . . . . 0.0 112.294 -170.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -73.63 -40.6 63.65 Favored 'General case' 0 N--CA 1.462 0.129 0 O-C-N 121.283 -0.886 . . . . 0.0 109.837 177.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 54.2 mt-10 -61.36 -41.35 96.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.224 0.61 . . . . 0.0 109.917 174.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.43 -49.41 75.57 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 117.983 0.356 . . . . 0.0 110.416 178.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 86.3 mtm180 -63.7 -40.2 96.19 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 119.13 -0.462 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.2 -41.9 99.24 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 118.759 0.709 . . . . 0.0 110.954 176.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.3 m -67.49 -38.64 84.66 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 122.083 -0.386 . . . . 0.0 110.282 178.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 53.0 mt -65.49 -38.03 88.57 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 119.079 0.854 . . . . 0.0 110.67 176.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -64.76 -43.86 91.93 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 118.605 0.639 . . . . 0.0 110.293 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.52 -43.24 99.29 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 122.962 0.505 . . . . 0.0 111.142 176.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -56.37 -42.76 78.37 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.405 1.082 . . . . 0.0 109.909 176.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -79.88 7.39 8.91 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 124.164 0.986 . . . . 0.0 113.053 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -132.46 -13.2 3.03 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 119.538 1.063 . . . . 0.0 112.996 -178.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 25.7 ptt? -56.55 -30.04 62.67 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 119.884 1.22 . . . . 0.0 112.385 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -90.14 11.3 21.34 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 125.48 1.512 . . . . 0.0 112.253 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -128.91 -36.96 1.76 Allowed 'General case' 0 N--CA 1.464 0.25 0 C-N-CA 124.578 1.151 . . . . 0.0 111.503 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.4 m -70.13 -16.89 20.51 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.605 0 CA-C-N 118.615 0.643 . . . . 0.0 111.411 171.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -138.93 157.12 72.15 Favored Pre-proline 0 CA--C 1.536 0.43 0 C-N-CA 126.607 1.963 . . . . 0.0 106.868 173.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -69.13 -15.26 39.29 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 122.382 2.055 . . . . 0.0 112.359 175.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 35.2 t70 47.09 -118.48 0.89 Allowed 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 126.013 1.725 . . . . 0.0 109.593 -173.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.4 p -56.42 -27.27 24.29 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 C-N-CA 124.627 1.171 . . . . 0.0 112.329 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -55.48 -23.84 36.46 Favored Glycine 0 CA--C 1.529 0.964 0 C-N-CA 124.62 1.105 . . . . 0.0 112.94 174.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -60.75 -14.75 23.29 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 118.805 1.302 . . . . 0.0 113.624 176.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.7 tp -133.8 -29.21 1.34 Allowed 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.285 1.034 . . . . 0.0 110.881 176.081 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 57.5 tp -73.89 -25.01 59.8 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 123.836 0.855 . . . . 0.0 111.969 177.17 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 24.8 t80 -129.96 26.91 5.2 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.193 0.997 . . . . 0.0 111.129 -169.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -177.26 168.28 39.94 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 172.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 36.7 mm-40 -61.89 -40.75 96.51 Favored 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 172.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -164.95 169.86 15.94 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 127.863 2.465 . . . . 0.0 106.822 169.434 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 62.3 mttm . . . . . 0 C--O 1.25 1.11 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 172.188 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.0 ttt . . . . . 0 N--CA 1.486 1.332 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 9.8 p -69.69 -23.59 63.46 Favored 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 114.228 1.196 . . . . 0.0 114.228 -174.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 32.3 pt -62.73 146.95 12.24 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 124.062 0.945 . . . . 0.0 111.826 -172.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -169.36 49.76 0.21 Allowed Glycine 0 CA--C 1.529 0.936 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -172.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 98.5 t -143.88 139.39 16.03 Favored Pre-proline 0 CA--C 1.536 0.426 0 N-CA-C 105.277 -2.119 . . . . 0.0 105.277 -171.109 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -61.83 159.89 31.44 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 121.666 1.577 . . . . 0.0 112.582 -179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -155.3 168.1 33.04 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 172.294 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -89.9 143.02 27.15 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 174.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 70.0 mt -74.17 76.64 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 C-N-CA 125.32 1.448 . . . . 0.0 107.205 176.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.8 tpp180 -64.87 -39.18 93.14 Favored 'General case' 0 CA--C 1.529 0.163 0 C-N-CA 126.088 1.755 . . . . 0.0 110.916 -177.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 2.0 m -150.26 153.78 36.78 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.8 mt -112.35 147.2 16.28 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 178.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -116.39 -22.33 8.84 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 125.37 1.468 . . . . 0.0 111.565 -169.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 154.29 -122.92 1.3 Allowed Glycine 0 C--N 1.335 0.528 0 N-CA-C 105.094 -3.203 . . . . 0.0 105.094 -177.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.3 p-10 -72.81 15.68 0.18 Allowed 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 124.101 0.961 . . . . 0.0 111.121 168.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.419 ' H ' ' C ' ' A' ' 14' ' ' GLY . 20.6 mt-30 -141.53 169.87 16.79 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 128.03 2.532 . . . . 0.0 106.569 -174.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.78 21.27 Favored 'General case' 0 N--CA 1.452 -0.34 0 C-N-CA 124.399 1.08 . . . . 0.0 109.4 173.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 46.3 mttp -118.26 72.58 0.87 Allowed 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 105.604 -1.999 . . . . 0.0 105.604 -179.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.5 m -70.13 137.2 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 C-N-CA 124.553 1.141 . . . . 0.0 109.326 -169.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -85.19 111.89 20.23 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 175.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.2 m -80.45 38.94 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.78 0 C-N-CA 124.181 0.992 . . . . 0.0 110.979 178.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 75.8 m 48.13 53.53 11.56 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.349 1.86 . . . . 0.0 111.855 -169.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -179.52 -41.3 0.07 OUTLIER Glycine 0 CA--C 1.524 0.62 0 CA-C-O 119.721 -0.488 . . . . 0.0 112.415 173.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.4 tp -156.0 156.06 5.01 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 43.5 mt-30 -77.12 138.73 39.68 Favored 'General case' 0 N--CA 1.454 -0.237 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 173.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 38.7 mmt180 -130.9 131.99 44.85 Favored 'General case' 0 C--N 1.333 -0.12 0 C-N-CA 125.466 1.506 . . . . 0.0 107.789 178.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -72.29 130.96 42.01 Favored 'General case' 0 CA--C 1.532 0.257 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 49.1 t -141.44 133.55 28.68 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 125.683 1.593 . . . . 0.0 107.323 -173.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -64.79 136.71 57.2 Favored 'General case' 0 C--O 1.233 0.216 0 C-N-CA 122.689 0.395 . . . . 0.0 110.407 172.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 16.9 mt -112.92 0.74 15.21 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.165 -0.921 . . . . 0.0 111.569 173.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.3 m -54.99 -31.75 61.21 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 121.061 1.755 . . . . 0.0 111.724 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 56.8 mt -67.87 -15.26 63.53 Favored 'General case' 0 CA--C 1.54 0.588 0 N-CA-C 113.642 0.979 . . . . 0.0 113.642 178.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.8 m -132.64 -10.83 1.46 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 C-N-CA 124.481 1.112 . . . . 0.0 112.79 -175.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.31 141.02 0.83 Allowed Glycine 0 CA--C 1.529 0.922 0 C-N-CA 125.527 1.537 . . . . 0.0 110.397 -170.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.4 m -76.29 -6.2 50.43 Favored 'General case' 0 CA--C 1.536 0.432 0 O-C-N 121.817 -0.813 . . . . 0.0 112.533 174.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 80.4 m -110.32 147.96 32.87 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 124.139 0.976 . . . . 0.0 109.489 175.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.3 t0 -68.94 171.65 7.75 Favored 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 126.635 1.974 . . . . 0.0 110.564 176.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 21.9 mm-40 -58.25 -15.36 9.79 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 125.149 1.38 . . . . 0.0 113.505 -177.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 23.1 p-10 -117.96 8.66 12.6 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.529 1.532 . . . . 0.0 112.896 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.73 -2.11 69.47 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-O 118.805 -0.997 . . . . 0.0 114.545 170.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 36.2 mt-30 -67.01 154.54 92.28 Favored Pre-proline 0 CA--C 1.537 0.444 0 CA-C-N 119.373 1.586 . . . . 0.0 108.797 169.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -64.84 143.32 79.48 Favored 'Trans proline' 0 CA--C 1.538 0.706 0 CA-C-N 121.18 1.457 . . . . 0.0 109.382 169.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.1 mtt-85 -70.51 10.96 0.4 Allowed 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 113.966 1.098 . . . . 0.0 113.966 178.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 13.9 p -56.44 132.34 20.4 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 O-C-N 120.759 -1.213 . . . . 0.0 109.03 -175.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.7 -15.79 49.74 Favored Glycine 0 CA--C 1.533 1.195 0 CA-C-O 118.097 -1.391 . . . . 0.0 114.076 -178.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.2 mt-30 -69.05 170.28 10.21 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 120.023 1.912 . . . . 0.0 108.906 169.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 49.2 m95 -119.66 157.62 28.1 Favored 'General case' 0 C--O 1.233 0.202 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 177.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.3 p -151.56 136.3 9.92 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -171.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 81.0 mt -71.35 145.37 49.47 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 169.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 39.1 t -117.06 143.24 27.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.258 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 176.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 79.5 t60 -139.14 118.84 13.09 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 173.154 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . 0.286 29.4 m 44.45 28.87 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 127.461 2.304 . . . . 0.0 115.686 -177.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 98.81 10.87 48.55 Favored Glycine 0 CA--C 1.531 1.033 0 O-C-N 121.188 -0.945 . . . . 0.0 114.392 178.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -125.79 146.62 49.71 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 119.044 1.422 . . . . 0.0 108.484 -179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.12 114.44 3.12 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 123.615 0.766 . . . . 0.0 109.523 172.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 12.7 tpt -80.91 -42.71 20.96 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 58.3 m -166.02 147.54 6.88 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.865 1.666 . . . . 0.0 108.328 171.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 96.6 t -75.54 143.56 13.07 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 169.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 33.7 pt -139.36 162.19 27.32 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.028 1.331 . . . . 0.0 109.782 -175.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.6 t30 -74.14 165.22 25.53 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-O 121.48 0.657 . . . . 0.0 110.262 172.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -56.62 -43.2 79.99 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.191 1.396 . . . . 0.0 111.318 176.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.37 -38.85 85.39 Favored 'General case' 0 C--N 1.338 0.1 0 C-N-CA 122.801 0.44 . . . . 0.0 110.825 -177.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -65.97 -40.36 91.18 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 177.613 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.31 -49.38 74.23 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 117.939 0.336 . . . . 0.0 110.478 178.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 47.6 mtm105 -61.57 -42.17 98.46 Favored 'General case' 0 N--CA 1.462 0.156 0 CA-C-O 119.12 -0.467 . . . . 0.0 110.809 179.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.4 -42.83 99.73 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-N 118.5 0.591 . . . . 0.0 111.102 177.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.7 m -65.84 -41.31 91.92 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 122.841 0.456 . . . . 0.0 110.273 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 76.0 mt -65.23 -40.67 94.36 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 118.981 0.809 . . . . 0.0 110.426 178.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -64.4 -44.1 92.36 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 118.717 0.689 . . . . 0.0 110.696 177.114 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.3 -46.03 92.01 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 122.95 0.5 . . . . 0.0 110.509 176.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 26.0 mt -61.68 -44.92 96.03 Favored 'General case' 0 C--O 1.227 -0.101 0 CA-C-O 118.771 -0.633 . . . . 0.0 110.758 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -61.71 -39.96 93.33 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 119.065 0.848 . . . . 0.0 110.66 178.027 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 15.8 m-80 -63.84 -37.69 88.31 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 118.261 0.482 . . . . 0.0 110.636 175.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 89.6 mtp -78.18 32.07 0.18 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.096 1.758 . . . . 0.0 111.414 172.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 17.9 p90 46.89 32.45 1.82 Allowed 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 127.276 2.23 . . . . 0.0 113.754 178.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 26.9 t70 47.51 26.87 0.86 Allowed 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 127.411 2.284 . . . . 0.0 113.301 -174.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 1.7 t 54.39 23.85 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.953 0 C-N-CA 126.575 1.95 . . . . 0.0 111.866 -176.519 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -140.88 71.64 29.13 Favored Pre-proline 0 CA--C 1.534 0.355 0 C-N-CA 125.254 1.421 . . . . 0.0 107.366 179.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -62.7 -21.91 73.42 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.914 2.41 . . . . 0.0 113.173 -169.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -55.36 -24.17 28.07 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 124.868 1.267 . . . . 0.0 112.802 175.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.9 m -122.51 -34.36 1.26 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.257 0 C-N-CA 124.064 0.946 . . . . 0.0 110.559 171.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -59.04 -34.73 80.51 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-O 118.938 -0.923 . . . . 0.0 112.742 -177.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -61.58 -27.14 68.42 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 118.846 1.323 . . . . 0.0 112.275 177.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 60.5 tp -94.12 -44.56 7.95 Favored 'General case' 0 CA--C 1.529 0.141 0 C-N-CA 123.867 0.867 . . . . 0.0 110.36 177.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -69.15 -36.23 77.19 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.083 0.553 . . . . 0.0 111.701 -174.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 19.7 m-85 -134.8 -21.09 1.72 Allowed 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 123.992 0.917 . . . . 0.0 112.197 -170.05 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -85.3 -150.93 14.03 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 125.062 1.315 . . . . 0.0 111.694 178.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -119.55 11.09 11.97 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 125.688 1.595 . . . . 0.0 112.116 -169.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -69.04 -22.9 64.01 Favored 'General case' 0 CA--C 1.545 0.753 0 O-C-N 121.414 -0.804 . . . . 0.0 110.599 171.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 60.0 tptt . . . . . 0 C--O 1.249 1.036 0 C-N-CA 124.573 1.149 . . . . 0.0 109.823 175.431 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.6 ttt . . . . . 0 N--CA 1.482 1.172 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 56.2 m -63.11 154.3 31.45 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 122.941 0.496 . . . . 0.0 110.845 178.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 46.4 pt -134.39 -168.54 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 C-N-CA 126.713 2.005 . . . . 0.0 106.959 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.6 67.25 0.08 OUTLIER Glycine 0 CA--C 1.519 0.315 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 -177.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 9.0 p -148.44 149.95 32.86 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 123.69 0.796 . . . . 0.0 109.121 -169.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -67.03 168.58 16.95 Favored 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 122.549 2.166 . . . . 0.0 111.882 169.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.66 172.9 41.27 Favored Glycine 0 CA--C 1.529 0.913 0 C-N-CA 126.621 2.057 . . . . 0.0 108.621 170.375 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.9 tt0 -116.71 129.58 56.21 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 118.216 1.008 . . . . 0.0 108.982 -177.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 63.8 mt -70.27 127.63 32.45 Favored 'Isoleucine or valine' 0 C--O 1.234 0.276 0 N-CA-C 106.969 -1.493 . . . . 0.0 106.969 -178.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -120.99 -29.65 4.54 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 118.247 -0.882 . . . . 0.0 112.448 -170.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.3 m -149.6 155.32 40.09 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -178.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 70.0 mt -132.37 124.81 52.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 N-CA-C 106.642 -1.614 . . . . 0.0 106.642 -177.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -86.89 -32.24 20.3 Favored 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 123.506 0.722 . . . . 0.0 110.4 172.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 164.58 -114.03 0.58 Allowed Glycine 0 C--N 1.335 0.509 0 N-CA-C 107.69 -2.164 . . . . 0.0 107.69 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -67.22 -0.66 3.6 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 124.287 1.035 . . . . 0.0 112.997 172.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 54.0 mt-30 -135.95 155.57 50.08 Favored 'General case' 0 C--O 1.239 0.505 0 C-N-CA 125.632 1.573 . . . . 0.0 107.438 177.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.23 151.69 38.8 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 124.321 1.048 . . . . 0.0 110.04 -171.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 43.0 tttt -90.85 133.1 35.49 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 65.9 t -126.23 130.49 72.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 -174.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -82.31 110.0 17.08 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 106.052 -1.833 . . . . 0.0 106.052 169.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 8.5 t -84.4 64.86 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 N-CA-C 106.813 -1.551 . . . . 0.0 106.813 178.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 48.6 m 52.76 29.43 7.51 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 126.615 1.966 . . . . 0.0 114.94 171.386 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 158.27 -23.67 0.37 Allowed Glycine 0 CA--C 1.525 0.675 0 CA-C-N 119.121 0.873 . . . . 0.0 113.584 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.7 tp -146.45 149.63 15.86 Favored 'Isoleucine or valine' 0 C--O 1.233 0.233 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 174.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -88.51 150.27 23.2 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 120.983 0.42 . . . . 0.0 110.236 -175.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -139.5 150.08 44.71 Favored 'General case' 0 N--CA 1.464 0.227 0 C-N-CA 124.566 1.146 . . . . 0.0 108.703 169.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.54 138.83 35.38 Favored 'General case' 0 C--O 1.237 0.416 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 169.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 50.5 t -136.38 131.88 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.313 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 -173.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -79.34 138.64 37.77 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 123.468 0.707 . . . . 0.0 109.71 175.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mp -114.99 10.83 16.35 Favored 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 123.946 0.898 . . . . 0.0 112.211 -171.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 8.9 m -53.1 -34.07 55.03 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 120.265 1.393 . . . . 0.0 111.991 -177.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 85.2 mt -73.38 -12.93 60.99 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.769 0.827 . . . . 0.0 113.136 -176.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m -136.36 -20.3 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 CA-C-N 119.516 1.053 . . . . 0.0 113.188 -169.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.54 146.32 6.03 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 124.334 0.968 . . . . 0.0 111.457 -177.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 5.1 p -74.41 -6.71 49.81 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 125.949 1.7 . . . . 0.0 113.581 -176.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.8 m -135.49 157.14 47.64 Favored 'General case' 0 C--O 1.234 0.28 0 C-N-CA 125.385 1.474 . . . . 0.0 108.177 171.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -66.07 165.11 14.06 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 125.079 1.352 . . . . 0.0 110.451 169.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -53.95 -38.33 64.84 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.935 1.294 . . . . 0.0 111.657 176.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -87.06 11.83 12.83 Favored 'General case' 0 CA--C 1.542 0.64 0 C-N-CA 123.861 0.865 . . . . 0.0 111.85 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.98 6.97 88.48 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 124.583 1.087 . . . . 0.0 113.492 174.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -67.71 134.2 92.45 Favored Pre-proline 0 CA--C 1.54 0.567 0 CA-C-N 118.588 1.194 . . . . 0.0 108.206 179.084 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.27 143.29 53.62 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 122.531 2.154 . . . . 0.0 111.44 171.633 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -69.7 -17.79 63.5 Favored 'General case' 0 CA--C 1.535 0.366 0 CA-C-O 118.043 -0.98 . . . . 0.0 112.836 175.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 46.6 t -55.32 134.82 18.72 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 CA-C-N 120.297 1.408 . . . . 0.0 109.125 178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.02 -21.27 20.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 124.561 1.077 . . . . 0.0 112.735 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -71.87 159.64 33.94 Favored 'General case' 0 C--O 1.238 0.461 0 CA-C-N 119.09 1.445 . . . . 0.0 108.162 171.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 40.6 m95 -106.7 158.41 16.99 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 -179.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.67 139.52 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.526 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -169.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -83.18 133.08 35.04 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 169.686 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 9.2 t -121.44 135.76 60.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 4.7 t60 -137.12 -48.38 0.6 Allowed 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.269 0.628 . . . . 0.0 111.108 -170.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.4 m -136.3 27.63 0.78 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 C-N-CA 123.75 0.82 . . . . 0.0 111.205 -174.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.12 15.53 78.56 Favored Glycine 0 CA--C 1.531 1.068 0 O-C-N 121.531 -0.73 . . . . 0.0 112.464 -174.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -126.39 147.8 49.71 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 125.578 1.551 . . . . 0.0 107.095 174.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -66.44 105.18 1.4 Allowed 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 124.379 1.071 . . . . 0.0 108.257 172.009 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.4 ttt -70.6 -46.17 63.91 Favored 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 24.6 m -152.53 158.69 42.89 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 126.136 1.774 . . . . 0.0 107.445 175.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 44.1 t -121.0 140.25 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 174.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 29.0 pt -141.66 161.93 20.95 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 C-N-CA 125.712 1.605 . . . . 0.0 110.081 -171.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 p30 -74.66 168.34 20.0 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.669 0.788 . . . . 0.0 110.507 171.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -63.1 -42.29 99.55 Favored 'General case' 0 C--O 1.227 -0.09 0 CA-C-O 119.167 -0.444 . . . . 0.0 111.963 -173.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.83 -41.41 87.49 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 118.499 0.59 . . . . 0.0 110.315 -173.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -62.59 -36.43 82.7 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 122.578 0.351 . . . . 0.0 110.49 173.403 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.88 -40.57 83.54 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-N 119.05 0.841 . . . . 0.0 111.507 176.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 10.0 mmt85 -66.59 -38.83 87.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 119.291 0.95 . . . . 0.0 109.513 178.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.48 -42.71 99.68 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 118.015 0.371 . . . . 0.0 110.919 174.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 60.6 m -62.06 -40.87 97.24 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 123.34 0.656 . . . . 0.0 110.417 176.418 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 21.4 mt -63.86 -39.15 93.54 Favored 'General case' 0 C--N 1.338 0.073 0 O-C-N 121.668 -0.645 . . . . 0.0 110.943 178.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -68.2 -44.33 76.06 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.383 0.992 . . . . 0.0 110.677 175.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.53 -31.41 70.49 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 124.247 1.019 . . . . 0.0 111.821 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 62.3 tp -78.79 -59.64 2.7 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 123.558 0.743 . . . . 0.0 110.339 174.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 34.6 mt-30 -55.55 -40.97 72.59 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-O 118.437 -0.792 . . . . 0.0 112.866 -169.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -61.65 -10.76 9.15 Favored 'General case' 0 CA--C 1.541 0.603 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 -177.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -131.1 11.94 5.09 Favored 'General case' 0 CA--C 1.54 0.592 0 C-N-CA 124.458 1.103 . . . . 0.0 112.379 175.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 76.7 t80 -137.67 -44.88 0.54 Allowed 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 123.786 0.835 . . . . 0.0 111.575 -171.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -67.63 -31.14 70.95 Favored 'General case' 0 N--CA 1.468 0.434 0 O-C-N 121.407 -0.808 . . . . 0.0 110.498 174.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 23.8 m -71.21 -2.93 3.07 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.694 0 C-N-CA 125.39 1.476 . . . . 0.0 112.678 172.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 81.9 mm-40 -130.96 67.98 81.42 Favored Pre-proline 0 CA--C 1.538 0.491 0 C-N-CA 125.37 1.468 . . . . 0.0 107.748 178.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -63.15 -20.91 72.11 Favored 'Trans proline' 0 C--N 1.348 0.503 0 C-N-CA 122.718 2.278 . . . . 0.0 113.644 -169.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -65.91 -41.87 90.9 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-N 119.121 0.873 . . . . 0.0 110.986 171.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 34.2 t -69.67 -34.74 62.56 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 174.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -54.86 -54.36 33.89 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 170.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -62.5 -37.2 85.07 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 117.735 0.767 . . . . 0.0 111.593 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -65.35 -57.63 7.9 Favored 'General case' 0 N--CA 1.456 -0.155 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -85.59 -64.03 1.22 Allowed 'General case' 0 N--CA 1.457 -0.095 0 CA-C-N 118.1 0.409 . . . . 0.0 110.448 -169.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 92.3 t80 -70.02 -37.87 75.76 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.132 0.424 . . . . 0.0 110.417 -175.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.64 -5.09 82.7 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-O 118.55 -1.139 . . . . 0.0 112.701 176.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 49.81 47.0 23.63 Favored 'General case' 0 CA--C 1.543 0.702 0 CA-C-N 119.002 1.401 . . . . 0.0 110.842 -178.291 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 66.44 7.05 4.72 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 127.479 2.312 . . . . 0.0 113.677 -179.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 29.6 mtpp . . . . . 0 C--O 1.25 1.095 0 C-N-CA 127.381 2.272 . . . . 0.0 111.111 -179.47 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 55.0 tpp . . . . . 0 N--CA 1.483 1.191 0 N-CA-C 109.842 -0.429 . . . . 0.0 109.842 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 17.8 p -150.62 172.86 14.85 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 125.146 1.378 . . . . 0.0 109.074 178.037 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 15.9 tt -150.8 150.15 13.67 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 176.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.39 54.79 0.26 Allowed Glycine 0 CA--C 1.529 0.92 0 N-CA-C 109.331 -1.508 . . . . 0.0 109.331 -175.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 21.1 t -139.24 143.41 36.28 Favored Pre-proline 0 CA--C 1.543 0.688 0 C-N-CA 124.296 1.038 . . . . 0.0 109.007 -169.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_exo -56.25 155.62 24.0 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.632 2.221 . . . . 0.0 112.301 169.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.12 170.66 39.44 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 169.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 49.1 tt0 -116.3 125.25 51.88 Favored 'General case' 0 C--O 1.233 0.189 0 C-N-CA 123.982 0.913 . . . . 0.0 108.836 -174.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 77.1 mt -64.03 129.33 27.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 51.7 tpt85 -114.42 -33.93 5.43 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 118.058 -0.972 . . . . 0.0 111.663 -176.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.4 p -148.15 157.25 43.39 Favored 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 47.1 mt -132.51 144.14 37.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -123.15 -19.29 6.07 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 124.364 1.066 . . . . 0.0 111.875 -176.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 167.46 -127.18 1.53 Allowed Glycine 0 C--N 1.336 0.562 0 N-CA-C 106.815 -2.514 . . . . 0.0 106.815 -179.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.7 p-10 -63.92 -10.23 19.86 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 117.514 0.657 . . . . 0.0 112.365 169.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -119.92 159.2 25.14 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.523 1.129 . . . . 0.0 110.509 179.304 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.48 167.72 27.11 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 125.746 1.618 . . . . 0.0 109.544 -172.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.33 132.28 54.52 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 105.94 -1.874 . . . . 0.0 105.94 171.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 52.7 t -126.35 123.78 64.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -174.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -72.81 111.13 7.67 Favored 'General case' 0 C--O 1.234 0.269 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 171.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.8 t -90.2 63.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.414 0 N-CA-C 106.495 -1.669 . . . . 0.0 106.495 176.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 39.9 m 47.18 42.47 13.31 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.885 2.074 . . . . 0.0 114.026 175.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.55 -31.17 0.19 Allowed Glycine 0 CA--C 1.524 0.652 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.169 174.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 18.9 tt -152.41 151.45 11.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 177.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 71.5 mt-30 -73.14 137.5 45.19 Favored 'General case' 0 C--O 1.234 0.266 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -122.53 148.26 45.4 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 124.595 1.158 . . . . 0.0 108.188 169.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -72.82 134.71 45.01 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 123.82 0.848 . . . . 0.0 108.983 172.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -140.5 157.28 24.21 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 C-N-CA 124.787 1.235 . . . . 0.0 108.096 -176.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -112.61 142.58 45.03 Favored 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 125.415 1.486 . . . . 0.0 108.815 172.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 49.9 mt -113.3 7.59 17.78 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.284 1.034 . . . . 0.0 112.328 -169.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 28.9 p -57.55 -29.15 64.16 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.599 1.545 . . . . 0.0 113.124 -173.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -70.53 -16.36 62.88 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.691 0.797 . . . . 0.0 112.534 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 24.2 m -130.0 -12.63 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 C-N-CA 124.606 1.162 . . . . 0.0 112.312 -173.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.62 141.34 1.19 Allowed Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.993 1.282 . . . . 0.0 109.939 -170.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 15.6 m -73.15 -10.58 59.92 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -178.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.4 m -121.36 145.62 47.71 Favored 'General case' 0 N--CA 1.453 -0.297 0 C-N-CA 124.229 1.012 . . . . 0.0 109.238 177.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -69.81 157.55 37.14 Favored 'General case' 0 N--CA 1.451 -0.42 0 C-N-CA 125.227 1.411 . . . . 0.0 109.894 172.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -51.54 -35.07 39.26 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 125.128 1.371 . . . . 0.0 112.139 176.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 45.8 m-80 -70.45 -8.86 54.2 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.746 0.818 . . . . 0.0 112.417 -178.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 98.43 25.04 10.42 Favored Glycine 0 CA--C 1.53 1.019 0 CA-C-N 119.6 1.091 . . . . 0.0 113.946 170.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -125.92 149.21 65.36 Favored Pre-proline 0 CA--C 1.535 0.399 0 CA-C-N 118.775 1.287 . . . . 0.0 108.26 179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.77 143.91 36.59 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 122.966 2.444 . . . . 0.0 111.272 170.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 89.1 mtt-85 -70.61 18.79 0.05 Allowed 'General case' 0 CA--C 1.543 0.701 0 N-CA-C 114.421 1.267 . . . . 0.0 114.421 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.2 m -56.55 136.32 19.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.441 0 O-C-N 120.394 -1.441 . . . . 0.0 109.547 179.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.11 -14.64 43.14 Favored Glycine 0 CA--C 1.53 0.997 0 CA-C-O 118.373 -1.237 . . . . 0.0 113.586 -178.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -75.23 152.05 38.36 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 120.134 1.967 . . . . 0.0 109.184 176.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 59.7 m95 -95.07 150.28 20.35 Favored 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 174.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 15.2 m -142.2 153.5 18.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 C-N-CA 124.663 1.185 . . . . 0.0 109.04 -178.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -85.37 107.09 17.2 Favored 'General case' 0 C--N 1.333 -0.141 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 169.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 18.0 t -78.02 120.87 29.62 Favored 'Isoleucine or valine' 0 C--O 1.234 0.269 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 174.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.3 m-70 -134.62 120.09 19.16 Favored 'General case' 0 C--N 1.331 -0.202 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.0 t 49.58 33.61 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 C-N-CA 125.146 1.378 . . . . 0.0 112.105 178.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.96 6.94 78.59 Favored Glycine 0 CA--C 1.531 1.094 0 O-C-N 121.029 -1.044 . . . . 0.0 114.054 176.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -119.99 146.03 46.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-N 119.339 1.57 . . . . 0.0 109.055 176.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -75.5 104.83 6.23 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 41.0 tpp -68.2 -46.28 71.05 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 122.72 0.408 . . . . 0.0 110.704 -174.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 15.2 m -152.02 165.75 33.71 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 125.953 1.701 . . . . 0.0 107.98 -178.568 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 6.5 t -111.38 141.34 27.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.351 0 C-N-CA 125.049 1.34 . . . . 0.0 107.742 -178.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 35.8 pt -140.81 165.86 19.49 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.767 1.227 . . . . 0.0 110.556 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 38.1 m-80 -80.39 165.48 22.2 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 124.582 1.153 . . . . 0.0 109.889 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -64.65 -32.41 74.06 Favored 'General case' 0 N--CA 1.468 0.425 0 O-C-N 121.763 -0.586 . . . . 0.0 111.505 -179.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.54 -43.11 77.39 Favored 'General case' 0 N--CA 1.462 0.172 0 O-C-N 121.432 -0.793 . . . . 0.0 110.429 177.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -65.08 -39.32 93.03 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 123.314 0.646 . . . . 0.0 109.646 178.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.98 -49.55 74.26 Favored 'General case' 0 N--CA 1.453 -0.311 0 O-C-N 122.17 -0.331 . . . . 0.0 110.364 177.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.2 mtm180 -62.53 -40.01 95.42 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 119.103 -0.475 . . . . 0.0 111.008 179.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -61.48 -43.77 98.28 Favored 'General case' 0 CA--C 1.529 0.165 0 CA-C-N 118.494 0.588 . . . . 0.0 110.898 175.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.9 m -66.79 -40.49 88.16 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 123.075 0.55 . . . . 0.0 110.643 179.175 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 41.7 mt -63.06 -35.66 81.0 Favored 'General case' 0 C--N 1.338 0.101 0 C-N-CA 124.066 0.946 . . . . 0.0 110.759 178.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -70.06 -48.89 55.97 Favored 'General case' 0 C--O 1.226 -0.132 0 CA-C-N 118.492 0.587 . . . . 0.0 109.905 171.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -59.08 -40.49 85.4 Favored 'General case' 0 C--O 1.233 0.2 0 C-N-CA 123.617 0.767 . . . . 0.0 111.744 -171.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 4.0 pp -69.83 -10.56 58.89 Favored 'General case' 0 CA--C 1.537 0.473 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 -114.9 -19.0 11.15 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.352 1.461 . . . . 0.0 111.093 178.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 14.0 t-20 -55.73 -31.92 62.93 Favored 'General case' 0 CA--C 1.528 0.105 0 C-N-CA 125.848 1.659 . . . . 0.0 112.823 -169.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 96.7 mtp -58.38 -22.02 52.36 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.798 0.839 . . . . 0.0 112.887 177.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -60.67 -22.27 63.7 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-N 119.159 0.89 . . . . 0.0 111.686 174.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -59.18 -22.88 61.66 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 123.96 0.904 . . . . 0.0 112.581 174.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 34.8 t -76.66 -22.92 15.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.751 0 C-N-CA 123.929 0.892 . . . . 0.0 110.577 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 30.2 mm-40 -71.28 150.48 94.31 Favored Pre-proline 0 CA--C 1.539 0.548 0 O-C-N 121.245 -0.91 . . . . 0.0 109.387 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -70.08 -16.69 36.3 Favored 'Trans proline' 0 CA--C 1.535 0.556 0 C-N-CA 122.388 2.058 . . . . 0.0 113.01 -178.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -57.88 -38.06 75.1 Favored 'General case' 0 N--CA 1.464 0.267 0 C-N-CA 123.851 0.86 . . . . 0.0 112.578 -174.103 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 18.5 m -65.09 -17.59 22.19 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 CA-C-N 117.99 0.359 . . . . 0.0 111.966 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -56.93 -32.94 62.9 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 119.292 -0.727 . . . . 0.0 111.871 174.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -63.81 -25.27 68.1 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 118.487 1.144 . . . . 0.0 112.367 177.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 55.0 tp -91.79 -46.86 7.66 Favored 'General case' 0 CA--C 1.527 0.076 0 C-N-CA 123.581 0.753 . . . . 0.0 109.908 174.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 44.9 tp -68.41 -47.23 67.83 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 123.053 0.541 . . . . 0.0 111.42 -172.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 57.4 m-85 -114.96 -25.06 8.32 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.184 0.994 . . . . 0.0 111.494 -175.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -79.5 -162.18 23.81 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 124.435 1.017 . . . . 0.0 111.392 173.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -121.02 20.97 11.46 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.603 1.161 . . . . 0.0 111.104 -169.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 39.3 mm-40 -71.65 -0.47 10.87 Favored 'General case' 0 CA--C 1.548 0.888 0 O-C-N 121.2 -0.938 . . . . 0.0 112.025 170.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 57.0 mttp . . . . . 0 C--O 1.249 1.036 0 C-N-CA 126.259 1.824 . . . . 0.0 110.288 173.023 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.1 ttt . . . . . 0 N--CA 1.485 1.275 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.2 m -70.46 -41.92 72.16 Favored 'General case' 0 CA--C 1.535 0.378 0 O-C-N 121.7 -0.625 . . . . 0.0 111.66 -174.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 17.5 pt -145.96 155.12 12.77 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 126.282 1.833 . . . . 0.0 106.871 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.68 44.39 0.08 OUTLIER Glycine 0 CA--C 1.525 0.717 0 N-CA-C 108.133 -1.987 . . . . 0.0 108.133 -177.098 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.9 m -146.89 168.18 12.01 Favored Pre-proline 0 CA--C 1.543 0.69 0 C-N-CA 125.462 1.505 . . . . 0.0 110.108 -168.634 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -57.37 162.73 9.43 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.052 2.501 . . . . 0.0 113.37 169.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.86 176.75 41.22 Favored Glycine 0 CA--C 1.526 0.729 0 C-N-CA 125.978 1.752 . . . . 0.0 109.666 170.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 56.9 tt0 -116.86 136.92 52.58 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 45.6 mt -72.89 71.29 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 174.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -68.69 -33.52 74.1 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.156 0.982 . . . . 0.0 111.647 -169.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -146.3 156.06 43.09 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 174.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt -128.66 146.7 33.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.322 0 N-CA-C 106.471 -1.678 . . . . 0.0 106.471 178.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -117.14 -27.27 6.54 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 123.918 0.887 . . . . 0.0 111.415 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.5 -123.17 1.08 Allowed Glycine 0 C--N 1.334 0.465 0 N-CA-C 107.335 -2.306 . . . . 0.0 107.335 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.1 t-20 -62.71 -23.52 67.2 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.292 0.637 . . . . 0.0 111.848 169.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 25.2 mm100 -99.04 155.28 17.52 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.022 0.929 . . . . 0.0 109.278 169.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -140.11 163.13 33.54 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 125.014 1.326 . . . . 0.0 109.538 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 4.1 mptp? -110.46 77.72 1.07 Allowed 'General case' 0 C--O 1.234 0.252 0 N-CA-C 105.688 -1.968 . . . . 0.0 105.688 -175.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 93.0 t -70.85 127.74 33.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -177.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -74.83 107.61 7.03 Favored 'General case' 0 CA--C 1.52 -0.187 0 N-CA-C 105.898 -1.89 . . . . 0.0 105.898 168.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 10.5 t -84.26 58.09 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.515 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -178.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 38.0 m 45.57 44.6 10.16 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 127.274 2.23 . . . . 0.0 113.208 -179.729 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.26 -38.65 0.14 Allowed Glycine 0 CA--C 1.525 0.713 0 CA-C-O 119.478 -0.624 . . . . 0.0 112.708 176.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 9.6 tp -153.09 153.79 8.49 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 175.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 58.6 mt-30 -73.63 138.04 44.58 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 174.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.9 mmt180 -127.0 144.89 50.9 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 125.608 1.563 . . . . 0.0 107.151 172.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -75.01 131.19 40.45 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 72.9 t -140.16 138.77 37.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 C-N-CA 125.126 1.37 . . . . 0.0 107.933 -171.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -80.72 130.64 35.2 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 125.778 1.631 . . . . 0.0 109.264 175.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 21.0 mt -105.46 6.66 32.63 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 123.676 0.79 . . . . 0.0 112.989 -176.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 7.5 m -55.61 -32.67 63.31 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 120.807 1.64 . . . . 0.0 112.853 -171.527 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.8 mt -71.02 -13.95 62.17 Favored 'General case' 0 CA--C 1.538 0.493 0 N-CA-C 112.816 0.672 . . . . 0.0 112.816 -178.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.6 m -131.33 -15.55 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.372 1.069 . . . . 0.0 112.581 -174.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 75.91 143.88 1.31 Allowed Glycine 0 CA--C 1.528 0.871 0 C-N-CA 125.394 1.474 . . . . 0.0 110.683 -173.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.4 m -76.62 -7.32 55.02 Favored 'General case' 0 CA--C 1.536 0.415 0 O-C-N 121.944 -0.739 . . . . 0.0 112.871 178.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.9 m -114.71 139.57 49.57 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.072 0.949 . . . . 0.0 109.676 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -75.56 155.76 35.7 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 126.809 2.044 . . . . 0.0 109.733 170.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -58.04 -25.96 61.85 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.034 1.334 . . . . 0.0 112.883 -173.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 -71.56 -6.97 44.66 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 121.506 -0.746 . . . . 0.0 112.525 178.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 85.13 47.44 5.24 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -179.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.7 pt20 -142.44 153.51 62.49 Favored Pre-proline 0 CA--C 1.535 0.392 0 C-N-CA 125.724 1.61 . . . . 0.0 107.577 -178.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -67.51 147.23 76.53 Favored 'Trans proline' 0 CA--C 1.539 0.726 0 C-N-CA 121.645 1.563 . . . . 0.0 109.687 174.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 92.1 mtt-85 -70.88 17.96 0.07 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -175.306 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 89.4 t -56.53 126.2 13.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 O-C-N 120.848 -1.157 . . . . 0.0 108.599 -174.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.63 -13.59 66.25 Favored Glycine 0 CA--C 1.53 1.024 0 CA-C-O 118.324 -1.265 . . . . 0.0 113.632 176.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 80.1 mt-30 -68.04 154.58 41.34 Favored 'General case' 0 C--O 1.236 0.343 0 CA-C-N 119.566 1.683 . . . . 0.0 109.106 174.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.9 m95 -96.19 160.7 14.3 Favored 'General case' 0 C--O 1.234 0.249 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 8.8 p -155.53 156.7 4.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -169.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 96.0 mt -101.68 133.0 47.06 Favored 'General case' 0 CA--C 1.518 -0.261 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 169.158 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.9 m -128.3 139.07 52.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 118.853 0.751 . . . . 0.0 109.113 -177.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.6 t-80 -142.48 132.77 24.82 Favored 'General case' 0 C--O 1.232 0.132 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 -176.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 36.2 t 59.77 -61.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 128.146 2.579 . . . . 0.0 112.79 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -174.37 21.04 0.06 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 126.182 1.849 . . . . 0.0 111.596 179.245 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -132.38 141.86 49.07 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 118.78 1.29 . . . . 0.0 108.69 -172.718 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -73.26 124.03 24.88 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 169.422 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 90.4 mmm -90.86 -49.16 6.6 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 123.148 0.579 . . . . 0.0 109.966 -178.017 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 16.3 m -149.52 140.85 23.21 Favored 'General case' 0 C--N 1.339 0.145 0 C-N-CA 124.271 1.029 . . . . 0.0 108.775 178.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 84.0 t -81.78 142.93 13.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 169.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 32.1 pt -139.58 162.78 26.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 C-N-CA 124.885 1.274 . . . . 0.0 109.647 -173.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -79.67 163.79 24.27 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.658 0.742 . . . . 0.0 110.53 175.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -55.89 -39.35 71.43 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 126.26 1.824 . . . . 0.0 111.729 175.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.59 -50.06 34.51 Favored 'General case' 0 C--N 1.338 0.091 0 O-C-N 121.864 -0.523 . . . . 0.0 110.253 -173.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -72.35 -27.48 62.43 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 119.296 -0.383 . . . . 0.0 110.73 -177.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.29 -52.04 66.98 Favored 'General case' 0 C--N 1.342 0.254 0 CA-C-N 118.877 0.762 . . . . 0.0 110.056 170.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 87.8 mtm180 -64.43 -37.64 88.22 Favored 'General case' 0 N--CA 1.46 0.054 0 CA-C-O 118.859 -0.591 . . . . 0.0 110.93 179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -62.65 -40.63 97.64 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 118.971 0.805 . . . . 0.0 111.176 175.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 35.8 m -65.39 -40.98 94.12 Favored 'General case' 0 CA--C 1.534 0.357 0 O-C-N 121.978 -0.452 . . . . 0.0 110.035 176.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 88.4 mt -65.07 -38.34 90.48 Favored 'General case' 0 CA--C 1.528 0.125 0 O-C-N 121.349 -0.845 . . . . 0.0 110.762 176.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.8 t70 -66.28 -39.11 89.19 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.624 0.647 . . . . 0.0 110.906 177.113 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.09 -50.46 71.85 Favored 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.463 0.705 . . . . 0.0 110.404 173.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.2 mt -59.98 -20.3 56.93 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.386 1.074 . . . . 0.0 112.6 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 -93.33 -66.21 0.94 Allowed 'General case' 0 N--CA 1.454 -0.255 0 CA-C-N 118.66 0.664 . . . . 0.0 109.724 174.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -64.24 -29.35 70.45 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 114.028 1.121 . . . . 0.0 114.028 -169.101 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.3 mtp -78.81 -3.89 46.73 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 119.126 0.875 . . . . 0.0 112.185 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -132.0 -23.59 2.21 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 123.987 0.915 . . . . 0.0 111.934 -172.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -59.9 -16.99 33.8 Favored 'General case' 0 N--CA 1.471 0.579 0 C-N-CA 125.497 1.519 . . . . 0.0 112.796 172.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 26.2 m -61.16 -11.18 4.16 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 125.117 1.367 . . . . 0.0 112.813 170.015 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 -131.69 154.17 81.72 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 125.399 1.479 . . . . 0.0 108.824 176.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.43 -6.0 18.06 Favored 'Trans proline' 0 CA--C 1.536 0.59 0 C-N-CA 122.998 2.465 . . . . 0.0 113.446 -176.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -57.76 -42.39 83.91 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 119.129 0.877 . . . . 0.0 112.259 -175.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 27.5 m -71.7 -29.64 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 118.101 0.41 . . . . 0.0 111.097 176.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -61.49 -46.67 93.86 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 173.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.34 -8.1 43.24 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 124.768 1.227 . . . . 0.0 113.5 176.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 57.6 tp -98.18 -42.41 7.45 Favored 'General case' 0 N--CA 1.462 0.175 0 CA-C-N 119.15 0.886 . . . . 0.0 109.905 174.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 60.7 tp -68.09 -39.95 82.74 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.763 0.825 . . . . 0.0 109.984 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -152.12 -158.95 0.95 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 126.379 1.872 . . . . 0.0 106.577 -173.102 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 76.82 -66.98 2.71 Favored Glycine 0 CA--C 1.526 0.743 0 C-N-CA 124.576 1.084 . . . . 0.0 112.666 169.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -138.3 -18.94 1.12 Allowed 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 125.726 1.61 . . . . 0.0 111.43 -176.534 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 32.1 tt0 46.17 62.59 2.2 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.734 1.614 . . . . 0.0 110.794 -170.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 29.3 mmmt . . . . . 0 C--O 1.249 1.056 0 C-N-CA 123.998 0.919 . . . . 0.0 111.357 -177.489 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 20.5 mmt . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 109.692 -0.485 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 55.5 m -74.55 155.94 37.37 Favored 'General case' 0 CA--C 1.533 0.32 0 O-C-N 121.935 -0.478 . . . . 0.0 109.722 169.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . 0.25 48.4 pt 40.26 45.58 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 126.663 1.985 . . . . 0.0 113.292 175.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.94 69.39 3.08 Favored Glycine 0 CA--C 1.525 0.709 0 C-N-CA 125.007 1.289 . . . . 0.0 110.08 179.489 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.0 t -140.21 139.3 20.68 Favored Pre-proline 0 CA--C 1.54 0.565 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -169.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -76.65 168.98 22.67 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.384 2.056 . . . . 0.0 111.83 173.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -171.02 -174.9 39.18 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.251 -1.14 . . . . 0.0 110.251 173.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 57.7 tt0 -116.67 131.15 57.02 Favored 'General case' 0 C--N 1.333 -0.123 0 C-N-CA 123.659 0.784 . . . . 0.0 108.99 -176.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 89.7 mt -67.06 122.65 18.5 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.8 mtm105 -119.62 -10.15 9.66 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 112.894 0.702 . . . . 0.0 112.894 177.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -152.55 151.55 30.81 Favored 'General case' 0 CA--C 1.534 0.348 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 172.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.9 mt -133.19 140.24 47.52 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 N-CA-C 105.966 -1.864 . . . . 0.0 105.966 172.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -108.01 -23.97 11.79 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 124.471 1.108 . . . . 0.0 112.438 -174.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.83 -62.37 0.15 Allowed Glycine 0 C--N 1.338 0.666 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 175.24 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 -144.42 27.92 1.36 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-O 122.912 1.339 . . . . 0.0 110.381 169.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -137.62 156.2 48.33 Favored 'General case' 0 C--O 1.239 0.541 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 169.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -144.25 166.54 24.75 Favored 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 123.867 0.867 . . . . 0.0 110.001 -170.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -117.38 84.35 2.14 Favored 'General case' 0 C--O 1.236 0.39 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 -179.057 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 9.1 p -69.22 131.08 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.332 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.5 t0 -83.24 109.72 17.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 169.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.8 t -85.35 62.23 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 -175.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 56.5 m 48.77 40.7 16.72 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.329 1.852 . . . . 0.0 113.161 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 172.17 -49.0 0.18 Allowed Glycine 0 CA--C 1.525 0.658 0 CA-C-O 119.304 -0.72 . . . . 0.0 112.126 173.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 13.1 mm -138.0 145.59 28.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 -173.216 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 63.7 mt-30 -73.74 145.72 44.9 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 121.288 0.566 . . . . 0.0 111.307 175.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -133.84 139.68 46.4 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 125.481 1.512 . . . . 0.0 107.804 170.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -71.56 136.2 47.37 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 m -142.89 155.17 17.46 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.231 0 C-N-CA 125.396 1.478 . . . . 0.0 109.162 177.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -98.07 141.53 30.9 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 124.636 1.175 . . . . 0.0 110.223 -177.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.7 mp -117.23 15.41 14.9 Favored 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.828 1.251 . . . . 0.0 111.871 -170.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 11.4 p -53.22 -33.65 53.75 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 119.966 1.257 . . . . 0.0 112.267 176.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.5 mt -77.78 -12.05 59.94 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 123.848 0.859 . . . . 0.0 112.986 -174.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.9 m -135.07 -17.05 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.652 0 CA-C-N 119.699 1.136 . . . . 0.0 113.364 -171.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.98 148.95 4.5 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -176.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 m -74.09 -14.22 60.95 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 124.244 1.018 . . . . 0.0 113.23 -174.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 71.6 m -126.19 143.67 51.05 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.975 0.91 . . . . 0.0 109.902 -171.256 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -70.8 155.7 40.45 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 126.463 1.905 . . . . 0.0 109.954 170.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -58.57 -25.75 62.88 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.638 1.175 . . . . 0.0 112.531 -175.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -61.98 -22.74 65.92 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.74 0.816 . . . . 0.0 112.924 175.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 93.18 47.38 3.09 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 -174.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -142.14 151.26 58.28 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 125.819 1.648 . . . . 0.0 107.488 -178.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -65.72 148.46 86.83 Favored 'Trans proline' 0 CA--C 1.535 0.552 0 C-N-CA 121.882 1.721 . . . . 0.0 109.879 176.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -70.78 16.65 0.08 Allowed 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 -176.529 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 98.6 t -60.66 133.44 26.28 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 O-C-N 120.565 -1.334 . . . . 0.0 107.878 -179.139 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 87.92 -15.2 56.46 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-O 118.303 -1.276 . . . . 0.0 113.064 -178.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 67.9 mt-30 -71.88 149.57 45.04 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 119.818 1.809 . . . . 0.0 108.907 175.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.7 m95 -85.15 152.4 23.4 Favored 'General case' 0 N--CA 1.45 -0.445 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 170.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 13.7 p -146.46 138.42 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.592 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 -178.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 62.9 tp -89.0 128.76 35.71 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 169.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.8 m -124.83 151.34 30.29 Favored 'Isoleucine or valine' 0 C--O 1.235 0.324 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.3 m-70 -142.57 148.47 37.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 104.958 -2.238 . . . . 0.0 104.958 169.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.7 m 44.81 28.51 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 126.097 1.759 . . . . 0.0 115.368 171.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.48 14.03 64.4 Favored Glycine 0 CA--C 1.531 1.074 0 CA-C-O 118.472 -1.182 . . . . 0.0 113.857 176.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 62.5 m-85 -129.13 144.11 51.09 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 119.818 1.809 . . . . 0.0 109.692 179.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.54 112.37 4.66 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 169.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.4 mmt -91.15 -34.89 14.85 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-O 119.094 -0.479 . . . . 0.0 111.114 -178.213 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 70.7 m -155.58 144.46 20.59 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 119.276 0.944 . . . . 0.0 109.283 169.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 48.3 t -79.99 140.37 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 169.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 9.2 pt -135.07 -175.2 1.3 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 C-N-CA 124.156 0.982 . . . . 0.0 108.865 -173.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -131.18 176.58 8.15 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 124.763 1.225 . . . . 0.0 108.597 178.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 68.4 mm-40 -52.78 -47.78 67.28 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 125.895 1.678 . . . . 0.0 110.908 -171.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -69.47 -40.86 76.86 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.673 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 34.0 mm-40 -66.19 -37.8 86.46 Favored 'General case' 0 C--O 1.232 0.153 0 C-N-CA 123.033 0.533 . . . . 0.0 109.568 176.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.94 -45.11 94.03 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-O 118.513 -0.755 . . . . 0.0 110.37 175.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 28.9 mmt-85 -63.92 -42.43 97.4 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 119.691 1.132 . . . . 0.0 110.6 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -62.16 -43.1 99.58 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.513 0.597 . . . . 0.0 110.948 178.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 26.7 m -68.18 -37.3 80.79 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 122.75 0.42 . . . . 0.0 110.432 178.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 54.8 mt -67.29 -33.42 75.25 Favored 'General case' 0 CA--C 1.529 0.17 0 O-C-N 121.122 -0.986 . . . . 0.0 110.658 176.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -67.04 -35.78 80.62 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 118.842 0.746 . . . . 0.0 111.457 174.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.04 -46.32 81.73 Favored 'General case' 0 CA--C 1.535 0.379 0 O-C-N 121.915 -0.49 . . . . 0.0 109.893 169.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -59.0 -43.54 91.52 Favored 'General case' 0 C--N 1.338 0.073 0 C-N-CA 123.629 0.772 . . . . 0.0 110.725 -176.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 24.2 pt20 -68.46 6.58 0.77 Allowed 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -137.05 12.81 3.09 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.85 1.26 . . . . 0.0 111.004 169.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 26.0 ttt -134.52 -9.34 2.49 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.499 1.52 . . . . 0.0 111.755 -178.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -56.8 -18.54 13.21 Favored 'General case' 0 CA--C 1.536 0.418 0 O-C-N 120.803 -1.186 . . . . 0.0 112.807 169.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -55.29 -20.8 12.33 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.153 1.781 . . . . 0.0 112.64 169.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.6 t -106.65 -11.95 10.18 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 C-N-CA 125.559 1.544 . . . . 0.0 110.312 -176.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 69.3 mm-40 -76.13 122.78 87.5 Favored Pre-proline 0 CA--C 1.536 0.43 0 O-C-N 120.837 -1.164 . . . . 0.0 109.262 -176.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -73.39 -15.04 25.21 Favored 'Trans proline' 0 CA--C 1.536 0.585 0 C-N-CA 122.455 2.103 . . . . 0.0 112.527 -177.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -77.11 69.14 3.35 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 124.541 1.137 . . . . 0.0 109.693 175.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . 0.285 26.0 m 51.71 -6.08 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 129.999 3.32 . . . . 0.0 117.095 -176.465 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -58.28 -42.87 95.71 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-N 120.965 1.711 . . . . 0.0 111.057 175.795 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -57.02 -31.16 64.85 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.187 0.995 . . . . 0.0 112.59 176.037 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 58.4 tp -80.0 -59.29 2.78 Favored 'General case' 0 C--N 1.338 0.092 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 174.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 98.9 mt -61.61 -26.16 67.81 Favored 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 125.058 1.343 . . . . 0.0 112.969 -169.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 41.7 m-85 -129.91 19.9 5.5 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.367 1.067 . . . . 0.0 111.029 -172.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -153.27 -73.3 0.01 OUTLIER Glycine 0 C--N 1.341 0.806 0 CA-C-N 118.418 0.554 . . . . 0.0 111.903 177.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -69.85 -24.68 63.48 Favored 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 117.632 0.716 . . . . 0.0 111.762 -170.403 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 32.0 tt0 -135.61 57.06 1.81 Allowed 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.244 1.418 . . . . 0.0 108.215 177.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 60.0 tptt . . . . . 0 C--O 1.25 1.09 0 C-N-CA 125.452 1.501 . . . . 0.0 107.591 177.677 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.8 tpt . . . . . 0 N--CA 1.483 1.188 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 85.5 m -140.45 175.37 9.66 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 126.628 1.971 . . . . 0.0 106.758 173.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 2.5 pp -129.89 -171.61 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 169.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -164.51 61.19 0.25 Allowed Glycine 0 CA--C 1.52 0.388 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -179.031 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.8 t -140.32 137.41 17.79 Favored Pre-proline 0 CA--C 1.537 0.468 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 -169.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.0 Cg_endo -72.88 174.42 11.93 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.129 1.886 . . . . 0.0 111.56 174.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -154.11 -177.52 27.61 Favored Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 124.405 1.003 . . . . 0.0 111.065 172.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 48.7 tt0 -116.77 142.29 47.11 Favored 'General case' 0 N--CA 1.453 -0.299 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 173.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 59.6 mt -74.58 85.05 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.1 tpp180 -71.48 -37.14 71.34 Favored 'General case' 0 CA--C 1.527 0.081 0 C-N-CA 124.882 1.273 . . . . 0.0 109.932 -172.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -157.83 144.61 17.91 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 125.645 1.578 . . . . 0.0 107.224 -175.04 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 61.4 mt -110.23 149.44 13.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -132.97 -0.19 3.41 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 124.668 1.187 . . . . 0.0 112.435 -169.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.405 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 146.83 -128.1 2.9 Favored Glycine 0 C--N 1.337 0.605 0 N-CA-C 106.931 -2.468 . . . . 0.0 106.931 178.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 15.9 t30 -72.51 12.75 0.43 Allowed 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 123.79 0.836 . . . . 0.0 110.96 169.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.405 ' H ' ' C ' ' A' ' 14' ' ' GLY . 36.7 mt-30 -140.44 161.68 37.13 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 127.505 2.322 . . . . 0.0 107.278 -169.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -143.78 153.41 42.37 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 176.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 14.2 mptt -104.62 69.6 0.9 Allowed 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 105.884 -1.895 . . . . 0.0 105.884 178.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 10.7 m -69.21 138.85 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 -171.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -81.2 102.89 10.63 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.7 t -78.09 62.76 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 C-N-CA 125.637 1.575 . . . . 0.0 108.519 -179.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.8 m 43.76 42.49 4.39 Favored 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 127.285 2.234 . . . . 0.0 113.23 -179.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 167.69 -34.7 0.21 Allowed Glycine 0 CA--C 1.526 0.751 0 CA-C-O 119.037 -0.868 . . . . 0.0 113.535 177.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.4 tt -150.33 149.36 14.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 CA-C-N 118.627 1.213 . . . . 0.0 108.753 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -76.77 135.43 38.98 Favored 'General case' 0 C--O 1.234 0.282 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 176.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 76.2 mtp85 -137.88 137.19 37.83 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 124.4 1.08 . . . . 0.0 108.227 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -68.51 137.3 54.28 Favored 'General case' 0 C--O 1.234 0.268 0 C-N-CA 122.744 0.417 . . . . 0.0 110.032 177.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 m -140.81 145.54 25.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 124.826 1.25 . . . . 0.0 107.955 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -83.49 144.63 29.42 Favored 'General case' 0 C--O 1.236 0.349 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 169.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 5.5 mp -110.36 10.44 23.45 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 118.029 -0.986 . . . . 0.0 113.207 -169.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 27.2 m -52.04 -32.18 33.28 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 121.006 1.73 . . . . 0.0 112.809 -177.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.4 mt -68.55 -15.85 63.67 Favored 'General case' 0 CA--C 1.54 0.591 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -178.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.38 -18.5 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 C-N-CA 124.2 1.0 . . . . 0.0 112.913 -173.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 74.37 149.74 1.82 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.965 1.269 . . . . 0.0 110.694 -169.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 19.0 m -74.81 -5.1 41.62 Favored 'General case' 0 CA--C 1.538 0.511 0 O-C-N 121.806 -0.82 . . . . 0.0 112.952 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.7 m -126.56 157.68 38.18 Favored 'General case' 0 N--CA 1.455 -0.187 0 C-N-CA 124.443 1.097 . . . . 0.0 110.026 178.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -54.57 -53.4 55.08 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 126.756 2.022 . . . . 0.0 112.931 -171.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 176.07 -48.11 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 128.766 2.826 . . . . 0.0 106.793 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -79.71 -40.71 28.34 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.414 1.086 . . . . 0.0 111.144 -178.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 148.18 6.56 0.25 Allowed Glycine 0 CA--C 1.531 1.052 0 CA-C-O 118.7 -1.056 . . . . 0.0 114.089 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 38.3 mt-30 -76.99 124.18 87.4 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 119.352 1.576 . . . . 0.0 107.195 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.49 139.69 65.38 Favored 'Trans proline' 0 CA--C 1.534 0.482 0 C-N-CA 122.39 2.06 . . . . 0.0 111.142 174.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 88.7 mtt-85 -71.2 6.39 1.7 Allowed 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 114.463 1.283 . . . . 0.0 114.463 -177.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.1 t -51.88 129.08 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 120.121 1.328 . . . . 0.0 109.113 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.93 -19.29 54.76 Favored Glycine 0 CA--C 1.53 1.002 0 C-N-CA 124.781 1.181 . . . . 0.0 113.458 178.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -68.32 163.4 23.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 119.338 1.569 . . . . 0.0 109.179 173.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.9 m95 -105.42 163.04 12.94 Favored 'General case' 0 C--O 1.234 0.238 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.09 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.49 148.08 14.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 C-N-CA 123.194 0.598 . . . . 0.0 109.425 -169.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 74.9 mt -90.63 141.47 28.74 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 107.639 -1.245 . . . . 0.0 107.639 169.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.7 t -132.18 147.82 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 12.2 t60 -148.26 -45.85 0.16 Allowed 'General case' 0 C--O 1.232 0.144 0 C-N-CA 124.89 1.276 . . . . 0.0 109.009 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.6 m -126.97 -166.97 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 126.412 1.885 . . . . 0.0 106.673 171.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -72.37 37.68 0.69 Allowed Glycine 0 CA--C 1.534 1.222 0 C-N-CA 124.673 1.13 . . . . 0.0 114.112 -177.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -139.59 147.36 41.01 Favored 'General case' 0 N--CA 1.455 -0.2 0 C-N-CA 125.342 1.457 . . . . 0.0 109.288 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -72.66 104.57 3.96 Favored 'General case' 0 N--CA 1.454 -0.263 0 N-CA-C 105.887 -1.894 . . . . 0.0 105.887 169.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 88.7 mmm -69.05 -45.05 71.38 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 118.369 0.532 . . . . 0.0 110.447 -169.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 62.5 m -161.76 152.84 18.16 Favored 'General case' 0 C--O 1.235 0.323 0 C-N-CA 126.156 1.783 . . . . 0.0 107.144 169.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.8 m -75.11 149.43 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 170.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -141.64 -167.55 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 C-N-CA 126.487 1.915 . . . . 0.0 108.293 176.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 17.4 p30 -123.63 174.17 7.62 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 125.098 1.359 . . . . 0.0 109.804 175.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -60.0 -40.17 88.31 Favored 'General case' 0 CA--C 1.527 0.083 0 C-N-CA 123.895 0.878 . . . . 0.0 112.399 -172.616 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.36 -37.81 56.74 Favored 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 118.183 0.447 . . . . 0.0 109.923 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -61.8 -36.15 80.27 Favored 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.333 0.653 . . . . 0.0 109.878 173.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.52 -42.35 98.45 Favored 'General case' 0 CA--C 1.534 0.352 0 O-C-N 121.504 -0.748 . . . . 0.0 110.809 174.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.6 mpt_? -64.59 -43.39 93.96 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 119.275 0.943 . . . . 0.0 109.995 177.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -60.27 -40.13 89.29 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 118.064 0.393 . . . . 0.0 111.065 177.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.4 m -65.67 -43.61 88.77 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.091 0.557 . . . . 0.0 110.452 176.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 59.4 mt -63.64 -38.9 92.87 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 118.873 0.761 . . . . 0.0 110.639 178.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -64.69 -45.35 87.01 Favored 'General case' 0 C--O 1.226 -0.132 0 C-N-CA 123.408 0.683 . . . . 0.0 110.427 175.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -61.23 -42.73 99.12 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 118.425 0.557 . . . . 0.0 110.995 177.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -59.81 -55.38 34.92 Favored 'General case' 0 C--O 1.234 0.246 0 C-N-CA 123.514 0.726 . . . . 0.0 109.909 -178.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -68.18 -31.3 70.74 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 117.878 0.308 . . . . 0.0 111.181 -178.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -62.97 -45.63 91.52 Favored 'General case' 0 C--N 1.339 0.137 0 CA-C-N 118.5 0.591 . . . . 0.0 110.675 175.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 76.0 mtm -62.84 -42.94 99.94 Favored 'General case' 0 C--N 1.339 0.113 0 CA-C-N 118.302 0.501 . . . . 0.0 110.452 175.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 38.8 t80 -63.42 -23.11 67.26 Favored 'General case' 0 CA--C 1.54 0.595 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -74.12 -16.09 61.02 Favored 'General case' 0 CA--C 1.539 0.546 0 O-C-N 121.174 -0.954 . . . . 0.0 112.516 175.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 34.8 m -128.29 -8.24 3.71 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 C-N-CA 123.747 0.819 . . . . 0.0 113.14 -172.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 81.9 mm-40 -135.65 141.99 39.22 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 125.207 1.403 . . . . 0.0 107.685 174.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.93 -18.65 21.43 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 122.645 2.23 . . . . 0.0 113.354 -171.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.3 t70 48.95 38.37 12.24 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 125.647 1.579 . . . . 0.0 112.742 -177.331 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.1 t 52.51 40.12 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.853 0 C-N-CA 125.32 1.448 . . . . 0.0 111.187 -175.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 66.91 15.2 64.46 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 124.892 1.234 . . . . 0.0 112.774 -179.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . 55.62 -2.08 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 128.033 2.533 . . . . 0.0 115.058 -169.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 53.5 tp -63.17 -42.63 99.43 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 120.394 1.452 . . . . 0.0 110.529 -177.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -66.33 -6.84 15.55 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 124.151 0.981 . . . . 0.0 112.164 177.432 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -133.64 30.3 3.79 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.97 1.708 . . . . 0.0 109.792 -174.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -159.36 -28.87 0.02 OUTLIER Glycine 0 CA--C 1.53 1.014 0 C-N-CA 124.611 1.101 . . . . 0.0 112.529 -177.271 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 22.7 tt0 53.26 37.79 26.09 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 125.307 1.443 . . . . 0.0 111.171 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -69.72 -10.11 57.07 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 124.565 1.146 . . . . 0.0 112.786 -176.525 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 40.6 ttpt . . . . . 0 C--O 1.249 1.057 0 C-N-CA 126.356 1.863 . . . . 0.0 106.387 178.398 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.5 ptm . . . . . 0 N--CA 1.484 1.243 0 N-CA-C 110.386 -0.228 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 84.7 m -69.54 119.78 14.32 Favored 'General case' 0 CA--C 1.533 0.32 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 169.468 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 11.0 tp -157.41 156.14 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.6 54.69 0.17 Allowed Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 -172.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 10.6 p -148.87 154.05 39.56 Favored Pre-proline 0 CA--C 1.544 0.719 0 C-N-CA 123.848 0.859 . . . . 0.0 109.54 -169.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -58.54 161.92 13.6 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.711 2.274 . . . . 0.0 113.364 169.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.55 175.35 38.97 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 108.654 -1.779 . . . . 0.0 108.654 169.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -116.89 131.88 56.84 Favored 'General case' 0 C--N 1.331 -0.196 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 176.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 73.9 mt -66.41 119.06 10.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 177.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 8.5 tpp180 -107.4 -40.6 5.32 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 118.507 -0.759 . . . . 0.0 109.713 -169.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.9 p -142.37 161.8 37.11 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.493 1.117 . . . . 0.0 108.438 169.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 66.4 mt -132.64 148.81 31.64 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -179.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -124.54 -24.56 4.19 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 124.299 1.04 . . . . 0.0 112.028 -179.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 171.66 -126.74 1.33 Allowed Glycine 0 C--N 1.333 0.416 0 N-CA-C 106.757 -2.537 . . . . 0.0 106.757 179.351 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 11.8 t30 -65.48 -24.44 67.16 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.722 0.761 . . . . 0.0 110.254 169.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 81.0 mt-30 -93.39 155.6 17.28 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-O 122.054 0.93 . . . . 0.0 110.282 172.119 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -149.64 175.03 11.91 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 125.65 1.58 . . . . 0.0 108.863 -178.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -128.71 99.83 5.49 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 176.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 6.3 m -69.12 165.88 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 169.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -111.74 112.95 25.01 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 169.029 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 21.2 t -88.26 60.58 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 -177.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.6 m 46.45 41.31 9.26 Favored 'General case' 0 CA--C 1.541 0.625 0 C-N-CA 127.094 2.157 . . . . 0.0 113.586 178.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 164.56 -26.95 0.2 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.106 -0.83 . . . . 0.0 114.248 175.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.5 tp -149.34 149.91 14.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.447 0 CA-C-N 118.646 1.223 . . . . 0.0 107.742 177.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 37.6 mt-30 -76.21 147.79 38.15 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 175.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -140.16 132.59 28.51 Favored 'General case' 0 CA--C 1.52 -0.21 0 C-N-CA 124.563 1.145 . . . . 0.0 108.823 176.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -69.98 140.69 52.99 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 123.976 0.91 . . . . 0.0 110.185 176.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 16.9 m -148.49 167.13 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 126.136 1.774 . . . . 0.0 109.162 -178.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -107.03 143.59 34.92 Favored 'General case' 0 C--O 1.234 0.252 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 169.623 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 26.6 mt -114.58 21.35 14.59 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 125.279 1.431 . . . . 0.0 110.854 -173.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -53.07 -35.45 59.56 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.699 1.199 . . . . 0.0 112.584 -171.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 83.7 mt -80.34 -8.96 59.72 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 123.679 0.791 . . . . 0.0 112.617 -176.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 19.7 m -126.92 -5.83 4.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.253 1.021 . . . . 0.0 111.815 -177.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 73.23 14.27 79.21 Favored Glycine 0 CA--C 1.532 1.099 0 C-N-CA 124.99 1.281 . . . . 0.0 114.918 169.609 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 14.5 m 58.5 -14.28 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 127.167 2.187 . . . . 0.0 116.711 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 83.6 m -136.5 153.39 51.04 Favored 'General case' 0 N--CA 1.454 -0.249 0 C-N-CA 124.828 1.251 . . . . 0.0 109.598 -177.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -64.97 157.91 26.94 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.472 1.109 . . . . 0.0 108.899 169.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -48.2 -41.65 27.78 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 125.279 1.431 . . . . 0.0 112.445 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -80.73 -16.84 52.86 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 118.91 -0.566 . . . . 0.0 112.152 -176.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 131.92 -12.6 5.32 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-O 118.504 -1.164 . . . . 0.0 115.817 169.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -66.06 135.36 95.14 Favored Pre-proline 0 N--CA 1.469 0.477 0 CA-C-N 119.662 1.731 . . . . 0.0 109.341 -172.24 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.11 140.33 71.25 Favored 'Trans proline' 0 CA--C 1.534 0.475 0 C-N-CA 121.707 1.605 . . . . 0.0 109.162 171.439 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 95.0 mtt-85 -73.42 11.25 0.81 Allowed 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 114.517 1.302 . . . . 0.0 114.517 -172.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.0 m -53.14 133.99 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 120.251 1.387 . . . . 0.0 109.698 176.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 91.8 -18.61 52.56 Favored Glycine 0 CA--C 1.531 1.081 0 CA-C-O 118.433 -1.204 . . . . 0.0 112.992 -177.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -73.52 142.18 46.73 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 119.89 1.845 . . . . 0.0 108.974 177.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 66.3 m95 -85.04 151.24 24.31 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 170.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.69 145.02 14.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 -170.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 86.0 mt -79.1 132.74 36.69 Favored 'General case' 0 C--O 1.234 0.247 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 169.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 50.2 t -118.63 123.69 71.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 2.1 m-70 -135.04 137.56 43.06 Favored 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 106.792 -1.559 . . . . 0.0 106.792 177.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 34.7 m 44.1 28.45 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.988 0 C-N-CA 126.61 1.964 . . . . 0.0 115.405 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 96.76 4.65 58.98 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 124.698 1.142 . . . . 0.0 113.892 175.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -125.79 144.55 50.59 Favored 'General case' 0 C--O 1.235 0.314 0 CA-C-N 119.093 1.447 . . . . 0.0 109.719 -176.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -71.16 120.04 16.16 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 169.381 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 25.8 mmt -91.47 -45.52 8.49 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-O 119.001 -0.523 . . . . 0.0 111.436 -178.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 10.5 m -152.19 138.47 18.42 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -176.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.1 t -74.12 142.2 15.11 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.403 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 169.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 25.9 pt -138.53 -169.52 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.672 0 C-N-CA 125.695 1.598 . . . . 0.0 109.133 -178.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 21.4 p30 -128.16 174.79 8.95 Favored 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 125.803 1.641 . . . . 0.0 108.791 177.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -62.51 -36.52 82.83 Favored 'General case' 0 N--CA 1.462 0.129 0 CA-C-O 118.955 -0.545 . . . . 0.0 112.434 -173.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.99 -44.67 76.08 Favored 'General case' 0 CA--C 1.53 0.178 0 CA-C-N 118.936 0.789 . . . . 0.0 109.464 -177.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 29.3 mm-40 -64.58 -41.34 96.34 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 123.136 0.574 . . . . 0.0 110.259 176.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.97 -49.14 75.91 Favored 'General case' 0 N--CA 1.455 -0.179 0 C-N-CA 122.86 0.464 . . . . 0.0 110.431 179.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.5 mtt-85 -64.67 -41.25 96.21 Favored 'General case' 0 N--CA 1.463 0.195 0 C-N-CA 123.156 0.583 . . . . 0.0 110.376 -178.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -62.5 -43.23 99.33 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 118.397 0.544 . . . . 0.0 110.939 176.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -69.59 -37.46 76.93 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 122.097 -0.377 . . . . 0.0 110.506 179.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 27.7 mt -62.79 -40.15 96.45 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 119.113 0.87 . . . . 0.0 110.293 176.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -66.32 -43.54 85.92 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 118.375 0.534 . . . . 0.0 110.701 175.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -57.7 -43.06 84.9 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.103 0.411 . . . . 0.0 110.478 176.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -66.18 -5.19 9.34 Favored 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 124.994 1.317 . . . . 0.0 113.748 178.335 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -123.03 -20.44 5.76 Favored 'General case' 0 CA--C 1.531 0.239 0 C-N-CA 124.167 0.987 . . . . 0.0 111.987 -178.127 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -57.72 -32.38 67.35 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 119.261 0.937 . . . . 0.0 113.476 -172.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 1.5 pmm? -72.68 -34.37 67.15 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-N 118.538 0.608 . . . . 0.0 111.607 177.219 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -79.35 -27.7 42.02 Favored 'General case' 0 C--O 1.226 -0.168 0 C-N-CA 123.423 0.689 . . . . 0.0 110.774 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -59.85 -19.99 54.38 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 124.32 1.048 . . . . 0.0 112.809 177.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 38.9 t -63.92 -29.44 47.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 O-C-N 121.533 -0.729 . . . . 0.0 110.932 173.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -66.11 -54.0 29.38 Favored Pre-proline 0 CA--C 1.54 0.569 0 CA-C-O 117.721 -1.133 . . . . 0.0 111.95 -175.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -67.73 -24.65 40.68 Favored 'Trans proline' 0 C--N 1.351 0.673 0 CA-C-N 121.947 1.731 . . . . 0.0 112.163 175.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -67.35 -50.58 59.26 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-N 118.962 0.801 . . . . 0.0 110.918 177.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 6.7 p -69.93 -29.45 40.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 O-C-N 121.862 -0.524 . . . . 0.0 110.074 175.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -57.53 -51.05 60.13 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 172.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.1 -44.58 87.75 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 117.862 0.831 . . . . 0.0 110.939 178.06 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -60.59 -44.27 96.44 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.152 0.581 . . . . 0.0 110.807 178.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -61.65 -43.95 97.89 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 123.665 0.786 . . . . 0.0 109.89 177.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -63.08 -34.85 78.49 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-O 118.833 -0.603 . . . . 0.0 111.65 179.381 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 157.59 -149.98 20.76 Favored Glycine 0 C--N 1.338 0.687 0 CA-C-N 119.169 0.895 . . . . 0.0 111.735 175.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 38.7 mm-40 -71.77 19.41 0.07 Allowed 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.235 1.414 . . . . 0.0 111.949 175.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 35.1 tt0 -66.15 -35.13 79.67 Favored 'General case' 0 CA--C 1.538 0.508 0 O-C-N 120.887 -1.133 . . . . 0.0 110.169 175.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 83.1 tttt . . . . . 0 C--O 1.248 1.005 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 169.704 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 97.4 mmm . . . . . 0 N--CA 1.485 1.298 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 63.8 m -78.32 47.36 0.68 Allowed 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.012 1.325 . . . . 0.0 112.02 -177.642 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 12.2 pt -61.01 159.82 2.01 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 124.304 1.041 . . . . 0.0 110.307 174.407 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.2 55.11 0.12 Allowed Glycine 0 CA--C 1.525 0.713 0 N-CA-C 108.238 -1.945 . . . . 0.0 108.238 -177.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.0 p -150.67 157.2 36.31 Favored Pre-proline 0 CA--C 1.542 0.65 0 C-N-CA 124.613 1.165 . . . . 0.0 109.44 -168.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -67.62 158.37 57.49 Favored 'Trans proline' 0 CA--C 1.537 0.662 0 C-N-CA 121.962 1.775 . . . . 0.0 110.477 168.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.45 177.28 39.43 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 109.844 -1.303 . . . . 0.0 109.844 171.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 51.3 tt0 -116.11 138.41 51.28 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 117.565 0.683 . . . . 0.0 109.334 -175.489 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 60.6 mt -73.7 83.29 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 N-CA-C 107.032 -1.469 . . . . 0.0 107.032 176.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 19.9 mmm180 -76.48 -29.71 56.97 Favored 'General case' 0 N--CA 1.465 0.286 0 O-C-N 121.624 -0.672 . . . . 0.0 111.553 179.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.73 154.83 38.1 Favored 'General case' 0 CA--C 1.534 0.352 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 -178.747 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 64.5 mt -129.66 147.98 33.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -121.32 -24.87 5.34 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.463 1.105 . . . . 0.0 112.121 -176.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 161.06 -113.0 0.55 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 108.307 -1.917 . . . . 0.0 108.307 178.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 9.3 t30 -69.37 2.04 3.35 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 123.656 0.782 . . . . 0.0 111.875 169.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -139.23 159.3 42.48 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 126.925 2.09 . . . . 0.0 107.679 -170.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -142.02 169.14 18.14 Favored 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 125.26 1.424 . . . . 0.0 110.035 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -115.82 73.09 0.83 Allowed 'General case' 0 C--O 1.234 0.241 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 -174.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.0 t -71.56 125.53 30.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 -172.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.1 t0 -77.18 112.05 13.45 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 169.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.9 m -82.56 43.08 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 C-N-CA 124.211 1.005 . . . . 0.0 110.718 177.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 66.7 m 48.5 49.93 17.58 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 126.077 1.751 . . . . 0.0 112.211 -172.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -177.71 -41.64 0.06 OUTLIER Glycine 0 CA--C 1.524 0.622 0 CA-C-O 119.644 -0.531 . . . . 0.0 112.404 174.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.6 tt -155.86 153.76 7.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 51.2 mt-30 -71.96 139.85 48.87 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 170.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 39.2 mmt180 -128.94 142.75 50.83 Favored 'General case' 0 CA--C 1.522 -0.119 0 C-N-CA 125.273 1.429 . . . . 0.0 107.977 176.246 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -65.08 131.47 46.65 Favored 'General case' 0 C--O 1.235 0.318 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 67.5 t -140.68 129.56 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 178.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -83.36 144.19 29.82 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 123.517 0.727 . . . . 0.0 110.14 174.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 63.7 mt -109.6 7.85 24.73 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 124.312 1.045 . . . . 0.0 113.322 -169.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 25.2 m -53.1 -34.34 56.22 Favored 'General case' 0 CA--C 1.541 0.635 0 CA-C-N 120.987 1.721 . . . . 0.0 112.482 -175.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 78.3 mt -74.98 -11.09 60.03 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 113.163 0.801 . . . . 0.0 113.163 -176.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.47 -17.0 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.643 0 CA-C-N 119.43 1.013 . . . . 0.0 112.563 -175.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.74 133.18 0.52 Allowed Glycine 0 CA--C 1.527 0.794 0 C-N-CA 125.264 1.411 . . . . 0.0 110.781 -175.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 21.4 m -67.86 156.65 36.66 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 169.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 75.0 m 61.97 145.48 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.227 2.211 . . . . 0.0 112.535 -169.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.95 155.31 38.79 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 125.207 1.403 . . . . 0.0 109.484 173.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -57.68 -27.56 62.99 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 124.646 1.179 . . . . 0.0 112.484 -176.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -62.69 -21.95 66.13 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.813 0.845 . . . . 0.0 113.043 175.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 91.99 47.9 3.25 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -174.185 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.9 pt20 -143.18 157.33 60.48 Favored Pre-proline 0 CA--C 1.536 0.426 0 C-N-CA 125.751 1.621 . . . . 0.0 107.93 -178.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -64.51 144.09 83.92 Favored 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 121.701 1.601 . . . . 0.0 110.375 174.286 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 90.6 mtt-85 -71.5 11.2 0.5 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 124.358 1.063 . . . . 0.0 113.621 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 10.1 m -57.45 131.69 21.45 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.404 0 O-C-N 120.616 -1.303 . . . . 0.0 109.817 -173.405 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 89.7 -17.44 52.63 Favored Glycine 0 CA--C 1.532 1.11 0 CA-C-O 118.306 -1.274 . . . . 0.0 113.413 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -66.57 156.34 35.28 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-N 119.693 1.746 . . . . 0.0 108.948 172.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 57.3 m95 -105.15 159.99 15.42 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 176.122 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 6.3 p -157.06 135.55 3.05 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 -171.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 98.2 mt -75.68 131.37 39.85 Favored 'General case' 0 C--O 1.233 0.23 0 N-CA-C 104.561 -2.385 . . . . 0.0 104.561 168.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 33.6 m -126.72 135.05 64.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 119.344 0.974 . . . . 0.0 108.402 -178.228 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 53.8 t-80 -141.83 120.81 12.83 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.684 1.193 . . . . 0.0 107.945 -169.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.2 t 41.6 47.95 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.867 0 C-N-CA 126.671 1.988 . . . . 0.0 112.02 177.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 85.22 6.95 83.78 Favored Glycine 0 CA--C 1.531 1.06 0 CA-C-O 118.337 -1.257 . . . . 0.0 114.771 172.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -127.18 149.02 50.17 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 119.803 1.802 . . . . 0.0 110.017 177.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.47 116.16 7.9 Favored 'General case' 0 CA--C 1.53 0.191 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 169.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.9 ttt -76.75 -48.46 18.64 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.532 0.733 . . . . 0.0 109.497 177.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 65.4 m -163.11 144.54 9.75 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 124.975 1.31 . . . . 0.0 108.833 171.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 93.6 t -72.32 146.29 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 169.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.3 pt -137.8 157.91 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 C-N-CA 125.236 1.414 . . . . 0.0 109.02 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -80.83 169.19 17.89 Favored 'General case' 0 CA--C 1.536 0.406 0 CA-C-O 120.927 0.394 . . . . 0.0 110.773 176.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -61.14 -44.57 97.11 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 123.385 0.674 . . . . 0.0 111.993 -173.224 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.66 -37.1 62.82 Favored 'General case' 0 C--N 1.332 -0.163 0 C-N-CA 122.759 0.424 . . . . 0.0 109.953 -174.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 56.4 tt0 -60.27 -39.31 86.37 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 124.846 1.258 . . . . 0.0 110.033 172.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.96 -44.95 87.71 Favored 'General case' 0 N--CA 1.455 -0.193 0 O-C-N 121.618 -0.676 . . . . 0.0 111.322 173.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 26.5 mmt-85 -62.49 -40.88 98.13 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 119.103 0.865 . . . . 0.0 110.441 178.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.96 -41.97 99.69 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.887 0.475 . . . . 0.0 110.907 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 28.0 m -65.07 -42.95 93.67 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.62 0.368 . . . . 0.0 110.232 177.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 42.5 mt -62.54 -43.58 98.45 Favored 'General case' 0 C--N 1.338 0.107 0 C-N-CA 123.269 0.628 . . . . 0.0 110.311 178.247 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.84 -44.95 94.78 Favored 'General case' 0 N--CA 1.46 0.073 0 C-N-CA 123.06 0.544 . . . . 0.0 110.845 177.112 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -62.12 -41.19 98.0 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 122.903 0.481 . . . . 0.0 111.191 178.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -65.35 -51.12 62.63 Favored 'General case' 0 C--N 1.338 0.104 0 C-N-CA 123.173 0.589 . . . . 0.0 109.577 177.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -61.35 -32.88 72.78 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.915 0.486 . . . . 0.0 111.341 -178.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 20.0 t-20 -56.65 -31.27 64.21 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 123.306 0.643 . . . . 0.0 112.069 178.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 54.9 mtt -64.42 -14.24 55.65 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 124.06 0.944 . . . . 0.0 112.624 178.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -124.66 -22.29 4.62 Favored 'General case' 0 CA--C 1.529 0.154 0 C-N-CA 124.995 1.318 . . . . 0.0 111.157 -176.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -59.67 -30.55 68.84 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 118.981 0.809 . . . . 0.0 111.593 172.341 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 27.9 m -69.96 -8.72 11.18 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.705 0 C-N-CA 124.458 1.103 . . . . 0.0 112.979 174.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -134.67 71.75 70.24 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 125.647 1.579 . . . . 0.0 107.132 178.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -63.25 -19.59 68.8 Favored 'Trans proline' 0 CA--C 1.533 0.466 0 C-N-CA 122.681 2.254 . . . . 0.0 113.407 -169.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -60.33 -36.16 77.31 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 119.02 0.827 . . . . 0.0 111.465 170.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 40.9 t -81.6 -44.86 20.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 173.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -53.05 -43.3 62.13 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 123.813 0.72 . . . . 0.0 112.424 -177.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.06 -0.27 5.55 Favored 'General case' 0 CA--C 1.54 0.576 0 C-N-CA 124.647 1.179 . . . . 0.0 114.094 -179.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 47.8 tp -124.12 -32.08 3.27 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 124.631 1.172 . . . . 0.0 110.578 174.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 39.9 tp -65.86 -30.38 70.98 Favored 'General case' 0 CA--C 1.538 0.504 0 O-C-N 121.475 -0.765 . . . . 0.0 110.899 170.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -131.91 29.34 4.43 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.749 1.62 . . . . 0.0 110.052 -178.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -169.96 -160.03 17.27 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -175.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 44.5 mt-10 -136.94 17.85 3.03 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 124.324 1.049 . . . . 0.0 110.756 -176.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -65.42 143.94 57.38 Favored 'General case' 0 CA--C 1.538 0.501 0 O-C-N 121.258 -0.901 . . . . 0.0 110.207 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 40.6 ttpt . . . . . 0 C--O 1.247 0.964 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 178.35 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.9 tpt . . . . . 0 N--CA 1.482 1.165 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.4 m -61.7 149.81 38.51 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.426 0.69 . . . . 0.0 110.954 178.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.7 tp -154.98 175.73 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 C-N-CA 125.86 1.664 . . . . 0.0 106.864 178.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.11 42.28 5.02 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -169.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.6 m -141.61 162.14 48.39 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.036 1.334 . . . . 0.0 109.288 -169.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -56.28 155.81 23.4 Favored 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 122.802 2.334 . . . . 0.0 113.447 172.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -158.32 167.97 34.59 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 107.951 -2.06 . . . . 0.0 107.951 169.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 15.8 tt0 -116.8 133.57 55.85 Favored 'General case' 0 CA--C 1.522 -0.104 0 N-CA-C 108.836 -0.801 . . . . 0.0 108.836 -178.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 83.1 mt -70.19 97.01 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 4.4 mmp_? -83.34 -41.95 17.64 Favored 'General case' 0 N--CA 1.462 0.139 0 O-C-N 121.701 -0.625 . . . . 0.0 109.97 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 p -145.58 157.97 43.91 Favored 'General case' 0 C--O 1.238 0.448 0 C-N-CA 124.651 1.181 . . . . 0.0 108.83 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 54.4 mt -132.78 146.97 31.85 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 N-CA-C 106.737 -1.579 . . . . 0.0 106.737 -174.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -123.55 -15.24 7.13 Favored 'General case' 0 N--CA 1.469 0.477 0 C-N-CA 124.393 1.077 . . . . 0.0 112.091 -177.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' A' ' 16' ' ' GLN . . . 163.89 -131.56 2.48 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 106.459 -2.657 . . . . 0.0 106.459 -178.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -74.09 22.48 0.09 Allowed 'General case' 0 CA--C 1.54 0.575 0 CA-C-N 118.057 0.929 . . . . 0.0 111.515 169.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . 0.415 ' H ' ' C ' ' A' ' 14' ' ' GLY . 41.1 mt-30 -140.5 148.61 41.35 Favored 'General case' 0 N--CA 1.444 -0.728 0 C-N-CA 126.594 1.958 . . . . 0.0 106.803 -179.056 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -138.61 163.46 32.0 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 124.454 1.102 . . . . 0.0 109.926 -179.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -110.79 78.37 1.11 Allowed 'General case' 0 C--O 1.233 0.232 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.306 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 3.0 m -70.59 130.88 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 C-N-CA 123.477 0.711 . . . . 0.0 109.508 -177.82 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.1 t0 -76.84 111.3 12.22 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 168.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 5.4 t -84.75 54.67 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.0 m 44.74 45.72 8.31 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 126.984 2.113 . . . . 0.0 113.215 -177.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 173.3 -36.07 0.13 Allowed Glycine 0 CA--C 1.526 0.781 0 CA-C-O 119.468 -0.629 . . . . 0.0 113.003 176.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 17.8 tt -153.51 151.66 11.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 177.174 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.2 mt-30 -73.79 138.11 44.32 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 172.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 36.6 mmt180 -130.75 145.38 51.93 Favored 'General case' 0 N--CA 1.463 0.186 0 C-N-CA 125.261 1.424 . . . . 0.0 107.91 171.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -70.94 144.36 50.6 Favored 'General case' 0 C--O 1.235 0.32 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 173.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 9.8 p -142.48 139.76 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.234 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -81.5 146.59 30.12 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 125.11 1.364 . . . . 0.0 110.284 172.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 86.1 mt -117.17 16.0 14.94 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 124.559 1.143 . . . . 0.0 112.404 -170.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 5.8 p -53.31 -34.98 59.61 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 120.561 1.528 . . . . 0.0 112.854 -176.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 73.9 mt -83.53 -6.04 59.34 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 118.46 -0.781 . . . . 0.0 112.865 -175.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.6 m -132.42 -20.41 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 119.536 1.062 . . . . 0.0 112.919 -174.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.29 147.83 7.6 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -177.32 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.6 m -68.23 -20.78 64.84 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 124.877 1.271 . . . . 0.0 113.364 -171.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.6 m -127.41 152.34 47.65 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 124.876 1.27 . . . . 0.0 109.283 -175.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -65.49 145.99 55.43 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.344 1.458 . . . . 0.0 109.972 172.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -53.99 -31.01 49.54 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 125.169 1.388 . . . . 0.0 113.517 -169.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -84.87 -7.86 59.01 Favored 'General case' 0 CA--C 1.541 0.625 0 CA-C-N 118.863 0.756 . . . . 0.0 112.986 -178.045 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 106.34 52.65 0.76 Allowed Glycine 0 CA--C 1.527 0.793 0 CA-C-N 119.043 0.838 . . . . 0.0 112.728 170.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 30.0 pt20 -144.4 160.65 47.63 Favored Pre-proline 0 CA--C 1.538 0.503 0 C-N-CA 124.898 1.279 . . . . 0.0 108.697 175.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -63.74 143.76 87.36 Favored 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 121.627 1.551 . . . . 0.0 109.97 169.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 79.6 mtt-85 -70.56 12.93 0.21 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -177.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.8 m -57.91 135.1 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 O-C-N 120.59 -1.319 . . . . 0.0 109.984 -175.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.52 -14.57 54.82 Favored Glycine 0 CA--C 1.531 1.061 0 C-N-CA 124.889 1.233 . . . . 0.0 113.484 -178.183 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 83.6 mt-30 -73.99 155.17 38.88 Favored 'General case' 0 C--O 1.235 0.321 0 CA-C-N 119.709 1.754 . . . . 0.0 109.373 177.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 83.5 m95 -97.95 159.16 15.11 Favored 'General case' 0 N--CA 1.452 -0.357 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 7.8 p -157.07 147.53 10.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 107.78 -1.192 . . . . 0.0 107.78 -175.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 91.9 mt -82.99 128.22 34.27 Favored 'General case' 0 C--O 1.234 0.237 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 171.129 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 20.6 t -111.23 105.26 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -169.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . 0.412 ' CG ' ' H ' ' A' ' 52' ' ' VAL . 6.7 t-160 -77.09 -171.37 1.99 Allowed 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.903 0.881 . . . . 0.0 109.092 169.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.412 ' H ' ' CG ' ' A' ' 51' ' ' HIS . 36.0 m -52.89 -26.84 11.81 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.651 0 C-N-CA 124.54 1.136 . . . . 0.0 113.795 -174.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.08 18.15 0.1 Allowed Glycine 0 CA--C 1.528 0.872 0 CA-C-O 118.841 -0.977 . . . . 0.0 113.213 171.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -139.47 142.54 37.36 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 119.094 1.447 . . . . 0.0 109.12 -172.068 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.16 125.54 27.06 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 169.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 46.3 mtt -74.07 -57.59 3.86 Favored 'General case' 0 CA--C 1.533 0.299 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 32.4 m -157.77 145.21 18.41 Favored 'General case' 0 C--O 1.238 0.462 0 C-N-CA 126.356 1.863 . . . . 0.0 107.643 -176.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 4.1 m -74.44 148.99 7.68 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 169.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 24.0 pt -138.71 168.05 20.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 125.048 1.339 . . . . 0.0 108.575 -178.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -97.59 174.85 6.44 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.0 0.52 . . . . 0.0 110.134 176.267 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -62.55 -33.67 75.4 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.715 0.806 . . . . 0.0 111.481 -174.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.84 -49.1 61.25 Favored 'General case' 0 CA--C 1.528 0.129 0 O-C-N 121.72 -0.612 . . . . 0.0 110.251 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 24.2 mm-40 -64.25 -38.91 92.73 Favored 'General case' 0 C--O 1.233 0.195 0 C-N-CA 122.777 0.431 . . . . 0.0 110.342 178.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -52.3 65.13 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 118.049 0.386 . . . . 0.0 110.176 177.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 89.2 mtm180 -64.47 -39.03 93.03 Favored 'General case' 0 N--CA 1.462 0.135 0 CA-C-O 118.677 -0.678 . . . . 0.0 111.005 -178.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.52 -43.03 99.81 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 119.088 0.858 . . . . 0.0 110.943 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 27.7 m -66.99 -42.75 84.51 Favored 'General case' 0 CA--C 1.537 0.466 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 178.418 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 78.2 mt -64.51 -35.58 81.41 Favored 'General case' 0 CA--C 1.528 0.099 0 O-C-N 121.449 -0.782 . . . . 0.0 110.923 178.082 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -66.89 -43.47 83.37 Favored 'General case' 0 C--O 1.232 0.179 0 C-N-CA 123.403 0.681 . . . . 0.0 110.672 176.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -58.29 -47.72 82.75 Favored 'General case' 0 CA--C 1.532 0.252 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 174.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 49.5 mt -61.93 -8.43 5.1 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.665 1.186 . . . . 0.0 113.699 -178.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -126.55 17.91 7.5 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-N 119.695 1.134 . . . . 0.0 112.51 178.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -147.76 -17.86 0.36 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 114.79 1.404 . . . . 0.0 114.79 169.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 46.0 tpp -60.63 -23.08 64.48 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 120.102 1.319 . . . . 0.0 112.776 -173.337 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 11.3 p90 -52.81 -28.24 21.74 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.808 0.843 . . . . 0.0 112.764 173.105 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -64.46 -12.01 39.41 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.213 1.405 . . . . 0.0 113.198 -179.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 12.8 m -130.95 17.0 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 124.925 1.29 . . . . 0.0 111.1 -179.016 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 14.0 mm-40 -134.55 168.22 18.9 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 124.555 1.142 . . . . 0.0 110.055 -170.517 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_exo -51.72 -21.87 12.21 Favored 'Trans proline' 0 C--N 1.349 0.561 0 C-N-CA 124.203 3.269 . . . . 0.0 116.643 -176.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 30.2 t70 -62.92 -36.55 83.78 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 118.721 0.691 . . . . 0.0 112.101 -178.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 11.6 p -158.02 -35.1 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 CA-C-N 118.362 0.528 . . . . 0.0 111.714 173.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -54.02 -38.52 60.83 Favored Glycine 0 CA--C 1.526 0.759 0 CA-C-N 119.558 1.072 . . . . 0.0 113.241 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -66.6 -20.12 65.93 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 118.193 0.997 . . . . 0.0 113.4 178.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 48.8 tp -90.14 -41.34 11.69 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.399 1.08 . . . . 0.0 109.261 171.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.09 -39.2 91.65 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.411 1.084 . . . . 0.0 110.798 -177.48 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 77.1 m-85 -126.34 36.64 4.46 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.3 1.44 . . . . 0.0 110.612 -170.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -162.4 178.37 38.21 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 176.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -64.49 149.31 48.84 Favored 'General case' 0 C--O 1.238 0.463 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 170.018 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -65.29 156.31 32.43 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-O 121.472 0.653 . . . . 0.0 112.423 -173.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 62.1 mttp . . . . . 0 C--O 1.251 1.156 0 C-N-CA 125.9 1.68 . . . . 0.0 107.434 -169.811 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.6 mtt . . . . . 0 N--CA 1.485 1.314 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 7.0 p -143.75 171.24 14.47 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 124.269 1.027 . . . . 0.0 109.197 170.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 44.2 mt -133.28 158.37 42.97 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 -173.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.79 45.69 0.1 OUTLIER Glycine 0 CA--C 1.526 0.781 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 -178.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.7 t -143.72 146.87 36.67 Favored Pre-proline 0 CA--C 1.542 0.649 0 C-N-CA 125.224 1.41 . . . . 0.0 107.583 -169.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -55.83 161.25 8.47 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.69 2.26 . . . . 0.0 113.339 169.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.93 177.3 39.78 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 169.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -116.78 137.19 52.38 Favored 'General case' 0 C--N 1.334 -0.105 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 39.1 mt -76.77 71.85 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 C-N-CA 124.89 1.276 . . . . 0.0 108.129 -175.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 53.3 tpt85 -63.76 -30.36 71.46 Favored 'General case' 0 CA--C 1.531 0.213 0 C-N-CA 124.363 1.065 . . . . 0.0 112.445 -172.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.9 m -149.76 155.81 40.77 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 177.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.1 141.48 45.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.298 0 N-CA-C 106.03 -1.841 . . . . 0.0 106.03 177.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -106.77 -28.33 10.22 Favored 'General case' 0 N--CA 1.466 0.341 0 C-N-CA 124.039 0.936 . . . . 0.0 110.781 174.023 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.81 -121.88 0.98 Allowed Glycine 0 C--N 1.334 0.441 0 N-CA-C 106.78 -2.528 . . . . 0.0 106.78 177.243 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 20.4 t30 -65.34 -15.31 62.42 Favored 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 116.935 0.368 . . . . 0.0 111.693 169.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 8.1 mm100 -105.85 153.12 22.37 Favored 'General case' 0 C--O 1.237 0.443 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 172.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -146.71 169.12 19.71 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.33 1.052 . . . . 0.0 110.167 -177.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -124.39 75.1 1.37 Allowed 'General case' 0 CA--C 1.519 -0.233 0 N-CA-C 106.521 -1.659 . . . . 0.0 106.521 -171.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 59.6 t -73.6 128.26 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -173.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -74.06 106.17 5.62 Favored 'General case' 0 C--O 1.233 0.188 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 169.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 14.9 t -83.71 57.85 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 58.1 m 43.35 48.42 5.9 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 127.566 2.347 . . . . 0.0 113.427 179.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 175.0 -39.26 0.11 Allowed Glycine 0 CA--C 1.523 0.552 0 CA-C-O 119.592 -0.56 . . . . 0.0 112.305 176.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 16.5 tt -153.69 152.65 9.69 Favored 'Isoleucine or valine' 0 C--O 1.237 0.397 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 52.0 mt-30 -69.56 136.54 51.45 Favored 'General case' 0 N--CA 1.454 -0.234 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 170.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 22.7 mmm180 -122.36 128.29 50.81 Favored 'General case' 0 C--O 1.233 0.224 0 N-CA-C 106.092 -1.818 . . . . 0.0 106.092 175.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -74.79 119.88 19.57 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 176.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.2 m -142.99 172.33 7.91 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 125.47 1.508 . . . . 0.0 109.579 -170.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -108.88 143.22 38.38 Favored 'General case' 0 C--O 1.235 0.315 0 C-N-CA 124.729 1.211 . . . . 0.0 111.056 -169.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 53.7 mt -114.03 9.88 17.41 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.47 1.108 . . . . 0.0 112.734 -175.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 6.4 m -55.06 -33.87 63.09 Favored 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 120.943 1.701 . . . . 0.0 112.154 -172.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.23 -9.82 58.93 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.661 0.785 . . . . 0.0 113.055 -177.351 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.9 -15.94 1.63 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 CA-C-N 119.498 1.045 . . . . 0.0 112.651 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.13 147.49 7.2 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 124.983 1.278 . . . . 0.0 110.536 -176.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.5 m -65.57 -21.82 66.63 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.84 1.256 . . . . 0.0 112.184 177.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 76.3 m -126.71 168.43 14.38 Favored 'General case' 0 N--CA 1.452 -0.362 0 C-N-CA 125.452 1.501 . . . . 0.0 109.734 -175.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -117.79 154.02 32.46 Favored 'General case' 0 C--N 1.325 -0.499 0 C-N-CA 126.95 2.1 . . . . 0.0 109.239 -169.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -57.78 -25.91 61.17 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.661 1.185 . . . . 0.0 112.711 -173.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -60.85 -23.77 65.38 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 123.863 0.865 . . . . 0.0 113.007 174.37 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 95.03 47.7 2.59 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -175.237 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 28.8 pt20 -145.7 154.39 51.9 Favored Pre-proline 0 CA--C 1.535 0.375 0 C-N-CA 125.398 1.479 . . . . 0.0 108.638 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -66.48 152.04 81.72 Favored 'Trans proline' 0 CA--C 1.537 0.63 0 C-N-CA 121.828 1.685 . . . . 0.0 108.847 169.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 64.7 mtt-85 -70.19 10.57 0.42 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 114.339 1.237 . . . . 0.0 114.339 -177.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 8.7 p -61.51 137.57 23.47 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 O-C-N 120.849 -1.157 . . . . 0.0 108.933 -172.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 79.71 -11.37 33.79 Favored Glycine 0 CA--C 1.532 1.106 0 CA-C-O 118.187 -1.34 . . . . 0.0 114.028 179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -67.64 163.05 22.26 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 119.91 1.855 . . . . 0.0 109.219 171.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 61.2 m95 -104.25 155.47 18.72 Favored 'General case' 0 C--O 1.234 0.256 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 12.2 p -153.24 142.77 14.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -171.103 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -84.47 113.1 20.96 Favored 'General case' 0 N--CA 1.451 -0.408 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 169.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 38.9 t -93.42 137.09 23.39 Favored 'Isoleucine or valine' 0 C--O 1.233 0.213 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 178.346 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -137.12 142.83 42.28 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 124.273 1.029 . . . . 0.0 108.702 175.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 22.5 t 56.37 -75.99 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 C-N-CA 127.071 2.148 . . . . 0.0 111.439 -173.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -165.24 27.8 0.19 Allowed Glycine 0 CA--C 1.535 1.31 0 C-N-CA 127.761 2.6 . . . . 0.0 110.088 175.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -139.53 144.08 37.71 Favored 'General case' 0 C--O 1.235 0.342 0 C-N-CA 126.215 1.806 . . . . 0.0 107.847 -170.144 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -63.74 122.94 17.61 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 169.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 52.0 ttp -80.32 -57.9 3.39 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 171.042 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 17.8 m -150.64 138.03 19.55 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 123.77 0.828 . . . . 0.0 109.517 -172.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 59.0 t -72.09 144.6 12.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 169.416 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 18.4 pt -138.29 158.8 32.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 124.781 1.232 . . . . 0.0 108.846 -176.223 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -81.91 167.84 18.54 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 121.078 0.466 . . . . 0.0 110.593 175.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -67.37 -33.43 75.21 Favored 'General case' 0 CA--C 1.536 0.413 0 C-N-CA 123.549 0.74 . . . . 0.0 112.341 -169.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -78.9 -39.94 33.61 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.308 -0.87 . . . . 0.0 109.637 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 53.2 tt0 -59.8 -40.78 89.52 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 125.011 1.325 . . . . 0.0 110.146 173.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.46 -50.8 71.31 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.145 0.578 . . . . 0.0 110.662 175.042 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 84.2 mtm180 -63.29 -40.17 96.61 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 119.072 -0.489 . . . . 0.0 111.201 -178.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -63.25 -43.62 97.5 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 118.582 0.628 . . . . 0.0 110.785 176.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 30.2 m -65.63 -39.24 91.25 Favored 'General case' 0 CA--C 1.537 0.462 0 CA-C-O 119.276 -0.392 . . . . 0.0 110.35 178.625 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 35.8 mt -64.62 -42.21 95.67 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 119.099 0.863 . . . . 0.0 110.536 176.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -64.68 -39.33 93.49 Favored 'General case' 0 CA--C 1.528 0.13 0 C-N-CA 123.164 0.586 . . . . 0.0 110.961 179.302 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -65.13 -51.05 63.56 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 122.495 0.318 . . . . 0.0 110.24 173.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -56.11 -47.63 77.72 Favored 'General case' 0 N--CA 1.462 0.139 0 C-N-CA 124.39 1.076 . . . . 0.0 110.679 -174.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -73.52 5.48 3.78 Favored 'General case' 0 CA--C 1.542 0.643 0 N-CA-C 113.619 0.97 . . . . 0.0 113.619 -177.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 -127.96 -29.28 2.57 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 124.334 1.054 . . . . 0.0 111.616 178.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 37.7 mtt -59.83 -19.52 51.43 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 124.161 0.985 . . . . 0.0 113.146 -179.162 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 15.3 p90 -57.3 -22.55 42.64 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 119.713 1.142 . . . . 0.0 112.3 174.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -65.19 -19.89 66.18 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 124.094 0.958 . . . . 0.0 112.775 176.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 5.5 m -129.1 -18.53 1.85 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.482 0 C-N-CA 124.761 1.224 . . . . 0.0 112.369 -174.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -145.28 78.84 12.0 Favored Pre-proline 0 CA--C 1.539 0.53 0 C-N-CA 125.402 1.481 . . . . 0.0 107.913 175.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -62.91 -11.72 25.85 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 123.59 2.86 . . . . 0.0 114.191 -170.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -52.59 -38.28 59.76 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.557 0.743 . . . . 0.0 111.309 169.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.9 m -68.89 -28.54 40.04 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.346 0 CA-C-N 119.255 0.934 . . . . 0.0 110.97 179.24 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -68.64 -49.93 40.22 Favored Glycine 0 C--N 1.338 0.662 0 N-CA-C 108.864 -1.694 . . . . 0.0 108.864 175.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -58.12 -44.92 88.01 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-N 117.565 0.682 . . . . 0.0 110.878 176.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.406 HD13 ' C ' ' A' ' 84' ' ' LEU . 2.7 tm? -57.36 -48.87 77.9 Favored 'General case' 0 CA--C 1.528 0.099 0 C-N-CA 124.584 1.153 . . . . 0.0 110.304 176.539 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 68.5 tp -60.46 -40.6 91.79 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 123.238 0.615 . . . . 0.0 110.499 177.48 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 13.3 m-30 -64.24 -32.42 74.0 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 118.956 -0.545 . . . . 0.0 111.32 176.072 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . 159.68 -20.75 0.26 Allowed Glycine 0 CA--C 1.53 0.999 0 CA-C-O 118.224 -1.32 . . . . 0.0 115.387 169.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -149.33 132.36 16.24 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 119.982 1.891 . . . . 0.0 110.077 -170.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -56.52 157.6 5.05 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 123.546 0.738 . . . . 0.0 111.431 170.299 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 63.7 tttp . . . . . 0 C--O 1.247 0.923 0 C-N-CA 124.601 1.161 . . . . 0.0 108.254 -173.533 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 58.5 ttm . . . . . 0 N--CA 1.484 1.256 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 59.8 m -76.21 47.07 0.44 Allowed 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 125.373 1.469 . . . . 0.0 112.498 -177.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 14.0 pt -61.14 160.02 2.0 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 123.591 0.756 . . . . 0.0 109.648 170.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -172.25 42.05 0.17 Allowed Glycine 0 CA--C 1.528 0.888 0 N-CA-C 111.673 -0.571 . . . . 0.0 111.673 -175.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 41.3 t -146.69 151.94 43.77 Favored Pre-proline 0 CA--C 1.541 0.624 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 -169.599 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_exo -54.92 157.56 12.86 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 122.153 1.902 . . . . 0.0 112.728 169.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -157.25 172.49 34.71 Favored Glycine 0 CA--C 1.526 0.767 0 C-N-CA 124.474 1.035 . . . . 0.0 110.765 174.206 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 55.1 tt0 -119.81 130.6 54.99 Favored 'General case' 0 CA--C 1.522 -0.108 0 C-N-CA 124.023 0.929 . . . . 0.0 109.032 -176.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 65.4 mt -69.3 130.26 34.07 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 177.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 22.3 mmt85 -119.8 -31.73 4.44 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 118.564 -0.731 . . . . 0.0 111.274 -177.557 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.1 m -146.93 153.68 40.38 Favored 'General case' 0 CA--C 1.531 0.238 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 175.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 20.1 mt -132.49 141.67 44.57 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 177.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -122.25 -15.41 7.69 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 124.057 0.943 . . . . 0.0 111.664 -176.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 169.77 -135.51 3.6 Favored Glycine 0 C--N 1.334 0.445 0 N-CA-C 107.12 -2.392 . . . . 0.0 107.12 -179.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 57.5 t30 -66.52 5.0 0.65 Allowed 'General case' 0 CA--C 1.546 0.817 0 C-N-CA 123.972 0.909 . . . . 0.0 113.031 169.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 39.0 mt-30 -133.45 153.05 51.94 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 126.138 1.775 . . . . 0.0 107.799 178.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -145.77 158.09 43.88 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 124.763 1.225 . . . . 0.0 110.254 -171.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.73 122.72 37.63 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.108 -1.812 . . . . 0.0 106.108 170.345 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.2 t -125.46 123.45 64.88 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 -173.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.1 t0 -67.71 128.24 35.74 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 172.13 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 47.2 t -128.42 124.19 61.43 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 171.142 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 57.3 m 50.16 26.45 2.15 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 125.304 1.441 . . . . 0.0 114.376 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 106.69 -1.33 36.43 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-O 118.451 -1.194 . . . . 0.0 113.766 172.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 32.6 mm -134.21 132.04 55.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 119.451 1.625 . . . . 0.0 107.279 -173.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -66.53 140.13 57.97 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.932 0.396 . . . . 0.0 110.526 178.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 20.6 mmt-85 -126.43 149.01 49.55 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.531 1.932 . . . . 0.0 106.789 169.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 19.4 t70 -80.01 136.07 36.51 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 169.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 59.4 t -137.76 135.77 45.82 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 -176.193 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -79.87 140.12 36.88 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.995 1.318 . . . . 0.0 110.033 174.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 42.5 mt -113.98 14.33 18.41 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 124.051 0.941 . . . . 0.0 112.911 -171.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 23.7 m -52.24 -36.69 53.08 Favored 'General case' 0 CA--C 1.541 0.627 0 CA-C-N 120.604 1.547 . . . . 0.0 112.623 -173.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.9 mt -80.74 -6.96 59.17 Favored 'General case' 0 CA--C 1.537 0.47 0 N-CA-C 112.927 0.714 . . . . 0.0 112.927 -174.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.6 m -131.98 -17.56 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-N 119.476 1.034 . . . . 0.0 112.452 -174.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.14 151.54 5.27 Favored Glycine 0 CA--C 1.528 0.893 0 C-N-CA 124.601 1.096 . . . . 0.0 110.947 -174.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.8 p -74.31 -18.6 60.68 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.558 1.143 . . . . 0.0 112.836 179.742 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 82.5 m -124.01 150.07 45.31 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.492 1.117 . . . . 0.0 109.442 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 26.1 t70 -78.09 161.86 27.1 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 124.447 1.099 . . . . 0.0 110.625 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -45.98 -41.27 11.56 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 126.078 1.751 . . . . 0.0 112.087 170.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 30.9 t30 -65.84 -14.72 61.97 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.53 1.132 . . . . 0.0 112.943 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 96.82 35.14 5.47 Favored Glycine 0 CA--C 1.526 0.78 0 CA-C-O 119.027 -0.874 . . . . 0.0 113.835 169.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -142.75 164.22 33.79 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 118.566 1.183 . . . . 0.0 109.192 172.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo -51.14 146.4 23.17 Favored 'Trans proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.599 2.866 . . . . 0.0 112.508 175.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 77.8 mtt-85 -71.06 18.72 0.06 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 114.243 1.201 . . . . 0.0 114.243 179.316 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 15.6 m -58.0 138.09 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 O-C-N 120.234 -1.541 . . . . 0.0 110.005 -176.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 82.21 -17.61 17.33 Favored Glycine 0 CA--C 1.531 1.092 0 CA-C-O 118.465 -1.186 . . . . 0.0 113.537 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 85.9 mt-30 -70.44 161.11 31.13 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-N 119.491 1.646 . . . . 0.0 109.447 175.215 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 56.2 m95 -106.21 157.45 17.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -144.65 142.85 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 124.796 1.239 . . . . 0.0 107.711 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -86.64 116.47 24.78 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 103.781 -2.674 . . . . 0.0 103.781 169.029 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 31.7 m -116.98 137.04 52.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -171.567 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.93 139.15 36.1 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 33.6 m 45.46 27.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.88 0 C-N-CA 126.457 1.903 . . . . 0.0 115.453 172.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 97.81 7.32 56.65 Favored Glycine 0 CA--C 1.531 1.076 0 CA-C-O 118.527 -1.152 . . . . 0.0 114.069 176.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.13 141.78 51.08 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-N 119.706 1.753 . . . . 0.0 109.394 -177.415 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.16 114.45 14.83 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 169.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 24.9 mmt -88.59 -26.22 22.06 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 122.911 0.484 . . . . 0.0 110.762 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 66.1 m -155.19 156.29 35.43 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 124.714 1.206 . . . . 0.0 108.687 171.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.5 p -106.03 137.72 34.83 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.576 -1.638 . . . . 0.0 106.576 172.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 22.1 pt -140.11 159.95 26.1 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 C-N-CA 124.55 1.14 . . . . 0.0 110.419 -169.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -81.02 169.07 17.96 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.603 0.761 . . . . 0.0 110.305 173.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 8.5 mt-10 -69.38 -30.34 68.3 Favored 'General case' 0 CA--C 1.533 0.324 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -170.25 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -74.19 -41.45 61.41 Favored 'General case' 0 N--CA 1.461 0.102 0 O-C-N 121.024 -1.047 . . . . 0.0 109.79 179.163 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -61.91 -41.36 97.82 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 123.565 0.746 . . . . 0.0 109.65 174.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.78 -49.05 77.9 Favored 'General case' 0 C--N 1.34 0.177 0 O-C-N 121.934 -0.479 . . . . 0.0 110.807 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -64.6 -38.58 91.51 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-O 118.977 -0.535 . . . . 0.0 111.354 -179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -64.73 -41.54 95.88 Favored 'General case' 0 CA--C 1.529 0.148 0 CA-C-N 118.969 0.804 . . . . 0.0 110.856 176.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 24.2 m -68.01 -37.48 81.47 Favored 'General case' 0 CA--C 1.539 0.553 0 O-C-N 122.02 -0.425 . . . . 0.0 110.328 178.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 37.5 mt -62.74 -44.71 95.5 Favored 'General case' 0 N--CA 1.462 0.147 0 O-C-N 121.43 -0.794 . . . . 0.0 109.761 174.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -62.06 -40.74 96.83 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 118.775 0.716 . . . . 0.0 111.131 177.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.39 -34.42 77.68 Favored 'General case' 0 CA--C 1.536 0.412 0 O-C-N 121.897 -0.502 . . . . 0.0 111.83 175.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -75.5 -39.2 58.84 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.761 0.824 . . . . 0.0 110.66 177.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -67.03 -29.75 69.64 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 123.737 0.815 . . . . 0.0 111.382 175.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -58.43 141.3 51.99 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 172.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 9.7 mmt 64.67 8.74 4.65 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 125.67 1.588 . . . . 0.0 114.201 -178.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.2 t80 -141.33 -41.6 0.38 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 119.905 1.23 . . . . 0.0 112.919 -170.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -133.37 -22.57 1.96 Allowed 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 124.482 1.113 . . . . 0.0 111.835 -170.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 30.1 m -64.69 -16.2 19.21 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 O-C-N 121.688 -0.632 . . . . 0.0 111.088 169.243 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -134.91 157.57 76.81 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 127.908 2.483 . . . . 0.0 105.554 170.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -74.93 31.29 0.36 Allowed 'Trans proline' 0 CA--C 1.544 1.021 0 C-N-CA 123.842 3.028 . . . . 0.0 113.86 -171.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -60.53 -39.45 87.9 Favored 'General case' 0 N--CA 1.465 0.278 0 O-C-N 120.711 -1.243 . . . . 0.0 111.129 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.9 p -59.41 -41.57 84.88 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 C-N-CA 123.106 0.562 . . . . 0.0 110.56 171.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -64.69 -39.59 96.81 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.269 -0.733 . . . . 0.0 111.269 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -60.08 -18.07 44.19 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 123.889 0.876 . . . . 0.0 112.918 177.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -102.66 -46.49 4.71 Favored 'General case' 0 CA--C 1.528 0.115 0 C-N-CA 124.402 1.081 . . . . 0.0 110.212 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 46.5 tp -64.14 -34.64 78.53 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 123.485 0.714 . . . . 0.0 111.781 -174.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -135.05 -20.25 1.7 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.503 1.121 . . . . 0.0 112.346 -177.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.84 -165.32 35.25 Favored Glycine 0 CA--C 1.527 0.818 0 CA-C-O 122.214 0.897 . . . . 0.0 113.388 -172.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 36.3 mm-40 -70.58 -19.53 62.85 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.977 0.911 . . . . 0.0 112.323 -169.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -80.78 -9.53 59.8 Favored 'General case' 0 CA--C 1.546 0.793 0 CA-C-N 118.515 0.598 . . . . 0.0 111.15 -179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 54.8 tttp . . . . . 0 C--O 1.251 1.154 0 C-N-CA 124.716 1.206 . . . . 0.0 110.601 178.285 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 97.5 mmm . . . . . 0 N--CA 1.484 1.234 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 63.7 m -78.39 56.36 1.73 Allowed 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 124.808 1.243 . . . . 0.0 111.485 -176.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 34.8 pt -126.39 21.74 3.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 C-N-CA 125.006 1.322 . . . . 0.0 111.791 -172.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.77 91.69 0.27 Allowed Glycine 0 CA--C 1.522 0.475 0 C-N-CA 125.833 1.682 . . . . 0.0 110.738 -179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 22.9 t -139.51 144.21 38.74 Favored Pre-proline 0 CA--C 1.541 0.615 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 -177.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -72.35 160.4 47.06 Favored 'Trans proline' 0 CA--C 1.534 0.516 0 C-N-CA 122.534 2.156 . . . . 0.0 111.957 174.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -164.04 172.92 40.0 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 171.109 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -95.34 137.04 34.93 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 22.9 mt -69.94 93.3 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 169.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 20.6 tpt180 -79.55 -33.59 41.74 Favored 'General case' 0 CA--C 1.53 0.177 0 CA-C-O 119.108 -0.472 . . . . 0.0 110.38 -170.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 1.2 m -149.48 152.73 36.12 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -179.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 51.3 mt -131.69 144.41 37.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 106.172 -1.788 . . . . 0.0 106.172 179.041 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -124.02 -20.44 5.35 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.187 0.995 . . . . 0.0 111.967 -178.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.8 -129.54 1.89 Allowed Glycine 0 C--N 1.335 0.499 0 N-CA-C 107.226 -2.35 . . . . 0.0 107.226 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.6 p-10 -65.91 -3.65 5.54 Favored 'General case' 0 CA--C 1.537 0.446 0 CA-C-N 117.599 0.699 . . . . 0.0 112.559 169.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 89.5 mt-30 -125.38 157.43 36.83 Favored 'General case' 0 C--O 1.238 0.488 0 C-N-CA 124.763 1.225 . . . . 0.0 109.602 175.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -154.69 160.42 41.36 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.52 1.528 . . . . 0.0 109.911 -171.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -101.17 112.17 24.58 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 175.611 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 66.7 t -92.13 124.11 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 170.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 7.2 t0 -84.91 108.7 17.68 Favored 'General case' 0 C--O 1.233 0.218 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 169.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 45.0 t -83.19 61.02 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 C-N-CA 125.858 1.663 . . . . 0.0 107.046 174.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 62.5 m 38.42 45.95 0.89 Allowed 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 128.044 2.538 . . . . 0.0 114.41 178.384 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 153.22 -17.12 0.69 Allowed Glycine 0 CA--C 1.526 0.724 0 CA-C-O 119.093 -0.837 . . . . 0.0 113.806 177.501 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 10.6 tp -143.83 145.08 22.43 Favored 'Isoleucine or valine' 0 C--O 1.233 0.189 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 173.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -94.72 134.37 37.4 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 51.2 mtp180 -126.42 118.99 26.13 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 178.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -70.49 131.01 43.39 Favored 'General case' 0 C--O 1.235 0.321 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 173.466 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.5 m -139.79 155.3 24.72 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.11 0.964 . . . . 0.0 109.374 179.223 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -84.35 146.48 27.68 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.721 0.808 . . . . 0.0 109.524 171.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 31.7 mt -112.25 3.17 16.95 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 124.424 1.09 . . . . 0.0 112.573 -173.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 4.6 m -59.03 -26.17 64.33 Favored 'General case' 0 CA--C 1.544 0.725 0 CA-C-N 120.595 1.543 . . . . 0.0 112.227 -173.207 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.7 mt -65.67 -19.96 66.11 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 121.608 -0.683 . . . . 0.0 112.708 176.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -129.25 -10.92 2.85 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 C-N-CA 124.785 1.234 . . . . 0.0 112.013 -174.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 76.35 139.94 0.96 Allowed Glycine 0 CA--C 1.528 0.856 0 C-N-CA 125.365 1.46 . . . . 0.0 109.916 -170.232 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 18.3 m -71.11 -12.17 61.36 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.934 -0.745 . . . . 0.0 112.833 178.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 72.4 m -119.36 146.42 45.34 Favored 'General case' 0 N--CA 1.453 -0.288 0 C-N-CA 124.655 1.182 . . . . 0.0 109.311 178.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -79.94 160.55 25.92 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 124.156 0.982 . . . . 0.0 110.087 176.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -50.7 -33.27 22.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.216 1.406 . . . . 0.0 112.421 173.18 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -67.44 -13.4 62.0 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.165 0.802 . . . . 0.0 113.165 -179.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 100.09 31.52 5.9 Favored Glycine 0 CA--C 1.529 0.946 0 CA-C-O 118.893 -0.948 . . . . 0.0 114.428 169.323 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -146.11 167.57 13.75 Favored Pre-proline 0 CA--C 1.539 0.528 0 CA-C-N 118.813 1.307 . . . . 0.0 109.003 172.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -50.59 150.75 11.42 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 C-N-CA 123.394 2.729 . . . . 0.0 112.837 174.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 87.4 mtt-85 -74.21 20.99 0.1 Allowed 'General case' 0 CA--C 1.541 0.627 0 O-C-N 121.143 -0.973 . . . . 0.0 113.332 177.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.6 m -56.26 131.94 19.94 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 O-C-N 120.783 -1.198 . . . . 0.0 109.658 -176.458 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 83.97 -11.88 55.64 Favored Glycine 0 CA--C 1.531 1.069 0 CA-C-O 118.055 -1.414 . . . . 0.0 113.968 177.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 77.5 mt-30 -70.34 169.43 13.89 Favored 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 119.631 1.716 . . . . 0.0 109.692 172.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 51.4 m95 -118.56 149.58 41.1 Favored 'General case' 0 N--CA 1.456 -0.167 0 C-N-CA 123.686 0.794 . . . . 0.0 109.58 -178.21 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 3.9 m -147.51 156.51 9.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 124.555 1.142 . . . . 0.0 109.417 -175.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 92.9 mt -84.47 140.12 31.71 Favored 'General case' 0 C--O 1.233 0.235 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 168.255 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 4.1 m -132.04 127.33 57.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 174.744 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -144.07 -29.47 0.49 Allowed 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 -169.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.8 m -136.2 20.37 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 118.665 0.666 . . . . 0.0 112.362 -169.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 86.59 10.16 73.82 Favored Glycine 0 CA--C 1.532 1.149 0 O-C-N 121.45 -0.781 . . . . 0.0 112.629 -175.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 70.1 m-85 -135.44 153.58 51.73 Favored 'General case' 0 C--O 1.237 0.412 0 C-N-CA 125.222 1.409 . . . . 0.0 107.937 177.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.91 105.37 2.79 Favored 'General case' 0 CA--C 1.531 0.24 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 169.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 27.6 ttt -70.09 -39.28 75.66 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.882 0.873 . . . . 0.0 110.929 -170.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 74.5 m -160.29 155.21 24.4 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 125.369 1.467 . . . . 0.0 108.563 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.1 t -78.08 146.72 7.82 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 107.745 -1.205 . . . . 0.0 107.745 169.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 19.4 pt -138.26 161.15 31.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 C-N-CA 125.502 1.521 . . . . 0.0 108.53 177.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 65.9 t30 -73.97 163.58 27.72 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-O 121.932 0.872 . . . . 0.0 110.583 174.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -57.68 -40.97 80.66 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 126.402 1.881 . . . . 0.0 111.809 178.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -81.87 -34.72 29.93 Favored 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 123.801 0.841 . . . . 0.0 110.801 -179.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 60.7 tt0 -62.52 -34.35 76.73 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 124.641 1.176 . . . . 0.0 110.287 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.26 -43.03 87.7 Favored 'General case' 0 CA--C 1.532 0.252 0 O-C-N 122.002 -0.437 . . . . 0.0 111.359 171.325 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.8 mmt85 -69.7 -41.33 75.54 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 118.416 0.553 . . . . 0.0 109.609 -177.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -61.13 -40.24 93.05 Favored 'General case' 0 CA--C 1.53 0.187 0 C-N-CA 122.54 0.336 . . . . 0.0 110.67 175.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 40.9 m -66.61 -41.26 88.69 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 123.154 0.582 . . . . 0.0 110.57 177.196 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 69.6 mt -62.18 -40.61 96.63 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 119.448 1.022 . . . . 0.0 110.313 175.296 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -64.79 -41.79 95.56 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 118.113 0.415 . . . . 0.0 110.843 177.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -60.96 -41.77 97.0 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 118.56 0.618 . . . . 0.0 111.083 174.371 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -61.0 -52.76 63.65 Favored 'General case' 0 CA--C 1.53 0.174 0 C-N-CA 123.824 0.85 . . . . 0.0 109.804 -179.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -66.53 -31.33 71.98 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 118.369 0.531 . . . . 0.0 111.588 178.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -66.12 -38.53 88.4 Favored 'General case' 0 CA--C 1.519 -0.213 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 -177.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -51.84 -57.81 8.27 Favored 'General case' 0 N--CA 1.453 -0.282 0 C-N-CA 124.233 1.013 . . . . 0.0 110.853 -179.714 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 11.4 p90 -73.5 -18.87 61.05 Favored 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 118.852 -0.594 . . . . 0.0 112.283 -178.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 35.2 t70 -73.69 -31.54 63.48 Favored 'General case' 0 CA--C 1.536 0.404 0 CA-C-N 119.371 0.987 . . . . 0.0 111.982 174.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 15.7 m -105.1 -15.91 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 118.877 0.762 . . . . 0.0 112.553 -175.343 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 81.6 mm-40 -130.56 55.47 19.1 Favored Pre-proline 0 CA--C 1.543 0.687 0 C-N-CA 124.498 1.119 . . . . 0.0 110.072 173.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -62.31 -22.99 74.93 Favored 'Trans proline' 0 C--N 1.349 0.599 0 C-N-CA 122.575 2.183 . . . . 0.0 112.72 -176.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -57.48 -23.05 47.69 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 124.862 1.265 . . . . 0.0 112.858 176.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.7 p -120.73 -30.49 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 C-N-CA 124.153 0.981 . . . . 0.0 110.226 172.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -54.81 -38.42 64.53 Favored Glycine 0 CA--C 1.528 0.848 0 C-N-CA 124.09 0.852 . . . . 0.0 112.47 175.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -66.64 -7.78 22.9 Favored 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 118.389 1.095 . . . . 0.0 113.576 178.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 59.1 tp -117.22 -43.47 2.84 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 124.314 1.046 . . . . 0.0 110.061 178.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 46.4 tp -66.93 -32.11 73.14 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.849 0.859 . . . . 0.0 111.28 177.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -136.56 33.22 2.74 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.021 1.728 . . . . 0.0 109.677 -176.875 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -160.5 -167.08 20.52 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 124.224 0.916 . . . . 0.0 110.959 -176.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 75.9 mm-40 -125.94 29.12 5.96 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.695 1.198 . . . . 0.0 110.891 -169.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 31.4 tp10 -55.37 -27.72 49.3 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 124.133 0.973 . . . . 0.0 112.774 179.43 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 87.4 tttt . . . . . 0 C--O 1.249 1.045 0 N-CA-C 106.73 -1.582 . . . . 0.0 106.73 173.075 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 tpt . . . . . 0 N--CA 1.482 1.145 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 92.0 m -135.86 155.13 50.79 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 125.007 1.323 . . . . 0.0 108.736 178.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 27.8 pt -139.34 46.56 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 126.105 1.762 . . . . 0.0 108.891 -175.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -65.66 68.4 0.11 Allowed Glycine 0 CA--C 1.528 0.894 0 C-N-CA 127.196 2.331 . . . . 0.0 113.789 -174.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 25.2 t -146.76 148.23 32.53 Favored Pre-proline 0 CA--C 1.544 0.715 0 C-N-CA 126.249 1.82 . . . . 0.0 106.998 -171.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_exo -57.44 163.79 8.03 Favored 'Trans proline' 0 CA--C 1.536 0.609 0 C-N-CA 122.432 2.088 . . . . 0.0 112.426 169.144 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -160.46 163.33 33.93 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.327 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLN . . . . . . . . . . . . . 58.3 tt0 -116.93 131.79 56.86 Favored 'General case' 0 C--O 1.233 0.197 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 94.6 mt -70.36 117.66 13.69 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 N-CA-C 107.421 -1.325 . . . . 0.0 107.421 -178.475 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.6 mpt_? -90.19 -32.77 16.47 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 118.666 -0.683 . . . . 0.0 110.502 172.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.12 152.92 35.51 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -170.115 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.8 mt -132.43 141.03 46.28 Favored 'Isoleucine or valine' 0 C--O 1.234 0.253 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 172.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -120.84 -18.86 7.51 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 124.425 1.09 . . . . 0.0 111.47 -176.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 170.22 -126.6 1.36 Allowed Glycine 0 C--N 1.336 0.538 0 N-CA-C 107.146 -2.382 . . . . 0.0 107.146 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASN . . . . . . . . . . . . . 8.8 t30 -67.28 -8.63 33.52 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 117.052 0.426 . . . . 0.0 112.11 169.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -119.81 159.44 24.57 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 125.486 1.514 . . . . 0.0 109.538 178.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -151.04 177.09 10.51 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 126.177 1.791 . . . . 0.0 109.568 -170.085 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -129.31 126.97 40.17 Favored 'General case' 0 CA--C 1.516 -0.363 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 178.755 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 1.6 m -119.47 138.7 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 C-N-CA 125.001 1.32 . . . . 0.0 108.357 -177.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 12.7 t0 -85.36 107.88 17.57 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 104.497 -2.408 . . . . 0.0 104.497 168.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 13.7 t -81.49 57.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 C-N-CA 125.362 1.465 . . . . 0.0 107.971 -176.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 50.7 m 45.42 43.34 8.53 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 127.007 2.123 . . . . 0.0 113.159 -177.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 170.28 -42.57 0.2 Allowed Glycine 0 CA--C 1.527 0.8 0 CA-C-O 119.303 -0.72 . . . . 0.0 112.641 175.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ILE . . . . . . . . . . . . . 26.4 pt -141.8 150.17 19.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.271 0 C-N-CA 124.562 1.145 . . . . 0.0 109.514 -179.183 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -76.99 138.25 39.49 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.703 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . . . . . . . . . 32.4 mmt180 -136.77 148.55 47.3 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 124.927 1.291 . . . . 0.0 109.307 173.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -68.05 148.22 51.3 Favored 'General case' 0 C--O 1.236 0.353 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 169.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -147.48 143.27 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 173.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -92.36 145.23 24.63 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.593 0.757 . . . . 0.0 109.44 170.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 46.9 mt -112.53 13.48 20.08 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 118.2 -0.905 . . . . 0.0 112.959 -170.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' THR . . . . . . . . . . . . . 46.7 m -50.66 -37.13 39.15 Favored 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 120.889 1.677 . . . . 0.0 112.539 -178.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 80.8 mt -75.74 -11.71 60.04 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.5 m -135.41 -17.86 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 CA-C-N 119.445 1.021 . . . . 0.0 113.343 -169.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 78.35 146.44 3.03 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 124.698 1.142 . . . . 0.0 111.139 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.7 p -75.88 -17.68 59.7 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.662 1.185 . . . . 0.0 112.552 177.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' CYS . . . . . . . . . . . . . 73.2 m -112.84 161.95 16.36 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.432 1.093 . . . . 0.0 109.2 174.008 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -106.72 -179.41 3.93 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 124.701 1.2 . . . . 0.0 113.171 -169.397 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 23.0 mp0 -67.41 -14.37 62.87 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.895 2.078 . . . . 0.0 112.627 -176.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ASN . . . . . . . . . . . . . 65.4 m-80 -96.7 -37.32 10.36 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 124.176 0.99 . . . . 0.0 110.185 -178.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 125.79 28.59 1.04 Allowed Glycine 0 CA--C 1.53 1.025 0 C-N-CA 125.299 1.428 . . . . 0.0 112.507 178.257 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -127.63 158.24 70.68 Favored Pre-proline 0 CA--C 1.538 0.5 0 CA-C-N 119.149 1.474 . . . . 0.0 109.316 -176.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -64.36 144.43 85.81 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 121.867 1.712 . . . . 0.0 109.548 174.163 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 82.9 mtt-85 -69.54 13.14 0.14 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 114.619 1.34 . . . . 0.0 114.619 -174.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 87.6 t -53.62 131.02 15.76 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 CA-C-N 120.379 1.445 . . . . 0.0 108.446 176.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 86.36 -14.59 54.08 Favored Glycine 0 CA--C 1.53 0.978 0 CA-C-O 118.531 -1.15 . . . . 0.0 113.589 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -77.05 162.02 27.84 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-N 119.715 1.758 . . . . 0.0 109.195 176.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -106.43 151.25 25.17 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 179.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 17.0 m -140.78 150.38 20.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 177.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -88.36 124.99 34.47 Favored 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 103.662 -2.718 . . . . 0.0 103.662 168.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 7.4 p -116.86 156.99 18.0 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.389 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 177.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 6.3 t-80 -154.02 -32.83 0.11 Allowed 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 123.0 0.52 . . . . 0.0 111.315 -175.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 17.2 m -133.79 -163.24 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 170.183 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -68.06 19.91 0.33 Allowed Glycine 0 CA--C 1.538 1.471 0 CA-C-N 119.64 1.109 . . . . 0.0 114.817 179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -133.9 139.82 46.42 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.768 1.627 . . . . 0.0 107.956 -179.298 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.06 116.11 10.05 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 170.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' MET . . . . . . . . . . . . . 86.6 mmm -74.33 -43.69 55.63 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 4.1 p -155.71 153.03 29.31 Favored 'General case' 0 C--O 1.234 0.245 0 C-N-CA 123.781 0.833 . . . . 0.0 110.067 179.297 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 13.6 t -79.65 143.38 12.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 169.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 27.2 pt -138.55 160.76 31.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 124.175 0.99 . . . . 0.0 108.849 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ASN . . . . . . . . . . . . . 14.3 t-20 -80.62 164.91 22.52 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 169.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -53.91 -41.85 68.09 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 123.608 0.763 . . . . 0.0 111.439 170.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.62 -37.08 85.96 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.857 0.463 . . . . 0.0 110.99 -177.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -71.1 -38.84 72.36 Favored 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 177.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.98 -48.7 80.6 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 118.415 0.552 . . . . 0.0 110.157 174.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.3 mtt180 -61.62 -43.26 99.18 Favored 'General case' 0 N--CA 1.462 0.151 0 C-N-CA 123.489 0.715 . . . . 0.0 110.45 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -62.93 -41.35 99.46 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 118.688 0.676 . . . . 0.0 111.295 177.167 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 41.5 m -64.69 -41.47 96.02 Favored 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 122.807 0.443 . . . . 0.0 110.096 177.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . . . . . . . . . 83.7 mt -66.51 -36.85 83.72 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 119.053 0.842 . . . . 0.0 110.941 177.222 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -66.05 -40.66 91.12 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 118.607 0.64 . . . . 0.0 110.822 177.273 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -63.03 -52.37 63.14 Favored 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 122.704 0.402 . . . . 0.0 109.997 173.442 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 6.6 tt -55.43 -52.03 64.94 Favored 'General case' 0 C--O 1.233 0.187 0 C-N-CA 124.44 1.096 . . . . 0.0 109.984 -175.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -65.27 -15.63 62.7 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -172.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -121.69 -10.48 8.76 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 119.594 1.088 . . . . 0.0 113.79 -176.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 72.1 mtm -126.63 -5.71 6.39 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 119.423 1.01 . . . . 0.0 113.141 179.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -125.49 -48.82 1.67 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 119.147 0.885 . . . . 0.0 109.721 175.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -79.51 -16.99 55.06 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 122.73 0.412 . . . . 0.0 111.389 170.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . 0.293 35.6 m 45.35 44.17 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.581 0 C-N-CA 126.992 2.117 . . . . 0.0 113.43 -179.324 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 81.89 141.11 0.06 OUTLIER Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 128.948 2.899 . . . . 0.0 111.313 169.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' PRO . . . . . 0.452 ' HA ' ' H ' ' A' ' 83' ' ' ALA . 37.5 Cg_endo -63.95 -23.19 68.19 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.543 2.162 . . . . 0.0 112.731 -172.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -53.98 -20.94 7.01 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 125.696 1.598 . . . . 0.0 113.238 175.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 13.6 p -132.33 -36.25 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 C-N-CA 123.365 0.666 . . . . 0.0 111.108 170.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -67.09 -54.67 19.78 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 119.507 1.049 . . . . 0.0 111.64 -176.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.452 ' H ' ' HA ' ' A' ' 79' ' ' PRO . . . -67.92 -34.73 77.18 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 117.551 0.675 . . . . 0.0 110.492 178.034 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 19.7 tp -58.76 -46.25 87.9 Favored 'General case' 0 CA--C 1.537 0.464 0 C-N-CA 123.43 0.692 . . . . 0.0 110.696 176.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 10.3 tt -69.42 -41.63 76.1 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 124.11 0.964 . . . . 0.0 110.66 177.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' TYR . . . . . . . . . . . . . 82.6 t80 -60.52 -35.12 75.21 Favored 'General case' 0 CA--C 1.538 0.489 0 CA-C-N 118.494 0.588 . . . . 0.0 111.332 178.339 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -78.44 0.63 74.76 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 124.539 1.066 . . . . 0.0 113.094 175.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 55.01 26.5 8.1 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 126.938 2.095 . . . . 0.0 112.211 -176.325 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 8.9 tp10 -73.86 -20.58 60.39 Favored 'General case' 0 CA--C 1.542 0.644 0 O-C-N 121.561 -0.712 . . . . 0.0 110.41 175.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt . . . . . 0 C--O 1.248 1.025 0 C-N-CA 127.219 2.208 . . . . 0.0 106.367 172.226 . . . . . . . . 0 0 . 1 stop_ save_